# **CANCER COUNTY PROFILES**2016–2020 Incidence Years

#### March 2023

A Publication of the Cancer Data Registry of Idaho



#### **Editors:**

Christopher J. Johnson, MPH, Epidemiologist Bożena M. Morawski, PhD, MPH, Epidemiologist

#### Contributors:

Randi K. Rycroft, MSPH, CTR, Registry Manager
Denise Jozwik, RHIT, CTR, Director of Data Quality
Teresa Chapple, CTR, Data Quality & Collection Coordinator
Shannon Makinen, RHIT, CTR, Data Quality & Collection Coordinator
Tessa Morrison, CTR, Data Quality & Collection Coordinator
Patti Rose, RHIT, CTR, Data Quality & Collection Coordinator
Regina Eck, Database Administrator

CANCER DATA REGISTRY OF IDAHO
P.O. Box 1278
Boise, Idaho 83701-1278
Phone: 208-489-1380

https://www.idcancer.org





# ADA COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

### Cancer Incidence 2016–2020 Cancer Mortality 2017–2021 BRFSS 2011–2021

#### **RISK FACTORS AND INTERVENTIONS**

#### CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/jama.2016.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

#### Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

#### **Smoking:**

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

#### Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <a href="https://www.dietaryguidelines.gov">https://www.dietaryguidelines.gov</a>

#### Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute
Cancer Information Services
1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society <a href="https://www.cancer.org">https://www.cancer.org</a>

#### **CANCER INCIDENCE 2016–2020**

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016–2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 11,968 cases of invasive cancer were diagnosed among Ada County residents (Table 1).

**Table 1:** Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Ada County and the State of Idaho. 2016–2020

Cancer Incidence 2016–2020	Ada County	State of Idaho
All Sites/Types	11,968	45,610
Female Breast	1,983	6,687
Prostate	1,744	6,417
Lung & Bronchus	1,167	4,887
Colorectal	780	3,451

Table 3 (Cancer Incidence 2016–2020, Comparison between Ada County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Ada County. The table also shows the number of observed cases, person-years, and

crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Ada County was 509.8 cases per 100,000 person-years per year during 2016–2020. Comparing this crude rate with the crude rate for the remainder of Idaho (523.7) gives an estimate of the relative burden of disease in Ada County.

The age- and sex-adjusted incidence rate of invasive cancer in Ada County, all sites combined, was 540.8 cases per 100,000 persons per year during 2016–2020. There were statistically significantly more cases of cancer in Ada County (11,968) than expected (11,588.4) based upon rates in the remainder of the state (p<.001).

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

#### **CANCER MORTALITY 2017–2021**

During 2017–2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 3,650 Ada County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

**Table 2:** Overall and Cancer Mortality in Ada County and the State of Idaho, 2017–2021

Mortality 2017–2021	-			
All Deaths	17,582	77,431		
Cancer Deaths	3,650	15,121		
% of All Deaths	20.8%	19.5%		
Lung & Bronchus	677	2,961		
Colorectal	283	1,319		
Pancreas	306	1,190		
Female Breast	298	1,086		
Prostate	200	949		

Table 4 (Cancer Mortality 2017–2021, Comparison between Ada County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Ada County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Ada County, all sites combined, was 164.3 deaths per 100,000 persons per year during 2017–2021, compared with 174.5 for the remainder of the state. There were statistically significantly fewer cancer deaths in Ada County (3,650) than expected (3,875.8) based upon rates in the remainder of the state (p<.001).

**Statistical Note:** Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

## TABLE 3: CANCER INCIDENCE 2016–2020 COMPARISON BETWEEN ADA COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

		Ada County						Remainder of Idaho		
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)
All Sites Combined	Total	11,968	2,347,363	509.8	540.8	11,588.4	0.000 >>	33,642	6,424,465	523.7
All Sites Combined All Sites Combined	Male Female	6,199 5,769	1,175,230 1,172,133	527.5 492.2	582.6 504.9	5,974.1 5,548.0	0.004 >> 0.003 >>	18,090 15,552	3,221,680 3,202,785	561.5 485.6
Bladder	Total	575	2,347,363	24.5	27.1	530.6	0.059	1,609	6,424,465	25.0
Bladder	Male	446	1,175,230	38.0	43.8	412.7	0.109	1,305	3,221,680	40.5
Bladder	Female	129	1,172,133	11.0	11.7	104.6	0.023 >>	304	3,202,785	9.5
Brain - malignant	Total	168	2,347,363	7.2	7.4	162.5	0.684	457	6,424,465	7.1
Brain - malignant Brain - malignant	Male Female	101 67	1,175,230 1,172,133	8.6 5.7	8.9 5.8	96.4 65.5	0.664 0.887	274 183	3,221,680 3,202,785	8.5 5.7
Brain - manghant Brain and other CNS - non-malignant	Total	365	2,347,363	15.5	16.1	373.6	0.682	1,059	6,424,465	16.5
Brain and other CNS - non-malignant	Male	119	1,175,230	10.1	10.6	126.3	0.552	361	3,221,680	11.2
Brain and other CNS - non-malignant	Female	246	1,172,133	21.0	21.5	249.7	0.848	698	3,202,785	21.8
Breast	Total	2,004	2,347,363	85.4	87.7	1,686.1	0.000 >>	4,742	6,424,465	73.8
Breast	Male	21	1,175,230	1.8	2.0	12.2	0.027 >>	38	3,221,680	1.2
Breast Breast - in situ	Female Total	1,983 415	1,172,133 2,347,363	169.2 17.7	171.1 17.9	1,701.9 296.9	0.000 >> 0.000 >>	4,704 824	3,202,785 6,424,465	146.9 12.8
Breast - in situ	Male	1	1,175,230	0.1	0.1	1.4	1.000	4	3,221,680	0.1
Breast - in situ	Female	414	1,172,133	35.3	35.4	299.7	0.000 >>	820	3,202,785	25.6
Cervix	Female	57	1,172,133	4.9	4.5	97.7	0.000 <<	247	3,202,785	7.7
Colorectal	Total	780	2,347,363	33.2	35.0	927.8	0.000 <<	2,671	6,424,465	41.6
Colorectal Colorectal	Male Female	405 375	1,175,230 1,172,133	34.5 32.0	37.0 33.0	508.7 415.7	0.000 << 0.046 <<	1,498 1,173	3,221,680 3,202,785	46.5 36.6
Corpus Uteri	Female	375	1,172,133	32.0 27.5	28.0	362.5	0.046 <<	1,173	3,202,785	31.5
Esophagus	Total	127	2,347,363	5.4	5.9	127.9	0.984	379	6,424,465	5.9
Esophagus	Male	106	1,175,230	9.0	10.1	104.1	0.877	318	3,221,680	9.9
Esophagus	Female	21	1,172,133	1.8	1.9	21.1	1.000	61	3,202,785	1.9
Hodgkin Lymphoma	Total	74	2,347,363	3.2	3.2	49.5	0.001 >>	136	6,424,465	2.1
Hodgkin Lymphoma Hodgkin Lymphoma	Male Female	38 36	1,175,230 1,172,133	3.2 3.1	3.2 3.1	29.1 20.3	0.130 0.002 >>	80 56	3,221,680 3,202,785	2.5 1.7
Kidney and Renal Pelvis	Total	424	2,347,363	18.1	18.9	484.8	0.002 >>	1,391	6,424,465	21.7
Kidney and Renal Pelvis	Male	281	1,175,230	23.9	25.5	307.8	0.130	901	3,221,680	28.0
Kidney and Renal Pelvis	Female	143	1,172,133	12.2	12.6	173.5	0.019 <<	490	3,202,785	15.3
Larynx	Total	44	2,347,363	1.9	2.0	57.8	0.072	171	6,424,465	2.7
Larynx	Male Female	34 10	1,175,230 1,172,133	2.9 0.9	3.2 0.9	41.0 15.7	0.309 0.174	126 45	3,221,680 3,202,785	3.9 1.4
Larynx Leukemia	Total	421	2,347,363	17.9	19.3	410.7	0.174	1,210	6,424,465	18.8
Leukemia	Male	250	1,175,230	21.3	23.5	244.2	0.726	739	3,221,680	22.9
Leukemia	Female	171	1,172,133	14.6	15.4	163.7	0.588	471	3,202,785	14.7
Liver and Bile Duct	Total	210	2,347,363	8.9	9.6	210.8	0.990	619	6,424,465	9.6
Liver and Bile Duct	Male	147	1,175,230	12.5	13.8	146.8	1.000	443	3,221,680	13.8
Liver and Bile Duct Lung and Bronchus	Female Total	63 1,167	1,172,133 2,347,363	5.4 49.7	5.6 54.9	61.4 1,231.0	0.876 0.069	176 3,720	3,202,785 6,424,465	5.5 57.9
Lung and Bronchus	Male	541	1,175,230	46.0	52.8	608.2	0.006 <<	1,911	3,221,680	59.3
Lung and Bronchus	Female	626	1,172,133	53.4	57.1	618.9	0.785	1,809	3,202,785	56.5
Melanoma of the Skin	Total	916	2,347,363	39.0	40.5	712.7	0.000 >>	2,026	6,424,465	31.5
Melanoma of the Skin	Male	550	1,175,230	46.8	50.8	408.1	0.000 >>	1,215	3,221,680	37.7
Melanoma of the Skin	Female	366 181	1,172,133	31.2	31.1	297.7	0.000 >>	811 527	3,202,785	25.3
Myeloma Myeloma	Total Male	112	2,347,363 1.175,230	7.7 9.5	8.4 10.7	176.8 106.5	0.775 0.621	327 329	6,424,465 3.221.680	8.2 10.2
Myeloma	Female	69	1,173,230	5.9	6.2	68.7	1.000	198	3,202,785	6.2
Non-Hodgkin Lymphoma	Total	490	2,347,363	20.9	22.3	496.3	0.800	1,450	6,424,465	22.6
Non-Hodgkin Lymphoma	Male	299	1,175,230	25.4	27.8	277.3	0.204	830	3,221,680	25.8
Non-Hodgkin Lymphoma	Female	191	1,172,133	16.3	17.0	216.9	0.080	620	3,202,785	19.4
Oral Cavity and Pharynx Oral Cavity and Pharynx	Total Male	337 232	2,347,363 1,175,230	14.4 19.7	15.1 21.2	332.9 238.8	0.835 0.688	958 704	6,424,465 3,221,680	14.9 21.9
Oral Cavity and Pharynx	Female	105	1,173,230	9.0	9.2	90.2	0.000	254	3,202,785	7.9
Ovary	Female	123	1,172,133	10.5	10.7	147.8	0.041 <<	410	3,202,785	12.8
Pancreas	Total	356	2,347,363	15.2	16.5	358.4	0.925	1,067	6,424,465	16.6
Pancreas	Male	189	1,175,230	16.1	18.0	193.5	0.780	595 470	3,221,680	18.5
Pancreas Prostate	Female Male	167 1,744	1,172,133 1,175,230	14.2 148.4	15.1 166.1	163.0 1,523.4	0.776 0.000 >>	472 4,673	3,202,785 3,221,680	14.7 145.0
Stomach	Total	1,744	2,347,363	4.7	5.1	1,323.4	0.000 >>	356	6,424,465	5.5
Stomach	Male	73	1,175,230	6.2	6.9	77.2	0.685	236	3,221,680	7.3
Stomach	Female	38	1,172,133	3.2	3.3	42.6	0.537	120	3,202,785	3.7
Testis	Male	79	1,175,230	6.7	6.2	73.7	0.563	186	3,221,680	5.8
Thyroid	Total	336	2,347,363	14.3	13.8	335.1	0.975	884	6,424,465	13.8
Thyroid	Male	92	1,175,230	7.8	7.8	96.5	0.691	263	3,221,680	8.2
Thyroid	Female	244	1,172,133	20.8	19.9	237.9	0.711	621	3,202,785	19.4
Pediatric Age 0 to 19 Pediatric Age 0 to 19	Total Male	116 56	613,273 313,621	18.9 17.9	19.0 17.9	101.0 55.3	0.154 0.959	305 167	1,847,250 942,889	16.5 17.7
Pediatric Age 0 to 19 Pediatric Age 0 to 19	Female	56 60	299,652	20.0	20.1	55.3 45.7	0.959	138	942,889	17.7
			ne number of case					100	50-7,001	10.0

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

<sup>2.</sup> Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

<sup>&</sup>quot;<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

## TABLE 4: CANCER MORTALITY 2017–2021 COMPARISON BETWEEN ADA COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

		Ada County						Remainder of Idaho		
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	17,582	2,414,365	728.2	790.5	20,247.8	0.000 <<	59,848	6,574,350	910.3
All Causes of Death	Male	9,010	1,210,250	744.5	828.7	10,553.5	0.000 <<	32,046	3,301,618	970.6
All Causes of Death	Female	8,572	1,204,115	711.9	757.0	9,619.7	0.000 <<	27,802	3,272,732	849.5
All Malignant Cancers	Total	3,650	2,414,365	151.2	164.3	3,875.8	0.000 <<	11,471	6,574,350	174.5
All Malignant Cancers	Male	1,868	1,210,250	154.3	174.3	2,047.0	0.000 <<	6,308	3,301,618	191.1
All Malignant Cancers	Female	1,782	1,204,115	148.0	155.8	1,804.1	0.614	5,163	3,272,732	157.8
Bladder	Total	121	2,414,365	5.0	5.6	120.6	0.996	368	6,574,350	5.6
Bladder	Male	87	1,210,250	7.2	8.4	91.2	0.711	291	3,301,618	8.8
Bladder	Female	34	1,204,115	2.8	3.1	26.1	0.156	77	3,272,732	2.4
Brain and Other Nervous System	Total	131	2,414,365	5.4	5.7	131.4	1.000	373	6,574,350	5.7
Brain and Other Nervous System	Male	76 55	1,210,250	6.3	6.7 4.7	76.4 54.3	1.000	222	3,301,618	6.7
Brain and Other Nervous System Breast	Female Total	302	1,204,115 2,414,365	4.6 12.5	13.2	277.5	0.958 0.152	151 800	3,272,732 6,574,350	4.6 12.2
Breast	Male	4	1,210,250	0.3	0.4	3.8	1.000	12	3,301,618	0.4
Breast	Female	298	1,204,115	24.7	25.6	280.2	0.302	788	3,272,732	24.1
Cervix	Female	230	1,204,115	1.9	1.8	23.1	1.000	60	3,272,732	1.8
Colorectal	Total	283	2,414,365	11.7	12.5	356.1	0.000 <<	1,036	6,574,350	15.8
Colorectal	Male	147	1,210,250	12.1	13.2	192.5	0.001 <<	572	3,301,618	17.3
Colorectal	Female	136	1,204,115	11.3	11.9	162.4	0.037 <<	464	3,272,732	14.2
Corpus Uteri	Female	55	1,204,115	4.6	4.8	41.2	0.046 >>	118	3,272,732	3.6
Esophagus	Total	123	2,414,365	5.1	5.5	120.4	0.837	354	6,574,350	5.4
Esophagus	Male	102	1,210,250	8.4	9.3	98.8	0.774	299	3,301,618	9.1
Esophagus	Female	21	1,204,115	1.7	1.9	19.0	0.704	55	3,272,732	1.7
Hodgkin Lymphoma	Total	8	2,414,365	0.3	0.4	7.2	0.852	21	6,574,350	0.3
Hodgkin Lymphoma	Male	5	1,210,250	0.4	0.5	2.9	0.330	9	3,301,618	0.3
Hodgkin Lymphoma	Female	3	1,204,115	0.2	0.3	4.3	0.767	12	3,272,732	0.4
Kidney	Total Male	92 60	2,414,365	3.8	4.2	98.0	0.589 0.945	293	6,574,350 3,301,618	4.5 5.5
Kidney Kidney	Female	32	1,210,250 1,204,115	5.0 2.7	5.6 2.9	59.1 38.0	0.945	182 111	3,272,732	3.4
Larynx	Total	19	2,414,365	0.8	0.9	17.5	0.376	52	6,574,350	0.8
Larynx	Male	14	1,210,250	1.2	1.3	14.3	1.000	44	3,301,618	1.3
Larynx	Female	5	1,204,115	0.4	0.4	2.8	0.314	8	3,272,732	0.2
Leukemia	Total	183	2,414,365	7.6	8.3	159.3	0.071	477	6,574,350	7.3
Leukemia	Male	94	1,210,250	7.8	8.8	94.2	1.000	292	3,301,618	8.8
Leukemia	Female	89	1,204,115	7.4	7.9	63.6	0.003 >>	185	3,272,732	5.7
Liver and Bile Duct	Total	148	2,414,365	6.1	6.6	154.3	0.648	455	6,574,350	6.9
Liver and Bile Duct	Male	100	1,210,250	8.3	9.2	101.1	0.964	308	3,301,618	9.3
Liver and Bile Duct	Female	48	1,204,115	4.0	4.2	51.3	0.712	147	3,272,732	4.5
Lung and Bronchus	Total	677	2,414,365	28.0	30.8	763.7	0.002 <<	2,284	6,574,350	34.7
Lung and Bronchus	Male	341	1,210,250	28.2	32.1	390.7	0.011 <<	1,215	3,301,618	36.8
Lung and Bronchus	Female	336	1,204,115	27.9	29.7	369.6	0.082	1,069	3,272,732	32.7
Melanoma of the Skin Melanoma of the Skin	Total Male	79 52	2,414,365 1,210,250	3.3 4.3	3.5 4.8	71.7 45.9	0.421 0.401	210 140	6,574,350 3 301 618	3.2 4.2
Melanoma of the Skin	Female	52 27	1,210,250	2.2	2.3	45.9 24.9	0.401	70	3,301,618 3,272,732	2.1
Myeloma	Total	90	2,414,365	3.7	4.2	79.3	0.723	241	6,574,350	3.7
Myeloma	Male	45	1,210,250	3.7	4.3	47.7	0.771	151	3,301,618	4.6
Myeloma	Female	45	1,204,115	3.7	4.0	30.7	0.018 >>	90	3,272,732	2.7
Non-Hodgkin Lymphoma	Total	117	2,414,365	4.8	5.4	149.9	0.006 <<	452	6,574,350	6.9
Non-Hodgkin Lymphoma	Male	64	1,210,250	5.3	6.0	78.0	0.121	243	3,301,618	7.4
Non-Hodgkin Lymphoma	Female	53	1,204,115	4.4	4.7	71.4	0.028 <<		3,272,732	6.4
Oral Cavity and Pharynx	Total	67	2,414,365	2.8	3.0	67.8	0.986	199	6,574,350	3.0
Oral Cavity and Pharynx	Male	51	1,210,250	4.2	4.7	44.7	0.379	136	3,301,618	4.1
Oral Cavity and Pharynx	Female	16	1,204,115	1.3	1.4	22.3	0.213	63	3,272,732	1.9
Ovary	Female	85	1,204,115	7.1	7.4	93.2	0.428	265	3,272,732	8.1
Pancreas	Total	306	2,414,365	12.7	13.8	297.9	0.655	884	6,574,350	13.4
Pancreas	Male	160	1,210,250	13.2	14.9	156.9	0.825	482	3,301,618	14.6
Pancreas Prostate	Female Male	146 200	1,204,115 1,210,250	12.1 16.5	12.8 19.4	139.6 233.5	0.610 0.028 <b>&lt;&lt;</b>	402 749	3,272,732 3,301,618	12.3 22.7
Stomach	Total	200 50	2,414,365	2.1	2.2	233.5 51.4	0.026 <<	148	6,574,350	22.7
Stomach	Male	25	1,210,250	2.1	2.2	31.4	0.921	96	3,301,618	2.3
Stomach	Female	25 25	1,204,115	2.1	2.3	18.9	0.233	52	3,272,732	1.6
			ne number of cases r				0.200	UZ	0,212,102	1.0

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

<sup>2.</sup> Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

<sup>&</sup>quot;<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

#### Cancer Screening and Risk Factor Prevalence Estimates, 2011–2021

	State of								
Measure	Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	Ada County
Access to Care									
Have Health Insurance, Age <65 (2015–2021)	83.1%	82.8%	85.1%	77.2%	85.8%	78.9%	85.4%	85.4%	86.1%
Not See Doctor Due to Cost in Past Year (2015–2021)	12.6%	11.4%	11.8%	14.5%	12.4%	12.3%	11.8%	12.9%	12.4%
Cancer Screening									
Mammogram Past 2 Years, Age 50–74 (2014, 2016, 2018, 2020)	69.1%	67.0%	73.8%	68.2%	73.2%	64.8%	64.5%	67.1%	73.1%
Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020)	71.2%	73.6%	73.6%	70.8%	72.9%	69.1%	69.5%	65.9%	73.8%
Colorectal Cancer Screening, Age 50–75 (2018, 2020)	67.9%	66.9%	73.6%	71.4%	70.6%	61.7%	61.5%	64.7%	70.6%
Tobacco Use									
Current Tobacco User (2016–2021)	22.3%	26.7%	23.1%	23.6%	21.8%	21.4%	22.7%	16.9%	20.7%
Other Cancer-Related									
Healthy Weight by Body Mass Index, Age 20+ (2015–2021)	32.1%	32.8%	31.7%	27.9%	36.1%	29.8%	27.9%	31.9%	36.3%
Any Physical Activity Besides Job Past 30 Days (2015-2021)	78.7%	79.2%	78.1%	74.5%	83.2%	73.4%	76.3%	79.7%	83.9%
Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019)	21.9%	22.8%	19.4%	20.0%	25.2%	19.5%	20.4%	20.2%	25.5%
Home Ever Tested for Radon (2016, 2018, 2020)	23.0%	30.9%	18.2%	16.9%	25.1%	19.9%	23.0%	21.8%	25.6%

#### **Access to Care**

#### Have Health Insurance – 2015–2021

Statewide, 83.1% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 86.0% of white non-Hispanics, compared to 64.8% of Hispanics and 83.3% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3%) than English-speaking respondents (84.2%). Health care coverage differed significantly by age of respondent, with 79.8% of persons aged 18–29, and 87.8% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 62.1% in Adams County to 91.6% in Oneida County having health insurance.

#### Not See Doctor Due to Cost in Past Year - 2015-2021

Statewide, 12.6% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (11.5% of white non-Hispanics, 19.2% of Hispanics, and 21.0% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9% for less than \$15,000, 6.1% for greater than \$50,000). Inability to see a doctor due to cost differed significantly by county, with a range of 7.4% in Franklin County to 17.5% in Power County.

#### **Cancer Screening**

Mammogram - 2014, 2016, 2018, 2020

Statewide, 69.1% of women aged 50–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (72.1% versus 36.7%). Mammography rates differed significantly by county, with a range in screening of 45.9% in Benewah County to 77.0% in Nez Perce County. In 2020, Idaho ranked 48<sup>th</sup> among states and the District of Columbia for mammography screening rates among women aged 50–74 and also 48<sup>th</sup> among ages 40+.

#### Pap Test - 2018, 2020

Statewide, 71.2% of women with an intact cervix and aged 21–65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.1% versus 52.6% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.7% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49<sup>th</sup> among states and the District of Columbia for Pap screening rate.

#### Colorectal Cancer Screening – 2018, 2020

Statewide, 67.9% of adults aged 50–75 reported being current for colorectal cancer screening.\*\* Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked 47<sup>th</sup> among states and the District of Columbia in the percentage of adults aged 50–75 and older who reported being up-to-date for colorectal cancer screening.

<sup>\*\*</sup> Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

#### **Tobacco Use**

#### Current Tobacco Use - 2016-2021

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.3% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 29.9% of persons aged 18-29, and 11.1% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (22.4%) than among Native Americans (40.0%). Tobacco use differed significantly by county, with a range of 5.4% in Madison County to 41.6% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

#### **Other Cancer-Related**

#### Healthy Weight by Body Mass Index - 2015-2021

Statewide, 32.1% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 32.5% of white non-Hispanics, compared to 28.2% of Hispanics and 24.6% of Native Americans, being in the healthy weight range. Males (25.5%) were significantly less likely to be in the healthy weight range than females (38.6%). BMI differed significantly by age of respondent, with 43.3% of persons aged 18–29, and 26.0% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 19.8% in Power County to 47.4% in Blaine County of adults being in the healthy weight range.

#### Any Physical Activity - 2015-2021

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 78.7% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.3% of persons aged 18–29, and 72.3% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 64.3% in Clark County to 84.6% in Teton County.

Physical Activity Guidelines – 2011, 2013, 2015, 2017, 2019 Statewide, 21.9% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.3% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6% in Franklin County to 30.6% in Blaine County.

#### Home Radon Testing - 2016, 2018, 2020

Statewide, 23.0% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.4% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.5% in Cassia County to 54.4% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006l and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.





## ADAMS COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016–2020 Cancer Mortality 2017–2021 BRFSS 2011–2021

#### **RISK FACTORS AND INTERVENTIONS**

#### CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/jama.2016.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

#### Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

#### **Smoking:**

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

#### Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <a href="https://www.dietaryguidelines.gov">https://www.dietaryguidelines.gov</a>

#### Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute
Cancer Information Services
1-800-4CANCER
<a href="https://www.cancer.gov/contact">https://www.cancer.gov/contact</a>

American Cancer Society <a href="https://www.cancer.org">https://www.cancer.org</a>

#### **CANCER INCIDENCE 2016–2020**

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016–2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 164 cases of invasive cancer were diagnosed among Adams County residents (Table 1).

**Table 1:** Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Adams County and the State of Idaho. 2016–2020

	,	
Cancer Incidence 2016–2020	Adams County	State of Idaho
All Sites/Types	164	45,610
Female Breast	15	6,687
Prostate	29	6,417
Lung & Bronchus	23	4,887
Colorectal	7	3,451

Table 3 (Cancer Incidence 2016–2020, Comparison between Adams County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Adams County. The table also shows the number of observed cases, person-

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Adams County was 781.0 cases per 100,000 person-years per year during 2016–2020. Comparing this crude rate with the crude rate for the remainder of Idaho (519.3) gives an estimate of the relative burden of disease in Adams County.

The age- and sex-adjusted incidence rate of invasive cancer in Adams County, all sites combined, was 480.4 cases per 100,000 persons per year during 2016–2020. There were fewer cases of cancer in Adams County (164) than expected (177.3) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

#### **CANCER MORTALITY 2017–2021**

During 2017–2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 63 Adams County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

**Table 2:** Overall and Cancer Mortality in Adams County and the State of Idaho, 2017–2021

Mortality 2017–2021	Adams County	State of Idaho
All Deaths	236	77,431
Cancer Deaths	63	15,121
% of All Deaths	26.7%	19.5%
Lung & Bronchus	16	2,961
Colorectal	4	1,319
Pancreas	4	1,190
Female Breast	6	1,086
Prostate	3	949

Table 4 (Cancer Mortality 2017–2021, Comparison between Adams County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Adams County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Adams County, all sites combined, was 174.2 deaths per 100,000 persons per year during 2017–2021, compared with 167.9 for the remainder of the state. There were more cancer deaths in Adams County (63) than expected (60.7) based upon rates in the remainder of the state, but the difference was not statistically significant.

**Statistical Note:** Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

#### TABLE 3: CANCER INCIDENCE 2016–2020 COMPARISON BETWEEN ADAMS COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

		Adams County					Ren	Remainder of Idaho		
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)
All Sites Combined	Total	164	20,999	781.0	480.4	177.3	0.337	45,446	8,750,829	519.3
All Sites Combined All Sites Combined	Male Female	100 64	10,860 10,139	920.8 631.2	517.1 422.4	106.7 73.8	0.558 0.277	24,189 21,257	4,386,050 4.364.779	551.5 487.0
Bladder	Total	12	20,999	57.1	33.0	9.0	0.401	21,237	8,750,829	24.8
Bladder	Male	11	10,860	101.3	53.7	8.1	0.394	1,740	4,386,050	39.7
Bladder	Female	1	10,139	9.9	6.2	1.6	1.000	432	4,364,779	9.9
Brain - malignant	Total	-	20,999	-	-	2.2	0.230	625	8,750,829	7.1
Brain - malignant Brain - malignant	Male Female	-	10,860 10,139	-	_	1.4 0.8	0.491 0.893	375 250	4,386,050 4,364,779	8.5 5.7
Brain and other CNS - non-malignant	Total	1	20,999	4.8	3.2	5.1	0.077	1,423	8,750,829	16.3
Brain and other CNS - non-malignant	Male	-	10,860	-	-	1.8	0.332	480	4,386,050	10.9
Brain and other CNS - non-malignant	Female	1	10,139	9.9	6.9	3.1	0.362	943	4,364,779	21.6
Breast Breast	Total Male	16 1	20,999 10,860	76.2 9.2	48.7 5.2	25.2 0.3	0.068 0.447	6,730 58	8,750,829 4,386,050	76.9 1.3
Breast	Female	15	10,139	147.9	98.8	23.2	0.095	6,672	4,364,779	152.9
Breast - in situ	Total	5	20,999	23.8	15.3	4.6	0.974	1,234	8,750,829	14.1
Breast - in situ	Male		10,860	-	-	0.0	1.000	5	4,386,050	0.1
Breast - in situ	Female Female	5	10,139	49.3	32.8	4.3	0.857 0.912	1,229	4,364,779	28.2
Cervix Colorectal	Total	- 7	10,139 20,999	33.3	- 21.0	0.8 13.1	0.912	304 3,444	4,364,779 8.750.829	7.0 39.4
Colorectal	Male	4	10,860	36.8	21.9	7.9	0.208	1,899	4,386,050	43.3
Colorectal	Female	3	10,139	29.6	19.9	5.3	0.444	1,545	4,364,779	35.4
Corpus Uteri	Female	1	10,139	9.9	6.3	4.8	0.092	1,329	4,364,779	30.4
Esophagus Esophagus	Total Male	1 1	20,999 10,860	4.8 9.2	2.8 5.1	2.1 1.9	0.776 0.867	505 423	8,750,829 4,386,050	5.8 9.6
Esophagus	Female	_ '	10,139	- 9.2	J.1	0.3	1.000	82	4,364,779	1.9
Hodgkin Lymphoma	Total	2	20,999	9.5	8.5	0.6	0.218	208	8,750,829	2.4
Hodgkin Lymphoma	Male	2	10,860	18.4	15.5	0.3	0.093	116	4,386,050	2.6
Hodgkin Lymphoma	Female		10,139	-	-	0.2	1.000	92	4,364,779	2.1
Kidney and Renal Pelvis Kidney and Renal Pelvis	Total Male	5 3	20,999 10,860	23.8 27.6	14.9 16.4	6.9 4.9	0.620 0.555	1,810 1,179	8,750,829 4,386,050	20.7 26.9
Kidney and Renal Pelvis	Female	2	10,139	19.7	13.1	2.2	1.000	631	4,364,779	14.5
Larynx	Total	1	20,999	4.8	2.8	0.9	1.000	214	8,750,829	2.4
Larynx	Male .		10,860	-	-	0.7	0.958	160	4,386,050	3.6
Larynx	Female Total	1 2	10,139 20,999	9.9 9.5	6.2 6.1	0.2 6.1	0.362 0.112	54 1,629	4,364,779 8,750,829	1.2 18.6
Leukemia Leukemia	Male	2	10,860	18.4	11.0	4.1	0.112	987	4,386,050	22.5
Leukemia	Female		10,139	-	-	2.2	0.223	642	4,364,779	14.7
Liver and Bile Duct	Total	1	20,999	4.8	2.8	3.4	0.288	828	8,750,829	9.5
Liver and Bile Duct	Male	1	10,860	9.2	5.0	2.7	0.508 0.829	589 239	4,386,050 4,364,779	13.4
Liver and Bile Duct Lung and Bronchus	Female Total	- 23	10,139 20,999	- 109.5	62.3	0.9 20.5	0.829	4,864	8,750,829	5.5 55.6
Lung and Bronchus	Male	12	10,860	110.5	57.9	11.5	0.969	2,440	4,386,050	55.6
Lung and Bronchus	Female	11	10,139	108.5	66.7	9.2	0.626	2,424	4,364,779	55.5
Melanoma of the Skin	Total	13	20,999	61.9	40.4	10.8	0.571	2,929	8,750,829	33.5
Melanoma of the Skin	Male	8 5	10,860 10,139	73.7 49.3	43.4 35.8	7.4 3.8	0.914 0.646	1,757 1,172	4,386,050	40.1 26.9
Melanoma of the Skin Myeloma	Female Total	3	20,999	14.3	8.4	2.9	1.000	705	4,364,779 8,750,829	8.1
Myeloma	Male	2	10,860	18.4	10.0	2.0	1.000	439	4,386,050	10.0
Myeloma	Female	1	10,139	9.9	6.2	1.0	1.000	266	4,364,779	6.1
Non-Hodgkin Lymphoma	Total	9	20,999	42.9 55.2	26.6	7.5 4.7	0.669	1,931	8,750,829	22.1
Non-Hodgkin Lymphoma Non-Hodgkin Lymphoma	Male Female	6 3	10,860 10.139	55.2 29.6	32.4 19.4	4.7 2.9	0.676 1.000	1,123 808	4,386,050 4,364,779	25.6 18.5
Oral Cavity and Pharynx	Total	8	20,999	38.1	22.9	5.1	0.297	1,287	8,750,829	14.7
Oral Cavitý and Pharýnx	Male	5	10,860	46.0	26.3	4.0	0.757	931	4,386,050	21.2
Oral Cavity and Pharynx	Female	3	10,139	29.6	19.0	1.3	0.279	356	4,364,779	8.2
Ovary Pancreas	Female Total	3 7	10,139 20,999	29.6 33.3	19.9 19.6	1.8 5.8	0.557 0.712	530 1,416	4,364,779 8,750,829	12.1 16.2
Pancreas	Male	4	10,860	36.8	20.1	3.5	0.712	780	4,386,050	17.8
Pancreas	Female	3	10,139	29.6	18.8	2.3	0.819	636	4,364,779	14.6
Prostate	Male	29	10,860	267.0	141.0	30.0	0.958	6,388	4,386,050	145.6
Stomach Stomach	Total Male	1	20,999	4.8	2.9	1.8 1.4	0.916	466 300	8,750,829	5.3
Stomach	Female	- 1	10,860 10,139	9.9	- 6.8	0.5	0.514 0.818	309 157	4,386,050 4,364,779	7.0 3.6
Testis	Male	- '	10,139		-	0.5	1.000	265	4,386,050	6.0
Thyroid	Total	4	20,999	19.0	15.9	3.5	0.925	1,216	8,750,829	13.9
Thyroid	Male	1	10,860	9.2	6.8	1.2	1.000	354	4,386,050	8.1
Thyroid	Female	3	10,139	29.6	26.0	2.3	0.798	862	4,364,779	19.7
Pediatric Age 0 to 19	Total	2	3,954	50.6	51.6	0.7	0.285	419	2,456,569	17.1
Pediatric Age 0 to 19	Male	1 1	2,085	48.0 53.5	49.0 54.0	0.4 0.3	0.606	222	1,254,425	17.7
Pediatric Age 0 to 19	Female	•	1,869	53.5	54.0	0.3	0.524	197	1,202,144	16.4

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

<sup>2.</sup> Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

<sup>&</sup>quot;<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

#### **TABLE 4: CANCER MORTALITY 2017–2021** COMPARISON BETWEEN ADAMS COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

		Adams County						Remainder of Idaho		
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	236	21,680	1,088.6	698.0	291.1	0.001 <<	77,194	8,967,035	860.9
All Causes of Death	Male	141	11,248	1,253.6	750.8	170.7	0.022 <<	40,915	4,500,620	909.1
All Causes of Death	Female	95	10,432	910.7	621.8	124.1	>> 800.0	36,279	4,466,415	812.3
All Malignant Cancers	Total	63	21,680	290.6	174.2	60.7	0.803	15,058	8,967,035	167.9
All Malignant Cancers	Male	38	11,248	337.8	187.7	36.6	0.861	8,138	4,500,620	180.8
All Malignant Cancers Bladder	Female Total	25 1	10,432 21,680	239.6 4.6	154.0 2.8	25.1 2.0	1.000 0.837	6,920 488	4,466,415 8,967,035	154.9 5.4
Bladder	Male	1	11,248	8.9	2.0 5.0	2.0 1.7	0.837	377	4,500,620	8.4
Bladder	Female	_ '	10,432	0.9	5.0	0.4	1.000	111	4,466,415	2.5
Brain and Other Nervous System	Total	1	21,680	4.6	2.9	1.9	0.856	503	8.967.035	5.6
Brain and Other Nervous System	Male	1	11,248	8.9	5.4	1.2	1.000	297	4,500,620	6.6
Brain and Other Nervous System	Female	-	10,432	-	-	0.7	0.964	206	4,466,415	4.6
Breast	Total	6	21,680	27.7	17.3	4.2	0.507	1,096	8,967,035	12.2
Breast	Male	-	11,248	-	-	0.1	1.000	16	4,500,620	0.4
Breast	Female	6	10,432	57.5	37.7	3.8	0.382	1,080	4,466,415	24.2
Cervix	Female	- 4	10,432	- 40 F	- 44 4	0.2	1.000	83	4,466,415	1.9
Colorectal Colorectal	Total Male	4 2	21,680 11,248	18.5 17.8	11.4 10.4	5.1 3.1	0.830 0.812	1,315 717	8,967,035 4,500,620	14.7 15.9
Colorectal	Female	2	10,432	17.6	10.4	2.1	1.000	598	4,466,415	13.4
Corpus Uteri	Female	-	10,432	- 19.2	-	0.7	1.000	173	4.466.415	3.9
Esophagus	Total	2	21,680	9.2	5.4	1.9	1.000	475	8,967,035	5.3
Esophagus	Male	2	11,248	17.8	9.8	1.8	1.000	399	4,500,620	8.9
Esophagus	Female	-	10,432	-	-	0.3	1.000	76	4,466,415	1.7
Hodgkin Lymphoma	Total	-	21,680	-	-	0.1	1.000	29	8,967,035	0.3
Hodgkin Lymphoma	Male	-	11,248	-	-	0.1	1.000	14	4,500,620	0.3
Hodgkin Lymphoma	Female	-	10,432	-	-	0.1	1.000	15	4,466,415	0.3
Kidney	Total	-	21,680	-	-	1.6	0.410	385	8,967,035 4.500.620	4.3 5.4
Kidney Kidney	Male Female	-	11,248 10,432	-	-	1.1 0.5	0.665 1.000	242 143	4,466,415	3.4
Larynx	Total		21.680	-	-	0.3	1.000	71	8,967,035	0.8
Larynx	Male	_	11,248	_	_	0.3	1.000	58	4,500,620	1.3
Larynx	Female	_	10,432	-	_	0.0	1.000	13	4,466,415	0.3
Leukemia	Total	1	21,680	4.6	2.8	2.6	0.543	659	8,967,035	7.3
Leukemia	Male	1	11,248	8.9	5.1	1.7	0.996	385	4,500,620	8.6
Leukemia	Female	-	10,432	-	-	1.0	0.766	274	4,466,415	6.1
Liver and Bile Duct	Total	1	21,680	4.6	2.7	2.5	0.566	602	8,967,035	6.7
Liver and Bile Duct	Male	1	11,248	8.9	4.8	1.9	0.877	407	4,500,620	9.0
Liver and Bile Duct	Female	- 16	10,432	72.0	- 40 F	0.7	0.963	195	4,466,415	4.4
Lung and Bronchus Lung and Bronchus	Total Male	16 9	21,680 11,248	73.8 80.0	42.5 42.6	12.4 7.3	0.365 0.610	2,945 1,547	8,967,035 4,500,620	32.8 34.4
Lung and Bronchus	Female	7	10,432	67.1	42.0	5.3	0.552	1,347	4,466,415	31.3
Melanoma of the Skin	Total	2	21,680	9.2	5.7	1.1	0.621	287	8,967,035	3.2
Melanoma of the Skin	Male	2	11,248	17.8	10.2	0.8	0.403	190	4,500,620	4.2
Melanoma of the Skin	Female	-	10,432	-	-	0.3	1.000	97	4,466,415	2.2
Myeloma	Total	2	21,680	9.2	5.4	1.4	0.794	329	8,967,035	3.7
Myeloma	Male	2	11,248	17.8	9.5	0.9	0.462	194	4,500,620	4.3
Myeloma	Female		10,432	-	-	0.5	1.000	135	4,466,415	3.0
Non-Hodgkin Lymphoma	Total	3	21,680	13.8	8.3	2.3	0.799	566	8,967,035	6.3
Non-Hodgkin Lymphoma	Male	2	11,248	17.8	10.0	1.4	0.787	305	4,500,620 4,466,415	6.8
Non-Hodgkin Lymphoma Oral Cavity and Pharynx	Female Total	1 4	10,432 21,680	9.6 18.5	6.1 10.9	1.0 1.1	1.000 0.047 >>	261 262	8,967,035	5.8 2.9
Oral Cavity and Pharynx	Male	3	11,248	26.7	14.7	0.8	0.104	184	4,500,620	4.1
Oral Cavity and Pharynx	Female	1	10,432	9.6	6.2	0.3	0.494	78	4,466,415	1.7
Ovary	Female	1	10,432	9.6	6.0	1.3	1.000	349	4,466,415	7.8
Pancreas	Total	4	21,680	18.5	10.8	4.9	0.909	1,186	8,967,035	13.2
Pancreas	Male	3	11,248	26.7	14.5	2.9	1.000	639	4,500,620	14.2
Pancreas	Female	1	10,432	9.6	6.0	2.1	0.785	547	4,466,415	12.2
Prostate	Male	3	11,248	26.7	14.7	4.3	0.758	946	4,500,620	21.0
Stomach	Total	-	21,680	-	-	0.8	0.944	198	8,967,035	2.2
Stomach	Male	-	11,248	-	-	0.5	1.000	121	4,500,620	2.7
Stomach	Female	-	10,432	-	-	0.3	1.000	77	4,466,415	1.7

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

<sup>2.</sup> Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

#### Cancer Screening and Risk Factor Prevalence Estimates, 2011–2021

	State of								Adams
Measure	Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	County
Access to Care									_
Have Health Insurance, Age <65 (2015–2021)	83.1%	82.8%	85.1%	77.2%	85.8%	78.9%	85.4%	85.4%	62.1%
Not See Doctor Due to Cost in Past Year (2015–2021)	12.6%	11.4%	11.8%	14.5%	12.4%	12.3%	11.8%	12.9%	8.9%
Cancer Screening									
Mammogram Past 2 Years, Age 50–74 (2014, 2016, 2018, 2020)	69.1%	67.0%	73.8%	68.2%	73.2%	64.8%	64.5%	67.1%	
Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020)	71.2%	73.6%	73.6%	70.8%	72.9%	69.1%	69.5%	65.9%	
Colorectal Cancer Screening, Age 50–75 (2018, 2020)	67.9%	66.9%	73.6%	71.4%	70.6%	61.7%	61.5%	64.7%	
Tobacco Use									
Current Tobacco User (2016–2021)	22.3%	26.7%	23.1%	23.6%	21.8%	21.4%	22.7%	16.9%	24.7%
Other Cancer-Related									
Healthy Weight by Body Mass Index, Age 20+ (2015–2021)	32.1%	32.8%	31.7%	27.9%	36.1%	29.8%	27.9%	31.9%	24.7%
Any Physical Activity Besides Job Past 30 Days (2015-2021)	78.7%	79.2%	78.1%	74.5%	83.2%	73.4%	76.3%	79.7%	68.3%
Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019)	21.9%	22.8%	19.4%	20.0%	25.2%	19.5%	20.4%	20.2%	12.3%
Home Ever Tested for Radon (2016, 2018, 2020)	23.0%	30.9%	18.2%	16.9%	25.1%	19.9%	23.0%	21.8%	21.1%

#### **Access to Care**

#### Have Health Insurance – 2015–2021

Statewide, 83.1% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 86.0% of white non-Hispanics, compared to 64.8% of Hispanics and 83.3% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3%) than English-speaking respondents (84.2%). Health care coverage differed significantly by age of respondent, with 79.8% of persons aged 18–29, and 87.8% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 62.1% in Adams County to 91.6% in Oneida County having health insurance.

#### Not See Doctor Due to Cost in Past Year – 2015–2021

Statewide, 12.6% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (11.5% of white non-Hispanics, 19.2% of Hispanics, and 21.0% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9% for less than \$15,000, 6.1% for greater than \$50,000). Inability to see a doctor due to cost differed significantly by county, with a range of 7.4% in Franklin County to 17.5% in Power County.

#### **Cancer Screening**

Mammogram - 2014, 2016, 2018, 2020

Statewide, 69.1% of women aged 50–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (72.1% versus 36.7%). Mammography rates differed significantly by county, with a range in screening of 45.9% in Benewah County to 77.0% in Nez Perce County. In 2020, Idaho ranked 48th among states and the District of Columbia for mammography screening rates among women aged 50–74 and also 48th among ages 40+.

#### Pap Test - 2018, 2020

Statewide, 71.2% of women with an intact cervix and aged 21–65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.1% versus 52.6% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.7% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49<sup>th</sup> among states and the District of Columbia for Pap screening rate.

#### Colorectal Cancer Screening - 2018, 2020

Statewide, 67.9% of adults aged 50–75 reported being current for colorectal cancer screening.\*\* Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked 47<sup>th</sup> among states and the District of Columbia in the percentage of adults aged 50–75 and older who reported being up-to-date for colorectal cancer screening.

<sup>\*\*</sup> Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

#### **Tobacco Use**

#### Current Tobacco Use - 2016-2021

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.3% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 29.9% of persons aged 18-29, and 11.1% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (22.4%) than among Native Americans (40.0%). Tobacco use differed significantly by county, with a range of 5.4% in Madison County to 41.6% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

#### **Other Cancer-Related**

#### Healthy Weight by Body Mass Index - 2015-2021

Statewide, 32.1% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 32.5% of white non-Hispanics, compared to 28.2% of Hispanics and 24.6% of Native Americans, being in the healthy weight range. Males (25.5%) were significantly less likely to be in the healthy weight range than females (38.6%). BMI differed significantly by age of respondent, with 43.3% of persons aged 18–29, and 26.0% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 19.8% in Power County to 47.4% in Blaine County of adults being in the healthy weight range.

#### Any Physical Activity - 2015-2021

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 78.7% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.3% of persons aged 18–29, and 72.3% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 64.3% in Clark County to 84.6% in Teton County.

Physical Activity Guidelines – 2011, 2013, 2015, 2017, 2019 Statewide, 21.9% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.3% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6% in Franklin County to 30.6% in Blaine County.

#### Home Radon Testing - 2016, 2018, 2020

Statewide, 23.0% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.4% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.5% in Cassia County to 54.4% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006l and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.





# BANNOCK COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

#### **RISK FACTORS AND INTERVENTIONS**

#### CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/jama.2016.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

#### Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

#### **Smoking:**

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

#### Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <a href="https://www.dietaryguidelines.gov">https://www.dietaryguidelines.gov</a>

#### Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute
Cancer Information Services
1-800-4CANCER
<a href="https://www.cancer.gov/contact">https://www.cancer.gov/contact</a>

American Cancer Society <a href="https://www.cancer.org">https://www.cancer.org</a>

#### **CANCER INCIDENCE 2016–2020**

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016–2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 1,884 cases of invasive cancer were diagnosed among Bannock County residents (Table 1).

**Table 1:** Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Bannock County and the State of Idaho. 2016–2020

Cancer Incidence 2016–2020				
All Sites/Types	1,884	45,610		
Female Breast	293	6,687		
Prostate	216	6,417		
Lung & Bronchus	183	4,887		
Colorectal	140	3,451		

Table 3 (Cancer Incidence 2016–2020, Comparison between Bannock County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Bannock County. The table also shows the number of observed cases, person-

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Bannock County was 434.4 cases per 100,000 person-years per year during 2016–2020. Comparing this crude rate with the crude rate for the remainder of Idaho (524.4) gives an estimate of the relative burden of disease in Bannock County.

The age- and sex-adjusted incidence rate of invasive cancer in Bannock County, all sites combined, was 475.6 cases per 100,000 persons per year during 2016–2020. There were statistically significantly fewer cases of cancer in Bannock County (1,884) than expected (2,077.4) based upon rates in the remainder of the state (p<.001).

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

#### **CANCER MORTALITY 2017–2021**

During 2017–2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 689 Bannock County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

**Table 2:** Overall and Cancer Mortality in Bannock County and the State of Idaho, 2017–2021

Mortality 2017–2021	Bannock County	State of Idaho
All Deaths	4,061	77,431
Cancer Deaths	689	15,121
% of All Deaths	17.0%	19.5%
Lung & Bronchus	126	2,961
Colorectal	60	1,319
Pancreas	62	1,190
Female Breast	47	1,086
Prostate	48	949

Table 4 (Cancer Mortality 2017–2021, Comparison between Bannock County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Bannock County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Bannock County, all sites combined, was 175.2 deaths per 100,000 persons per year during 2017–2021, compared with 168.8 for the remainder of the state. There were more cancer deaths in Bannock County (689) than expected (663.9) based upon rates in the remainder of the state, but the difference was not statistically significant.

**Statistical Note:** Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

#### TABLE 3: CANCER INCIDENCE 2016–2020 COMPARISON BETWEEN BANNOCK COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Ban	nock Count	.y			Rem	nainder of Ida	iho
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)
All Sites Combined	Total	1,884	433,711	434.4	475.6	2,077.4	0.000 <<	43,726	8,338,117	524.4
All Sites Combined	Male	964	215,729	446.9	494.8 457.3	1,086.8	0.000 <<	23,325	4,181,181	557.9
All Sites Combined Bladder	Female Total	920 80	217,982 433,711	422.1 18.4	20.6	987.4 98.2	0.032 <b>&lt;&lt;</b> 0.068	20,401 2,104	4,156,936 8,338,117	490.8 25.2
Bladder	Male	65	215,729	30.1	34.0	77.0	0.184	1,686	4,181,181	40.3
Bladder	Female	15	217,982	6.9	7.6	19.9	0.323	418	4,156,936	10.1
Brain - malignant	Total	36	433,711	8.3	8.8	28.8	0.215	589	8,338,117	7.1
Brain - malignant	Male	23	215,729	10.7	11.4	17.0	0.187	352	4,181,181	8.4
Brain - malignant	Female	13	217,982	6.0	6.3	11.7	0.783	237	4,156,936	5.7
Brain and other CNS - non-malignant	Total	42	433,711	9.7	10.5	66.4	0.002 <<	1,382	8,338,117	16.6
Brain and other CNS - non-malignant	Male	12	215,729	5.6	6.0	22.3	0.027 <<	468	4,181,181	11.2
Brain and other CNS - non-malignant Breast	Female Total	30 296	217,982 433,711	13.8 68.2	14.8 74.5	44.5 307.2	0.028 <b>&lt;&lt;</b> 0.544	914 6,450	4,156,936 8,338,117	22.0 77.4
Breast	Male	3	215,729	1.4	1.6	2.6	0.953	56	4,181,181	1.3
Breast	Female	293	217,982	134.4	146.0	308.8	0.386	6,394	4,156,936	153.8
Breast - in situ	Total	52	433,711	12.0	13.1	56.5	0.607	1,187	8,338,117	14.2
Breast - in situ	Male	-	215,729	-	-	0.2	1.000	5	4,181,181	0.1
Breast - in situ	Female	52	217,982	23.9	26.0	56.9	0.568	1,182	4,156,936	28.4
Celeratel	Female	25	217,982	11.5	11.8	14.3	0.013 >>	279	4,156,936	6.7
Colorectal Colorectal	Total Male	140 76	433,711 215,729	32.3 35.2	35.5 39.1	156.8 85.0	0.189 0.360	3,311 1,827	8,338,117 4,181,181	39.7 43.7
Colorectal	Female	64	213,729	29.4	32.0	71.5	0.300	1,627	4,156,936	45.7 35.7
Corpus Uteri	Female	58	217,982	26.6	28.9	61.4	0.723	1,272	4,156,936	30.6
Esophagus	Total	20	433,711	4.6	5.1	22.9	0.640	486	8,338,117	5.8
Esophagus	Male	17	215,729	7.9	8.8	18.8	0.788	407	4,181,181	9.7
Esophagus	Female	3	217,982	1.4	1.5	3.8	0.953	79	4,156,936	1.9
Hodgkin Lymphoma	Total	11	433,711	2.5	2.6	10.3	0.897	199	8,338,117	2.4
Hodgkin Lymphoma	Male	7	215,729	3.2	3.3	5.6	0.665	111	4,181,181	2.7
Hodgkin Lymphoma Kidney and Renal Pelvis	Female Total	4 88	217,982 433,711	1.8 20.3	1.8 22.2	4.6 82.0	1.000 0.538	88 1,727	4,156,936 8,338,117	2.1 20.7
Kidney and Renal Pelvis	Male	66	215,729	30.6	33.8	52.1	0.071	1,727	4,181,181	26.7
Kidney and Renal Pelvis	Female	22	217,982	10.1	11.0	29.5	0.191	611	4,156,936	14.7
Larynx	Total	12	433,711	2.8	3.0	9.6	0.519	203	8,338,117	2.4
Larynx	Male	10	215,729	4.6	5.2	7.0	0.331	150	4,181,181	3.6
Larynx	Female	2	217,982	0.9	1.0	2.6	1.000	53	4,156,936	1.3
Leukemia	Total	64	433,711	14.8	16.1	74.6	0.238	1,567	8,338,117	18.8
Leukemia	Male	36 28	215,729	16.7	18.4	44.6 29.7	0.221	953 614	4,181,181	22.8
Leukemia Liver and Bile Duct	Female Total	41	217,982 433,711	12.8 9.5	13.9 10.4	37.4	0.855 0.593	788	4,156,936 8,338,117	14.8 9.5
Liver and Bile Duct	Male	26	215,729	12.1	13.3	26.4	1.000	564	4,181,181	13.5
Liver and Bile Duct	Female	15	217,982	6.9	7.5	10.7	0.255	224	4,156,936	5.4
Lung and Bronchus	Total	183	433,711	42.2	47.0	219.7	0.012 <<	4,704	8,338,117	56.4
Lung and Bronchus	Male	92	215,729	42.6	48.0	108.2	0.126	2,360	4,181,181	56.4
Lung and Bronchus	Female	91	217,982	41.7	46.1	111.3	0.055	2,344	4,156,936	56.4
Melanoma of the Skin	Total	138	433,711	31.8	34.5	134.5	0.786	2,804	8,338,117	33.6
Melanoma of the Skin	Male Female	80 50	215,729	37.1	41.0	78.6	0.906	1,685	4,181,181	40.3
Melanoma of the Skin Myeloma	Total	58 33	217,982 433,711	26.6 7.6	28.3 8.5	55.2 31.6	0.743 0.852	1,119 675	4,156,936 8,338,117	26.9 8.1
Myeloma	Male	20	215,729	9.3	10.4	19.3	0.928	421	4,181,181	10.1
Myeloma	Female	13	217,982	6.0	6.5	12.2	0.887	254	4,156,936	6.1
Non-Hodgkin Lymphoma	Total	83	433,711	19.1	20.9	88.3	0.619	1,857	8,338,117	22.3
Non-Hodgkin Lymphoma	Male	50	215,729	23.2	25.5	50.6	1.000	1,079	4,181,181	25.8
Non-Hodgkin Lymphoma	Female	33	217,982	15.1	16.5	37.5	0.524	778	4,156,936	18.7
Oral Cavity and Pharmy	Total	46	433,711	10.6	11.6	59.3	0.089	1,249	8,338,117	15.0
Oral Cavity and Pharynx Oral Cavity and Pharynx	Male Female	28 18	215,729 217,982	13.0 8.3	14.3 9.0	42.5 16.4	0.024 <b>&lt;&lt;</b> 0.762	908 341	4,181,181 4,156,936	21.7 8.2
Ovary	Female	21	217,982	9.6	10.4	24.8	0.762	512	4,156,936	12.3
Pancreas	Total	77	433,711	17.8	19.7	63.1	0.098	1,346	8,338,117	16.1
Pancreas	Male	38	215,729	17.6	19.7	34.3	0.575	746	4,181,181	17.8
Pancreas	Female	39	217,982	17.9	19.7	28.6	0.073	600	4,156,936	14.4
Prostate	Male	216	215,729	100.1	110.8	289.0	0.000 <<	6,201	4,181,181	148.3
Stomach	Total	22	433,711	5.1	5.6	21.0	0.890	445	8,338,117	5.3
Stomach	Male	16	215,729	7.4	8.3	13.5	0.570	293	4,181,181	7.0
Stomach	Female	6	217,982	2.8	3.0	7.4	0.793	152	4,156,936	3.7
Testis Thyroid	Male Total	10 40	215,729 433,711	4.6 9.2	4.5 9.5	13.7	0.393 0.010 <b>&lt;&lt;</b>	255 1,180	4,181,181	6.1 14.2
Thyroid	Male	40 10	215,729	9.2 4.6	9.5 4.9	59.5 16.9	0.010 <<	345	8,338,117 4,181,181	8.3
Thyroid	Female	30	215,729	13.8	14.0	43.0	0.105	835	4,156,936	20.1
Pediatric Age 0 to 19	Total	21	126,491	16.6	16.5	21.8	0.046	400	2,334,032	17.1
Pediatric Age 0 to 19 Pediatric Age 0 to 19	Male	12	64,568	18.6	18.5	11.5	0.970	211	1,191,942	17.1
Pediatric Age 0 to 19 Pediatric Age 0 to 19	Female	9	61,923	14.5	14.4	10.3	0.834	189	1,142,090	16.5
Note:		ra avarassad as th	·	ne per 100 000		ar (person yea		.00	.,,	

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

<sup>2.</sup> Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

<sup>&</sup>quot;<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

## TABLE 4: CANCER MORTALITY 2017–2021 COMPARISON BETWEEN BANNOCK COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Ban	nock Count	ty			Re	mainder of Idah	10
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	4,061	437,212	928.8	1,027.7	3,390.3	0.000 >>	73,369	8,551,503	858.0
All Causes of Death	Male	2,122	217,682	974.8	1,091.7	1.762.3	0.000 >>	38,934	4.294.186	906.7
All Causes of Death	Female	1,939	219,530	883.3	968.6	1,619.2	0.000 >>	34,435	4,257,317	8.808
All Malignant Cancers	Total	689	437,212	157.6	175.2	663.9	0.339	14,432	8,551,503	168.8
All Malignant Cancers	Male	358	217,682	164.5	185.4	351.5	0.745	7,818	4,294,186	182.1
All Malignant Cancers	Female	331	219,530	150.8	165.9	310.0	0.245	6,614	4,257,317	155.4
Bladder Bladder	Total	17	437,212 217,682	3.9 5.1	4.4 5.8	21.4 16.2	0.400 0.238	472 367	8,551,503 4,294,186	5.5 8.5
Bladder	Male Female	11 6	219,530	2.7	3.0	4.9	0.236	105	4,257,317	2.5
Brain and Other Nervous System	Total	32	437,212	7.3	7.9	22.2	0.060	472	8,551,503	5.5
Brain and Other Nervous System	Male	17	217,682	7.8	8.5	13.0	0.333	281	4,294,186	6.5
Brain and Other Nervous System	Female	15	219,530	6.8	7.4	9.1	0.092	191	4,257,317	4.5
Breast	Total	48	437,212	11.0	12.1	48.8	0.983	1,054	8,551,503	12.3
Breast	Male	1	217,682	0.5	0.5	0.7	1.000	15	4,294,186	0.3
Breast	Female	47	219,530	21.4	23.4	48.9	0.856	1,039	4,257,317	24.4
Cervix	Female	6	219,530	2.7	2.9	3.8	0.356	77	4,257,317	1.8
Colorectal	Total	60	437,212	13.7	15.2	58.1	0.837	1,259	8,551,503	14.7
Colorectal	Male Female	30 30	217,682 219,530	13.8 13.7	15.4 15.0	31.3 26.7	0.914 0.575	689 570	4,294,186 4,257,317	16.0 13.4
Colorectal Corpus Uteri	Female	5	219,530	2.3	2.5	7.9	0.575	168	4,257,317	3.9
Esophagus	Total	12	437,212	2.7	3.1	21.4	0.041 <<	465	8,551,503	5.4
Esophagus	Male	11	217,682	5.1	5.7	17.6	0.129	390	4,294,186	9.1
Esophagus	Female	1	219,530	0.5	0.5	3.5	0.270	75	4,257,317	1.8
Hodgkin Lymphoma	Total	3	437,212	0.7	0.7	1.2	0.260	26	8,551,503	0.3
Hodgkin Lymphoma	Male	1	217,682	0.5	0.5	0.6	0.923	13	4,294,186	0.3
Hodgkin Lymphoma	Female	2	219,530	0.9	1.0	0.6	0.260	13	4,257,317	0.3
Kidney	Total	21	437,212	4.8	5.3	16.7	0.350	364	8,551,503	4.3
Kidney Kidney	Male Female	15 6	217,682 219,530	6.9 2.7	7.7 3.0	10.2 6.4	0.194 1.000	227 137	4,294,186 4,257,317	5.3 3.2
Larynx	Total	5	437,212	1.1	1.3	3.1	0.388	66	8,551,503	0.8
Larynx	Male	5	217,682	2.3	2.6	2.4	0.387	53	4,294,186	1.2
Larynx	Female	-	219,530	-	-	0.6	1.000	13	4,257,317	0.3
Leukemia	Total	29	437,212	6.6	7.4	29.0	1.000	631	8,551,503	7.4
Leukemia	Male	18	217,682	8.3	9.3	16.5	0.782	368	4,294,186	8.6
Leukemia	Female	11	219,530	5.0	5.5	12.3	0.854	263	4,257,317	6.2
Liver and Bile Duct	Total	33	437,212	7.5	8.3	26.4	0.236	570	8,551,503	6.7
Liver and Bile Duct	Male	21	217,682	9.6	10.7	17.7	0.489	387	4,294,186	9.0
Liver and Bile Duct	Female	12	219,530	5.5	6.0 32.2	8.5	0.309	183	4,257,317	4.3
Lung and Bronchus Lung and Bronchus	Total Male	126 61	437,212 217,682	28.8 28.0	32.2 31.6	129.8 67.2	0.783 0.492	2,835 1,495	8,551,503 4,294,186	33.2 34.8
Lung and Bronchus	Female	65	219,530	29.6	32.8	62.4	0.492	1,340	4,257,317	31.5
Melanoma of the Skin	Total	11	437,212	2.5	2.8	12.9	0.725	278	8,551,503	3.3
Melanoma of the Skin	Male	5	217,682	2.3	2.6	8.5	0.301	187	4,294,186	4.4
Melanoma of the Skin	Female	6	219,530	2.7	3.0	4.3	0.533	91	4,257,317	2.1
Myeloma	Total	14	437,212	3.2	3.6	14.4	1.000	317	8,551,503	3.7
Myeloma	Male	8	217,682	3.7	4.2	8.3	1.000	188	4,294,186	4.4
Myeloma	Female	6	219,530	2.7	3.0	6.0	1.000	129	4,257,317	3.0
Non-Hodgkin Lymphoma	Total	29 11	437,212	6.6 5.1	7.4 5.7	24.7	0.442	540 206	8,551,503 4,204,186	6.3 6.9
Non-Hodgkin Lymphoma Non-Hodgkin Lymphoma	Male Female	11 18	217,682 219,530	5.1 8.2	5.7 9.1	13.3 11.4	0.646 0.085	296 244	4,294,186 4,257,317	5.7
Oral Cavity and Pharynx	Total	10	437,212	2.3	2.5	11.4	0.065	256	8,551,503	3.7
Oral Cavity and Pharynx	Male	8	217,682	3.7	4.1	8.1	1.000	179	4,294,186	4.2
Oral Cavity and Pharynx	Female	2	219,530	0.9	1.0	3.6	0.596	77	4,257,317	1.8
Ovary	Female	17	219,530	7.7	8.5	15.6	0.794	333	4,257,317	7.8
Pancreas	Total	62	437,212	14.2	15.8	51.8	0.184	1,128	8,551,503	13.2
Pancreas	Male	31	217,682	14.2	16.0	27.6	0.559	611	4,294,186	14.2
Proctets	Female	31	219,530	14.1	15.6	24.1	0.199	517	4,257,317	12.1
Prostate Stomach	Male	48	217,682	22.1	25.4	39.6	0.216	901	4,294,186	21.0
Stomach Stomach	Total Male	10 8	437,212 217,682	2.3 3.7	2.5 4.2	8.7 5.1	0.748 0.281	188 113	8,551,503 4,294,186	2.2 2.6
Stomach	Female	2	219,530	0.9	1.0	3.6	0.261	75	4,257,317	1.8
			2 19,000				0.011	13	7,201,011	1.0

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

<sup>2.</sup> Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

#### Cancer Screening and Risk Factor Prevalence Estimates, 2011–2021

	State of								Bannock
Measure	Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	County
Access to Care									
Have Health Insurance, Age <65 (2015–2021)	83.1%	82.8%	85.1%	77.2%	85.8%	78.9%	85.4%	85.4%	86.1%
Not See Doctor Due to Cost in Past Year (2015–2021)	12.6%	11.4%	11.8%	14.5%	12.4%	12.3%	11.8%	12.9%	12.3%
Cancer Screening									
Mammogram Past 2 Years, Age 50–74 (2014, 2016, 2018, 2020)	69.1%	67.0%	73.8%	68.2%	73.2%	64.8%	64.5%	67.1%	65.2%
Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020)	71.2%	73.6%	73.6%	70.8%	72.9%	69.1%	69.5%	65.9%	78.9%
Colorectal Cancer Screening, Age 50–75 (2018, 2020)	67.9%	66.9%	73.6%	71.4%	70.6%	61.7%	61.5%	64.7%	65.8%
Tobacco Use									
Current Tobacco User (2016–2021)	22.3%	26.7%	23.1%	23.6%	21.8%	21.4%	22.7%	16.9%	24.4%
Other Cancer-Related \									
Healthy Weight by Body Mass Index, Age 20+ (2015–2021)	32.1%	32.8%	31.7%	27.9%	36.1%	29.8%	27.9%	31.9%	29.7%
Any Physical Activity Besides Job Past 30 Days (2015-2021)	78.7%	79.2%	78.1%	74.5%	83.2%	73.4%	76.3%	79.7%	78.2%
Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019)	21.9%	22.8%	19.4%	20.0%	25.2%	19.5%	20.4%	20.2%	24.0%
Home Ever Tested for Radon (2016, 2018, 2020)	23.0%	30.9%	18.2%	16.9%	25.1%	19.9%	23.0%	21.8%	24.3%

#### **Access to Care**

#### Have Health Insurance – 2015–2021

Statewide, 83.1% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 86.0% of white non-Hispanics, compared to 64.8% of Hispanics and 83.3% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3%) than English-speaking respondents (84.2%). Health care coverage differed significantly by age of respondent, with 79.8% of persons aged 18–29, and 87.8% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 62.1% in Adams County to 91.6% in Oneida County having health insurance.

#### Not See Doctor Due to Cost in Past Year - 2015-2021

Statewide, 12.6% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (11.5% of white non-Hispanics, 19.2% of Hispanics, and 21.0% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9% for less than \$15,000, 6.1% for greater than \$50,000). Inability to see a doctor due to cost differed significantly by county, with a range of 7.4% in Franklin County to 17.5% in Power County.

#### **Cancer Screening**

Mammogram - 2014, 2016, 2018, 2020

Statewide, 69.1% of women aged 50–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (72.1% versus 36.7%). Mammography rates differed significantly by county, with a range in screening of 45.9% in Benewah County to 77.0% in Nez Perce County. In 2020, Idaho ranked 48th among states and the District of Columbia for mammography screening rates among women aged 50–74 and also 48th among ages 40+.

#### Pap Test - 2018, 2020

Statewide, 71.2% of women with an intact cervix and aged 21–65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.1% versus 52.6% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.7% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49<sup>th</sup> among states and the District of Columbia for Pap screening rate.

#### Colorectal Cancer Screening – 2018, 2020

Statewide, 67.9% of adults aged 50–75 reported being current for colorectal cancer screening.\*\* Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked 47<sup>th</sup> among states and the District of Columbia in the percentage of adults aged 50–75 and older who reported being up-to-date for colorectal cancer screening.

<sup>\*\*</sup> Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

#### **Tobacco Use**

#### Current Tobacco Use - 2016-2021

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.3% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 29.9% of persons aged 18-29, and 11.1% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (22.4%) than among Native Americans (40.0%). Tobacco use differed significantly by county, with a range of 5.4% in Madison County to 41.6% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

#### **Other Cancer-Related**

#### Healthy Weight by Body Mass Index - 2015-2021

Statewide, 32.1% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 32.5% of white non-Hispanics, compared to 28.2% of Hispanics and 24.6% of Native Americans, being in the healthy weight range. Males (25.5%) were significantly less likely to be in the healthy weight range than females (38.6%). BMI differed significantly by age of respondent, with 43.3% of persons aged 18–29, and 26.0% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 19.8% in Power County to 47.4% in Blaine County of adults being in the healthy weight range.

#### Any Physical Activity - 2015-2021

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 78.7% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.3% of persons aged 18–29, and 72.3% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 64.3% in Clark County to 84.6% in Teton County.

Physical Activity Guidelines – 2011, 2013, 2015, 2017, 2019 Statewide, 21.9% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.3% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6% in Franklin County to 30.6% in Blaine County.

#### Home Radon Testing - 2016, 2018, 2020

Statewide, 23.0% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.4% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.5% in Cassia County to 54.4% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006l and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.





# BEAR LAKE COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

### Cancer Incidence 2016–2020 Cancer Mortality 2017–2021 BRFSS 2011–2021

#### **RISK FACTORS AND INTERVENTIONS**

#### **CANCER**

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/jama.2016.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

#### Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

#### **Smoking:**

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

#### Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <a href="https://www.dietaryguidelines.gov">https://www.dietaryguidelines.gov</a>

#### Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute
Cancer Information Services
1-800-4CANCER
<a href="https://www.cancer.gov/contact">https://www.cancer.gov/contact</a>

American Cancer Society <a href="https://www.cancer.org">https://www.cancer.org</a>

#### **CANCER INCIDENCE 2016–2020**

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016–2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 170 cases of invasive cancer were diagnosed among Bear Lake County residents (Table 1).

**Table 1:** Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Bear Lake County and the State of Idaho. 2016–2020

,	,	
Cancer Incidence 2016–2020	Bear Lake County	State of Idaho
All Sites/Types	170	45,610
Female Breast	21	6,687
Prostate	24	6,417
Lung & Bronchus	13	4,887
Colorectal	16	3,451

Table 3 (Cancer Incidence 2016–2020, Comparison between Bear Lake County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Bear Lake County. The table also shows the number of observed cases,

person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Bear Lake County was 561.6 cases per 100,000 person-years per year during 2016–2020. Comparing this crude rate with the crude rate for the remainder of Idaho (519.8) gives an estimate of the relative burden of disease in Bear Lake County.

The age- and sex-adjusted incidence rate of invasive cancer in Bear Lake County, all sites combined, was 469.4 cases per 100,000 persons per year during 2016–2020. There were fewer cases of cancer in Bear Lake County (170) than expected (188.2) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

#### **CANCER MORTALITY 2017–2021**

During 2017–2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 62 Bear Lake County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

**Table 2:** Overall and Cancer Mortality in Bear Lake County and the State of Idaho, 2017–2021

Mortality 2017–2021	Bear Lake County	State of Idaho
All Deaths	354	77,431
Cancer Deaths	62	15,121
% of All Deaths	17.5%	19.5%
Lung & Bronchus	9	2,961
Colorectal	9	1,319
Pancreas	3	1,190
Female Breast	5	1,086
Prostate	4	949

Table 4 (Cancer Mortality 2017–2021, Comparison between Bear Lake County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Bear Lake County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Bear Lake County, all sites combined, was 160.8 deaths per 100,000 persons per year during 2017–2021, compared with 168.1 for the remainder of the state. There were fewer cancer deaths in Bear Lake County (62) than expected (64.8) based upon rates in the remainder of the state, but the difference was not statistically significant.

**Statistical Note:** Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

## TABLE 3: CANCER INCIDENCE 2016–2020 COMPARISON BETWEEN BEAR LAKE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Bear	Lake Cour	ity			Ren	nainder of Ida	aho
Cancer		Observed	Person	Crude	A.A.I.	Expected	D./ I. //	Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)
All Sites Combined All Sites Combined	Total	170 102	30,269 15,068	561.6 676.9	469.4 547.3	188.2 102.9	0.193 0.983	45,440 24,187	8,741,559 4,381,842	519.8 552.0
All Sites Combined	Male Female	68	15,000	447.3	386.3	85.8	0.963	24,167	4,361,642	487.5
Bladder	Total	8	30,269	26.4	20.7	9.6	0.055	2,176	8,741,559	24.9
Bladder	Male	7	15,068	46.5	35.6	7.8	0.955	1,744	4,381,842	39.8
Bladder	Female	1	15,201	6.6	5.3	1.9	0.891	432	4,359,717	9.9
Brain - malignant	Total	5	30,269	16.5	14.6	2.4	0.199	620	8,741,559	7.1
Brain - malignant	Male	2	15,068	13.3	11.6	1.5	0.859	373	4,381,842	8.5
Brain - malignant	Female	3	15,201	19.7	17.6	1.0	0.148	247	4,359,717	5.7
Brain and other CNS - non-malignant	Total	10	30,269	33.0	28.7	5.6	0.123	1,414	8,741,559	16.2
Brain and other CNS - non-malignant	Male	3	15,068	19.9	17.3	1.9	0.587	477	4,381,842	10.9
Brain and other CNS - non-malignant	Female	7	15,201	46.0	40.2	3.7	0.171	937	4,359,717	21.5
Breast	Total	21	30,269	69.4	60.2	26.8	0.303	6,725	8,741,559	76.9
Breast	Male	-	15,068	-	-	0.3	1.000	59	4,381,842	1.3
Breast	Female	21	15,201	138.1	121.7	26.4	0.343	6,666	4,359,717	152.9
Breast - in situ	Total Male	2	30,269	6.6	5.9	4.8	0.283 1.000	1,237	8,741,559	14.2
Breast - in situ Breast - in situ	Female	2	15,068 15,201	13.2	- 11.9	0.0 4.8	0.292	5 1,232	4,381,842 4,359,717	0.1 28.3
Cervix	Female	2	15,201	13.2	13.5	1.0	0.292	302	4,359,717	6.9
Colorectal	Total	16	30,269	52.9	44.5	14.1	0.689	3,435	8,741,559	39.3
Colorectal	Male	10	15,068	66.4	55.3	7.8	0.521	1,893	4,381,842	43.2
Colorectal	Female	6	15,201	39.5	33.4	6.4	1.000	1,542	4,359,717	35.4
Corpus Uteri	Female	3	15,201	19.7	17.5	5.2	0.470	1,327	4,359,717	30.4
Esophagus	Total	2	30,269	6.6	5.4	2.2	1.000	504	8,741,559	5.8
Esophagus	Male	2	15,068	13.3	10.6	1.8	1.000	422	4,381,842	9.6
Esophagus	Female	-	15,201	-	-	0.3	1.000	82	4,359,717	1.9
Hodgkin Lymphoma	Total	1	30,269	3.3	3.3	0.7	1.000	209	8,741,559	2.4
Hodgkin Lymphoma	Male	-	15,068	-	-	0.4	1.000	118	4,381,842	2.7
Hodgkin Lymphoma	Female	1	15,201	6.6	6.6	0.3	0.545	91	4,359,717	2.1
Kidney and Renal Pelvis	Total	5	30,269	16.5	14.0	7.4	0.508	1,810	8,741,559	20.7
Kidney and Renal Pelvis	Male	5	15,068	33.2	27.8	4.8	1.000	1,177	4,381,842	26.9
Kidney and Renal Pelvis	Female		15,201	-	-	2.6	0.151	633	4,359,717	14.5
Larynx	Total Male	2	30,269	6.6	5.4	0.9	0.458 0.996	213	8,741,559	2.4 3.6
Larynx Larynx	Female	1	15,068 15,201	6.6 6.6	5.3 5.7	0.7 0.2	0.996	159 54	4,381,842 4,359,717	1.2
Leukemia	Total	6	30,269	19.8	16.4	6.8	0.953	1,625	8,741,559	18.6
Leukemia	Male	5	15,068	33.2	27.0	4.2	0.806	984	4,381,842	22.5
Leukemia	Female	ĭ	15,201	6.6	5.5	2.7	0.506	641	4,359,717	14.7
Liver and Bile Duct	Total	3	30,269	9.9	8.2	3.5	1.000	826	8,741,559	9.4
Liver and Bile Duct	Male	2	15,068	13.3	10.8	2.5	1.000	588	4,381,842	13.4
Liver and Bile Duct	Female	1	15,201	6.6	5.5	1.0	1.000	238	4,359,717	5.5
Lung and Bronchus	Total	13	30,269	42.9	33.9	21.4	0.072	4,874	8,741,559	55.8
Lung and Bronchus	Male	8	15,068	53.1	41.0	10.9	0.486	2,444	4,381,842	55.8
Lung and Bronchus	Female	.5	15,201	32.9	26.4	10.6	0.098	2,430	4,359,717	55.7
Melanoma of the Skin	Total	13	30,269	42.9	36.9	11.8	0.804	2,929	8,741,559	33.5
Melanoma of the Skin	Male	8	15,068	53.1	43.7	7.3	0.902	1,757	4,381,842	40.1
Melanoma of the Skin	Female	5 3	15,201	32.9	29.8	4.5	0.940	1,172	4,359,717	26.9
Myeloma Myeloma	Total Male	3	30,269 15,068	9.9 19.9	7.9 15.6	3.1 1.9	1.000 0.601	705 438	8,741,559 4,381,842	8.1 10.0
Myeloma	Female	│	15,000	19.9	15.6	1.9	0.632	267	4,351,642	6.1
Non-Hodgkin Lymphoma	Total	11	30,269	36.3	30.3	8.0	0.370	1,929	8,741,559	22.1
Non-Hodgkin Lymphoma	Male	9	15,068	59.7	49.2	4.7	0.098	1,120	4,381,842	25.6
Non-Hodgkin Lymphoma	Female	2	15,201	13.2	11.0	3.4	0.694	809	4,359,717	18.6
Oral Cavity and Pharynx	Total	4	30,269	13.2	11.2	5.3	0.788	1,291	8,741,559	14.8
Oral Cavity and Pharynx	Male	3	15,068	19.9	16.6	3.9	0.926	933	4,381,842	21.3
Oral Cavity and Pharynx	Female	1	15,201	6.6	5.7	1.5	1.000	358	4,359,717	8.2
Ovary	Female	1	15,201	6.6	5.8	2.1	0.755	532	4,359,717	12.2
Pancreas	Total	3	30,269	9.9	7.9	6.1	0.278	1,420	8,741,559	16.2
Pancreas	Male	2	15,068	13.3	10.5	3.4	0.674	782	4,381,842	17.8
Pancreas	Female	1	15,201	6.6	5.3	2.7	0.484	638	4,359,717	14.6
Prostate Stomach	Male Total	24 1	15,068 30.269	159.3 3.3	127.2 2.7	27.5 2.0	0.578 0.828	6,393 466	4,381,842 8,741,559	145.9 5.3
Stomach	Male		30,269 15,068			1.3	1.000	308	4,381,842	7.0
Stomach Stomach	Female	1	15,000	6.6	5.3	0.7	1.000	158	4,361,642	3.6
Testis	Male	- 1	15,201	6.6	7.5	0.7	1.000	264	4,381,842	6.0
Thyroid	Total	6	30,269	19.8	19.6	4.2	0.510	1,214	8,741,559	13.9
	Male		30,269 15,068							
Thyroid		3	,	19.9	18.6	1.3	0.285	352	4,381,842	8.0
Thyroid	Female	3	15,201	19.7	20.1	2.9	1.000	862	4,359,717	19.8
Pediatric Age 0 to 19	Total	3	8,859	33.9	34.0	1.5	0.384	418	2,451,664	17.0
Pediatric Age 0 to 19	Male	2	4,463	44.8	44.5	0.8	0.377	221	1,252,047	17.7
Pediatric Age 0 to 19	Female	1	4,396	22.7	23.1	0.7	1.000	197	1,199,617	16.4

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

<sup>2.</sup> Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

<sup>&</sup>quot;<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

#### **TABLE 4: CANCER MORTALITY 2017–2021** COMPARISON BETWEEN BEAR LAKE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Bear	Lake Coun	ity			Re	mainder of Idah	10
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	354	30,874	1,146.6	918.3	331.7	0.233	77,076	8,957,841	860.4
All Causes of Death	Male	191	15,415	1,239.1	986.0	176.0	0.277	40,865	4,496,453	908.8
All Causes of Death	Female	163	15,459	1,054.4	849.5	155.7	0.582	36,211	4,461,388	811.7
All Malignant Cancers All Malignant Cancers	Total Male	62 38	30,874 15,415	200.8 246.5	160.8 193.4	64.8 35.6	0.790 0.725	15,059 8,138	8,957,841 4,496,453	168.1 181.0
All Malignant Cancers	Female	24	15,415	155.2	126.7	29.4	0.725	6,921	4,461,388	155.1
Bladder	Total	2	30,874	6.5	5.0	2.2	1.000	487	8,957,841	5.4
Bladder	Male	2	15,415	13.0	9.7	1.7	1.000	376	4,496,453	8.4
Bladder	Female	-	15,459	-	-	0.5	1.000	111	4,461,388	2.5
Brain and Other Nervous System	Total	3	30,874	9.7	8.3	2.0	0.657	501	8,957,841	5.6
	Male	1	15,415	6.5	5.5	1.2	1.000	297	4,496,453	6.6
Brain and Other Nervous System	Female	2	15,459	12.9	11.2	0.8	0.392	204	4,461,388	4.6
Breast	Total	5	30,874	16.2	13.4	4.6	0.961	1,097	8,957,841	12.2
Breast Breast	Male Female	- 5	15,415 15,459	32.3	27.3	0.1 4.4	1.000 0.915	16 1,081	4,496,453 4,461,388	0.4 24.2
Cervix	Female	- J	15,459	32.3	21.3	0.3	1.000	1,061	4,461,388	1.9
Colorectal	Total	9	30,874	29.2	23.9	5.5	0.214	1,310	8,957,841	14.6
Colorectal	Male	5	15,415	32.4	26.5	3.0	0.370	714	4,496,453	15.9
Colorectal	Female	4	15,459	25.9	21.2	2.5	0.494	596	4,461,388	13.4
Corpus Uteri	Female	1	15,459	6.5	5.4	0.7	1.000	172	4,461,388	3.9
Esophagus	Total	2	30,874	6.5	5.3	2.0	1.000	475	8,957,841	5.3
Esophagus	Male	2	15,415	13.0	10.4	1.7	1.000	399	4,496,453	8.9
Esophagus	Female	-	15,459	-	-	0.3	1.000	76	4,461,388	1.7
Hodgkin Lymphoma	Total	-	30,874	-	-	0.1 0.1	1.000 1.000	29 14	8,957,841 4,496,453	0.3
Hodgkin Lymphoma Hodgkin Lymphoma	Male Female	-	15,415 15,459	-	_	0.1	1.000	15	4,490,453	0.3 0.3
Kidney	Total	1	30,874	3.2	2.6	1.7	1.000	384	8,957,841	4.3
Kidney	Male	1	15,415	6.5	5.1	1.1	1.000	241	4,496,453	5.4
Kidney	Female	_ `	15,459	-	-	0.6	1.000	143	4,461,388	3.2
Larynx	Total	-	30,874	-	-	0.3	1.000	71	8,957,841	0.8
Larynx	Male	-	15,415	-	-	0.3	1.000	58	4,496,453	1.3
Larynx	Female		15,459	-	-	0.1	1.000	13	4,461,388	0.3
Leukemia	Total	4	30,874	13.0	10.2	2.9	0.648	656	8,957,841	7.3
Leukemia	Male Female	3	15,415	19.5	15.2	1.7	0.475 1.000	383	4,496,453	8.5 6.1
Leukemia Liver and Bile Duct	Total	1 3	15,459 30,874	6.5 9.7	5.1 7.9	1.2 2.5	0.934	273 600	4,461,388 8,957,841	6.7
Liver and Bile Duct	Male	-	15,415	5.7	7.5	1.7	0.348	408	4,496,453	9.1
Liver and Bile Duct	Female	3	15,459	19.4	16.0	0.8	0.097	192	4,461,388	4.3
Lung and Bronchus	Total	9	30,874	29.2	23.0	12.9	0.349	2,952	8,957,841	33.0
Lung and Bronchus	Male	6	15,415	38.9	30.3	6.8	0.954	1,550	4,496,453	34.5
Lung and Bronchus	Female	3	15,459	19.4	15.5	6.1	0.288	1,402	4,461,388	31.4
Melanoma of the Skin	Total	2	30,874	6.5	5.3	1.2	0.686	287	8,957,841	3.2
Melanoma of the Skin	Male	2	15,415	13.0	10.3	0.8	0.399	190	4,496,453	4.2
Melanoma of the Skin	Female Total	- 4	15,459	2.0	2.5	0.4	1.000	97	4,461,388 8,957,841	2.2
Myeloma Myeloma	i otai Male	1	30,874 15,415	3.2 6.5	2.5 4.9	1.5 0.9	1.000 1.000	330 195	8,957,841 4,496,453	3.7 4.3
Myeloma	Female	_ '	15,415	- 0.5	4.9	0.9	1.000	135	4,461,388	3.0
Non-Hodgkin Lymphoma	Total	3	30,874	9.7	7.6	2.5	0.906	566	8,957,841	6.3
Non-Hodgkin Lymphoma	Male	3	15,415	19.5	15.3	1.3	0.297	304	4,496,453	6.8
Non-Hodgkin Lymphoma	Female	-	15,459	-	-	1.2	0.621	262	4,461,388	5.9
Oral Cavity and Pharynx	Total	1	30,874	3.2	2.6	1.1	1.000	265	8,957,841	3.0
Oral Cavity and Pharynx	Male	1	15,415	6.5	5.2	0.8	1.000	186	4,496,453	4.1
Oral Cavity and Pharynx	Female	-	15,459	-	-	0.3	1.000	79	4,461,388	1.8
Ovary	Female	1	15,459	6.5	5.3	1.5	1.000	349	4,461,388	7.8
Pancreas Pancreas	Total	3	30,874 15,415	9.7	7.8 10.2	5.1	0.498	1,187	8,957,841	13.3
Pancreas Pancreas	Male Female	2	15,415 15,459	13.0 6.5	10.2 5.2	2.8 2.3	0.949 0.644	640 547	4,496,453 4.461.388	14.2 12.3
Prostate	Male	4	15,415	25.9	19.3	4.3	1.000	945	4,496,453	21.0
Stomach	Total		30,874	-	-	0.8	0.876	198	8,957,841	2.2
Stomach	Male	-	15,415	-	_	0.5	1.000	121	4,496,453	2.7
Stomach	Female	_	15,459	_	_	0.3	1.000	77	4,461,388	1.7
			ne number of cases r					, ,	1, 101,000	

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

<sup>2.</sup> Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

#### Cancer Screening and Risk Factor Prevalence Estimates, 2011–2021

	State of								Bear Lake
Measure	Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	County
Access to Care									
Have Health Insurance, Age <65 (2015–2021)	83.1%	82.8%	85.1%	77.2%	85.8%	78.9%	85.4%	85.4%	85.4%
Not See Doctor Due to Cost in Past Year (2015–2021)	12.6%	11.4%	11.8%	14.5%	12.4%	12.3%	11.8%	12.9%	11.1%
Cancer Screening									
Mammogram Past 2 Years, Age 50–74 (2014, 2016, 2018, 2020)	69.1%	67.0%	73.8%	68.2%	73.2%	64.8%	64.5%	67.1%	
Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020)	71.2%	73.6%	73.6%	70.8%	72.9%	69.1%	69.5%	65.9%	
Colorectal Cancer Screening, Age 50–75 (2018, 2020)	67.9%	66.9%	73.6%	71.4%	70.6%	61.7%	61.5%	64.7%	
Tobacco Use									
Current Tobacco User (2016–2021)	22.3%	26.7%	23.1%	23.6%	21.8%	21.4%	22.7%	16.9%	17.9%
Other Cancer-Related \									
Healthy Weight by Body Mass Index, Age 20+ (2015–2021)	32.1%	32.8%	31.7%	27.9%	36.1%	29.8%	27.9%	31.9%	30.6%
Any Physical Activity Besides Job Past 30 Days (2015-2021)	78.7%	79.2%	78.1%	74.5%	83.2%	73.4%	76.3%	79.7%	79.2%
Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019)	21.9%	22.8%	19.4%	20.0%	25.2%	19.5%	20.4%	20.2%	18.9%
Home Ever Tested for Radon (2016, 2018, 2020)	23.0%	30.9%	18.2%	16.9%	25.1%	19.9%	23.0%	21.8%	33.7%

#### Access to Care

#### Have Health Insurance – 2015–2021

Statewide, 83.1% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 86.0% of white non-Hispanics, compared to 64.8% of Hispanics and 83.3% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3%) than English-speaking respondents (84.2%). Health care coverage differed significantly by age of respondent, with 79.8% of persons aged 18–29, and 87.8% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 62.1% in Adams County to 91.6% in Oneida County having health insurance.

#### Not See Doctor Due to Cost in Past Year - 2015-2021

Statewide, 12.6% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (11.5% of white non-Hispanics, 19.2% of Hispanics, and 21.0% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9% for less than \$15,000, 6.1% for greater than \$50,000). Inability to see a doctor due to cost differed significantly by county, with a range of 7.4% in Franklin County to 17.5% in Power County.

#### **Cancer Screening**

<u>Mammogram</u> – 2014, 2016, 2018, 2020

Statewide, 69.1% of women aged 50–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (72.1% versus 36.7%). Mammography rates differed significantly by county, with a range in screening of 45.9% in Benewah County to 77.0% in Nez Perce County. In 2020, Idaho ranked 48<sup>th</sup> among states and the District of Columbia for mammography screening rates among women aged 50–74 and also 48<sup>th</sup> among ages 40+.

#### Pap Test - 2018, 2020

Statewide, 71.2% of women with an intact cervix and aged 21–65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.1% versus 52.6% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.7% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49<sup>th</sup> among states and the District of Columbia for Pap screening rate.

#### Colorectal Cancer Screening – 2018, 2020

Statewide, 67.9% of adults aged 50–75 reported being current for colorectal cancer screening.\*\* Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked 47<sup>th</sup> among states and the District of Columbia in the percentage of adults aged 50–75 and older who reported being up-to-date for colorectal cancer screening.

<sup>\*\*</sup> Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

#### **Tobacco Use**

#### Current Tobacco Use - 2016-2021

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.3% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 29.9% of persons aged 18-29, and 11.1% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (22.4%) than among Native Americans (40.0%). Tobacco use differed significantly by county, with a range of 5.4% in Madison County to 41.6% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

#### **Other Cancer-Related**

#### Healthy Weight by Body Mass Index - 2015-2021

Statewide, 32.1% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 32.5% of white non-Hispanics, compared to 28.2% of Hispanics and 24.6% of Native Americans, being in the healthy weight range. Males (25.5%) were significantly less likely to be in the healthy weight range than females (38.6%). BMI differed significantly by age of respondent, with 43.3% of persons aged 18–29, and 26.0% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 19.8% in Power County to 47.4% in Blaine County of adults being in the healthy weight range.

#### Any Physical Activity - 2015-2021

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 78.7% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.3% of persons aged 18–29, and 72.3% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 64.3% in Clark County to 84.6% in Teton County.

Physical Activity Guidelines – 2011, 2013, 2015, 2017, 2019 Statewide, 21.9% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.3% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6% in Franklin County to 30.6% in Blaine County.

#### Home Radon Testing - 2016, 2018, 2020

Statewide, 23.0% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.4% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.5% in Cassia County to 54.4% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006l and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.





# BENEWAH COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016–2020 Cancer Mortality 2017–2021 BRFSS 2011–2021

#### **RISK FACTORS AND INTERVENTIONS**

#### **CANCER**

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/jama.2016.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

#### Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

#### **Smoking:**

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

#### Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <a href="https://www.dietaryguidelines.gov">https://www.dietaryguidelines.gov</a>

#### Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute
Cancer Information Services
1-800-4CANCER
<a href="https://www.cancer.gov/contact">https://www.cancer.gov/contact</a>

American Cancer Society <a href="https://www.cancer.org">https://www.cancer.org</a>

#### **CANCER INCIDENCE 2016–2020**

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016–2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 291 cases of invasive cancer were diagnosed among Benewah County residents (Table 1).

**Table 1:** Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Benewah County and the State of Idaho, 2016–2020

Cancer Incidence 2016–2020	Benewah County	State of Idaho
All Sites/Types	291	45,610
Female Breast	38	6,687
Prostate	37	6,417
Lung & Bronchus	37	4,887
Colorectal	21	3,451

Table 3 (Cancer Incidence 2016–2020, Comparison between Benewah County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Benewah County. The table also shows the number of observed cases,

person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Benewah County was 630.5 cases per 100,000 person-years per year during 2016–2020. Comparing this crude rate with the crude rate for the remainder of Idaho (519.4) gives an estimate of the relative burden of disease in Benewah County.

The age- and sex-adjusted incidence rate of invasive cancer in Benewah County, all sites combined, was 474.9 cases per 100,000 persons per year during 2016–2020. There were fewer cases of cancer in Benewah County (291) than expected (318.2) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

#### **CANCER MORTALITY 2017–2021**

During 2017–2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 118 Benewah County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

**Table 2:** Overall and Cancer Mortality in Benewah County and the State of Idaho, 2017–2021

Mortality 2017–2021	Benewah County	State of Idaho
All Deaths	655	77,431
Cancer Deaths	118	15,121
% of All Deaths	18.0%	19.5%
Lung & Bronchus	30	2,961
Colorectal	5	1,319
Pancreas	7	1,190
Female Breast	9	1,086
Prostate	5	949

Table 4 (Cancer Mortality 2017–2021, Comparison between Benewah County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Benewah County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Benewah County, all sites combined, was 188.0 deaths per 100,000 persons per year during 2017–2021, compared with 167.8 for the remainder of the state. There were more cancer deaths in Benewah County (118) than expected (105.3) based upon rates in the remainder of the state, but the difference was not statistically significant.

**Statistical Note:** Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

#### TABLE 3: CANCER INCIDENCE 2016–2020 COMPARISON BETWEEN BENEWAH COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

SiteType				Ben	ewah Coun	ty			Ren	nainder of Ida	aho
All Sites Combined Male Male Male Male Male Male Male Male	Cancer		Observed	Person	Crude	A.A.I.			Observed	Person	Crude
All Sites Combined  Male	Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)
All Sites Combined	_										519.4
Bladder	_										551.4
Bladder   Male   16   23,514   68.0   46.2   13.7   0.612   1,735   4,373.396   Bladder   Total   4   45,155   8.7   7.0   4.0   1.000   430   4302.277   1.000   430   4302.277   1.000   430   4302.277   1.000   430   4302.277   1.000   430   4302.277   1.000   430   4302.277   1.000   430   4302.277   1.000   430   4302.277   1.000   430   4302.277   1.000   430   4302.277   1.000   430   4302.277   1.000   430   4302.277   1.000   430   4.000   430   4.000   430   4.000   430   4.000   430   4.000   430   4.000   430   4.000   430   4.000   430   4.000   4											487.2
Bladder											24.8 39.7
Brain - mailignant											9.9
Brain - malignant   Female   2   23,514   8,5   6,7   2,5   1,000   373   4,373,396   Brain - malignant   Female   2   22,641   8,6   7,4   1,5   0,917   246   4,352,277   248   4,352,277   248   4,352,277   248   4,373,396   248											7.1
Brain and other CNS- non-malignant Male 4 23,514 17.0 13.3 3.3 0.826 476 4,373.396 Brain and other CNS- non-malignant Brain and other CNS- non-malignant Female 6 22,641 26.5 21.7 5.9 1.000 938 4,352.277 10dal 39 46,155 84.5 65.0 46.2 0.328 6,707 8,725.673 Breast Male 4 22,641 4.3 13.0 4.0 7.71 6.89 4,773.396 Breast Male 7 23,514 16.3 13.0 4.0 7.71 6.89 4,773.396 Breast In situ Female 12 23,514 16.3 13.0 4.0 10.71 6.89 4,773.396 Breast In situ Male 12 23,514 16.3 13.0 4.0 10.71 6.89 4,773.396 Breast In situ Male 12 23,514 4.3 13.5 0.0 0.052 1.2 4.373.396 Breast In situ Male 12 23,641 4.4 3.3 15.0 0.0 0.052 1.2 4.373.396 Breast In situ Male Female 11 22,641 4.4 4.2 1.7 1.000 303 4,352.277 Colorectal Male 12 22,641 4.4 4.2 1.7 1.000 303 4,352.277 Colorectal Male 14 23,514 59.5 43.3 14.0 1.000 1.889 4,373.396 Colorectal Male 14 23,514 59.5 43.3 14.0 1.000 1.889 4,373.396 Esophagus Total 5 46,155 10.8 7.9 3.6 0.0 0.443 1.541 4,352.277 Esophagus Male 5 22,641 2.5 2.3 14.8 10.0 0.443 1.541 4,352.277 Esophagus Male 5 23,544 5.5 34.7 2.8 10.0 0.443 1.541 4,352.277 Esophagus Male 5 23,544 5.5 34.7 2.8 10.0 0.443 1.541 4,352.277 Esophagus Male 6 22,641 2.5 2.0 4.9 9.0 0.422 1.324 4,352.277 Esophagus Male 12 22,641 4.4 5.5 34.7 2.8 0.0 0.042 1.324 4,352.277 Esophagus Male 12 23,514 5.5 20.4 9.0 0.422 1.324 4,352.277 Esophagus Male 12 23,514 5.5 20.4 9.0 0.422 1.324 4,352.277 Esophagus Male 12 23,514 5.5 20.4 9.0 0.422 1.324 4,352.277 Esophagus Male 12 23,514 5.5 20.4 9.0 0.422 1.324 4,352.277 Esophagus Male 12 23,514 5.5 20.4 9.0 0.422 1.324 4,352.277 Esophagus Male 12 23,514 5.5 20.4 9.0 0.422 1.324 4,352.277 Esophagus Male 12 23,514 5.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0		Male	2				2.5	1.000			8.5
Brain and other CNS - non-malignant   Male   4   23,514   17.0   13.3   3.3   0.826   476   4,373,396   Brain and other CNS - non-malignant   Female   6   22,641   26.5   21.7   5.9   1.000   938   4,352,277   1.000   1.											5.7
Brain and other CNS - non-mailgnant   Female   6   22,641   26.5   21.7   5.9   1,000   938   4,352,277   Breast   Male   1   23,514   4.3   3.0   0.4   0.717   656   4,373,396   Breast   Female   38   22,641   6.78   132.1   44.0   0.7415   6,649   4,352,277   Breast - In situ   Total   12   461,155   26.0   19.9   8.5   0.296   1,227   8,725,673   Breast - In situ   Female   1   22,641   4.8   6.37.8   8.2   0.406   1,223   4,352,277   Breast - In situ   Female   1   22,641   4.8   6.37.8   8.2   0.406   1,223   4,352,277   Colorectal   Total   21   461,155   4.5   4.5   4.2   1.7   1,000   303   4,352,277   Colorectal   Total   21   461,155   4.5   4.5   4.2   1.7   1,000   303   4,352,277   Colorectal   Total   21   461,155   4.5   4.5   4.5   4.2   1.7   1,000   303   4,352,277   Colorectal   Total   21   461,155   4.											16.2
Breast   Total   39   46,155   84.5   65.0   46.2   0,328   6,707   8,725,673   87.25,673	Brain and other CNS - non-malignant										10.9
Breast   Male   1   23,514   4.3   3.0   0.4   0,717   58   4,373,396     Breast   Female   38   22,641   4.8   3.5   0.906   1,227     Breast   In situ   Total   12   46,155   26.0   19.9   8.5   0.296   1,227   8,725,673     Breast   In situ   Female   11   22,641   48.6   37.8   8.2   0.406   1,223   4,352,277     Breast   In situ   Female   11   22,641   48.6   37.8   8.2   0.406   1,223   4,352,277     Colorectal   Total   21   46,155   45.5   34.7   23.8   0.661   3.430   8,725,673     Colorectal   Male   14   23,514   59.5   43.3   14.0   1.000   3.03   4,352,277     Colorectal   Female   7   22,641   30.5   24.8   10.0   0.442   1.541   4,352,277     Colorectal   Female   7   22,641   30.5   24.8   10.0   0.442   1.541   4,352,277     Esophagus   Male   5   22,641   30.5   24.8   10.0   0.442   1.541   4,352,277     Esophagus   Male   5   22,541   21.3   41.8   3.2   0.450   4.73,396     Esophagus   Female   7   22,641   3.7   3.7   3.7   3.7   3.7   3.7   3.7   3.7   3.7     Hodgkin Lymphoma   Total   - 46,155   1,2   0.621   210   8,225,673     Hodgkin Lymphoma   Female   - 22,641   0,7   0.000   118   4373,396     Hodgkin Lymphoma   Female   - 22,641   0,5   1.000   9.2   4.352,277     Hodgkin Lymphoma   Female   - 22,641   0,5   1.000   9.2   4.352,277     Layrix   Total   17   46,155   36.8   27.9   12.5   0.266   1.798   8,725,673     Kidney and Renal Pelvis   Male   12   23,514   51.0   37.4   8.6   0.319   1.170   4.373,396     Layrix   Female   - 22,641   0.5   0.000   9.2   4.352,277     Layrix   Female   - 22,6											21.6 76.9
Breast   Female   38   22,641   167.8   132.1   44.0   0.415   6,649   4,352,277											1.3
Breast - in situ         Male         1         24,6155         26.0         19.9         8.5         0.296         1,227         8,725,673           Breast - in situ         Male         1         23,514         4.3         3.5         0.0         0.052         4,4373,396           Corvix         Female         1         22,641         4.4         4.2         1.7         1.000         303         4,352,277           Colorectal         Male         14         23,514         59.5         34.7         23.8         0.661         3,430         8,725,673           Colorectal         Male         14         23,514         59.5         34.7         23.8         10.0         0.432         1,373,396           Colorectal         Female         6         22,641         30.9         24.8         10.0         0.443         1,541         4,352,277           Esophagus         Total         5         46,155         10.8         7.9         3.6         0.597         501         8,725,673           Esophagus         Female         -         22,641         -         -         0.6         10.00         82         4,352,277           Hodgkin Lymphoma         Total			-							4.352.277	152.8
Breast - in situ											14.1
Cervix	Breast - in situ		1							4,373,396	0.1
Colorectal   Male   14   23,514   59,5   34,7   23,8   0.661   3,430   8,726,73   Colorectal   Male   14   23,514   59,5   43,3   14,0   1,000   1,889   4,373,396   Colorectal   Female   7   22,641   30,9   24,8   10,0   0.443   1,541   4,352,277   Corpus Utleri   Female   6   22,641   26,5   20,4   10,0   0.442   1,324   4,352,277   Esophagus   Total   5   46,155   10,8   7,9   3,6   0.597   501   8,725,673   Esophagus   Male   5   23,514   21,3   14,8   3,2   0.450   419   4,373,396   Esophagus   Female   - 22,641   -   -   0.6   1,000   82   4,352,277   Hodgkin Lymphoma   Total   -   46,155   -   -   1,000   118   4,373,396   Esophagus   Female   -   22,641   -   -   0.6   1,000   82   4,352,277   Hodgkin Lymphoma   Male   -   23,514   -   -   0.7   1,000   118   4,373,396   Hodgkin Lymphoma   Female   -   22,641   -   -   0.7   1,000   118   4,373,396   Hodgkin Lymphoma   Female   -   22,641   -   -   0.7   1,000   118   4,373,396   Hodgkin Lymphoma   Female   -   22,641   -   -   0.7   1,000   118   4,373,396   Hodgkin Lymphoma   Female   -   22,641   -   -   0.7   1,000   118   4,373,396   Hodgkin Lymphoma   Female   -   22,641   -   -   0.7   1,000   118   4,373,396   Hodgkin Lymphoma   Female   -   22,641   -   -   0.7   1,000   118   4,373,396   Hodgkin Lymphoma   Female   -   22,641   -   -   0.7   1,000   118   4,373,396   Hodgkin Lymphoma   Female   -   22,641   -   -   0.7   1,000   118   4,373,396   Hodgkin Lymphoma   Female   -   22,641   -   -   0.7   1,000   118   4,373,396   Hodgkin Lymphoma   Hodgkin Lymphoma   Female   -   22,641   -   -   0.7   1,000   118   4,373,396   Hodgkin Lymphoma   Hodgkin											28.1
Colorectal   Male   14   23,514   59.5   43.3   14.0   1.000   1,889   4,373,396	=										7.0
Colorectal   Female   7   22,641   30.9   24.8   10.0   0.443   1,541   4,352,277											39.3 43.2
Corpus Uteri											35.4
Esophagus	=										30.4
Esophagus							3.6				5.7
Hodgkin Lymphoma   Total			5							4,373,396	9.6
Hodgkin Lymphoma	1 0		-		-	-					1.9
Hodgkin Lýmphoma   Female   -					-	-					2.4
Kidney and Renal Pelvis   Male   17   46,155   36.8   27.9   12.5   0.266   1.798   8,725,673			-		-	-					2.7 2.1
Kidney and Renal Pelvis   Male   12   23.514   51.0   37.4   8.6   0.319   1.170   4.373.396   Kidney and Renal Pelvis   Female   5   22.641   22.1   17.4   4.1   0.797   628   4.352.277   1.2   1			17		- 36.8	27.0					20.6
Kidney and Renal Pelvis											26.8
Larynx											14.4
Larymx											2.4
Leukemia	Larynx		2		8.5	5.9				4,373,396	3.6
Leukemia   Male   3   23,514   12.8   9.3   7.3   0.139   986   4,373,396   Leukemia   Female   - 22,641   4.2   0.031 << 64   4,373,396   Leukemia   Female   - 4.2   0.031 << 64   4,373,396   Male   7   23,514   29.8   20.9   4.5   0.331   583   4,373,396   Liver and Bile Duct   Male   7   23,514   29.8   20.9   4.5   0.331   583   4,373,396   Liver and Bile Duct   Female   1   22,641   4.4   3.4   1.6   1.000   238   4,352,277   Ling and Bronchus   Total   37   46,155   80.2   57.3   35.9   0.893   4.850   8,725,673   Ling and Bronchus   Male   17   23,514   72.3   48.9   19.4   0.696   2.435   4,373,396   Ling and Bronchus   Female   20   22,641   88.3   66.4   16.7   0.481   2.415   4,352,277   Melanoma of the Skin   Total   7   46,155   15.2   11.9   19.8   0.002 << 1,235   8,725,673   Melanoma of the Skin   Male   5   23,514   21.3   15.5   13.0   0.0022 << 1,760   4,373,396   Myeloma   Male   5   23,514   21.3   15.5   13.0   0.0022 << 1,760   4,373,396   Myeloma   Male   5   23,514   21.3   14.6   3.4   0.518   436   4,373,396   Myeloma   Male   5   23,514   21.3   14.6   3.4   0.518   436   4,373,396   Myeloma   Male   5   23,514   21.3   14.6   3.4   0.518   436   4,373,396   Myeloma   Male   5   23,514   21.3   14.6   3.4   0.518   436   4,373,396   Myeloma   Male   5   23,514   21.3   14.6   3.4   0.518   436   4,373,396   Myeloma   Male   5   23,514   21.3   14.6   3.4   0.554   1,924   8,725,673   Mon-Hodgkin Lymphoma   Total   16   46,155   34.7   26.2   13.4   0.554   1,924   8,725,673   Mon-Hodgkin Lymphoma   Total   16   46,155   21.7   16.1   9.2   0.866   1,285   8,725,673   Mon-Hodgkin Lymphoma   Female   7   22,641   30.9   24.3   5.3   0.571   804   4,352,277   Mon-Hodgkin Lymphoma   Female   8   23,514   34.0   24.3   7.0   0.795   928   4,373,396   37.8   38.3   0.894   1,120   4,373,396   37.8   38.3   37.8   38.3   37.8   38.3   37.8   38.3   37.8   38.3   37.8   38.3   37.8   38.3   37.8   38.3   37.8   38.3   37.8   37.8   38.3   37.8   37.8   37.8   37.8   37.8   37.8   37.8											1.3
Leukemia											18.7
Liver and Bile Duct   Total   8			3		12.8	9.3					22.5 14.8
Liver and Bile Duct   Male   7   23,514   29.8   20.9   4.5   0.331   583   4,373,396   Liver and Bile Duct   Female   1   22,641   4.4   3.4   1.6   1.000   238   4,352,277   1.000   238   4,352,277   1.000   238   4,352,277   1.000   238   4,352,277   1.000   238   4,352,277   1.000   238   2,3514   22.641   24.4   3.4   1.6   1.000   238   4,352,277   1.000   238   2,3514   23.3   24.9   24.3   2,415   2,435   4,373,396   1.000   2,435   2,435   4,373,396   1.000   2,435   2,415   4,352,277   1.000   2,435   2,415   4,352,277   1.000   2,435   2,415   4,352,277   1.000   2,435   2,415   4,352,277   1.000   2,435   2,415   4,352,277   1.000   2,435   2,415   4,352,277   1.000   2,435   2,415   4,352,277   1.000   2,435   2,415   4,352,277   1.000   2,435   2,415   4,352,277   1.000   2,435   2,415   4,352,277   1.000   2,435   2,415   4,352,277   1.000   2,435   2,415   4,352,277   1.000   2,435   2,415   4,352,277   1.000   2,435   2,415   4,352,277   1.000   2,435   2,415   4,352,277   1.000   2,435   2,415   4,352,277   1.000   2,435   2,415   4,352,277   1.000   2,435   2,415   2,435   2			- 8		17.3	12.6					9.4
Liver and Bile Duct   Female   1   22,641   4.4   3.4   1.6   1.000   238   4,352,277   Lung and Bronchus   Total   37   46,155   80.2   57.3   35.9   0.893   4,850   8,725,673   373,396   35.9   0.893   4,850   8,725,673   373,396   37									583		13.3
Lung and Bronchus         Male         17         23,514         72.3         48.9         19.4         0.696         2,435         4,373,396           Lung and Bronchus         Female         20         22,641         88.3         66.4         16.7         0.481         2,415         4,373,396           Melanoma of the Skin         Total         7         46,155         15.2         11.9         19.8         0.002 <											5.5
Lung and Bronchus	Lung and Bronchus	Total	37		80.2	57.3	35.9	0.893		8,725,673	55.6
Melanoma of the Skin         Total         7         46,155         15.2         11.9         19.8         0.002         2         2,935         8,725,673           Melanoma of the Skin         Male         5         23,514         21.3         15.5         13.0         0.002         1,760         4,373,396           Melanoma of the Skin         Female         2         22,641         8.8         7.4         7.3         0.046         1,775         4,352,277           Myeloma         Total         10         46,155         21.7         15.8         5.1         0.069         698         8,725,673           Myeloma         Male         5         23,514         21.3         14.6         3.4         0.518         436         4,373,396           Myeloma         Female         5         22,641         22.1         16.9         1.8         0.070         262         4,352,277           Non-Hodgkin Lymphoma         Total         16         46,155         34.7         26.2         13.4         0.554         1,924         8,725,673           Non-Hodgkin Lymphoma         Female         9         23,514         38.3         27.8         8.3         0.894         1,120         4,3											55.7
Melanoma of the Skin         Male         5         23,514         21.3         15.5         13.0         0.022 <         1,760         4,373,396           Melanoma of the Skin         Female         2         22,641         8.8         7.4         7.3         0.046 <											55.5
Melanoma of the Skin         Female         2         22,641         8.8         7.4         7.3         0.046 <         1,175         4,352,277           Myeloma         Total         10         46,155         21.7         15.8         5.1         0.069         698         8,725,673           Myeloma         Male         5         23,514         21.3         14.6         3.4         0.518         436         4,373,396           Myeloma         Female         5         22,641         22.1         16.9         1.8         0.518         436         4,373,396           Non-Hodgkin Lymphoma         Total         16         46,155         34.7         26.2         13.4         0.554         1,924         8,725,673           Non-Hodgkin Lymphoma         Male         9         23,514         38.3         27.8         8.3         0.894         1,120         4,373,396           Non-Hodgkin Lymphoma         Female         7         22,641         30.9         24.3         5.3         0.571         804         4,352,277           Oral Cavity and Pharynx         Total         10         46,155         21.7         16.1         9.2         0.866         1,285         8,725,673     <											33.6
Myeloma         Total Myeloma         Male         5         23,514         21.7         15.8         5.1         0.069         698         8,725,673           Myeloma         Male         5         23,514         21.3         14.6         3.4         0.518         436         4,373,396           Myeloma         Female         5         22,641         22.1         16.9         1.8         0.070         262         4,352,277           Non-Hodgkin Lymphoma         Male         9         23,514         38.3         27.8         8.3         0.894         1,120         4,373,396           Non-Hodgkin Lymphoma         Female         7         22,641         30.9         24.3         5.3         0.571         804         4,352,277           Oral Cavity and Pharynx         Total         10         46,155         21.7         16.1         9.2         0.866         1,285         8,725,673           Oral Cavity and Pharynx         Male         8         23,514         34.0         24.3         7.0         0.795         928         4,373,396           Oral Cavity and Pharynx         Female         2         22,641         8.8         6.9         2.4         1.000         357											40.2 27.0
Myeloma         Male         5         23,514         21.3         14.6         3.4         0.518         436         4,373,396           Myeloma         Female         5         22,641         22.1         16.9         1.8         0.070         262         4,352,277           Non-Hodgkin Lymphoma         Total         16         46,155         34.7         26.2         13.4         0.554         1,924         8,725,673           Non-Hodgkin Lymphoma         Male         9         23,514         38.3         27.8         8.3         0.894         1,120         4,373,396           Non-Hodgkin Lymphoma         Female         7         22,641         30.9         24.3         5.3         0.897         1,804         4,352,277           Oral Cavity and Pharynx         Total         10         46,155         21.7         16.1         9.2         0.866         1,285         8,725,673           Oral Cavity and Pharynx         Male         8         23,514         34.0         24.3         7.0         0.795         928         4,373,396           Oral Cavity and Pharynx         Female         2         22,641         8.8         6.9         2.4         1.000         357         4,352											8.0
Myeloma         Female         5         22,641         22.1         16.9         1.8         0.070         262         4,352,277           Non-Hodgkin Lymphoma         Total         16         46,155         34.7         26.2         13.4         0.554         1,924         8,725,673           Non-Hodgkin Lymphoma         Male         9         23,514         38.3         27.8         8.3         0.894         1,120         4,373,396           Non-Hodgkin Lymphoma         Female         7         22,641         30.9         24.3         5.3         0.894         1,120         4,373,396           Non-Hodgkin Lymphoma         Female         7         22,641         30.9         24.3         5.3         0.894         1,120         4,373,396           Noral Cavity and Pharynx         Total         10         46,155         21.7         16.1         9.2         0.866         1,285         8,725,673           Oral Cavity and Pharynx         Male         8         23,514         34.0         24.3         7.0         0.795         928         4,373,396           Oral Cavity and Pharynx         Female         2         22,641         8.8         6.9         2.4         1.000         357	,										10.0
Non-Hodgkin Lymphoma         Total         16         46,155         34.7         26.2         13.4         0.554         1,924         8,725,673           Non-Hodgkin Lymphoma         Male         9         23,514         38.3         27.8         8.3         0.894         1,120         4,373,396           Non-Hodgkin Lymphoma         Female         7         22,641         30.9         24.3         5.3         0.571         804         4,352,277           Oral Cavity and Pharynx         Total         10         46,155         21.7         16.1         9.2         0.866         1,285         8,725,673           Oral Cavity and Pharynx         Male         8         23,514         34.0         24.3         7.0         0.795         928         4,373,396           Oral Cavity and Pharynx         Female         2         22,641         8.8         6.9         2.4         1.000         357         4,352,277           Ovary         Female         4         22,641         17.7         14.1         3.5         0.906         529         4,352,277           Pancreas         Total         10         46,155         21.7         15.9         10.2         1.000         1,413         8,7	Myeloma	Female	5	22,641	22.1	16.9	1.8	0.070	262	4,352,277	6.0
Non-Hodgkin Lýmphoma         Female         7         22,641         30.9         24.3         5.3         0.571         804         4,352,277           Oral Cavity and Pharynx         Total         10         46,155         21.7         16.1         9.2         0.866         1,285         8,725,673           Oral Cavity and Pharynx         Male         8         23,514         34.0         24.3         7.0         0.795         928         4,373,396           Oral Cavity and Pharynx         Female         2         22,641         8.8         6.9         2.4         1.000         357         4,352,277           Ovary         Female         4         22,641         17.7         14.1         3.5         0.906         529         4,352,277           Pancreas         Total         10         46,155         21.7         15.9         10.2         1.000         1,413         8,725,673           Pancreas         Male         6         23,514         25.5         17.7         6.0         1.000         778         4,373,396           Pancreas         Female         4         22,641         17.7         13.8         4.2         1.000         635         4,373,396 <tr< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>22.0</td></tr<>											22.0
Oral Cavity and Pharynx         Total         10         46,155         21.7         16.1         9.2         0.866         1,285         8,725,673           Oral Cavity and Pharynx         Male         8         23,514         34.0         24.3         7.0         0.795         928         4,373,396           Oral Cavity and Pharynx         Female         2         22,641         8.8         6.9         2.4         1.000         357         4,352,277           Ovary         Female         4         22,641         17.7         14.1         3.5         0.906         529         4,352,277           Pancreas         Total         10         46,155         21.7         15.9         10.2         1.000         1,413         8,725,673           Pancreas         Male         6         23,514         25.5         17.7         6.0         1.000         778         4,373,396           Pancreas         Female         4         22,641         17.7         13.8         4.2         1.000         635         4,352,277           Prostate         Male         37         23,514         157.4         108.1         49.9         0.069         6,380         4,373,396											25.6
Oral Cavity and Pharynx         Male         8         23,514         34.0         24.3         7.0         0.795         928         4,373,396           Oral Cavity and Pharynx         Female         2         22,641         8.8         6.9         2.4         1.000         357         4,352,277           Ovary         Female         4         22,641         17.7         14.1         3.5         0.906         529         4,352,277           Pancreas         Total         10         46,155         21.7         15.9         10.2         1.000         1,413         8,725,673           Pancreas         Male         6         23,514         25.5         17.7         6.0         1.000         778         4,373,396           Pancreas         Female         4         22,641         17.7         13.8         4.2         1.000         635         4,352,277           Prostate         Male         37         23,514         157.4         108.1         49.9         0.069         6,380         4,373,396           Stomach         Total         7         46,155         15.2         11.5         3.2         0.092         460         8,725,673											18.5
Oral Cavity and Pharynx         Female         2         22,641         8.8         6.9         2.4         1.000         357         4,352,277           Ovary         Female         4         22,641         17.7         14.1         3.5         0.906         529         4,352,277           Pancreas         Total         10         46,155         21.7         15.9         10.2         1.000         1,413         8,725,673           Pancreas         Male         6         23,514         25.5         17.7         6.0         1.000         778         4,373,396           Pancreas         Female         4         22,641         17.7         13.8         4.2         1.000         635         4,352,277           Prostate         Male         37         23,514         157.4         108.1         49.9         0.069         6,380         4,373,396           Stomach         Total         7         46,155         15.2         11.5         3.2         0.092         460         8,725,673	Oral Cavity and Pharynx Oral Cavity and Pharynx									0,125,013	14.7 21.2
Ovary         Female         4         22,641         17.7         14.1         3.5         0.906         529         4,352,277           Pancreas         Total         10         46,155         21.7         15.9         10.2         1.000         1,413         8,725,673           Pancreas         Male         6         23,514         25.5         17.7         6.0         1.000         78         4,373,396           Pancreas         Female         4         22,641         17.7         13.8         4.2         1.000         635         4,352,277           Prostate         Male         37         23,514         157.4         108.1         49.9         0.069         6,380         4,373,396           Stomach         Total         7         46,155         15.2         11.5         3.2         0.092         460         8,725,673											8.2
Pancreas         Total         10         46,155         21.7         15.9         10.2         1.000         1,413         8,725,673           Pancreas         Male         6         23,514         25.5         17.7         6.0         1.000         778         4,373,396           Pancreas         Female         4         22,641         17.7         13.8         4.2         1.000         635         4,352,277           Prostate         Male         37         23,514         157.4         108.1         49.9         0.069         6,380         4,373,396           Stomach         Total         7         46,155         15.2         11.5         3.2         0.092         460         8,725,673										4.352.277	12.2
Pancreas         Male         6         23,514         25.5         17.7         6.0         1.000         778         4,373,396           Pancreas         Female         4         22,641         17.7         13.8         4.2         1.000         635         4,352,277           Prostate         Male         37         23,514         157.4         108.1         49.9         0.069         6,380         4,373,396           Stomach         Total         7         46,155         15.2         11.5         3.2         0.092         460         8,725,673					21.7						16.2
Pancreas         Female         4         22,641         17.7         13.8         4.2         1.000         635         4,352,277           Prostate         Male         37         23,514         157.4         108.1         49.9         0.069         6,380         4,373,396           Stomach         Total         7         46,155         15.2         11.5         3.2         0.092         460         8,725,673	Pancreas	Male	6	23,514	25.5	17.7	6.0	1.000	778	4,373,396	17.8
Stomach Total 7 46,155 15.2 11.5 3.2 0.092 460 8,725,673											14.6
											145.9
											5.3 6.9
Stomach         Male         7         23,514         29.8         20.9         2.3         0.019 >>         302         4,373,396           Stomach         Female         -         22,641         -         -         1.0         0.742         158         4,352,277			/			20.9					3.6
Testis   Male   3   23,514   12.8   15.1   1.2   0.237   262   4,373,396			3			15.1					6.0
Thyroid Total 5 46,155 10.8 9.9 7.1 0.586 1,215 8,725,673											13.9
Thyroid Male 1 23,514 4.3 3.6 2.2 0.687 354 4,373,396	,										8.1
Thyroid Female 4 22,641 17.7 16.5 4.8 0.956 861 4,352,277											19.8
Pediatric Age 0 to 19 Total 2 11,243 17.8 18.0 1.9 1.000 419 2,449,280											17.1
Pediatric Age 0 to 19 Male 2 5,853 34.2 34.4 1.0 0.548 221 1,250,657											17.7
Pediatric Age 0 to 19   Female   -   5,390   -   -   0.9   0.834   198   1,198,623					-	-					16.5

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

<sup>2.</sup> Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

#### **TABLE 4: CANCER MORTALITY 2017–2021** COMPARISON BETWEEN BENEWAH COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

Cancer Sile/Type				Ben	ewah Coun	ty			Re	mainder of Idah	10
All Causes of Death Male 351 24,039 1,460 1,063 4,099 1,000 >> 76,775 8,941,662 859 All Causes of Death Male 351 24,039 1,460 1,063 4,099 4,000 >> 76,776 4,487,829 9,000 All Causes of Death Female 304 23,014 1,320,9 1,155 2,213.1 0,000 >> 80,070 4,453,833 800 All Causes of Death Female 304 23,014 1,320,9 1,155 2,213.1 0,000 >> 80,070 4,453,833 800 All Malignant Cancers Male 67 24,039 270.7 194.5 02.7 0,530 6,109 4,457,623 100 All Malignant Cancers Male 67 24,039 270.7 194.5 02.7 0,530 6,109 4,457,623 100 All Malignant Cancers Male 6 7,405 10 All Malignant Cancers Male 6 24,039 25.0 17.2 0,9 0,146 372 4,487,829 10 All Malignant Cancers Male 6 24,039 25.0 17.2 0,9 0,146 372 4,487,829 8 Bladder Male 6 24,039 25.0 17.2 0,9 0,146 372 4,487,829 8 Brain and Other Nervous System Total 3 47,053 10 All Malignant Cancers Male 6 24,039 4.2 3,1 1,000 20 31 111 4,453,833 2 Earna and Other Nervous System Male 1 24,039 4.2 3,1 1,000 20 30 1 8,941,662 5 Earna and Other Nervous System Male 1 24,039 4.2 3,1 1,000 20 30 1 8,941,662 5 Earna and Other Nervous System Male 1 24,039 4.2 3,1 1,000 20 30 1 8,941,662 5 Earna and Other Nervous System Male 1 24,039 4.2 3,1 1,000 20 30 1 8,941,662 5 Earna and Other Nervous System Male 1 24,039 4.2 3,1 1,000 20 30 1 8,941,662 5 Earna All Malignant Cancers Male 2 33,014 3,16 6,9 0,511 1,077 4,457,833 24 Cervix Female 9 23,014 39,1 31,6 6,9 0,511 1,077 4,453,833 24 Cervix Female 9 23,014 39,1 31,6 6,9 0,511 1,077 4,453,833 24 Cervix Female 9 23,014 39,1 31,6 6,9 0,511 1,077 4,453,833 24 Cervix Female 9 23,014 39,1 31,6 6,9 0,511 1,077 4,453,833 24 Cervix Female 9 23,014 39,1 31,6 6,9 0,511 1,077 4,453,833 24 Cervix Female 9 23,014 39,1 31,6 6,9 0,511 1,077 4,453,833 3 24 Cervix Female 9 23,014 39,1 31,6 6,9 0,511 1,077 4,453,833 3 24 Cervix Female 9 23,014 39,1 31,6 6,9 0,511 1,077 4,453,833 3 24 Cervix Female 9 23,014 39,1 31,6 6,9 0,511 1,077 4,453,833 3 24 Cervix Female 9 23,014 39,1 31,6 6,9 0,511 1,077 4,453,833 3 24 Cervix Female 9 23,014 39,1 31,6 6,9 0,511 1,077 4,453,833 3 24 Cervix Fe	Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
All Causes of Death   Male   351   24,039   1,460.1   1,063.4   2994   0,004 >> 4,0705   4,487,829   800   All Causes of Death   Female   304   23,014   1,320.9   1,155.2   213.1   0,000 >> 36,070   4,437,829   800   All Malgnant Cancers   Nate   67   24,039   276.7   194.5   62.2   0,500   8,109   4,467,829   100	Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death   Male   351   24,039   1,460.1   1,063.4   2994   0,004 >> 4,0705   4,487,829   800   4,338,338   800   8	All Causes of Death	Total	655	47,053	1,392.0	1,106.9	508.1	0.000 >>	76,775	8,941,662	858.6
All Causes of Death Female 304 23.014 1.320.9 1,156.2 213.1 0.000 ≫ 36.070 4.453.833 89.8 1 Malignant Cancers 7 Total 18 47.053 250.8 188.0 180.3 1.053 0.238 15.003 5.941.662 157. All Malignant Cancers Male 67 24,039 278.7 194.5 62.2 0.580 8.109 4.478.289 150.01 4.10 16.0 16.0 16.0 16.0 17.6 17.6 17.6 17.6 17.6 17.6 17.6 17.6	All Causes of Death	Male	351	24,039		1,063.4		0.004 >>	40,705	4,487,829	907.0
All Malignant Cancers   Male   67   24,039   278.7   194.5   62.2   0.580   8,109   4,487,829   180     Bladder   Total   6   47,053   12.8   9.7   3.3   0.240   483   8,941,652   58     Bladder   Total   6   47,053   12.8   9.7   3.3   0.240   483   8,941,652   58     Bladder   Bladder   Total   6   47,053   12.8   9.7   3.3   0.240   483   8,941,652   58     Bladder   Bladder   Total   6   47,053   12.8   9.7   3.3   0.240   483   8,941,652   58     Bladder   Bladder   Total   6   47,053   12.8   4.9   1.0   1.0   4.43,133   1.0     Bladder   Bladder   Total   6   47,053   1.3   4.4   4.9   4.9   4.9   4.43,133   1.0     Brain and Other Nevous System   Male   1   24,039   4.2   3.1   2.1   0.742   9.1   4.43,183   2.2     Breast   Male   1   24,039   4.2   2.9   0.1   0.220   1.5   4.43,183   4.4   4.7   5.5   6.9   1.3   0.771   2.04   4.43,183   4.4   4.7   5.5   6.9   1.3   0.771   2.04   4.43,183   4.4   4.7   5.5   6.9   1.3   0.771   2.04   4.43,183   4.4   4.7   5.5   6.9   1.3   0.771   2.04   4.43,183   4.4   4.7   5.5   6.9										4,453,833	809.9
All Malignant Cancers   Female   51   23,014   221,6   176,6   44,7   0.382   6,894   4,453,833   612   614											167.8
Bladder											180.7
Bladder   Male   6   24,039   25.0   17.2   2.9   0.146   372   4.487,829   8   8   8   8   8   6   24,039   25.0   17.2   2.9   0.146   372   4.487,829   8   8   8   8   8   8   1   24,039   4.2   3.1   2.1   0.742   297   4.487,829   5   8   8   8   8   8   1   24,039   4.2   3.1   2.1   0.742   297   4.487,829   6   8   8   8   8   8   8   8   8   8											
Bladder   Female   -				47,053							5.4 8.3
Brain and Other Nervous System Male Frain and Other Nervous System Male Frain and Other Nervous System Male Frain and Other Nervous System Male 1 24,039 4.2 3.1 2.1 0.742 297 4,467,829 6 Brain and Other Nervous System Male 1 24,039 4.2 3.1 0.1 0.742 297 4,467,829 6 Breast Male 1 24,039 4.2 3.1 0.1 0.771 204 4,453,833 4 Breast Male 1 24,039 4.2 2.9 0.1 0.220 15 4,487,829 0 Breast Male 1 24,039 4.2 2.9 0.1 0.220 15 4,487,829 0 Breast Male 1 24,039 4.2 2.9 0.1 0.220 15 4,487,829 0 Breast Female 9 23,014 39.1 31.6 6.9 0.511 1,077 4,445,833 1 Cervix Female 1 23,014 9.1 0.5 10.00 177 4,453,833 1 Cervix Female 1 23,014 9.1 0.5 10.00 170 171 4,443,833 1 Cervix Female 1 23,014 9.1 0.5 10.00 170 171 4,443,833 1 Coppus Uter Female 1 23,014 4.3 3.3 3 1.2 0.270 170 171 4,443,833 1 Esophagus Total 6 4 70,03 12.8 9,4 3.4 0.249 471 8,941,662 5 Esophagus Female 1 23,014 0.5 1.000 172 4,453,833 1 Esophagus Female 1 23,014 0.5 1.000 172 4,453,833 1 Esophagus Female 1 23,014 0.5 1.000 172 4,453,833 1 Esophagus Female 1 23,014 0.5 1.000 76 4,453,833 1 Hodglin Lymphoma Male 1 24,039 0.1 1.000 174 4,453,833 1 Hodglin Lymphoma Male 1 24,039 0.1 1.000 14 4,487,829 0 Hodglin Lymphoma Male 1 24,039 0.1 1.000 14 4,487,829 0 Hodglin Lymphoma Male 1 24,039 0.1 1.000 14 4,487,829 0 Hodglin Lymphoma Male 1 24,039 0.1 1.000 14 4,487,829 0 Hodglin Lymphoma Male 1 24,039 0.1 1.000 15 4,453,833 1 Esophagus Female 1 23,014 0.1 1.000 14 4,487,829 0 Hodglin Lymphoma Male 1 24,039 0.1 1.000 14 4,487,829 0 Hodglin Lymphoma Male 1 24,039 0.1 1.000 15 4,453,833 1 Esophagus Female 1 23,014 0.1 1.000 14 4,487,829 0 Hodglin Lymphoma Male 1 24,039 16 6 11.6 1.8 2.9 2.8 447 8.9 8.9 41,662 4 Kidney Male 1 24,039 16 6 11.6 1.8 1.9 1.000 14 4,453,833 3 Esophagus 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1					23.0	17.2					2.5
Brain and Other Nervous System Male Parla nand Other Nervous System Female 2 23,014 8,7 6,9 1.3, 0,771 204 4,487,829 6 Breast Male 1 24,039 4.2 2.9 0.1 0,220 155 4,465,833 4 Breast Male 1 24,039 4.2 2.9 0.1 0,220 155 4,465,833 4 Great Female 9 23,014 39.1 31.6 6.9 0,511 1,077 4,453,833 24 Cervix Female - 23,014 0.5 1,000 83 4,453,833 24 Colorectal Total 5 47,053 10.6 8.1 9.0 0,226 1,314 8,941,662 15 Colorectal Male 4 24,039 16.6 12.0 5.3 0,770 715 4,453,833 3 3 Corpus Uteri Female 1 23,014 4.3 3.6 3.8 0,220 599 4,453,833 3 3 Corpus Uteri Female 1 23,014 4.3 3.6 3.8 0,220 599 4,453,833 3 3 Esophagus Total 6 47,053 12.8 9,4 3.4 0,249 4/1 8,941,662 5 Esophagus Female - 23,014 4.3 3.3 1,2 0,173 20,173 20,174 20,173 20,174 20,					6.4	49					5.6
Brain and Other Nervous System   Female   2   23,014   8.7   6.9   1.3   0.771   204   4.453,833   4   Breast   Male   1   24,039   4.2   2.9   0.1   0.220   15   4.487,829   0   Breast   Female   9   23,014   3.16   6.9   0.511   1.077   4.453,833   24   Cervix   Female   - 23,014     0.5   1.000   83   4.453,833   24   Cervix   Female   - 23,014     0.5   1.000   83   4.453,833   24   Colorectal   Male   4   24,039   16.6   12.0   5.3   0.770   715   4.487,829   10   Colorectal   Male   4   24,039   16.6   12.0   5.3   0.770   715   4.487,829   15   Colorectal   Female   1   23,014   4.3   3.6   3.8   0.220   559   4.487,829   15   Colorectal   Female   1   23,014   4.3   3.3   3.12   1.000   172   4.453,833   3   Corpus Uteri   Female   1   23,014   4.3   3.3   3.12   1.000   172   4.453,833   3   Esophagus   Male   6   24,039   25.0   17.4   3.0   0.173   395   4.487,829   8   Esophagus   Male   6   24,039   25.0   17.4   3.0   0.173   395   4.487,829   8   Esophagus   Total   -	Brain and Other Nervous System										6.6
Breast											4.6
Breast   Female   9   23,014   39,1   31,6   6.9   0.511   1,077   4,453,833   24			10					0.438			12.2
Cervix	Breast	Male	1	24,039	4.2	2.9	0.1	0.220	15	4,487,829	0.3
Colorectal			9		39.1	31.6					24.2
Colorectal   Male   4   24,039   16.6   12.0   5.3   0.770   715   4,487,829   15   Colorectal   Female   1   23,014   4.3   3.6   3.8   0.220   599   4,453,833   13   Corpus Uteri   Female   1   23,014   4.3   3.3   1.2   1.000   172   4,453,833   3   Esophagus   Total   6   47,053   12.8   9.4   3.3   3.4   0.249   471   8,941,662   5   Esophagus   Male   6   24,039   25.0   17.4   3.0   0.173   395   4,487,829   8   Esophagus   Female   -   23,014   -   -   0.5   1.000   76   4,453,833   3   Hodgkin Lymphoma   Total   -   47,053   -   0.2   1.000   29   8,941,662   0   Hodgkin Lymphoma   Female   -   23,014   -   -   0.1   1.000   14   4,487,829   0   Hodgkin Lymphoma   Female   -   23,014   -   -   0.1   1.000   15   4,453,833   0   Kidney   Male   4   24,039   16.6   11.6   18   0.227   238   8,941,662   4,878,829   16   Kidney   Male   4   24,039   16.6   11.6   18   0.227   238   8,941,662   5   Kidney   Male   4   24,039   16.6   11.6   18   0.227   238   4,878,29   5   Kidney   Female   1   23,014   4   3   3.5   0   0.700   14   4,487,829   5   Kidney   Male   1   24,039   2.2   1.6   0.5   0.788   70   8,941,662   0   Larynx   Total   1   47,053   2.1   1.6   0.5   0.788   70   8,941,662   0   Larynx   Female   -   23,014   -     0.1   1.000   13   4,453,833   0   Larynx   Female   -   23,014   3   3   3   5   5   5   5   Leukemia   Male   4   24,039   16.6   11.8   2.9   0.658   382   4,487,829   8   Leukemia   Male   4   24,039   16.6   11.8   2.9   0.658   382   4,487,829   8   Leukemia   Male   4   24,039   16.6   11.8   2.9   0.658   382   4,487,829   8   Leukemia   Male   4   24,039   16.6   11.8   2.9   0.658   382   4,487,829   8   Leukemia   Total   6   47,053   12.8   9.8   6.5   0.593   6.54   8.941,662   0.659   0.788   0.654   0.941,662   0.659   0.788   0.654   0.941,662   0.659   0.788   0.654   0.941,662   0.659   0.788   0.654   0.941,662   0.659   0.788   0.658   0.788   0.941,662   0.941,662   0.941,662   0.941,662   0.941,662   0.941,662   0.941,662   0.941,662   0.941,662   0.9											1.9
Colorectal   Female   1   23,014   4.3   3.6   3.8   0.220   599   4.453,833   3   3.6   3.8   0.220   599   4.453,833   3   3.8	=			47,053							14.7
Corpus Uten											15.9
Esophagus											13.4 3.9
Esophagus	•										5.3
Esophagus	, 0										8.8
Hodgkin Lymphoma			-								1.7
Hodgkin Lymphoma			_			-					0.3
Kidney			-		-	-					0.3
Kidney		Female	-		-	-					0.3
Kidney				47,053							4.2
Larynx											5.3
Larynx											3.2
Laiynx			•								0.8
Leukemia	,		_ '		4.2						0.3
Leukemia   Female   2   24,039   16.6   11.8   2.9   0.658   382   4,487,829   8   Leukemia   Female   2   23,014   8.7   7.2   1.7   1.000   272   4,453,833   6   6   6   6   6   6   6   6   6			- 6	47 053	12.8						7.3
Leukemia											8.5
Liver and Bile Duct Male			2	23,014							6.1
Liver and Bile Duct	Liver and Bile Duct	Total			10.6		4.3	0.864	598	8,941,662	6.7
Lung and Bronchus         Total         30         47,053         63.8         46.3         21.2         0.084         2,931         8,941,662         32           Lung and Bronchus         Male         14         24,039         58.2         39.8         12.1         0.658         1,542         4,487,829         34           Lung and Bronchus         Female         16         23,014         69.5         53.6         9.3         0.057         1,389         4,487,829         34           Melanoma of the Skin         Total         1         47,053         2.1         1.6         2.0         0.819         288         8,941,662         32           Melanoma of the Skin         Male         -         24,039         -         -         1.4         0.473         192         4,487,829         4           Melanoma of the Skin         Female         1         23,014         4.3         3.5         0.6         0.921         96         4,453,833         2           Myeloma         Total         5         47,053         10.6         7.8         2.3         0.179         326         8,941,662         3           Myeloma         Male         2         24,039         8.3 <td>Liver and Bile Duct</td> <td>Male</td> <td></td> <td>24,039</td> <td></td> <td>8.7</td> <td></td> <td></td> <td></td> <td></td> <td>9.0</td>	Liver and Bile Duct	Male		24,039		8.7					9.0
Lung and Bronchus											4.3
Lung and Bronchus         Female         16         23,014         69.5         53.6         9.3         0.057         1,389         4,453,833         31.           Melanoma of the Skin         Male         1         47,053         2.1         1.6         2.0         0.819         288         8,941,662         3           Melanoma of the Skin         Male         -         24,039         -         -         1.4         0.473         192         4,487,829         4           Melanoma of the Skin         Female         1         23,014         4.3         3.5         0.6         0.921         96         4,453,833         2           Myeloma         Total         5         47,053         10.6         7.8         2.3         0.179         326         8,941,662         3           Myeloma         Male         2         24,039         8.3         5.6         1.5         0.909         194         4,487,829         4           Myeloma         Female         3         23,014         13.0         10.2         0.9         0.117         132         4,453,833         3           Non-Hodgkin Lymphoma         Male         1         24,039         4.2         2.9<											32.8
Melanoma of the Skin         Total         1         47,053         2.1         1.6         2.0         0.819         288         8,941,662         3           Melanoma of the Skin         Male         -         24,039         -         -         1.4         0.473         192         4,487,829         4           Melanoma of the Skin         Female         1         23,014         4.3         3.5         0.6         0.921         96         4,453,833         2           Myeloma         Total         5         47,053         10.6         7.8         2.3         0.179         326         8,941,662         3           Myeloma         Male         2         24,039         8.3         5.6         1.5         0.909         194         4,487,829         4           Myeloma         Female         3         23,014         13.0         10.2         0.9         0.117         132         4,487,829         4           Myeloma         Female         3         23,014         13.0         10.2         0.9         0.117         132         4,487,829         4           Myeloma         Total         2         47,053         4.3         3.2         4.0											34.4
Melanoma of the Skin         Male         -         24,039         -         -         1.4         0.473         192         4,487,829         4           Melanoma of the Skin         Female         1         23,014         4.3         3.5         0.6         0.921         96         4,453,833         2           Myeloma         Total         5         47,053         10.6         7.8         2.3         0.179         326         8,941,662         3           Myeloma         Male         2         24,039         8.3         5.6         1.5         0.909         194         4,487,829         4           Myeloma         Female         3         23,014         13.0         10.2         0.9         0.117         132         4,487,829         4           Myeloma         Female         3         23,014         13.0         10.2         0.9         0.117         132         4,487,829         4           Myeloma         Female         3         23,014         13.0         10.2         0.9         0.117         132         4,487,829         4           Non-Hodgkin Lymphoma         Male         1         24,039         4.2         2.9         2.3 <td></td> <td>31.2</td>											31.2
Melanoma of the Skin         Female         1         23,014         4.3         3.5         0.6         0.921         96         4,453,833         2           Myeloma         Total         5         47,053         10.6         7.8         2.3         0.179         326         8,941,662         3           Myeloma         Male         2         24,039         8.3         5.6         1.5         0.909         194         4,487,829         4           Myeloma         Female         3         23,014         13.0         10.2         0.9         0.117         132         4,453,833         3           Non-Hodgkin Lymphoma         Total         2         47,053         4.3         3.2         4.0         0.482         567         8,941,662         6           Non-Hodgkin Lymphoma         Male         1         24,039         4.2         2.9         2.3         0.643         306         4,487,829         6           Non-Hodgkin Lymphoma         Female         1         23,014         4.3         3.5         1.7         1.000         261         4,453,833         5           Oral Cavity and Pharynx         Total         2         47,053         4.3 <td< td=""><td></td><td></td><td>_ '</td><td>24 N30</td><td></td><td>1.0</td><td></td><td></td><td></td><td></td><td>4.3</td></td<>			_ '	24 N30		1.0					4.3
Myeloma         Total         5         47,053         10.6         7.8         2.3         0.179         326         8,941,662         3           Myeloma         Male         2         24,039         8.3         5.6         1.5         0.909         194         4,487,829         4           Myeloma         Female         3         23,014         13.0         10.2         0.9         0.117         132         4,453,833         3           Non-Hodgkin Lymphoma         Total         2         47,053         4.3         3.2         4.0         0.482         567         8,941,662         6           Non-Hodgkin Lymphoma         Male         1         24,039         4.2         2.9         2.3         0.643         306         4,487,829         6           Non-Hodgkin Lymphoma         Female         1         23,014         4.3         3.5         1.7         1.000         261         4,453,833         5           Oral Cavity and Pharynx         Total         2         47,053         4.3         3.1         1.9         1.000         264         8,941,662         3           Oral Cavity and Pharynx         Male         2         24,039         8.3         <			1			3.5					2.2
Myeloma         Male         2         24,039         8.3         5.6         1.5         0.909         194         4,487,829         4.487,829										8.941.662	3.6
Nón-Hodgkin Lymphoma         Total         2         47,053         4.3         3.2         4.0         0.482         567         8,941,662         6           Non-Hodgkin Lymphoma         Male         1         24,039         4.2         2.9         2.3         0.643         306         4,487,829         6           Non-Hodgkin Lymphoma         Female         1         23,014         4.3         3.5         1.7         1.000         261         4,453,833         5           Oral Cavity and Pharynx         Total         2         47,053         4.3         3.1         1.9         1.000         264         8,941,662         3           Oral Cavity and Pharynx         Male         2         24,039         8.3         5.8         1.4         0.834         185         4,487,829         4           Oval Cavity and Pharynx         Female         -         23,014         -         -         0.5         1.000         79         4,453,833         1           Ovary         Female         -         23,014         -         -         2.3         0.193         350         4,453,833         7           Pancreas         Total         7         47,053         14.9	Myeloma	Male									4.3
Non-Hodgkin Lymphoma         Male         1         24,039         4.2         2.9         2.3         0.643         306         4,487,829         6           Non-Hodgkin Lymphoma         Female         1         23,014         4.3         3.5         1.7         1.000         261         4,453,833         5           Oral Cavity and Pharynx         Total         2         47,053         4.3         3.1         1.9         1.000         264         8,941,662         3           Oral Cavity and Pharynx         Male         2         24,039         8.3         5.8         1.4         0.834         185         4,487,829         4           Ovary         Female         -         23,014         -         -         0.5         1.000         79         4,453,833         1           Pancreas         Total         7         47,053         14.9         10.9         8.5         0.770         1,183         8,941,662         13           Pancreas         Male         3         24,039         12.5         8.6         4.9         0.546         639         4,487,829         14	Myeloma		3	23,014	13.0	10.2	0.9	0.117	132		3.0
Non-Hodgkin Lymphoma         Female         1         23,014         4.3         3.5         1.7         1.000         261         4,453,833         5           Oral Cavity and Pharynx         Total         2         47,053         4.3         3.1         1.9         1.000         264         8,941,662         3           Oral Cavity and Pharynx         Male         2         24,039         8.3         5.8         1.4         0.834         185         4,487,829         4           Oral Cavity and Pharynx         Female         -         23,014         -         -         0.5         1.000         79         4,453,833         1           Ovary         Female         -         23,014         -         -         2.3         0.193         350         4,453,833         7           Pancreas         Total         7         47,053         14.9         10.9         8.5         0.770         1,183         8,941,662         13           Pancreas         Male         3         24,039         12.5         8.6         4.9         0.546         639         4,487,829         14	0 , .										6.3
Oral Cavity and Pharynx         Total         2         47,053         4.3         3.1         1.9         1.000         264         8,941,662         3           Oral Cavity and Pharynx         Male         2         24,039         8.3         5.8         1.4         0.834         185         4,487,829         4           Oral Cavity and Pharynx         Female         -         23,014         -         -         0.5         1.000         79         4,453,833         1           Ovary         Female         -         23,014         -         -         2.3         0.193         350         4,453,833         7           Pancreas         Total         7         47,053         14.9         10.9         8.5         0.770         1,183         8,941,662         13           Pancreas         Male         3         24,039         12.5         8.6         4.9         0.546         639         4,487,829         14											6.8
Oral Cavity and Pharynx         Male Oral Cavity and Pharynx         2         24,039 (23,014)         8.3 (24,039)         5.8 (24,039)         1.4 (24,039)         0.834 (24,039)         185 (24,487,829)         4.447,829 (24,039)         4.453,833 (24,039)         1.000 (24,000)         79 (24,453,833)         1.000 (24,000)         79 (24,453,833)         70 (24,000)         79 (24,000)					4.3						5.9
Oral Cavity and Pharynx         Female         -         23,014         -         -         0.5         1.000         79         4,453,833         1.000           Ovary         Female         -         23,014         -         -         2.3         0.193         350         4,453,833         7.0           Pancreas         Total         7         47,053         14.9         10.9         8.5         0.770         1,183         8,941,662         13.0           Pancreas         Male         3         24,039         12.5         8.6         4.9         0.546         639         4,487,829         14.9											3.0
Ovary         Female         -         23,014         -         -         2.3         0.193         350         4,453,833         7.           Pancreas         Total         7         47,053         14.9         10.9         8.5         0.770         1,183         8,941,662         13.           Pancreas         Male         3         24,039         12.5         8.6         4.9         0.546         639         4,487,829         14.											4.1 1.8
Pancreas         Total         7         47,053         14.9         10.9         8.5         0.770         1,183         8,941,662         13.           Pancreas         Male         3         24,039         12.5         8.6         4.9         0.546         639         4,487,829         14.	,				-						7.9
Pancreas   Male   3   24,039   12.5   8.6   4.9   0.546   639   4,487,829   14.					14.9						13.2
											14.2
	Pancreas	Female	4	23,014	17.4	13.4	3.6	0.986	544	4,453,833	12.2
Prostate Male 5 24,039 20.8 14.3 7.4 0.512 944 4,487,829 21.	Prostate		5	24,039	20.8	14.3	7.4	0.512		4,487,829	21.0
											2.2
	Stomach		3		12.5	8.9			118		2.6
Stomach         Female         -         23,014         -         -         0.5         1.000         77         4,453,833         1	Stomach	Female	-	23,014	-		0.5	1.000	77	4,453,833	1.7

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

<sup>2.</sup> Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

#### Cancer Screening and Risk Factor Prevalence Estimates, 2011–2021

	State of								Benewah
Measure	Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	County
Access to Care									
Have Health Insurance, Age <65 (2015–2021)	83.1%	82.8%	85.1%	77.2%	85.8%	78.9%	85.4%	85.4%	82.0%
Not See Doctor Due to Cost in Past Year (2015–2021)	12.6%	11.4%	11.8%	14.5%	12.4%	12.3%	11.8%	12.9%	10.1%
Cancer Screening									
Mammogram Past 2 Years, Age 50–74 (2014, 2016, 2018, 2020)	69.1%	67.0%	73.8%	68.2%	73.2%	64.8%	64.5%	67.1%	45.9%
Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020)	71.2%	73.6%	73.6%	70.8%	72.9%	69.1%	69.5%	65.9%	
Colorectal Cancer Screening, Age 50–75 (2018, 2020)	67.9%	66.9%	73.6%	71.4%	70.6%	61.7%	61.5%	64.7%	58.3%
Tobacco Use									
Current Tobacco User (2016–2021)	22.3%	26.7%	23.1%	23.6%	21.8%	21.4%	22.7%	16.9%	27.1%
Other Cancer-Related									
Healthy Weight by Body Mass Index, Age 20+ (2015–2021)	32.1%	32.8%	31.7%	27.9%	36.1%	29.8%	27.9%	31.9%	33.5%
Any Physical Activity Besides Job Past 30 Days (2015-2021)	78.7%	79.2%	78.1%	74.5%	83.2%	73.4%	76.3%	79.7%	72.5%
Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019)	21.9%	22.8%	19.4%	20.0%	25.2%	19.5%	20.4%	20.2%	22.7%
Home Ever Tested for Radon (2016, 2018, 2020)	23.0%	30.9%	18.2%	16.9%	25.1%	19.9%	23.0%	21.8%	15.5%

#### **Access to Care**

#### Have Health Insurance – 2015–2021

Statewide, 83.1% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 86.0% of white non-Hispanics, compared to 64.8% of Hispanics and 83.3% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3%) than English-speaking respondents (84.2%). Health care coverage differed significantly by age of respondent, with 79.8% of persons aged 18–29, and 87.8% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 62.1% in Adams County to 91.6% in Oneida County having health insurance.

#### Not See Doctor Due to Cost in Past Year – 2015–2021

Statewide, 12.6% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (11.5% of white non-Hispanics, 19.2% of Hispanics, and 21.0% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9% for less than \$15,000, 6.1% for greater than \$50,000). Inability to see a doctor due to cost differed significantly by county, with a range of 7.4% in Franklin County to 17.5% in Power County.

#### **Cancer Screening**

<u>Mammogram</u> – 2014, 2016, 2018, 2020

Statewide, 69.1% of women aged 50–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (72.1% versus 36.7%). Mammography rates differed significantly by county, with a range in screening of 45.9% in Benewah County to 77.0% in Nez Perce County. In 2020, Idaho ranked 48<sup>th</sup> among states and the District of Columbia for mammography screening rates among women aged 50–74 and also 48<sup>th</sup> among ages 40+.

#### Pap Test - 2018, 2020

Statewide, 71.2% of women with an intact cervix and aged 21–65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.1% versus 52.6% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.7% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49<sup>th</sup> among states and the District of Columbia for Pap screening rate.

#### Colorectal Cancer Screening – 2018, 2020

Statewide, 67.9% of adults aged 50–75 reported being current for colorectal cancer screening.\*\* Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked 47<sup>th</sup> among states and the District of Columbia in the percentage of adults aged 50–75 and older who reported being up-to-date for colorectal cancer screening.

<sup>\*\*</sup> Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

#### **Tobacco Use**

#### Current Tobacco Use - 2016-2021

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.3% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 29.9% of persons aged 18-29, and 11.1% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (22.4%) than among Native Americans (40.0%). Tobacco use differed significantly by county, with a range of 5.4% in Madison County to 41.6% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

#### **Other Cancer-Related**

#### Healthy Weight by Body Mass Index - 2015-2021

Statewide, 32.1% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 32.5% of white non-Hispanics, compared to 28.2% of Hispanics and 24.6% of Native Americans, being in the healthy weight range. Males (25.5%) were significantly less likely to be in the healthy weight range than females (38.6%). BMI differed significantly by age of respondent, with 43.3% of persons aged 18–29, and 26.0% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 19.8% in Power County to 47.4% in Blaine County of adults being in the healthy weight range.

#### Any Physical Activity - 2015-2021

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 78.7% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.3% of persons aged 18–29, and 72.3% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 64.3% in Clark County to 84.6% in Teton County.

Physical Activity Guidelines – 2011, 2013, 2015, 2017, 2019 Statewide, 21.9% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.3% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6% in Franklin County to 30.6% in Blaine County.

#### Home Radon Testing - 2016, 2018, 2020

Statewide, 23.0% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.4% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.5% in Cassia County to 54.4% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006l and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.





# BINGHAM COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

#### **RISK FACTORS AND INTERVENTIONS**

#### **CANCER**

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/jama.2016.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

#### Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

#### **Smoking:**

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

#### Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <a href="https://www.dietaryguidelines.gov">https://www.dietaryguidelines.gov</a>

#### Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute
Cancer Information Services
1-800-4CANCER
<a href="https://www.cancer.gov/contact">https://www.cancer.gov/contact</a>

American Cancer Society <a href="https://www.cancer.org">https://www.cancer.org</a>

#### **CANCER INCIDENCE 2016–2020**

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016–2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 1,059 cases of invasive cancer were diagnosed among Bingham County residents (Table 1).

**Table 1:** Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Bingham County and the State of Idaho. 2016–2020

,	,	
Cancer Incidence 2016–2020	Bingham County	State of Idaho
All Sites/Types	1,059	45,610
Female Breast	122	6,687
Prostate	140	6,417
Lung & Bronchus	104	4,887
Colorectal	97	3,451

Table 3 (Cancer Incidence 2016–2020, Comparison between Bingham County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Bingham County. The table also shows the number of observed cases, person-

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Bingham County was 458.0 cases per 100,000 person-years per year during 2016–2020. Comparing this crude rate with the crude rate for the remainder of Idaho (521.6) gives an estimate of the relative burden of disease in Bingham County.

The age- and sex-adjusted incidence rate of invasive cancer in Bingham County, all sites combined, was 500.8 cases per 100,000 persons per year during 2016–2020. There were fewer cases of cancer in Bingham County (1,059) than expected (1,103.0) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

#### **CANCER MORTALITY 2017–2021**

During 2017–2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 360 Bingham County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

**Table 2:** Overall and Cancer Mortality in Bingham County and the State of Idaho, 2017–2021

Mortality 2017–2021	Bingham County	State of Idaho
All Deaths	2,165	77,431
Cancer Deaths	360	15,121
% of All Deaths	16.6%	19.5%
Lung & Bronchus	65	2,961
Colorectal	41	1,319
Pancreas	26	1,190
Female Breast	25	1,086
Prostate	25	949

Table 4 (Cancer Mortality 2017–2021, Comparison between Bingham County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Bingham County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Bingham County, all sites combined, was 168.6 deaths per 100,000 persons per year during 2017–2021, compared with 168.6 for the remainder of the state. There were more cancer deaths in Bingham County (360) than expected (360.0) based upon rates in the remainder of the state, but the difference was not statistically significant.

**Statistical Note:** Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

## TABLE 3: CANCER INCIDENCE 2016–2020 COMPARISON BETWEEN BINGHAM COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

		Bingham County				Remainder of Idaho				
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)
All Sites Combined	Total	1,059	231,229	458.0	500.8	1,103.0	0.189	44,551	8,540,599	521.6
All Sites Combined All Sites Combined	Male Female	572 487	115,694 115,535	494.4 421.5	532.1 466.0	595.6 511.2	0.345 0.294	23,717 20,834	4,281,216 4,259,383	554.0 489.1
Bladder	Total	42	231,229	18.2	20.0	52.6	0.156	2,142	8,540,599	25.1
Bladder	Male	35	115,694	30.3	32.6	43.1	0.245	1,716	4,281,216	40.1
Bladder	Female	7	115,535	6.1	6.8	10.3	0.388	426	4,259,383	10.0
Brain - malignant Brain - malignant	Total Male	12 5	231,229 115,694	5.2 4.3	5.5 4.6	15.6 9.5	0.441 0.182	613 370	8,540,599 4,281,216	7.2 8.6
Brain - malignant Brain - malignant	Female	7	115,535	6.1	6.5	6.2	0.162	243	4,259,383	5.7
Brain and other CNS - non-malignant	Total	31	231,229	13.4	14.5	34.9	0.582	1,393	8,540,599	16.3
Brain and other CNS - non-malignant	Male	8	115,694	6.9	7.3	12.0	0.308	472	4,281,216	11.0
Brain and other CNS - non-malignant Breast	Female Total	23 122	115,535 231,229	19.9 52.8	21.9 57.6	22.7 164.1	1.000 0.001 <b>&lt;&lt;</b>	921 6,624	4,259,383 8,540,599	21.6 77.6
Breast	Male	122	115,694	J2.0 -	- 37.0	1.5	0.453	59	4,281,216	1.4
Breast	Female	122	115,535	105.6	116.8	161.0	0.002 <<	6,565	4,259,383	154.1
Breast - in situ	Total	23	231,229	9.9	10.9	30.1	0.224	1,216	8,540,599	14.2
Breast - in situ	Male	-	115,694	-	-	0.1	1.000	5	4,281,216	0.1
Breast - in situ Cervix	Female Female	23 10	115,535 115,535	19.9 8.7	22.0 9.2	29.7 7.5	0.253 0.448	1,211 294	4,259,383 4,259,383	28.4 6.9
Colorectal	Total	97	231,229	41.9	45.7	83.3	0.153	3,354	8,540,599	39.3
Colorectal	Male	56	115,694	48.4	51.8	46.6	0.198	1,847	4,281,216	43.1
Colorectal	Female	41	115,535	35.5	39.3	36.9	0.541	1,507	4,259,383	35.4
Corpus Uteri	Female Total	33 10	115,535 231,229	28.6 4.3	31.6 4.7	31.8 12.3	0.878 0.643	1,297 496	4,259,383 8,540,599	30.5 5.8
Esophagus Esophagus	Male	10 8	231,229 115,694	4.3 6.9	4.7 7.4	12.3	0.643	496 416	4,281,216	5.8 9.7
Esophagus	Female	2	115,535	1.7	1.9	2.0	1.000	80	4,259,383	1.9
Hodgkin Lymphoma	Total	2	231,229	0.9	0.9	5.4	0.194	208	8,540,599	2.4
Hodgkin Lymphoma	Male	1	115,694	0.9	0.9	3.0	0.397	117	4,281,216	2.7
Hodgkin Lymphoma Kidney and Renal Pelvis	Female Total	1 48	115,535 231,229	0.9 20.8	0.9 22.7	2.4 43.8	0.635 0.568	91 1,767	4,259,383 8,540,599	2.1 20.7
Kidney and Renal Pelvis	Male	27	115,694	23.3	25.1	29.0	0.798	1,767	4,281,216	27.0
Kidney and Renal Pelvis	Female	21	115,535	18.2	20.1	15.0	0.167	612	4,259,383	14.4
Larynx	Total	4	231,229	1.7	1.9	5.2	0.801	211	8,540,599	2.5
Larynx	Male	4	115,694	3.5	3.7	3.9	1.000	156	4,281,216	3.6
Larynx Leukemia	Female Total	39	115,535 231,229	- 16.9	- 18.2	1.3 40.0	0.524 0.960	55 1,592	4,259,383 8,540,599	1.3 18.6
Leukemia	Male	20	115,694	17.3	18.3	24.8	0.396	969	4,281,216	22.6
Leukemia	Female	19	115,535	16.4	18.1	15.4	0.416	623	4,259,383	14.6
Liver and Bile Duct	Total	22	231,229	9.5	10.4	19.9	0.704	807	8,540,599	9.4
Liver and Bile Duct Liver and Bile Duct	Male Female	15 7	115,694 115,535	13.0 6.1	13.9 6.7	14.5 5.6	0.957 0.675	575 232	4,281,216 4,259,383	13.4 5.4
Lung and Bronchus	Total	104	231,229	45.0	49.7	117.3	0.073	4,783	8,540,599	56.0
Lung and Bronchus	Male	64	115,694	55.3	59.9	59.6	0.605	2,388	4,281,216	55.8
Lung and Bronchus	Female	40	115,535	34.6	38.9	57.8	0.017 <<	2,395	4,259,383	56.2
Melanoma of the Skin	Total	56	231,229	24.2	26.4	71.6	0.066	2,886	8,540,599	33.8
Melanoma of the Skin Melanoma of the Skin	Male Female	39 17	115,694 115,535	33.7 14.7	36.3 16.1	43.4 28.8	0.569 0.026 <b>&lt;&lt;</b>	1,726 1,160	4,281,216 4,259,383	40.3 27.2
Myeloma	Total	16	231,229	6.9	7.6	17.0	0.936	692	8,540,599	8.1
Myeloma	Male	9	115,694	7.8	8.4	10.8	0.725	432	4,281,216	10.1
Myeloma	Female	7	115,535	6.1	6.8	6.3	0.882	260	4,259,383	6.1
Non-Hodgkin Lymphoma Non-Hodgkin Lymphoma	Total Male	53 25	231,229 115,694	22.9 21.6	25.0 23.1	46.9 27.9	0.409 0.669	1,887 1,104	8,540,599 4,281,216	22.1 25.8
Non-Hodgkin Lymphoma	Female	28	115,694	24.2	26.9	19.2	0.069	783	4,259,383	18.4
Oral Cavity and Pharynx	Total	26	231,229	11.2	12.3	31.4	0.384	1,269	8,540,599	14.9
Oral Cavity and Pharynx	Male	19	115,694	16.4	17.6	23.1	0.466	917	4,281,216	21.4
Oral Cavity and Pharynx	Female Female	7 16	115,535 115,535	6.1 13.8	6.7 15.2	8.6 12.7	0.747 0.428	352 517	4,259,383 4,259,383	8.3 12.1
Ovary Pancreas	Total	29	231,229	13.8	13.8	34.3	0.428	1,394	8,540,599	16.3
Pancreas	Male	18	115,694	15.6	16.8	19.2	0.898	766	4,281,216	17.9
Pancreas	Female	11	115,535	9.5	10.7	15.2	0.342	628	4,259,383	14.7
Prostate	Male	140	115,694	121.0	131.3	156.3	0.203	6,277	4,281,216	146.6
Stomach Stomach	Total Male	14 9	231,229 115,694	6.1 7.8	6.6 8.3	11.2 7.6	0.482 0.695	453 300	8,540,599 4,281,216	5.3 7.0
Stomach	Female	5	115,694	4.3	4.8	3.8	0.649	153	4,259,383	3.6
Testis	Male	5	115,694	4.3	4.7	6.5	0.731	260	4,281,216	6.1
Thyroid	Total	62	231,229	26.8	28.8	29.2	0.000 >>	1,158	8,540,599	13.6
Thyroid	Male	18	115,694	15.6	16.8	8.5	0.006 >>	337	4,281,216	7.9
Thyroid	Female	44	115,535	38.1	40.8	20.8	0.000 >>	821	4,259,383	19.3
Pediatric Age 0 to 19	Total	14	77,207	18.1	18.4	13.0	0.850	407	2,383,316	17.1
Pediatric Age 0 to 19 Pediatric Age 0 to 19	Male Female	7 7	39,334 37,873	17.8 18.5	18.0 18.9	6.9 6.1	1.000 0.806	216 191	1,217,176 1,166,140	17.7 16.4
			37,073			0.1	0.000	191	1,100,140	10.4

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

<sup>2.</sup> Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

<sup>&</sup>quot;<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

#### **TABLE 4: CANCER MORTALITY 2017–2021** COMPARISON BETWEEN BINGHAM COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Bing	ham Count	ty			Remainder of Idah		10
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	2,165	234,792	922.1	1,003.3	1,855.3	0.000 >>	75,265	8,753,923	859.8
All Causes of Death	Male	1,168	117,603	993.2	1,057.6	1,002.5	0.000 >>	39,888	4,394,265	907.7
All Causes of Death	Female	997	117,189	850.8	944.6	856.5	0.000 >>	35,377	4,359,658	811.5
All Malignant Cancers	Total	360	234,792	153.3	168.6	360.0	1.000	14,761	8,753,923	168.6
All Malignant Cancers	Male	199	117,603	169.2	181.9	198.6	0.995	7,977	4,394,265	181.5
All Malignant Cancers	Female	161	117,189	137.4	154.0	162.7	0.933	6,784	4,359,658	155.6
Bladder	Total	14	234,792	6.0	6.6	11.6	0.552	475	8,753,923	5.4
Bladder	Male	10	117,603	8.5	9.1	9.3	0.891	368	4,394,265	8.4
Bladder	Female	4	117,189	3.4	3.9	2.5	0.500	107	4,359,658	2.5
Brain and Other Nervous System	Total	8	234,792	3.4	3.7	12.3	0.273	496	8,753,923	5.7
Brain and Other Nervous System	Male	5	117,603	4.3	4.5	7.4	0.516	293	4,394,265	6.7
Brain and Other Nervous System	Female	3	117,189	2.6	2.8	5.0	0.534	203	4,359,658	4.7
Breast	Total	25	234,792	10.6	11.6	26.4	0.886	1,077	8,753,923	12.3
Breast	Male	-	117,603	-	- 02.0	0.4	1.000	16	4,394,265	0.4
Breast	Female	25 3	117,189	21.3	23.8	25.6	1.000	1,061	4,359,658	24.3
Cervix Colorectal	Female Total	41	117,189 234,792	2.6 17.5	2.8 19.1	2.0 31.4	0.637 0.112	80 1,278	4,359,658 8,753,923	1.8 14.6
Colorectal	Male	41 27	234,792 117,603	23.0	24.6	31.4 17.3	0.112	692	8,753,923 4,394,265	14.6
Colorectal	Female	14	117,003	11.9	13.3	17.3	1.000	586	4,359,658	13.4
Corpus Uteri	Female	4	117,189	3.4	3.8	4.0	1.000	169	4,359,658	3.9
Esophagus	Total	10	234,792	4.3	4.7	11.4	0.836	467	8,753,923	5.3
Esophagus	Male	8	117,603	6.8	7.3	9.8	0.723	393	4,394,265	8.9
Esophagus	Female	2	117,189	1.7	1.9	1.8	1.000	74	4,359,658	1.7
Hodgkin Lymphoma	Total	1	234.792	0.4	0.5	0.7	0.999	28	8,753,923	0.3
Hodgkin Lymphoma	Male	-	117,603	-	-	0.3	1.000	14	4,394,265	0.3
Hodgkin Lymphoma	Female	1	117,189	0.9	0.9	0.3	0.585	14	4,359,658	0.3
Kidney	Total	14	234,792	6.0	6.6	9.0	0.151	371	8,753,923	4.2
Kidney	Male	9	117,603	7.7	8.2	5.8	0.263	233	4,394,265	5.3
Kidney	Female	5	117,189	4.3	4.8	3.3	0.473	138	4,359,658	3.2
Larynx	Total	-	234,792	-	-	1.8	0.347	71	8,753,923	0.8
Larynx	Male	-	117,603	-	-	1.5	0.462	58	4,394,265	1.3
Larynx	Female		117,189			0.3	1.000	13	4,359,658	0.3
Leukemia	Total	15	234,792	6.4	7.0	15.8	0.975	645	8,753,923	7.4
Leukemia	Male	6	117,603	5.1	5.5	9.5	0.330	380	4,394,265	8.6
Leukemia	Female	9	117,189	7.7	8.6	6.4	0.386	265	4,359,658	6.1
Liver and Bile Duct	Total	13	234,792	5.5	6.1	14.3	0.861 0.689	590	8,753,923	6.7 9.1
Liver and Bile Duct Liver and Bile Duct	Male Female	8 5	117,603 117,189	6.8 4.3	7.4 4.8	9.9 4.5	0.869	400 190	4,394,265 4,359,658	9.1 4.4
Lung and Bronchus	Total	65	234,792	27.7	30.7	70.1	0.932	2,896	8,753,923	33.1
Lung and Bronchus	Male	41	117,603	34.9	37.8	37.4	0.600	1,515	4,394,265	34.5
Lung and Bronchus	Female	24	117,189	20.5	23.1	32.9	0.134	1,381	4,359,658	31.7
Melanoma of the Skin	Total	2	234,792	0.9	0.9	7.0	0.058	287	8,753,923	3.3
Melanoma of the Skin	Male	1	117,603	0.9	0.9	4.8	0.099	191	4,394,265	4.3
Melanoma of the Skin	Female	1	117,189	0.9	0.9	2.3	0.653	96	4,359,658	2.2
Myeloma	Total	8	234,792	3.4	3.8	7.8	1.000	323	8,753,923	3.7
Myeloma	Male	5	117,603	4.3	4.6	4.7	1.000	191	4,394,265	4.3
Myeloma	Female	3	117,189	2.6	2.9	3.1	1.000	132	4,359,658	3.0
Nón-Hodgkin Lymphoma	Total	13	234,792	5.5	6.1	13.6	1.000	556	8,753,923	6.4
Non-Hodgkin Lymphoma	Male	5	117,603	4.3	4.6	7.5	0.473	302	4,394,265	6.9
Non-Hodgkin Lymphoma	Female	8	117,189	6.8	7.7	6.1	0.531	254	4,359,658	5.8
Oral Cavity and Pharynx	Total	5	234,792	2.1	2.4	6.3	0.786	261	8,753,923	3.0
Oral Cavity and Pharynx	Male	3	117,603	2.6	2.8	4.5	0.669	184	4,394,265	4.2
Oral Cavity and Pharynx	Female	2	117,189	1.7	1.9	1.9	1.000	77	4,359,658	1.8
Ovary	Female	15	117,189	12.8	14.4	8.0	0.035 >>	335	4,359,658	7.7
Pancreas	Total	26	234,792	11.1	12.3	28.2	0.776	1,164	8,753,923	13.3
Pancreas	Male	17	117,603	14.5	15.7	15.4	0.754	625	4,394,265	14.2
Pancreas Prostato	Female Male	9 25	117,189	7.7 21.3	8.7 22.7	12.8 23.2	0.357	539 924	4,359,658 4,394,265	12.4 21.0
Prostate Stomach		25 6	117,603 234,792	21.3	22.7	4.7	0.757 0.669	192	4,394,265 8,753,923	21.0
Stomach	Total Male	4	234,792 117,603	3.4	3.7	4.7 2.9	0.668	192	4,394,265	2.2
				1.7						
Stomach	Female	2	117,189		1.9	1.8	1.000	75	4,359,658	1.7

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

<sup>2.</sup> Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

#### Cancer Screening and Risk Factor Prevalence Estimates, 2011–2021

	State of								Bingham
Measure	Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	County
Access to Care									
Have Health Insurance, Age <65 (2015–2021)	83.1%	82.8%	85.1%	77.2%	85.8%	78.9%	85.4%	85.4%	86.3%
Not See Doctor Due to Cost in Past Year (2015–2021)	12.6%	11.4%	11.8%	14.5%	12.4%	12.3%	11.8%	12.9%	11.3%
Cancer Screening									
Mammogram Past 2 Years, Age 50–74 (2014, 2016, 2018, 2020)	69.1%	67.0%	73.8%	68.2%	73.2%	64.8%	64.5%	67.1%	61.3%
Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020)	71.2%	73.6%	73.6%	70.8%	72.9%	69.1%	69.5%	65.9%	50.7%
Colorectal Cancer Screening, Age 50–75 (2018, 2020)	67.9%	66.9%	73.6%	71.4%	70.6%	61.7%	61.5%	64.7%	55.2%
Tobacco Use									
Current Tobacco User (2016–2021)	22.3%	26.7%	23.1%	23.6%	21.8%	21.4%	22.7%	16.9%	22.1%
Other Cancer-Related									
Healthy Weight by Body Mass Index, Age 20+ (2015–2021)	32.1%	32.8%	31.7%	27.9%	36.1%	29.8%	27.9%	31.9%	24.8%
Any Physical Activity Besides Job Past 30 Days (2015-2021)	78.7%	79.2%	78.1%	74.5%	83.2%	73.4%	76.3%	79.7%	75.5%
Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019)	21.9%	22.8%	19.4%	20.0%	25.2%	19.5%	20.4%	20.2%	18.9%
Home Ever Tested for Radon (2016, 2018, 2020)	23.0%	30.9%	18.2%	16.9%	25.1%	19.9%	23.0%	21.8%	24.1%

#### **Access to Care**

#### Have Health Insurance - 2015-2021

Statewide, 83.1% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 86.0% of white non-Hispanics, compared to 64.8% of Hispanics and 83.3% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3%) than English-speaking respondents (84.2%). Health care coverage differed significantly by age of respondent, with 79.8% of persons aged 18–29, and 87.8% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 62.1% in Adams County to 91.6% in Oneida County having health insurance.

#### Not See Doctor Due to Cost in Past Year - 2015-2021

Statewide, 12.6% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (11.5% of white non-Hispanics, 19.2% of Hispanics, and 21.0% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9% for less than \$15,000, 6.1% for greater than \$50,000). Inability to see a doctor due to cost differed significantly by county, with a range of 7.4% in Franklin County to 17.5% in Power County.

#### **Cancer Screening**

Mammogram - 2014, 2016, 2018, 2020

Statewide, 69.1% of women aged 50–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (72.1% versus 36.7%). Mammography rates differed significantly by county, with a range in screening of 45.9% in Benewah County to 77.0% in Nez Perce County. In 2020, Idaho ranked 48<sup>th</sup> among states and the District of Columbia for mammography screening rates among women aged 50–74 and also 48<sup>th</sup> among ages 40+.

#### Pap Test - 2018, 2020

Statewide, 71.2% of women with an intact cervix and aged 21–65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.1% versus 52.6% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.7% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49<sup>th</sup> among states and the District of Columbia for Pap screening rate.

#### Colorectal Cancer Screening - 2018, 2020

Statewide, 67.9% of adults aged 50–75 reported being current for colorectal cancer screening.\*\* Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked 47<sup>th</sup> among states and the District of Columbia in the percentage of adults aged 50–75 and older who reported being up-to-date for colorectal cancer screening.

<sup>\*\*</sup> Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

### **Tobacco Use**

### Current Tobacco Use - 2016-2021

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.3% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 29.9% of persons aged 18-29, and 11.1% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (22.4%) than among Native Americans (40.0%). Tobacco use differed significantly by county, with a range of 5.4% in Madison County to 41.6% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

### **Other Cancer-Related**

### Healthy Weight by Body Mass Index - 2015-2021

Statewide, 32.1% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 32.5% of white non-Hispanics, compared to 28.2% of Hispanics and 24.6% of Native Americans, being in the healthy weight range. Males (25.5%) were significantly less likely to be in the healthy weight range than females (38.6%). BMI differed significantly by age of respondent, with 43.3% of persons aged 18–29, and 26.0% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 19.8% in Power County to 47.4% in Blaine County of adults being in the healthy weight range.

### Any Physical Activity - 2015-2021

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 78.7% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.3% of persons aged 18–29, and 72.3% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 64.3% in Clark County to 84.6% in Teton County.

Physical Activity Guidelines – 2011, 2013, 2015, 2017, 2019 Statewide, 21.9% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.3% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6% in Franklin County to 30.6% in Blaine County.

### Home Radon Testing - 2016, 2018, 2020

Statewide, 23.0% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.4% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.5% in Cassia County to 54.4% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006l and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.





# BLAINE COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016–2020 Cancer Mortality 2017–2021 BRFSS 2011–2021

### **RISK FACTORS AND INTERVENTIONS**

### **CANCER**

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/jama.2016.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

### Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

### **Smoking:**

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

### Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <a href="https://www.dietaryguidelines.gov">https://www.dietaryguidelines.gov</a>

### Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute
Cancer Information Services
1-800-4CANCER
<a href="https://www.cancer.gov/contact">https://www.cancer.gov/contact</a>

American Cancer Society <a href="https://www.cancer.org">https://www.cancer.org</a>

### **CANCER INCIDENCE 2016–2020**

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016–2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 693 cases of invasive cancer were diagnosed among Blaine County residents (Table 1).

**Table 1:** Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Blaine County and the State of Idaho, 2016–2020

Cancer Incidence 2016–2020	Blaine County	State of Idaho
All Sites/Types	693	45,610
Female Breast	114	6,687
Prostate	109	6,417
Lung & Bronchus	43	4,887
Colorectal	40	3,451

Table 3 (Cancer Incidence 2016–2020, Comparison between Blaine County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Blaine County. The table also shows the number of observed cases, person-

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Blaine County was 609.8 cases per 100,000 person-years per year during 2016–2020. Comparing this crude rate with the crude rate for the remainder of Idaho (518.8) gives an estimate of the relative burden of disease in Blaine County.

The age- and sex-adjusted incidence rate of invasive cancer in Blaine County, all sites combined, was 510.5 cases per 100,000 persons per year during 2016–2020. There were fewer cases of cancer in Blaine County (693) than expected (704.3) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

### **CANCER MORTALITY 2017–2021**

During 2017–2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 148 Blaine County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

**Table 2:** Overall and Cancer Mortality in Blaine County and the State of Idaho, 2017–2021

Mortality 2017–2021	Blaine County	State of Idaho
All Deaths	648	77,431
Cancer Deaths	148	15,121
% of All Deaths	22.8%	19.5%
Lung & Bronchus	16	2,961
Colorectal	13	1,319
Pancreas	10	1,190
Female Breast	10	1,086
Prostate	14	949

Table 4 (Cancer Mortality 2017–2021, Comparison between Blaine County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Blaine County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Blaine County, all sites combined, was 106.9 deaths per 100,000 persons per year during 2017–2021, compared with 168.8 for the remainder of the state. There were statistically significantly fewer cancer deaths in Blaine County (148) than expected (233.7) based upon rates in the remainder of the state (p<.001).

**Statistical Note:** Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

# TABLE 3: CANCER INCIDENCE 2016–2020 COMPARISON BETWEEN BLAINE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

Cancer   Sex	551.0 486.4 424.9 39.8 3 9.9 4 7.1 8.6 3 5.6 4 16.2 10.9 3 21.5 4 76.6 1.4 3 152.2 4 14.1 0.1 3 28.1 6.9
All Sites Combined   Total   693   113,644   609.8   510.5   704.3   0.688   44,917   8,658,18	518.8 551.0 3 486.4 4 24.9 39.8 3 9.9 4 7.1 8.6 3 5.6 4 16.2 1 10.9 3 21.5 4 76.6 1 1.4 3 152.2 4 14.1 0.1 3 28.1
All Sites Combined	551.0 486.4 424.9 39.8 3 9.9 4 7.1 8.6 3 5.6 4 16.2 10.9 3 21.5 4 76.6 1.4 3 152.2 4 14.1 0.1 3 28.1 6.9
All Sites Combined	3 486.4 4 24.9 39.8 9.9 4 7.1 8.6 3 5.6 4 16.2 10.9 3 21.5 4 76.6 1 1.4 3 152.2 4 14.1 0.1 3 28.1 6.9
Bladder	4 24.9 39.8 9.9 7.1 1 8.6 3 5.6 4 16.2 1 10.9 21.5 4 76.6 1 1.4 3 152.2 4 14.1 0.1 3 28.1
Bladder   Bladder   Bladder   Bladder   Female   5   56,989   42.1   33.7   28.3   0.482   1,727   4,339,92	39.8 9.9 7.1 8.6 1 16.2 1 10.9 3 21.5 4 76.6 1 1.4 3 152.2 4 14.1 0.1 3 28.1 6.9
Bladder	9.9 7.1 8.6 5.6 10.9 21.5 76.6 1.4 152.2 14.1 0.1 3.28.1 6.9
Brain - malignant Female Total September 113,644 September 114 September 113,644 September 113,644 September 113,644 September 113,644 September 114,000 September 113,644 September 114,000 September 114,000 September 115,000 September 115,000 September 114,000 September 115,000 September 114,000 S	7.1 8.6 5.6 10.2 10.9 3 21.5 4 76.6 1 1.4 3 152.2 4 14.1 0.1 3 28.1 6.9
Brain - malignant         Male Brain - malignant         3         56,989         5.3         4.5         5.7         0.362         372         4,339,92           Brain - malignant Brain and other CNS - non-malignant Breast         Male         7         56,989         12.3         10.5         7.3         1.000         473         4,339,92           Breast Breast         Male         -         56,989         12.3         10.5         7.3         1.000         473         4,318,26           Breast Breast         Male         -         56,989         12.3         10.5         7.3         1.000         473         4,318,26           Breast Breast         Male         -         56,989         -         -         0.9         0.775         59         4,339,92           Breast In situ         Total         122         113,644         19.4         15.8         19.6         0.645         1,217         8,658,18           Breast - in situ         Male         -         56,989         -         -         0.1         1.000         5         4,339,92	8.6 5.6 10.2 10.9 21.5 76.6 1.4 3.152.2 14.1 0.1 3.28.1 6.9
Brain and other CNS - non-malignant Breast         Total Total Interest Interes	1 16.2 1 10.9 3 21.5 76.6 1 1.4 1 152.2 4 14.1 0.1 3 28.1 8 6.9
Brain and other CNS - non-malignant Breain and other CNS - non-malignant Brain and other CNS - non-malignant Breast         Male Female         7         56,989 56,655 26.5         23.2 23.2         13.9 0.837         929 4,318,26         4,318,26           Breast Bre	1 10.9 3 21.5 4 76.6 1 1.4 152.2 3 152.2 1 0.1 3 28.1 3 6.9
Brain and other CNS - non-malignant         Female         15         56,655         26.5         23.2         13.9         0.837         929         4,318,26           Breast         Total         114         113,644         100.3         83.3         104.8         0.392         6,632         8,658,18           Breast         Male         -         56,989         -         -         0.9         0.775         59         4,339,92           Breast - in situ         Total         22         113,644         19.4         15.8         19.6         0.645         1,217         8,658,18           Breast - in situ         Male         -         56,989         -         -         0.1         1,000         5         4,318,26           Breast - in situ         Female         22         56,655         38.8         31.6         19.6         0.645         1,217         8,658,18           Breast - in situ         Female         22         56,655         38.8         31.6         19.6         0.645         1,217         8,658,18           Cervix         Female         4         56,655         7.1         6.4         4.4         1.000         300         4,318,26	21.5 4 76.6 1 1.4 3 152.2 4 14.1 1 0.1 3 28.1 6 9
Breast         Total         114         113,644         100.3         83.3         104.8         0.392         6,632         8,658,18           Breast         Male         -         56,989         -         -         0.9         0.775         59         4,339,92           Breast         Female         114         56,655         201.2         168.5         103.0         0.301         6,573         4,318,26           Breast - in situ         Total         22         113,644         19.4         15.8         19.6         0.645         1,217         8,658,18           Breast - in situ         Male         -         56,989         -         -         0.1         1,000         5         4,339,92           Breast - in situ         Female         22         56,655         38.8         31.6         19.6         0.638         1,212         4,318,26           Cervix         Female         4         56,655         7.1         6.4         4.4         1.000         300         4,318,26           Colorectal         Total         40         113,644         35.2         29.7         53.0         0.076         3,411         8,658,18           Colorectal	76.6 1 1.4 3 152.2 4 14.1 1 0.1 3 28.1 3 6.9
Breast         Male         -         56,989         -         -         0.9         0.775         59         4,339,92           Breast east in situ         Total         22         113,644         19.4         15.8         19.6         0.645         1,217         8,658,18           Breast in situ         Male         -         56,989         -         -         0.1         1,000         5         4,339,92           Breast in situ         Female         22         56,655         38.8         31.6         19.6         0.645         1,217         8,658,18           Cervix         Female         22         56,655         38.8         31.6         19.6         0.638         1,212         4,318,26           Cervix         Female         4         56,655         7.1         6.4         4.4         1.000         300         4,318,26           Colorectal         Total         40         113,644         35.2         29.7         53.0         0.076         3,411         8,658,18           Colorectal         Male         25         56,989         43.9         35.9         30.1         0.403         1,878         4,339,92           Colorectal         F	1 1.4 152.2 1 14.1 1 0.1 3 28.1 3 6.9
Breast         Female         114         56,655         201.2         168.5         103.0         0.301         6,573         4,318,26           Breast - in situ         Total         22         113,644         19.4         15.8         19.6         0.645         1,217         8,658,18           Breast - in situ         Male         -         56,989         -         -         0.1         1,000         5         4,338,26           Cervix         Female         22         56,655         38.8         31.6         19.6         0.638         1,212         4,318,26           Cervix         Female         4         56,655         7.1         6.4         4.4         1,000         300         4,318,26           Colorectal         Total         40         113,644         35.2         29.7         53.0         0.076         3,411         8,658,18           Colorectal         Male         25         56,989         43.9         35.9         30.1         0.403         1,878         4,339,92           Colorectal         Female         15         56,655         26.5         23.2         23.0         0.105         1,533         4,318,26           Corpus Uteri	3 152.2 4 14.1 1 0.1 3 28.1 3 6.9
Breast - in situ         Total         22         113,644         19.4         15.8         19.6         0.645         1,217         8,658,18           Breast - in situ         Male         -         56,989         -         -         0.1         1,000         5         4,339,92           Breast - in situ         Female         22         56,989         -         -         0.1         1,000         5         4,339,92           Cervix         Female         4         56,655         7.1         6.4         4.4         1,000         300         4,318,26           Colorectal         Total         40         113,644         35.2         29.7         53.0         0.076         3,411         8,658,18           Colorectal         Male         25         56,989         43.9         35.9         30.1         0.403         1,878         4,339,92           Colorectal         Female         15         56,655         26.5         23.2         23.0         0.105         1,533         4,318,26           Corpus Uteri         Female         16         56,655         28.2         23.2         21.0         0.323         1,314         4,318,26           Esophagus	14.1 0.1 3 28.1 3 6.9
Breast - in situ         Male         -         56,989         -         -         0.1         1.000         5         4,339,92           Breast - in situ         Female         22         56,655         38.8         31.6         19.6         0.638         1,212         4,318,26           Cervix         Female         4         56,655         7.1         6.4         4.4         1.000         300         4,318,26           Colorectal         Total         40         113,644         35.2         29.7         53.0         0.076         3,411         8,658,18           Colorectal         Male         25         56,989         43.9         35.9         30.1         0.403         1,878         4,339,92           Colorectal         Female         15         56,655         26.5         23.2         23.0         0.105         1,533         4,318,26           Corpus Uteri         Female         16         56,655         28.2         23.2         21.0         0.323         1,314         4,318,26           Esophagus         Total         7         113,644         6.2         5.1         7.9         0.931         499         8,658,18           Esophagus	3 28.1 3 6.9
Cervix         Female         4         56,655         7.1         6.4         4.4         1.000         300         4,318,26           Colorectal         Total         40         113,644         35.2         29.7         53.0         0.076         3,411         8,658,18           Colorectal         Male         25         56,989         43.9         35.9         30.1         0.403         1,878         4,339,92           Colorectal         Female         15         56,655         26.5         23.2         23.0         0.105         1,533         4,318,26           Corpus Uteri         Female         16         56,655         28.2         23.2         21.0         0.323         1,314         4,318,26           Esophagus         Total         7         113,644         6.2         5.1         7.9         0.931         499         8,658,18           Esophagus         Male         7         56,989         12.3         9.9         6.8         1.000         417         4,339,92           Esophagus         Female         -         56,655         -         -         1.3         0.563         82         4,318,26	6.9
Colorectal         Total         40         113,644         35.2         29.7         53.0         0.076         3,411         8,658,18           Colorectal         Male         25         56,989         43.9         35.9         30.1         0.403         1,878         4,339,92           Colorectal         Female         15         56,655         26.5         23.2         23.0         0.105         1,533         4,318,26           Corpus Uteri         Female         16         56,655         28.2         23.2         21.0         0.323         1,314         4,318,26           Esophagus         Total         7         113,644         6.2         5.1         7.9         0.931         499         8,658,18           Esophagus         Male         7         56,989         12.3         9.9         6.8         1.000         417         4,339,92           Esophagus         Female         -         56,655         -         -         1.3         0.563         82         4,318,26	
Colorectal         Male         25         56,989         43.9         35.9         30.1         0.403         1,878         4,339,92           Colorectal         Female         15         56,655         26.5         23.2         23.0         0.105         1,533         4,318,26           Corpus Uteri         Female         16         56,655         28.2         23.2         21.0         0.323         1,314         4,318,26           Esophagus         Total         7         113,644         6.2         5.1         7.9         0.931         499         8,658,18           Esophagus         Male         7         56,989         12.3         9.9         6.8         1.000         417         4,339,92           Esophagus         Female         -         56,655         -         -         1.3         0.563         82         4,318,26	+ı 394
Colorectal         Female         15         56,655         26.5         23.2         23.0         0.105         1,533         4,318,26           Corpus Uteri         Female         16         56,655         28.2         23.2         21.0         0.323         1,314         4,318,26           Esophagus         Total         7         113,644         6.2         5.1         7.9         0.931         499         8,658,18           Esophagus         Male         7         56,989         12.3         9.9         6.8         1.000         417         4,339,92           Esophagus         Female         -         56,655         -         -         1.3         0.563         82         4,318,26	
Corpus Uteri         Female         16         56,655         28.2         23.2         21.0         0.323         1,314         4,318,26           Esophagus         Total         7         113,644         6.2         5.1         7.9         0.931         499         8,658,18           Esophagus         Male         7         56,989         12.3         9.9         6.8         1.000         417         4,339,92           Esophagus         Female         -         56,655         -         -         1.3         0.563         82         4,318,26	
Esophagus         Total         7         113,644         6.2         5.1         7.9         0.931         499         8,658,18           Esophagus         Male         7         56,989         12.3         9.9         6.8         1.000         417         4,339,92           Esophagus         Female         -         56,655         -         -         1.3         0.563         82         4,318,26	
Esophagus         Male         7         56,989         12.3         9.9         6.8         1.000         417         4,339,92           Esophagus         Female         -         56,655         -         -         1.3         0.563         82         4,318,26	
	9.6
[Hodgkin Lymphoma   Total   2   113,644   1.8   1.7   2.9   0.915   208   8.658.18	
Hodgkin Lymphoma   Male   -   56,989   -   -   1.7   0.380   118   4,339,92 Hodgkin Lymphoma   Female   2   56,655   3.5   3.5   1.2   0.662   90   4,318,26	
Hodgkin Lymphoma         Female         2         56,655         3.5         3.5         1.2         0.662         90         4,318,26           Kidney and Renal Pelvis         Total         21         113,644         18.5         15.4         28.3         0.196         1,794         8,658,18	
Kidney and Renal Pelvis Male 10 56,989 17.5 14.3 18.9 0.040 << 1,172 4,339,92	
Kidney and Renal Pelvis Female 11 56,655 19.4 16.6 9.5 0.719 622 4,318,26	
Larynx Total 2 113,644 1.8 1.4 3.4 0.677 213 8,658,18	
Larynx   Male   1   56,989   1.8   1.4   2.6   0.528   159   4,339,92	
Larynx Female 1 56,655 1.8 1.5 0.9 1.000 54 4,318,26	
Leukemia Total 26 113,644 22.9 19.8 24.4 0.799 1,605 8,658,18	
Leukemia         Male         15         56,989         26.3         22.0         15.3         1.000         974         4,339,92           Leukemia         Female         11         56,655         19.4         17.3         9.3         0.656         631         4,318,26	
Leukemia         Female         11         56,655         19.4         17.3         9.3         0.656         631         4,318,26           Liver and Bile Duct         Total         10         113,644         8.8         7.2         13.1         0.481         819         8,658,18	
Liver and Bile Duct Male 8 56,989 14.0 11.2 9.6 0.767 582 4,339,92	
Liver and Bile Duct Female 2 56,655 3.5 3.0 3.6 0.590 237 4,318,26	
Lung and Bronchus Total 43 113,644 37.8 31.2 77.1 0.000 << 4,844 8,658,18	55.9
Lung and Bronchus   Male   25   56,989   43.9   34.7   40.3   0.013 <<   2,427   4,339,92	
Lung and Bronchus Female 18 56,655 31.8 27.1 37.1 0.001 << 2,417 4,318,26	
Melanoma of the Skin Total 89 113,644 78.3 66.9 43.9 0.000 >> 2,853 8,658,18	
Melanoma of the Skin         Male         52         56,989         91.2         75.1         27.3         0.000 >>         1,713         4,339,92           Melanoma of the Skin         Female         37         56,655         65.3         57.4         17.0         0.000 >>         1,140         4,318,26	
Myeloma   Total   16   113,644   14.1   11.7   10.9   0.176   692   8,658,18	
Myeloma   Male   11   56,989   19.3   15.4   7.1   0.208   430   4,339,92	
Myeloma   Female   5   56,655   8.8   7.6   4.0   0.735   262   4,318,26	6.1
Non-Hodgkin Lymphoma Total 27 113,644 23.8 20.0 29.8 0.694 1,913 8,658,18	22.1
Non-Hodgkin Lymphoma Male 16 56,989 28.1 23.0 17.8 0.783 1,113 4,339,92	
Non-Hodgkin Lymphoma Female 11 56,655 19.4 16.8 12.1 0.899 800 4,318,26	
Oral Cavity and Pharynx         Total         29         113,644         25.5         20.9         20.3         0.080         1,266         8,658,18           Oral Cavity and Pharynx         Male         23         56,989         40.4         32.5         14.9         0.061         913         4,339,92	
Oral Cavity and Pharynx   Male   23   56,969   40.4   32.5   14.9   0.061   913   4,359,92   Oral Cavity and Pharynx   Female   6   56,655   10.6   8.9   5.5   0.942   353   4,318,26	
Ovary Female 15 56,655 26.5 22.6 8.0 0.033 >> 518 4,318,26	
Pancreas Total 14 113,644 12.3 10.3 22.1 0.093 1,409 8,658,18	
Pancreas   Male   7   56,989   12.3   9.9   12.7   0.126   777   4,339,92	1 17.9
Pancreas Female 7 56,655 12.4 10.8 9.5 0.541 632 4,318,26	
Prostate Male 109 56,989 191.3 150.5 105.2 0.740 6,308 4,339,92	
Stomach         Total         4         113,644         3.5         3.0         7.2         0.314         463         8,658,18           Stomach         Male         2         56,989         3.5         2.8         5.0         0.252         307         4,339,92	
Stomach         Male         2         56,989         3.5         2.8         5.0         0.252         307         4,339,92           Stomach         Female         2         56,655         3.5         3.2         2.3         1.000         156         4,318,26	
Testis   Male   7   56,989   12.3   13.0   3.2   0.089   258   4,339,92	
Thyroid Total 15 113,644 13.2 12.0 17.4 0.674 1,205 8,658,18	
Thyroid Male 7 56,989 12.3 10.8 5.2 0.535 348 4,339,92	
Thyroid Female 8 56,655 14.1 13.0 12.2 0.281 857 4,318,26	
Pediatric Age 0 to 19 Total 6 27,113 22.1 22.3 4.6 0.623 415 2,433,41	
Pediatric Age 0 to 19 Male 2 13,885 14.4 14.7 2.4 1.000 221 1,242,62	
Pediatric Age 0 to 19   Female   4   13,228   30.2   30.1   2.2   0.349   194   1,190,78	5   17.8

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

<sup>2.</sup> Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

<sup>&</sup>quot;<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

### **TABLE 4: CANCER MORTALITY 2017–2021** COMPARISON BETWEEN BLAINE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

		Blaine County						Remainder of Idaho		
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	648	116,341	557.0	494.3	1,134.4	0.000 <<	76,782	8,872,374	865.4
All Causes of Death	Male	379	58,302	650.1	537.4	644.1	0.000 <<	40,677	4,453,566	913.4
All Causes of Death	Female	269	58,039	463.5	443.1	496.0	0.000 <<	36,105	4,418,808	817.1
All Malignant Cancers	Total	148	116,341	127.2	106.9	233.7	0.000 <<	14,973	8,872,374	168.8
All Malignant Cancers All Malignant Cancers	Male Female	89 59	58,302 58,039	152.7 101.7	121.5 89.3	133.1 102.9	0.000 <b>&lt;&lt;</b> 0.000 <b>&lt;&lt;</b>	8,087 6,886	4,453,566 4,418,808	181.6 155.8
Bladder	Total	4	116,341	3.4	3.0	7.3	0.300	485	8,872,374	5.5
Bladder	Male	3	58,302	5.1	4.2	6.1	0.290	375	4,453,566	8.4
Bladder	Female	1	58,039	1.7	1.6	1.6	1.000	110	4,418,808	2.5
Brain and Other Nervous System	Total	6	116,341	5.2	4.3	7.8	0.683	498	8,872,374	5.6
	Male	2	58,302	3.4	2.8	4.7	0.297	296	4,453,566	6.6
Brain and Other Nervous System	Female	4	58,039	6.9	5.9	3.1	0.745	202	4,418,808	4.6
Breast	Total	10	116,341	8.6	7.3	16.9	0.102	1,092	8,872,374	12.3
Breast	Male	-	58,302	-	-	0.3	1.000	16	4,453,566	0.4
Breast	Female	10	58,039	17.2	15.0	16.2	0.141	1,076	4,418,808	24.4
Cervix	Female	1	58,039	1.7	1.5	1.2	1.000	1 206	4,418,808	1.9
Colorectal Colorectal	Total Male	13 9	116,341 58,302	11.2 15.4	9.4 12.4	20.3 11.6	0.118 0.566	1,306 710	8,872,374 4,453,566	14.7 15.9
Colorectal	iviale Female	9	58,302 58,039	6.9	6.2	8.7	0.566	596	4,453,566 4,418,808	13.5
Corpus Uteri	Female	3	58,039	5.2	4.4	2.6	0.129	170	4,418,808	3.8
Esophagus	Total	4	116,341	3.4	2.8	7.6	0.256	473	8,872,374	5.3
Esophagus	Male	4	58,302	6.9	5.4	6.6	0.428	397	4,453,566	8.9
Esophagus	Female	-	58,039	-	-	1.1	0.640	76	4,418,808	1.7
Hodgkin Lymphoma	Total	-	116,341	-	-	0.4	1.000	29	8,872,374	0.3
Hodgkin Lymphoma	Male	-	58,302	-	-	0.2	1.000	14	4,453,566	0.3
Hodgkin Lymphoma	Female		58,039	-	-	0.2	1.000	15	4,418,808	0.3
Kidney	Total	2	116,341	1.7	1.4	6.0	0.125	383	8,872,374	4.3
Kidney	Male	1	58,302	1.7	1.4	4.0	0.187	241	4,453,566	5.4
Kidney	Female Total	1	58,039	1.7	1.6	2.1	0.780	142	4,418,808	3.2
Larynx Larynx	Male	-	116,341 58,302	-	-	1.1 1.0	0.652 0.772	71 58	8,872,374 4,453,566	0.8 1.3
Larynx	Female	_	58,039	_	_	0.2	1.000	13	4,418,808	0.3
Leukemia	Total	9	116,341	7.7	6.7	9.9	0.946	651	8,872,374	7.3
Leukemia	Male	6	58,302	10.3	8.3	6.2	1.000	380	4,453,566	8.5
Leukemia	Female	3	58,039	5.2	4.8	3.9	0.925	271	4,418,808	6.1
Liver and Bile Duct	Total	7	116,341	6.0	4.9	9.6	0.522	596	8,872,374	6.7
Liver and Bile Duct	Male	5	58,302	8.6	6.7	6.7	0.677	403	4,453,566	9.0
Liver and Bile Duct	Female	2	58,039	3.4	2.9	3.0	0.862	193	4,418,808	4.4
Lung and Bronchus	Total	16	116,341	13.8	11.3	46.9	0.000 <<	2,945	8,872,374	33.2
Lung and Bronchus	Male	7	58,302	12.0	9.4	26.0	0.000 <<	1,549	4,453,566	34.8
Lung and Bronchus Melanoma of the Skin	Female	9	58,039	15.5 3.4	13.4	21.2	0.005 <<	1,396	4,418,808	31.6
Melanoma of the Skin	Total Male	4 4	116,341 58,302	5.4 6.9	2.9 5.6	4.4 3.0	1.000 0.724	285 188	8,872,374 4,453,566	3.2 4.2
Melanoma of the Skin	Female	_ 4	58,039	- 0.9	3.0	1.5	0.724	97	4,418,808	2.2
Myeloma	Total	5	116,341	4.3	3.6	5.1	1.000	326	8,872,374	3.7
Myeloma	Male	4	58,302	6.9	5.4	3.2	0.805	192	4,453,566	4.3
Myeloma	Female	1	58,039	1.7	1.5	2.0	0.822	134	4,418,808	3.0
Non-Hodgkin Lymphoma	Total	4	116,341	3.4	2.9	8.7	0.131	565	8,872,374	6.4
Non-Hodgkin Lymphoma	Male	3	58,302	5.1	4.1	5.0	0.533	304	4,453,566	6.8
Non-Hodgkin Lymphoma	Female	1	58,039	1.7	1.6	3.8	0.223	261	4,418,808	5.9
Oral Cavity and Pharynx	Total	1	116,341	0.9	0.7	4.2	0.150	265	8,872,374	3.0
Oral Cavity and Pharynx	Male	1	58,302	1.7	1.3	3.1	0.369	186	4,453,566	4.2
Oral Cavity and Pharynx	Female		58,039	- 0.6	- 7 /	1.2	0.609	79	4,418,808	1.8
Ovary Pancreas	Female Total	5 10	58,039 116,341	8.6 8.6	7.4 7.1	5.3 18.8	1.000 0.040 <b>&lt;&lt;</b>	345 1,180	4,418,808 8,872,374	7.8 13.3
Pancreas	Male	6	58,302	10.3	8.1	10.6	0.040 <<	636	6,672,374 4,453,566	14.3
Pancreas	Female	4	58,039	6.9	5.9	8.3	0.192	544	4,418,808	12.3
Prostate	Male	14	58,302	24.0	19.3	15.2	0.100	935	4,453,566	21.0
Stomach	Total	-	116,341	-	-	3.0	0.095	198	8,872,374	2.2
Stomach	Male	-	58,302	-	_	2.0	0.276	121	4,453,566	2.7
Stomach	Female	_	58,039	_	_	1.1	0.666	77	4,418,808	1.7
			ne number of cases r						., ,	

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

<sup>2.</sup> Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

### Cancer Screening and Risk Factor Prevalence Estimates, 2011–2021

	State of								Blaine
Measure	Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	County
Access to Care									
Have Health Insurance, Age <65 (2015–2021)	83.1%	82.8%	85.1%	77.2%	85.8%	78.9%	85.4%	85.4%	79.5%
Not See Doctor Due to Cost in Past Year (2015–2021)	12.6%	11.4%	11.8%	14.5%	12.4%	12.3%	11.8%	12.9%	11.7%
Cancer Screening									
Mammogram Past 2 Years, Age 50–74 (2014, 2016, 2018, 2020)	69.1%	67.0%	73.8%	68.2%	73.2%	64.8%	64.5%	67.1%	73.6%
Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020)	71.2%	73.6%	73.6%	70.8%	72.9%	69.1%	69.5%	65.9%	
Colorectal Cancer Screening, Age 50–75 (2018, 2020)	67.9%	66.9%	73.6%	71.4%	70.6%	61.7%	61.5%	64.7%	74.9%
Tobacco Use									
Current Tobacco User (2016–2021)	22.3%	26.7%	23.1%	23.6%	21.8%	21.4%	22.7%	16.9%	17.9%
Other Cancer-Related									
Healthy Weight by Body Mass Index, Age 20+ (2015–2021)	32.1%	32.8%	31.7%	27.9%	36.1%	29.8%	27.9%	31.9%	47.4%
Any Physical Activity Besides Job Past 30 Days (2015-2021)	78.7%	79.2%	78.1%	74.5%	83.2%	73.4%	76.3%	79.7%	80.9%
Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019)	21.9%	22.8%	19.4%	20.0%	25.2%	19.5%	20.4%	20.2%	30.6%
Home Ever Tested for Radon (2016, 2018, 2020)	23.0%	30.9%	18.2%	16.9%	25.1%	19.9%	23.0%	21.8%	54.4%

### **Access to Care**

### Have Health Insurance – 2015–2021

Statewide, 83.1% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 86.0% of white non-Hispanics, compared to 64.8% of Hispanics and 83.3% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3%) than English-speaking respondents (84.2%). Health care coverage differed significantly by age of respondent, with 79.8% of persons aged 18–29, and 87.8% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 62.1% in Adams County to 91.6% in Oneida County having health insurance.

### Not See Doctor Due to Cost in Past Year - 2015-2021

Statewide, 12.6% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (11.5% of white non-Hispanics, 19.2% of Hispanics, and 21.0% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9% for less than \$15,000, 6.1% for greater than \$50,000). Inability to see a doctor due to cost differed significantly by county, with a range of 7.4% in Franklin County to 17.5% in Power County.

### **Cancer Screening**

Mammogram - 2014, 2016, 2018, 2020

Statewide, 69.1% of women aged 50–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (72.1% versus 36.7%). Mammography rates differed significantly by county, with a range in screening of 45.9% in Benewah County to 77.0% in Nez Perce County. In 2020, Idaho ranked 48<sup>th</sup> among states and the District of Columbia for mammography screening rates among women aged 50–74 and also 48<sup>th</sup> among ages 40+.

### Pap Test - 2018, 2020

Statewide, 71.2% of women with an intact cervix and aged 21–65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.1% versus 52.6% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.7% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49<sup>th</sup> among states and the District of Columbia for Pap screening rate.

### Colorectal Cancer Screening – 2018, 2020

Statewide, 67.9% of adults aged 50–75 reported being current for colorectal cancer screening.\*\* Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked 47<sup>th</sup> among states and the District of Columbia in the percentage of adults aged 50–75 and older who reported being up-to-date for colorectal cancer screening.

<sup>\*\*</sup> Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

### **Tobacco Use**

### Current Tobacco Use - 2016-2021

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.3% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 29.9% of persons aged 18-29, and 11.1% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (22.4%) than among Native Americans (40.0%). Tobacco use differed significantly by county, with a range of 5.4% in Madison County to 41.6% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

### **Other Cancer-Related**

### Healthy Weight by Body Mass Index - 2015-2021

Statewide, 32.1% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 32.5% of white non-Hispanics, compared to 28.2% of Hispanics and 24.6% of Native Americans, being in the healthy weight range. Males (25.5%) were significantly less likely to be in the healthy weight range than females (38.6%). BMI differed significantly by age of respondent, with 43.3% of persons aged 18–29, and 26.0% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 19.8% in Power County to 47.4% in Blaine County of adults being in the healthy weight range.

### Any Physical Activity - 2015-2021

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 78.7% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.3% of persons aged 18–29, and 72.3% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 64.3% in Clark County to 84.6% in Teton County.

Physical Activity Guidelines – 2011, 2013, 2015, 2017, 2019 Statewide, 21.9% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.3% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6% in Franklin County to 30.6% in Blaine County.

### Home Radon Testing - 2016, 2018, 2020

Statewide, 23.0% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.4% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.5% in Cassia County to 54.4% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006l and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.





# BOISE COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016–2020 Cancer Mortality 2017–2021 BRFSS 2011–2021

### RISK FACTORS AND INTERVENTIONS

### **CANCER**

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/jama.2016.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

### Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

### **Smoking:**

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

### Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <a href="https://www.dietaryguidelines.gov">https://www.dietaryguidelines.gov</a>

### Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute
Cancer Information Services
1-800-4CANCER
<a href="https://www.cancer.gov/contact">https://www.cancer.gov/contact</a>

American Cancer Society <a href="https://www.cancer.org">https://www.cancer.org</a>

### **CANCER INCIDENCE 2016–2020**

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016–2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 279 cases of invasive cancer were diagnosed among Boise County residents (Table 1).

**Table 1:** Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Boise County and the State of Idaho, 2016–2020

Cancer Incidence 2016–2020	Boise County	State of Idaho
All Sites/Types	279	45,610
Female Breast	30	6,687
Prostate	61	6,417
Lung & Bronchus	31	4,887
Colorectal	11	3,451

Table 3 (Cancer Incidence 2016–2020, Comparison between Boise County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Boise County. The table also shows the number of observed cases, person-

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Boise County was 731.8 cases per 100,000 person-years per year during 2016–2020. Comparing this crude rate with the crude rate for the remainder of Idaho (519.0) gives an estimate of the relative burden of disease in Boise County.

The age- and sex-adjusted incidence rate of invasive cancer in Boise County, all sites combined, was 481.9 cases per 100,000 persons per year during 2016–2020. There were fewer cases of cancer in Boise County (279) than expected (300.5) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

### **CANCER MORTALITY 2017–2021**

During 2017–2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 61 Boise County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

**Table 2:** Overall and Cancer Mortality in Boise County and the State of Idaho, 2017–2021

Mortality 2017–2021	Boise County	State of Idaho
All Deaths	342	77,431
Cancer Deaths	61	15,121
% of All Deaths	17.8%	19.5%
Lung & Bronchus	17	2,961
Colorectal	3	1,319
Pancreas	8	1,190
Female Breast	7	1,086
Prostate	2	949

Table 4 (Cancer Mortality 2017–2021, Comparison between Boise County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Boise County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Boise County, all sites combined, was 104.9 deaths per 100,000 persons per year during 2017–2021, compared with 168.3 for the remainder of the state. There were statistically significantly fewer cancer deaths in Boise County (61) than expected (97.9) based upon rates in the remainder of the state (p<.001).

**Statistical Note:** Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

# TABLE 3: CANCER INCIDENCE 2016–2020 COMPARISON BETWEEN BOISE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

Cancer   Site/Type   Sex   Cases   Person   Crude   Rate (1)   Rate (1,2)   Cases (3)   P-Value (4)   Cases   Person   Years   Rate (1)   Rate (1,2)   Cases (3)   P-Value (4)   Cases   Person   Years   Person   Person   Years   Person   Person   Years   Person   Years   Person   Person   Years   Person   Person   Person   Years   Person   Person   Years   Person   Years   Person   Person   Years   Person   Person   Person   Years   Person   Years   Person   Years   Person   Person   Person   Years   Person   Person   Person   Person   Person	Crude Rate (1) 519.0 551.0 486.9 24.8 39.5 7.1 8.5 5.7 16.2 10.9 21.6 76.9 1.3 152.8
All Sites Combined	519.0 551.0 486.9 24.8 39.5 9.9 7.1 8.5 5.7 16.2 10.9 21.6 76.9 1.3 152.8
All Sites Combined   Female   170   19,672   864.2   511.9   183.0   0.357   24,119   4,377,238   590.7   427.5   124.1   0.185   21,212   4,356,464   22   38,126   57.7   37.4   14.5   0.082   2,162   8,733,702   37.28   37.4   37.28   37.	551.0 486.9 24.8 39.5 9.9 7.1 8.5 5.7 16.2 10.9 21.6 76.9 1.3 152.8
All Sites Combined	486.9 24.8 39.5 9.9 7.1 8.5 5.7 16.2 10.9 21.6 76.9 1.3 152.8
Bladder	24.8 39.5 9.9 7.1 8.5 5.7 16.2 10.9 21.6 76.9 1.3 152.8
Bladder   Bladder   Female   21   19,672   106.8   61.9   13.4   0.066   1,730   4,377,238   13.4   13.4   13.4   13.4   13.4   13.4   13.4   13.4   13.4   13.4   13.4   13.4   13.4   13.5	39.5 9.9 7.1 8.5 5.7 16.2 10.9 21.6 76.9 1.3 152.8
Bladder	7.1 8.5 5.7 16.2 10.9 21.6 76.9 1.3 152.8
Brain - malignant   Brain - malignant   Female   -   18,454   -   -   1.4   0.507   250   4,356,464     Brain and other CNS - non-malignant   Female   4   19,672   20.3   13.8   3.1   0.972   476   4,377,238     Breast   Female   4   18,454   21.7   16.4   5.3   0.795   940   4,356,464     Breast   Total   30   38,126   78.7   52.1   44.3   0.030   6,716   8,733,702     Breast   Female   30   18,454   162.6   114.0   40.2   0.115   6,657   4,356,464     Breast - in situ   Total   12   38,126   31.5   20.3   8.3   0.0267   1,227   8,733,702     Breast - in situ   Female   1   19,672   5.1   3.8   0.0   0.047 >>   4   4,377,238     Breast - in situ   Female   11   18,454   59.6   40.3   7.7   0.303   1,223   4,356,464     Cervix   Female   1   18,454   5.4   4.6   1.5   1.000   303   4,356,464     Colorectal   Total   11   38,126   28.9   19.5   22.2   0.013   <   3,440   8,733,702     Colorectal   Female   6   18,454   32.5   24.2   8.8   0.457   1,542   4,356,464     Corpus Uteri   Female   7   18,454   37.9   25.2   8.4   0.789   1,323   4,356,464     Corpus Uteri   Female   7   18,454   37.9   25.2   8.4   0.789   1,323   4,356,464     Corpus Uteri   Female   7   18,454   37.9   25.2   8.4   0.789   1,323   4,356,464     Corpus Uteri   Female   7   18,454   37.9   25.2   8.4   0.789   1,323   4,356,464     Corpus Uteri   Female   7   18,454   37.9   25.2   8.4   0.789   1,323   4,356,464     Corpus Uteri   Female   7   18,454   37.9   25.2   8.4   0.789   1,323   4,356,464     Corpus Uteri   Female   7   18,454   37.9   25.2   8.4   0.789   1,323   4,356,464     Corpus Uteri   Female   7   18,454   37.9   25.2   8.4   0.789   1,323   4,356,464     Corpus Uteri   Female   7   18,454   37.9   25.2   8.4   0.789   1,323   4,356,464     Corpus Uteri	8.5 5.7 16.2 10.9 21.6 76.9 1.3 152.8
Brain - malignant   Female   -   18,454   -   -   1.4   0.507   250   4,356,464	5.7 16.2 10.9 21.6 76.9 1.3 152.8
Brain and other CNS - non-malignant Breast         Total SO SS, 126         4 19,672         20.3 13.8 3.1 0.772         476 4,377,238         4,377,238         4,377,238         52.1 44.3 0.030 <	16.2 10.9 21.6 76.9 1.3 152.8
Brain and other CNS - non-malignant         Male         4         19,672         20.3         13.8         3.1         0.772         476         4,377,238           Brain and other CNS - non-malignant         Female         4         18,454         21.7         16.4         5.3         0.795         940         4,356,464           Breast         Total         30         38,126         78.7         52.1         44.3         0.030 <	10.9 21.6 76.9 1.3 152.8
Breast         Total         30         38,126         78.7         52.1         44.3         0.030 <         6,716         8,733,702           Breast         Male         -         19,672         -         -         0.4         1.000         59         4,377,238           Breast Female         30         18,454         162.6         114.0         40.2         0.115         6,657         4,356,464           Breast - in situ         Male         1         19,672         5.1         3.8         0.0         0.047         >         4,377,238           Breast - in situ         Female         1         18,454         59.6         40.3         7.7         0.303         1,223         4,356,464           Cervix         Female         1         18,454         5.4         4.6         1.5         1,000         303         4,356,464           Colorectal         Total         11         38,126         28.9         19.5         22.2         0.013 <	76.9 1.3 152.8
Breast         Male Female         -         19,672 19,672 19,672         -         -         0.4 1,000 19,000         59 4,377,238         4,377,238         4,377,238         4,377,238         4,377,238         4,377,238         4,377,238         4,377,238         4,377,238         8,3 0,267 19,227 19,227 19,233,702         8,73	1.3 152.8
Breast         Female         30         18,454         162.6         114.0         40.2         0.115         6,657         4,356,464           Breast - in situ         Total         12         38,126         31.5         20.3         8.3         0.267         1,227         8,733,702           Breast - in situ         Male         1         19,672         5.1         3.8         0.0         0.047 >>         4         4,377,238           Breast - in situ         Female         11         18,454         59.6         40.3         7.7         0.303         1,223         4,356,464           Cervix         Female         1         18,454         5.4         4.6         1.5         1.000         303         4,356,464           Colorectal         Total         11         38,126         28.9         19.5         22.2         0.013 <<	152.8
Breast - in situ         Total         12         38,126         31.5         20.3         8.3         0.267         1,227         8,733,702           Breast - in situ         Male         1         19,672         5.1         3.8         0.0         0.047 >>         4         4,377,238           Breast - in situ         Female         11         18,454         59.6         40.3         7.7         0.303         1,223         4,356,464           Cervix         Female         1         18,454         5.4         4.6         1.5         1.000         303         4,356,464           Colorectal         Total         11         38,126         28.9         19.5         22.2         0.013 <<	
Breast - in situ         Male         1         19,672         5.1         3.8         0.0         0.047 >>         4         4,377,238           Breast - in situ         Female         11         18,454         59.6         40.3         7.7         0.303         1,223         4,356,464           Cervix         Female         1         18,454         5.4         4.6         1.5         1.000         303         4,356,464           Colorectal         Total         11         38,126         28.9         19.5         22.2         0.013 <<	
Cervix         Female         1         18,454         5.4         4.6         1.5         1.000         303         4,356,464           Colorectal         Total         11         38,126         28.9         19.5         22.2         0.013 <	0.1
Colorectal         Total         11         38,126         28.9         19.5         22.2         0.013 <         3,440         8,733,702           Colorectal         Male         5         19,672         25.4         15.7         13.8         0.013 <	28.1
Colorectal         Male         5         19,672         25.4         15.7         13.8         0.013 <         1,898         4,377,238           Colorectal         Female         6         18,454         32.5         24.2         8.8         0.457         1,542         4,356,464           Corpus Uteri         Female         7         18,454         37.9         25.2         8.4         0.789         1,323         4,356,464	7.0
Colorectal         Female         6         18,454         32.5         24.2         8.8         0.457         1,542         4,356,464           Corpus Uteri         Female         7         18,454         37.9         25.2         8.4         0.789         1,323         4,356,464	39.4 43.4
Corpus Uteri Female 7 18,454 37.9 25.2 8.4 0.789 1,323 4,356,464	35.4
T. 1 7 00 400 401 447 04 0440 1 400 0 000 000	30.4
Esophagus Total 7 38,126 18.4 11.7 3.4 0.119 499 8,733,702	5.7
Esophagus   Male   6   19,672   30.5   17.8   3.2   0.215   418   4,377,238   Esophagus   Female   1   18,454   5.4   3.7   0.5   0.788   81   4,356,464	9.5 1.9
Hodgkin Lymphoma Total 2 38,126 5.2 4.7 1.0 0.539 208 8,733,702	2.4
Hodgkin Lymphoma Male - 19,672 0.6 1.000 118 4,377,238	2.7
Hodgkin Lymphoma   Female   2   18,454   10.8   10.5   0.4   0.120   90   4,356,464	2.1
Kidney and Renal Pelvis Total 8 38,126 21.0 13.9 11.9 0.323 1,807 8,733,702	20.7
Kidney and Renal Pelvis         Male         5         19,672         25.4         15.6         8.6         0.282         1,177         4,377,238           Kidney and Renal Pelvis         Female         3         18,454         16.3         11.8         3.7         0.998         630         4,356,464	26.9 14.5
Larynx Total - 38,126 1.5 0.444 215 8,733,702	2.5
Larynx Male - 19,672 1.3 0.568 160 4,377,238	3.7
Larynx Female - 18,454 0.3 1.000 55 4,356,464	1.3
Leukemia         Total         10         38,126         26.2         18.4         10.1         1.000         1,621         8,733,702           Leukemia         Male         6         19,672         30.5         19.5         6.9         0.922         983         4,377,238	18.6
Leukemia         Male         6         19,672         30.5         19.5         6.9         0.922         983         4,377,238           Leukemia         Female         4         18,454         21.7         16.7         3.5         0.926         638         4,356,464	22.5 14.6
Liver and Bile Duct Total 7 38,126 18.4 11.4 5.8 0.723 822 8,733,702	9.4
Liver and Bile Duct   Male   6   19,672   30.5   17.3   4.6   0.635   584   4,377,238	13.3
Liver and Bile Duct Female 1 18,454 5.4 3.8 1.4 1.000 238 4,356,464	5.5
Lung and Bronchus         Total         31         38,126         81.3         51.4         33.5         0.747         4,856         8,733,702           Lung and Bronchus         Male         12         19,672         61.0         34.5         19.4         0.103         2,440         4,377,238	55.6 55.7
Lung and Bronchus Female 19 18,454 103.0 72.8 14.5 0.291 2,446 4,357,236	55.5
Melanoma of the Skin Total 21 38,126 55.1 38.1 18.4 0.607 2,921 8,733,702	33.4
Melanoma of the Skin   Male   10   19,672   50.8   31.6   12.7   0.559   1,755   4,377,238	40.1
Melanoma of the Skin Female 11 18,454 59.6 45.2 6.5 0.135 1,166 4,356,464	26.8
Myeloma         Total         3         38,126         7.9         5.1         4.8         0.602         705         8,733,702           Myeloma         Male         3         19,672         15.3         8.9         3.4         1.000         438         4,377,238	8.1 10.0
Myeloma   Male   3   19,072   15.5   6.9   3.4   1.000   436   4,377,236   Myeloma   Female   -   18,454   -   -   1.6   0.413   267   4,356,464	6.1
Nón-Hodgkin Lymphoma Total 14 38,126 36.7 24.5 12.6 0.763 1,926 8,733,702	22.1
Non-Hodgkin Lymphoma   Male   5   19,672   25.4   15.6   8.2   0.344   1,124   4,377,238	25.7
Non-Hodgkin Lymphoma Female 9 18,454 48.8 35.5 4.7 0.098 802 4,356,464	18.4
Oral Cavity and Pharynx         Total         12         38,126         31.5         19.8         8.9         0.376         1,283         8,733,702           Oral Cavity and Pharynx         Male         11         19,672         55.9         32.7         7.1         0.214         925         4,377,238	14.7 21.1
Oral Cavity and Pharynx   Female   1   18,454   5.4   3.8   2.2   0.718   358   4,356,464	8.2
Ovary Female 2 18,454 10.8 7.8 3.1 0.783 531 4,356,464	12.2
Pancreas Total 9 38,126 23.6 15.4 9.5 1.000 1,414 8,733,702	16.2
Pancreas         Male         6         19,672         30.5         17.8         6.0         1.000         778         4,377,238           Pancreas         Female         3         18,454         16.3         11.9         3.7         0.998         636         4,356,464	17.8
Pancreas         Female         3         18,454         16.3         11.9         3.7         0.998         636         4,356,464           Prostate         Male         61         19,672         310.1         170.5         52.0         0.239         6,356         4,377,238	14.6 145.2
Stomach Total 6 38,126 15.7 10.6 3.0 0.166 461 8,733,702	5.3
Stomach   Male   4   19,672   20.3   12.1   2.3   0.401   305   4,377,238	7.0
Stomach         Female         2         18,454         10.8         8.5         0.8         0.415         156         4,356,464	3.6
Testis Male - 19,672 1.0 0.772 265 4,377,238	6.1
Thyroid Total 8 38,126 21.0 17.2 6.4 0.637 1,212 8,733,702	13.9
Thyroid Male 4 19,672 20.3 15.0 2.1 0.338 351 4,377,238 Thyroid Female 4 18,454 21.7 18.4 4.3 1.000 861 4,356,464	8.0 19.8
Pediatric Age 0 to 19   Total   5   6,998   71.4   70.9   1.2   0.015 >>   416   2,453,525	17.0
Pediatric Age 0 to 19 Male 1 3,727 26.8 27.2 0.7 0.957 222 1,252,783	17.7
Pediatric Age 0 to 19 Female 4 3,271 122.3 118.5 0.5 0.005 >> 194 1,200,742	

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

<sup>2.</sup> Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

<sup>&</sup>quot;<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

### **TABLE 4: CANCER MORTALITY 2017–2021** COMPARISON BETWEEN BOISE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Во	ise County				Re	mainder of Idah	0
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	342	39,121	874.2	645.8	456.2	0.000 <<	77,088	8,949,594	861.4
All Causes of Death	Male	214	20,168	1,061.1	690.5	281.8	0.000 <<	40,842	4,491,700	909.3
All Causes of Death	Female	128	18,953	675.4	570.4	182.4	0.000 <<	36,246	4,457,894	813.1
All Malignant Cancers	Total	61	39,121	155.9	104.9	97.9	0.000 <<	15,060	8,949,594	168.3
All Malignant Cancers	Male	30	20,168	148.8	89.0	61.2	0.000 <<	8,146	4,491,700	181.4
All Malignant Cancers	Female	31	18,953	163.6	123.1	39.1	0.221	6,914	4,457,894	155.1
Bladder	Total	3	39,121	7.7	5.5	3.0	1.000	486	8,949,594	5.4
Bladder	Male	2	20,168	9.9	6.2	2.7	0.991	376	4,491,700	8.4
Bladder Brain and Other Nervous System	Female Total	1	18,953 39,121	5.3 2.6	4.3 1.7	0.6 3.3	0.876 0.327	110 503	4,457,894 8,949,594	2.5 5.6
Brain and Other Nervous System	Male	1	20,168	5.0	3.1	2.1	0.327	297	4,491,700	6.6
Brain and Other Nervous System	Female	_ '	18,953	5.0	-	1.2	0.594	206	4.457.894	4.6
Breast	Total	7	39,121	17.9	12.2	7.0	1.000	1,095	8,949,594	12.2
Breast	Male	-	20,168	-	-	0.1	1.000	16	4,491,700	0.4
Breast	Female	7	18,953	36.9	27.5	6.2	0.842	1,079	4,457,894	24.2
Cervix	Female	1	18,953	5.3	4.1	0.4	0.724	82	4,457,894	1.8
Colorectal	Total	3	39,121	7.7	5.2	8.4	0.064	1,316	8,949,594	14.7
Colorectal	Male	2	20,168	9.9	6.1	5.2	0.210	717	4,491,700	16.0
Colorectal	Female	1	18,953	5.3	4.1	3.3	0.322	599	4,457,894	13.4
Corpus Uteri	Female Total	- 3	18,953	7.7	4.9	1.1 3.2	0.696 1.000	173 474	4,457,894 8,949,594	3.9 5.3
Esophagus Esophagus	Male	2	39,121 20,168	9.9	4.9 5.8	3.2	0.808	399	4,491,700	8.9
Esophagus	Female	1	18,953	5.3	4.0	0.4	0.694	75	4,457,894	1.7
Hodgkin Lymphoma	Total	_ '	39,121	-		0.2	1.000	29	8,949,594	0.3
Hodgkin Lymphoma	Male	_	20,168	_	-	0.1	1.000	14	4,491,700	0.3
Hodgkin Lymphoma	Female	-	18,953	-	-	0.1	1.000	15	4,457,894	0.3
Kidney	Total	-	39,121	-	-	2.5	0.157	385	8,949,594	4.3
Kidney	Male	-	20,168	-	-	1.9	0.312	242	4,491,700	5.4
Kidney	Female	-	18,953	-	-	0.8	0.909	143	4,457,894	3.2
Larynx	Total	-	39,121	-	-	0.5	1.000	71	8,949,594	0.8
Larynx	Male	-	20,168	-	-	0.4	1.000 1.000	58	4,491,700	1.3 0.3
Larynx Leukemia	Female Total	-	18,953 39,121	-	-	0.1 4.0	0.035 <<	13 660	4,457,894 8,949,594	7.4
Leukemia	Male	_	20,168	_	_	2.8	0.035	386	4,491,700	8.6
Leukemia	Female	_	18,953	_	_	1.4	0.489	274	4,457,894	6.1
Liver and Bile Duct	Total	4	39,121	10.2	6.4	4.2	1.000	599	8,949,594	6.7
Liver and Bile Duct	Male	3	20,168	14.9	8.5	3.2	1.000	405	4,491,700	9.0
Liver and Bile Duct	Female	1	18,953	5.3	3.8	1.2	1.000	194	4,457,894	4.4
Lung and Bronchus	Total	17	39,121	43.5	28.2	19.9	0.615	2,944	8,949,594	32.9
Lung and Bronchus	Male	7	20,168	34.7	19.8	12.2	0.165	1,549	4,491,700	34.5
Lung and Bronchus	Female	10	18,953	52.8	39.0	8.0	0.572	1,395	4,457,894	31.3
Melanoma of the Skin	Total Male	2 2	39,121 20,168	5.1 9.9	3.5	1.8	1.000 0.813	287	8,949,594 4,491,700	3.2 4.2
Melanoma of the Skin Melanoma of the Skin	riviale Female		18,953	9.9	6.1	1.4 0.5	1.000	190 97	4,491,700	2.2
Myeloma	Total	2	39,121	5.1	3.5	2.1	1.000	329	8,949,594	3.7
Myeloma	Male	1	20,168	5.0	2.9	1.5	1.000	195	4,491,700	4.3
Myeloma	Female	1	18,953	5.3	4.1	0.7	1.000	134	4,457,894	3.0
Non-Hodgkin Lymphoma	Total	2	39,121	5.1	3.5	3.6	0.612	567	8,949,594	6.3
Non-Hodgkin Lymphoma	Male	1	20,168	5.0	3.0	2.2	0.686	306	4,491,700	6.8
Non-Hodgkin Lymphoma	Female	1	18,953	5.3	4.2	1.4	1.000	261	4,457,894	5.9
Oral Cavity and Pharynx	Total	-	39,121	-	-	1.8	0.327	266	8,949,594	3.0
Oral Cavity and Pharmy	Male	-	20,168	-	-	1.5	0.462	187	4,491,700	4.2
Oral Cavity and Pharynx	Female	-	18,953	10.0	- 7.0	0.5	1.000	79	4,457,894	1.8
Ovary Pancreas	Female Total	2 8	18,953 39,121	10.6 20.4	7.6 13.2	2.1 8.0	1.000 1.000	348 1,182	4,457,894 8,949,594	7.8 13.2
Pancreas	Male	o 4	20,168	19.8	11.4	5.0	0.894	638	6,949,594 4,491,700	14.2
Pancreas	Female	4	18,953	21.1	15.4	3.2	0.783	544	4,457,894	12.2
Prostate	Male	2	20,168	9.9	6.1	6.9	0.765	947	4,491,700	21.1
Stomach	Total	-	39,121	-	-	1.2	0.581	198	8,949,594	2.2
Stomach	Male	-	20,168	-	-	0.9	0.823	121	4,491,700	2.7
Stomach	Female	-	18,953	-	-	0.4	1.000	77	4,457,894	1.7
		o overcoood so th	ne number of cases i	100 000	none per veer (r	noroon vooro)	-		*	

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

<sup>2.</sup> Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

### Cancer Screening and Risk Factor Prevalence Estimates, 2011–2021

	State of								Boise
Measure	Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	County
Access to Care									
Have Health Insurance, Age <65 (2015–2021)	83.1%	82.8%	85.1%	77.2%	85.8%	78.9%	85.4%	85.4%	81.1%
Not See Doctor Due to Cost in Past Year (2015–2021)	12.6%	11.4%	11.8%	14.5%	12.4%	12.3%	11.8%	12.9%	9.6%
Cancer Screening									
Mammogram Past 2 Years, Age 50–74 (2014, 2016, 2018, 2020)	69.1%	67.0%	73.8%	68.2%	73.2%	64.8%	64.5%	67.1%	
Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020)	71.2%	73.6%	73.6%	70.8%	72.9%	69.1%	69.5%	65.9%	
Colorectal Cancer Screening, Age 50–75 (2018, 2020)	67.9%	66.9%	73.6%	71.4%	70.6%	61.7%	61.5%	64.7%	
Tobacco Use									
Current Tobacco User (2016–2021)	22.3%	26.7%	23.1%	23.6%	21.8%	21.4%	22.7%	16.9%	18.1%
Other Cancer-Related									
Healthy Weight by Body Mass Index, Age 20+ (2015–2021)	32.1%	32.8%	31.7%	27.9%	36.1%	29.8%	27.9%	31.9%	32.2%
Any Physical Activity Besides Job Past 30 Days (2015-2021)	78.7%	79.2%	78.1%	74.5%	83.2%	73.4%	76.3%	79.7%	74.3%
Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019)	21.9%	22.8%	19.4%	20.0%	25.2%	19.5%	20.4%	20.2%	22.3%
Home Ever Tested for Radon (2016, 2018, 2020)	23.0%	30.9%	18.2%	16.9%	25.1%	19.9%	23.0%	21.8%	28.5%

### **Access to Care**

### Have Health Insurance - 2015-2021

Statewide, 83.1% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 86.0% of white non-Hispanics, compared to 64.8% of Hispanics and 83.3% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3%) than English-speaking respondents (84.2%). Health care coverage differed significantly by age of respondent, with 79.8% of persons aged 18–29, and 87.8% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 62.1% in Adams County to 91.6% in Oneida County having health insurance.

### Not See Doctor Due to Cost in Past Year – 2015–2021

Statewide, 12.6% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (11.5% of white non-Hispanics, 19.2% of Hispanics, and 21.0% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9% for less than \$15,000, 6.1% for greater than \$50,000). Inability to see a doctor due to cost differed significantly by county, with a range of 7.4% in Franklin County to 17.5% in Power County.

### **Cancer Screening**

<u>Mammogram</u> – 2014, 2016, 2018, 2020

Statewide, 69.1% of women aged 50–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (72.1% versus 36.7%). Mammography rates differed significantly by county, with a range in screening of 45.9% in Benewah County to 77.0% in Nez Perce County. In 2020, Idaho ranked 48th among states and the District of Columbia for mammography screening rates among women aged 50–74 and also 48th among ages 40+.

### Pap Test - 2018, 2020

Statewide, 71.2% of women with an intact cervix and aged 21–65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.1% versus 52.6% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.7% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49<sup>th</sup> among states and the District of Columbia for Pap screening rate.

### Colorectal Cancer Screening – 2018, 2020

Statewide, 67.9% of adults aged 50–75 reported being current for colorectal cancer screening.\*\* Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked 47<sup>th</sup> among states and the District of Columbia in the percentage of adults aged 50–75 and older who reported being up-to-date for colorectal cancer screening.

<sup>\*\*</sup> Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

### **Tobacco Use**

### Current Tobacco Use - 2016-2021

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.3% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 29.9% of persons aged 18-29, and 11.1% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (22.4%) than among Native Americans (40.0%). Tobacco use differed significantly by county, with a range of 5.4% in Madison County to 41.6% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

### **Other Cancer-Related**

### Healthy Weight by Body Mass Index - 2015-2021

Statewide, 32.1% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 32.5% of white non-Hispanics, compared to 28.2% of Hispanics and 24.6% of Native Americans, being in the healthy weight range. Males (25.5%) were significantly less likely to be in the healthy weight range than females (38.6%). BMI differed significantly by age of respondent, with 43.3% of persons aged 18–29, and 26.0% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 19.8% in Power County to 47.4% in Blaine County of adults being in the healthy weight range.

### Any Physical Activity - 2015-2021

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 78.7% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.3% of persons aged 18–29, and 72.3% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 64.3% in Clark County to 84.6% in Teton County.

Physical Activity Guidelines – 2011, 2013, 2015, 2017, 2019 Statewide, 21.9% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.3% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6% in Franklin County to 30.6% in Blaine County.

### Home Radon Testing - 2016, 2018, 2020

Statewide, 23.0% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.4% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.5% in Cassia County to 54.4% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006l and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.





# BONNER COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016–2020 Cancer Mortality 2017–2021 BRFSS 2011–2021

### **RISK FACTORS AND INTERVENTIONS**

### **CANCER**

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/jama.2016.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

### Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

### **Smoking:**

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

### Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <a href="https://www.dietaryguidelines.gov">https://www.dietaryguidelines.gov</a>

### Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute
Cancer Information Services
1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society <a href="https://www.cancer.org">https://www.cancer.org</a>

### **CANCER INCIDENCE 2016–2020**

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016–2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 1,653 cases of invasive cancer were diagnosed among Bonner County residents (Table 1).

**Table 1:** Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Bonner County and the State of Idaho, 2016–2020

Cancer Incidence 2016–2020	Bonner County	State of Idaho
All Sites/Types	1,653	45,610
Female Breast	223	6,687
Prostate	256	6,417
Lung & Bronchus	189	4,887
Colorectal	150	3,451

Table 3 (Cancer Incidence 2016–2020, Comparison between Bonner County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Bonner County. The table also shows the number of observed cases, person-

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Bonner County was 739.8 cases per 100,000 person-years per year during 2016–2020. Comparing this crude rate with the crude rate for the remainder of Idaho (514.2) gives an estimate of the relative burden of disease in Bonner County.

The age- and sex-adjusted incidence rate of invasive cancer in Bonner County, all sites combined, was 520.6 cases per 100,000 persons per year during 2016–2020. There were more cases of cancer in Bonner County (1,653) than expected (1,632.7) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

### **CANCER MORTALITY 2017–2021**

During 2017–2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 563 Bonner County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

**Table 2:** Overall and Cancer Mortality in Bonner County and the State of Idaho, 2017–2021

Mortality 2017–2021	Bonner County	State of Idaho
All Deaths	2,483	77,431
Cancer Deaths	563	15,121
% of All Deaths	22.7%	19.5%
Lung & Bronchus	117	2,961
Colorectal	48	1,319
Pancreas	49	1,190
Female Breast	39	1,086
Prostate	42	949

Table 4 (Cancer Mortality 2017–2021, Comparison between Bonner County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Bonner County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Bonner County, all sites combined, was 168.8 deaths per 100,000 persons per year during 2017–2021, compared with 166.2 for the remainder of the state. There were more cancer deaths in Bonner County (563) than expected (554.3) based upon rates in the remainder of the state, but the difference was not statistically significant.

**Statistical Note:** Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

### TABLE 3: CANCER INCIDENCE 2016–2020 COMPARISON BETWEEN BONNER COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

		Bonner County							Remainder of Idaho			
Cancer		Observed	Person	Crude	A.A.I.	Expected	5.7.1(4)	Observed	Person	Crude		
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)		
All Sites Combined All Sites Combined	Total	1,653 931	223,438 111,621	739.8 834.1	520.6 549.6	1,632.7 923.3	0.622 0.808	43,957 23,358	8,548,390 4,285,289	514.2 545.1		
All Sites Combined	Male Female	722	111,821	645.7	482.4	723.2	0.606	20,599	4,263,269	483.2		
Bladder	Total	79	223.438	35.4	23.8	81.8	0.816	2,105	8,548,390	24.6		
Bladder	Male	62	111.621	55.5	35.3	69.2	0.424	1,689	4,285,289	39.4		
Bladder	Female	17	111,817	15.2	10.8	15.3	0.737	416	4,263,101	9.8		
Brain - malignant	Total	24	223,438	10.7	8.3	20.3	0.467	601	8,548,390	7.0		
Brain - malignant	Male	18	111,621	16.1	12.1	12.4	0.160	357	4,285,289	8.3		
Brain - malignant	Female	6	111,817	5.4	4.3	8.0	0.615	244	4,263,101	5.7		
Brain and other CNS - non-malignant	Total	48	223,438	21.5	16.2	47.8	1.000	1,376	8,548,390	16.1		
Brain and other CNS - non-malignant	Male	18	111,621	16.1	12.0	16.2	0.721	462	4,285,289	10.8		
Brain and other CNS - non-malignant	Female	30	111,817	26.8	20.7	31.0	0.945	914	4,263,101	21.4		
Breast	Total	227	223,438	101.6	73.1	236.8	0.550	6,519	8,548,390	76.3		
Breast	Male .	4	111,621	3.6	2.4	2.1	0.337	55	4,285,289	1.3		
Breast	Female	223	111,817	199.4	148.3	228.0	0.776	6,464	4,263,101	151.6		
Breast - in situ	Total	45	223,438	20.1	14.4	43.5	0.860	1,194	8,548,390	14.0		
Breast - in situ Breast - in situ	Male Female	- 45	111,621 111,817	40.2	29.7	0.2 42.2	1.000 0.709	5 1,189	4,285,289 4,263,101	0.1 27.9		
Cervix	Female	11	111,817	9.8	8.9	8.5	0.469	293	4,263,101	6.9		
Colorectal	Total	150	223,438	67.1	48.1	120.5	0.469	3,301	8,548,390	38.6		
Colorectal	Male	81	111,621	72.6	49.8	69.2	0.180	1,822	4,285,289	42.5		
Colorectal	Female	69	111,817	61.7	46.2	51.8	0.026 >>	1,479	4,263,101	34.7		
Corpus Uteri	Female	43	111,817	38.5	27.9	46.6	0.667	1,287	4,263,101	30.2		
Esophagus	Total	24	223,438	10.7	7.3	18.5	0.250	482	8,548,390	5.6		
Esophagus	Male	19	111,621	17.0	11.1	16.2	0.556	405	4,285,289	9.5		
Esophagus	Female	5	111,817	4.5	3.2	2.8	0.318	77	4,263,101	1.8		
Hodgkin Lymphoma	Total	3	223,438	1.3	1.2	5.8	0.331	207	8,548,390	2.4		
Hodgkin Lymphoma	Male	2	111,621	1.8	1.6	3.4	0.675	116	4,285,289	2.7		
Hodgkin Lymphoma	Female	1	111,817	0.9	0.9	2.5	0.594	91	4,263,101	2.1		
Kidney and Renal Pelvis	Total	70	223,438	31.3	22.3	64.0	0.486	1,745	8,548,390	20.4		
Kidney and Renal Pelvis	Male	42	111,621	37.6	25.8	43.4	0.917	1,140	4,285,289	26.6		
Kidney and Renal Pelvis	Female	28	111,817	25.0	18.6	21.4	0.193	605	4,263,101	14.2		
Larynx	Total Male	9 6	223,438 111,621	4.0 5.4	2.7 3.5	7.9 6.2	0.789 1.000	206 154	8,548,390 4,285,289	2.4 3.6		
Larynx Larynx	Female	3	111,821	2.7	2.0	1.9	0.578	52	4,263,269	1.2		
Leukemia	Total	59	223,438	26.4	19.2	56.6	0.788	1,572	8,548,390	18.4		
Leukemia	Male	37	111,621	33.1	23.0	35.7	0.870	952	4,285,289	22.2		
Leukemia	Female	22	111,817	19.7	14.9	21.5	0.978	620	4,263,101	14.5		
Liver and Bile Duct	Total	39	223,438	17.5	11.8	30.6	0.160	790	8,548,390	9.2		
Liver and Bile Duct	Male	33	111,621	29.6	19.0	22.5	0.045 >>	557	4,285,289	13.0		
Liver and Bile Duct	Female	6	111,817	5.4	3.8	8.5	0.506	233	4,263,101	5.5		
Lung and Bronchus	Total	189	223,438	84.6	56.3	184.3	0.750	4,698	8,548,390	55.0		
Lung and Bronchus	Male	103	111,621	92.3	58.0	97.4	0.599	2,349	4,285,289	54.8		
Lung and Bronchus	Female	86	111,817	76.9	54.1	87.6	0.920	2,349	4,263,101	55.1		
Melanoma of the Skin	Total	75	223,438	33.6	24.6	102.2	0.006 <<	2,867	8,548,390	33.5		
Melanoma of the Skin	Male	48	111,621	43.0	29.4	65.5	0.029 <<	1,717	4,285,289	40.1		
Melanoma of the Skin	Female	27	111,817	24.1	19.1	38.2	0.073	1,150	4,263,101	27.0		
Myeloma	Total	25	223,438	11.2	7.6	26.3 17.2	0.901 1.000	683	8,548,390	8.0 9.9		
Myeloma Myeloma	Male Female	17 8	111,621 111,817	15.2 7.2	9.8 5.1	9.5	0.782	424 259	4,285,289 4,263,101	6.1		
Non-Hodgkin Lymphoma	Total	58	223,438	26.0	18.4	69.4	0.186	1,882	8,548,390	22.0		
Non-Hodgkin Lymphoma	Male	31	111,621	27.8	18.9	42.0	0.094	1,098	4,285,289	25.6		
Non-Hodgkin Lymphoma	Female	27	111,817	24.1	17.8	28.0	0.955	784	4,263,101	18.4		
Oral Cavity and Pharynx	Total	43	223,438	19.2	13.3	47.4	0.582	1,252	8,548,390	14.6		
Oral Cavity and Pharynx	Male	31	111,621	27.8	18.4	35.7	0.495	905	4,285,289	21.1		
Oral Cavity and Pharynx	Female	12	111,817	10.7	7.8	12.5	1.000	347	4,263,101	8.1		
Ovary	Female	22	111,817	19.7	14.8	17.8	0.378	511	4,263,101	12.0		
Pancreas	Total	59	223,438	26.4	18.1	52.1	0.376	1,364	8,548,390	16.0		
Pancreas	Male .	33	111,621	29.6	19.2	30.2	0.657	751	4,285,289	17.5		
Pancreas	Female	26	111,817	23.3	16.8	22.3	0.487	613	4,263,101	14.4		
Prostate	Male	256	111,621	229.3	143.2	256.9	0.987	6,161	4,285,289	143.8		
Stomach	Total	13	223,438	5.8	4.1	16.8	0.425	454	8,548,390	5.3		
Stomach	Male	9	111,621	8.1	5.3	11.8	0.513	300	4,285,289	7.0		
Stomach	Female	4 5	111,817	3.6	2.7	5.3	0.786	154	4,263,101	3.6 6.1		
Testis Thursid	Male		111,621	4.5	5.2	5.9	0.938	260	4,285,289			
Thyroid	Total	31	223,438	13.9	12.1	35.7	0.491	1,189	8,548,390	13.9		
Thyroid	Male	12	111,621	10.8	8.6	11.2	0.891	343	4,285,289	8.0		
Thyroid	Female	19	111,817	17.0	15.4	24.5	0.309	846	4,263,101	19.8		
Pediatric Age 0 to 19	Total	5	48,024	10.4	10.4	8.3	0.333	416	2,412,499	17.2		
Pediatric Age 0 to 19	Male	3	24,279	12.4	12.4	4.3	0.750	220	1,232,231	17.9		
Pediatric Age 0 to 19	Female	2	23,745	8.4	8.4	4.0	0.485	196	1,180,268	16.6		

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

<sup>2.</sup> Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

<sup>&</sup>quot;<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

### **TABLE 4: CANCER MORTALITY 2017–2021** COMPARISON BETWEEN BONNER COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

		Bonner County						Remainder of Idaho		
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	2,483	230,506	1,077.2	785.2	2,706.1	0.000 <<	74,947	8,758,209	855.7
All Causes of Death	Male	1,377	115,499	1,192.2	827.8	1,501.3	0.001 <<	39,679	4,396,369	902.5
All Causes of Death	Female	1,106	115,007	961.7	732.6	1,220.6	0.001 <<	35,268	4,361,840	808.6
All Malignant Cancers	Total	563	230,506	244.2	168.8	554.3	0.724	14,558	8,758,209	166.2
All Malignant Cancers	Male	318	115,499	275.3	179.8	316.1	0.931	7,858	4,396,369	178.7
All Malignant Cancers	Female	245	115,007	213.0	155.1	242.7	0.897	6,700	4,361,840	153.6
Bladder	Total	23	230,506	10.0	6.9	17.6	0.250	466	8,758,209	5.3
Bladder	Male	21	115,499	18.2	12.0	14.2	0.109	357	4,396,369	8.1
Bladder	Female	2	115,007	1.7	1.3	3.9	0.494	109	4,361,840	2.5
Brain and Other Nervous System	Total	19	230,506	8.2	5.9	17.7	0.828	485	8,758,209	5.5
Brain and Other Nervous System	Male	12	115,499	10.4	7.2	10.9	0.812	286	4,396,369	6.5
Brain and Other Nervous System	Female	7	115,007	6.1	4.5	7.0	1.000	199	4,361,840	4.6
Breast	Total	40	230,506	17.4	12.3	39.3	0.954	1,062	8,758,209	12.1
Breast	Male	1 39	115,499	0.9	0.5 25.1	0.6	0.927	15	4,396,369	0.3
Breast	Female	39 1	115,007	33.9 0.9		37.4 2.6	0.830 0.523	1,047	4,361,840 4,361,840	24.0 1.9
Cervix Colorectal	Female Total	48	115,007 230,506	20.8	0.7 14.7	47.4	0.523	82 1,271	8,758,209	14.5
Colorectal	Male	28	115,499	24.2	16.4	26.9	0.885	691	4,396,369	15.7
Colorectal	Female	20	115,007	17.4	12.9	20.7	0.996	580	4,361,840	13.7
Corpus Uteri	Female	5	115,007	4.3	3.1	6.3	0.807	168	4,361,840	3.9
Esophagus	Total	28	230,506	12.1	8.3	17.3	0.022 >>	449	8,758,209	5.1
Esophagus	Male	23	115,499	19.9	12.9	15.3	0.078	378	4,396,369	8.6
Esophagus	Female	5	115,007	4.3	3.2	2.6	0.235	71	4,361,840	1.6
Hodgkin Lymphoma	Total	2	230,506	0.9	0.7	0.9	0.482	27	8,758,209	0.3
Hodgkin Lymphoma	Male	1	115,499	0.9	0.6	0.5	0.742	13	4,396,369	0.3
Hodgkin Lymphoma	Female	1	115,007	0.9	0.7	0.5	0.757	14	4,361,840	0.3
Kidney	Total	19	230,506	8.2	5.6	14.2	0.253	366	8,758,209	4.2
Kidney	Male	8	115,499	6.9	4.5	9.5	0.782	234	4,396,369	5.3
Kidney	Female	11	115,007	9.6	6.8	4.9	0.023 >>	132	4,361,840	3.0
Larynx	Total	2	230,506	0.9	0.6	2.7	1.000	69	8,758,209	0.8
Larynx	Male	2	115,499	1.7	1.1	2.3	1.000	56	4,396,369	1.3
Larynx Leukemia	Female Total	- 27	115,007 230,506	- 11.7	- 8.3	0.5 23.5	1.000 0.526	13 633	4,361,840 8,758,209	0.3 7.2
Leukemia	Male	12	115,499	10.4	7.0	23.3 14.7	0.520	374	4,396,369	8.5
Leukemia	Female	15	115,007	13.0	9.7	9.2	0.093	259	4,361,840	5.9
Liver and Bile Duct	Total	27	230,506	11.7	7.8	22.6	0.409	576	8,758,209	6.6
Liver and Bile Duct	Male	22	115,499	19.0	12.1	16.0	0.176	386	4,396,369	8.8
Liver and Bile Duct	Female	5	115,007	4.3	3.1	7.1	0.587	190	4,361,840	4.4
Lung and Bronchus	Total	117	230,506	50.8	34.0	111.6	0.637	2,844	8,758,209	32.5
Lung and Bronchus	Male	59	115,499	51.1	32.2	62.4	0.729	1,497	4,396,369	34.1
Lung and Bronchus	Female	58	115,007	50.4	35.8	50.0	0.288	1,347	4,361,840	30.9
Melanoma of the Skin	Total	10	230,506	4.3	3.1	10.4	1.000	279	8,758,209	3.2
Melanoma of the Skin	Male	7	115,499	6.1	4.1	7.3	1.000	185	4,396,369	4.2
Melanoma of the Skin	Female	3	115,007	2.6	1.9	3.3	1.000	94	4,361,840	2.2
Myeloma	Total	1	230,506	0.4	0.3	12.9	0.000 <<	330	8,758,209	3.8
Myeloma	Male	1	115,499	0.9	0.5	8.1	0.006 <<	195	4,396,369	4.4
Myeloma	Female	-	115,007			5.0	0.014 <<	135	4,361,840	3.1
Non-Hodgkin Lymphoma	Total	14	230,506	6.1	4.2	21.1	0.137	555 200	8,758,209	6.3
Non-Hodgkin Lymphoma Non-Hodgkin Lymphoma	Male Female	7 7	115,499 115,007	6.1 6.1	4.0 4.4	12.0 9.3	0.182 0.588	300 255	4,396,369 4,361,840	6.8 5.8
Oral Cavity and Pharynx	Total	9	230,506	3.9	2.7	9.3	0.388	257	8,758,209	2.9
Oral Cavity and Pharynx	Male	6	115,499	5.2	3.3	7.4	0.782	181	4,396,369	4.1
Oral Cavity and Pharynx	Female	3	115,007	2.6	1.9	2.8	1.000	76	4,361,840	1.7
Ovary	Female	9	115,007	7.8	5.6	12.5	0.397	341	4,361,840	7.8
Pancreas	Total	49	230,506	21.3	14.4	44.5	0.537	1,141	8,758,209	13.0
Pancreas	Male	23	115,499	19.9	12.7	25.4	0.726	619	4,396,369	14.1
Pancreas	Female	26	115,007	22.6	16.1	19.4	0.173	522	4,361,840	12.0
Prostate	Male	42	115,499	36.4	23.8	36.4	0.389	907	4,396,369	20.6
Stomach	Total	6	230,506	2.6	1.9	7.0	0.901	192	8,758,209	2.2
Stomach	Male	4	115,499	3.5	2.3	4.5	1.000	117	4,396,369	2.7
Stomach	Female	2	115,007	1.7	1.4	2.5	1.000	75	4,361,840	1.7
Notes:	1 Rates ar	e expressed as th	ne number of cases	ner 100 000 nei	rsons ner vear (	nerson-vears)				

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

<sup>2.</sup> Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

### Cancer Screening and Risk Factor Prevalence Estimates, 2011–2021

	State of								Bonner
Measure	Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	County
Access to Care									
Have Health Insurance, Age <65 (2015–2021)	83.1%	82.8%	85.1%	77.2%	85.8%	78.9%	85.4%	85.4%	80.4%
Not See Doctor Due to Cost in Past Year (2015–2021)	12.6%	11.4%	11.8%	14.5%	12.4%	12.3%	11.8%	12.9%	12.8%
Cancer Screening									
Mammogram Past 2 Years, Age 50–74 (2014, 2016, 2018, 2020)	69.1%	67.0%	73.8%	68.2%	73.2%	64.8%	64.5%	67.1%	65.5%
Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020)	71.2%	73.6%	73.6%	70.8%	72.9%	69.1%	69.5%	65.9%	68.9%
Colorectal Cancer Screening, Age 50–75 (2018, 2020)		66.9%	73.6%	71.4%	70.6%	61.7%	61.5%	64.7%	57.8%
Tobacco Use									
Current Tobacco User (2016–2021)	22.3%	26.7%	23.1%	23.6%	21.8%	21.4%	22.7%	16.9%	28.8%
Other Cancer-Related									
Healthy Weight by Body Mass Index, Age 20+ (2015–2021)	32.1%	32.8%	31.7%	27.9%	36.1%	29.8%	27.9%	31.9%	36.1%
Any Physical Activity Besides Job Past 30 Days (2015-2021)	78.7%	79.2%	78.1%	74.5%	83.2%	73.4%	76.3%	79.7%	79.2%
Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019)	21.9%	22.8%	19.4%	20.0%	25.2%	19.5%	20.4%	20.2%	22.3%
Home Ever Tested for Radon (2016, 2018, 2020)	23.0%	30.9%	18.2%	16.9%	25.1%	19.9%	23.0%	21.8%	24.3%

### **Access to Care**

### Have Health Insurance - 2015-2021

Statewide, 83.1% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 86.0% of white non-Hispanics, compared to 64.8% of Hispanics and 83.3% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3%) than English-speaking respondents (84.2%). Health care coverage differed significantly by age of respondent, with 79.8% of persons aged 18–29, and 87.8% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 62.1% in Adams County to 91.6% in Oneida County having health insurance.

### Not See Doctor Due to Cost in Past Year - 2015-2021

Statewide, 12.6% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (11.5% of white non-Hispanics, 19.2% of Hispanics, and 21.0% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9% for less than \$15,000, 6.1% for greater than \$50,000). Inability to see a doctor due to cost differed significantly by county, with a range of 7.4% in Franklin County to 17.5% in Power County.

### **Cancer Screening**

<u>Mammogram</u> – 2014, 2016, 2018, 2020

Statewide, 69.1% of women aged 50–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (72.1% versus 36.7%). Mammography rates differed significantly by county, with a range in screening of 45.9% in Benewah County to 77.0% in Nez Perce County. In 2020, Idaho ranked 48<sup>th</sup> among states and the District of Columbia for mammography screening rates among women aged 50–74 and also 48<sup>th</sup> among ages 40+.

### Pap Test - 2018, 2020

Statewide, 71.2% of women with an intact cervix and aged 21–65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.1% versus 52.6% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.7% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49<sup>th</sup> among states and the District of Columbia for Pap screening rate.

### Colorectal Cancer Screening – 2018, 2020

Statewide, 67.9% of adults aged 50–75 reported being current for colorectal cancer screening.\*\* Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked 47<sup>th</sup> among states and the District of Columbia in the percentage of adults aged 50–75 and older who reported being up-to-date for colorectal cancer screening.

<sup>\*\*</sup> Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

### **Tobacco Use**

### Current Tobacco Use - 2016-2021

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.3% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 29.9% of persons aged 18-29, and 11.1% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (22.4%) than among Native Americans (40.0%). Tobacco use differed significantly by county, with a range of 5.4% in Madison County to 41.6% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

### **Other Cancer-Related**

### Healthy Weight by Body Mass Index - 2015-2021

Statewide, 32.1% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 32.5% of white non-Hispanics, compared to 28.2% of Hispanics and 24.6% of Native Americans, being in the healthy weight range. Males (25.5%) were significantly less likely to be in the healthy weight range than females (38.6%). BMI differed significantly by age of respondent, with 43.3% of persons aged 18–29, and 26.0% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 19.8% in Power County to 47.4% in Blaine County of adults being in the healthy weight range.

### Any Physical Activity - 2015-2021

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 78.7% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.3% of persons aged 18–29, and 72.3% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 64.3% in Clark County to 84.6% in Teton County.

Physical Activity Guidelines – 2011, 2013, 2015, 2017, 2019 Statewide, 21.9% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.3% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6% in Franklin County to 30.6% in Blaine County.

### Home Radon Testing - 2016, 2018, 2020

Statewide, 23.0% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.4% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.5% in Cassia County to 54.4% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006l and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.





# BONNEVILLE COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016–2020 Cancer Mortality 2017–2021 BRFSS 2011–2021

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

**RISK FACTORS AND INTERVENTIONS** 

### **Smoking:**

Aging:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

### Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <a href="https://www.dietaryguidelines.gov">https://www.dietaryguidelines.gov</a>

### Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

### CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/jama.2016.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute
Cancer Information Services
1-800-4CANCER
<a href="https://www.cancer.gov/contact">https://www.cancer.gov/contact</a>

American Cancer Society <a href="https://www.cancer.org">https://www.cancer.org</a>

### **CANCER INCIDENCE 2016–2020**

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016–2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 2,722 cases of invasive cancer were diagnosed among Bonneville County residents (Table 1).

**Table 1:** Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Bonneville County and the State of Idaho. 2016–2020

,	,	
Cancer Incidence 2016–2020	Bonneville County	State of Idaho
All Sites/Types	2,722	45,610
Female Breast	375	6,687
Prostate	376	6,417
Lung & Bronchus	204	4,887
Colorectal	221	3,451

Table 3 (Cancer Incidence 2016–2020, Comparison between Bonneville County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Bonneville County. The table also shows the number of observed cases,

person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Bonneville County was 465.4 cases per 100,000 person-years per year during 2016–2020. Comparing this crude rate with the crude rate for the remainder of Idaho (523.9) gives an estimate of the relative burden of disease in Bonneville County.

The age- and sex-adjusted incidence rate of invasive cancer in Bonneville County, all sites combined, was 543.0 cases per 100,000 persons per year during 2016–2020. There were more cases of cancer in Bonneville County (2,722) than expected (2,626.1) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

### **CANCER MORTALITY 2017–2021**

During 2017–2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 815 Bonneville County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

**Table 2:** Overall and Cancer Mortality in Bonneville County and the State of Idaho, 2017–2021

Mortality 2017–2021	Bonneville County	State of Idaho
All Deaths	5,016	77,431
Cancer Deaths	815	15,121
% of All Deaths	16.2%	19.5%
Lung & Bronchus	132	2,961
Colorectal	82	1,319
Pancreas	60	1,190
Female Breast	65	1,086
Prostate	47	949

Table 4 (Cancer Mortality 2017–2021, Comparison between Bonneville County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Bonneville County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Bonneville County, all sites combined, was 160.7 deaths per 100,000 persons per year during 2017–2021, compared with 170.6 for the remainder of the state. There were fewer cancer deaths in Bonneville County (815) than expected (864.7) based upon rates in the remainder of the state, but the difference was not statistically significant.

**Statistical Note:** Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

# TABLE 3: CANCER INCIDENCE 2016–2020 COMPARISON BETWEEN BONNEVILLE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

All Sites Combined         Male         1,423         291,696         487.8         579.3         1,368.2         0.143         22,866         4           All Sites Combined         Female         1,299         293,155         443.1         509.6         1,250.5         0.176         20,022         2           Bladder         Total         124         584,851         21.2         25.2         124.0         1.000         2,060         8           Bladder         Male         98         291,696         33.6         40.6         97.3         0.968         1,653         4           Brain - malignant         Total         42         584,851         7.2         8.9         10.4         25.0         0.895         407         40.491         583         8           Brain - malignant         Male         23         291,696         7.9         8.9         22.2         0.918         352         4           Brain - malignant         Female         19         293,155         6.5         7.1         15.0         0.368         231         4           Brain and other CNS - non-malignant         Total         108         584,851         18.5         21.0         82.7         0.009 <th>Person Years 8,186,977 4,105,214 4,081,763 8,186,977 4,105,214 4,081,763 8,186,977 4,105,214 4,081,763 8,186,977 4,105,214 4,081,763 8,186,977</th> <th>Crude Rate (1) 523.9 557.0 490.5 25.2 40.3 10.0 7.1 8.6 5.7</th>	Person Years 8,186,977 4,105,214 4,081,763 8,186,977 4,105,214 4,081,763 8,186,977 4,105,214 4,081,763 8,186,977 4,105,214 4,081,763 8,186,977	Crude Rate (1) 523.9 557.0 490.5 25.2 40.3 10.0 7.1 8.6 5.7
All Sites Combined         Total         2,722         584,851         465.4         543.0         2,626.1         0.064         42,888         8           All Sites Combined         Male         1,423         291,696         487.8         579.3         1,368.2         0.143         22,866         4           All Sites Combined         Female         1,299         293,155         443.1         509.6         1,250.5         0.176         20,022         4           Bladder         Total         124         584,851         21.2         25.2         124.0         1.000         2,060         8           Bladder         Male         98         291,696         33.6         40.6         97.3         0.968         1,653         4           Brain - malignant         Total         42         584,851         7.2         8.9         10.4         25.0         0.895         407	8,186,977 4,105,214 4,081,763 8,186,977 4,105,214 4,081,763 8,186,977 4,105,214 4,081,763 8,186,977 4,105,214 4,081,763	523.9 557.0 490.5 25.2 40.3 10.0 7.1 8.6 5.7 16.1
All Sites Combined       Male       1,423       291,696       487.8       579.3       1,368.2       0.143       22,866       4         All Sites Combined       Female       1,299       293,155       443.1       509.6       1,250.5       0.176       20,022       2         Bladder       Total       124       584,851       21.2       25.2       124.0       1.000       2,060       8         Bladder       Male       98       291,696       33.6       40.6       97.3       0.968       1,653       4         Brain - malignant       Total       42       584,851       7.2       8.9       10.4       25.0       0.895       407         Brain - malignant       Male       23       291,696       7.9       8.9       22.2       0.918       352       4         Brain and other CNS - non-malignant       Female       19       293,155       6.5       7.1       15.0       0.368       231       4         Brain and other CNS - non-malignant       Male       33       291,696       11.3       12.8       28.1       0.400       447         Brain and other CNS - non-malignant       Male       33       291,696       11.3       12.8	4,105,214 4,081,763 8,186,977 4,105,214 4,081,763 8,186,977 4,105,214 4,081,763 8,186,977 4,105,214 4,081,763	557.0 490.5 25.2 40.3 10.0 7.1 8.6 5.7 16.1
All Sites Combined         Female         1,299         293,155         443.1         509.6         1,250.5         0.176         20,022         4           Bladder         Total         124         584,851         21.2         25.2         124.0         1.000         2,060         8           Bladder         Male         98         291,696         33.6         40.6         97.3         0.968         1,653         4           Brain - malignant         Total         42         584,851         7.2         8.0         37.4         0.491         583         8           Brain - malignant         Male         23         291,696         7.9         8.9         22.2         0.918         352         4           Brain - malignant         Female         19         293,155         6.5         7.1         15.0         0.368         231         4           Brain and other CNS - non-malignant         Total         108         584,851         18.5         21.0         82.7         0.009         >         1,316         8           Brain and other CNS - non-malignant         Male         33         291,696         11.3         12.8         28.1         0.400         447         4 <td>4,081,763 8,186,977 4,105,214 4,081,763 8,186,977 4,105,214 4,081,763 8,186,977 4,105,214 4,081,763</td> <td>490.5 25.2 40.3 10.0 7.1 8.6 5.7 16.1</td>	4,081,763 8,186,977 4,105,214 4,081,763 8,186,977 4,105,214 4,081,763 8,186,977 4,105,214 4,081,763	490.5 25.2 40.3 10.0 7.1 8.6 5.7 16.1
Bladder         Total Bladder         Total Male         124 S84,851         21.2 25.2 25.2 124.0 1.000 2,060 8         2,060 8         8           Bladder         Male Female         98 291,696 33.6 40.6 97.3 0.968 1,653 4         40.6 97.3 0.968 1,653 4         40.6 97.3 0.968 1,653 4         40.6 97.3 0.968 1,653 4         40.6 97.3 0.968 1,653 4         40.7 4 </td <td>8,186,977 4,105,214 4,081,763 8,186,977 4,105,214 4,081,763 8,186,977 4,105,214 4,081,763</td> <td>25.2 40.3 10.0 7.1 8.6 5.7 16.1</td>	8,186,977 4,105,214 4,081,763 8,186,977 4,105,214 4,081,763 8,186,977 4,105,214 4,081,763	25.2 40.3 10.0 7.1 8.6 5.7 16.1
Bladder         Male         98         291,696         33.6         40.6         97.3         0.968         1,653         4           Bladder         Female         26         293,155         8.9         10.4         25.0         0.895         407         4           Brain - malignant         Total         42         584,851         7.2         8.0         37.4         0.491         583         8           Brain - malignant         Male         23         291,696         7.9         8.9         22.2         0.918         352         4           Brain and other CNS - non-malignant         Female         19         293,155         6.5         7.1         15.0         0.368         23.1         4           Brain and other CNS - non-malignant         Total         108         584,851         18.5         21.0         82.7         0.000         1,316         8           Brain and other CNS - non-malignant         Male         33         291,696         11.3         12.8         28.1         0.400         447         4           Brain and other CNS - non-malignant         Female         75         293,155         25.6         29.0         55.0         0.012         869         4<	4,105,214 4,081,763 8,186,977 4,105,214 4,081,763 8,186,977 4,105,214 4,081,763	40.3 10.0 7.1 8.6 5.7 16.1
Bladder         Female         26         293,155         8.9         10.4         25.0         0.895         407         4           Brain - malignant         Total         42         584,851         7.2         8.0         37.4         0.491         583         8           Brain - malignant         Male         23         291,696         7.9         8.9         22.2         0.918         352         4           Brain - malignant         Female         19         293,155         6.5         7.1         15.0         0.368         231         4           Brain and other CNS - non-malignant         Total         108         584,851         18.5         21.0         82.7         0.009         1,316         8           Brain and other CNS - non-malignant         Male         33         291,696         11.3         12.8         28.1         0.400         447         4           Brain and other CNS - non-malignant         Female         75         293,155         25.6         29.0         55.0         0.012         869         4           Breast         Total         378         584,851         64.6         75.1         391.7         0.506         6,368         8 </td <td>4,081,763 8,186,977 4,105,214 4,081,763 8,186,977 4,105,214 4,081,763</td> <td>10.0 7.1 8.6 5.7 16.1</td>	4,081,763 8,186,977 4,105,214 4,081,763 8,186,977 4,105,214 4,081,763	10.0 7.1 8.6 5.7 16.1
Brain - malignant         Total         42         584,851         7.2         8.0         37.4         0.491         583         8           Brain - malignant         Male         23         291,696         7.9         8.9         22.2         0.918         352         4           Brain - malignant         Female         19         293,155         6.5         7.1         15.0         0.368         231         4           Brain and other CNS - non-malignant         Total         108         584,851         18.5         21.0         82.7         0.009 >>         1,316         8           Brain and other CNS - non-malignant         Male         33         291,696         11.3         12.8         28.1         0.0400         447         447           Brain and other CNS - non-malignant         Female         75         293,155         25.6         29.0         55.0         0.012 >>         869         4           Breast         Total         378         584,851         64.6         75.1         391.7         0.506         6,368         8	8,186,977 4,105,214 4,081,763 8,186,977 4,105,214 4,081,763	7.1 8.6 5.7 16.1
Brain - malignant         Male         23         291,696         7.9         8.9         22.2         0.918         352         4           Brain - malignant         Female         19         293,155         6.5         7.1         15.0         0.368         231         4           Brain and other CNS - non-malignant         Total         108         584,851         18.5         21.0         82.7         0.009 >>         1,316         8           Brain and other CNS - non-malignant         Male         33         291,696         11.3         12.8         28.1         0.400         447           Female         75         293,155         25.6         29.0         55.0         0.012 >>         869         4           Breast         Total         378         584,851         64.6         75.1         391.7         0.506         6,368         8	4,105,214 4,081,763 8,186,977 4,105,214 4,081,763	8.6 5.7 16.1
Brain and other CNS - non-malignant         Total         108         584,851         18.5         21.0         82.7         0.009 >>         1,316         8           Brain and other CNS - non-malignant         Male         33         291,696         11.3         12.8         28.1         0.400         447         4           Brain and other CNS - non-malignant         Female         75         293,155         25.6         29.0         55.0         0.012 >>         869         4           Breast         Total         378         584,851         64.6         75.1         391.7         0.506         6,368         8	8,186,977 4,105,214 4,081,763	16.1
Brain and other CNS - non-malignant         Male         33         291,696         11.3         12.8         28.1         0.400         447         4           Brain and other CNS - non-malignant         Female         75         293,155         25.6         29.0         55.0         0.012 >>         869         4           Breast         Total         378         584,851         64.6         75.1         391.7         0.506         6,368         8	4,105,214 4,081,763	
Brain and other CNS - non-malignant         Female         75         293,155         25.6         29.0         55.0         0.012 >>         869         4           Breast         Total         378         584,851         64.6         75.1         391.7         0.506         6,368         8	4,081,763	
Breast   Total   378   584,851   64.6   75.1   391.7   0.506   6,368   8		10.9
	0,100,911	21.3 77.8
Breast   Male   3   291,696   1.0   1.2   3.4   1.000   56   4	4,105,214	1.4
	4,081,763	154.6
	8,186,977	14.3
	4,105,214	0.1
	4,081,763	28.5
Cervix Female 18 293,155 6.1 6.6 19.2 0.910 286 4	4,081,763	7.0
	8,186,977 4,105,214	39.5 43.6
	4,105,214	43.6 35.3
	4,081,763	30.3
	8,186,977	5.9
Esophagus   Male   19   291,696   6.5   7.8   24.1   0.351   405   4	4,105,214	9.9
	4,081,763	1.8
	8,186,977	2.5
	4,105,214	2.7 2.2
	4,081,763 8,186,977	20.8
	4,105,214	27.2
	4,081,763	14.3
	8,186,977	2.6
	4,105,214	3.8
Larynx Female 2 293,155 0.7 0.8 3.2 0.742 53 4	4,081,763	1.3
Leukemia Total 114 584,851 19.5 22.2 95.2 0.066 1,517 8	8,186,977	18.5
	4,105,214 4,081,763	22.4 14.6
	8,186,977	9.7
	4,105,214	13.7
	4,081,763	5.6
	8,186,977	57.2
	4,105,214	57.1
	4,081,763	57.3
	8,186,977 4,105,214	33.4 40.1
	4,081,763	26.7
	8,186,977	8.1
Myeloma   Male   29   291,696   9.9   12.0   24.2   0.379   412   4	4,105,214	10.0
Myeloma   Female   17   293,155   5.8   6.8   15.4   0.740   250   4	4,081,763	6.1
	8,186,977	22.2
	4,105,214	25.9
	4,081,763	18.6
	8,186,977 4,105,214	14.9 21.4
Oral Cavity and Pharynx   Naie   37   291,090   15.5   25.1   32.7   0.394   679   291,090   15.5   25.1   32.7   0.394   679   291,090   15.5   25.1   32.7   0.394   679   291,090   15.5   25.1   32.7   0.394   679   291,090   15.5   25.1   32.7   0.394   679   291,090   15.5   25.1   25.7   25	4,081,763	8.4
	4,081,763	12.4
Pancreas   Total   78   584,851   13.3   15.7   81.4   0.763   1,345   8	8,186,977	16.4
	4,105,214	18.1
	4,081,763	14.7
	4,105,214	147.2
	8,186,977	5.4 7.0
	4,105,214 4,081,763	7.0 3.7
	4,105,214	6.0
	8,186,977	13.3
	4,105,214	7.7
	4,081,763	18.8
	2,266,682	17.1
	1,157,602	17.6
	1,109,080	16.5

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

<sup>2.</sup> Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

<sup>&</sup>quot;<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

### **TABLE 4: CANCER MORTALITY 2017–2021** COMPARISON BETWEEN BONNEVILLE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

		Bonneville County						Remainder of Idaho			
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude	
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)	
All Causes of Death	Total	5,016	600,619	835.1	967.3	4,476.6	0.000 >>	72,414	8,388,096	863.3	
All Causes of Death	Male	2,606	300,057	868.5	1,019.0	2,334.7	0.000 >>	38,450	4,211,811	912.9	
All Causes of Death	Female	2,410	300,562	801.8	919.7	2,131.1	0.000 >>	33,964	4,176,285	813.3	
All Malignant Cancers	Total	815	600,619	135.7	160.7	864.7	0.092	14,306	8,388,096	170.6	
All Malignant Cancers	Male	428	300,057	142.6	171.7	458.4	0.160	7,748	4,211,811	184.0	
All Malignant Cancers	Female	387	300,562	128.8	150.5	403.7	0.422	6,558	4,176,285	157.0	
Bladder	Total	25	600,619	4.2	4.9	28.1	0.640	464	8,388,096	5.5	
Bladder	Male	20	300,057	6.7	8.0	21.3	0.896	358	4,211,811	8.5	
Bladder	Female	5	300,562	1.7	1.9	6.5	0.733	106	4,176,285	2.5	
Brain and Other Nervous System	Total	39 25	600,619	6.5	7.5	28.8	0.080	465	8,388,096	5.5	
Brain and Other Nervous System Brain and Other Nervous System	Male Female	25 14	300,057 300,562	8.3 4.7	9.8 5.3	16.6 12.1	0.064 0.655	273 192	4,211,811 4,176,285	6.5 4.6	
Breast	Total	67	600,619	11.2	13.1	63.2	0.666	1,035	8,388,096	12.3	
Breast	Male	2	300,057	0.7	0.8	0.8	0.406	1,033	4,211,811	0.3	
Breast	Female	65	300,562	21.6	25.2	63.1	0.839	1,021	4,176,285	24.4	
Cervix	Female	5	300,562	1.7	1.9	5.0	1.000	78	4,176,285	1.9	
Colorectal	Total	82	600,619	13.7	16.1	75.3	0.469	1,237	8,388,096	14.7	
Colorectal	Male	43	300,057	14.3	17.0	40.6	0.743	676	4,211,811	16.1	
Colorectal	Female	39	300,562	13.0	15.1	34.7	0.506	561	4,176,285	13.4	
Corpus Uteri	Female	4	300,562	1.3	1.6	10.2	0.050 <<	169	4,176,285	4.0	
Esophagus	Total	23	600,619	3.8	4.6	27.2	0.487	454	8,388,096	5.4	
Esophagus	Male	20	300,057	6.7	8.1	22.4	0.706	381	4,211,811	9.0	
Esophagus	Female	3	300,562	1.0	1.2	4.5	0.697	73	4,176,285	1.7	
Hodgkin Lymphoma	Total	3	600,619	0.5	0.6	1.6	0.444	26	8,388,096	0.3	
Hodgkin Lymphoma	Male	1	300,057	0.3 0.7	0.4	0.8 0.8	1.000	13	4,211,811	0.3 0.3	
Hodgkin Lymphoma Kidney	Female Total	2 19	300,562 600,619	3.2	0.8 3.8	22.0	0.398 0.609	13 366	4,176,285 8,388,096	4.4	
Kidney	Male	13	300,057	4.3	5.0 5.2	13.5	1.000	229	4,211,811	5.4	
Kidney	Female	6	300,562	2.0	2.3	8.4	0.533	137	4,176,285	3.3	
Larynx	Total	3	600,619	0.5	0.6	4.1	0.829	68	8,388,096	0.8	
Larynx	Male	3	300,057	1.0	1.2	3.3	1.000	55	4,211,811	1.3	
Larynx	Female	-	300,562	-	-	0.8	0.913	13	4,176,285	0.3	
Leukemia	Total	35	600,619	5.8	6.8	38.2	0.676	625	8,388,096	7.5	
Leukemia	Male	22	300,057	7.3	8.7	21.8	1.000	364	4,211,811	8.6	
Leukemia	Female	13	300,562	4.3	5.0	16.3	0.506	261	4,176,285	6.2	
Liver and Bile Duct	Total	27	600,619	4.5	5.4	34.4	0.231	576	8,388,096	6.9	
Liver and Bile Duct	Male	14	300,057	4.7	5.7	23.2	0.058	394	4,211,811	9.4	
Liver and Bile Duct	Female	13	300,562	4.3	5.1	11.1	0.644	182	4,176,285	4.4	
Lung and Bronchus	Total	132	600,619	22.0	26.4	168.8	0.004 <b>&lt;&lt;</b> 0.127	2,829	8,388,096	33.7	
Lung and Bronchus Lung and Bronchus	Male Female	72 60	300,057 300,562	24.0 20.0	29.3 23.6	86.5 82.0	0.127	1,484 1,345	4,211,811 4,176,285	35.2 32.2	
Melanoma of the Skin	Total	19	600,619	3.2	3.7	16.5	0.592	270	8,388,096	3.2	
Melanoma of the Skin	Male	11	300,057	3.7	4.4	10.3	1.000	181	4,211,811	4.3	
Melanoma of the Skin	Female	8	300,562	2.7	3.1	5.5	0.385	89	4,176,285	2.1	
Myeloma	Total	21	600,619	3.5	4.2	18.5	0.627	310	8,388,096	3.7	
Myeloma	Male	13	300,057	4.3	5.3	10.6	0.547	183	4,211,811	4.3	
Myeloma	Female	8	300,562	2.7	3.1	7.8	1.000	127	4,176,285	3.0	
Non-Hodgkin Lymphoma	Total	39	600,619	6.5	7.7	32.1	0.262	530	8,388,096	6.3	
Non-Hodgkin Lymphoma	Male	19	300,057	6.3	7.6	17.1	0.716	288	4,211,811	6.8	
Non-Hodgkin Lymphoma	Female	20	300,562	6.7	7.8	14.9	0.238	242	4,176,285	5.8	
Oral Cavity and Pharynx	Total	13	600,619	2.2	2.6	15.2	0.693	253	8,388,096	3.0	
Oral Cavity and Phanynx	Male	8 5	300,057 300,562	2.7 1.7	3.2 2.0	10.5 4.5	0.557 0.947	179	4,211,811 4,176,285	4.2 1.8	
Oral Cavity and Pharynx Ovary	Female Female	26	300,562	8.7	10.2	19.8	0.947	74 324	4,176,285	7.8	
Pancreas	Total	60	600,619	10.0	11.9	67.7	0.206	1,130	8,388,096	13.5	
Pancreas	Male	27	300,057	9.0	10.9	36.1	0.360	615	4,211,811	14.6	
Pancreas	Female	33	300,562	11.0	12.9	31.4	0.829	515	4,176,285	12.3	
Prostate	Male	47	300,057	15.7	18.9	53.4	0.424	902	4,211,811	21.4	
Stomach	Total	5	600,619	0.8	1.0	11.9	0.044 <<		8,388,096	2.3	
Stomach	Male	5	300,057	1.7	2.0	6.9	0.620	116	4,211,811	2.8	
Stomach	Female	-	300,562	-	-	4.9	0.015 <<	77	4,176,285	1.8	
			ne number of cases r	100.000				•	,		

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

<sup>2.</sup> Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

### Cancer Screening and Risk Factor Prevalence Estimates, 2011–2021

		State of								Bonneville	
	Measure	Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	County	
	Access to Care Have Health Insurance, Age <65 (2015–2021) Not See Doctor Due to Cost in Past Year (2015–2021) Cancer Screening	83.1% 12.6%	82.8% 11.4%	85.1% 11.8%	77.2% 14.5%	85.8% 12.4%	78.9% 12.3%	85.4% 11.8%	85.4% 12.9%	85.7% 14.8%	
	Mammogram Past 2 Years, Age 50–74 (2014, 2016, 2018, 2020) Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020) Colorectal Cancer Screening, Age 50–75 (2018, 2020) Tobacco Use	69.1% 71.2% 67.9%	67.0% 73.6% 66.9%	73.8% 73.6% 73.6%	68.2% 70.8% 71.4%	73.2% 72.9% 70.6%	64.8% 69.1% 61.7%	64.5% 69.5% 61.5%	67.1% 65.9% 64.7%	70.5% 68.6% 69.2%	
	Current Tobacco User (2016–2021) Other Cancer-Related	22.3%	26.7%	23.1%	23.6%	21.8%	21.4%	22.7%	16.9%	20.3%	
İ	Healthy Weight by Body Mass Index, Age 20+ (2015–2021)	32.1%	32.8%	31.7%	27.9%	36.1%	29.8%	27.9%	31.9%	30.5%	
İ	Any Physical Activity Besides Job Past 30 Days (2015-2021)	78.7%	79.2%	78.1%	74.5%	83.2%	73.4%	76.3%	79.7%	78.8%	
ı	Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019)	21.9%	22.8%	19.4%	20.0%	25.2%	19.5%	20.4%	20.2%	21.0%	
	Home Ever Tested for Radon (2016, 2018, 2020)	23.0%	30.9%	18.2%	16.9%	25.1%	19.9%	23.0%	21.8%	21.9%	

### **Access to Care**

### Have Health Insurance - 2015-2021

Statewide, 83.1% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 86.0% of white non-Hispanics, compared to 64.8% of Hispanics and 83.3% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3%) than English-speaking respondents (84.2%). Health care coverage differed significantly by age of respondent, with 79.8% of persons aged 18–29, and 87.8% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 62.1% in Adams County to 91.6% in Oneida County having health insurance.

### Not See Doctor Due to Cost in Past Year - 2015-2021

Statewide, 12.6% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (11.5% of white non-Hispanics, 19.2% of Hispanics, and 21.0% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9% for less than \$15,000, 6.1% for greater than \$50,000). Inability to see a doctor due to cost differed significantly by county, with a range of 7.4% in Franklin County to 17.5% in Power County.

### **Cancer Screening**

Mammogram - 2014, 2016, 2018, 2020

Statewide, 69.1% of women aged 50–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (72.1% versus 36.7%). Mammography rates differed significantly by county, with a range in screening of 45.9% in Benewah County to 77.0% in Nez Perce County. In 2020, Idaho ranked 48th among states and the District of Columbia for mammography screening rates among women aged 50–74 and also 48th among ages 40+.

### Pap Test - 2018, 2020

Statewide, 71.2% of women with an intact cervix and aged 21–65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.1% versus 52.6% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.7% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49<sup>th</sup> among states and the District of Columbia for Pap screening rate.

### Colorectal Cancer Screening - 2018, 2020

Statewide, 67.9% of adults aged 50–75 reported being current for colorectal cancer screening.\*\* Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked 47<sup>th</sup> among states and the District of Columbia in the percentage of adults aged 50–75 and older who reported being up-to-date for colorectal cancer screening.

<sup>\*\*</sup> Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

### **Tobacco Use**

### Current Tobacco Use - 2016-2021

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.3% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 29.9% of persons aged 18-29, and 11.1% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (22.4%) than among Native Americans (40.0%). Tobacco use differed significantly by county, with a range of 5.4% in Madison County to 41.6% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

### **Other Cancer-Related**

### Healthy Weight by Body Mass Index - 2015-2021

Statewide, 32.1% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 32.5% of white non-Hispanics, compared to 28.2% of Hispanics and 24.6% of Native Americans, being in the healthy weight range. Males (25.5%) were significantly less likely to be in the healthy weight range than females (38.6%). BMI differed significantly by age of respondent, with 43.3% of persons aged 18–29, and 26.0% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 19.8% in Power County to 47.4% in Blaine County of adults being in the healthy weight range.

### Any Physical Activity - 2015-2021

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 78.7% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.3% of persons aged 18–29, and 72.3% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 64.3% in Clark County to 84.6% in Teton County.

Physical Activity Guidelines – 2011, 2013, 2015, 2017, 2019 Statewide, 21.9% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.3% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6% in Franklin County to 30.6% in Blaine County.

### Home Radon Testing - 2016, 2018, 2020

Statewide, 23.0% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.4% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.5% in Cassia County to 54.4% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006l and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.





# BOUNDARY COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016–2020 Cancer Mortality 2017–2021 BRFSS 2011–2021

### RISK FACTORS AND INTERVENTIONS

### **CANCER**

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/jama.2016.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

### Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

### **Smoking:**

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

### Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <a href="https://www.dietaryguidelines.gov">https://www.dietaryguidelines.gov</a>

### Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute
Cancer Information Services
1-800-4CANCER
<a href="https://www.cancer.gov/contact">https://www.cancer.gov/contact</a>

American Cancer Society <a href="https://www.cancer.org">https://www.cancer.org</a>

### **CANCER INCIDENCE 2016–2020**

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016–2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 410 cases of invasive cancer were diagnosed among Boundary County residents (Table 1).

**Table 1:** Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Boundary County and the State of Idaho, 2016–2020

Cancer Incidence 2016–2020	Boundary County	State of Idaho		
All Sites/Types	410	45,610		
Female Breast	53	6,687		
Prostate	55	6,417		
Lung & Bronchus	50	4,887		
Colorectal	48	3,451		

Table 3 (Cancer Incidence 2016–2020, Comparison between Boundary County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Boundary County. The table also shows the number of observed cases,

person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Boundary County was 674.6 cases per 100,000 person-years per year during 2016–2020. Comparing this crude rate with the crude rate for the remainder of Idaho (518.9) gives an estimate of the relative burden of disease in Boundary County.

The age- and sex-adjusted incidence rate of invasive cancer in Boundary County, all sites combined, was 522.2 cases per 100,000 persons per year during 2016–2020. There were more cases of cancer in Boundary County (410) than expected (407.4) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

### **CANCER MORTALITY 2017–2021**

During 2017–2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 154 Boundary County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

**Table 2:** Overall and Cancer Mortality in Boundary County and the State of Idaho, 2017–2021

Mortality 2017–2021	Boundary County	State of Idaho
All Deaths	669	77,431
Cancer Deaths	154	15,121
% of All Deaths	23.0%	19.5%
Lung & Bronchus	33	2,961
Colorectal	12	1,319
Pancreas	4	1,190
Female Breast	8	1,086
Prostate	14	949

Table 4 (Cancer Mortality 2017–2021, Comparison between Boundary County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Boundary County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Boundary County, all sites combined, was 186.5 deaths per 100,000 persons per year during 2017–2021, compared with 167.7 for the remainder of the state. There were more cancer deaths in Boundary County (154) than expected (138.5) based upon rates in the remainder of the state, but the difference was not statistically significant.

**Statistical Note:** Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

# TABLE 3: CANCER INCIDENCE 2016–2020 COMPARISON BETWEEN BOUNDARY COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

		Boundary County							nainder of Ida	aho
Cancer		Observed	Person	Crude	A.A.I.	Expected	D./ I. //	Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)
All Sites Combined All Sites Combined	Total Male	410 222	60,778 30,616	674.6 725.1	522.2 535.9	407.4 228.3	0.910 0.707	45,200 24,067	8,711,050 4.366.294	518.9 551.2
All Sites Combined	Female	188	30,162	623.3	502.9	181.8	0.707	24,007	4,344,756	486.4
Bladder	Total	14	60,778	23.0	17.0	20.5	0.175	2,170	8,711,050	24.9
Bladder	Male	12	30,616	39.2	27.9	17.1	0.257	1,739	4,366,294	39.8
Bladder	Female	2	30,162	6.6	5.1	3.9	0.503	431	4,344,756	9.9
Brain - malignant	Total	7	60,778	11.5	9.6	5.2	0.525	618	8,711,050	7.1
Brain - malignant	Male .	3	30,616	9.8	8.0	3.2	1.000	372	4,366,294	8.5
Brain - malignant	Female Total	4 11	30,162 60.778	13.3 18.1	11.2 14.7	2.0 12.1	0.295 0.891	246 1,413	4,344,756 8,711,050	5.7 16.2
Brain and other CNS - non-malignant Brain and other CNS - non-malignant	Male	5	30,616	16.3	13.3	4.1	0.783	475	4,366,294	10.2
Brain and other CNS - non-malignant	Female	6	30,162	19.9	16.4	7.9	0.650	938	4,344,756	21.6
Breast	Total	53	60,778	87.2	69.1	58.9	0.486	6,693	8,711,050	76.8
Breast	Male	-	30,616	-	-	0.6	1.000	59	4,366,294	1.4
Breast	Female	53	30,162	175.7	142.3	56.9	0.667	6,634	4,344,756	152.7
Breast - in situ	Total	7	60,778	11.5	9.2	10.8	0.313	1,232	8,711,050	14.1
Breast - in situ Breast - in situ	Male Female	- 7	30,616 30,162	23.2	18.8	0.0 10.5	1.000 0.358	5 1,227	4,366,294 4,344,756	0.1 28.2
Cervix	Female	4	30,162	13.3	12.7	2.2	0.354	300	4,344,756	6.9
Colorectal	Total	48	60,778	79.0	61.8	30.3	0.004 >>	3,403	8,711,050	39.1
Colorectal	Male	26	30,616	84.9	64.8	17.2	0.058	1,877	4,366,294	43.0
Colorectal	Female	22	30,162	72.9	58.6	13.2	0.033 >>	1,526	4,344,756	35.1
Corpus Uteri	Female	16	30,162	53.0	42.2	11.5	0.240	1,314	4,344,756	30.2
Esophagus	Total	5	60,778	8.2	6.2	4.6	0.991	501	8,711,050	5.8
Esophagus Esophagus	Male Female	4 1	30,616 30,162	13.1 3.3	9.5 2.6	4.0 0.7	1.000 1.000	420 81	4,366,294 4,344,756	9.6 1.9
Hodgkin Lymphoma	Total		60,778	-	2.0	1.5	0.436	210	8,711,050	2.4
Hodgkin Lymphoma	Male	_	30.616	_	_	0.9	0.823	118	4,366,294	2.7
Hodgkin Lymphoma	Female	-	30,162	-	_	0.6	1.000	92	4,344,756	2.1
Kidney and Renal Pelvis	Total	11	60,778	18.1	14.2	16.1	0.246	1,804	8,711,050	20.7
Kidney and Renal Pelvis	Male	8	30,616	26.1	20.0	10.8	0.506	1,174	4,366,294	26.9
Kidney and Renal Pelvis	Female	3	30,162	9.9	8.0	5.4	0.418	630	4,344,756	14.5
Larynx	Total Male	3 1	60,778 30,616	4.9 3.3	3.7 2.4	2.0 1.5	0.623 1.000	212 159	8,711,050 4,366,294	2.4 3.6
Larynx Larynx	Female	2	30,162	5.5 6.6	5.2	0.5	0.163	53	4,344,756	1.2
Leukemia	Total	18	60,778	29.6	23.2	14.4	0.402	1,613	8,711,050	18.5
Leukemia	Male	12	30,616	39.2	29.9	9.0	0.392	977	4,366,294	22.4
Leukemia	Female	6	30,162	19.9	16.0	5.5	0.942	636	4,344,756	14.6
Liver and Bile Duct	Total	1	60,778	1.6	1.2	7.7	0.008 <<	828	8,711,050	9.5
Liver and Bile Duct	Male	1	30,616	3.3	2.4	5.7	0.047 <<	589 239	4,366,294	13.5
Liver and Bile Duct Lung and Bronchus	Female Total	- 50	30,162 60,778	- 82.3	60.7	2.1 45.7	0.238 0.566	4,837	4,344,756 8,711,050	5.5 55.5
Lung and Bronchus	Male	29	30.616	94.7	67.0	24.0	0.357	2,423	4,366,294	55.5
Lung and Bronchus	Female	21	30,162	69.6	53.4	21.9	0.967	2,414	4,344,756	55.6
Melanoma of the Skin	Total	22	60,778	36.2	29.0	25.4	0.581	2,920	8,711,050	33.5
Melanoma of the Skin	Male	15	30,616	49.0	37.3	16.1	0.912	1,750	4,366,294	40.1
Melanoma of the Skin	Female	7	30,162	23.2	19.7	9.6	0.522	1,170	4,344,756	26.9
Myeloma	Total	5 4	60,778	8.2	6.2	6.5	0.724	703	8,711,050	8.1
Myeloma Myeloma	Male Female		30,616 30,162	13.1 3.3	9.4 2.6	4.2 2.4	1.000 0.623	437 266	4,366,294 4,344,756	10.0 6.1
Non-Hodgkin Lymphoma	Total	22	60,778	36.2	28.1	17.2	0.302	1,918	8,711,050	22.0
Non-Hodgkin Lymphoma	Male	14	30,616	45.7	34.7	10.3	0.319	1,115	4,366,294	25.5
Non-Hodgkin Lymphoma	Female	8	30,162	26.5	21.0	7.0	0.812	803	4,344,756	18.5
Oral Cavity and Pharynx	Total	9	60,778	14.8	11.4	11.7	0.540	1,286	8,711,050	14.8
Oral Cavity and Pharynx	Male	8	30,616	26.1	19.5	8.7	0.991	928	4,366,294	21.3
Oral Cavity and Pharynx Ovary	Female Female	1 9	30,162 30,162	3.3 29.8	2.6 24.1	3.1 4.5	0.358 0.080	358 524	4,344,756 4,344,756	8.2 12.1
Pancreas	Total	10	60,778	16.5	12.3	13.1	0.080	1,413	8,711,050	16.2
Pancreas	Male	8	30,616	26.1	19.0	7.5	0.946	776	4,366,294	17.8
Pancreas	Female	2	30,162	6.6	5.1	5.7	0.152	637	4,344,756	14.7
Prostate	Male	55	30,616	179.6	127.8	62.7	0.365	6,362	4,366,294	145.7
Stomach	Total	7	60,778	11.5	8.9	4.2	0.257	460	8,711,050	5.3
Stomach	Male	4	30,616	13.1	9.7	2.9	0.658	305	4,366,294	7.0 3.6
Stomach Testis	Female Male	3 2	30,162 30,616	9.9 6.5	8.0 7.7	1.3 1.6	0.304 0.929	155 263	4,344,756 4,366,294	6.0
Thyroid	Total	6	60,778	9.9	9.2	9.1	0.929	1,214	8,711,050	13.9
Thyroid	Male	1	30,616	3.3	2.8	2.8	0.397	354	4,366,294	8.1
Thyroid	Female	5	30,162	16.6	15.8	6.2	0.447	860	4,366,294	19.8
Pediatric Age 0 to 19	Total	5	15,601	32.0	31.7	2.7	0.814	416	2,444,922	17.0
Pediatric Age 0 to 19	Male	4	8,145	49.1	48.4	1.4	0.271	219	1,248,365	17.5
Pediatric Age 0 to 19	Female	1	7,456	13.4	13.2	1.2	1.000	197	1,196,557	16.5

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

<sup>2.</sup> Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

<sup>&</sup>quot;<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

# TABLE 4: CANCER MORTALITY 2017–2021 COMPARISON BETWEEN BOUNDARY COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

		Boundary County					Remainder of Idaho			
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	669	61,625	1.085.6	823.3	698.7	0.269	76,761	8.927.090	859.9
All Causes of Death	Male	370	31,109	1,189.4	899.7	373.4	0.887	40,686	4,480,759	908.0
All Causes of Death	Female	299	30,516	979.8	738.5	328.5	0.107	36,075	4,446,331	811.3
All Malignant Cancers	Total	154	61,625	249.9	186.5	138.5	0.204	14,967	8,927,090	167.7
All Malignant Cancers	Male	83	31,109	266.8	193.5	77.5	0.559	8,093	4,480,759	180.6
All Malignant Cancers	Female	71	30,516	232.7	178.2	61.6	0.259	6,874	4,446,331	154.6
Bladder	Total	4	61,625	6.5	4.7	4.6	1.000	485	8,927,090	5.4
Bladder	Male	4	31,109	12.9	9.2	3.6	0.975	374	4,480,759	8.3
Bladder	Female	-	30,516	-	-	1.0	0.717	111	4,446,331	2.5
Brain and Other Nervous System	Total	6	61,625	9.7	7.7	4.4	0.548	498	8,927,090	5.6
Brain and Other Nervous System	Male	3	31,109	9.6	7.4	2.7	0.995	295	4,480,759	6.6
Brain and Other Nervous System	Female	3	30,516	9.8	7.9	1.7	0.505	203	4,446,331	4.6
Breast	Total	8	61,625	13.0	9.9	9.9	0.691	1,094	8,927,090	12.3
Breast	Male	- 0	31,109	-	20.3	0.2 9.5	1.000 0.775	16	4,480,759	0.4 24.2
Breast	Female	8	30,516 30,516	26.2 3.3	20.3	0.6	0.775	1,078 82	4,446,331 4,446,331	1.8
Cervix Colorectal	Female Total	1 12	61,625	19.5	14.8	11.9	1.000	1,307	8,927,090	14.6
Colorectal	Male	5	31,109	16.1	12.0	6.6	0.705	714	4,480,759	15.9
Colorectal	Female	7	30,516	22.9	17.5	5.3	0.703	593	4,446,331	13.3
Corpus Uteri	Female	3	30,516	9.8	7.4	1.5	0.406	170	4,446,331	3.8
Esophagus	Total	4	61,625	6.5	4.8	4.4	1.000	473	8,927,090	5.3
Esophagus	Male	3	31,109	9.6	7.0	3.8	0.946	398	4,480,759	8.9
Esophagus	Female	1	30,516	3.3	2.5	0.7	0.980	75	4,446,331	1.7
Hodgkin Lymphoma	Total	1	61,625	1.6	1.3	0.2	0.428	28	8,927,090	0.3
Hodgkin Lymphoma	Male	1	31,109	3.2	2.6	0.1	0.212	13	4,480,759	0.3
Hodgkin Lymphoma	Female	-	30,516	-	-	0.1	1.000	15	4,446,331	0.3
Kidney	Total	3	61,625	4.9	3.6	3.6	1.000	382	8,927,090	4.3
Kidney	Male	3	31,109	9.6	7.0	2.3	0.807	239	4,480,759	5.3
Kidney	Female	-	30,516	-	-	1.3	0.533	143	4,446,331	3.2
Larynx	Total	-	61,625	-	-	0.7	1.000	71	8,927,090	0.8
Larynx	Male	-	31,109	-	-	0.5	1.000	58	4,480,759	1.3
Larynx	Female	-	30,516	-	-	0.1	1.000	13	4,446,331	0.3
Leukemia	Total	6	61,625	9.7	7.3	6.0	1.000	654	8,927,090	7.3
Leukemia	Male	4	31,109	12.9	9.5 5.0	3.6	0.972 1.000	382 272	4,480,759	8.5
Leukemia Liver and Bile Duct	Female Total	2 2	30,516 61,625	6.6 3.2	2.4	2.4 5.6	0.163	601	4,446,331 8,927,090	6.1 6.7
Liver and Bile Duct	Male	2	31,109	3.2	2.4	4.0	0.103	408	4,480,759	9.1
Liver and Bile Duct	Female	2	30,516	6.6	5.0	1.7	1.000	193	4,446,331	4.3
Lung and Bronchus	Total	33	61,625	53.5	39.3	27.5	0.342	2,928	8,927,090	32.8
Lung and Bronchus	Male	21	31,109	67.5	47.7	15.1	0.172	1,535	4,480,759	34.3
Lung and Bronchus	Female	12	30,516	39.3	29.8	12.6	1.000	1,393	4,446,331	31.3
Melanoma of the Skin	Total	1	61,625	1.6	1.2	2.6	0.536	288	8,927,090	3.2
Melanoma of the Skin	Male	1	31,109	3.2	2.4	1.8	0.941	191	4,480,759	4.3
Melanoma of the Skin	Female	-	30,516	-	-	0.8	0.867	97	4,446,331	2.2
Myeloma	Total	2	61,625	3.2	2.4	3.1	0.799	329	8,927,090	3.7
Myeloma	Male	1	31,109	3.2	2.3	1.9	0.852	195	4,480,759	4.4
Myeloma	Female	1	30,516	3.3	2.5	1.2	1.000	134	4,446,331	3.0
Non-Hodgkin Lymphoma	Total	11	61,625	17.8	13.3	5.2	0.035 >>	558	8,927,090	6.3
Non-Hodgkin Lymphoma	Male	7	31,109	22.5	16.4	2.9	0.053	300	4,480,759	6.7
Non-Hodgkin Lymphoma	Female	4	30,516	13.1	9.9	2.3	0.419	258	4,446,331	5.8
Oral Cavity and Pharmy	Total	2	61,625	3.2	2.4	2.4	1.000	264	8,927,090	3.0
Oral Cavity and Pharynx Oral Cavity and Pharynx	Male	1 1	31,109 30,516	3.2 3.3	2.3 2.5	1.8	0.939 1.000	186	4,480,759 4,446,331	4.2 1.8
Ovary	Female Female	10	30,516	32.8	25.2	0.7 3.0	0.002 >>	78 340	4,446,331	7.6
Pancreas	Total	4	61,625	6.5	4.8	11.1	0.002 >>	1,186	8,927,090	13.3
Pancreas	Male	4	31,109	12.9	9.2	6.2	0.029	638	4,480,759	14.2
Pancreas	Female	- 4	30,516	-	- 5.2	4.9	0.014 <<	548	4,446,331	12.3
Prostate	Male	14	31,109	45.0	32.2	9.1	0.157	935	4,480,759	20.9
Stomach	Total	3	61,625	4.9	3.8	1.7	0.504	195	8,927,090	2.2
Stomach	Male	1	31,109	3.2	2.4	1.1	1.000	120	4,480,759	2.7
Stomach	Female	2	30,516	6.6	5.2	0.6	0.273	75	4,446,331	1.7
			ne number of cases p						, -,	

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

<sup>2.</sup> Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

### Cancer Screening and Risk Factor Prevalence Estimates, 2011–2021

	State of								Boundary
Measure	Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	County
Access to Care									
Have Health Insurance, Age <65 (2015–2021)	83.1%	82.8%	85.1%	77.2%	85.8%	78.9%	85.4%	85.4%	72.0%
Not See Doctor Due to Cost in Past Year (2015–2021)	12.6%	11.4%	11.8%	14.5%	12.4%	12.3%	11.8%	12.9%	8.9%
<u>Cancer Screening</u>									
Mammogram Past 2 Years, Age 50–74 (2014, 2016, 2018, 2020)	69.1%	67.0%	73.8%	68.2%	73.2%	64.8%	64.5%	67.1%	
Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020)	71.2%	73.6%	73.6%	70.8%	72.9%	69.1%	69.5%	65.9%	
Colorectal Cancer Screening, Age 50–75 (2018, 2020)	67.9%	66.9%	73.6%	71.4%	70.6%	61.7%	61.5%	64.7%	
Tobacco Use									
Current Tobacco User (2016–2021)	22.3%	26.7%	23.1%	23.6%	21.8%	21.4%	22.7%	16.9%	20.1%
Other Cancer-Related									
Healthy Weight by Body Mass Index, Age 20+ (2015–2021)	32.1%	32.8%	31.7%	27.9%	36.1%	29.8%	27.9%	31.9%	29.6%
Any Physical Activity Besides Job Past 30 Days (2015-2021)	78.7%	79.2%	78.1%	74.5%	83.2%	73.4%	76.3%	79.7%	76.2%
Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019)	21.9%	22.8%	19.4%	20.0%	25.2%	19.5%	20.4%	20.2%	21.3%
Home Ever Tested for Radon (2016, 2018, 2020)	23.0%	30.9%	18.2%	16.9%	25.1%	19.9%	23.0%	21.8%	17.4%

### **Access to Care**

### Have Health Insurance - 2015-2021

Statewide, 83.1% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 86.0% of white non-Hispanics, compared to 64.8% of Hispanics and 83.3% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3%) than English-speaking respondents (84.2%). Health care coverage differed significantly by age of respondent, with 79.8% of persons aged 18–29, and 87.8% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 62.1% in Adams County to 91.6% in Oneida County having health insurance.

### Not See Doctor Due to Cost in Past Year - 2015-2021

Statewide, 12.6% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (11.5% of white non-Hispanics, 19.2% of Hispanics, and 21.0% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9% for less than \$15,000, 6.1% for greater than \$50,000). Inability to see a doctor due to cost differed significantly by county, with a range of 7.4% in Franklin County to 17.5% in Power County.

### **Cancer Screening**

<u>Mammogram</u> – 2014, 2016, 2018, 2020

Statewide, 69.1% of women aged 50–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (72.1% versus 36.7%). Mammography rates differed significantly by county, with a range in screening of 45.9% in Benewah County to 77.0% in Nez Perce County. In 2020, Idaho ranked 48<sup>th</sup> among states and the District of Columbia for mammography screening rates among women aged 50–74 and also 48<sup>th</sup> among ages 40+.

### Pap Test - 2018, 2020

Statewide, 71.2% of women with an intact cervix and aged 21–65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.1% versus 52.6% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.7% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49<sup>th</sup> among states and the District of Columbia for Pap screening rate.

### Colorectal Cancer Screening - 2018, 2020

Statewide, 67.9% of adults aged 50–75 reported being current for colorectal cancer screening.\*\* Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked 47<sup>th</sup> among states and the District of Columbia in the percentage of adults aged 50–75 and older who reported being up-to-date for colorectal cancer screening.

<sup>\*\*</sup> Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

### **Tobacco Use**

### Current Tobacco Use - 2016-2021

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.3% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 29.9% of persons aged 18-29, and 11.1% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (22.4%) than among Native Americans (40.0%). Tobacco use differed significantly by county, with a range of 5.4% in Madison County to 41.6% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

### **Other Cancer-Related**

### Healthy Weight by Body Mass Index - 2015-2021

Statewide, 32.1% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 32.5% of white non-Hispanics, compared to 28.2% of Hispanics and 24.6% of Native Americans, being in the healthy weight range. Males (25.5%) were significantly less likely to be in the healthy weight range than females (38.6%). BMI differed significantly by age of respondent, with 43.3% of persons aged 18–29, and 26.0% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 19.8% in Power County to 47.4% in Blaine County of adults being in the healthy weight range.

### Any Physical Activity - 2015-2021

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 78.7% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.3% of persons aged 18–29, and 72.3% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 64.3% in Clark County to 84.6% in Teton County.

Physical Activity Guidelines – 2011, 2013, 2015, 2017, 2019 Statewide, 21.9% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.3% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6% in Franklin County to 30.6% in Blaine County.

### Home Radon Testing - 2016, 2018, 2020

Statewide, 23.0% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.4% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.5% in Cassia County to 54.4% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006l and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.





# BUTTE COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016–2020 Cancer Mortality 2017–2021 BRFSS 2011–2021

### **RISK FACTORS AND INTERVENTIONS**

### CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/jama.2016.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

### Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

### **Smoking:**

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

### Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <a href="https://www.dietaryguidelines.gov">https://www.dietaryguidelines.gov</a>

### Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute
Cancer Information Services
1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society <a href="https://www.cancer.org">https://www.cancer.org</a>

### **CANCER INCIDENCE 2016–2020**

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016–2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 88 cases of invasive cancer were diagnosed among Butte County residents (Table 1).

**Table 1:** Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Butte County and the State of Idaho, 2016–2020

Cancer Incidence 2016–2020	Butte County	State of Idaho
All Sites/Types	88	45,610
Female Breast	8	6,687
Prostate	6	6,417
Lung & Bronchus	14	4,887
Colorectal	5	3,451

Table 3 (Cancer Incidence 2016–2020, Comparison between Butte County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Butte County. The table also shows the number of observed cases, person-

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Butte County was 676.2 cases per 100,000 person-years per year during 2016–2020. Comparing this crude rate with the crude rate for the remainder of Idaho (519.7) gives an estimate of the relative burden of disease in Butte County.

The age- and sex-adjusted incidence rate of invasive cancer in Butte County, all sites combined, was 496.0 cases per 100,000 persons per year during 2016–2020. There were fewer cases of cancer in Butte County (88) than expected (92.2) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

### **CANCER MORTALITY 2017–2021**

During 2017–2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 37 Butte County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

**Table 2:** Overall and Cancer Mortality in Butte County and the State of Idaho, 2017–2021

Mortality 2017–2021	Butte County	State of Idaho
All Deaths	183	77,431
Cancer Deaths	37	15,121
% of All Deaths	20.2%	19.5%
Lung & Bronchus	10	2,961
Colorectal	3	1,319
Pancreas	0	1,190
Female Breast	2	1,086
Prostate	0	949

Table 4 (Cancer Mortality 2017–2021, Comparison between Butte County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Butte County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Butte County, all sites combined, was 191.7 deaths per 100,000 persons per year during 2017–2021, compared with 168.1 for the remainder of the state. There were more cancer deaths in Butte County (37) than expected (32.4) based upon rates in the remainder of the state, but the difference was not statistically significant.

**Statistical Note:** Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

### TABLE 3: CANCER INCIDENCE 2016–2020 COMPARISON BETWEEN BUTTE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

		Butte County						Remainder of Idaho			
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude	
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)	
All Sites Combined	Total	88	13,013	676.2	496.0	92.2	0.710	45,522	8,758,815	519.7	
All Sites Combined All Sites Combined	Male Female	49 39	6,622 6,391	740.0 610.2	507.5 476.4	53.3 39.9	0.613 0.973	24,240 21,282	4,390,288 4,368,527	552.1 487.2	
Bladder	Total	4	13,013	30.7	20.7	4.8	0.949	2,180	8,758,815	24.9	
Bladder	Male	4	6,622	60.4	38.5	4.1	1.000	1,747	4,390,288	39.8	
Bladder	Female	-	6,391	-	-	0.9	0.824	433	4,368,527	9.9	
Brain - malignant Brain - malignant	Total Male	3 1	13,013 6,622	23.1 15.1	18.5 11.8	1.2 0.7	0.220 1.000	622 374	8,758,815 4,390,288	7.1 8.5	
Brain - malignant Brain - malignant	Female	2	6,391	31.3	25.5	0.7	0.148	248	4,368,527	5.7	
Brain and other CNS - non-malignant	Total	3	13,013	23.1	17.9	2.7	1.000	1,421	8,758,815	16.2	
Brain and other CNS - non-malignant	Male	2	6,622	30.2	23.2	0.9	0.484	478	4,390,288	10.9	
Brain and other CNS - non-malignant Breast	Female Total	1 8	6,391 13,013	15.6 61.5	12.4 47.3	1.7 13.0	0.964 0.200	943 6,738	4,368,527 8,758,815	21.6 76.9	
Breast	Male	-	6,622	- 01.5	47.3	0.1	1.000	59	4,390,288	1.3	
Breast	Female	8	6,391	125.2	100.3	12.2	0.285	6,679	4,368,527	152.9	
Breast - in situ	Total	4	13,013	30.7	24.4	2.3	0.406	1,235	8,758,815	14.1	
Breast - in situ	Male	- 4	6,622	- 60.6	- 51.0	0.0	1.000	5	4,390,288	0.1	
Breast - in situ Cervix	Female Female	- 4	6,391 6,391	62.6	51.8	2.2 0.4	0.351 1.000	1,230 304	4,368,527 4,368,527	28.2 7.0	
Colorectal	Total	5	13,013	38.4	28.4	6.9	0.618	3,446	8,758,815	39.3	
Colorectal	Male	3	6,622	45.3	32.5	4.0	0.869	1,900	4,390,288	43.3	
Colorectal	Female	2	6,391	31.3	23.7	3.0	0.855	1,546	4,368,527	35.4	
Corpus Uteri	Female Total	2	6,391 13,013	31.3 7.7	24.7 5.4	2.5 1.1	1.000 1.000	1,328 505	4,368,527 8,758,815	30.4 5.8	
Esophagus Esophagus	Male		6,622	15.1	10.2	0.9	1.000	423	4,390,288	9.6	
Esophagus	Female	- '	6,391	-		0.2	1.000	82	4,368,527	1.9	
Hodgkin Lymphoma	Total	-	13,013	-	-	0.3	1.000	210	8,758,815	2.4	
Hodgkin Lymphoma	Male .	-	6,622	-	-	0.2	1.000	118	4,390,288	2.7	
Hodgkin Lymphoma Kidney and Renal Pelvis	Female Total	- 3	6,391 13,013	23.1	17.3	0.1 3.6	1.000 1.000	92 1,812	4,368,527 8,758,815	2.1 20.7	
Kidney and Renal Pelvis	Male	2	6,622	30.2	21.8	2.5	1.000	1,180	4,390,288	26.9	
Kidney and Renal Pelvis	Female	1	6,391	15.6	12.1	1.2	1.000	632	4,368,527	14.5	
Larynx	Total	-	13,013	-	-	0.5	1.000	215	8,758,815	2.5	
Larynx	Male	-	6,622	-	-	0.4	1.000	160	4,390,288	3.6	
Larynx Leukemia	Female Total	- 5	6,391 13,013	38.4	28.0	0.1 3.3	1.000 0.482	55 1,626	4,368,527 8,758,815	1.3 18.6	
Leukemia	Male	3	6,622	45.3	31.7	2.1	0.715	986	4,390,288	22.5	
Leukemia	Female	2	6,391	31.3	23.7	1.2	0.702	640	4,368,527	14.7	
Liver and Bile Duct	Total	1	13,013	7.7	5.5	1.7	0.977	828	8,758,815	9.5	
Liver and Bile Duct Liver and Bile Duct	Male Female	1	6,622 6,391	15.1	10.4	1.3 0.5	1.000 1.000	589 239	4,390,288 4,368,527	13.4 5.5	
Lung and Bronchus	Total	14	13,013	107.6	73.0	10.7	0.378	4,873	8,758,815	55.6	
Lung and Bronchus	Male	8	6,622	120.8	77.3	5.8	0.448	2,444	4,390,288	55.7	
Lung and Bronchus	Female	6	6,391	93.9	67.3	5.0	0.753	2,429	4,368,527	55.6	
Melanoma of the Skin	Total	8	13,013	61.5	47.0	5.7	0.432	2,934	8,758,815	33.5	
Melanoma of the Skin Melanoma of the Skin	Male Female	4 4	6,622 6,391	60.4 62.6	42.7 52.3	3.8 2.1	1.000 0.305	1,761 1,173	4,390,288 4,368,527	40.1 26.9	
Myeloma	Total	6	13,013	46.1	31.9	1.5	0.009 >>	702	8,758,815	8.0	
Myeloma	Male	5	6,622	75.5	49.3	1.0	0.008 >>	436	4,390,288	9.9	
Myeloma	Female	1	6,391	15.6	11.4	0.5	0.830	266	4,368,527	6.1	
Non-Hodgkin Lymphoma Non-Hodgkin Lymphoma	Total Male	4 2	13,013 6,622	30.7 30.2	22.5 21.2	3.9 2.4	1.000 1.000	1,936 1,127	8,758,815 4,390,288	22.1 25.7	
Non-Hodgkin Lymphoma	Female	2	6,391	31.3	23.5	1.6	0.934	809	4,390,266	18.5	
Oral Cavity and Pharynx	Total	4	13,013	30.7	22.8	2.6	0.523	1,291	8,758,815	14.7	
Oral Cavity and Pharynx	Male	3	6,622	45.3	32.4	2.0	0.630	933	4,390,288	21.3	
Oral Cavity and Pharynx	Female	1 2	6,391	15.6	12.1	0.7	0.986 0.515	358	4,368,527 4,368,527	8.2	
Ovary Pancreas	Female Total		6,391 13,013	31.3	24.7	1.0 3.1	0.515	531 1,423	8,758,815	12.2 16.2	
Pancreas	Male	_	6,622	_	-	1.8	0.334	784	4,390,288	17.9	
Pancreas	Female		6,391		-	1.3	0.547	639	4,368,527	14.6	
Prostate	Male	6	6,622	90.6	60.6	14.5	0.021 <<	6,411	4,390,288	146.0	
Stomach Stomach	Total Male	1	13,013 6,622	7.7	5.5	1.0 0.7	1.000 1.000	466 309	8,758,815 4,390,288	5.3 7.0	
Stomach	Female	1	6,391	- 15.6	11.8	0.7	0.526	157	4,390,266	3.6	
Testis	Male	- :	6,622	-		0.3	1.000	265	4,390,288	6.0	
Thyroid	Total	4	13,013	30.7	28.9	1.9	0.257	1,216	8,758,815	13.9	
Thyroid	Male	1	6,622	15.1	12.8	0.6	0.935	354	4,390,288	8.1	
Thyroid	Female	3	6,391	46.9	46.3	1.3	0.276	862	4,368,527	19.7	
Pediatric Age 0 to 19	Total	1	3,406	29.4	30.1	0.6	0.868	420	2,457,117	17.1	
Pediatric Age 0 to 19 Pediatric Age 0 to 19	Male Female	- 1	1,748 1,658	- 60.3	- 62.3	0.3 0.3	1.000 0.463	223 197	1,254,762 1,202,355	17.8 16.4	
			1,000			0.3	0.403	197	1,202,333	I 10.4	

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

<sup>2.</sup> Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

<sup>&</sup>quot;<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

### **TABLE 4: CANCER MORTALITY 2017–2021** COMPARISON BETWEEN BUTTE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

Cause of Death Cancer Site/Type         Sex         Deaths         Person Years         Crude Rate (1)         A.A.M. Rate (1,2)         Expected Deaths (3)         P-Value (4)         Observed Deaths         Person Years           All Causes of Death All Causes of Death All Causes of Death Female         1483         13,094         1,397.6         944.3         166.8         0.226         77,247         8,975,62           All Causes of Death All Causes of Death Female         69         6,447         1,715.1         1,164.7         89.0         0.012 >>         40,942         4,505,22           All Causes of Death All Malignant Cancers         Total         37         13,094         282.6         191.7         32.4         0.467         15,084         8,975,62           All Malignant Cancers         Male         23         6,647         346.0         225.7         18.4         0.342         8,153         4,505,22           All Malignant Cancers         Female         14         6,447         217.2         153.1         14.2         1.000         6,931         4,470,44           Bladder         Total         2         13,094         15.3         9.7         1.1         0.616         487         8,975,62           Bladder         Female         -	1 908.8 0 812.1 1 168.1 1 181.0 0 155.0 1 8.3 0 2.5 1 5.6
Cancer Site/Type         Sex         Deaths         Years         Rate (1)         Rate (1,2)         Deaths (3)         P-Value (4)         Deaths         Years           All Causes of Death         Total         183         13,094         1,397.6         944.3         166.8         0.226         77,247         8,975,62           All Causes of Death         Male         114         6,647         1,715.1         1,164.7         89.0         0.012 >>         40,942         4,505,22           All Causes of Death         Female         69         6,447         1,070.3         709.9         78.9         0.287         36,305         4,470,44           All Malignant Cancers         Total         37         13,094         282.6         191.7         32.4         0.467         15,084         8,975,62           All Malignant Cancers         Male         23         6,647         346.0         225.7         18.4         0.342         8,153         4,505,22           All Malignant Cancers         Female         14         6,447         217.2         153.1         14.2         1.000         6,931         4,470,44           Bladder         Total         2         13,094         15.3         9.7         1.1	Rate (1) 1 860.6 1 908.8 0 812.1 1 168.1 1 181.0 0 155.0 1 5.4 1 8.3 0 2.5 1 5.6
All Causes of Death         Total         183         13,094         1,397.6         944.3         166.8         0.226         77,247         8,975,62           All Causes of Death         Male         114         6,647         1,715.1         1,164.7         89.0         0.012 >>         40,942         4,505,22           All Causes of Death         Female         69         6,447         1,070.3         709.9         78.9         0.287         36,305         4,470,44           All Malignant Cancers         Total         37         13,094         282.6         191.7         32.4         0.467         15,084         8,975,62           All Malignant Cancers         Male         23         6,647         346.0         225.7         18.4         0.342         8,153         4,505,22           All Malignant Cancers         Female         14         6,447         217.2         153.1         14.2         1.000         6,931         4,470,44           Bladder         Total         2         13,094         15.3         9.7         1.1         0.616         487         8,975,62           Bladder         Male         2         6,647         30.1         18.9         0.9         0.443         376<	1 860.6 1 908.8 0 812.1 1 168.1 1 181.0 0 155.0 1 8.3 0 2.5 1 5.6
All Causes of Death       Male       114       6,647       1,715.1       1,164.7       89.0       0.012 >>       40,942       4,505,22         All Causes of Death       Female       69       6,447       1,070.3       709.9       78.9       0.287       36,305       4,470,44         All Malignant Cancers       Total       37       13,094       282.6       191.7       32.4       0.467       15,084       8,975,62         All Malignant Cancers       Male       23       6,647       346.0       225.7       18.4       0.342       8,153       4,505,22         All Malignant Cancers       Female       14       6,447       217.2       153.1       14.2       1.000       6,931       4,470,44         Bladder       Total       2       13,094       15.3       9.7       1.1       0.616       487       8,975,62         Bladder       Male       2       6,647       30.1       18.9       0.9       0.443       376       4,505,22         Bladder       Female       -       6,447       -       -       0.2       1.000       111       4,470,40         Brain and Other Nervous System       Male       1       13,094       7.6	1 908.8 0 812.1 1 168.1 1 181.0 0 155.0 1 8.3 0 2.5 1 5.6
All Causes of Death         Female         69         6,447         1,070.3         709.9         78.9         0.287         36,305         4,470,40           All Malignant Cancers         Total         37         13,094         282.6         191.7         32.4         0.467         15,084         8,975,62           All Malignant Cancers         Male         23         6,647         346.0         225.7         18.4         0.342         8,153         4,505,22           All Malignant Cancers         Female         14         6,447         217.2         153.1         14.2         1.000         6,931         4,470,40           Bladder         Total         2         13,094         15.3         9.7         1.1         0.616         487         8,975,62           Bladder         Male         2         6,647         30.1         18.9         0.9         0.443         376         4,505,22           Bladder         Female         -         6,447         -         -         0.2         1.000         111         4,470,40           Brain and Other Nervous System         Total         1         13,094         7.6         5.7         1.0         1.000         503         8,975,62	0 812.1 1 168.1 1 181.0 0 155.0 1 5.4 1 8.3 0 2.5 1 5.6
All Malignant Cancers         Total         37         13,094         282.6         191.7         32.4         0.467         15,084         8,975,62           All Malignant Cancers         Male         23         6,647         346.0         225.7         18.4         0.342         8,153         4,505,22           All Malignant Cancers         Female         14         6,447         217.2         153.1         14.2         1.000         6,931         4,470,40           Bladder         Total         2         13,094         15.3         9.7         1.1         0.616         487         8,975,62           Bladder         Male         2         6,647         30.1         18.9         0.9         0.443         376         4,505,22           Bladder         Female         -         6,447         -         -         0.2         1.000         111         4,470,40           Brain and Other Nervous System         Total         1         13,094         7.6         5.7         1.0         1.000         503         8,975,62           Brain and Other Nervous System         Male         1         6,647         15.0         10.9         0.6         0.909         297         4,505,22	1 168.1 1 181.0 0 155.0 1 5.4 1 8.3 0 2.5 1 5.6
All Malignant Cancers         Male         23         6,647         346.0         225.7         18.4         0.342         8,153         4,505,22           All Malignant Cancers         Female         14         6,447         217.2         153.1         14.2         1.000         6,931         4,470,40           Bladder         Total         2         13,094         15.3         9.7         1.1         0.616         487         8,975,62           Bladder         Male         2         6,647         30.1         18.9         0.9         0.443         376         4,505,22           Bladder         Female         -         6,447         -         -         0.2         1.000         111         4,470,40           Brain and Other Nervous System         Total         1         13,094         7.6         5.7         1.0         1.000         503         8,975,62           Brain and Other Nervous System         Male         1         6,647         15.0         10.9         0.6         0.909         297         4,505,22           Breast         Total         3         13,094         22.9         16.2         2.3         0.793         1,099         8,975,62	1     181.0       0     155.0       1     5.4       1     8.3       0     2.5       1     5.6
All Malignant Cancers         Female         14         6,447         217.2         153.1         14.2         1.000         6,931         4,470,40           Bladder         Total         2         13,094         15.3         9.7         1.1         0.616         487         8,975,62           Bladder         Male         2         6,647         30.1         18.9         0.9         0.443         376         4,505,22           Bladder         Female         -         6,447         -         -         0.2         1.000         111         4,470,40           Brain and Other Nervous System Brain and Other Nervous System Brain and Other Nervous System Brain and Other Nervous System         1         6,647         15.0         10.9         0.6         0.909         297         4,505,22           Breast         Total         3         13,094         22.9         16.2         2.3         0.793         1,099         8,975,62           Breast         Male         1         6,647         15.0         9.9         0.0         0.066         15         4,505,22	0 155.0 1 5.4 1 8.3 0 2.5 1 5.6
Bladder         Male         2         6,647         30.1         18.9         0.9         0.443         376         4,505,22           Bladder         Female         -         6,447         -         -         0.2         1.000         111         4,470,46           Brain and Other Nervous System Brain and Other Nervou	1 8.3 0 2.5 1 5.6
Bladder         Female         -         6,447         -         -         0.2         1.000         111         4,470,40           Brain and Other Nervous System Brain and Other Nervous System Brain and Other Nervous System Brain and Other Nervous System Brain and Other Nervous System Breast         1         6,647         15.0         10.9         0.6         0.909         297         4,505,22           Breast         Total         3         13,094         22.9         16.2         2.3         0.793         1,099         8,975,62           Breast         Male         1         6,647         15.0         9.9         0.0         0.066         15         4,505,22	0 2.5 1 5.6
Brain and Other Nervous System Brain and Other Nervous System Brain and Other Nervous System Brain and Other Nervous System Brain and Other Nervous System Brain and Other Nervous System Brain and Other Nervous System Breast Total 3 13,094 22.9 16.2 2.3 0.793 1,099 8,975,62         1.0 1.000 503 8,975,62           Brain and Other Nervous System Breast Male         1 6,647 15.0 10.9 0.6 0.909 297 4,505,22           Breast Male         - 6,447 0.4 1.000 206 4,470,40           Breast Male         3 13,094 22.9 16.2 2.3 0.793 1,099 8,975,62           Breast Male         1 6,647 15.0 9.9 0.0 0.066 15 4,505,22	1 5.6
Brain and Other Nervous System         Male         1         6,647         15.0         10.9         0.6         0.909         297         4,505,22           Brain and Other Nervous System         Female         -         6,447         -         -         0.4         1.000         206         4,470,40           Breast         Total         3         13,094         22.9         16.2         2.3         0.793         1,099         8,975,62           Breast         Male         1         6,647         15.0         9.9         0.0         0.066         15         4,505,22	
Brain and Other Nervous System         Female         -         6,447         -         -         0.4         1.000         206         4,470,40           Breast         Total         3         13,094         22.9         16.2         2.3         0.793         1,099         8,975,62           Breast         Male         1         6,647         15.0         9.9         0.0         0.066         15         4,505,22	11 66
Breast Total 3 13,094 22.9 16.2 2.3 0.793 1,099 8,975,62 Breast Male 1 6,647 15.0 9.9 0.0 0.066 15 4,505,22	
Breast   Male   1   6,647   15.0   9.9   0.0   0.066   15   4,505,22	
Breast   Male   1   6,647   15.0   9.9   0.0   0.066   15   4,505,2	
Breast Female 2 6,447 31.0 22.5 2.2 1.000 1,084 4,470,40	
Breast         Female         2         6,447         31.0         22.5         2.2         1.000         1,084         4,470,40           Cervix         Female         -         6,447         -         -         0.1         1.000         83         4,470,40	
Colorectal Total 3 13,094 22.9 16.0 2.8 1.000 1,316 8,975,62	
Colorectal Male 2 6,647 30.1 20.8 1.5 0.904 717 4,505,22	1 15.9
Colorectal Female 1 6.447 15.5 10.8 1.2 1.000 599 4.470,40	
Corpus Uteri   Female   -   6,447   -   -   0.3   1.000   173   4,470,41	
Esophagus Total - 13,094 1.0 0.729 477 8,975,62	
Esophagus   Male   -   6,647   -   -   0.9   0.819   401   4,505,22	
Esophagus   Female   -   6,447   -   -   0.2   1.000   76   4,470,40	0 1.7
Hodgkin Lymphoma Total - 13,094 0.1 1.000 29 8,975,62	
Hodgkin Lymphoma   Male   -   6,647   -   -   0.0   1.000   14   4,505,22	
Hodgkin Lymphoma Female - 6,447 0.0 1.000 15 4,470,40	0.3
Kidney Total 2 13,094 15.3 10.2 0.8 0.409 383 8,975,62	
Kidney Male 2 6,647 30.1 19.6 0.5 0.207 240 4,505,22	
Kidney Female - 6,447 0.3 1.000 143 4,470,40	
Larynx Total - 13,094 0.2 1.000 71 8,975,62	
1,500,22	
Larynx Female - 6,447 0.0 1.000 13 4,470,40 Leukemia Total 2 13,094 15.3 10.2 1.4 0.844 658 8,975,62	
Leukemia Male - 6,647 0.9 0.834 386 4,505,22	
Leukemia Female 2 6,447 31.0 21.0 0.6 0.230 272 4,470,40	
Liver and Bile Duct Total 2 13,094 15.3 10.6 1.3 0.723 601 8,975,62	
Liver and Bile Duct Male 2 6,647 30.1 19.9 0.9 0.458 406 4,505,22	
Liver and Bile Duct Female - 6,447 0.4 1.000 195 4,470,40	0 4.4
Lung and Bronchus Total 10 13,094 76.4 51.0 6.4 0.237 2,951 8,975,62	1 32.9
Lung and Bronchus   Male   6   6,647   90.3   57.6   3.6   0.308   1,550   4,505,22	1 34.4
Lung and Bronchus   Female   4   6,447   62.0   43.2   2.9   0.662   1,401   4,470,40	
Melanoma of the Skin Total 1 13,094 7.6 5.3 0.6 0.906 288 8,975,62	
Melanoma of the Skin Male - 6,647 0.4 1.000 192 4,505,22	1 4.3
Melanoma of the Skin Female 1 6,447 15.5 11.5 0.2 0.341 96 4,470,40	
Myeloma Total 2 13,094 15.3 9.9 0.7 0.338 329 8,975,62	
Myeloma Male 2 6,647 30.1 18.8 0.5 0.156 194 4,505,22 Myeloma Female - 6.447 0.3 1,000 135 4,470,40	
Myeloma         Female         -         6,447         -         -         0.3         1.000         135         4,470,40           Non-Hodgkin Lymphoma         Total         2         13,094         15.3         10.1         1.2         0.709         567         8,975,62	
Non-Hodgkin Lymphoma Male 1 6,647 15.0 9.9 0.7 0.996 306 4,505,22	
Non-Hodgkin Lymphoma Female 1 6,447 15.5 10.3 0.6 0.867 261 4,470,40	
Oral Cavity and Pharynx Total - 13,094 0.6 1.000 266 8,975,62	
Oral Cavity and Pharynx Male - 6,647 0.4 1.000 187 4,505,22	
Oral Cavity and Pharynx   Female   -   6,447   -   -   0.2   1.000   79   4,470,44	
Ovary Female 1 6,447 15.5 11.1 0.7 1.000 349 4,470,40	
Pancreas Total - 13,094 2.6 0.154 1,190 8,975,62	
Pancreas   Male   -   6,647   -   1.5   0.463   642   4,505,22	
Pancreas   Female   -   6,447   -   -   1.1   0.655   548   4,470,40	
Prostate Male - 6,647 2.3 0.210 949 4,505,22	
Stomach Total 1 13,094 7.6 5.4 0.4 0.666 197 8,975,62	
Stomach Male - 6,647 0.3 1.000 121 4,505,22	
Stomach   Female   1   6,447   15.5   11.3   0.2   0.279   76   4,470,40	0 1.7

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

<sup>2.</sup> Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

### Cancer Screening and Risk Factor Prevalence Estimates, 2011–2021

	State of								Butte
Measure	Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	County
Access to Care									
Have Health Insurance, Age <65 (2015–2021)	83.1%	82.8%	85.1%	77.2%	85.8%	78.9%	85.4%	85.4%	77.8%
Not See Doctor Due to Cost in Past Year (2015–2021)	12.6%	11.4%	11.8%	14.5%	12.4%	12.3%	11.8%	12.9%	9.9%
Cancer Screening									
Mammogram Past 2 Years, Age 50–74 (2014, 2016, 2018, 2020)	69.1%	67.0%	73.8%	68.2%	73.2%	64.8%	64.5%	67.1%	
Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020)	71.2%	73.6%	73.6%	70.8%	72.9%	69.1%	69.5%	65.9%	
Colorectal Cancer Screening, Age 50–75 (2018, 2020)	67.9%	66.9%	73.6%	71.4%	70.6%	61.7%	61.5%	64.7%	
Tobacco Use									
Current Tobacco User (2016–2021)	22.3%	26.7%	23.1%	23.6%	21.8%	21.4%	22.7%	16.9%	24.8%
Other Cancer-Related \									
Healthy Weight by Body Mass Index, Age 20+ (2015–2021)	32.1%	32.8%	31.7%	27.9%	36.1%	29.8%	27.9%	31.9%	33.0%
Any Physical Activity Besides Job Past 30 Days (2015-2021)	78.7%	79.2%	78.1%	74.5%	83.2%	73.4%	76.3%	79.7%	71.6%
Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019)	21.9%	22.8%	19.4%	20.0%	25.2%	19.5%	20.4%	20.2%	17.2%
Home Ever Tested for Radon (2016, 2018, 2020)	23.0%	30.9%	18.2%	16.9%	25.1%	19.9%	23.0%	21.8%	39.5%

### **Access to Care**

### Have Health Insurance – 2015–2021

Statewide, 83.1% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 86.0% of white non-Hispanics, compared to 64.8% of Hispanics and 83.3% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3%) than English-speaking respondents (84.2%). Health care coverage differed significantly by age of respondent, with 79.8% of persons aged 18–29, and 87.8% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 62.1% in Adams County to 91.6% in Oneida County having health insurance.

### Not See Doctor Due to Cost in Past Year - 2015-2021

Statewide, 12.6% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (11.5% of white non-Hispanics, 19.2% of Hispanics, and 21.0% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9% for less than \$15,000, 6.1% for greater than \$50,000). Inability to see a doctor due to cost differed significantly by county, with a range of 7.4% in Franklin County to 17.5% in Power County.

### **Cancer Screening**

Mammogram - 2014, 2016, 2018, 2020

Statewide, 69.1% of women aged 50–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (72.1% versus 36.7%). Mammography rates differed significantly by county, with a range in screening of 45.9% in Benewah County to 77.0% in Nez Perce County. In 2020, Idaho ranked 48th among states and the District of Columbia for mammography screening rates among women aged 50–74 and also 48th among ages 40+.

### Pap Test - 2018, 2020

Statewide, 71.2% of women with an intact cervix and aged 21–65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.1% versus 52.6% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.7% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49<sup>th</sup> among states and the District of Columbia for Pap screening rate.

### Colorectal Cancer Screening – 2018, 2020

Statewide, 67.9% of adults aged 50–75 reported being current for colorectal cancer screening.\*\* Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked 47<sup>th</sup> among states and the District of Columbia in the percentage of adults aged 50–75 and older who reported being up-to-date for colorectal cancer screening.

<sup>\*\*</sup> Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

### **Tobacco Use**

### Current Tobacco Use - 2016-2021

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.3% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 29.9% of persons aged 18-29, and 11.1% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (22.4%) than among Native Americans (40.0%). Tobacco use differed significantly by county, with a range of 5.4% in Madison County to 41.6% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

### **Other Cancer-Related**

### Healthy Weight by Body Mass Index - 2015-2021

Statewide, 32.1% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 32.5% of white non-Hispanics, compared to 28.2% of Hispanics and 24.6% of Native Americans, being in the healthy weight range. Males (25.5%) were significantly less likely to be in the healthy weight range than females (38.6%). BMI differed significantly by age of respondent, with 43.3% of persons aged 18–29, and 26.0% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 19.8% in Power County to 47.4% in Blaine County of adults being in the healthy weight range.

### Any Physical Activity - 2015-2021

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 78.7% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.3% of persons aged 18–29, and 72.3% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 64.3% in Clark County to 84.6% in Teton County.

Physical Activity Guidelines – 2011, 2013, 2015, 2017, 2019 Statewide, 21.9% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.3% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6% in Franklin County to 30.6% in Blaine County.

### Home Radon Testing - 2016, 2018, 2020

Statewide, 23.0% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.4% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.5% in Cassia County to 54.4% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006l and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.





# CAMAS COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

### Cancer Incidence 2016–2020 Cancer Mortality 2017–2021 BRFSS 2011–2021

### **RISK FACTORS AND INTERVENTIONS**

### **CANCER**

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/jama.2016.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

### Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

### **Smoking:**

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

### Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <a href="https://www.dietaryguidelines.gov">https://www.dietaryguidelines.gov</a>

### Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute
Cancer Information Services
1-800-4CANCER
<a href="https://www.cancer.gov/contact">https://www.cancer.gov/contact</a>

American Cancer Society <a href="https://www.cancer.org">https://www.cancer.org</a>

### **CANCER INCIDENCE 2016–2020**

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016–2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 35 cases of invasive cancer were diagnosed among Camas County residents (Table 1).

**Table 1:** Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Camas County and the State of Idaho, 2016–2020

Cancer Incidence 2016–2020	Camas County	State of Idaho
All Sites/Types	35	45,610
Female Breast	2	6,687
Prostate	7	6,417
Lung & Bronchus	5	4,887
Colorectal	3	3,451

Table 3 (Cancer Incidence 2016–2020, Comparison between Camas County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Camas County. The table also shows the number of observed cases, person-

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Camas County was 637.6 cases per 100,000 person-years per year during 2016–2020. Comparing this crude rate with the crude rate for the remainder of Idaho (519.9) gives an estimate of the relative burden of disease in Camas County.

The age- and sex-adjusted incidence rate of invasive cancer in Camas County, all sites combined, was 485.6 cases per 100,000 persons per year during 2016–2020. There were fewer cases of cancer in Camas County (35) than expected (37.5) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

### **CANCER MORTALITY 2017–2021**

During 2017–2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 16 Camas County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

**Table 2:** Overall and Cancer Mortality in Camas County and the State of Idaho, 2017–2021

Mortality 2017–2021	Camas County	State of Idaho
All Deaths	60	77,431
Cancer Deaths	16	15,121
% of All Deaths	26.7%	19.5%
Lung & Bronchus	2	2,961
Colorectal	1	1,319
Pancreas	0	1,190
Female Breast	0	1,086
Prostate	4	949

Table 4 (Cancer Mortality 2017–2021, Comparison between Camas County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Camas County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Camas County, all sites combined, was 217.2 deaths per 100,000 persons per year during 2017–2021, compared with 168.1 for the remainder of the state. There were more cancer deaths in Camas County (16) than expected (12.4) based upon rates in the remainder of the state, but the difference was not statistically significant.

**Statistical Note:** Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

### TABLE 3: CANCER INCIDENCE 2016–2020 COMPARISON BETWEEN CAMAS COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

		Camas County					Remainder of Idaho			
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)
All Sites Combined	Total	35	5,489	637.6	485.6	37.5	0.766	45,575	8,766,339	519.9
All Sites Combined	Male	19	2,830	671.4	455.1	23.1	0.468	24,270	4,394,080	552.3
All Sites Combined Bladder	Female Total	16	2,659 5,489	601.7 18.2	510.1 13.5	15.3 1.8	0.922 0.897	21,305 2,183	4,372,259 8,766,339	487.3 24.9
Bladder	Male		2,830	35.3	23.2	1.7	0.897	1,750	4,394,080	39.8
Bladder	Female	- '	2,659	-	-	0.3	1.000	433	4,372,259	9.9
Brain - malignant	Total	-	5,489	-	-	0.5	1.000	625	8,766,339	7.1
Brain - malignant	Male	-	2,830	-	-	0.3	1.000	375	4,394,080	8.5
Brain - malignant	Female Total	- 3	2,659 5,489	- 54.7	- 43.5	0.2 1.1	1.000 0.206	250 1,421	4,372,259 8,766,339	5.7 16.2
Brain and other CNS - non-malignant Brain and other CNS - non-malignant	Male	2	2,830	70.7	43.5 53.2	0.4	0.206	478	4,394,080	10.2
Brain and other CNS - non-malignant	Female	1	2,659	37.6	32.3	0.7	0.974	943	4,372,259	21.6
Breast	Total	2	5,489	36.4	27.9	5.5	0.174	6,744	8,766,339	76.9
Breast	Male		2,830		-	0.1	1.000	59	4,394,080	1.3
Breast in city	Female Total	2	2,659 5,489	75.2 -	62.8	4.9 1.0	0.272 0.718	6,685 1,239	4,372,259 8,766,339	152.9 14.1
Breast - in situ Breast - in situ	Male	-	2,830	_	_	0.0	1.000	1,239	4,394,080	0.1
Breast - in situ	Female	_	2,659	-	_	0.0	0.803	1,234	4,372,259	28.2
Cervix	Female	-	2,659	-	-	0.2	1.000	304	4,372,259	7.0
Colorectal	Total	3	5,489	54.7	42.4	2.8	1.000	3,448	8,766,339	39.3
Colorectal	Male	3	2,830	106.0	75.2	1.7	0.498 0.662	1,900	4,394,080	43.2
Colorectal Corpus Uteri	Female Female	- 1	2,659 2,659	37.6	30.9	1.1 1.0	1.000	1,548 1,329	4,372,259 4,372,259	35.4 30.4
Esophagus	Total	- '	5,489	-	-	0.4	1.000	506	8,766,339	5.8
Esophagus	Male	-	2,830	-	-	0.4	1.000	424	4,394,080	9.6
Esophagus	Female	-	2,659	-	-	0.1	1.000	82	4,372,259	1.9
Hodgkin Lymphoma	Total	-	5,489	-	-	0.1	1.000	210	8,766,339	2.4
Hodgkin Lymphoma Hodgkin Lymphoma	Male Female	-	2,830 2,659	-	-	0.1 0.1	1.000 1.000	118 92	4,394,080 4,372,259	2.7 2.1
Kidney and Renal Pelvis	Total	1	5,489	18.2	14.0	1.5	1.000	1,814	8.766.339	20.7
Kidney and Renal Pelvis	Male	- '	2,830	-	-	1.1	0.676	1,182	4,394,080	26.9
Kidney and Renal Pelvis	Female	1	2,659	37.6	32.1	0.5	0.726	632	4,372,259	14.5
Larynx	Total	-	5,489	-	-	0.2	1.000	215	8,766,339	2.5
Larynx Larynx	Male Female	-	2,830 2,659	-	-	0.2 0.0	1.000 1.000	160 55	4,394,080 4,372,259	3.6 1.3
Leukemia	Total	2	5,489	36.4	28.6	1.3	0.746	1,629	8,766,339	18.6
Leukemia	Male	1	2,830	35.3	25.2	0.9	1.000	988	4,394,080	22.5
Leukemia	Female	1	2,659	37.6	32.8	0.4	0.721	641	4,372,259	14.7
Liver and Bile Duct	Total	2	5,489	36.4	26.8	0.7	0.314	827	8,766,339	9.4
Liver and Bile Duct Liver and Bile Duct	Male Female	1 1	2,830 2,659	35.3 37.6	23.3 31.4	0.6 0.2	0.875 0.318	589 238	4,394,080 4,372,259	13.4
Lung and Bronchus	Total	5	5,489	91.1	67.1	4.2	0.802	4,882	8,766,339	55.7
Lung and Bronchus	Male	1	2,830	35.3	22.9	2.4	0.602	2,451	4,394,080	55.8
Lung and Bronchus	Female	4	2,659	150.4	126.3	1.8	0.205	2,431	4,372,259	55.6
Melanoma of the Skin	Total	1 1	5,489	18.2	14.3	2.3	0.642	2,941	8,766,339	33.5
Melanoma of the Skin Melanoma of the Skin	Male Female	_ '	2,830 2,659	35.3	24.8	1.6 0.8	1.000 0.880	1,764 1,177	4,394,080 4,372,259	40.1 26.9
Myeloma	Total	_	5,489	-	_	0.6	1.000	708	8,766,339	8.1
Myeloma	Male	-	2,830	-	-	0.4	1.000	441	4,394,080	10.0
Myeloma	Female	- ,	2,659	-	-	0.2	1.000	267	4,372,259	6.1
Non-Hodgkin Lymphoma Non-Hodgkin Lymphoma	Total Male	1	5,489 2,830	18.2	14.0	1.6	1.000 0.697	1,939 1,129	8,766,339 4,394,080	22.1 25.7
Non-Hodgkin Lymphoma Non-Hodgkin Lymphoma	Female	- 1	2,830 2,659	- 37.6	- 31.9	1.1 0.6	0.880	810	4,394,080	18.5
Oral Cavity and Pharynx	Total	2	5,489	36.4	27.2	1.1	0.590	1,293	8,766,339	14.7
Oral Cavity and Pharynx	Male	1	2,830	35.3	24.0	0.9	1.000	935	4,394,080	21.3
Oral Cavity and Pharynx	Female	1	2,659	37.6	31.2	0.3	0.462	358	4,372,259	8.2
Ovary Pancreas	Female Total	1 -	2,659 5,489	37.6	31.8	0.4 1.2	0.636 0.606	532 1,423	4,372,259 8,766,339	12.2 16.2
Pancreas Pancreas	Male	-	2,830	_		0.8	0.000	784	4,394,080	17.8
Pancreas	Female	-	2,659	-	-	0.5	1.000	639	4,372,259	14.6
Prostate	Male	7	2,830	247.3	158.6	6.4	0.927	6,410	4,394,080	145.9
Stomach	Total	-	5,489	-	-	0.4	1.000	467	8,766,339	5.3
Stomach	Male Female	-	2,830 2,659	-	-	0.3	1.000 1.000	309 158	4,394,080 4,372,259	7.0 3.6
Stomach Testis	Male	-	2,830	-	-	0.1 0.1	1.000	265	4,372,259	6.0
Thyroid	Total	2	5,489	36.4	32.7	0.1	0.419	1,218	8,766,339	13.9
Thyroid	Male		2,830	-	-	0.3	1.000	355	4,394,080	8.1
Thyroid	Female	2	2,659	75.2	71.7	0.6	0.212	863	4,372,259	19.7
Pediatric Age 0 to 19	Total	-	1,357	•	-	0.2	1.000	421	2,459,166	17.1
Pediatric Age 0 to 19	Male	-	642	-	-	0.1	1.000	223	1,255,868	17.8
Pediatric Age 0 to 19	Female	-	715	-	-	0.1	1.000	198	1,203,298	16.5

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

<sup>2.</sup> Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

<sup>&</sup>quot;<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

### **TABLE 4: CANCER MORTALITY 2017–2021** COMPARISON BETWEEN CAMAS COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

		Camas County						Remainder of Idaho		
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	60	5,550	1,081.1	843.0	61.3	0.935	77,370	8,983,165	861.3
All Causes of Death	Male	40	2,861	1,398.1	1,035.5	35.1	0.454	41,016	4.509.007	909.6
All Causes of Death	Female	20	2,689	743.8	598.8	27.1	0.194	36,354	4,474,158	812.5
All Malignant Cancers	Total	16	5,550	288.3	217.2	12.4	0.370	15,105	8,983,165	168.1
All Malignant Cancers	Male	12	2,861	419.4	290.3	7.5	0.157	8,164	4,509,007	181.1
All Malignant Cancers	Female	4	2,689	148.8	121.8	5.1	0.849	6,941	4,474,158	155.1
Bladder Bladder	Total Male	2 2	5,550 2,861	36.0 69.9	27.3 50.6	0.4 0.3	0.121 0.087	487 276	8,983,165 4,509,007	5.4 8.3
Bladder	Female		2,689	09.9	50.6	0.3	1.000	376 111	4,309,007	2.5
Brain and Other Nervous System	Total	-	5,550	-	-	0.1	1.000	504	8,983,165	5.6
Brain and Other Nervous System	Male	_	2,861	_	_	0.3	1.000	298	4,509,007	6.6
Brain and Other Nervous System	Female	_	2,689	_	_	0.1	1.000	206	4,474,158	4.6
Breast	Total	-	5,550	-	-	0.9	0.814	1,102	8,983,165	12.3
Breast	Male	-	2,861	-	-	0.0	1.000	16	4,509,007	0.4
Breast	Female	-	2,689	-	-	8.0	0.895	1,086	4,474,158	24.3
Cervix	Female	- ,	2,689	-	-	0.1	1.000	83	4,474,158	1.9
Colorectal	Total	1	5,550	18.0	13.8	1.1	1.000	1,318	8,983,165	14.7
Colorectal	Male	1	2,861	35.0	24.7	0.6	0.951	718	4,509,007	15.9
Colorectal Corpus Uteri	Female Female	-	2,689 2,689	-	-	0.4 0.1	1.000 1.000	600 173	4,474,158 4.474.158	13.4 3.9
Esophagus	Total	-	2,009 5,550	-	-	0.1	1.000	477	8,983,165	5.3
Esophagus	Male	-	2,861	_		0.4	1.000	401	4,509,007	8.9
Esophagus	Female	_	2,689	_	_	0.1	1.000	76	4,474,158	1.7
Hodgkin Lymphoma	Total	-	5,550	-	-	0.0	1.000	29	8,983,165	0.3
Hodgkin Lymphoma	Male	-	2,861	-	-	0.0	1.000	14	4,509,007	0.3
Hodgkin Lymphoma	Female	-	2,689	-	-	0.0	1.000	15	4,474,158	0.3
Kidney	Total	-	5,550	-	-	0.3	1.000	385	8,983,165	4.3
Kidney	Male	-	2,861	-	-	0.2	1.000	242	4,509,007	5.4
Kidney	Female Total	- 4	2,689	-	- 12.0	0.1	1.000	143	4,474,158	3.2
Larynx Larynx	Male	1	5,550 2,861	18.0 35.0	13.9 25.2	0.1 0.1	0.109 0.098	70 57	8,983,165 4,509,007	0.8 1.3
Larynx	Female	_ '	2,689	33.0	25.2	0.0	1.000	13	4,474,158	0.3
Leukemia	Total	1	5,550	18.0	14.0	0.5	0.816	659	8,983,165	7.3
Leukemia	Male	-	2,861	-	-	0.3	1.000	386	4,509,007	8.6
Leukemia	Female	1	2,689	37.2	30.9	0.2	0.359	273	4,474,158	6.1
Liver and Bile Duct	Total	2	5,550	36.0	26.4	0.5	0.185	601	8,983,165	6.7
Liver and Bile Duct	Male	1	2,861	35.0	23.1	0.4	0.648	407	4,509,007	9.0
Liver and Bile Duct	Female	1	2,689	37.2	30.3	0.1	0.267	194	4,474,158	4.3
Lung and Bronchus	Total	2	5,550 2,861	36.0	26.7	2.5 1.5	1.000	2,959 1,555	8,983,165	32.9 34.5
Lung and Bronchus Lung and Bronchus	Male Female	1 1	2,861 2,689	35.0 37.2	23.2 30.7	1.5	1.000 1.000	1,555 1,404	4,509,007 4,474,158	34.5
Melanoma of the Skin	Total	_ '	5,550	- 31.2	30.7	0.2	1.000	289	8,983,165	31.4
Melanoma of the Skin	Male	_	2,861	-	_	0.2	1.000	192	4,509,007	4.3
Melanoma of the Skin	Female	-	2,689	-	-	0.1	1.000	97	4,474,158	2.2
Myeloma	Total	-	5,550	-	-	0.3	1.000	331	8,983,165	3.7
Myeloma	Male	-	2,861	-	-	0.2	1.000	196	4,509,007	4.3
Myeloma	Female	-	2,689	-	-	0.1	1.000	135	4,474,158	3.0
Non-Hodgkin Lymphoma	Total	1	5,550	18.0	14.0	0.5	0.729	568	8,983,165	6.3
Non-Hodgkin Lymphoma	Male	- 1	2,861	- 27.0	-	0.3	1.000	307	4,509,007	6.8
Non-Hodgkin Lymphoma	Female	1	2,689 5,550	37.2	31.1	0.2	0.342	261 266	4,474,158	5.8 3.0
Oral Cavity and Pharynx Oral Cavity and Pharynx	Total Male	-	2,861	-	1 [ ]	0.2 0.2	1.000 1.000	266 187	8,983,165 4,509,007	4.1
Oral Cavity and Pharynx	Female	-	2,689	-	-	0.2	1.000	79	4,474,158	1.8
Ovary	Female	-	2,689	-	-	0.3	1.000	350	4,474,158	7.8
Pancreas	Total	-	5,550	-	-	1.0	0.738	1,190	8,983,165	13.2
Pancreas	Male	-	2,861	-	-	0.6	1.000	642	4,509,007	14.2
Pancreas	Female	-	2,689	-	-	0.4	1.000	548	4,474,158	12.2
Prostate	Male	4	2,861	139.8	99.9	0.8	0.021 >>	945	4,509,007	21.0
Stomach	Total	-	5,550	-	-	0.2	1.000	198	8,983,165	2.2
Stomach	Male	-	2,861	-	-	0.1	1.000	121	4,509,007	2.7
Stomach	Female	-	2,689	-		0.1	1.000	77	4,474,158	1.7

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

<sup>2.</sup> Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

### Cancer Screening and Risk Factor Prevalence Estimates, 2011–2021

	State of								Camas
Measure	Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	County
Access to Care									
Have Health Insurance, Age <65 (2015–2021)	83.1%	82.8%	85.1%	77.2%	85.8%	78.9%	85.4%	85.4%	
Not See Doctor Due to Cost in Past Year (2015–2021)	12.6%	11.4%	11.8%	14.5%	12.4%	12.3%	11.8%	12.9%	14.0%
Cancer Screening									
Mammogram Past 2 Years, Age 50–74 (2014, 2016, 2018, 2020)	69.1%	67.0%	73.8%	68.2%	73.2%	64.8%	64.5%	67.1%	
Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020)	71.2%	73.6%	73.6%	70.8%	72.9%	69.1%	69.5%	65.9%	
Colorectal Cancer Screening, Age 50–75 (2018, 2020)	67.9%	66.9%	73.6%	71.4%	70.6%	61.7%	61.5%	64.7%	
Tobacco Use									
Current Tobacco User (2016–2021)	22.3%	26.7%	23.1%	23.6%	21.8%	21.4%	22.7%	16.9%	
Other Cancer-Related									
Healthy Weight by Body Mass Index, Age 20+ (2015–2021)	32.1%	32.8%	31.7%	27.9%	36.1%	29.8%	27.9%	31.9%	
Any Physical Activity Besides Job Past 30 Days (2015-2021)	78.7%	79.2%	78.1%	74.5%	83.2%	73.4%	76.3%	79.7%	67.0%
Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019)	21.9%	22.8%	19.4%	20.0%	25.2%	19.5%	20.4%	20.2%	
Home Ever Tested for Radon (2016, 2018, 2020)	23.0%	30.9%	18.2%	16.9%	25.1%	19.9%	23.0%	21.8%	

### **Access to Care**

### Have Health Insurance - 2015-2021

Statewide, 83.1% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 86.0% of white non-Hispanics, compared to 64.8% of Hispanics and 83.3% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3%) than English-speaking respondents (84.2%). Health care coverage differed significantly by age of respondent, with 79.8% of persons aged 18–29, and 87.8% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 62.1% in Adams County to 91.6% in Oneida County having health insurance.

### Not See Doctor Due to Cost in Past Year - 2015-2021

Statewide, 12.6% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (11.5% of white non-Hispanics, 19.2% of Hispanics, and 21.0% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9% for less than \$15,000, 6.1% for greater than \$50,000). Inability to see a doctor due to cost differed significantly by county, with a range of 7.4% in Franklin County to 17.5% in Power County.

### **Cancer Screening**

<u>Mammogram</u> – 2014, 2016, 2018, 2020

Statewide, 69.1% of women aged 50–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (72.1% versus 36.7%). Mammography rates differed significantly by county, with a range in screening of 45.9% in Benewah County to 77.0% in Nez Perce County. In 2020, Idaho ranked 48<sup>th</sup> among states and the District of Columbia for mammography screening rates among women aged 50–74 and also 48<sup>th</sup> among ages 40+.

### Pap Test - 2018, 2020

Statewide, 71.2% of women with an intact cervix and aged 21–65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.1% versus 52.6% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.7% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49<sup>th</sup> among states and the District of Columbia for Pap screening rate.

### Colorectal Cancer Screening – 2018, 2020

Statewide, 67.9% of adults aged 50–75 reported being current for colorectal cancer screening.\*\* Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked 47<sup>th</sup> among states and the District of Columbia in the percentage of adults aged 50–75 and older who reported being up-to-date for colorectal cancer screening.

<sup>\*\*</sup> Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

### **Tobacco Use**

### Current Tobacco Use - 2016-2021

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.3% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 29.9% of persons aged 18-29, and 11.1% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (22.4%) than among Native Americans (40.0%). Tobacco use differed significantly by county, with a range of 5.4% in Madison County to 41.6% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

### **Other Cancer-Related**

### Healthy Weight by Body Mass Index - 2015-2021

Statewide, 32.1% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 32.5% of white non-Hispanics, compared to 28.2% of Hispanics and 24.6% of Native Americans, being in the healthy weight range. Males (25.5%) were significantly less likely to be in the healthy weight range than females (38.6%). BMI differed significantly by age of respondent, with 43.3% of persons aged 18–29, and 26.0% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 19.8% in Power County to 47.4% in Blaine County of adults being in the healthy weight range.

### Any Physical Activity - 2015-2021

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 78.7% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.3% of persons aged 18–29, and 72.3% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 64.3% in Clark County to 84.6% in Teton County.

Physical Activity Guidelines – 2011, 2013, 2015, 2017, 2019 Statewide, 21.9% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.3% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6% in Franklin County to 30.6% in Blaine County.

### Home Radon Testing - 2016, 2018, 2020

Statewide, 23.0% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.4% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.5% in Cassia County to 54.4% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006l and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.





# CANYON COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

### Cancer Incidence 2016–2020 Cancer Mortality 2017–2021 BRFSS 2011–2021

### **RISK FACTORS AND INTERVENTIONS**

### CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/jama.2016.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

### Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

### **Smoking:**

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

### Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <a href="https://www.dietaryguidelines.gov">https://www.dietaryguidelines.gov</a>

### Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute
Cancer Information Services
1-800-4CANCER
<a href="https://www.cancer.gov/contact">https://www.cancer.gov/contact</a>

American Cancer Society <a href="https://www.cancer.org">https://www.cancer.org</a>

### **CANCER INCIDENCE 2016–2020**

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016–2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 5,395 cases of invasive cancer were diagnosed among Canyon County residents (Table 1).

**Table 1:** Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Canyon County and the State of Idaho. 2016–2020

Cancer Incidence	Canyon	State of
2016–2020	County	ldaho
All Sites/Types	5,395	45,610
Female Breast	825	6,687
Prostate	721	6,417
Lung & Bronchus	593	4,887
Colorectal	413	3,451

Table 3 (Cancer Incidence 2016–2020, Comparison between Canyon County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Canyon County. The table also shows the number of observed cases, person-

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Canyon County was 481.9 cases per 100,000 person-years per year during 2016–2020. Comparing this crude rate with the crude rate for the remainder of Idaho (525.5) gives an estimate of the relative burden of disease in Canyon County.

The age- and sex-adjusted incidence rate of invasive cancer in Canyon County, all sites combined, was 548.8 cases per 100,000 persons per year during 2016–2020. There were statistically significantly more cases of cancer in Canyon County (5,395) than expected (5,166.5) based upon rates in the remainder of the state (p=.002).

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

### **CANCER MORTALITY 2017–2021**

During 2017–2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 1,723 Canyon County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

**Table 2:** Overall and Cancer Mortality in Canyon County and the State of Idaho, 2017–2021

Mortality 2017–2021	Canyon County	State of Idaho
All Deaths	8,896	77,431
Cancer Deaths	1,723	15,121
% of All Deaths	19.4%	19.5%
Lung & Bronchus	341	2,961
Colorectal	165	1,319
Pancreas	130	1,190
Female Breast	137	1,086
Prostate	90	949

Table 4 (Cancer Mortality 2017–2021, Comparison between Canyon County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Canyon County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Canyon County, all sites combined, was 175.3 deaths per 100,000 persons per year during 2017–2021, compared with 170.9 for the remainder of the state. There were more cancer deaths in Canyon County (1,723) than expected (1,680.1) based upon rates in the remainder of the state, but the difference was not statistically significant.

**Statistical Note:** Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

### TABLE 3: CANCER INCIDENCE 2016–2020 COMPARISON BETWEEN CANYON COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

	Sex	Observed	Person	Crude	A.A.I.	Expected		01 1		
All Sites Combined To		O-1		0.440	A.A.I.			Observed	Person	Crude
		Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)
	Γotal	5,395	1,119,451	481.9	548.8	5,166.5	0.002 >>	40,215	7,652,377	525.5
_	Male	2,808	555,176	505.8	585.9	2,679.6	0.014 >>	21,481	3,841,734	559.1
	emale	2,587	564,275	458.5 22.9	514.2 26.7	2,473.4	0.024 <b>&gt;&gt;</b> 0.354	18,734	3,810,643	491.6 25.2
	Гotal Иale	256 208	1,119,451 555,176	22.9 37.5	20.7 44.4	241.1 188.3	0.354 0.165	1,928 1,543	7,652,377 3,841,734	40.2
	emale	48	564,275	8.5	9.9	49.2	0.103	385	3,810,643	10.1
	Total	76	1,119,451	6.8	7.5	73.2	0.771	549	7,652,377	7.2
	Male	47	555,176	8.5	9.4	42.8	0.564	328	3,841,734	8.5
	emale	29	564,275	5.1	5.6	29.9	0.961	221	3,810,643	5.8
	Γotal	193	1,119,451	17.2	19.1	162.2	0.020 >>	1,231	7,652,377	16.1
	Male	77	555,176	13.9	15.3	52.7	0.002 >>	403	3,841,734	10.5
	Female Fotal	116 827	564,275 1,119,451	20.6 73.9	22.8 83.0	110.6 771.0	0.630 0.048 >>	828 5,919	3,810,643 7,652,377	21.7 77.3
	Male	2	555,176	0.4	0.4	7.71.0	0.048	57	3,841,734	1.5
	emale	825	564,275	146.2	163.0	778.4	0.101	5,862	3,810,643	153.8
	Γotal	150	1,119,451	13.4	14.9	143.2	0.591	1,089	7,652,377	14.2
	Male	-	555,176	-	-	0.6	1.000	5	3,841,734	0.1
	emale	150	564,275	26.6	29.4	145.2	0.714	1,084	3,810,643	28.4
	emale	54	564,275	9.6	9.9	35.8	0.005 >>	250	3,810,643	6.6
	Гotal Иale	413 230	1,119,451 555,176	36.9 41.4	42.0 47.5	390.4 210.9	0.265 0.203	3,038 1,673	7,652,377 3,841,734	39.7 43.5
	emale	183	564,275	32.4	47.5 36.7	178.6	0.203	1,873	3,810,643	35.8
	emale	166	564.275	29.4	33.1	153.2	0.739	1,363	3,810,643	30.5
- 1	Γotal	58	1,119,451	5.2	6.0	56.5	0.877	448	7,652,377	5.9
Esophagus M	Male	47	555,176	8.5	9.9	46.5	0.982	377	3,841,734	9.8
	emale	11	564,275	1.9	2.3	9.1	0.607	71	3,810,643	1.9
	Γotal	27	1,119,451	2.4	2.5	25.9	0.873	183	7,652,377	2.4
	Male	13	555,176	2.3 2.5	2.5	14.4	0.841 0.503	105	3,841,734	2.7 2.0
	Female Fotal	14 241	564,275 1,119,451	2.5	2.5 24.4	11.3 203.5	0.503	78 1,574	3,810,643 7,652,377	20.6
	Male	145	555,176	26.1	29.8	131.4	0.254	1,037	3,841,734	27.0
	emale	96	564,275	17.0	19.1	70.8	0.005 >>	537	3,810,643	14.1
	Γotal	31	1,119,451	2.8	3.2	23.1	0.134	184	7,652,377	2.4
	Male	24	555,176	4.3	5.1	16.6	0.105	136	3,841,734	3.5
	emale	7	564,275	1.2	1.4	6.2	0.860	48	3,810,643	1.3
	Γotal	193	1,119,451	17.2	19.4	186.6	0.658	1,438	7,652,377	18.8
	Male Female	112 81	555,176 564,275	20.2 14.4	22.9 16.1	111.7 74.0	1.000 0.443	877 561	3,841,734 3,810,643	22.8 14.7
	Total	107	1,119,451	9.6	11.0	91.7	0.128	722	7,652,377	9.4
	Male	77	555,176	13.9	16.2	63.6	0.114	513	3,841,734	13.4
	emale	30	564,275	5.3	6.0	27.2	0.642	209	3,810,643	5.5
3	Γotal	593	1,119,451	53.0	61.8	538.4	0.021 >>	4,294	7,652,377	56.1
	Male	308	555,176	55.5	65.5	262.3	0.006 >>	2,144	3,841,734	55.8
	emale	285	564,275	50.5	58.4	275.3	0.576	2,150	3,810,643	56.4
	Гotal Иale	282 167	1,119,451 555,176	25.2 30.1	28.3 34.5	346.7 201.6	0.000 <b>&lt;&lt;</b> 0.014 <b>&lt;&lt;</b>	2,660 1,598	7,652,377 3,841,734	34.8 41.6
	emale	115	564.275	20.4	22.3	143.5	0.014 <<	1,062	3.810.643	27.9
	Total	85	1,119,451	7.6	8.8	78.6	0.499	623	7,652,377	8.1
	Male	43	555,176	7.7	9.1	49.2	0.423	398	3,841,734	10.4
Myeloma F	emale	42	564,275	7.4	8.6	28.9	0.026 >>	225	3,810,643	5.9
	Γotal	232	1,119,451	20.7	23.6	219.7	0.424	1,708	7,652,377	22.3
	Male	139	555,176	25.0	28.6	125.1	0.233	990	3,841,734	25.8
	emale	93	564,275	16.5	18.7	93.7	1.000 0.694	718	3,810,643	18.8
	Гotal Иale	142 108	1,119,451 555,176	12.7 19.5	14.5 22.5	147.4 103.5	0.694 0.683	1,153 828	7,652,377 3,841,734	15.1 21.6
	emale	34	564,275	6.0	6.8	42.6	0.210	325	3,810,643	8.5
	emale	68	564,275	12.1	13.5	61.5	0.439	465	3,810,643	12.2
	Γotal	157	1,119,451	14.0	16.3	159.5	0.882	1,266	7,652,377	16.5
	Male	84	555,176	15.1	17.7	86.3	0.858	700	3,841,734	18.2
	emale	73	564,275	12.9	14.9	72.7	1.000	566	3,810,643	14.9
	Male	721	555,176	129.9	152.5	701.2	0.464	5,696	3,841,734	148.3
	Гotal Иale	66 40	1,119,451 555,176	5.9 7.2	6.8 8.4	50.9 33.3	0.048 >>	401 269	7,652,377 3,841,734	5.2 7.0
	emale	26	564,275	7.2 4.6	5.3	33.3 17.2	0.287 0.055	132	3,810,643	7.0 3.5
	Male	32	555,176	5.8	5.8	33.4	0.055	233	3,841,734	6.1
	Total	113	1,119,451	10.1	10.7	153.4	0.003	1,107	7,652,377	14.5
	Male	27	555,176	4.9	5.3	43.8	0.009 <<	328	3,841,734	8.5
	emale	86	564,275	15.2	15.9	110.9	0.003 <<	779	3,810,643	20.4
	Γotal	50	348,816	14.3	14.4	61.0	0.171	371	2,111,707	17.6
•	Male	30	178,131	16.8	16.9	31.8	0.834	193	1,078,379	17.9
	emale	20	170,685	11.7	11.8	29.2	0.095	178	1,033,328	17.2

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

<sup>2.</sup> Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

<sup>&</sup>quot;<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

### **TABLE 4: CANCER MORTALITY 2017–2021** COMPARISON BETWEEN CANYON COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

Cause of Death   Sex   Death   Sex   Death   Vears   Rate (1) Rate (1) Death (2) Death (3)   P-Value (4)   Death   Vears   Rate (1) Rate (1) Death (3)   P-Value (4)   Death   Vears   Rate (1) Rate (1) Death (3)   P-Value (4)   Death   Vears   Rate (1) Rate (1) Death (3)   P-Value (4)   Death   Vears   Rate (1) Rate (1) Death (3)   P-Value (4)   Death   Vears   Rate (1) Rate (1) Death (3)   P-Value (4)   P-Value (4)   P-Value (4)   Death (3)   P-Value (4)   P-			Canyon County						Re	Remainder of Idaho		
Cancer Site/Type	Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude	
All Causes of Death   Male   4,752   571,865   831,0   973.7   4,496.9   0,000   36,304   3,940,003   9,214   All Causes of Death   Famale   4,144   579,128   715.6   841.6   4,072   0,176   3,223   3,987,719   826.9   All Malignant Cancers   Total   1,723   1,150,1993   149.7   175.3   1,880.1   0,301   13,389   7,887,722   170.9   All Malignant Cancers   Male   82   571,886   161.2   161.0   869.0   0,276   3,400,003   164.1   Bladder   Male   82   571,886   161.2   161.0   869.0   0,276   3,400,003   164.1   Bladder   Male   87   1,150,1993   3,22   3,387,722   1,737,722   5.8   Bladder   Male   8   579,128   1,4   1,6   12.9   0,207   103   3,997,719   2,6   Brain and Other Nervous System   Total   55   1,150,1993   4.9   5.5   58.3   0,332   4.4   7,837,722   5.7   Brain and Other Nervous System   Male   31   571,869   5.4   0,2   34.0   0,689   267   3,340,003   6.8   Breast   All Causes   All Ca	Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)		P-Value (4)	Deaths	Years	Rate (1)	
All Causes of Death   Male   4,752   571,865   831.0   973.7   4,496.9   0.000 >> 36,304   3,340,003   9,214   All Causes of Death   Female   4,144   579,128   715.0   715.0   1,801.0   1,801.0   All Malignant Cancers   Total   1,723   1,350,393   1,497.1   1,752   1,350,393   1,497.1   1,752   1,350,393   1,497.1   1,472   1,753   1,801.1   1,301.0   All Malignant Cancers   Total   1,723   1,350,393   1,497.1   1,472	All Causes of Death	Total	8,896	1,150,993	772.9	906.7	8,579.3	0.001 >>	68,534	7,837,722	874.4	
All Melignant Cancers   Total   1,723   1,150,993   149,7   175,3   1,680,1   0,301   13,398   7,837,722   170,941   175,8163   180,816	All Causes of Death	Male			831.0	973.7	4,496.9	0.000 >>		3,940,003	921.4	
All Melignant Cancers   Male   922   571,865   161.2   191.0   888.9   0.276   7.254   3,940,003   184.1	All Causes of Death	Female			715.6	844.6	4,057.2	0.176		3,897,719	826.9	
All Melighant Cancers   Female   801   579,128   138.3   160.6   786.2   0.608   6,144   3,897,719   157.6   Bladder   Total   Male   29   571,865   5.1   6.2   41.8   0.048 < 49   3,940,003   8.9   Bladder   Male   29   571,865   5.1   6.2   41.8   0.048 < 49   3,940,003   8.9   Bladder   Male   29   571,865   5.1   6.2   41.8   0.048 < 49   3,940,003   8.9   Bladder   Male   29   571,865   5.1   6.2   41.8   0.048 < 49   3,940,003   8.9   Bladder   Male   51   1,791,865   5.4   6.2   53.4   0.088   427   7,940,003   5.6   Brain and Other Nervous System   Female   51   1,791,865   5.4   6.2   53.4   0.088   427   7,940,003   5.6   Breast   Female   137   1,150,993   11.9   13.8   122.2   0.200   965   7,837,722   12.3   Breast   Female   137   579,128   23.7   27.2   122.4   0.207   949   3,897,719   24.3   Cerivx   Female   16   579,128   23.7   27.2   122.4   0.207   949   3,897,719   24.3   Cerivx   Female   16   579,128   23.3   16.5   16.8												
Bladder												
Bladder   Male   29   571,865   5.1   6.2   41.8   0.048   34.9   3,940,003   8.9   Brain and Other Nervous System   Total   56   1,150,993   4.9   5.5   58.3   0.832   448   7,837,722   5.7   Brain and Other Nervous System   Male   31   571,865   5.4   6.2   34.0   0.089   26.7   3,940,003   6.6   Brain and Other Nervous System   Male   37   671,865   5.4   6.2   34.0   0.089   26.7   3,940,003   6.6   Brain and Other Nervous System   Male   37   671,865   1.0   1.3   2.22   0.200   365   7,837,722   12.3   Breast   Female   137   679,128   2.3   7.7   122.4   0.207   0.949   3,897,719   24.3   Breast   Female   137   679,128   2.3   7.7   122.4   0.207   0.949   3,897,719   24.3   Colorectal   Total   165   1,150,993   14.3   16.7   145.8   0.126   1,154   7,837,722   14.7   Colorectal   Male   88   571,865   1.4   17.9   78.6   0.317   33.1   3,940,003   6.0   Colorectal   Female   77   579,128   2.3   13.0   13.1   6.6   0.239   3.20   3.807,719   1.7   Colorectal   Female   77   579,128   13.3   13.4   16.7   145.8   0.126   1.54   7.837,722   14.7   Colorectal   Female   77   579,128   13.3   13.4   13.4   16.7   145.8   0.126   1.54   7.837,722   14.7   Colorectal   Female   77   579,128   13.3   13.4   13.4   16.7   145.8   0.126   1.54   7.837,722   13.4												
Bladder												
Brain and Other Nervous System   Total   56   1,160,993   4.9   5.5   58.3   0.832   448   7,837,722   5.7   5.7   5.7   5.7   5.8   5.8   3.4   0.885   267   3,940,003   6.8   5.8												
Brain and Other Nervous System Male Brain and Other Nervous System Female 25 579,128 4.3 4.8 24.0 0.689 267 3,940,003 6.8 Breast Total 137 1,150,993 11.9 13.8 122.2 0.200 965 7,837,722 12.3 Breast Male 1.7 579,128 23.7 27.2 12.24 0.207 949 3,887,719 4.6 Breast Female 137 579,128 23.7 27.2 12.24 0.207 949 3,887,719 24.3 Cerix Female 137 579,128 23.7 27.2 12.24 0.207 949 3,887,719 1.7 Colorectal Research 16 579,128 23.7 27.2 12.3 0.057 67 3,887,719 1.7 Colorectal Research 16 579,128 23.7 27.2 12.3 0.057 67 3,887,719 1.7 Colorectal Research 17 150,989 14.4 16.7 16.8 0.120 1.154 7.8 87,70 14.0 Colorectal Research 17 150,989 14.4 16.0 16.8 0.120 1.154 7.8 87,70 14.0 Colorectal Research 17 150,983 14.0 16.0 16.8 15.8 0.237 22.3 3,887,719 13.9 Esophagus Total 18 150,983 14.0 16.0 16.8 15.8 0.237 22.3 3,887,719 13.9 Esophagus Male 55 571,865 9.6 11.3 42.7 0.078 346 3,940,003 8.8 Esophagus Female 12 579,128 13.6 11.3 42.7 0.078 346 3,940,003 8.8 Esophagus Female 12 579,128 0.1 11.3 42.7 0.078 346 3,940,003 8.8 Esophagus Female 4 579,128 0.7 0.6 11.3 42.7 0.078 346 3,940,003 0.8 8.8 Esophagus Female 4 579,128 0.7 0.8 11.3 42.7 0.078 346 3,940,003 0.3 14.0 Glogkin Lymphoma Male 32 571,865 0.5 0.6 14.0 0.347 11 3,940,003 0.3 14.0 Glogkin Lymphoma Female 4 579,128 0.7 0.8 1.5 0.120 11 3,887,719 1.3 14.0 14.0 14.0 14.0 14.0 14.0 14.0 14.0												
Brain and Other Nervous System   Female   25   579,128   4.3   4.8   24.0   0.895   181   3,897,719   4.6   Breast   Male   - 571,865     2.0   0.202   968   7,837,722   12.3   12.3   11.50,993   11.9   13.8   12.2   0.200   968   7,837,722   12.3   12.3   12.4   0.207   949   3.897,719   24.3   3.6   2.2									-			
Breast   Total   137   1,150,993   11.9   13.8   12.22   0.200   965   7,837,722   12.3   12				579 128								
Breast Male Female 137 571,865 - 2 2.0 0.282 16 3,940,003 0.4 4 8 18 18 137 579,128 23.7 27.2 12.24 0.207 949 3,897,719 24.3 Cervix Female 16 579,128 2.8 3.0 9.3 0.057 67 3,897,719 24.3 Cervix Female 165 579,128 2.8 3.0 9.3 0.057 67 3,897,719 1.7 Colorectal Total 165 1,150,993 14.3 16.7 14.5 6.0 1.15 7,837,722 14.7 Colorectal Male 88 571,865 15.4 17.9 78.6 0.317 631 3,940,003 16.0 Colorectal Female 27 579,128 13.3 15.5 68.8 0.237 523 3,897,719 13.9 Colorectal Female 27 579,128 13.3 15.5 68.8 0.237 523 3,897,719 13.9 Colorectal Female 27 579,128 13.3 15.5 68.8 16.8 0.237 523 3,897,719 13.9 Colorectal Female 27 579,128 13.3 15.5 68.8 16.8 0.237 523 3,897,719 3.3 15.2 0.208 10.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2				, -								
Breast Female 137 579,128 23.7 27.2 122.4 0.207 949 3,897,719 24.3 Cervix Female 16 579,128 2.8 3.0 9.3 0.93 0.057 67 3,897,719 24.3 Colorectal Total 165 1,150,993 14.3 16.7 145.8 0.126 1,154 7,837,722 14.7 Colorectal Male 88 571,865 15.4 17.9 78.6 0.217 631 3,940,003 16.0 Colorectal Female 77 579,128 13.3 15.5 66.8 0.237 523 3,897,719 13.4 Corpus Uteri Female 21 579,128 13.3 15.5 66.8 0.237 523 3,897,719 13.4 Esophagus Total 67 1,150,993 5.8 6.8 51.6 0.045 >> 410 7,837,722 52 52 52 59,800 10 1 7,800 10 1 7,800 10 1 7,837,722 52 52 59,800 10 1 7,800 10 1 7,800 10 1 7,837,722 52 52 59,800 10 1 7,800 10 1 7,800 10 1 7,837,722 52 52 59,800 10 1 7,800 10 1 7,800 10 1 7,837,722 52 52 50 1 7,800 10 1 7,800 10 1 7,800 10 1 7,837,722 52 52 50 1 7,800 10 1 7,800 10 1 7,800 10 1 7,837,722 52 52 50 1 7,800 10 1 7,800 10 1 7,800 10 1 7,837,722 52 52 50 1 7,800 10 1 7,800 10 1 7,800 10 1 7,837,722 52 52 50 1 7,800 10 1 7,8			-		-	-				, ,		
Cervix			137		23.7	27.2						
Colorectal Male Remale 77 F79,128 13.3 17.5 66.8 0.317 631 3,940,003 16.0 Colorectal Female 77 579,128 13.3 15.5 66.8 0.237 523 3,897,719 3.9 Esophagus Total 67 1,150,993 5.8 6.8 51.6 0.045 7 410 7,837,722 5.2 Esophagus Male 56 571,865 9.6 11.3 42.7 0.078 346 3,940,003 8.8 Esophagus Female 12 579,128 2.1 2.4 8.1 0.243 64 3,940,003 8.8 Esophagus Total 7 1,150,993 0.6 0.7 2.9 0.057 22 7,837,722 0.3 10-05/10/10/10/10/10/10/10/10/10/10/10/10/10/			16	579,128	2.8	3.0	9.3	0.057	67		1.7	
Colorectal   Female   77   579,128   13.3   15.5   66.8   0.237   523   3,897,719   13.4												
Corpus Uteri												
Esophagus				579,128								
Esophagus Hemale 15 5 571,865 9,6 11.3 42.7 0.078 346 3,940,003 8.8 Esophagus Female 12 579,128 2.1 2.4 8.1 0.243 64 3,897,719 1.6 Hodgkin Lymphoma Total 7 1,150,993 0.6 0.7 2.9 0.057 22 7,837,722 0.3 Hodgkin Lymphoma Female 4 579,128 0.7 0.8 1.5 0.120 11 3,897,719 0.3 Hodgkin Lymphoma Female 4 579,128 0.7 0.8 1.5 0.120 11 3,897,719 0.3 Kidney Male 32 571,865 1.6 6.6 25.7 0.258 210 3,940,003 5.3 Hodgkin Lymphoma Female 24 579,128 4.1 4.9 1.9 0.03 > 11 3,897,719 0.3 Kidney Male 32 571,865 5.6 6.6 25.7 0.258 210 3,940,003 5.3 Hodgkin Lymphoma Total 14 1,150,993 1.2 1.4 7.1 0.028 > 57 7,837,722 0.7 Larynx Total 14 1,150,993 1.2 1.4 7.1 0.028 > 57 7,837,722 0.7 Larynx Female 2.2 579,128 0.3 1.2 1.4 7.1 0.028 > 57 7,837,722 0.7 Larynx Female 2.2 579,128 0.3 0.4 1.4 0.840 11 3,897,719 0.3 Euikemia Male 12 571,865 2.1 2.5 5 0.024 > 46 3,940,003 1.2 Larynx Female 2.3 579,128 0.3 0.4 1.4 0.840 11 3,897,719 0.3 Leukemia Male 51 571,865 2.1 2.5 5 0.025 2.5 5 0.025 2.5 5 0.025 2.5 5 0.0 5 0.0	-											
Esophagus												
Hodgin Lymphoma	. 0		55									
Hodgkin Lymphoma   Male   3												
Hodgikn Lýmphoma   Female   4   579,128   0.7   0.8   1.5   0.120   11   3,897,719   0.3   3,807,719   3,807,719												
Kidney												
Kidney												
Kidney												
Larynx Male 12 571,865 2.1 2.5 5.6 0.024 ≫ 46 3,940,003 1.2 Larynx Female 2 579,128 0.3 0.4 1.4 0.840 11 3,897,719 0.3 Leukemia Male 51 571,865 8.9 10.5 41.3 0.160 335 3,940,003 8.5 Leukemia Bile Duct Total 67 1,150,993 5.8 6.8 67.6 1.000 536 7,837,722 7.5 1.2 Leure and Bile Duct Total 67 1,150,993 5.8 6.8 67.6 1.000 536 7,837,722 6.8 1.2 Liver and Bile Duct Male 46 571,865 8.0 9.5 44.6 0.870 362 3,940,003 9.2 Liver and Bile Duct Female 21 579,128 3.6 4.2 22.4 0.877 1.74 3,897,719 6.4 1.2 Liver and Bile Duct Female 21 579,128 3.6 4.2 22.4 0.877 1.74 3,897,719 4.5 1.0 Liver and Bile Duct Female 21 579,128 3.6 4.2 22.4 0.877 1.74 3,897,719 3.4 1.0 Liver and Bile Duct Female 21 579,128 3.6 4.2 22.4 0.877 1.74 3,897,719 3.4 1.0 Liver and Bile Duct Female 197 571,865 34.4 40.9 166.0 0.021 № 1,359 3,940,003 34.5 1.0 Jung and Bronchus Female 144 579,128 24.9 29.1 160.4 0.207 1,261 3,897,719 32.4 Melanoma of the Skin Male 22 571,865 3.8 4.9 29.1 160.4 0.207 1,261 3,897,719 3.2 Melanoma of the Skin Male 22 571,865 3.8 4.5 20.9 0.864 170 3,940,003 4.3 Melanoma of the Skin Male 18 571,865 3.8 4.5 20.9 0.864 170 3,940,003 4.3 Melanoma of the Skin Male 18 571,865 3.8 4.5 20.9 0.864 170 3,940,003 4.3 Melanoma of the Skin Female 7 579,128 1.2 1.4 11.8 0.202 90 3,897,719 2.3 Myeloma Male 18 571,865 3.1 3.8 21.5 0.527 178 3,940,003 4.5 Myeloma Male 18 571,865 3.1 3.8 21.5 0.527 178 3,940,003 4.5 Myeloma Male 18 571,865 5.9 7.0 33.5 0.981 273 3,940,003 4.5 Myeloma Male 34 1,150,993 2.5 4.8 3.2 15.1 0.877 19 3,897,719 3.1 Myeloma Male 34 1,150,993 2.1 2.4 3.8 3.2 15.1 0.877 19 3,897,719 3.1 Myeloma Male 34 571,865 5.9 7.0 33.5 0.981 273 3,940,003 4.5 Myeloma Male 34 571,865 5.9 7.0 33.5 0.981 273 3,940,003 4.5 Myeloma Male 34 571,865 5.9 7.0 33.5 0.981 273 3,940,003 6.9 7,9128 1.2 2 8.7 0.507 68 3,897,719 7.9 3.1 Non-Hodgkin Lymphoma Female 16 579,128 2.8 3.2 15.1 0.877 19 3,897,719 3.1 Non-Hodgkin Lymphoma Female 41 579,128 7.1 8.2 39.7 0.080 504 7,837,722 3.1 7.2 3.1 0.940 4.4 4.5 3.940,003 4.4 4.5 4.5 4.5 4.5 4.5 4.5 4.5 4.5		Female								3,897,719		
Larynx         Female         2         579,128         0.3         0.4         1.4         0.840         11         3,897,719         0.3           Leukemia         Total         74         1,150,993         6.4         7.5         73.4         0.977         586         7,837,722         7.5           Leukemia         Male         51         571,865         8.9         10.5         41.3         0.160         335         3,940,003         8.5           Leukemia         Description         70 total         67         1,150,993         5.8         6.8         67.6         1.000         536         7,837,722         6.8           Liver and Bile Duct         Male         46         571,865         8.0         9.5         44.6         0.870         362         3,940,003         9.2           Liver and Bile Duct         Female         21         579,128         3.6         4.2         22.4         0.877         174         3,897,719         4.5           Lung and Bronchus         Total         341         1,150,993         29.6         34.8         327.1         0.456         2,620         7,837,722         33.4           Lung and Bronchus         Female         197	Larynx				1.2	1.4	7.1	0.028 >>	57	7,837,722	0.7	
Leukemia         Total         74         1,150,993         6.4         7.5         73.4         0.977         586         7,837,722         7.5           Leukemia         Female         51         571,865         8.9         10.5         41.3         0.160         335         3,940,003         8.5           Leukemia         Female         23         571,865         8.9         10.5         41.3         0.160         335         3,940,003         8.5           Liver and Bile Duct         Male         46         571,865         8.0         9.5         44.6         0.870         362         3,940,003         9.5         4.8         6.8         67.6         1.000         536         7,837,722         6.8         6.8         67.6         1.000         536         7,837,722         6.8         6.8         67.6         1.000         536         7,837,722         6.8         6.8         67.6         1.000         536         7,837,722         6.8         6.8         67.6         1.000         536         7,837,722         6.8         6.8         67.6         1.000         536         7,837,722         6.8         4.5         4.0         0.0         1.0         536         3.4	Larynx								46	3,940,003		
Leukemia         Male         51         571,865         8.9         10.5         41.3         0.160         335         3,940,003         8.5           Leukemia         Female         23         579,128         4.0         4.7         31.8         0.132         251         3,897,719         6.4           Liver and Bile Duct         Male         46         571,865         8.0         9.5         44.6         0.870         362         3,940,003         9.2           Liver and Bile Duct         Female         21         579,128         3.6         9.5         44.6         0.870         362         3,940,003         9.2           Lung and Bronchus         Total         341         1,150,993         29.6         34.8         327.1         0.456         2,620         7,837,722         33.4           Lung and Bronchus         Female         144         579,128         24.9         9.1         160.0         0.021 >>         1,359         3,940,003         34.5           Lung and Bronchus         Female         147         571,865         34.4         40.9         166.0         0.021 >>         1,359         3,940,003         34.5           Lung and Bronchus         Female												
Leukemia         Female         23         579,128         4.0         4.7         31.8         0.132         251         3,897,719         6.4           Liver and Bile Duct         Male         46         571,865         8.0         9.5         44.6         0.870         362         3,940,003         9.2           Liver and Bile Duct         Female         21         579,128         3.6         4.2         22.4         0.877         174         3,897,719         4.5           Lung and Bronchus         Total         341         1,150,993         29.6         34.8         327.1         0.456         2,620         7,837,722         33.4           Lung and Bronchus         Male         197         571,865         34.4         40.9         166.0         0.021         1,359         3,940,003         34.5           Lung and Bronchus         Female         144         579,128         24.9         29.1         160.4         0.207         1,261         3,897,719         32.4           Melanoma of the Skin         Total         29         1,150,993         2.5         2.9         32.9         0.570         260         7,837,722         3.8           Melanoma of the Skin         Male										, ,		
Liver and Bile Duct Male 46 571,865 8.0 9.5 44.6 0.870 362 3,940,003 9.22   Liver and Bile Duct Female 21 579,128 3.6 4.2 22.4 0.877 174 3,897,719 4.5   Lung and Bronchus Total 341 1,150,993 29.6 34.8 327.1 0.456 2,620 7,837,722 33.4   Lung and Bronchus Male 197 571,865 34.4 40.9 166.0 0.021 ≫ 1,359 3,940,003 34.5   Lung and Bronchus Female 144 579,128 24.9 29.1 160.4 0.207 1,261 3,897,719 32.4   Melanoma of the Skin Male 29 1,150,993 2.5 2.9 32.9 0.570 260 7,837,722 33.3   Melanoma of the Skin Male 22 571,865 34.4 40.9 0.864 170 3,940,003 4.5   Melanoma of the Skin Male 22 571,865 34.8 4.5 20.9 0.864 170 3,940,003 4.3   Melanoma of the Skin Female 7 579,128 1.2 1.4 11.8 0.202 90 3,897,719 2.3   Myeloma Male 18 571,865 3.1 3.8 21.5 0.527 178 3,940,003 4.5   Myeloma Male 18 571,865 3.1 3.8 21.5 0.527 178 3,940,003 4.5   Myeloma Female 16 579,128 2.8 3.2 15.1 0.877 119 3,897,719 3.1   Non-Hodgkin Lymphoma Total 65 1,150,993 5.6 6.7 62.7 0.800 504 7,837,722 6.4   Non-Hodgkin Lymphoma Female 31 579,128 5.4 6.4 28.9 0.748 231 3,897,719 5.9   Non-Hodgkin Lymphoma Female 13 571,865 5.9 7.0 33.5 0.981 273 3,940,003 4.4   Oral Cavity and Pharynx Male 13 571,865 2.3 2.7 21.6 0.068 174 3,940,003 4.4   Oral Cavity and Pharynx Female 11 579,128 1.9 2.2 8.7 0.507 68 3,897,719 7.9   Pancreas Female 41 579,128 1.9 2.2 8.7 0.507 68 3,897,719 7.9   Pancreas Female 63 579,128 1.9 2.2 8.7 0.507 68 3,897,719 7.9   Pancreas Female 63 579,128 1.9 2.2 8.7 0.507 68 3,897,719 7.9   Pancreas Female 63 579,128 1.9 12.6 62.1 0.944 485 3,897,719 7.9   Pancreas Female 63 579,128 1.9 12.6 62.1 0.944 485 3,897,719 12.4   Prostate Male 90 571,865 15.7 19.2 102.4 0.236 859 3,940,003 21.8   Stomach Male 90 571,865 3.3 3.9 12.7 0.116 102 3,940,003 2.6    Male 19 571,865 3.3 3.9 12.7 0.116 102 3,940,003 2.6    Male 90 571,865 3.3 3.9 12.7 0.116 102 3,940,003 2.6    Male 90 571,865 3.3 3.9 12.7 0.116 102 3,940,003 2.6    Male 90 571,865 3.3 3.9 12.7 0.116 102 3,940,003 2.6    Male 90 571,865 3.3 3.9 12.7 0.116 102 3,940,003 2.6    Male 90 571,865 3										3,940,003		
Liver and Bile Duct Female 21 579,128 3.6 4.2 22.4 0.877 174 3,897,719 4.5 Liver and Bile Duct Female 21 579,128 3.6 4.2 22.4 0.877 174 3,897,719 4.5 Lung and Bronchus Total 341 1,150,993 29.6 34.8 327.1 0,456 2,620 7,837,722 33.4 Lung and Bronchus Male 197 571,865 34.4 40.9 166.0 0.021 → 1,359 3,940,003 34.5 Lung and Bronchus Female 144 579,128 24.9 29.1 160.4 0.207 1,261 3,897,719 32.4 Melanoma of the Skin Total 29 1,150,993 2.5 2.9 32.9 0.570 260 7,837,722 33.4 Melanoma of the Skin Male 22 571,865 3.8 4.5 20.9 0.864 170 3,940,003 4.3 Melanoma of the Skin Female 7 579,128 1.2 1.4 11.8 0.202 90 3,897,719 2.3 Myeloma Male 18 571,865 3.1 3.8 21.5 0.527 178 3,940,003 4.5 Myeloma Female 16 579,128 2.8 3.2 15.1 0.877 119 3,897,719 3.1 Mon-Hodgkin Lymphoma Male 34 571,865 5.9 7.0 33.5 0.981 273 3,940,003 6.9 Non-Hodgkin Lymphoma Female 31 579,128 5.4 6.4 28.9 0.748 231 3,940,003 6.9 Oral Cavity and Pharynx Male 13 571,865 2.3 2.7 21.6 0.068 174 3,940,003 4.4 Oral Cavity and Pharynx Male 13 571,865 1.1 0.993 11.3 13.2 13.2 13.2 13.2 0.824 1,060 7,837,722 3.1 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.800 5.04 7,837,722 3.1 0.7 0.7 0.7 0.7 0.7 0.800 5.04 7,837,722 3.1 0.7 0.7 0.7 0.7 0.7 0.7 0.8 0.7 0.7 0.8 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.8 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.8 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7										3,897,719		
Liver and Bile Duct Female 21 579,128 3.6 4.2 22.4 0.877 174 3,897,719 4.5 Lung and Bronchus Total 341 1,150,993 29.6 34.8 327.1 0.456 2,620 7,837,722 33.4 Lung and Bronchus Male 197 571,865 34.4 40.9 166.0 0.021 ≫ 1,359 3,940,003 34.5 Lung and Bronchus Female 144 579,128 24.9 29.1 160.4 0.207 1,261 3,897,719 32.4 Melanoma of the Skin Total 29 1,150,993 2.5 2.9 32.9 0.570 260 7,837,722 3.3 Melanoma of the Skin Male 22 571,865 3.8 4.5 20.9 0.864 170 3,940,003 4.3 Melanoma of the Skin Female 7 579,128 1.2 1.4 11.8 0.202 90 3,897,719 2.3 Myeloma Total 34 1,150,993 3.0 3.5 36.8 0.723 297 7,837,722 3.8 Myeloma Male 18 571,865 3.1 3.8 21.5 0.527 178 3,940,003 4.5 Myeloma Female 16 579,128 2.8 3.2 15.1 0.877 119 3,897,719 3.1 Non-Hodgkin Lymphoma Male 34 571,865 5.9 7.0 33.5 0.981 273 3,940,003 6.9 Non-Hodgkin Lymphoma Male 34 571,865 5.9 7.0 33.5 0.981 273 3,940,003 6.9 Non-Hodgkin Lymphoma Female 31 579,128 5.4 6.4 28.9 0.748 231 3,897,719 5.9 Oral Cavity and Pharynx Total 35 71,865 2.3 2.7 21.6 0.068 174 3,940,003 4.4 Coral Cavity and Pharynx Female 11 579,128 7.1 8.2 39.7 0.877 309 3,897,719 7.9 Pancreas Total 30 1,150,993 11.3 13.2 133.2 0.824 1,060 7,837,722 13.5 0.931 1.7 0.937 1.3 13.2 133.2 0.824 1,060 7,837,722 13.5 0.931 1.7 0.937 1.7 0.937 1.7 0.944 485 3,897,719 1.7 0.937 1.9 1.9 0.937 1.9 1.9 1.0 0.944 485 3,897,719 1.2 4.9 0.900 1.946 1.9 0.900 1.950 1.950 1.950 1.950												
Lung and Bronchus         Total         341         1,150,993         29.6         34.8         327.1         0.456         2,620         7,837,722         33.4           Lung and Bronchus         Male         197         571,865         34.4         40.9         166.0         0.021         >         1,359         3,940,003         34.5           Lung and Bronchus         Female         144         579,128         24.9         29.1         160.4         0.207         1,261         3,897,719         32.4           Melanoma of the Skin         Total         29         1,150,993         2.5         2.9         32.9         0.570         260         7,837,722         3.3           Melanoma of the Skin         Male         22         571,865         3.8         4.5         20.9         0.864         170         3,940,003         4.3           Melanoma of the Skin         Female         7         579,128         1.2         1.4         11.8         0.202         90         3,897,719         2.3           Myeloma         Female         18         571,865         3.1         3.8         21.5         0.527         178         3,940,003         4.5           Myeloma         Mela												
Lung and Bronchus         Male Female         197         571,865         34.4         40.9         166.0         0.021 ⇒>         1,359         3,940,003         34.5           Lung and Bronchus         Female         144         579,128         24.9         29.1         166.0         0.021 ⇒>         1,359         3,940,003         34.5           Melanoma of the Skin         Male         29         1,150,993         2.5         2.9         32.9         0.570         260         7,837,722         3.3           Melanoma of the Skin         Male         22         571,865         3.8         4.5         20.9         0.864         170         3,940,003         4.3           Melanoma of the Skin         Female         7         579,128         1.2         1.4         11.8         0.202         90         3,897,719         2.3           Myeloma         Total         34         1,150,993         3.0         3.5         36.8         0.723         297         7,837,722         3.8           Myeloma         Male         18         571,865         3.1         3.8         21.5         0.527         178         3,940,003         4.5           Myeloma         Total         16										, ,		
Lung and Bronchus         Female         144         579,128         24.9         29.1         160.4         0.207         1,261         3,897,719         32.4           Melanoma of the Skin         Total         29         1,150,993         2.5         2.9         32.9         0.570         260         7,837,722         3.3           Melanoma of the Skin         Male         22         571,865         3.8         4.5         20.9         0.864         170         3,940,003         4.3           Melanoma of the Skin         Female         7         579,128         1.2         1.4         11.8         0.202         90         3,897,719         2.3           Myeloma         Total         34         1,150,993         3.0         3.5         36.8         0.723         297         7,837,722         3.8           Myeloma         Male         18         571,865         3.1         3.8         21.5         0.527         178         3,940,003         4.5           Myeloma         Female         16         579,128         2.8         3.2         15.1         0.877         119         3.897,719         3.1           Non-Hodgkin Lymphoma         Male         34         571,865												
Melanoma of the Skin         Total         29         1,150,993         2.5         2.9         32.9         0.570         260         7,837,722         3.3           Melanoma of the Skin         Male         22         571,865         3.8         4.5         20.9         0.864         170         3,940,003         4.3           Melanoma of the Skin         Female         7         579,128         1.2         1.4         11.8         0.202         90         3,897,719         2.3           Myeloma         Male         18         571,865         3.1         3.8         21.5         0.527         178         3,940,003         4.5           Myeloma         Male         18         571,865         3.1         3.8         21.5         0.527         178         3,940,003         4.5           Myeloma         Female         16         579,128         2.8         3.2         15.1         0.877         119         3,897,719         3.1           Myeloma         Female         16         579,128         2.8         3.2         15.1         0.877         119         3,897,719         3.1           Mon-Hodgkin Lymphoma         Male         34         571,865         5.												
Melanoma of the Skin         Male         22         571,865         3.8         4.5         20.9         0.864         170         3,940,003         4.3           Melanoma of the Skin         Female         7         579,128         1.2         1.4         11.8         0.202         90         3,897,719         2.3           Myeloma         Total         34         1,150,993         3.0         3.5         36.8         0.723         297         7,837,722         3.8           Myeloma         Male         18         571,865         3.1         3.8         21.5         0.527         178         3,940,003         4.5           Myeloma         Female         16         579,128         2.8         3.2         15.1         0.877         119         3,940,003         4.5           Myeloma         Female         16         579,128         2.8         3.2         15.1         0.877         119         3,940,003         4.5           Myeloma         Female         16         579,128         2.8         3.2         15.1         0.877         119         3,940,003         4.5           Mon-Hodgkin Lymphoma         Male         34         571,865         5.9												
Myeloma         Total         34         1,150,993         3.0         3.5         36.8         0.723         297         7,837,722         3.8           Myeloma         Male         18         571,865         3.1         3.8         21.5         0.527         178         3,940,003         4.5           Myeloma         Female         16         579,128         2.8         3.2         15.1         0.877         119         3,897,719         3.1           Non-Hodgkin Lymphoma         Total         65         1,150,993         5.6         6.7         62.7         0.800         504         7,837,722         6.4           Non-Hodgkin Lymphoma         Male         34         571,865         5.9         7.0         33.5         0.981         273         3,940,003         6.9           Non-Hodgkin Lymphoma         Female         31         579,128         5.4         6.4         28.9         0.748         231         3,897,719         5.9           Oral Cavity and Pharynx         Total         24         1,150,993         2.1         2.4         30.5         0.273         242         7,837,722         3.1           Oral Cavity and Pharynx         Male         13         571	Melanoma of the Skin	Male						0.864	170	3,940,003		
Myeloma         Male         18         571,865         3.1         3.8         21.5         0.527         178         3,940,003         4.5           Myeloma         Female         16         579,128         2.8         3.2         15.1         0.877         119         3,897,719         3.1           Non-Hodgkin Lymphoma         Total         65         1,150,993         5.6         6.7         62.7         0.800         504         7,837,722         6.4           Non-Hodgkin Lymphoma         Male         34         571,865         5.9         7.0         33.5         0.981         273         3,940,003         6.9           Non-Hodgkin Lymphoma         Female         31         579,128         5.9         7.0         33.5         0.981         273         3,940,003         6.9           Non-Hodgkin Lymphoma         Female         31         579,128         5.9         7.0         33.5         0.981         273         3,940,003         6.9           Non-Hodgkin Lymphoma         Female         31         579,128         5.4         6.4         28.9         0.748         231         3,897,719         5.9           Oral Cavity and Pharynx         Male         13												
Myeloma         Female         16         579,128         2.8         3.2         15.1         0.877         119         3,897,719         3.1           Non-Hodgkin Lymphoma         Total         65         1,150,993         5.6         6.7         62.7         0.800         504         7,837,722         6.4           Non-Hodgkin Lymphoma         Male         34         571,865         5.9         7.0         33.5         0.981         273         3,940,003         6.9           Non-Hodgkin Lymphoma         Female         31         579,128         5.4         6.4         28.9         0.748         231         3,897,719         5.9           Non-Hodgkin Lymphoma         Female         31         579,128         5.4         6.4         28.9         0.748         231         3,897,719         5.9           Oral Cavity and Pharynx         Total         24         1,150,993         2.1         2.4         30.5         0.273         242         7,837,722         3.1           Oral Cavity and Pharynx         Male         13         579,128         1.9         2.2         8.7         0.507         68         3,897,719         1.7           Ovary         Female         41												
Nón-Hodgkin Lymphoma         Total         65         1,150,993         5.6         6.7         62.7         0.800         504         7,837,722         6.4           Non-Hodgkin Lymphoma         Male         34         571,865         5.9         7.0         33.5         0.981         273         3,940,003         6.9           Non-Hodgkin Lymphoma         Female         31         579,128         5.4         6.4         28.9         0.748         231         3,897,719         5.9           Oral Cavity and Pharynx         Total         24         1,150,993         2.1         2.4         30.5         0.273         242         7,837,722         3.1           Oral Cavity and Pharynx         Male         13         571,865         2.3         2.7         21.6         0.068         174         3,940,003         4.4           Oral Cavity and Pharynx         Male         13         571,865         2.3         2.7         21.6         0.068         174         3,940,003         4.4           Oral Cavity and Pharynx         Male         13         571,285         2.3         2.7         21.6         0.068         174         3,940,003         4.4           Oral Cavity and Pharynx         Fe												
Non-Hodgkin Lymphoma         Male         34         571,865         5.9         7.0         33.5         0.981         273         3,940,003         6.9           Non-Hodgkin Lymphoma         Female         31         579,128         5.4         6.4         28.9         0.748         231         3,897,719         5.9           Oral Cavity and Pharynx         Total         24         1,150,993         2.1         2.4         30.5         0.273         242         7,837,722         3.1           Oral Cavity and Pharynx         Male         13         571,865         2.3         2.7         21.6         0.068         174         3,940,003         4.4           Oral Cavity and Pharynx         Male         13         571,865         2.3         2.7         21.6         0.068         174         3,940,003         4.4           Oral Cavity and Pharynx         Female         11         579,128         1.9         2.2         8.7         0.507         68         3,897,719         1.7           Ovary         Female         41         579,128         7.1         8.2         39.7         0.877         309         3,897,719         7.9           Pancreas         Total         130												
Non-Hodgkin Lymphoma         Female         31         579,128         5.4         6.4         28.9         0.748         231         3,897,719         5.9           Oral Cavity and Pharynx         Total         24         1,150,993         2.1         2.4         30.5         0.273         242         7,837,722         3.1           Oral Cavity and Pharynx         Male         13         571,865         2.3         2.7         21.6         0.068         174         3,940,003         4.4           Oral Cavity and Pharynx         Female         11         579,128         1.9         2.2         8.7         0.507         68         3,897,719         1.7           Ovary         Female         41         579,128         7.1         8.2         39.7         0.877         309         3,897,719         7.9           Pancreas         Total         130         1,150,993         11.3         13.2         133.2         0.824         1,060         7,837,722         13.5           Pancreas         Male         67         571,865         11.7         13.8         70.8         0.708         575         3,940,003         14.6           Pancreas         Female         63         579	, , ,											
Oral Cavity and Pharynx         Total         24         1,150,993         2.1         2.4         30.5         0.273         242         7,837,722         3.1           Oral Cavity and Pharynx         Male         13         571,865         2.3         2.7         21.6         0.068         174         3,940,003         4.4           Oral Cavity and Pharynx         Female         11         579,128         1.9         2.2         8.7         0.507         68         3,897,719         1.7           Ovary         Female         41         579,128         7.1         8.2         39.7         0.877         309         3,897,719         7.9           Pancreas         Total         130         1,150,993         11.3         13.2         133.2         0.824         1,060         7,837,722         13.5           Pancreas         Male         67         571,865         11.7         13.8         70.8         0.708         575         3,940,003         14.6           Pancreas         Female         63         579,128         10.9         12.6         62.1         0.944         485         3,897,719         12.4           Prostate         Male         90         571,865	Non-Hodgkin Lymphoma											
Oral Cavity and Pharynx         Male         13         571,865         2.3         2.7         21.6         0.068         174         3,940,003         4.4           Oral Cavity and Pharynx         Female         11         579,128         1.9         2.2         8.7         0.507         68         3,897,719         1.7           Ovary         Female         41         579,128         7.1         8.2         39.7         0.877         309         3,897,719         7.9           Pancreas         Total         130         1,150,993         11.3         13.2         133.2         0.824         1,060         7,837,722         13.5           Pancreas         Male         67         571,865         11.7         13.8         70.8         0.708         575         3,940,003         14.6           Pancreas         Female         63         579,128         10.9         12.6         62.1         0.944         485         3,897,719         12.4           Prostate         Male         90         571,865         15.7         19.2         102.4         0.236         859         3,940,003         21.8           Stomach         Total         35         1,150,993         3	Oral Cavity and Pharvny											
Oral Cavity and Pharynx         Female         11         579,128         1.9         2.2         8.7         0.507         68         3,897,719         1.7           Ovary         Female         41         579,128         7.1         8.2         39.7         0.877         309         3,897,719         7.9           Pancreas         Total         130         1,150,993         11.3         13.2         133.2         0.824         1,060         7,837,722         13.5           Pancreas         Male         67         571,865         11.7         13.8         70.8         0.708         575         3,940,003         14.6           Pancreas         Female         63         579,128         10.9         12.6         62.1         0.944         485         3,897,719         12.4           Prostate         Male         90         571,865         15.7         19.2         102.4         0.236         859         3,940,003         21.8           Stomach         Total         35         1,150,993         3.0         3.5         20.7         0.005 >>         163         7,837,722         2.1           Stomach         Male         19         571,865         3.3												
Ovary         Female         41         579,128         7.1         8.2         39.7         0.877         309         3,897,719         7.9           Pancreas         Total         130         1,150,993         11.3         13.2         133.2         0.824         1,060         7,837,722         13.5           Pancreas         Male         67         571,865         11.7         13.8         70.8         0.708         575         3,940,003         14.6           Pancreas         Female         63         579,128         10.9         12.6         62.1         0.944         485         3,897,719         12.4           Prostate         Male         90         571,865         15.7         19.2         102.4         0.236         859         3,940,003         21.8           Stomach         Total         35         1,150,993         3.0         3.5         20.7         0.005 >>         163         7,837,722         2.1           Stomach         Male         19         571,865         3.3         3.9         12.7         0.116         102         3,940,003         2.6												
Pancreas         Total Pancreas         130 Pancreas         1,150,993 Pancreas         11.3 Pancreas         13.2 Pancreas         13.2 Pancreas         13.2 Pancreas         13.3 Pancreas         13.4 Pancreas         13.5 Pancreas         13.6 Pancreas         13.6 Pancreas         13.6 Pancreas         13.6 Pancreas         13.6 Pancreas         13.6 Pancreas         13.6 Pancreas         13.6 Pancreas         13.6 Pancreas         13.6 Pancreas         13.6 Pancreas         13.6 Pancreas         13.6 Pancreas         13.6 Pancreas         13.6 Pancreas         13.6 Pancreas         13.6 Pancreas         13.6 Pancreas         14.6 Pan	,											
Pancreas         Male         67         571,865         11.7         13.8         70.8         0.708         575         3,940,003         14.6           Pancreas         Female         63         579,128         10.9         12.6         62.1         0.944         485         3,897,719         12.4           Prostate         Male         90         571,865         15.7         19.2         102.4         0.236         859         3,940,003         21.8           Stomach         Total         35         1,150,993         3.0         3.5         20.7         0.005 >>         163         7,837,722         2.1           Stomach         Male         19         571,865         3.3         3.9         12.7         0.116         102         3,940,003         2.6						13.2						
Pancreas         Female         63         579,128         10.9         12.6         62.1         0.944         485         3,897,719         12.4           Prostate         Male         90         571,865         15.7         19.2         102.4         0.236         859         3,940,003         21.8           Stomach         Total         35         1,150,993         3.0         3.5         20.7         0.005 >>         163         7,837,722         2.1           Stomach         Male         19         571,865         3.3         3.9         12.7         0.116         102         3,940,003         2.6												
Stomach         Total         35         1,150,993         3.0         3.5         20.7         0.005 >>         163         7,837,722         2.1           Stomach         Male         19         571,865         3.3         3.9         12.7         0.116         102         3,940,003         2.6			63			12.6	62.1	0.944	485	3,897,719		
Stomach   Male   19   571,865   3.3   3.9   12.7   0.116   102   3,940,003   2.6												
Stomach   Female   16   579,128   2.8   3.2   7.9   0.014 >>   61   3,897,719   1.6												
	Stomach	Female	16	579,128	2.8	3.2	7.9	0.014 >>	61	3,897,719	1.6	

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

<sup>2.</sup> Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

### Cancer Screening and Risk Factor Prevalence Estimates, 2011–2021

	State of								Canyon
Measure	Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	County
Access to Care									
Have Health Insurance, Age <65 (2015–2021)	83.1%	82.8%	85.1%	77.2%	85.8%	78.9%	85.4%	85.4%	77.3%
Not See Doctor Due to Cost in Past Year (2015–2021)	12.6%	11.4%	11.8%	14.5%	12.4%	12.3%	11.8%	12.9%	14.5%
Cancer Screening									
Mammogram Past 2 Years, Age 50–74 (2014, 2016, 2018, 2020)	69.1%	67.0%	73.8%	68.2%	73.2%	64.8%	64.5%	67.1%	69.6%
Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020)	71.2%	73.6%	73.6%	70.8%	72.9%	69.1%	69.5%	65.9%	72.2%
Colorectal Cancer Screening, Age 50–75 (2018, 2020)	67.9%	66.9%	73.6%	71.4%	70.6%	61.7%	61.5%	64.7%	71.5%
Tobacco Use									
Current Tobacco User (2016–2021)	22.3%	26.7%	23.1%	23.6%	21.8%	21.4%	22.7%	16.9%	22.7%
Other Cancer-Related									
Healthy Weight by Body Mass Index, Age 20+ (2015–2021)	32.1%	32.8%	31.7%	27.9%	36.1%	29.8%	27.9%	31.9%	28.5%
Any Physical Activity Besides Job Past 30 Days (2015-2021)	78.7%	79.2%	78.1%	74.5%	83.2%	73.4%	76.3%	79.7%	75.2%
Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019)	21.9%	22.8%	19.4%	20.0%	25.2%	19.5%	20.4%	20.2%	20.7%
Home Ever Tested for Radon (2016, 2018, 2020)	23.0%	30.9%	18.2%	16.9%	25.1%	19.9%	23.0%	21.8%	17.0%

### **Access to Care**

### Have Health Insurance - 2015-2021

Statewide, 83.1% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 86.0% of white non-Hispanics, compared to 64.8% of Hispanics and 83.3% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3%) than English-speaking respondents (84.2%). Health care coverage differed significantly by age of respondent, with 79.8% of persons aged 18–29, and 87.8% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 62.1% in Adams County to 91.6% in Oneida County having health insurance.

### Not See Doctor Due to Cost in Past Year - 2015-2021

Statewide, 12.6% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (11.5% of white non-Hispanics, 19.2% of Hispanics, and 21.0% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9% for less than \$15,000, 6.1% for greater than \$50,000). Inability to see a doctor due to cost differed significantly by county, with a range of 7.4% in Franklin County to 17.5% in Power County.

### **Cancer Screening**

<u>Mammogram</u> – 2014, 2016, 2018, 2020

Statewide, 69.1% of women aged 50–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (72.1% versus 36.7%). Mammography rates differed significantly by county, with a range in screening of 45.9% in Benewah County to 77.0% in Nez Perce County. In 2020, Idaho ranked 48th among states and the District of Columbia for mammography screening rates among women aged 50–74 and also 48th among ages 40+.

### Pap Test - 2018, 2020

Statewide, 71.2% of women with an intact cervix and aged 21–65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.1% versus 52.6% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.7% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49<sup>th</sup> among states and the District of Columbia for Pap screening rate.

### Colorectal Cancer Screening – 2018, 2020

Statewide, 67.9% of adults aged 50–75 reported being current for colorectal cancer screening.\*\* Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked 47<sup>th</sup> among states and the District of Columbia in the percentage of adults aged 50–75 and older who reported being up-to-date for colorectal cancer screening.

<sup>\*\*</sup> Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

### **Tobacco Use**

### Current Tobacco Use - 2016-2021

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.3% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 29.9% of persons aged 18-29, and 11.1% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (22.4%) than among Native Americans (40.0%). Tobacco use differed significantly by county, with a range of 5.4% in Madison County to 41.6% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

### **Other Cancer-Related**

### Healthy Weight by Body Mass Index - 2015-2021

Statewide, 32.1% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 32.5% of white non-Hispanics, compared to 28.2% of Hispanics and 24.6% of Native Americans, being in the healthy weight range. Males (25.5%) were significantly less likely to be in the healthy weight range than females (38.6%). BMI differed significantly by age of respondent, with 43.3% of persons aged 18–29, and 26.0% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 19.8% in Power County to 47.4% in Blaine County of adults being in the healthy weight range.

### Any Physical Activity - 2015-2021

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 78.7% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.3% of persons aged 18–29, and 72.3% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 64.3% in Clark County to 84.6% in Teton County.

Physical Activity Guidelines – 2011, 2013, 2015, 2017, 2019 Statewide, 21.9% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.3% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6% in Franklin County to 30.6% in Blaine County.

### Home Radon Testing - 2016, 2018, 2020

Statewide, 23.0% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.4% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.5% in Cassia County to 54.4% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006l and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.





# CARIBOU COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

### Cancer Incidence 2016–2020 Cancer Mortality 2017–2021 BRFSS 2011–2021

### **RISK FACTORS AND INTERVENTIONS**

### **CANCER**

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/jama.2016.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

### Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

### **Smoking:**

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

### Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <a href="https://www.dietaryguidelines.gov">https://www.dietaryguidelines.gov</a>

### Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute
Cancer Information Services
1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society <a href="https://www.cancer.org">https://www.cancer.org</a>

### **CANCER INCIDENCE 2016–2020**

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016–2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 199 cases of invasive cancer were diagnosed among Caribou County residents (Table 1).

**Table 1:** Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Caribou County and the State of Idaho, 2016–2020

	,	
Cancer Incidence 2016–2020	Caribou County	State of Idaho
All Sites/Types	199	45,610
Female Breast	28	6,687
Prostate	33	6,417
Lung & Bronchus	16	4,887
Colorectal	11	3,451

Table 3 (Cancer Incidence 2016–2020, Comparison between Caribou County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Caribou County. The table also shows the number of observed cases, person-

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Caribou County was 566.3 cases per 100,000 person-years per year during 2016–2020. Comparing this crude rate with the crude rate for the remainder of Idaho (519.8) gives an estimate of the relative burden of disease in Caribou County.

The age- and sex-adjusted incidence rate of invasive cancer in Caribou County, all sites combined, was 531.4 cases per 100,000 persons per year during 2016–2020. There were more cases of cancer in Caribou County (199) than expected (194.7) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

### **CANCER MORTALITY 2017–2021**

During 2017–2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 59 Caribou County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

**Table 2:** Overall and Cancer Mortality in Caribou County and the State of Idaho, 2017–2021

Mortality 2017–2021	Caribou County	State of Idaho
All Deaths	381	77,431
Cancer Deaths	59	15,121
% of All Deaths	15.5%	19.5%
Lung & Bronchus	12	2,961
Colorectal	2	1,319
Pancreas	4	1,190
Female Breast	3	1,086
Prostate	0	949

Table 4 (Cancer Mortality 2017–2021, Comparison between Caribou County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Caribou County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Caribou County, all sites combined, was 152.9 deaths per 100,000 persons per year during 2017–2021, compared with 168.2 for the remainder of the state. There were fewer cancer deaths in Caribou County (59) than expected (64.9) based upon rates in the remainder of the state, but the difference was not statistically significant.

**Statistical Note:** Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

## TABLE 3: CANCER INCIDENCE 2016–2020 COMPARISON BETWEEN CARIBOU COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Car	ibou Count	У			Ren	nainder of Ida	aho
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)
All Sites Combined	Total	199	35,141	566.3	531.4	194.7	0.774	45,411	8,736,687	519.8
All Sites Combined All Sites Combined	Male Female	115 84	17,849 17,292	644.3 485.8	608.5 455.2	104.3 89.9	0.319 0.575	24,174 21,237	4,379,061 4,357,626	552.0 487.4
Bladder	Total	9	35,141	25.6	23.2	9.7	0.998	2,175	8,736,687	24.9
Bladder	Male	9	17,849	50.4	46.7	7.7	0.723	1,742	4,379,061	39.8
Bladder	Female		17,292	-	-	1.9	0.293	433	4,357,626	9.9
Brain - malignant Brain - malignant	Total Male	5 3	35,141 17,849	14.2 16.8	13.6 16.2	2.6 1.6	0.246 0.419	620 372	8,736,687 4,379,061	7.1 8.5
Brain - malignant	Female	2	17,292	11.6	11.0	1.0	0.557	248	4,357,626	5.7
Brain and other CNS - non-malignant	Total	12	35,141	34.1	32.4	6.0	0.039 >>	1,412	8,736,687	16.2
Brain and other CNS - non-malignant	Male	2	17,849	11.2	10.9	2.0	1.000	478	4,379,061	10.9
Brain and other CNS - non-malignant Breast	Female Total	10 28	17,292 35,141	57.8 79.7	54.2 76.3	4.0 28.2	0.015 <b>&gt;&gt;</b> 1.000	934 6,718	4,357,626 8,736,687	21.4 76.9
Breast	Male	-	17,849	-	70.5	0.3	1.000	59	4,379,061	1.3
Breast	Female	28	17,292	161.9	154.5	27.7	1.000	6,659	4,357,626	152.8
Breast - in situ	Total	2	35,141	5.7	5.5	5.1	0.232	1,237	8,736,687	14.2
Breast - in situ	Male	- 2	17,849 17,292	- 11.6	- 11.3	0.0 5.0	1.000 0.248	5 1,232	4,379,061	0.1 28.3
Breast - in situ Cervix	Female Female	3	17,292	17.3	17.8	1.2	0.246	301	4,357,626 4,357,626	6.9
Colorectal	Total	11	35,141	31.3	29.4	14.8	0.403	3,440	8,736,687	39.4
Colorectal	Male	5	17,849	28.0	26.7	8.1	0.363	1,898	4,379,061	43.3
Colorectal	Female	6	17,292	34.7	31.9	6.7	1.000	1,542	4,357,626	35.4
Corpus Uteri Esophagus	Female Total	9	17,292 35.141	52.0	50.1	5.4 2.2	0.203 0.222	1,321 506	4,357,626 8,736,687	30.3 5.8
Esophagus	Male	-	17,849	_	_	1.8	0.222	424	4,379,061	9.7
Esophagus	Female	-	17,292	-	-	0.4	1.000	82	4,357,626	1.9
Hodgkin Lymphoma	Total	3	35,141	8.5	8.7	0.8	0.101	207	8,736,687	2.4
Hodgkin Lymphoma	Male	1	17,849	5.6	5.6	0.5	0.757	117	4,379,061	2.7
Hodgkin Lymphoma Kidney and Renal Pelvis	Female Total	2	17,292 35,141	11.6 11.4	11.9 10.8	0.3 7.7	0.096 0.235	90 1,811	4,357,626 8,736,687	2.1 20.7
Kidney and Renal Pelvis	Male	4	17,849	22.4	21.5	5.0	0.876	1,178	4,379,061	26.9
Kidney and Renal Pelvis	Female	-	17,292	_	-	2.7	0.134	633	4,357,626	14.5
Larynx	Total	3	35,141	8.5	8.0	0.9	0.130	212	8,736,687	2.4
Larynx	Male Female	2	17,849 17,292	11.2 5.8	10.5 5.5	0.7 0.2	0.302 0.404	158 54	4,379,061	3.6 1.2
Larynx Leukemia	Total	8	35,141	22.8	21.0	7.1	0.404	1,623	4,357,626 8,736,687	18.6
Leukemia	Male	5	17,849	28.0	26.4	4.3	0.842	984	4,379,061	22.5
Leukemia	Female	3	17,292	17.3	15.8	2.8	1.000	639	4,357,626	14.7
Liver and Bile Duct	Total	3	35,141	8.5	8.0	3.6	1.000	826	8,736,687	9.5
Liver and Bile Duct Liver and Bile Duct	Male Female	2	17,849 17,292	11.2 5.8	10.5 5.3	2.6 1.0	1.000 1.000	588 238	4,379,061 4,357,626	13.4 5.5
Lung and Bronchus	Total	16	35.141	45.5	41.5	21.5	0.277	4,871	8,736,687	55.8
Lung and Bronchus	Male	9	17,849	50.4	46.9	10.7	0.747	2,443	4,379,061	55.8
Lung and Bronchus	Female	7	17,292	40.5	36.2	10.8	0.318	2,428	4,357,626	55.7
Melanoma of the Skin Melanoma of the Skin	Total Male	14 8	35,141 17,849	39.8 44.8	37.9 42.7	12.4 7.5	0.722 0.958	2,928 1,757	8,736,687 4,379,061	33.5 40.1
Melanoma of the Skin	Female	6	17,049	34.7	33.4	4.8	0.938	1,737	4,357,626	26.9
Myeloma	Total	6	35,141	17.1	15.6	3.1	0.185	702	8,736,687	8.0
Myeloma	Male	4	17,849	22.4	21.0	1.9	0.252	437		10.0
Myeloma	Female	2	17,292	11.6	10.4	1.2	0.650	265	4,357,626	6.1
Non-Hodgkin Lymphoma Non-Hodgkin Lymphoma	Total Male	11 9	35,141 17,849	31.3 50.4	29.3 47.7	8.3 4.8	0.430 0.115	1,929 1,120	8,736,687 4,379,061	22.1 25.6
Non-Hodgkin Lymphoma	Female	2	17,049	11.6	10.6	3.5	0.644	809	4,357,626	18.6
Oral Cavity and Pharynx	Total	5	35,141	14.2	13.5	5.5	1.000	1,290	8,736,687	14.8
Oral Cavity and Pharynx	Male	3	17,849	16.8	16.0	4.0	0.867	933	4,379,061	21.3
Oral Cavity and Pharynx Ovary	Female Female	2	17,292 17,292	11.6	10.9	1.5 2.2	0.890 0.216	357 533	4,357,626 4,357,626	8.2 12.2
Pancreas	Total	- 6	35,141	17.1	15.6	6.2	1.000	1,417	8,736,687	16.2
Pancreas	Male	4	17,849	22.4	21.0	3.4	0.879	780	4,379,061	17.8
Pancreas	Female	2	17,292	11.6	10.4	2.8	0.927	637	4,357,626	14.6
Prostate Stomach	Male Total	33 1	17,849 35,141	184.9 2.8	173.9 2.6	27.7 2.0	0.355 0.799	6,384 466	4,379,061 8,736,687	145.8 5.3
Stomach	Male	1	17,849	2.8 5.6	2.6 5.3	1.3	1.000	308	4,379,061	7.0
Stomach	Female	_ '	17,292	-	-	0.7	1.000	158	4,357,626	3.6
Testis	Male	2	17,849	11.2	12.2	1.0	0.518	263	4,379,061	6.0
Thyroid	Total	4	35,141	11.4	11.6	4.8	0.952	1,216	8,736,687	13.9
Thyroid	Male	4	17,849	22.4	22.3	1.4	0.116	351	4,379,061	8.0
Thyroid	Female		17,292	-	-	3.3	0.073	865	4,357,626	19.9
Pediatric Age 0 to 19	Total	1	10,899	9.2	9.3	1.8	0.898	420	2,449,624	17.1
Pediatric Age 0 to 19 Pediatric Age 0 to 19	Male Female	- 1	5,636 5,263	- 19.0	- 19.4	1.0 0.8	0.736 1.000	223 197	1,250,874 1,198,750	17.8 16.4
			o,200			0.0	1.000	107	1,100,700	1 10.4

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

<sup>2.</sup> Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

<sup>&</sup>quot;<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

### **TABLE 4: CANCER MORTALITY 2017–2021** COMPARISON BETWEEN CARIBOU COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Car	ibou Count	у			Re	mainder of Idah	10
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	381	35,382	1,076.8	974.0	336.6	0.019 >>	77,049	8,953,333	860.6
All Causes of Death	Male	197	17,961	1,096.8	1,036.5	172.8	0.076	40,859	4,493,907	909.2
All Causes of Death	Female	184	17,421	1,056.2	912.4	163.7	0.125	36,190	4,459,426	811.5
All Malignant Cancers	Total	59	35,382	166.8	152.9	64.9	0.508	15,062	8,953,333	168.2
All Malignant Cancers	Male	33	17,961	183.7	172.7	34.6	0.871	8,143	4,493,907	181.2
All Malignant Cancers	Female	26	17,421	149.2	134.2	30.1	0.527	6,919	4,459,426	155.2
Bladder Bladder	Total Male	2 2	35,382 17,961	5.7	5.0 10.3	2.2	1.000 0.965	487	8,953,333 4,493,907	5.4 8.4
Bladder	Female		17,421	11.1	10.3	1.6 0.5	1.000	376 111	4,493,907	2.5
Brain and Other Nervous System	Total	2	35,382	5.7	5.4	2.1	1.000	502	8,953,333	5.6
Brain and Other Nervous System	Male	1	17,961	5.6	5.4	1.2	1.000	297	4,493,907	6.6
Brain and Other Nervous System	Female	1	17,421	5.7	5.4	0.8	1.000	205	4,459,426	4.6
Breast	Total	3	35,382	8.5	7.9	4.7	0.628	1,099	8,953,333	12.3
Breast	Male	-	17,961	-	-	0.1	1.000	16	4,493,907	0.4
Breast	Female	3	17,421	17.2	15.8	4.6	0.645	1,083	4,459,426	24.3
Cervix	Female	-	17,421	-	-	0.3	1.000	83	4,459,426	1.9
Colorectal	Total	2	35,382 17,061	5.7 5.6	5.2	5.6	0.161	1,317	8,953,333	14.7
Colorectal	Male	1 1	17,961 17,421	5.6 5.7	5.3 5.1	3.0 2.6	0.391 0.527	718 599	4,493,907	16.0
Colorectal Corpus Uteri	Female Female	1	17,421 17,421	5.7	5.1	0.7	1.000	172	4,459,426 4,459,426	13.4 3.9
Esophagus	Total	2	35,382	5.7	5.3	2.0	1.000	475	8,953,333	5.3
Esophagus	Male	2	17,961	11.1	10.5	1.7	1.000	399	4,493,907	8.9
Esophagus	Female		17,421	-	-	0.3	1.000	76	4,459,426	1.7
Hodgkin Lymphoma	Total	-	35,382	-	-	0.1	1.000	29	8,953,333	0.3
Hodgkin Lymphoma	Male	-	17,961	-	-	0.1	1.000	14	4,493,907	0.3
Hodgkin Lymphoma	Female	-	17,421	-	-	0.1	1.000	15	4,459,426	0.3
Kidney	Total	-	35,382	-	-	1.7	0.377	385	8,953,333	4.3
Kidney	Male	-	17,961	-	-	1.0	0.716	242	4,493,907	5.4
Kidney Larynx	Female Total	-	17,421 35,382	-	-	0.6 0.3	1.000 1.000	143 71	4,459,426 8,953,333	3.2 0.8
Larynx	Male	-	17,961	-		0.3	1.000	58	4,493,907	1.3
Larynx	Female	_	17,421	_	_	0.1	1.000	13	4,459,426	0.3
Leukemia	Total	5	35,382	14.1	12.8	2.9	0.325	655	8,953,333	7.3
Leukemia	Male	3	17,961	16.7	15.8	1.6	0.445	383	4,493,907	8.5
Leukemia	Female	2	17,421	11.5	9.9	1.2	0.694	272	4,459,426	6.1
Liver and Bile Duct	Total	2	35,382	5.7	5.3	2.5	1.000	601	8,953,333	6.7
Liver and Bile Duct	Male	1	17,961	5.6	5.3	1.7	0.974	407	4,493,907	9.1
Liver and Bile Duct	Female	1	17,421	5.7	5.2	0.8	1.000	194	4,459,426	4.4
Lung and Bronchus	Total	12	35,382	33.9	31.0	12.7	0.984	2,949	8,953,333	32.9
Lung and Bronchus Lung and Bronchus	Male Female	7 5	17,961 17,421	39.0 28.7	36.5 25.6	6.6 6.1	0.980 0.851	1,549 1,400	4,493,907 4,459,426	34.5 31.4
Melanoma of the Skin	Total	1	35,382	2.8	2.6	1.2	1.000	288	8,953,333	3.2
Melanoma of the Skin	Male	1	17,961	5.6	5.3	0.8	1.000	191	4,493,907	4.3
Melanoma of the Skin	Female	- '	17,421	-	-	0.4	1.000	97	4,459,426	2.2
Myeloma	Total	4	35,382	11.3	10.2	1.4	0.116	327	8,953,333	3.7
Myeloma	Male	4	17,961	22.3	20.7	0.8	0.020 >>	192	4,493,907	4.3
Myeloma	Female	-	17,421			0.6	1.000	135	4,459,426	3.0
Non-Hodgkin Lymphoma	Total	3	35,382	8.5	7.7	2.5	0.894	566	8,953,333	6.3
Non-Hodgkin Lymphoma	Male	2	17,961	11.1	10.5	1.3	0.741	305	4,493,907	6.8
Non-Hodgkin Lymphoma	Female	1	17,421 35,382	5.7 2.8	5.0 2.6	1.2 1.1	1.000	261 265	4,459,426	5.9 3.0
Oral Cavity and Pharynx Oral Cavity and Pharynx	Total Male	1	35,362 17,961	2.6 5.6	5.3	0.8	1.000 1.000	265 186	8,953,333 4,493,907	3.0 4.1
Oral Cavity and Pharynx	Female	- '	17,421	J.0 -	3.3	0.8	1.000	79	4,459,426	1.8
Ovary	Female	3	17,421	17.2	15.8	1.5	0.373	347	4,459,426	7.8
Pancreas	Total	4	35,382	11.3	10.4	5.1	0.852	1,186	8,953,333	13.2
Pancreas	Male	3	17,961	16.7	15.8	2.7	1.000	639	4,493,907	14.2
Pancreas	Female	1	17,421	5.7	5.2	2.4	0.630	547	4,459,426	12.3
Prostate	Male	-	17,961	-	-	4.1	0.033 <<	949	4,493,907	21.1
Stomach	Total	-	35,382	-	-	0.8	0.864	198	8,953,333	2.2
Stomach	Male	-	17,961	-	-	0.5	1.000	121	4,493,907	2.7
Stomach	Female	-	17,421	-		0.3	1.000	77	4,459,426	1.7

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

<sup>2.</sup> Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

### Cancer Screening and Risk Factor Prevalence Estimates, 2011–2021

	State of								Caribou
Measure	Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	County
Access to Care									
Have Health Insurance, Age <65 (2015–2021)	83.1%	82.8%	85.1%	77.2%	85.8%	78.9%	85.4%	85.4%	83.3%
Not See Doctor Due to Cost in Past Year (2015–2021)	12.6%	11.4%	11.8%	14.5%	12.4%	12.3%	11.8%	12.9%	11.5%
Cancer Screening									
Mammogram Past 2 Years, Age 50–74 (2014, 2016, 2018, 2020)	69.1%	67.0%	73.8%	68.2%	73.2%	64.8%	64.5%	67.1%	
Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020)	71.2%	73.6%	73.6%	70.8%	72.9%	69.1%	69.5%	65.9%	
Colorectal Cancer Screening, Age 50–75 (2018, 2020)	67.9%	66.9%	73.6%	71.4%	70.6%	61.7%	61.5%	64.7%	
Tobacco Use									
Current Tobacco User (2016–2021)	22.3%	26.7%	23.1%	23.6%	21.8%	21.4%	22.7%	16.9%	26.3%
Other Cancer-Related									
Healthy Weight by Body Mass Index, Age 20+ (2015–2021)	32.1%	32.8%	31.7%	27.9%	36.1%	29.8%	27.9%	31.9%	21.0%
Any Physical Activity Besides Job Past 30 Days (2015-2021)	78.7%	79.2%	78.1%	74.5%	83.2%	73.4%	76.3%	79.7%	78.9%
Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019)	21.9%	22.8%	19.4%	20.0%	25.2%	19.5%	20.4%	20.2%	17.4%
Home Ever Tested for Radon (2016, 2018, 2020)	23.0%	30.9%	18.2%	16.9%	25.1%	19.9%	23.0%	21.8%	17.1%

### **Access to Care**

### Have Health Insurance – 2015–2021

Statewide, 83.1% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 86.0% of white non-Hispanics, compared to 64.8% of Hispanics and 83.3% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3%) than English-speaking respondents (84.2%). Health care coverage differed significantly by age of respondent, with 79.8% of persons aged 18–29, and 87.8% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 62.1% in Adams County to 91.6% in Oneida County having health insurance.

### Not See Doctor Due to Cost in Past Year - 2015-2021

Statewide, 12.6% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (11.5% of white non-Hispanics, 19.2% of Hispanics, and 21.0% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9% for less than \$15,000, 6.1% for greater than \$50,000). Inability to see a doctor due to cost differed significantly by county, with a range of 7.4% in Franklin County to 17.5% in Power County.

### **Cancer Screening**

<u>Mammogram</u> – 2014, 2016, 2018, 2020

Statewide, 69.1% of women aged 50–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (72.1% versus 36.7%). Mammography rates differed significantly by county, with a range in screening of 45.9% in Benewah County to 77.0% in Nez Perce County. In 2020, Idaho ranked 48<sup>th</sup> among states and the District of Columbia for mammography screening rates among women aged 50–74 and also 48<sup>th</sup> among ages 40+.

### Pap Test - 2018, 2020

Statewide, 71.2% of women with an intact cervix and aged 21–65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.1% versus 52.6% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.7% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49<sup>th</sup> among states and the District of Columbia for Pap screening rate.

### Colorectal Cancer Screening - 2018, 2020

Statewide, 67.9% of adults aged 50–75 reported being current for colorectal cancer screening.\*\* Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked 47<sup>th</sup> among states and the District of Columbia in the percentage of adults aged 50–75 and older who reported being up-to-date for colorectal cancer screening.

<sup>\*\*</sup> Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

### **Tobacco Use**

### Current Tobacco Use - 2016-2021

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.3% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 29.9% of persons aged 18-29, and 11.1% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (22.4%) than among Native Americans (40.0%). Tobacco use differed significantly by county, with a range of 5.4% in Madison County to 41.6% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

### **Other Cancer-Related**

### Healthy Weight by Body Mass Index - 2015-2021

Statewide, 32.1% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 32.5% of white non-Hispanics, compared to 28.2% of Hispanics and 24.6% of Native Americans, being in the healthy weight range. Males (25.5%) were significantly less likely to be in the healthy weight range than females (38.6%). BMI differed significantly by age of respondent, with 43.3% of persons aged 18–29, and 26.0% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 19.8% in Power County to 47.4% in Blaine County of adults being in the healthy weight range.

### Any Physical Activity - 2015-2021

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 78.7% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.3% of persons aged 18–29, and 72.3% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 64.3% in Clark County to 84.6% in Teton County.

Physical Activity Guidelines – 2011, 2013, 2015, 2017, 2019 Statewide, 21.9% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.3% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6% in Franklin County to 30.6% in Blaine County.

### Home Radon Testing - 2016, 2018, 2020

Statewide, 23.0% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.4% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.5% in Cassia County to 54.4% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006l and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.





# CASSIA COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

### Cancer Incidence 2016–2020 Cancer Mortality 2017–2021 BRFSS 2011–2021

### **RISK FACTORS AND INTERVENTIONS**

### **CANCER**

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/jama.2016.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

### Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

### **Smoking:**

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

### Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <a href="https://www.dietaryguidelines.gov">https://www.dietaryguidelines.gov</a>

### Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute
Cancer Information Services
1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society <a href="https://www.cancer.org">https://www.cancer.org</a>

### **CANCER INCIDENCE 2016–2020**

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016–2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 486 cases of invasive cancer were diagnosed among Cassia County residents (Table 1).

**Table 1:** Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Cassia County and the State of Idaho. 2016–2020

Cancer Incidence 2016–2020	Cassia County	State of Idaho
All Sites/Types	486	45,610
Female Breast	81	6,687
Prostate	55	6,417
Lung & Bronchus	38	4,887
Colorectal	35	3,451

Table 3 (Cancer Incidence 2016–2020, Comparison between Cassia County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Cassia County. The table also shows the number of observed cases, person-

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Cassia County was 407.6 cases per 100,000 person-years per year during 2016–2020. Comparing this crude rate with the crude rate for the remainder of Idaho (521.5) gives an estimate of the relative burden of disease in Cassia County.

The age- and sex-adjusted incidence rate of invasive cancer in Cassia County, all sites combined, was 450.4 cases per 100,000 persons per year during 2016–2020. There were statistically significantly fewer cases of cancer in Cassia County (486) than expected (562.7) based upon rates in the remainder of the state (p=.001).

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

### **CANCER MORTALITY 2017–2021**

During 2017–2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 172 Cassia County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

**Table 2:** Overall and Cancer Mortality in Cassia County and the State of Idaho, 2017–2021

Mortality 2017–2021	Cassia County	State of Idaho
All Deaths	1,096	77,431
Cancer Deaths	172	15,121
% of All Deaths	15.7%	19.5%
Lung & Bronchus	17	2,961
Colorectal	18	1,319
Pancreas	13	1,190
Female Breast	12	1,086
Prostate	13	949

Table 4 (Cancer Mortality 2017–2021, Comparison between Cassia County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Cassia County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Cassia County, all sites combined, was 154.2 deaths per 100,000 persons per year during 2017–2021, compared with 168.6 for the remainder of the state. There were fewer cancer deaths in Cassia County (172) than expected (188.1) based upon rates in the remainder of the state, but the difference was not statistically significant.

**Statistical Note:** Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

### TABLE 3: CANCER INCIDENCE 2016–2020 COMPARISON BETWEEN CASSIA COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

Cancer   Site/Type   Sex   Cases   Person   Cases   Rate (1)   Rate (1,2)   Cases (3)   P-Value (4)   Cases   Person   Cases   Cases   Person   Person   Cases   Person   Cases   Person   Cases   Person   Person   Person   Cases   Person   Person   Person   Cases   Person	554.4 488.5 2 24.9 39.8 3 9.9 2 7.1 9 8.5 3 5.7 2 16.1 9 10.9 3 21.3 277.0 9 1.3 153.0 14.2 9 0.1 28.4
All Sites Combined	2 521.5 9 554.4 488.5 2 24.9 9 39.8 3 9.9 2 7.1 9 8.5 3 5.7 2 16.1 9 10.9 3 21.3 2 77.0 9 1.3 153.0 14.2 9 0.1 28.4
All Sites Combined	554.4 488.5 2 24.9 39.8 3 9.9 2 7.1 9 8.5 3 5.7 2 16.1 9 10.9 3 21.3 277.0 9 1.3 153.0 14.2 9 0.1 28.4
All Sites Combined   Female   234   58,325   401.2   437.7   261.1   0.096   21,087   4,316,59	38 488.5 22 24.9 39.8 39.9 2 7.1 9 8.5 3 5.7 2 16.1 10.9 9 12.3 21.3 27.0 9 1.3 153.0 14.2 9 0.1 28.4
Bladder	2 24.9 39.8 39.8 9.9 2 7.1 8.5 3 5.7 2 16.1 9 10.9 3 21.3 77.0 1.3 153.0 2 14.2 9 0.1 3 28.4
Bladder   Bladder   Female   7   58,325   12.0   12.9   5.4   0.584   4.766   4,335,99   12.0   12.9   5.4   0.588   426   4,316,59   12.0   12.0   12.0   12.9   12.0	9 39.8 9 9.9 2 7.1 8.5 3 5.7 2 16.1 10.9 3 21.3 77.0 1.3 153.0 2 14.2 9 0.1 3 28.4
Bladder   Female   7   58,325   12.0   12.9   5.4   0.588   426   4,316,59	9.9 2. 7.1 8.5 5.7 2. 16.1 10.9 3. 21.3 2. 77.0 1.3 153.0 2. 14.2 9. 0.1 3. 28.4
Brain - malignant         Total Brain - malignant         Total Male         7         119,236         5.9         6.3         7.9         0.933         618         8,652,59         Brain - malignant         Male         5         60,911         8.2         9.0         4.8         1.000         370         4,335,99         Brain and other CNS - non-malignant and other CNS - non-malignant Brain and other CNS - non-malignant Brain and other CNS - non-malignant Brain and other CNS - non-malignant Brain and other CNS - non-malignant Breast         Male         9         60,911         14.8         16.2         6.0         0.311         471         4,335,99         8,652,59         6.3         7.9         0.933         618         8,652,59         6.3         7.9         0.933         618         8,252,59         6.3         7.9         0.933         618         8,252,59         8,355,99         6.3         7.9         0.933         618         8,252,59         8,355,99         3.154         3.6         3.2         0.773         248         4,316,59         8,652,59         6.0         0.311         4,71         4,335,99         14,816,59         8.652,59         8.652,59         8.652,59         8.652,59         8.652,59         8.652,59         8.652,59         8.652,59         8.652,59         8.652,59         8.652,59<	7.1 9 8.5 3 5.7 16.1 9 10.9 3 21.3 2 77.0 9 1.3 153.0 14.2 9 0.1 28.4
Brain - malignant         Male         5         60,911         8.2         9.0         4.8         1.000         370         4,335,99           Brain - malignant         Female         2         58,325         3.4         3.6         3.2         0.773         248         4,316,59           Brain and other CNS - non-malignant         Total         32         119,236         26.8         29.3         17.6         0.003 >>         1,392         8,652,59           Brain and other CNS - non-malignant         Male         9         60,911         14.8         16.2         6.0         0.311         471         4,335,99           Breast         Total         82         119,236         68.8         76.8         82.2         1.000         6,664         8,652,59           Breast         Male         1         60,911         1.6         1.8         0.7         1.000         58         4,335,99           Breast - in situ         Total         8         119,236         68.8         76.8         82.2         1.000         58         4,335,99           Breast - in situ         Total         8         119,236         6.7         7.6         15.0         0.076         1,231         8,652,59	8.5 5.7 2 16.1 10.9 3 21.3 2 77.0 9 1.3 153.0 14.2 9 0.1 3 28.4
Brain and other CNS - non-malignant Brain and other CNS - non-malignant Brain and other CNS - non-malignant Brain and other CNS - non-malignant Brain and other CNS - non-malignant Brain and other CNS - non-malignant Breast         Total Brain and other CNS - non-malignant Breast         32	2 16.1 9 10.9 3 21.3 77.0 9 1.3 153.0 2 14.2 9 0.1 3 28.4
Brain and other CNS - non-malignant         Male         9         60,911         14.8         16.2         6.0         0.311         471         4,335,99           Brain and other CNS - non-malignant         Female         23         58,325         39.4         42.6         11.5         0.004 >>         921         4,316,59           Breast         Total         82         119,236         68.8         76.8         82.2         1.000         6,664         8,652,59           Breast         Male         1         60,911         1.6         1.8         0.7         1.000         58         4,335,99           Breast fin situ         Female         81         58,325         138.9         154.2         80.4         0.976         6,606         4,316,59           Breast in situ         Male         -         60,911         -         -         0.1         1.000         5         4,335,99           Breast in situ         Male         -         60,911         -         -         0.1         1.000         5         4,335,99           Breast in situ         Female         8         58,325         13.7         15.5         14.6         0.091         1,226         4,316,59	9 10.9 3 21.3 2 77.0 9 1.3 3 153.0 2 14.2 9 0.1 3 28.4
Brain and other CNS - non-malignant         Female         23         58,325         39.4         42.6         11.5         0.004 >>         921         4,316,59           Breast         Total         82         119,236         68.8         76.8         82.2         1.000         6,664         8,652,59           Breast         Male         1         60,911         1.6         1.8         0.7         1.000         58         4,335,99           Breast - in situ         Total         8         158,325         138.9         154.2         80.4         0.976         6,600         4,316,59           Breast - in situ         Male         -         60,911         -         -         0.1         1.000         5         4,335,99           Breast - in situ         Male         -         60,911         -         -         0.1         1.000         5         4,335,99           Breast - in situ         Female         8         58,325         13.7         15.5         14.6         0.091         1,226         4,316,59           Cervix         Female         2         58,325         3.4         3.8         3.7         0.569         302         4,316,59           Colo	3 21.3 2 77.0 9 1.3 3 153.0 2 14.2 9 0.1 3 28.4
Breast         Total         82         119,236         68.8         76.8         82.2         1.000         6,664         8,652,59           Breast         Male         1         60,911         1.6         1.8         0.7         1.000         58         4,335,99           Breast st         Female         81         58,325         138.9         154.2         80.4         0.976         6,606         4,316,59           Breast in situ         Total         8         119,236         6.7         7.6         15.0         0.076         1,231         8,652,59           Breast in situ         Male         -         60,911         -         -         0.1         1,000         5         4,335,99           Breast in situ         Female         8         58,325         13.7         15.5         14.6         0.091         1,226         4,316,59           Breast in situ         Female         8         58,325         13.7         15.5         14.6         0.091         1,226         4,316,59           Breast in situ         Female         8         58,325         3.4         3.8         3.7         0.569         302         4,316,59           Colvit	77.0 9 1.3 3 153.0 2 14.2 9 0.1 3 28.4
Breast Breast         Male Female         1         60,911 58,325         1.8         0.7         1.000 58         4,335,99           Breast Female Breast - in situ         Total         8         19,236 6.7         6.7         7.6         15.0 0.076 1.231         8,652,59           Breast - in situ         Male Female Breast - in situ         -         -         -         0.1 1.000 5 4.335,99           Breast - in situ         Female Breast - in situ         -         -         0.911 5.5 14.6 0.091 1.000 1.226 4.316,59           Cervix         Female Breast - in situ         -         -         -         0.1 1.000 1.000 1.226 4.316,59           Cervix         Female Breast - in situ         -         -         -         0.1 1.000 1.000 1.226 4.316,59           Cervix         Female Breast - in situ         -         -         -         0.01 1.000 1.000 1.226 4.316,59           Cervix         Female Breast - in situ         -         -         -         -         0.01 1.000 1.000 1.226 4.316,59           Cervix         Female Breast - in situ         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -	9 1.3 153.0 2 14.2 9 0.1 3 28.4
Breast         Female         81         58,325         138.9         154.2         80.4         0.976         6,606         4,316,59           Breast - in situ         Total         8         119,236         6.7         7.6         15.0         0.076         1,231         8,652,59           Breast - in situ         Male         -         60,911         -         0.1         1,000         5         4,335,99           Cervix         Female         8         58,325         13.7         15.5         14.6         0.091         1,226         4,316,59           Colorectal         Total         35         119,236         29.4         32.3         42.8         0.260         3,416         8,652,59           Colorectal         Male         19         60,911         31.2         34.9         23.7         0.396         1,884         4,335,99           Colorectal         Female         16         58,325         27.4         29.5         19.2         0.549         1,532         4,316,59           Corpus Uteri         Female         9         58,325         15.4         17.3         15.9         0.090         1,321         4,316,59           Cosphagus         Tota	3 153.0 2 14.2 9 0.1 3 28.4
Breast - in situ         Total         8         119,236         6.7         7.6         15.0         0.076         1,231         8,652,59           Breast - in situ         Male         -         60,911         -         -         0.1         1.000         5         4,335,99           Breast - in situ         Female         8         58,325         13.7         15.5         14.6         0.091         1,226         4,316,59           Cervix         Female         2         58,325         3.4         3.8         3.7         0.569         302         4,316,59           Colorectal         Total         35         119,236         29.4         32.3         42.8         0.260         3,416         8,652,59           Colorectal         Male         19         60,911         31.2         34.9         23.7         0.396         1,884         4,335,99           Colorectal         Female         16         58,325         27.4         29.5         19.2         0.549         1,532         4,316,59           Corpus Uteri         Female         9         58,325         15.4         17.3         15.9         0.090         1,321         4,316,59           Cosphagus<	2 14.2 9 0.1 3 28.4
Breast - in situ         Female         8         58,325         13.7         15.5         14.6         0.091         1,226         4,316,59           Cervix         Female         2         58,325         3.4         3.8         3.7         0.569         302         4,316,59           Colorectal         Total         35         119,236         29.4         32.3         42.8         0.260         3,416         8,652,59           Colorectal         Male         19         60,911         31.2         34.9         23.7         0.396         1,884         4,335,99           Colorectal         Female         16         58,325         27.4         29.5         19.2         0.549         1,532         4,316,59           Corpus Uteri         Female         9         58,325         15.4         17.3         15.9         0.090         1,321         4,316,59           Esophagus         Total         3         119,236         2.5         2.8         6.3         0.256         503         8,652,59           Esophagus         Male         3         60,911         4.9         5.5         5.3         0.459         421         4,335,99	3 28.4
Cervix         Female         2         58,325         3.4         3.8         3.7         0.569         302         4,316,59           Colorectal         Total         35         119,236         29.4         32.3         42.8         0.260         3,416         8,652,59           Colorectal         Male         19         60,911         31.2         34.9         23.7         0.396         1,884         4,335,99           Colorectal         Female         16         58,325         27.4         29.5         19.2         0.549         1,532         4,316,59           Corpus Uteri         Female         9         58,325         15.4         17.3         15.9         0.090         1,321         4,316,59           Esophagus         Total         3         119,236         2.5         2.8         6.3         0.256         503         8,652,59           Esophagus         Male         3         60,911         4.9         5.5         5.3         0.459         421         4,335,99	
Colorectal         Total         35         119,236         29.4         32.3         42.8         0.260         3,416         8,652,59           Colorectal         Male         19         60,911         31.2         34.9         23.7         0.396         1,884         4,335,99           Colorectal         Female         16         58,325         27.4         29.5         19.2         0.549         1,532         4,316,59           Corpus Uteri         Female         9         58,325         15.4         17.3         15.9         0.090         1,321         4,316,59           Esophagus         Total         3         119,236         2.5         2.8         6.3         0.256         503         8,652,59           Esophagus         Male         3         60,911         4.9         5.5         5.3         0.459         421         4,335,99	
Colorectal         Male         19         60,911         31.2         34.9         23.7         0.396         1,884         4,335,99           Colorectal         Female         16         58,325         27.4         29.5         19.2         0.549         1,532         4,316,59           Corpus Uteri         Female         9         58,325         15.4         17.3         15.9         0.090         1,321         4,316,59           Esophagus         Total         3         119,236         2.5         2.8         6.3         0.256         503         8,652,59           Esophagus         Male         3         60,911         4.9         5.5         5.3         0.459         421         4,335,99	
Colorectal         Female         16         58,325         27.4         29.5         19.2         0.549         1,532         4,316,59           Corpus Uteri         Female         9         58,325         15.4         17.3         15.9         0.090         1,321         4,316,59           Esophagus         Total         3         119,236         2.5         2.8         6.3         0.256         503         8,652,59           Esophagus         Male         3         60,911         4.9         5.5         5.3         0.459         421         4,335,99	
Corpus Uteri         Female         9         58,325         15.4         17.3         15.9         0.090         1,321         4,316,59           Esophagus         Total         3         119,236         2.5         2.8         6.3         0.256         503         8,652,59           Esophagus         Male         3         60,911         4.9         5.5         5.3         0.459         421         4,335,99	
Esophagus         Total         3         119,236         2.5         2.8         6.3         0.256         503         8,652,59           Esophagus         Male         3         60,911         4.9         5.5         5.3         0.459         421         4,335,99	
Esophagus   Male   3   60,911   4.9   5.5   5.3   0.459   421   4,335,99	
Foonboxus	9 9.7
Esophagus   Female   -   58,325   -   1.0   0.722   82   4,316,59	
Hodgkin Lymphoma Total 4 119,236 3.4 3.6 2.7 0.563 206 8,652,59	
Hodgkin Lymphoma   Male   3   60,911   4.9   5.3   1.5   0.383   115   4,335,99 Hodgkin Lymphoma   Female   1   58.325   1.7   1.8   1.2   1.000   91   4.316.59	
Hodgkin Lymphoma         Female         1         58,325         1.7         1.8         1.2         1.000         91         4,316,59           Kidney and Renal Pelvis         Total         21         119,236         17.6         19.5         22.3         0.892         1,794         8,652,59	
Kidney and Renal Pelvis Male 12 60,911 19.7 22.1 14.6 0.595 1,170 4,335,99	
Kidney and Renal Pelvis   Female   9   58,325   15.4   16.8   7.7   0.744   624   4,316,59	
Larynx Total 1 119,236 0.8 0.9 2.7 0.510 214 8,652,59	
Larynx   Male   -   60,911   -   2.0   0.267   160   4,335,99	
Larynx Female 1 58,325 1.7 1.9 0.7 0.968 54 4,316,59	
Leukemia Total 21 119,236 17.6 18.9 20.7 1.000 1,610 8,652,59	
Leukemia         Male         14         60,911         23.0         25.1         12.5         0.755         975         4,335,99           Leukemia         Female         7         58,325         12.0         12.7         8.1         0.868         635         4,316,59	
Liver and Bile Duct Total 8 119,236 6.7 7.5 10.1 0.633 821 8,652,59	
Liver and Bile Duct   Male   7   60.911   11.5   13.0   7.3   1.000   583   4.335.99	
Liver and Bile Duct   Female   1   58,325   1.7   1.9   3.0   0.412   238   4,316,59	
Lung and Bronchus Total 38 119,236 31.9 35.1 60.6 0.003 << 4,849 8,652,59	
Lung and Bronchus Male 23 60,911 37.8 42.6 30.3 0.212 2,429 4,335,99	
Lung and Bronchus Female 15 58,325 25.7 27.8 30.3 0.003 << 2,420 4,316,59	
Melanoma of the Skin         Total         39         119,236         32.7         36.1         36.3         0.693         2,903         8,652,59           Melanoma of the Skin         Male         22         60,911         36.1         40.4         21.9         1.000         1,743         4,335,99	
Melanoma of the Skin Female 17 58,325 29.1 31.9 14.3 0.546 1,160 4,316,59	
Myeloma Total 7 119,236 5.9 6.5 8.8 0.702 701 8,652,59	
Myeloma   Male   4   60,911   6.6   7.4   5.5   0.728   437   4,335,99	
Myeloma   Female   3   58,325   5.1   5.6   3.3   1.000   264   4,316,59	3 6.1
Non-Hodgkin Lymphoma Total 16 119,236 13.4 14.7 24.2 0.105 1,924 8,652,59	
Non-Hodgkin Lymphoma Male 11 60,911 18.1 20.1 14.1 0.499 1,118 4,335,99	
Non-Hodgkin Lymphoma         Female         5         58,325         8.6         9.3         10.1         0.128         806         4,316,59           Oral Cavity and Pharynx         Total         13         119,236         10.9         12.2         15.8         0.586         1,282         8,652,59	
Oral Cavity and Pharynx Total 13 119,236 10.9 12.2 15.8 0.586 1,282 8,652,59 Oral Cavity and Pharynx Male 9 60,911 14.8 16.7 11.5 0.570 927 4,335,99	
Oral Cavity and Pharynx   Nate   9   60,911   14.5   10.7   11.5   0.376   927   4,333,99   14.5   16.5   1	
Ovary Female 4 58,325 6.9 7.5 6.5 0.442 529 4,316,59	
Pancreas Total 16 119,236 13.4 14.7 17.7 0.806 1,407 8,652,59	2 16.3
Pancreas   Male   6   60,911   9.9   11.0   9.7   0.294   778   4,335,99	9 17.9
Pancreas Female 10 58,325 17.1 18.3 8.0 0.555 629 4,316,59	3 14.6
Prostate Male 55 60,911 90.3 102.9 78.4 0.007 << 6,362 4,335,99	
Stomach         Total         5         119,236         4.2         4.6         5.8         0.949         462         8,652,59           Stomach         Male         2         60,911         3.3         3.7         3.9         0.520         307         4,335,99	
Stomach         Male         2         60,911         3.3         3.7         3.9         0.520         307         4,335,99           Stomach         Female         3         58,325         5.1         5.4         2.0         0.637         155         4,316,59	
Testis   Male   4   60,911   6.6   7.0   3.4   0.897   261   4,335,99	
Thyroid Total 18 119,236 15.1 16.6 15.1 0.512 1,202 8,652,59	
Thyroid Male 5 60,911 8.2 9.1 4.4 0.910 350 4,335,99	
Thyroid Female 13 58,325 22.3 24.5 10.5 0.513 852 4,316,59	
Pediatric Age 0 to 19 Total 11 41,175 26.7 26.9 6.9 0.187 410 2,419,34	
Pediatric Age 0 to 19 Male 6 21,363 28.1 28.2 3.7 0.350 217 1,235,14	
Pediatric Age 0 to 19   Female   5   19,812   25.2   25.5   3.2   0.436   193   1,184,20	0.11

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

<sup>2.</sup> Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

<sup>&</sup>quot;<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

## TABLE 4: CANCER MORTALITY 2017–2021 COMPARISON BETWEEN CASSIA COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Ca	ssia County	,			Re	mainder of Idah	0
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	1,096	120,923	906.4	951.7	991.4	0.001 >>	76,334	8,867,792	860.8
All Causes of Death	Male	567	61,850	916.7	1,004.5	513.6	0.021 >>	40,489	4,450,018	909.9
All Causes of Death	Female	529	59,073	895.5	896.9	478.6	0.024 >>	35,845	4,417,774	811.4
All Malignant Cancers	Total	172	120,923	142.2	154.2	188.1	0.254	14,949	8,867,792	168.6
All Malignant Cancers	Male	97	61,850	156.8	174.7	100.8	0.753	8,079	4,450,018	181.5
All Malignant Cancers	Female	75	59,073	127.0	134.4	86.8	0.222	6,870	4,417,774	155.5
Bladder	Total	10	120,923	8.3	8.7	6.2	0.203	479	8,867,792	5.4
Bladder	Male	7	61,850	11.3	12.4	4.7	0.393	371	4,450,018	8.3
Bladder	Female	3	59,073	5.1	5.2	1.4	0.343	108	4,417,774	2.4
Brain and Other Nervous System	Total	6	120,923	5.0	5.4	6.2	1.000	498	8,867,792	5.6
Brain and Other Nervous System Brain and Other Nervous System	Male Female	5 1	61,850 59,073	8.1 1.7	9.0 1.8	3.7 2.5	0.612 0.560	293 205	4,450,018 4,417,774	6.6 4.6
Breast	Total	12	120,923	9.9	10.8	13.7	0.360	1,090	8,867,792	12.3
Breast	Male	- 12	61,850	5.5	10.0	0.2	1.000	1,090	4,450,018	0.4
Breast	Female	12	59,073	20.3	21.7	13.5	0.828	1,074	4,417,774	24.3
Cervix	Female	-	59,073	-	-	1.0	0.733	83	4,417,774	1.9
Colorectal	Total	18	120,923	14.9	16.1	16.4	0.751	1,301	8,867,792	14.7
Colorectal	Male	5	61,850	8.1	9.0	8.9	0.245	714	4,450,018	16.0
Colorectal	Female	13	59,073	22.0	23.0	7.5	0.087	587	4,417,774	13.3
Corpus Uteri	Female	2	59,073	3.4	3.7	2.1	1.000	171	4,417,774	3.9
Esophagus	Total	2	120,923	1.7	1.8	5.9	0.135	475	8,867,792	5.4
Esophagus	Male	2	61,850	3.2	3.6	4.9	0.260	399	4,450,018	9.0
Esophagus	Female	-	59,073	-	-	1.0	0.767	76	4,417,774	1.7
Hodgkin Lymphoma	Total	-	120,923	-	-	0.4	1.000	29	8,867,792	0.3
Hodgkin Lymphoma	Male	-	61,850	-	-	0.2 0.2	1.000 1.000	14 15	4,450,018	0.3
Hodgkin Lymphoma	Female Total	- 6	59,073 120,923	5.0	5.4	4.8	0.687	379	4,417,774 8,867,792	0.3 4.3
Kidney Kidney	Male	4	61,850	6.5	7.2	3.0	0.686	238	4,450,018	4.3 5.3
Kidney	Female	2	59,073	3.4	3.5	1.8	1.000	141	4,417,774	3.2
Larynx	Total	1	120,923	0.8	0.9	0.9	1.000	70	8,867,792	0.8
Larynx	Male	- '	61,850	-	-	0.7	0.964	58	4,450,018	1.3
Larynx	Female	1	59,073	1.7	1.9	0.1	0.269	12	4,417,774	0.3
Leukemia	Total	4	120,923	3.3	3.5	8.4	0.154	656	8,867,792	7.4
Leukemia	Male	2	61,850	3.2	3.6	4.9	0.274	384	4,450,018	8.6
Leukemia	Female	2	59,073	3.4	3.5	3.6	0.617	272	4,417,774	6.2
Liver and Bile Duct	Total	9	120,923	7.4	8.3	7.3	0.619	594	8,867,792	6.7
Liver and Bile Duct	Male	7	61,850	11.3	12.8	4.9	0.454	401	4,450,018	9.0
Liver and Bile Duct	Female	2	59,073	3.4	3.7	2.4	1.000	193	4,417,774	4.4
Lung and Bronchus	Total	17	120,923	14.1	15.4	36.7	0.000 <<	2,944	8,867,792	33.2
Lung and Bronchus	Male	14 3	61,850 59,073	22.6 5.1	25.5 5.4	19.0 17.6	0.295 0.000 <b>&lt;&lt;</b>	1,542 1,402	4,450,018 4,417,774	34.7 31.7
Lung and Bronchus Melanoma of the Skin	Female Total	7	120,923	5.8	6.3	3.5	0.000 <<	282	8,867,792	31.7
Melanoma of the Skin	Male	3	61,850	4.9	5.4	2.4	0.130	189	4.450.018	4.2
Melanoma of the Skin	Female	4	59,073	6.8	7.3	1.2	0.060	93	4,417,774	2.1
Myeloma	Total	8	120,923	6.6	7.1	4.1	0.000	323	8,867,792	3.6
Myeloma	Male	5	61,850	8.1	9.0	2.4	0.188	191	4,450,018	4.3
Myeloma	Female	3	59,073	5.1	5.3	1.7	0.477	132	4,417,774	3.0
Non-Hodgkin Lymphoma	Total	8	120,923	6.6	7.1	7.1	0.843	561	8,867,792	6.3
Non-Hodgkin Lymphoma	Male	6	61,850	9.7	10.7	3.8	0.362	301	4,450,018	6.8
Non-Hodgkin Lýmphoma	Female	2	59,073	3.4	3.5	3.4	0.692	260	4,417,774	5.9
Oral Cavity and Pharynx	Total	3	120,923	2.5	2.7	3.2	1.000	263	8,867,792	3.0
Oral Cavity and Pharynx	Male	2	61,850	3.2	3.6	2.3	1.000	185	4,450,018	4.2
Oral Cavity and Pharynx	Female	1	59,073	1.7	1.8	1.0	1.000	78	4,417,774	1.8
Ovary	Female	2	59,073	3.4	3.7	4.3	0.396	348	4,417,774	7.9
Pancreas Pancreas	Total	13 5	120,923	10.8 8.1	11.8	14.6	0.804 0.406	1,177	8,867,792	13.3 14.3
Pancreas Pancreas	Male Female	5 8	61,850 59,073	13.5	9.1 14.5	7.9 6.7	0.406	637 540	4,450,018 4,417,774	14.3
Prostate	Male	13	61,850	21.0	23.0	11.9	0.722	936	4,417,774	21.0
Stomach	Total	3	120,923	2.5	23.0	2.5	0.810	195	8,867,792	2.2
Stomach	Male	2	61,850	3.2	3.6	1.5	0.873	119	4,450,018	2.7
Stomach	Female	1	59.073	1.7	1.8	1.0	1.000	76	4,417,774	1.7
			ne number of cases p						.,,	

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

<sup>2.</sup> Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

### Cancer Screening and Risk Factor Prevalence Estimates, 2011–2021

	State of								Cassia
Measure	Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	County
Access to Care									
Have Health Insurance, Age <65 (2015–2021)	83.1%	82.8%	85.1%	77.2%	85.8%	78.9%	85.4%	85.4%	78.7%
Not See Doctor Due to Cost in Past Year (2015–2021)	12.6%	11.4%	11.8%	14.5%	12.4%	12.3%	11.8%	12.9%	13.6%
Cancer Screening									
Mammogram Past 2 Years, Age 50–74 (2014, 2016, 2018, 2020)	69.1%	67.0%	73.8%	68.2%	73.2%	64.8%	64.5%	67.1%	50.6%
Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020)	71.2%	73.6%	73.6%	70.8%	72.9%	69.1%	69.5%	65.9%	
Colorectal Cancer Screening, Age 50–75 (2018, 2020)	67.9%	66.9%	73.6%	71.4%	70.6%	61.7%	61.5%	64.7%	55.0%
Tobacco Use									
Current Tobacco User (2016–2021)	22.3%	26.7%	23.1%	23.6%	21.8%	21.4%	22.7%	16.9%	18.7%
Other Cancer-Related									
Healthy Weight by Body Mass Index, Age 20+ (2015–2021)	32.1%	32.8%	31.7%	27.9%	36.1%	29.8%	27.9%	31.9%	32.1%
Any Physical Activity Besides Job Past 30 Days (2015-2021)	78.7%	79.2%	78.1%	74.5%	83.2%	73.4%	76.3%	79.7%	69.7%
Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019)	21.9%	22.8%	19.4%	20.0%	25.2%	19.5%	20.4%	20.2%	14.2%
Home Ever Tested for Radon (2016, 2018, 2020)	23.0%	30.9%	18.2%	16.9%	25.1%	19.9%	23.0%	21.8%	8.5%

### **Access to Care**

### Have Health Insurance – 2015–2021

Statewide, 83.1% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 86.0% of white non-Hispanics, compared to 64.8% of Hispanics and 83.3% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3%) than English-speaking respondents (84.2%). Health care coverage differed significantly by age of respondent, with 79.8% of persons aged 18–29, and 87.8% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 62.1% in Adams County to 91.6% in Oneida County having health insurance.

### Not See Doctor Due to Cost in Past Year - 2015-2021

Statewide, 12.6% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (11.5% of white non-Hispanics, 19.2% of Hispanics, and 21.0% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9% for less than \$15,000, 6.1% for greater than \$50,000). Inability to see a doctor due to cost differed significantly by county, with a range of 7.4% in Franklin County to 17.5% in Power County.

### **Cancer Screening**

<u>Mammogram</u> – 2014, 2016, 2018, 2020

Statewide, 69.1% of women aged 50–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (72.1% versus 36.7%). Mammography rates differed significantly by county, with a range in screening of 45.9% in Benewah County to 77.0% in Nez Perce County. In 2020, Idaho ranked 48th among states and the District of Columbia for mammography screening rates among women aged 50–74 and also 48th among ages 40+.

### Pap Test - 2018, 2020

Statewide, 71.2% of women with an intact cervix and aged 21–65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.1% versus 52.6% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.7% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49<sup>th</sup> among states and the District of Columbia for Pap screening rate.

### Colorectal Cancer Screening – 2018, 2020

Statewide, 67.9% of adults aged 50–75 reported being current for colorectal cancer screening.\*\* Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked 47<sup>th</sup> among states and the District of Columbia in the percentage of adults aged 50–75 and older who reported being up-to-date for colorectal cancer screening.

<sup>\*\*</sup> Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

### **Tobacco Use**

### Current Tobacco Use - 2016-2021

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.3% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 29.9% of persons aged 18-29, and 11.1% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (22.4%) than among Native Americans (40.0%). Tobacco use differed significantly by county, with a range of 5.4% in Madison County to 41.6% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

### **Other Cancer-Related**

### Healthy Weight by Body Mass Index - 2015-2021

Statewide, 32.1% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 32.5% of white non-Hispanics, compared to 28.2% of Hispanics and 24.6% of Native Americans, being in the healthy weight range. Males (25.5%) were significantly less likely to be in the healthy weight range than females (38.6%). BMI differed significantly by age of respondent, with 43.3% of persons aged 18–29, and 26.0% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 19.8% in Power County to 47.4% in Blaine County of adults being in the healthy weight range.

### Any Physical Activity - 2015-2021

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 78.7% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.3% of persons aged 18–29, and 72.3% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 64.3% in Clark County to 84.6% in Teton County.

Physical Activity Guidelines – 2011, 2013, 2015, 2017, 2019 Statewide, 21.9% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.3% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6% in Franklin County to 30.6% in Blaine County.

### Home Radon Testing - 2016, 2018, 2020

Statewide, 23.0% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.4% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.5% in Cassia County to 54.4% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006l and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.





# CLARK COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

### Cancer Incidence 2016–2020 Cancer Mortality 2017–2021 BRFSS 2011–2021

### **RISK FACTORS AND INTERVENTIONS**

### CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/jama.2016.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

### Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

### **Smoking:**

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

### Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <a href="https://www.dietaryguidelines.gov">https://www.dietaryguidelines.gov</a>

### Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute
Cancer Information Services
1-800-4CANCER
<a href="https://www.cancer.gov/contact">https://www.cancer.gov/contact</a>

American Cancer Society <a href="https://www.cancer.org">https://www.cancer.org</a>

### **CANCER INCIDENCE 2016–2020**

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016–2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 16 cases of invasive cancer were diagnosed among Clark County residents (Table 1).

**Table 1:** Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Clark County and the State of Idaho, 2016–2020

Cancer Incidence 2016–2020	Clark County	State of Idaho
All Sites/Types	16	45,610
Female Breast	1	6,687
Prostate	1	6,417
Lung & Bronchus	1	4,887
Colorectal	1	3,451

Table 3 (Cancer Incidence 2016–2020, Comparison between Clark County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Clark County. The table also shows the number of observed cases, person-

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Clark County was 373.8 cases per 100,000 person-years per year during 2016–2020. Comparing this crude rate with the crude rate for the remainder of Idaho (520.0) gives an estimate of the relative burden of disease in Clark County.

The age- and sex-adjusted incidence rate of invasive cancer in Clark County, all sites combined, was 345.8 cases per 100,000 persons per year during 2016–2020. There were fewer cases of cancer in Clark County (16) than expected (24.1) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

### **CANCER MORTALITY 2017–2021**

During 2017–2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 7 Clark County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

**Table 2:** Overall and Cancer Mortality in Clark County and the State of Idaho, 2017–2021

Mortality 2017–2021	Clark County	State of Idaho
All Deaths	32	77,431
Cancer Deaths	7	15,121
% of All Deaths	21.9%	19.5%
Lung & Bronchus	1	2,961
Colorectal	0	1,319
Pancreas	1	1,190
Female Breast	0	1,086
Prostate	0	949

Table 4 (Cancer Mortality 2017–2021, Comparison between Clark County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Clark County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Clark County, all sites combined, was 142.6 deaths per 100,000 persons per year during 2017–2021, compared with 168.2 for the remainder of the state. There were fewer cancer deaths in Clark County (7) than expected (8.3) based upon rates in the remainder of the state, but the difference was not statistically significant.

**Statistical Note:** Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

### TABLE 3: CANCER INCIDENCE 2016–2020 COMPARISON BETWEEN CLARK COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

		Clark County					Remainder of Idaho			
Cancer		Observed	Person	Crude	A.A.I.	Expected	D. ( )	Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)
All Sites Combined All Sites Combined	Total Male	16 7	4,280 2,218	373.8 315.6	345.8 268.2	24.1 14.4	0.110 0.050	45,594 24,282	8,767,548 4,394,692	520.0 552.5
All Sites Combined	Female	9	2,210	436.5	435.3	10.1	0.897	24,262	4,394,092	487.4
Bladder	Total		4,280	-	-	1.2	0.601	2,184	8,767,548	24.9
Bladder	Male	-	2,218	_	-	1.1	0.665	1,751	4,394,692	39.8
Bladder	Female	-	2,062	-	-	0.2	1.000	433	4,372,856	9.9
Brain - malignant	Total	-	4,280	-	-	0.3	1.000	625	8,767,548	7.1
Brain - malignant	Male .	-	2,218	-	-	0.2	1.000	375	4,394,692	8.5
Brain - malignant	Female Total	- 1	2,062 4,280	23.4	- 21.7	0.1 0.7	1.000 1.000	250 1,423	4,372,856	5.7 16.2
Brain and other CNS - non-malignant Brain and other CNS - non-malignant	Male	_ '	2,218	23.4	21.7	0.7	1.000	480	8,767,548 4,394,692	10.2
Brain and other CNS - non-malignant	Female	1	2,062	48.5	47.9	0.5	0.725	943	4.372.856	21.6
Breast	Total	1	4,280	23.4	22.1	3.5	0.274	6,745	8,767,548	76.9
Breast	Male	-	2,218	-	-	0.0	1.000	59	4,394,692	1.3
Breast	Female	1	2,062	48.5	48.9	3.1	0.363	6,686	4,372,856	152.9
Breast - in situ	Total	-	4,280	-	-	0.6	1.000	1,239	8,767,548	14.1
Breast - in situ	Male Female	-	2,218 2,062	-	-	0.0 0.6	1.000 1.000	5 1,234	4,394,692 4,372,856	0.1 28.2
Breast - in situ Cervix	Female	-	2,062	-		0.6	1.000	304	4,372,856	7.0
Colorectal	Total	1	4,280	23.4	21.3	1.8	0.899	3,450	8,767,548	39.3
Colorectal	Male	i 1	2,218	45.1	38.1	1.1	1.000	1,902	4,394,692	43.3
Colorectal	Female	-	2,062	-	-	0.7	0.952	1,548	4,372,856	35.4
Corpus Uteri	Female	2	2,062	97.0	99.8	0.6	0.250	1,328	4,372,856	30.4
Esophagus	Total	-	4,280	-	-	0.3	1.000	506	8,767,548	5.8
Esophagus	Male Female	-	2,218 2,062	-	-	0.3 0.0	1.000 1.000	424 82	4,394,692	9.6 1.9
Esophagus Hodgkin Lymphoma	Total	-	4,280	-	-	0.0	1.000	210	4,372,856 8,767,548	2.4
Hodgkin Lymphoma	Male	_	2,218	_	_	0.1	1.000	118	4,394,692	2.7
Hodgkin Lymphoma	Female	_	2,062	_	_	0.0	1.000	92	4,372,856	2.1
Kidney and Renal Pelvis	Total	-	4,280	-	-	1.0	0.772	1,815	8,767,548	20.7
Kidney and Renal Pelvis	Male	-	2,218	-	-	0.7	1.000	1,182	4,394,692	26.9
Kidney and Renal Pelvis	Female	-	2,062	-	-	0.3	1.000	633	4,372,856	14.5
Larynx	Total	-	4,280	-	-	0.1	1.000	215	8,767,548	2.5
Larynx	Male Female	-	2,218 2,062	-	-	0.1 0.0	1.000 1.000	160 55	4,394,692 4,372,856	3.6 1.3
Larynx Leukemia	Total	- 1	4,280	23.4	21.3	0.0	1.000	1,630	8,767,548	18.6
Leukemia	Male	_ '	2,218	-	-	0.6	1.000	989	4,394,692	22.5
Leukemia	Female	1	2,062	48.5	47.0	0.3	0.535	641	4,372,856	14.7
Liver and Bile Duct	Total	-	4,280	-	-	0.4	1.000	829	8,767,548	9.5
Liver and Bile Duct	Male .	-	2,218	-	-	0.3	1.000	590	4,394,692	13.4
Liver and Bile Duct	Female	- ,	2,062	-	-	0.1	1.000	239	4,372,856	5.5
Lung and Bronchus Lung and Bronchus	Total Male	1 1	4,280 2,218	23.4 45.1	21.0 37.1	2.7 1.5	0.514 1.000	4,886 2,451	8,767,548 4,394,692	55.7 55.8
Lung and Bronchus	Female	_ '	2,210	45.1	37.1	1.3	0.617	2,435	4.372.856	55.7
Melanoma of the Skin	Total	2	4,280	46.7	43.4	1.5	0.914	2,940	8,767,548	33.5
Melanoma of the Skin	Male	2	2,218	90.2	76.4	1.1	0.566	1,763	4,394,692	40.1
Melanoma of the Skin	Female	-	2,062	-	-	0.6	1.000	1,177	4,372,856	26.9
Myeloma	Total	-	4,280	-	-	0.4	1.000	708	8,767,548	8.1
Myeloma	Male	-	2,218	-	-	0.3	1.000	441	4,394,692	10.0
Myeloma Non-Hodgkin Lymphoma	Female Total	- 2	2,062 4,280	- 46.7	43.0	0.1 1.0	1.000 0.549	267 1,938	4,372,856	6.1 22.1
Non-Hodgkin Lymphoma	Male	1	2,218	46.7 45.1	43.0 38.8	0.7	0.549	1,936	8,767,548 4,394,692	25.7
Non-Hodgkin Lymphoma	Female		2,210	48.5	48.0	0.7	0.641	810	4,394,092	18.5
Oral Cavity and Pharynx	Total	- '	4,280	-	-	0.7	1.000	1,295	8,767,548	14.8
Oral Cavity and Pharynx	Male	-	2,218	-	-	0.5	1.000	936	4,394,692	21.3
Oral Cavity and Pharynx	Female	- ,	2,062		-	0.2	1.000	359	4,372,856	8.2
Ovary	Female	1	2,062	48.5	48.9	0.2	0.441	532	4,372,856	12.2
Pancreas	Total	1	4,280	23.4	21.0	0.8	1.000	1,422	8,767,548	16.2
Pancreas Pancreas	Male Female	1	2,218 2,062	- 48.5	- 47.2	0.5 0.3	1.000 0.531	784 638	4,394,692 4,372,856	17.8 14.6
Prostate	Male	1	2,002	45.1	39.4	3.7	0.231	6,416	4,372,630	146.0
Stomach	Total	1	4,280	23.4	21.1	0.3	0.445	466	8,767,548	5.3
Stomach	Male	- 1	2,218	-	-	0.2	1.000	309	4,394,692	7.0
Stomach	Female	1	2,062	48.5	47.2	0.1	0.147	157	4,372,856	3.6
Testis	Male	-	2,218	•	-	0.1	1.000	265	4,394,692	6.0
Thyroid	Total	1	4,280	23.4	23.0	0.6	0.909	1,219	8,767,548	13.9
Thyroid	Male		2,218	-	-	0.2	1.000	355	4,394,692	8.1
Thyroid	Female	1	2,062	48.5	49.3	0.4	0.660	864	4,372,856	19.8
Pediatric Age 0 to 19	Total	-	1,168	-	-	0.2	1.000	421	2,459,355	17.1
Pediatric Age 0 to 19	Male	-	566	-	-	0.1	1.000	223	1,255,944	17.8
Pediatric Age 0 to 19	Female	-	602	-	-	0.1	1.000	198	1,203,411	16.5

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

<sup>2.</sup> Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

<sup>&</sup>quot;<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

### **TABLE 4: CANCER MORTALITY 2017–2021** COMPARISON BETWEEN CLARK COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

All Causes of Death Male				CI	ark County				Rer	mainder of Idah	0
All Causes of Death   Total   32   4,205   761.0   625.3   44.1   0.0717   77,398   8,984,510   881.5   All Causes of Death   Female   17   2,039   833.7   762.6   18.1   0.916   36.357   4.474,808   81.5   61.2	Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
All Causes of Death Male	Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death   Female   17   2,039   833,7   762,6   18.1   0,916   58,537   4,474,808   812,5	All Causes of Death	Total	32				44.1	0.071			861.5
All Melignant Cancers Male	All Causes of Death										
All Malignant Cancers   Male   2   2,166   92.3   70.1   5.2   0.222   8,174   4,509,702   813,3   155,1   Bladder   Total   - 4,205   - 0.3   1,000   489   8,984,510   5.4   Bladder   Total   - 4,205   - 0.3   1,000   489   8,984,510   5.4   Bladder   Total   - 4,205   - 0.3   1,000   489   8,984,510   5.4   Bladder   Total   - 4,205   - 0.3   1,000   489   8,984,510   5.4   Bladder   Total   - 4,205   - 0.3   1,000   489   8,984,510   5.4   Bladder   Total   - 4,205   - 0.3   1,000   206   4,748,08   6.6   Brain and Other Nervous System   Male   - 2,166   - 0.0   0.3   1,000   298   4,509,702   6.6   Brain and Other Nervous System   Female   - 2,039   - 0.1   1,000   206   4,474,808   4.6   Brain and Other Nervous System   Female   - 2,039   - 0.1   1,000   206   4,474,808   4.6   Brain and Other Nervous System   Female   - 2,039   - 0.1   1,000   206   4,474,808   4.6   Brain and Other Nervous System   Female   - 2,039   - 0.0   1,000   1,102   3,984,510   12.3   Breast   Male   - 2,169   - 0.0   0,000   1,102   3,984,510   12.3   Breast   Male   - 2,169   - 0.0   0,000   1,102   3,984,510   12.3   Breast   Male   - 2,169   - 0.0   0,000   1,000   1,000   4,474,808   4.6   Brain and Other Nervous System   Female   - 2,039   - 0.0   0,000   1,000   1,000   4,474,808   1.4   Colorectal   Male   - 2,166   - 0.0   0,000   1,000											
All Malighant Cancers   Female   5   2,039   245.2   234.3   3.3   0.478   6,940   4.474,808   155.1											
Bladder											
Bladder   Male   - 2,166   0.3   1,000   378   4,509,702   8,08   2.5     Brain and Other Nervous System   Total   - 4,205   0.3   1,000   111   4,474,808   2.5     Brain and Other Nervous System   Male   - 2,166   0.3   1,000   298   4,509,702   6.6     Brain and Other Nervous System   Male   - 2,166   0.2   1,000   298   4,509,702   6.6     Breast   Female   - 2,039   0.6   1,000   1,000   1,000   1,000     Breast   Female   - 2,039   0.5   1,000   1,000   1,000   4,474,808   2.5     Breast   Female   - 2,039   0.5   1,000   1,000   1,000   4,474,808   2.4     Breast   Female   - 2,039   0.5   1,000   1,000   4,474,808   2.4     Colorectal   Total   - 4,205   0.7   0,974   1,319   8,984,510   12.3     Colorectal   Male   - 2,166   0.4   1,000   719   4,997,200   1,59     Colorectal   Female   - 2,039   0.5   1,000   1,000   1,000   1,000   1,000     Colorectal   Female   - 2,039   0.7   0,974   1,319   8,984,510   1,50     Colorectal   Female   - 2,039   0.4   1,000   7,19   4,997,200   1,50     Colorectal   Female   - 2,039   0.4   1,000   1			-			-					
Biadder   Female   -   2,039   -   -   0.1   1,000   111   4,474,808   2,5     Brain and Other Nervous System   Male   -   2,166   -   -   0.2   1,000   504   8,984,510   5.6     Brain and Other Nervous System   Male   -   2,166   -   -   0.2   1,000   504   8,984,510   5.6     Brain and Other Nervous System   Male   -   2,166   -   -   0.6   1,000   208   4,509,702   6.6     Brain and Other Nervous System   Male   -   2,039   -   -   0.6   1,000   208   4,574,808   4.6     Breast   Female   -   2,039   -   -   0.6   1,000   1,068   4,474,808   1.9     Colivertal   Total   -   4,205   -     0.7   0,77   1,319   8,984,510   12,2     Colorectal   Male   -   2,166   -     0.4   1,000   719   4,509,702   15,9     Colorectal   Female   -   2,039   -     0.1   1,000   600   4,774,808   13,4     Colorectal   Female   -   2,039   -     0.1   1,000   600   4,774,808   13,4     Colorectal   Female   -   2,039   -     0.1   1,000   600   4,774,808   13,4     Corpus Uteri   Female   -   2,039   -     0.1   1,000   477   4,74,808   13,4     Corpus Uteri   Female   -   2,039   -     0.1   1,000   477   4,74,808   13,4     Corpus Uteri   Female   -   2,039   -     0.1   1,000   477   4,74,808   13,4     Corpus Uteri   Female   -   2,039   -     0.1   1,000   477   4,74,808   13,4     Corpus Uteri   Female   -   2,039   -     0.1   1,000   477   4,74,808   13,4     Corpus Uteri   Female   -   2,039   -     0.0   1,000   477   4,74,808   13,4     Corpus Uteri   Female   -   2,039   -     0.0   1,000   477   4,74,808   13,4     Corpus Uteri   Female   -   2,039   -     0.0   1,000   477   4,74,808   13,4     Corpus Uteri   Female   -   2,039   -     0.0   1,000   477   4,74,808   13,4     Corpus Uteri   Female   -   2,039   -     0.0   1,000   477   4,74,808   13,4     Corpus Uteri   Female   -   2,039   -     0.0   1,000   477   4,74,808   13,4     Corpus Uteri   Female   -   2,039   -     0.0   1,000   477   4,74,808   13,4     Corpus Uteri   Female   -   2,039   -     0.0   1,000   477   4,74,808   13,4     Corpus Uteri   F	Bladder		-			-		1.000			
Brain and Other Nervous System Male Parian and Other Nervous System Female - 2,039 0.1 1,000 206 4,474,808 4.6 Breast Total - 4,205 0.6 1,000 1,102 8,984,510 12.3 Breast Female - 2,039 0.5 1,000 1,000 16 4,509,702 0.4 Breast Female - 2,039 0.5 1,000 1,00		Female	-		-	-	0.1		111	4,474,808	
Brain and Other Nervous System   Female   -	Brain and Other Nervous System		-		-	-					
Breast   Total   - 4,205   - 0.6   1,000   1,102   8,984,510   12.3 Breast   Male   - 2,166   - 0.0   1,000   16   4,509,702   0.4 Breast   Female   - 2,039   - 0.0   1,000   1,000   1,006   4,474,808   1.9   1.0   1,000						-					
Breast   Male   -   2,166   -   -   0.0   1,000   1,66   4,509,702   0.4   Breast   Female   -   2,039   -   -   0.5   1,000   1,086   4,474,808   24,3   Corvix   Female   -   2,039   -   -   0.0   1,000   1,386   4,474,808   24,3   Colorectal   Total   -   4,205   -   0.7   0,974   1,319   8,984,510   14,7   Colorectal   Male   -   2,166   -   0.4   1,000   719   4,509,702   15,9   Colorectal   Female   -   2,039   -   0.3   1,000   600   4,474,808   13,9   Corpus Uleri   Female   -   2,039   -   0.3   1,000   600   4,474,808   33,9   Esophagus   Total   -   4,205   -   0.3   1,000   407   8,196,510   53,3   Esophagus   Male   -   2,168   -   0.2   1,000   407   8,196,510   53,3   Esophagus   Male   -   2,168   -   0.0   1,000   407   8,196,510   53,3   Esophagus   Female   -   2,039   -   0.0   1,000   407   8,196,510   53,3   Esophagus   Male   -   2,166   -   0.0   1,000   407   8,196,510   53,3   Hodgkin Lymphoma   Male   -   2,166   -   0.0   1,000   14   4,509,702   0.3   Hodgkin Lymphoma   Male   -   2,166   -   0.0   1,000   14   4,509,702   0.3   Kidney   Total   1   4,205   23,8   20,3   0.2   0.379   384   8,984,510   4,33   Kidney   Female   -   2,039   -   0.1   1,000   143   4,474,808   0.3   Larynx   Male   1   2,166   -   0.0   1,000   143   4,474,808   3.2   Larynx   Male   -   2,166   -   0.0   1,000   143   4,474,808   3.2   Larynx   Male   -   2,166   -   0.0   1,000   143   4,474,808   3.2   Larynx   Male   -   2,166   -   0.0   1,000   144   4,509,702   1.3   Larynx   Male   -   2,166   -   0.0   1,000   184   4,509,702   1.3   Larynx   Male   -   2,166   -   0.0   1,000   144   4,509,702   1.3   Larynx   Male   -   2,166   -   0.0   1,000   144   4,509,702   1.3   Larynx   Male   -   2,166   -   0.0   1,000   144   4,744,808   0.3   Larynx   Male   -   2,166   -   0.0   1,000   144   4,744,808   0.3   Larynx   Male   -   2,166   -   0.0   1,000   144   4,744,808   0.3   Larynx   Male   -   2,166   -   0.0   1,000   144   4,744,808   0.3   Larynx   Male   -   2,166   -   0.0   1,000   144											
Breast											
Cervix			_			_					
Colorectal			-			-					1.9
Colorectal   Female   -	Colorectal	Total	-	4,205	-	-	0.7	0.974	1,319	8,984,510	14.7
Corpus Uteri			-	2,166	-	-				4,509,702	
Esophagus	=					-					
Esophagus									-		
Esophagus											
Hodgin   Lymphoma			_		_	_					
Hodgkin Lymphoma   Male			-		_	-					
Kidney	Hodgkin Lymphoma		-	2,166	-	-		1.000	14	4,509,702	0.3
Kidney	Hodgkin Lymphoma	Female	-		-	-					0.3
Kidney	Kidney		1								4.3
Larynx			1			36.0					5.3
Larynx			-			-					
Larýnx Female - 2,039 0,0 1,000 13 4,474,808 0.3 Leukemia Total - 4,205 0,4 1,000 660 8,984,510 7.3 Leukemia Male - 2,166 0,2 1,000 386 4,509,702 8.6 Leukemia Bile Duct Total - 4,205 0,1 1,000 603 8,984,510 6.7 Liver and Bile Duct Male - 2,166 0,2 1,000 408 4,509,702 9.0 Liver and Bile Duct Female - 2,039 0,1 1,000 408 4,509,702 9.0 Liver and Bile Duct Female - 2,166 0,2 1,000 408 4,509,702 9.0 Liver and Bile Duct Female - 2,166 0,1 1,000 195 4,474,808 4,4 Lung and Bronchus Total 1 4,205 23.8 20.5 1.6 1,000 2,960 8,984,510 32.9 Lung and Bronchus Female - 2,039 0,1 1,000 1,555 4,509,702 34.5 Lung and Bronchus Female - 2,039 0,7 1,000 1,555 4,509,702 34.5 Lung and Bronchus Female - 2,166 46.2 36.0 1.0 1,000 1,555 4,509,702 34.5 Melanoma of the Skin Male - 2,166 0,2 1,000 289 8,984,510 32.9 Melanoma of the Skin Male - 2,166 0,1 1,000 192 4,509,702 4.3 Melanoma of the Skin Male - 2,166 0,1 1,000 192 4,509,702 4.3 Melanoma of the Skin Female - 2,039 0,0 1,000 97 4,474,808 2.2 Melanoma of the Skin Female - 2,039 0,0 1,000 97 4,474,808 2.2 Myeloma Male - 2,166 0,1 1,000 133 18,984,510 3.7 Myeloma Male - 2,166 0,1 1,000 136 4,509,702 4.3 Myeloma Male - 2,166 0,1 1,000 136 4,509,702 4.3 Myeloma Male - 2,166 0,1 1,000 136 4,509,702 4.3 Myeloma Male - 2,166 0,1 1,000 136 4,509,702 4.3 Myeloma Male - 2,166 0,1 1,000 136 4,509,702 4.3 Myeloma Male - 2,166 0,1 1,000 307 4,509,702 4.3 Non-Hodgkin Lymphoma Male - 2,166 0,1 1,000 377 4,509,702 4.3 Non-Hodgkin Lymphoma Male - 2,166 0,1 1,000 377 4,509,702 4.3 Non-Hodgkin Lymphoma Female - 2,039 0,1 1,000 377 4,509,702 4.3 Non-Hodgkin Lymphoma Male - 2,166 0,1 1,000 378 4,509,702 4.3 Non-Hodgkin Lymphoma Female - 2,039 0,0 1,000 379 4,509,702 4.3 Non-Hodgkin Lymphoma Female - 2,039 0,1 1,000 379 4,509,702 4.3 Non-Hodgkin Lymphoma Female - 2,039 0,0 1,000 379 4,509,702 4.3 Non-Hodgkin Lymphoma Female - 2,039 0,1 1,000 379 4,509,702 2.4 Non-Hodgkin Lymphoma Female											
Leukemia   Total   -											
Leukemia Female - 2,039 0.1 1,000 274 4,474,808 6.1 1 Liver and Bile Duct Total - 4,205 0.3 1,000 603 8,984,510 6.7 Liver and Bile Duct Male - 2,166 0.2 1,000 408 4,509,702 9.0 Liver and Bile Duct Female - 2,039 0.1 1,000 195 4,474,808 4,4 Ling and Bronchus Total 1 4,205 23.8 20.5 1.6 1,000 1,555 4,509,702 4.3 Lung and Bronchus Male 1 2,166 46.2 36.0 1.0 1,000 1,555 4,509,702 34.5 Lung and Bronchus Female - 2,039 0.7 1,000 1,405 4,474,808 31.4 Melanoma of the Skin Total - 4,205 0.2 1,000 289 8,984,510 32.9 Melanoma of the Skin Male - 2,166 0.1 1,000 192 4,509,702 4.3 Myeloma Total - 4,205 0.2 1,000 331 8,984,510 3.7 Myeloma Male - 2,166 0.1 1,000 197 4,474,808 2.2 Myeloma Male - 2,166 0.1 1,000 197 4,474,808 3.0 Myeloma Male - 2,166 0.1 1,000 196 4,509,702 4.3 Myeloma Male - 2,166 0.1 1,000 196 4,509,702 4.3 Myeloma Male - 2,166 0.1 1,000 196 4,509,702 4.3 Myeloma Male - 2,166 0.1 1,000 196 4,509,702 6.8 Mon-Hodgkin Lymphoma Total - 4,205 0.2 1,000 331 8,984,510 3.0 Non-Hodgkin Lymphoma Male - 2,166 0.3 1,000 569 8,984,510 3.0 Non-Hodgkin Lymphoma Female - 2,039 0.1 1,000 196 4,509,702 6.8 Non-Hodgkin Lymphoma Female - 2,039 0.1 1,000 262 4,474,808 5.9 Non-Hodgkin Lymphoma Female - 2,039 0.1 1,000 262 4,474,808 5.9 Noral Cavity and Pharynx Male - 2,166 0.1 1,000 350 4,474,808 5.9 Pancreas Female - 2,039 0.2 1,000 350 4,474,808 7.8 Pancreas Female - 2,039 0.2 1,000 350 4,474,808 7.8 Pancreas Female - 2,039 0.2 1,000 350 4,474,808 7.8 Pancreas Female - 2,039 49 47.3 0.3 0.456 547 4,474,808 12.2 Prostate Male - 2,166 0.7 1,000 949 4,509,702 21.0 Stomach Male - 2,166 0.7 1,000 121 4,509,702 2.7			-		-	-			-		7.3
Liver and Bile Duct Male	Leukemia	Male	-		-	-	0.2	1.000	386	4,509,702	8.6
Liver and Bile Duct Female - 2,166 0.2 1.000 408 4,509,702 9.0 Liver and Bile Duct Female - 2,039 0.1 1.000 195 4,474,808 4.4 1.000 195 4,474,808 4.4 1.000 195 4,474,808 4.4 1.000 195 4,474,808 1.4 1.000 195 4,474,808 1.4 1.000 195 4,474,808 1.4 1.000 195 4,474,808 1.4 1.000 195 4,474,808 1.4 1.000 195 1.00			-		-	-					
Liver and Bile Duct											
Lung and Bronchus         Total         1         4,205         23.8         20.5         1.6         1.000         2,960         8,984,510         32.9           Lung and Bronchus         Male         1         2,166         46.2         36.0         1.0         1.000         1,555         4,509,702         34.5           Lung and Bronchus         Female         -         2,039         -         -         0.7         1.000         1,405         4,474,808         31.4           Melanoma of the Skin         Mole         -         2,166         -         -         0.1         1.000         192         4,509,702         4.3           Melanoma of the Skin         Male         -         2,166         -         -         0.1         1.000         192         4,509,702         4.3           Melanoma of the Skin         Female         -         2,039         -         -         0.0         1.000         192         4,509,702         4.3           Myeloma         Female         -         2,039         -         -         0.1         1.000         135         4,474,808         3.0           Non-Hodgkin Lymphoma         Total         -         4,205         -			-		-	-					
Lung and Bronchus         Male Female         1         2,166         46.2         36.0         1.0         1.000         1,555         4,509,702         34.5           Lung and Bronchus         Female         -         2,039         -         -         0.7         1.000         1,555         4,509,702         34.5           Melanoma of the Skin         Male         -         4,205         -         0.1         1.000         192         4,509,702         4.3           Melanoma of the Skin         Female         -         2,166         -         -         0.1         1.000         192         4,509,702         4.3           Melanoma of the Skin         Female         -         2,039         -         -         0.0         1.000         97         4,474,808         2.2           Myeloma         Total         -         4,205         -         -         0.2         1.000         331         8,984,510         3.7           Myeloma         Female         -         2,039         -         -         0.1         1.000         135         4,474,808         3.0           Non-Hodgkin Lymphoma         Total         -         4,205         -         -         0.			- 1		- 23.8	20.5					
Lung and Bronchus         Female         -         2,039         -         -         0.7         1.000         1,405         4,474,808         31.4           Melanoma of the Skin         Total         -         4,205         -         -         0.2         1.000         289         8,984,510         3.2           Melanoma of the Skin         Male         -         2,166         -         -         0.0         1.000         192         4,509,702         4.3           Melanoma of the Skin         Female         -         2,039         -         -         0.0         1.000         197         4,474,808         2.2           Myeloma         Total         -         4,205         -         -         0.2         1.000         331         8,984,510         3.7           Myeloma         Male         -         2,166         -         -         0.1         1.000         196         4,509,702         4.3           Myeloma         Female         -         2,166         -         -         0.1         1.000         135         4,474,808         3.0           Non-Hodgkin Lymphoma         Male         -         2,166         -         -         0.2											
Melanoma of the Skin         Total         -         4,205         -         -         0.2         1.000         289         8,984,510         3.2           Melanoma of the Skin         Male         -         2,166         -         -         0.1         1.000         192         4,509,702         4.3           Melanoma of the Skin         Female         -         2,039         -         -         0.1         1.000         192         4,509,702         4.3           Myeloma         Male         -         2,166         -         -         0.2         1.000         331         8,984,510         3.7           Myeloma         Male         -         2,166         -         -         0.1         1.000         196         4,509,702         4.3           Myeloma         Female         -         2,039         -         -         0.1         1.000         196         4,509,702         4.3           Myeloma         Female         -         2,039         -         -         0.1         1.000         196         4,509,702         4.3           Myeloma         Male         -         2,166         -         -         0.2         1.000	Lung and Bronchus		•								31.4
Melanoma of the Skin         Male         -         2,166         -         -         0.1         1.000         192         4,509,702         4.3           Melanoma of the Skin         Female         -         2,039         -         -         0.0         1.000         97         4,474,808         2.2           Myeloma         Male         -         4,205         -         -         0.2         1.000         331         8,984,510         3.7           Myeloma         Female         -         2,039         -         -         0.1         1.000         196         4,509,702         4.3           Myeloma         Female         -         2,039         -         -         0.1         1.000         196         4,509,702         4.3           Myeloma         Female         -         2,039         -         -         0.1         1.000         135         4,474,808         3.0           Non-Hodgkin Lymphoma         Total         -         4,205         -         -         0.3         1.000         307         4,509,702         6.8           Non-Hodgkin Lymphoma         Female         -         2,166         -         -         0.1	Melanoma of the Skin		-	4,205	-	-		1.000		8,984,510	3.2
Myeloma         Total         -         4,205         -         -         0.2         1.000         331         8,984,510         3.7           Myeloma         Male         -         2,166         -         -         0.1         1.000         196         4,509,702         4.3           Myeloma         Female         -         2,039         -         -         0.1         1.000         135         4,474,808         3.0           Non-Hodgkin Lymphoma         Total         -         2,166         -         -         0.2         1.000         307         4,509,702         6.8           Non-Hodgkin Lymphoma         Male         -         2,166         -         -         0.2         1.000         307         4,509,702         6.8           Non-Hodgkin Lymphoma         Female         -         2,166         -         -         0.2         1.000         307         4,509,702         6.8           Non-Hodgkin Lymphoma         Female         -         2,039         -         -         0.1         1.000         307         4,509,702         6.8           Non-Hodgkin Lymphoma         Female         -         2,039         -         -         0.1	Melanoma of the Skin		-	2,166	-	-			192	4,509,702	
Myeloma         Male         -         2,166         -         -         0.1         1.000         196         4,509,702         4.3           Myeloma         Female         -         2,039         -         -         0.1         1.000         135         4,474,808         3.0           Non-Hodgkin Lymphoma         Total         -         4,205         -         -         0.3         1.000         569         8,984,510         6.3           Non-Hodgkin Lymphoma         Male         -         2,166         -         -         0.2         1.000         307         4,509,702         6.8           Non-Hodgkin Lymphoma         Female         -         2,166         -         -         0.2         1.000         307         4,509,702         6.8           Non-Hodgkin Lymphoma         Female         -         2,039         -         -         0.1         1.000         262         4,474,808         5.9           Oral Cavity and Pharynx         Total         -         4,205         -         -         0.1         1.000         187         4,509,702         4.1           Oral Cavity and Pharynx         Female         -         2,039         -         -						-					2.2
Myeloma         Female         -         2,039         -         -         0.1         1.000         135         4,474,808         3.0           Non-Hodgkin Lymphoma         Total         -         4,205         -         -         0.3         1.000         569         8,984,510         6.3           Non-Hodgkin Lymphoma         Male         -         2,166         -         -         0.2         1.000         307         4,509,702         6.8           Non-Hodgkin Lymphoma         Female         -         2,039         -         -         0.1         1.000         307         4,509,702         6.8           Non-Hodgkin Lymphoma         Female         -         2,039         -         -         0.1         1.000         307         4,509,702         6.8           Non-Hodgkin Lymphoma         Female         -         2,039         -         -         0.1         1.000         266         8,984,510         3.0           Oral Cavity and Pharynx         Male         -         2,166         -         -         0.1         1.000         187         4,509,702         4.1           Orary         Female         -         2,039         -         -											
Nón-Hodgkin Lymphoma         Total         -         4,205         -         -         0.3         1.000         569         8,984,510         6.3           Non-Hodgkin Lymphoma         Male         -         2,166         -         -         0.2         1.000         307         4,509,702         6.8           Non-Hodgkin Lymphoma         Female         -         2,039         -         -         0.1         1.000         262         4,474,808         5.9           Oral Cavity and Pharynx         Total         -         4,205         -         -         0.1         1.000         266         8,984,510         3.0           Oral Cavity and Pharynx         Male         -         2,166         -         -         0.1         1.000         266         8,984,510         3.0           Oral Cavity and Pharynx         Male         -         2,166         -         -         0.1         1.000         187         4,509,702         4.1           Oral Cavity and Pharynx         Female         -         2,039         -         -         0.0         1.000         187         4,509,702         4.1           Oral Cavity and Pharynx         Female         -         2,039											
Non-Hodgkin Lymphoma         Male         -         2,166         -         -         0.2         1.000         307         4,509,702         6.8           Non-Hodgkin Lymphoma         Female         -         2,039         -         -         0.1         1.000         262         4,474,808         5.9           Oral Cavity and Pharynx         Total         -         4,205         -         -         0.1         1.000         266         8,984,510         3.0           Oral Cavity and Pharynx         Male         -         2,166         -         -         0.1         1.000         187         4,509,702         4.1           Oral Cavity and Pharynx         Female         -         2,039         -         -         0.0         1.000         187         4,509,702         4.1           Oral Cavity and Pharynx         Female         -         2,039         -         -         0.0         1.000         187         4,509,702         4.1           Oral Cavity and Pharynx         Female         -         2,039         -         -         0.0         1.000         350         4,474,808         1.8           Ovary         Female         -         2,039         -											6.3
Non-Hodgkin Lymphoma         Female         -         2,039         -         -         0.1         1.000         262         4,474,808         5.9           Oral Cavity and Pharynx         Total         -         4,205         -         -         0.1         1.000         266         8,984,510         3.0           Oral Cavity and Pharynx         Male         -         2,166         -         -         0.1         1.000         187         4,509,702         4.1           Ovary         Female         -         2,039         -         -         0.0         1.000         350         4,474,808         7.8           Pancreas         Total         1         4,205         23.8         20.9         0.6         0.940         1,189         8,984,510         13.2           Pancreas         Male         -         2,166         -         -         0.4         1,000         642         4,509,702         14.2           Pancreas         Male         -         2,166         -         -         0.4         1,000         642         4,509,702         14.2           Prostate         Male         -         2,166         -         -         0.7 <t< td=""><td>Non-Hodgkin Lymphoma</td><td></td><td>_  </td><td></td><td>_</td><td>_  </td><td></td><td></td><td></td><td>4,509,702</td><td>6.8</td></t<>	Non-Hodgkin Lymphoma		_		_	_				4,509,702	6.8
Oral Cavity and Pharynx         Total         -         4,205         -         -         0.1         1.000         266         8,984,510         3.0           Oral Cavity and Pharynx         Male         -         2,166         -         -         0.1         1.000         187         4,509,702         4.1           Oral Cavity and Pharynx         Female         -         2,039         -         -         0.0         1.000         79         4,474,808         1.8           Ovary         Female         -         2,039         -         -         0.2         1.000         350         4,474,808         7.8           Pancreas         Total         1         4,205         23.8         20.9         0.6         0.940         1,189         8,984,510         13.2           Pancreas         Male         -         2,166         -         -         0.4         1.000         642         4,509,702         14.2           Pancreas         Female         1         2,039         49.0         47.3         0.3         0.456         547         4,474,808         12.2           Prostate         Male         -         2,166         -         -         0.7	Non-Hodgkin Lymphoma		-	2,039	-	-	0.1	1.000	262	4,474,808	5.9
Oral Cavitý and Pharýnx         Female         -         2,039         -         -         0.0         1.000         79         4,474,808         1.8           Ovary         Female         -         2,039         -         -         0.2         1.000         350         4,474,808         7.8           Pancreas         Total         1         4,205         23.8         20.9         0.6         0.940         1,189         8,984,510         13.2           Pancreas         Male         -         2,166         -         -         0.4         1.000         642         4,509,702         14.2           Prostate         Male         -         2,166         -         -         0.7         1.000         949         4,509,702         21.0           Stomach         Total         1         4,205         23.8         20.4         0.1         0.204         197         8,984,510         2.2           Stomach         Male         -         2,166         -         -         0.7         1.000         949         4,509,702         21.0	Oral Cavity and Pharynx					-				8,984,510	3.0
Ovary         Female         -         2,039         -         -         0.2         1.000         350         4,474,808         7.8           Pancreas         Total         1         4,205         23.8         20.9         0.6         0.940         1,189         8,984,510         13.2           Pancreas         Male         -         2,166         -         -         0.4         1.000         642         4,509,702         14.2           Prostate         Male         -         2,166         -         -         0.7         1.000         949         4,509,702         21.0           Stomach         Total         1         4,205         23.8         20.4         0.1         0.204         197         8,984,510         2.2           Stomach         Male         -         2,166         -         -         0.1         1.000         121         4,509,702         2.7											
Pancreas         Total         1         4,205         23.8         20.9         0.6         0.940         1,189         8,984,510         13.2           Pancreas         Male         -         2,166         -         -         0.4         1,000         642         4,509,702         14.2           Pancreas         Female         1         2,039         49.0         47.3         0.3         0.456         547         4,474,808         12.2           Prostate         Male         -         2,166         -         -         0.7         1.000         949         4,509,702         21.0           Stomach         Total         1         4,205         23.8         20.4         0.1         0.204         197         8,984,510         2.2           Stomach         Male         -         2,166         -         -         0.1         1.000         121         4,509,702         2.7											
Pancreas         Male Pancreas         -         2,166 Pancreas         -         -         0.4 Pancreas         1.000 Pancreas         642 Pancreas         4,509,702 Pancreas         14.2 Pancreas           Prostate         Male Pancreas         -         2,166 Pancreas         -         -         0.3 Pancreas         0.456 Pancreas         547 Pancreas         4,474,808 Pancreas         12.2 Pancreas           Prostate         Male Pancreas         -         2,166 Pancreas         -         -         0.7 Pancreas         1.000 Pancreas         949 Pancreas         4,509,702 Pancreas         21.0 Pancreas           Stomach         Total Pancreas         1 Pancreas         -         0.1 Pancreas         0.1 Pancreas         0.204 Pancreas         197 Pancreas         8,984,510 Pancreas         2.2 Pancreas         2.2 Pancreas         0.1 Pancreas         1.000 Pancreas         121 Pancreas         4,509,702 Pancreas         2.2 Pancreas         2											7.8 13.2
Pancreas         Female         1         2,039         49.0         47.3         0.3         0.456         547         4,474,808         12.2           Prostate         Male         -         2,166         -         -         0.7         1.000         949         4,509,702         21.0           Stomach         Total         1         4,205         23.8         20.4         0.1         0.204         197         8,984,510         2.2           Stomach         Male         -         2,166         -         -         0.1         1.000         121         4,509,702         2.7					23.0	- 20.9					
Prostate         Male         -         2,166         -         -         0.7         1.000         949         4,509,702         21.0           Stomach         Total         1         4,205         23.8         20.4         0.1         0.204         197         8,984,510         2.2           Stomach         Male         -         2,166         -         -         0.1         1.000         121         4,509,702         2.7	Pancreas				49.0	47.3					12.2
Stomach         Total         1         4,205         23.8         20.4         0.1         0.204         197         8,984,510         2.2           Stomach         Male         -         2,166         -         -         0.1         1.000         121         4,509,702         2.7	Prostate			2,166	-	-					21.0
			1	4,205	23.8	20.4				8,984,510	2.2
Stomach   Female   1   2,039   49.0   46.0   0.0   0.073   76   4,474,808   1.7					-	-					
	Stomach	Female	1	2,039	49.0	46.0	0.0	0.073	76	4,474,808	1.7

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

<sup>2.</sup> Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

### Cancer Screening and Risk Factor Prevalence Estimates, 2011–2021

	State of								Clark
Measure	Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	County
Access to Care									
Have Health Insurance, Age <65 (2015–2021)	83.1%	82.8%	85.1%	77.2%	85.8%	78.9%	85.4%	85.4%	
Not See Doctor Due to Cost in Past Year (2015–2021)	12.6%	11.4%	11.8%	14.5%	12.4%	12.3%	11.8%	12.9%	4.4%
Cancer Screening									
Mammogram Past 2 Years, Age 50–74 (2014, 2016, 2018, 2020)	69.1%	67.0%	73.8%	68.2%	73.2%	64.8%	64.5%	67.1%	
Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020)	71.2%	73.6%	73.6%	70.8%	72.9%	69.1%	69.5%	65.9%	
Colorectal Cancer Screening, Age 50–75 (2018, 2020)	67.9%	66.9%	73.6%	71.4%	70.6%	61.7%	61.5%	64.7%	
Tobacco Use									
Current Tobacco User (2016–2021)	22.3%	26.7%	23.1%	23.6%	21.8%	21.4%	22.7%	16.9%	
Other Cancer-Related									
Healthy Weight by Body Mass Index, Age 20+ (2015–2021)	32.1%	32.8%	31.7%	27.9%	36.1%	29.8%	27.9%	31.9%	
Any Physical Activity Besides Job Past 30 Days (2015-2021)	78.7%	79.2%	78.1%	74.5%	83.2%	73.4%	76.3%	79.7%	64.3%
Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019)	21.9%	22.8%	19.4%	20.0%	25.2%	19.5%	20.4%	20.2%	
Home Ever Tested for Radon (2016, 2018, 2020)	23.0%	30.9%	18.2%	16.9%	25.1%	19.9%	23.0%	21.8%	

### **Access to Care**

### Have Health Insurance – 2015–2021

Statewide, 83.1% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 86.0% of white non-Hispanics, compared to 64.8% of Hispanics and 83.3% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3%) than English-speaking respondents (84.2%). Health care coverage differed significantly by age of respondent, with 79.8% of persons aged 18–29, and 87.8% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 62.1% in Adams County to 91.6% in Oneida County having health insurance.

### Not See Doctor Due to Cost in Past Year - 2015-2021

Statewide, 12.6% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (11.5% of white non-Hispanics, 19.2% of Hispanics, and 21.0% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9% for less than \$15,000, 6.1% for greater than \$50,000). Inability to see a doctor due to cost differed significantly by county, with a range of 7.4% in Franklin County to 17.5% in Power County.

### **Cancer Screening**

<u>Mammogram</u> – 2014, 2016, 2018, 2020

Statewide, 69.1% of women aged 50–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (72.1% versus 36.7%). Mammography rates differed significantly by county, with a range in screening of 45.9% in Benewah County to 77.0% in Nez Perce County. In 2020, Idaho ranked 48th among states and the District of Columbia for mammography screening rates among women aged 50–74 and also 48th among ages 40+.

### Pap Test - 2018, 2020

Statewide, 71.2% of women with an intact cervix and aged 21–65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.1% versus 52.6% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.7% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49<sup>th</sup> among states and the District of Columbia for Pap screening rate.

### Colorectal Cancer Screening - 2018, 2020

Statewide, 67.9% of adults aged 50–75 reported being current for colorectal cancer screening.\*\* Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked 47<sup>th</sup> among states and the District of Columbia in the percentage of adults aged 50–75 and older who reported being up-to-date for colorectal cancer screening.

<sup>\*\*</sup> Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

### **Tobacco Use**

### Current Tobacco Use - 2016-2021

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.3% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 29.9% of persons aged 18-29, and 11.1% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (22.4%) than among Native Americans (40.0%). Tobacco use differed significantly by county, with a range of 5.4% in Madison County to 41.6% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

### **Other Cancer-Related**

### Healthy Weight by Body Mass Index - 2015-2021

Statewide, 32.1% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 32.5% of white non-Hispanics, compared to 28.2% of Hispanics and 24.6% of Native Americans, being in the healthy weight range. Males (25.5%) were significantly less likely to be in the healthy weight range than females (38.6%). BMI differed significantly by age of respondent, with 43.3% of persons aged 18–29, and 26.0% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 19.8% in Power County to 47.4% in Blaine County of adults being in the healthy weight range.

### Any Physical Activity - 2015-2021

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 78.7% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.3% of persons aged 18–29, and 72.3% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 64.3% in Clark County to 84.6% in Teton County.

Physical Activity Guidelines – 2011, 2013, 2015, 2017, 2019 Statewide, 21.9% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.3% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6% in Franklin County to 30.6% in Blaine County.

### Home Radon Testing - 2016, 2018, 2020

Statewide, 23.0% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.4% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.5% in Cassia County to 54.4% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006l and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.





# CLEARWATER COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

### Cancer Incidence 2016–2020 Cancer Mortality 2017–2021 BRFSS 2011–2021

### **RISK FACTORS AND INTERVENTIONS**

### **CANCER**

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/jama.2016.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

### Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

### **Smoking:**

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

### Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <a href="https://www.dietaryguidelines.gov">https://www.dietaryguidelines.gov</a>

### Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute
Cancer Information Services
1-800-4CANCER
<a href="https://www.cancer.gov/contact">https://www.cancer.gov/contact</a>

American Cancer Society <a href="https://www.cancer.org">https://www.cancer.org</a>

### **CANCER INCIDENCE 2016–2020**

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016–2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 362 cases of invasive cancer were diagnosed among Clearwater County residents (Table 1).

**Table 1:** Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Clearwater County and the State of Idaho, 2016–2020

Cancer Incidence 2016–2020	Clearwater County	State of Idaho
All Sites/Types	362	45,610
Female Breast	37	6,687
Prostate	57	6,417
Lung & Bronchus	58	4,887
Colorectal	34	3,451

Table 3 (Cancer Incidence 2016–2020, Comparison between Clearwater County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Clearwater County. The table also shows the number of observed cases,

person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Clearwater County was 828.8 cases per 100,000 person-years per year during 2016–2020. Comparing this crude rate with the crude rate for the remainder of Idaho (518.4) gives an estimate of the relative burden of disease in Clearwater County.

The age- and sex-adjusted incidence rate of invasive cancer in Clearwater County, all sites combined, was 540.4 cases per 100,000 persons per year during 2016–2020. There were more cases of cancer in Clearwater County (362) than expected (347.3) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

### **CANCER MORTALITY 2017–2021**

During 2017–2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 139 Clearwater County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

**Table 2:** Overall and Cancer Mortality in Clearwater County and the State of Idaho, 2017–2021

Mortality 2017–2021	Clearwater County	State of Idaho
All Deaths	569	77,431
Cancer Deaths	139	15,121
% of All Deaths	24.4%	19.5%
Lung & Bronchus	42	2,961
Colorectal	15	1,319
Pancreas	6	1,190
Female Breast	4	1,086
Prostate	6	949

Table 4 (Cancer Mortality 2017–2021, Comparison between Clearwater County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Clearwater County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Clearwater County, all sites combined, was 191.5 deaths per 100,000 persons per year during 2017–2021, compared with 167.5 for the remainder of the state. There were more cancer deaths in Clearwater County (139) than expected (121.6) based upon rates in the remainder of the state, but the difference was not statistically significant.

**Statistical Note:** Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

### TABLE 3: CANCER INCIDENCE 2016–2020 COMPARISON BETWEEN CLEARWATER COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

		Clearwater County						Remainder of Idaho			
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude	
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)	
All Sites Combined	Total	362	43,677	828.8	540.4	347.3	0.443	45,248	8,728,151	518.4	
All Sites Combined	Male	217	24,114	899.9	580.9 485.2	205.6	0.446 1.000	24,072	4,372,796	550.5	
All Sites Combined Bladder	Female Total	145 20	19,563 43,677	741.2 45.8	27.4	145.3 18.1	0.712	21,176 2,164	4,355,355 8,728,151	486.2 24.8	
Bladder	Male	18	24,114	74.6	45.1	15.8	0.649	1,733	4,372,796	39.6	
Bladder	Female	2	19,563	10.2	6.1	3.3	0.730	431	4,355,355	9.9	
Brain - malignant	Total	3	43,677	6.9	5.0	4.2	0.773	622	8,728,151	7.1	
Brain - malignant	Male	3	24,114	12.4	9.2	2.8	1.000	372	4,372,796	8.5	
Brain - malignant	Female		19,563	-		1.6	0.412	250	4,355,355	5.7	
Brain and other CNS - non-malignant Brain and other CNS - non-malignant	Total Male	11 4	43,677 24,114	25.2 16.6	17.4 11.9	10.2 3.6	0.887 0.988	1,413 476	8,728,151 4,372,796	16.2 10.9	
Brain and other CNS - non-malignant	Female	7	19,563	35.8	24.0	6.3	0.966	937	4,372,790	21.5	
Breast	Total	37	43,677	84.7	57.6	49.4	0.082	6,709	8,728,151	76.9	
Breast	Male	-	24,114	-	-	0.5	1.000	59	4,372,796	1.3	
Breast	Female	37	19,563	189.1	126.3	44.7	0.278	6,650	4,355,355	152.7	
Breast - in situ	Total	6	43,677	13.7	9.6	8.9	0.439	1,233	8,728,151	14.1	
Breast - in situ	Male	- 6	24,114	-	-	0.0	1.000	5	4,372,796	0.1	
Breast - in situ Cervix	Female Female	-	19,563 19,563	30.7	21.0	8.1 1.5	0.611 0.431	1,228 304	4,355,355 4,355,355	28.2 7.0	
Colorectal	Total	34	43,677	77.8	50.9	26.1	0.431	3,417	8,728,151	39.1	
Colorectal	Male	22	24,114	91.2	60.8	15.6	0.143	1,881	4,372,796	43.0	
Colorectal	Female	12	19,563	61.3	39.0	10.9	0.808	1,536	4,355,355	35.3	
Corpus Uteri	Female	5	19,563	25.6	16.9	9.0	0.230	1,325	4,355,355	30.4	
Esophagus	Total	10	43,677	22.9	14.3	4.0	0.016 >>	496	8,728,151	5.7	
Esophagus Esophagus	Male Female	10	24,114 19,563	41.5	26.3	3.6 0.6	0.008 <b>&gt;&gt;</b> 1.000	414 82	4,372,796 4,355,355	9.5 1.9	
Hodgkin Lymphoma	Total	-	43,677	-	-	1.2	0.616	210	8,728,151	2.4	
Hodgkin Lymphoma	Male	_	24,114	_	_	0.8	0.943	118	4,372,796	2.7	
Hodgkin Lymphoma	Female	-	19,563	_	-	0.4	1.000	92	4,355,355	2.1	
Kidney and Renal Pelvis	Total	17	43,677	38.9	25.8	13.6	0.415	1,798	8,728,151	20.6	
Kidney and Renal Pelvis	Male	13	24,114	53.9	36.3	9.6	0.340	1,169	4,372,796	26.7	
Kidney and Renal Pelvis	Female	4	19,563	20.4	13.3	4.4	1.000	629	4,355,355	14.4	
Larynx	Total Male	4 2	43,677 24,114	9.2 8.3	5.8 5.3	1.7 1.4	0.176 0.791	211 158	8,728,151 4,372,796	2.4 3.6	
Larynx Larynx	Female	2	19,563	10.2	6.5	0.4	0.791	53	4,372,790	1.2	
Leukemia	Total	16	43,677	36.6	24.1	12.3	0.355	1,615	8,728,151	18.5	
Leukemia	Male	10	24,114	41.5	27.7	8.1	0.585	979	4,372,796	22.4	
Leukemia	Female	6	19,563	30.7	19.6	4.5	0.585	636	4,355,355	14.6	
Liver and Bile Duct	Total	8	43,677	18.3	11.7	6.4	0.633	821	8,728,151	9.4	
Liver and Bile Duct	Male Female	8	24,114	33.2	21.6	4.9	0.252	582	4,372,796	13.3	
Liver and Bile Duct Lung and Bronchus	Total	- 58	19,563 43,677	132.8	- 80.1	1.7 40.1	0.355 0.009 >>	239 4,829	4,355,355 8,728,151	5.5 55.3	
Lung and Bronchus	Male	24	24,114	99.5	60.3	22.1	0.741	2,428	4,372,796	55.5	
Lung and Bronchus	Female	34	19,563	173.8	102.8	18.2	0.001 >>	2,401	4,355,355	55.1	
Melanoma of the Skin	Total	14	43,677	32.1	21.8	21.6	0.114	2,928	8,728,151	33.5	
Melanoma of the Skin	Male	8	24,114	33.2	21.9	14.7	0.089	1,757	4,372,796	40.2	
Melanoma of the Skin	Female	6	19,563	30.7	21.8	7.4	0.787	1,171	4,355,355	26.9	
Myeloma Myeloma	Total	-	43,677	-	-	5.8	0.006 <<	708 441	8,728,151	8.1	
Myeloma Myeloma	Male Female	-	24,114 19,563	-	-	3.9 2.0	0.039 <b>&lt;&lt;</b> 0.274	267	4,372,796 4,355,355	10.1 6.1	
Non-Hodgkin Lymphoma	Total	14	43,677	32.1	21.0	14.7	0.984	1,926	8,728,151	22.1	
Non-Hodgkin Lymphoma	Male	6	24,114	24.9	16.6	9.3	0.363	1,123	4,372,796	25.7	
Non-Hodgkin Lymphoma	Female	8	19,563	40.9	25.8	5.7	0.438	803	4,355,355	18.4	
Oral Cavity and Pharynx	Total	16	43,677	36.6	24.0	9.8	0.081	1,279	8,728,151	14.7	
Oral Cavity and Pharynx Oral Cavity and Pharynx	Male Female	10 6	24,114 19,563	41.5 30.7	27.7 19.7	7.7 2.5	0.483 0.080	926 353	4,372,796	21.2	
Ovary	Female	2	19,563	10.2	6.8	3.6	0.060	531	4,355,355 4,355,355	12.2	
Pancreas	Total	12	43,677	27.5	16.9	11.5	0.954	1,411	8,728,151	16.2	
Pancreas	Male	7	24,114	29.0	18.2	6.8	1.000	777	4,372,796	17.8	
Pancreas	Female	_5	19,563	25.6	15.3	4.8	1.000	634	4,355,355	14.6	
Prostate	Male	57	24,114	236.4	148.9	55.7	0.893	6,360	4,372,796	145.4	
Stomach	Total	2	43,677	4.6	2.9	3.7	0.581	465	8,728,151	5.3	
Stomach Stomach	Male Female	1 1	24,114 19,563	4.1 5.1	2.6 3.2	2.7 1.1	0.508 1.000	308 157	4,372,796 4,355,355	7.0 3.6	
Testis	Male	- '	24,114	J. I	3.2	1.1	0.500	265	4,355,355	6.1	
Thyroid	Total	- 5	43,677	11.4	9.7	7.2	0.552	1,215	8,728,151	13.9	
Thyroid	Male	2	24,114	8.3	6.5	2.5	1.000	353	4,372,796	8.1	
Thyroid	Female	3	19,563	15.3	13.5	4.4	0.722	862	4,355,355	19.8	
Pediatric Age 0 to 19	Total	1	7,688	13.0	12.9	1.3	1.000	420	2,452,835	17.1	
Pediatric Age 0 to 19	Male	_ '	4,343	-	-	0.8	0.920	223	1,252,167	17.8	
Pediatric Age 0 to 19	Female	1	3,345	29.9	29.8	0.6	0.846	197	1,200,668	16.4	
			o number of case			ar (person yea			, ,,,,,,		

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

<sup>2.</sup> Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

<sup>&</sup>quot;<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

### **TABLE 4: CANCER MORTALITY 2017–2021** COMPARISON BETWEEN CLEARWATER COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Clear	water Cour	nty			Re	mainder of Idah	10
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	569	43,912	1,295.8	784.9	622.9	0.030 <<	76,861	8,944,803	859.3
All Causes of Death	Male	317	24,311	1,303.9	819.0	351.4	0.068	40,739	4,487,557	907.8
All Causes of Death	Female	252	19,601	1,285.6	730.9	279.4	0.104	36,122	4,457,246	810.4
All Malignant Cancers	Total	139	43,912	316.5	191.5	121.6	0.129	14,982	8,944,803	167.5
All Malignant Cancers	Male	76	24,311	312.6	190.6	72.0	0.665	8,100	4,487,557	180.5
All Malignant Cancers	Female	63	19,601	321.4	190.2	51.1	0.119	6,882	4,457,246	154.4
Bladder	Total	3	43,912	6.8	3.9	4.2	0.787	486	8,944,803	5.4
Bladder	Male	3	24,311	12.3	7.1	3.5	1.000	375	4,487,557	8.4
Bladder	Female	-	19,601	-	-	0.9	0.824	111	4,457,246	2.5
Brain and Other Nervous System	Total	2	43,912	4.6	3.1	3.6	0.591	502	8,944,803	5.6
Brain and Other Nervous System	Male	2	24,311	8.2	5.6	2.3	1.000	296	4,487,557	6.6
Brain and Other Nervous System	Female		19,601		-	1.4	0.508	206	4,457,246	4.6
Breast	Total	5	43,912	11.4	7.2	8.6	0.289	1,097	8,944,803	12.3
Breast	Male	1	24,311	4.1	2.6	0.1	0.244	15	4,487,557	0.3
Breast Confix	Female	4	19,601 19,601	20.4	12.5	7.8 0.5	0.224 1.000	1,082	4,457,246	24.3 1.9
Cervix Colorectal	Female Total	- 15	43,912	34.2	21.2	10.3	0.201	83 1,304	4,457,246 8,944,803	14.6
Colorectal	Male	6	24,311	34.2 24.7	15.9	6.0	1.000	713	6,944,603 4,487,557	15.9
Colorectal	Female	9	19,601	45.9	27.0	4.4	0.073	713 591	4,457,246	13.3
Corpus Uteri	Female	3	19,601	15.3	9.2	1.2	0.073	170	4,457,246	3.8
Esophagus	Total	7	43,912	15.9	9.8	3.8	0.175	470	8,944,803	5.3
Esophagus	Male	7	24,311	28.8	18.0	3.4	0.119	394	4,487,557	8.8
Esophagus	Female	-	19,601	-	-	0.6	1.000	76	4,457,246	1.7
Hodgkin Lymphoma	Total	1	43,912	2.3	1.5	0.2	0.380	28	8,944,803	0.3
Hodgkin Lýmphoma	Male	-	24,311	-	-	0.1	1.000	14	4,487,557	0.3
Hodgkin Lymphoma	Female	1	19,601	5.1	3.1	0.1	0.193	14	4,457,246	0.3
Kidney	Total	5	43,912	11.4	6.8	3.1	0.415	380	8,944,803	4.2
Kidney	Male	3	24,311	12.3	7.6	2.1	0.708	239	4,487,557	5.3
Kidney	Female	2	19,601	10.2	5.7	1.1	0.602	141	4,457,246	3.2
Larynx	Total	-	43,912	-	-	0.6	1.000	71	8,944,803	0.8
Larynx	Male	-	24,311	-	-	0.5	1.000	58	4,487,557	1.3
Larynx	Female	- ,	19,601	-	- 27	0.1	1.000	13	4,457,246	0.3
Leukemia	Total	2	43,912	4.6	2.7	5.4	0.187 0.287	658	8,944,803	7.4 8.6
Leukemia Leukemia	Male Female	1 1	24,311 19,601	4.1 5.1	2.5 2.9	3.4 2.1	0.267	385 273	4,487,557 4,457,246	6.1
Liver and Bile Duct	Total	4	43,912	9.1	5.6	4.8	0.760	599	8,944,803	6.7
Liver and Bile Duct	Male	3	24,311	12.3	7.7	3.5	1.000	405	4,487,557	9.0
Liver and Bile Duct	Female	1	19,601	5.1	3.0	1.4	1.000	194	4,457,246	4.4
Lung and Bronchus	Total	42	43,912	95.6	56.8	24.1	0.001 >>	2,919	8,944,803	32.6
Lung and Bronchus	Male	18	24,311	74.0	44.4	13.9	0.330	1,538	4,487,557	34.3
Lung and Bronchus	Female	24	19,601	122.4	70.9	10.5	0.000 >>	1,381	4,457,246	31.0
Melanoma of the Skin	Total	1	43,912	2.3	1.4	2.3	0.678	288	8,944,803	3.2
Melanoma of the Skin	Male	1	24,311	4.1	2.6	1.7	1.000	191	4,487,557	4.3
Melanoma of the Skin	Female		19,601	-		0.7	1.000	97	4,457,246	2.2
Myeloma	Total	1	43,912	2.3	1.3	2.8	0.459	330	8,944,803	3.7
Myeloma	Male		24,311	-	-	1.8	0.320	196	4,487,557	4.4
Myeloma	Female	1	19,601	5.1	2.9	1.0	1.000	134	4,457,246	3.0
Non-Hodgkin Lymphoma	Total	6	43,912	13.7	8.1	4.7	0.655	563	8,944,803	6.3
Non-Hodgkin Lymphoma	Male	4	24,311	16.5	10.0	2.7	0.568	303	4,487,557	6.8
Non-Hodgkin Lymphoma Oral Cavity and Pharynx	Female Total	7	19,601 43,912	10.2 15.9	5.7 9.8	2.0 2.1	1.000 0.011 >>	260 259	4,457,246 8,944,803	5.8 2.9
Oral Cavity and Pharynx  Oral Cavity and Pharynx	Male	6	24,311	24.7	9.6 15.5	1.6	0.011 >>	181	6,944,603 4,487,557	4.0
Oral Cavity and Pharynx	Female	1	19,601	5.1	3.0	0.6	0.011	78	4,467,337	1.7
Ovary	Female	4	19,601	20.4	12.3	2.5	0.498	346	4,457,246	7.8
Pancreas	Total	6	43,912	13.7	8.2	9.6	0.310	1,184	8,944,803	13.2
Pancreas	Male	3	24,311	12.3	7.5	5.7	0.368	639	4,487,557	14.2
Pancreas	Female	3	19,601	15.3	9.0	4.1	0.837	545	4,457,246	12.2
Prostate	Male	6	24,311	24.7	14.1	8.9	0.430	943	4,487,557	21.0
Stomach	Total	2	43,912	4.6	2.9	1.5	0.903	196	8,944,803	2.2
Stomach	Male	1	24,311	4.1	2.6	1.0	1.000	120	4,487,557	2.7
Stomach	Female	1	19,601	5.1	3.2	0.5	0.830	76	4,457,246	1.7
			ne number of cases r							•

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

<sup>2.</sup> Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

### Cancer Screening and Risk Factor Prevalence Estimates, 2011–2021

	State of								Clearwater
Measure	Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	County
Access to Care									
Have Health Insurance, Age <65 (2015–2021)	83.1%	82.8%	85.1%	77.2%	85.8%	78.9%	85.4%	85.4%	82.3%
Not See Doctor Due to Cost in Past Year (2015–2021)	12.6%	11.4%	11.8%	14.5%	12.4%	12.3%	11.8%	12.9%	14.4%
Cancer Screening									
Mammogram Past 2 Years, Age 50–74 (2014, 2016, 2018, 2020)	69.1%	67.0%	73.8%	68.2%	73.2%	64.8%	64.5%	67.1%	59.8%
Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020)	71.2%	73.6%	73.6%	70.8%	72.9%	69.1%	69.5%	65.9%	
Colorectal Cancer Screening, Age 50–75 (2018, 2020)	67.9%	66.9%	73.6%	71.4%	70.6%	61.7%	61.5%	64.7%	75.2%
Tobacco Use									
Current Tobacco User (2016–2021)	22.3%	26.7%	23.1%	23.6%	21.8%	21.4%	22.7%	16.9%	27.1%
Other Cancer-Related									
Healthy Weight by Body Mass Index, Age 20+ (2015–2021)	32.1%	32.8%	31.7%	27.9%	36.1%	29.8%	27.9%	31.9%	29.3%
Any Physical Activity Besides Job Past 30 Days (2015-2021)	78.7%	79.2%	78.1%	74.5%	83.2%	73.4%	76.3%	79.7%	74.6%
Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019)	21.9%	22.8%	19.4%	20.0%	25.2%	19.5%	20.4%	20.2%	16.4%
Home Ever Tested for Radon (2016, 2018, 2020)	23.0%	30.9%	18.2%	16.9%	25.1%	19.9%	23.0%	21.8%	19.9%

### **Access to Care**

### Have Health Insurance - 2015-2021

Statewide, 83.1% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 86.0% of white non-Hispanics, compared to 64.8% of Hispanics and 83.3% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3%) than English-speaking respondents (84.2%). Health care coverage differed significantly by age of respondent, with 79.8% of persons aged 18–29, and 87.8% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 62.1% in Adams County to 91.6% in Oneida County having health insurance.

### Not See Doctor Due to Cost in Past Year - 2015-2021

Statewide, 12.6% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (11.5% of white non-Hispanics, 19.2% of Hispanics, and 21.0% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9% for less than \$15,000, 6.1% for greater than \$50,000). Inability to see a doctor due to cost differed significantly by county, with a range of 7.4% in Franklin County to 17.5% in Power County.

### **Cancer Screening**

<u>Mammogram</u> – 2014, 2016, 2018, 2020

Statewide, 69.1% of women aged 50–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (72.1% versus 36.7%). Mammography rates differed significantly by county, with a range in screening of 45.9% in Benewah County to 77.0% in Nez Perce County. In 2020, Idaho ranked 48th among states and the District of Columbia for mammography screening rates among women aged 50–74 and also 48th among ages 40+.

### Pap Test - 2018, 2020

Statewide, 71.2% of women with an intact cervix and aged 21–65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.1% versus 52.6% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.7% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49<sup>th</sup> among states and the District of Columbia for Pap screening rate.

### Colorectal Cancer Screening – 2018, 2020

Statewide, 67.9% of adults aged 50–75 reported being current for colorectal cancer screening.\*\* Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked 47<sup>th</sup> among states and the District of Columbia in the percentage of adults aged 50–75 and older who reported being up-to-date for colorectal cancer screening.

<sup>\*\*</sup> Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

### **Tobacco Use**

### Current Tobacco Use - 2016-2021

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.3% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 29.9% of persons aged 18-29, and 11.1% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (22.4%) than among Native Americans (40.0%). Tobacco use differed significantly by county, with a range of 5.4% in Madison County to 41.6% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

### **Other Cancer-Related**

### Healthy Weight by Body Mass Index - 2015-2021

Statewide, 32.1% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 32.5% of white non-Hispanics, compared to 28.2% of Hispanics and 24.6% of Native Americans, being in the healthy weight range. Males (25.5%) were significantly less likely to be in the healthy weight range than females (38.6%). BMI differed significantly by age of respondent, with 43.3% of persons aged 18–29, and 26.0% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 19.8% in Power County to 47.4% in Blaine County of adults being in the healthy weight range.

### Any Physical Activity - 2015-2021

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 78.7% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.3% of persons aged 18–29, and 72.3% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 64.3% in Clark County to 84.6% in Teton County.

Physical Activity Guidelines – 2011, 2013, 2015, 2017, 2019 Statewide, 21.9% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.3% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6% in Franklin County to 30.6% in Blaine County.

### Home Radon Testing - 2016, 2018, 2020

Statewide, 23.0% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.4% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.5% in Cassia County to 54.4% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006l and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.





# CUSTER COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016–2020 Cancer Mortality 2017–2021 BRFSS 2011–2021

### **RISK FACTORS AND INTERVENTIONS**

### **CANCER**

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/jama.2016.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

### Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

### **Smoking:**

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

### Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <a href="https://www.dietaryguidelines.gov">https://www.dietaryguidelines.gov</a>

### Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute
Cancer Information Services
1-800-4CANCER
<a href="https://www.cancer.gov/contact">https://www.cancer.gov/contact</a>

American Cancer Society <a href="https://www.cancer.org">https://www.cancer.org</a>

### **CANCER INCIDENCE 2016–2020**

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016–2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 154 cases of invasive cancer were diagnosed among Custer County residents (Table 1).

**Table 1:** Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Custer County and the State of Idaho. 2016–2020

Cancer Incidence 2016–2020	Custer County	State of Idaho
All Sites/Types	154	45,610
Female Breast	16	6,687
Prostate	28	6,417
Lung & Bronchus	19	4,887
Colorectal	14	3,451

Table 3 (Cancer Incidence 2016–2020, Comparison between Custer County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Custer County. The table also shows the number of observed cases, person-

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Custer County was 734.6 cases per 100,000 person-years per year during 2016–2020. Comparing this crude rate with the crude rate for the remainder of Idaho (519.4) gives an estimate of the relative burden of disease in Custer County.

The age- and sex-adjusted incidence rate of invasive cancer in Custer County, all sites combined, was 460.4 cases per 100,000 persons per year during 2016–2020. There were fewer cases of cancer in Custer County (154) than expected (173.7) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

### **CANCER MORTALITY 2017–2021**

During 2017–2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 73 Custer County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

**Table 2:** Overall and Cancer Mortality in Custer County and the State of Idaho, 2017–2021

Mortality 2017–2021	Custer County	State of Idaho
All Deaths	270	77,431
Cancer Deaths	73	15,121
% of All Deaths	27.0%	19.5%
Lung & Bronchus	18	2,961
Colorectal	9	1,319
Pancreas	5	1,190
Female Breast	8	1,086
Prostate	4	949

Table 4 (Cancer Mortality 2017–2021, Comparison between Custer County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Custer County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Custer County, all sites combined, was 203.6 deaths per 100,000 persons per year during 2017–2021, compared with 167.8 for the remainder of the state. There were more cancer deaths in Custer County (73) than expected (60.2) based upon rates in the remainder of the state, but the difference was not statistically significant.

**Statistical Note:** Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

## TABLE 3: CANCER INCIDENCE 2016–2020 COMPARISON BETWEEN CUSTER COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

		Custer County					Ren	Remainder of Idaho			
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude	
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)	
All Sites Combined	Total	154	20,965	734.6	460.4	173.7	0.140	45,456	8,750,863	519.4	
All Sites Combined All Sites Combined	Male Female	99 55	10,868 10,097	910.9 544.7	524.1 370.7	104.2 72.3	0.655 0.041 <b>&lt;&lt;</b>	24,190 21,266	4,386,042 4,364,821	551.5 487.2	
Bladder	Total	10	20,965	47.7	27.8	8.9	0.809	2,174	8,750,863	24.8	
Bladder	Male	7	10,868	64.4	35.1	7.9	0.928	1,744	4,386,042	39.8	
Bladder	Female	3	10,097	29.7	18.6	1.6	0.429	430	4,364,821	9.9	
Brain - malignant Brain - malignant	Total Male	1	20,965 10,868	4.8 9.2	3.4 6.2	2.1 1.4	0.754 1.000	624 374	8,750,863 4,386,042	7.1 8.5	
Brain - malignant	Female	_ '	10,000	-	-	0.8	0.912	250	4,364,821	5.7	
Brain and other CNS - non-malignant	Total	5	20,965	23.8	16.2	5.0	1.000	1,419	8,750,863	16.2	
Brain and other CNS - non-malignant	Male	3	10,868	27.6	18.5	1.8	0.520	477	4,386,042	10.9	
Brain and other CNS - non-malignant Breast	Female Total	2 16	10,097 20,965	19.8 76.3	13.9 49.7	3.1 24.7	0.797 0.084	942 6,730	4,364,821 8,750,863	21.6 76.9	
Breast	Male	-	10,868	-	-	0.3	1.000	59	4,386,042	1.3	
Breast	Female	16	10,097	158.5	108.9	22.5	0.199	6,671	4,364,821	152.8	
Breast - in situ	Total	3	20,965	14.3	9.4	4.5	0.682	1,236	8,750,863	14.1	
Breast - in situ	Male	- 3	10,868	20.7	20.6	0.0	1.000	5	4,386,042	0.1	
Breast - in situ Cervix	Female Female	-	10,097 10,097	29.7	20.6	4.1 0.8	0.824 0.918	1,231 304	4,364,821 4,364,821	28.2 7.0	
Colorectal	Total	14	20,965	66.8	42.8	12.9	0.823	3,437	8,750,863	39.3	
Colorectal	Male	12	10,868	110.4	67.4	7.7	0.180	1,891	4,386,042	43.1	
Colorectal	Female	2	10,097	19.8	13.3	5.3	0.199	1,546	4,364,821	35.4	
Corpus Uteri Esophagus	Female Total	3 2	10,097 20.965	29.7 9.5	20.0 5.7	4.6 2.0	0.662 1.000	1,327 504	4,364,821 8,750,863	30.4 5.8	
Esophagus	Male	2	10,868	18.4	10.4	1.8	1.000	422	4,386,042	9.6	
Esophagus	Female		10,097	-	-	0.3	1.000	82	4,364,821	1.9	
Hodgkin Lymphoma	Total	-	20,965	-	-	0.6	1.000	210	8,750,863	2.4	
Hodgkin Lymphoma	Male	-	10,868	-	-	0.4	1.000	118	4,386,042	2.7	
Hodgkin Lymphoma Kidney and Renal Pelvis	Female Total	- 6	10,097 20,965	28.6	18.3	0.2 6.8	1.000 0.965	92 1,809	4,364,821 8,750,863	2.1 20.7	
Kidney and Renal Pelvis	Male	4	10,868	36.8	22.4	4.8	0.950	1,178	4,386,042	26.9	
Kidney and Renal Pelvis	Female	2	10,097	19.8	13.3	2.2	1.000	631	4,364,821	14.5	
Larynx	Total	-	20,965	-	-	0.9	0.853	215	8,750,863	2.5	
Larynx	Male Female	-	10,868 10,097	-	-	0.7 0.2	0.991 1.000	160 55	4,386,042 4,364,821	3.6 1.3	
Larynx Leukemia	Total	7	20,965	33.4	21.5	6.0	0.802	1,624	8,750,863	18.6	
Leukemia	Male	6	10,868	55.2	33.8	4.0	0.421	983	4,386,042	22.4	
Leukemia	Female	1	10,097	9.9	6.7	2.2	0.710	641	4,364,821	14.7	
Liver and Bile Duct	Total	2	20,965	9.5	5.7	3.3	0.717	827	8,750,863	9.5	
Liver and Bile Duct Liver and Bile Duct	Male Female	2	10,868 10,097	18.4	10.3	2.6 0.9	1.000 0.846	588 239	4,386,042 4,364,821	13.4 5.5	
Lung and Bronchus	Total	19	20.965	90.6	52.6	20.1	0.923	4,868	8,750,863	55.6	
Lung and Bronchus	Male	9	10,868	82.8	44.7	11.2	0.634	2,443	4,386,042	55.7	
Lung and Bronchus	Female	10	10,097	99.0	61.6	9.0	0.829	2,425	4,364,821	55.6	
Melanoma of the Skin Melanoma of the Skin	Total Male	8 7	20,965 10,868	38.2 64.4	25.2 38.8	10.6 7.2	0.532 1.000	2,934 1,758	8,750,863 4,386,042	33.5 40.1	
Melanoma of the Skin	Female	1	10,000	9.9	7.3	3.7	0.233	1,736	4,364,821	26.9	
Myeloma	Total	3	20,965	14.3	8.5	2.8	1.000	705	8,750,863	8.1	
Myeloma	Male	2	10,868	18.4	10.3	1.9	1.000	439	4,386,042	10.0	
Myeloma	Female	1	10,097	9.9	6.3	1.0	1.000	266	4,364,821	6.1	
Non-Hodgkin Lymphoma Non-Hodgkin Lymphoma	Total Male	1	20,965 10,868	4.8 9.2	3.0 5.5	7.4 4.7	0.011 <b>&lt;&lt;</b> 0.106	1,939 1,128	8,750,863 4,386,042	22.2 25.7	
Non-Hodgkin Lymphoma	Female	- '	10,000	-	-	2.8	0.117	811	4,364,821	18.6	
Oral Cavity and Pharynx	Total	5	20,965	23.8	14.8	5.0	1.000	1,290	8,750,863	14.7	
Oral Cavity and Pharynx	Male	4	10,868	36.8	21.5	4.0	1.000	932	4,386,042	21.2	
Oral Cavity and Pharynx Ovary	Female Female	1 2	10,097 10,097	9.9 19.8	6.6 13.6	1.3 1.8	1.000 1.000	358 531	4,364,821 4,364,821	8.2 12.2	
Pancreas	Total	5	20,965	23.8	14.2	5.7	0.994	1,418	8,750,863	16.2	
Pancreas	Male	4	10,868	36.8	20.7	3.4	0.901	780	4,386,042	17.8	
Pancreas	Female	1	10,097	9.9	6.3	2.3	0.649	638	4,364,821	14.6	
Prostate Stomach	Male Total	28 1	10,868 20,965	257.6 4.8	139.0 3.0	29.4 1.8	0.899 0.929	6,389 466	4,386,042 8,750,863	145.7 5.3	
Stomach	Male	1	10,868	9.2	5.3	1.3	1.000	308	4,386,042	7.0	
Stomach	Female		10,097	-	-	0.5	1.000	158	4,364,821	3.6	
Testis	Male	-	10,868	-	-	0.5	1.000	265	4,386,042	6.0	
Thyroid	Total	4	20,965	19.1	16.0	3.5	0.917	1,216	8,750,863	13.9	
Thyroid	Male	1	10,868	9.2	6.8	1.2	1.000	354	4,386,042	8.1	
Thyroid	Female	3	10,097	29.7	26.5	2.2	0.772	862	4,364,821	19.7	
Pediatric Age 0 to 19 Pediatric Age 0 to 19	Total Male	1	3,910 2,007	25.6	25.3	0.7 0.4	0.983 1.000	420 223	2,456,613 1,254,503	17.1 17.8	
Pediatric Age 0 to 19 Pediatric Age 0 to 19	Female	- 1	2,007 1,903	- 52.5	- 52.3	0.4	0.538	223 197	1,202,110	16.4	
			no number of case			0.0	0.000	107	.,_0_,0	1	

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

<sup>2.</sup> Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

<sup>&</sup>quot;<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

## TABLE 4: CANCER MORTALITY 2017–2021 COMPARISON BETWEEN CUSTER COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Cu	ster County				Rei	mainder of Idah	0
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	270	21,304	1,267.4	780.8	297.5	0.113	77,160	8,967,411	860.4
All Causes of Death	Male	152	11,087	1,371.0	821.0	168.3	0.222	40,904	4,500,781	908.8
All Causes of Death	Female	118	10,217	1,154.9	721.5	132.8	0.213	36,256	4,466,630	811.7
All Malignant Cancers	Total	73	21,304	342.7	203.6	60.2	0.118	15,048	8,967,411	167.8
All Malignant Cancers	Male	42	11,087	378.8	212.3	35.8	0.335	8,134	4,500,781	180.7
All Malignant Cancers	Female	31	10,217	303.4	190.5	25.2	0.290	6,914	4,466,630	154.8
Bladder	Total	3	21,304	14.1	8.1	2.0	0.646	486	8,967,411	5.4
Bladder Bladder	Male	2 1	11,087 10,217	18.0	10.0 5.9	1.7 0.4	0.991	376	4,500,781	8.4
Brain and Other Nervous System	Female Total	2	21,304	9.8 9.4	6.1	1.8	0.686 1.000	110 502	4,466,630 8,967,411	2.5 5.6
Brain and Other Nervous System	Male	1	11,087	9.0	5.5	1.2	1.000	297	4,500,781	6.6
Brain and Other Nervous System	Female	i 1	10,217	9.8	6.6	0.7	0.999	205	4,466,630	4.6
Breast	Total	8	21,304	37.6	23.2	4.2	0.129	1,094	8,967,411	12.2
Breast	Male	-	11,087	-	-	0.1	1.000	16	4,500,781	0.4
Breast	Female	8	10,217	78.3	50.6	3.8	0.082	1,078	4,466,630	24.1
Cervix	Female	-	10,217	-	-	0.2	1.000	83	4,466,630	1.9
Colorectal	Total	9	21,304	42.2	25.9	5.1	0.146	1,310	8,967,411	14.6
Colorectal	Male	8	11,087	72.2	42.6	3.0	0.022 >>	711	4,500,781	15.8
Colorectal	Female	1	10,217	9.8	6.2	2.2	0.724	599	4,466,630	13.4
Corpus Uteri Esophagus	Female Total	- 1	10,217 21,304	4.7	2.8	0.6 1.9	1.000 0.864	173 476	4,466,630 8,967,411	3.9 5.3
Esophagus	Male	1	11,087	9.0	5.1	1.8	0.864	400	4,500,781	8.9
Esophagus	Female	_ '	10,217	3.0	J. 1 -	0.3	1.000	76	4,466,630	1.7
Hodgkin Lymphoma	Total	_	21,304	_	_	0.1	1.000	29	8,967,411	0.3
Hodgkin Lymphoma	Male	-	11,087	_	-	0.1	1.000	14	4,500,781	0.3
Hodgkin Lymphoma	Female	-	10,217	-	-	0.1	1.000	15	4,466,630	0.3
Kidney	Total	1	21,304	4.7	2.7	1.6	1.000	384	8,967,411	4.3
Kidney	Male	1	11,087	9.0	5.0	1.1	1.000	241	4,500,781	5.4
Kidney	Female	-	10,217	-	-	0.5	1.000	143	4,466,630	3.2
Larynx	Total	-	21,304	-	-	0.3	1.000	71	8,967,411	0.8
Larynx	Male	-	11,087	-	-	0.2 0.0	1.000 1.000	58	4,500,781	1.3 0.3
Larynx Leukemia	Female Total	- 1	10,217 21,304	4.7	2.8	2.6	0.534	13 659	4,466,630 8,967,411	7.3
Leukemia	Male	_ '	11,087	4.7	2.0	1.6	0.334	386	4,500,781	8.6
Leukemia	Female	1	10,217	9.8	6.1	1.0	1.000	273	4,466,630	6.1
Liver and Bile Duct	Total	3	21,304	14.1	8.2	2.4	0.882	600	8,967,411	6.7
Liver and Bile Duct	Male	2	11,087	18.0	9.9	1.8	1.000	406	4,500,781	9.0
Liver and Bile Duct	Female	1	10,217	9.8	6.1	0.7	1.000	194	4,466,630	4.3
Lung and Bronchus	Total	18	21,304	84.5	48.7	12.1	0.137	2,943	8,967,411	32.8
Lung and Bronchus	Male	9	11,087	81.2	43.7	7.1	0.563	1,547	4,500,781	34.4
Lung and Bronchus	Female	9	10,217	88.1	54.0	5.2	0.166	1,396	4,466,630	31.3
Melanoma of the Skin	Total	2	21,304	9.4	5.8	1.1	0.608	287	8,967,411	3.2
Melanoma of the Skin	Male Female	2	11,087 10,217	18.0	10.4	0.8 0.3	0.390 1.000	190 97	4,500,781 4,466,630	4.2 2.2
Melanoma of the Skin Myeloma	Total	- 1	21,304	4.7	2.7	1.4	1.000	330	8,967,411	3.7
Myeloma	Male		11,087	4.7	Z.1 -	0.9	0.817	196	4,500,781	4.4
Myeloma	Female	1	10,217	9.8	6.0	0.5	0.791	134	4,466,630	3.0
Non-Hodgkin Lymphoma	Total	1	21,304	4.7	2.8	2.3	0.672	568	8,967,411	6.3
Non-Hodgkin Lymphoma	Male	1	11,087	9.0	5.1	1.3	1.000	306	4,500,781	6.8
Non-Hodgkin Lymphoma	Female	-	10,217	-	-	1.0	0.746	262	4,466,630	5.9
Oral Cavity and Pharynx	Total	2	21,304	9.4	5.6	1.1	0.568	264	8,967,411	2.9
Oral Cavity and Pharynx	Male	2	11,087	18.0	10.0	0.8	0.397	185	4,500,781	4.1
Oral Cavity and Pharynx	Female	- 1	10,217	- 0.0	-	0.3	1.000	79 340	4,466,630	1.8
Ovary Pancreas	Female Total	1 5	10,217 21,304	9.8 23.5	6.2 13.7	1.3 4.8	1.000 1.000	349 1,185	4,466,630 8,967,411	7.8 13.2
Pancreas	Male	3	21,304 11,087	23.5 27.1	13.7	4.6 2.9	1.000	639	4,500,781	14.2
Pancreas	Female	2	10,217	19.6	12.1	2.9	1.000	546	4,466,630	12.2
Prostate	Male	4	11,087	36.1	19.9	4.2	1.000	945	4,500,781	21.0
Stomach	Total	-	21,304	-	-	0.7	0.951	198	8,967,411	2.2
Stomach	Male	-	11,087	-	-	0.5	1.000	121	4,500,781	2.7
Stomach	Female	-	10,217	-	-	0.3	1.000	77	4,466,630	1.7
		o overcoood oo th	ne number of cases p	100 000	none per veer (r				*	

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

<sup>2.</sup> Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

### Cancer Screening and Risk Factor Prevalence Estimates, 2011–2021

	State of								Custer
Measure	Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	County
Access to Care									
Have Health Insurance, Age <65 (2015–2021)	83.1%	82.8%	85.1%	77.2%	85.8%	78.9%	85.4%	85.4%	82.1%
Not See Doctor Due to Cost in Past Year (2015–2021)	12.6%	11.4%	11.8%	14.5%	12.4%	12.3%	11.8%	12.9%	12.0%
Cancer Screening									
Mammogram Past 2 Years, Age 50–74 (2014, 2016, 2018, 2020)	69.1%	67.0%	73.8%	68.2%	73.2%	64.8%	64.5%	67.1%	
Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020)	71.2%	73.6%	73.6%	70.8%	72.9%	69.1%	69.5%	65.9%	
Colorectal Cancer Screening, Age 50–75 (2018, 2020)	67.9%	66.9%	73.6%	71.4%	70.6%	61.7%	61.5%	64.7%	
Tobacco Use									
Current Tobacco User (2016–2021)	22.3%	26.7%	23.1%	23.6%	21.8%	21.4%	22.7%	16.9%	28.1%
Other Cancer-Related									
Healthy Weight by Body Mass Index, Age 20+ (2015–2021)	32.1%	32.8%	31.7%	27.9%	36.1%	29.8%	27.9%	31.9%	34.1%
Any Physical Activity Besides Job Past 30 Days (2015-2021)	78.7%	79.2%	78.1%	74.5%	83.2%	73.4%	76.3%	79.7%	75.1%
Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019)	21.9%	22.8%	19.4%	20.0%	25.2%	19.5%	20.4%	20.2%	27.5%
Home Ever Tested for Radon (2016, 2018, 2020)	23.0%	30.9%	18.2%	16.9%	25.1%	19.9%	23.0%	21.8%	43.2%

### Access to Care

### Have Health Insurance - 2015-2021

Statewide, 83.1% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 86.0% of white non-Hispanics, compared to 64.8% of Hispanics and 83.3% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3%) than English-speaking respondents (84.2%). Health care coverage differed significantly by age of respondent, with 79.8% of persons aged 18–29, and 87.8% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 62.1% in Adams County to 91.6% in Oneida County having health insurance.

### Not See Doctor Due to Cost in Past Year – 2015–2021

Statewide, 12.6% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (11.5% of white non-Hispanics, 19.2% of Hispanics, and 21.0% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9% for less than \$15,000, 6.1% for greater than \$50,000). Inability to see a doctor due to cost differed significantly by county, with a range of 7.4% in Franklin County to 17.5% in Power County.

### **Cancer Screening**

<u>Mammogram</u> – 2014, 2016, 2018, 2020

Statewide, 69.1% of women aged 50–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (72.1% versus 36.7%). Mammography rates differed significantly by county, with a range in screening of 45.9% in Benewah County to 77.0% in Nez Perce County. In 2020, Idaho ranked 48<sup>th</sup> among states and the District of Columbia for mammography screening rates among women aged 50–74 and also 48<sup>th</sup> among ages 40+.

### Pap Test - 2018, 2020

Statewide, 71.2% of women with an intact cervix and aged 21–65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.1% versus 52.6% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.7% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49<sup>th</sup> among states and the District of Columbia for Pap screening rate.

### Colorectal Cancer Screening – 2018, 2020

Statewide, 67.9% of adults aged 50–75 reported being current for colorectal cancer screening.\*\* Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked 47<sup>th</sup> among states and the District of Columbia in the percentage of adults aged 50–75 and older who reported being up-to-date for colorectal cancer screening.

<sup>\*\*</sup> Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

### **Tobacco Use**

### Current Tobacco Use - 2016-2021

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.3% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 29.9% of persons aged 18-29, and 11.1% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (22.4%) than among Native Americans (40.0%). Tobacco use differed significantly by county, with a range of 5.4% in Madison County to 41.6% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

### **Other Cancer-Related**

### Healthy Weight by Body Mass Index - 2015-2021

Statewide, 32.1% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 32.5% of white non-Hispanics, compared to 28.2% of Hispanics and 24.6% of Native Americans, being in the healthy weight range. Males (25.5%) were significantly less likely to be in the healthy weight range than females (38.6%). BMI differed significantly by age of respondent, with 43.3% of persons aged 18–29, and 26.0% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 19.8% in Power County to 47.4% in Blaine County of adults being in the healthy weight range.

### Any Physical Activity - 2015-2021

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 78.7% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.3% of persons aged 18–29, and 72.3% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 64.3% in Clark County to 84.6% in Teton County.

Physical Activity Guidelines – 2011, 2013, 2015, 2017, 2019 Statewide, 21.9% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.3% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6% in Franklin County to 30.6% in Blaine County.

### Home Radon Testing - 2016, 2018, 2020

Statewide, 23.0% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.4% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.5% in Cassia County to 54.4% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006l and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.





# ELMORE COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

### **RISK FACTORS AND INTERVENTIONS**

### **CANCER**

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/jama.2016.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

### Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

### **Smoking:**

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

### Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <a href="https://www.dietaryguidelines.gov">https://www.dietaryguidelines.gov</a>

### Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute
Cancer Information Services
1-800-4CANCER
<a href="https://www.cancer.gov/contact">https://www.cancer.gov/contact</a>

American Cancer Society <a href="https://www.cancer.org">https://www.cancer.org</a>

### **CANCER INCIDENCE 2016–2020**

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016–2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 713 cases of invasive cancer were diagnosed among Elmore County residents (Table 1).

**Table 1:** Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Elmore County and the State of Idaho, 2016–2020

Cancer Incidence 2016–2020	Elmore County	State of Idaho
All Sites/Types	713	45,610
Female Breast	78	6,687
Prostate	88	6,417
Lung & Bronchus	111	4,887
Colorectal	63	3,451

Table 3 (Cancer Incidence 2016–2020, Comparison between Elmore County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Elmore County. The table also shows the number of observed cases, person-

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Elmore County was 527.3 cases per 100,000 person-years per year during 2016–2020. Comparing this crude rate with the crude rate for the remainder of Idaho (519.8) gives an estimate of the relative burden of disease in Elmore County.

The age- and sex-adjusted incidence rate of invasive cancer in Elmore County, all sites combined, was 601.5 cases per 100,000 persons per year during 2016–2020. There were statistically significantly more cases of cancer in Elmore County (713) than expected (616.2) based upon rates in the remainder of the state (p<.001).

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

### **CANCER MORTALITY 2017–2021**

During 2017–2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 245 Elmore County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

**Table 2:** Overall and Cancer Mortality in Elmore County and the State of Idaho, 2017–2021

Mortality 2017–2021	Elmore County	State of Idaho
All Deaths	1,094	77,431
Cancer Deaths	245	15,121
% of All Deaths	22.4%	19.5%
Lung & Bronchus	69	2,961
Colorectal	25	1,319
Pancreas	21	1,190
Female Breast	5	1,086
Prostate	10	949

Table 4 (Cancer Mortality 2017–2021, Comparison between Elmore County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Elmore County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Elmore County, all sites combined, was 205.9 deaths per 100,000 persons per year during 2017–2021, compared with 168.1 for the remainder of the state. There were statistically significantly more cancer deaths in Elmore County (245) than expected (200.0) based upon rates in the remainder of the state (p=.002).

**Statistical Note:** Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

### TABLE 3: CANCER INCIDENCE 2016–2020 COMPARISON BETWEEN ELMORE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

All Steles Combined  Male  All Steles Combined  Fernale  Formale			Elmore County					Ren	Remainder of Idaho		
All Sites Combined  Mole   Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude	
All Steles Combined  Male  All Steles Combined  Fernale  Formale	Site/Type	Sex	Cases	Years	Rate (1)		Cases (3)	P-Value (4)	Cases	Years	Rate (1)
All States Combined  Fernale  All States Combined  Fernale  All States Combined  Fernale  All States Combined  Fernale  All States Combined  Fernale  All States Combined  Fernale  All States Combined  All States Combine	All Sites Combined										
Bladder	=										
Bladder   Male   35   70,728   40,5   60,6   22,9   0,022 >> 1,716   4,326,82   39,7   Bladder   Fernale   6   44,87   12,4   13,3   5,7   0,430   42,4   310,431   92,8   Brain - malignant   Total   6   135,227   5,5   6,5   6,8   8,8   0,809   69,8   8,806,131   72,8   Brain - malignant   Total   6   135,227   13,3   3,5   0,455   24,8   13,1   13,3   13,5   0,455   14,0   14,										, ,	
Bladder											
Brain - mailgriannt Male   6   70.728   8.5   9.5   5.4   0.909   369   4.326,182   8.5   8.5   8.5   8.5   8.5   8.5   9.5   5.4   0.909   369   4.326,182   8.5	Bladder										
Brain - malignant   Female   2   64.487   3.1   3.3   3.5   0.645   248   4.310.431   5.8   Brain and other CNS - non-malignant   Total   24   135.215   17.7   20.0   19.4   0.352   10.1   8.366.131   16.2   Brain and other CNS - non-malignant   Male   8   70.728   11.3   13.0   6.7   0.713   472   4.326.182   10.9   Brain and other CNS - non-malignant   Male   8   70.728   11.3   13.0   6.7   0.713   472   4.326.182   10.9   Brain and other CNS - non-malignant   Male   7   70.728   7   70.728   7   7   7   7   7   7   7   7   7	Brain - malignant										
Brain and other CNS - non-malignant   Total   24   135.215   17.7   20.0   19.4   0.352   1.400   8.08.613   162.2   1											
Brain and other CNS - non-melignant   Mele   8   70,728   11.3   13.0   6,7   0,713   472   4,326,182   10.9   Brain and other CNS - non-melignant   Female   16   64,487   24,8   24,8   27,2   12.7   0,413   27.5   6,667   8,636,613   71,2   Breast   Female   78   64,487   121.0   133.7   894   0,245   6,667   8,636,613   71,2   Breast   Instu   Total   20   135,215   14,8   17,0   16,6   0,469   1,219   8,636,613   14,1   Breast   Instu   Female   20   64,487   121.0   13,37   894   0,245   1,219   8,636,613   14,1   Breast   Instu   Female   20   64,487   121.0   13,37   894   0,245   1,219   8,636,613   14,1   Breast   Instu   Female   20   64,487   121.0   13,37   894   0,245   1,214   4,310,431   28,2   Colorectal   Female   20   64,487   71,0   16,6   0,469   1,219   8,636,613   14,1   Breast   Instu   Female   20   64,487   13,0   3,45   16,3   0,425   1,214   4,310,431   28,2   Colorectal   Female   36   64,487   71,8   63,6   25,8   0,028 >> 1,885   4,310,431   28,2   Colorectal   Female   25   64,487   38,8   42,7   20,7   0,333   3,4310,431   35,3   Corpus Uterl   Female   18   64,487   73,8   83,6   25,8   0,028 >> 1,885   4,310,431   35,3   Corpus Uterl   Female   18   64,487   73,8   83,6   25,8   0,000   3,132   4,310,431   35,3   Corpus Uterl   Female   36   64,487   38,8   4,79   20,8   17,8   1,000   1,312   4,310,431   35,3   Corpus Uterl   Female   36   64,487   73,8   83,6   25,8   0,000   3,132   4,310,431   35,3   Corpus Uterl   Female   37,0728   74,79   30,8   17,8   1,000   1,312   4,310,431   35,3   Corpus Uterl   Female   37,0728   74,79   30,8   17,8   1,000   1,312   4,310,431   35,3   Corpus Uterl   Female   37,0728   74,79   30,8   17,8   1,000   1,312   4,310,431   35,3   Corpus Uterl   Female   3,64,487   1,65   1,74   1,000   1,312   4,310,431   35,3   Corpus Uterl   Female   3,64,487   1,75   1,74   1,000   1,312   4,310,431   35,3   Corpus Uterl   Female   3,64,487   1,75   1,75   1,75   1,75   1,75   1,75   1,75   Corpus Uterl   Female   3,64,487   1,75   1,75   1,75   1,75											
Brain and other CNS - non-malignant   Female   16   64.487   24.8   27.2   12.7   0.413   928   4.310.431   21.5 Broast   70   13.215   58.4   66.9   91.2   0.217   0.667   8.686.813   72.2 Broast   70   13.515   70   70   70   70   70   70   70   7	Brain and other CNS - non-malignant										
Breast Male 1 70,728 1.4 1.7 0.8 1.000 5.6 4,326,182 1.3 Penals Femals Femals Femals 78 64.47 121.0 133.7 88.4 0,245 6.000 4.101.431 155.3 Breast in situ Total 20 135,215 14.8 17.0 16.6 0.489 1.219 8.536,613 14.1 Breast in situ Male 2 70,728 1.0 1.000 3.5 4,251,82 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0	Brain and other CNS - non-malignant				24.8					4,310,431	
Breast In situ   Total   20   135,215   148,   17.0   16.6   0.489   0.245   6,609   4,310,431   153.3   Breast In situ   Male   20   135,215   148,   17.0   16.6   0.489   1.219   8,058,613   14.1   Breast In situ   Male   20   14,000   14,000   1.219   8,058,613   14.1   Breast In situ   Male   20   14,000   14,000   14,000   12,000   14,000   12,000   14,000   14,000   12,000   14,000   14,000   12,000   14,000   14,000   12,000   14,000   12,000   14,000   14,000   12,000   14,000   14,000   12,000   14,000   14,000   12,000   14,000   14,000   12,000   14,000   14,000   14,000   12,000   14,00	Breast										
Breast in situ   Tolal   20   135,215   14.8   17.0   16.6   0.499   1.219   8,638,613   14.1   Breast in situ   Female   20   64.487   31.0   34.5   16.3   0.425   1.214   4,310,431   28.2   Cervix   Female   20   64.487   31.0   34.5   16.3   0.425   1.214   4,310,431   28.2   Cervix   Female   3   64.487   7.8   8.3   4.2   0.815   2.99   4,310,431   28.2   Colorectal   Male   33   17.72   63.6   25.8   0.022   3.9   3.10,431   36.2   Colorectal   Female   25   64.487   38.8   42.7   20.7   0.393   1.853   4.306,431   30.4   Colorectal   Female   18   64.487   27.9   30.8   17.8   1.000   1.312   4.310,431   30.4   Colorectal   Female   18   64.487   27.9   30.8   17.8   1.000   1.312   4.310,431   30.4   Esophagus   Tolal   10   135,215   7.4   8.5   6.7   0.268   496   6.368,613   57.4   Esophagus   Male   9   70,728   12.7   15.3   5.6   0.236   415   4.326,182   9.6   Esophagus   Male   9   70,728   12.7   15.3   5.6   0.236   415   4.326,182   9.6   Esophagus   Tolal   10   135,215   7.4   8.5   6.7   0.268   496   6.368,613   15.8   Esophagus   Tolal   10   136,415   22.2   22   3.2   3.0   3.0   3.0   Esophagus   Tolal   10   136,415   3.3   3.0   3.0   3.0   3.0   3.0   3.0   Esophagus   Tolal   10   136,415   3.0   3.0   3.0   3.0   3.0   3.0   3.0   3.0   Esophagus   Tolal   10   136,415   3.0   3.											
Breast - in situ											
Cervix	Breast - in situ		-		-	-					
Colorectal	Breast - in situ										
Colorectal   Male   26   64,887   38   70,728   53.7   63.6   25.8   0,028 >> 1,865   4,326,182   43.1	=										
Colorectal											
Corpus   Female   18											
Esophagus	=	Female	18	64,487	27.9	30.8	17.8	1.000	1,312		30.4
Esophagus											
Hodgkin Lymphoma											
Hodgkin Lymphoma   Male   -7 07,728   -7   -8   1,9   0,301   118   4,326,182   2.7			• 1								
Hodgikn Lymphoma			- "		-	-					
Kidney and Renal Pelvis Kidney and Renal Pelvis Female 10 64.487 15.5 17.0 8.8 16.0 0.182 1.160 4.326.182 26.8 Larynx Larynx Female 10 64.487 15.5 17.0 16.1 10.00 15.8 4.310.431 14.5 Larynx Female 11 64.487 16.5 17.0 0.7 10.00 15.8 4.326.182 3.7 Larynx Female 12 70.728 2.8 3.4 2.2 1.000 15.8 4.326.182 3.7 Larynx Female 13 64.487 16.6 1.7 0.7 1.000 54 4.310.431 1.3 Leukemia Leukemia Leukemia Male 19 70.728 2.8 9.31.4 13.6 0.189 970 4.326.182 22.4 Leukemia Female Female 17 64.487 10.9 11.8 8.7 0.708 635 4.310.431 1.3 Leukemia Leukemia Female 18 70.728 2.8.9 31.4 13.6 0.189 970 4.326.182 22.4 Leukemia Female 19 70.728 2.8.9 31.4 13.6 0.189 970 4.326.182 22.4 Leukemia Leukemia Female 10 70.728 11.1 16.9 7.9 0.554 801 4.310.431 14.7 Liver and Bile Duct 10 70.728 11.1 16.9 7.9 0.554 801 4.326.182 13.4 Liver and Bile Duct 10 70.728 11.1 16.9 7.9 0.554 801 4.326.182 13.4 Liver and Bile Duct 11 11 135.215 82.1 95.2 64.5 0.000 >> 4.776 8.636.613 55.3 Lung and Bronchus Male 13 70.728 74.9 91.1 32.2 0.001 >> 4.776 8.636.613 55.3 Lung and Bronchus Male 15 70.728 74.9 91.1 32.2 0.001 >> 2.399 4.326.182 55.5 Lung and Bronchus Male 15 70.728 74.9 91.1 32.2 0.000 >> 2.377 4.310.431 55.1 Melanoma of the Skin Male 15 70.728 74.9 91.1 3.2 2.0 0.000 >> 2.377 4.310.431 55.1 Melanoma of the Skin Male 15 70.728 74.9 99.4 3.2.2 0.000 >> 2.377 4.310.431 55.1 Melanoma of the Skin Male 15 70.728 74.9 99.4 3.2.2 0.000 >> 2.399 4.326.182 55.5 Melanoma of the Skin Male 15 70.728 74.9 99.4 3.2.2 0.000 >> 2.399 4.326.182 55.5 Melanoma of the Skin Male 15 70.728 74.9 99.4 3.2.2 0.000 >> 2.399 4.326.182 55.5 Melanoma of the Skin Male 16 70.728 74.9 99.4 3.2.2 0.000 >> 2.399 4.301.431 55.1 Non-Hodgkin Lymphoma Male 17 70.728 74.9 8.6 9.4 0.399 698 8.636.613 8.1 Myeloma Male 17 70.728 74.9 0.54 8.6 9.4 0.399 698 8.636.613 8.1 Myeloma Male 17 70.728 74.9 8.6 9.4 0.399 698 8.636.613 8.1 Myeloma Male 17 70.728 74.9 8.6 9.4 0.000 >> 0.817 79 4.310.431 8.5 Myeloma Male 17 70.728 74.9 8.6 9.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9	Hodgkin Lymphoma	Female								4,310,431	
Kidney and Renal Pelvis   Female   10   64.487   15.5   17.0   8.5   0.700   623   4.310,431   14.5	Kidney and Renal Pelvis										
Larynx Male 2 70,728 2.8 3.4 22 1.000 158 4.326,182 3.7 Larynx Male 2 70,728 2.8 3.4 22 1.000 158 4.326,182 3.7 Larynx Female 1 64,487 1.6 1.7 0.7 1.000 158 4.326,182 3.7 Larynx Female 1 64,487 1.6 1.7 0.7 1.000 154 4.310,431 1.3 Leukemia Total 26 135,215 19.2 21.7 0.7 1.000 158 4.326,182 3.7 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0											
Larýmx Female 1 64.487 1.6 1.77 0.77 1.000 158 4.326.182 3.7 1.2 1.2 1.2 1.000 158 4.326.182 3.7 1.2 1.2 1.2 1.2 1.000 158 4.3 1.0 431 1.3 1.3 Leukemia Male 19 70.728 2.9 31.4 1.3 6.0 1.89 970 4.326.182 2.2 1.2 1.2 1.3 0.486 1.605 8.636.613 1.8 6.0 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2											
Larynx Leukemia Total Zef 135,215 192, 22,17 Total Zef 315,215 192, 22,17 Zef 30, 486 Leukemia Leukemia Hendel Male H9 70,728 26,9 31,4 13,6 0,189 970 4,326,182 22,4 Leukemia Female Female Total Total Total Total Total H4 135,215 10,4 11,9 11,1 0,456 R815 8,636,613 R9,4 Liver and Bile Duct Liver and Bile Duct Hore and Bile Duct Hore and Bile Duct Hore and Bile Duct Hore and Bile Duct Hore and Bile Duct Hore and Bile Duct Female H6 4647 10,9 H1,8 H1,9 H1,1 H1,1 H1,1 H1,1 H1,1 H1,1 H1,1											
Leukemia Female											
Leukemia Female 7 64.487 10.9 11.8 8.7 0.708 635 4,310,431 14.7 Liver and Bile Duct Total 14 135,215 10.4 11.9 11.1 0.456 815 8.636 f13 9.4 Liver and Bile Duct Male 10 70,728 14.1 16.9 7.9 0.554 580 4,326,182 13.4 Liver and Bile Duct Female 4 64.487 6.2 6.8 3.2 0.789 235 4,310,431 55.5 Lung and Bronchus Total 111 135,215 82.1 99.2 64.5 0.000 >> 4,776 8.636,613 55.3 Lung and Bronchus Female 58 64,487 89.9 99.4 32.2 0.000 >> 2,377 4,310,431 55.5 Lung and Bronchus Female 58 64,487 89.9 99.4 32.2 0.000 >> 2,377 4,310,431 55.5 Lung and Bronchus Female 15 70,728 7.0 99.4 32.2 0.000 >> 2,377 4,310,431 55.5 Lung and Bronchus Female 19 64,487 20.5 31.9 16.0 0.518 1.158 4.310,431 55.1 Melanoma of the Skin Male 15 70,728 21.2 25.1 24.2 0.064 1.750 4.326,182 40.5 Melanoma of the Skin Female 19 64,487 20.5 31.9 16.0 0.518 1.158 4.310,431 26.9 Myeloma Male 5 70,728 7.1 8.6 5.9 0.933 436 4.326,182 40.5 Myeloma Male 5 70,728 7.1 8.6 5.9 0.933 436 4.326,182 10.1 Myeloma Male 5 70,728 7.1 8.6 5.9 0.933 436 4.326,182 10.1 Myeloma Male 7 70,728 24.0 28.2 15.5 0.770 1.112 4.326,182 25.7 Non-Hodgkin Lymphoma Male 17 70,728 24.0 28.2 15.5 0.770 1.112 4.326,182 25.7 Non-Hodgkin Lymphoma Male 17 70,728 24.0 28.2 15.5 0.770 1.112 4.326,182 25.7 Non-Hodgkin Lymphoma Male 17 70,728 24.0 28.2 15.5 0.770 1.112 4.326,182 25.7 Non-Hodgkin Lymphoma Male 17 70,728 24.0 28.2 15.5 0.770 1.112 4.326,182 25.7 Non-Hodgkin Lymphoma Female 8 64,487 12.4 13.6 7.2 0.847 525 4.310,431 18.5 07al Cavity and Pharynx Male 13 70,728 18.4 22.3 10.4 13.6 1.2 1.3 12.4 12.4 13.6 1.2 1.3 12.5 12.6 14.4 13.7 4.7 0.216 351 4.310,431 18.5 07al Cavity and Pharynx Male 13 70,728 18.4 22.3 10.4 1.9 0.817 7.9 4.310,431 18.5 07al Cavity and Pharynx Male 13 70,728 18.4 22.3 10.4 1.9 0.4 1.9 0.4 1.9 1.0 0.4 1.7 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1											
Liver and Bile Duct											
Liver and Bile Duct   Male   10   70,728   14.1   16.9   7.9   0.554   580   4,326,182   13.4   Liver and Bile Duct   Female   4   64,487   6.2   6.8   3.2   0.789   235   4,310,431   55.5   1.0   1										, ,	
Lung and Bronchus Male 53 70,728 74.9 91.1 32.2 0.001 >> 2,399 4,326,182 55.5 Lung and Bronchus Female 58 64,487 89.9 99.4 32.2 0.000 >> 2,377 4,310,431 55.1 Melanoma of the Skin Male 15 70,728 21.2 25.1 28.4 40.4 0.357 2.908 8,636,613 33.7 Melanoma of the Skin Male 15 70,728 21.2 25.1 22.4 20,664 1,750 4,326,182 40.5 Melanoma of the Skin Male 15 70,728 21.2 25.1 22.4 20,664 1,750 4,326,182 40.5 Melanoma of the Skin Female 19 64,487 29.5 31.9 16.0 0.518 1,158 4,310,431 26.9 Melanoma of the Skin Male 5 70,728 7.1 8.6 5.9 0,933 436 4,326,182 10.1 Myeloma Male 5 70,728 7.1 8.6 5.9 0,933 436 4,326,182 10.1 Myeloma Female 19 64,487 7.8 8.6 3.5 0.559 262 4,310,431 6.1 Myeloma Female 19 64,487 7.8 8.6 3.5 0.559 262 4,310,431 6.1 Myeloma Male 17 70,728 24.0 28.2 15.5 0,770 1,112 4,326,182 25.7 Non-Hodgkin Lymphoma Male 17 70,728 24.0 28.2 15.5 0,770 1,112 4,326,182 25.7 Non-Hodgkin Lymphoma Female 12 64,487 18.6 20.4 10.9 0.817 799 4,310,431 18.5 0ral Cavity and Pharynx Total 17 135,215 12.6 14.4 17.5 1,000 1,278 8,636,613 14.8 Oral Cavity and Pharynx Male 9 70,728 12.7 15.1 12.8 0.361 927 4,326,182 21.4 Oral Cavity and Pharynx Female 8 64,487 12.4 13.6 7.2 0.847 525 4,310,431 12.2 Pancreas Male 13 70,728 18.5 21.5 18.8 0.200 1,398 8,636,613 16.2 Pancreas Female 12 64,487 18.5 21.5 18.8 0.200 1,398 8,636,613 16.2 Pancreas Male 13 70,728 18.4 2.3 10.4 0,495 771 4,326,182 17.8 Pancreas Male 13 70,728 18.4 0.201 0.495 771 4,326,182 17.8 Pancreas Male 13 70,728 18.4 0.201 0.495 771 4,326,182 17.8 Pancreas Male 13 70,728 18.4 0.201 0.495 771 4,326,182 7.0 Male 6 70,728 18.4 0.201 0.481 303 4,326,182 7.0 Male 6 70,728 18.4 0.201 0.481 303 4,326,182 7.0 Male 6 70,728 18.4 0.201 0.481 303 4,326,182 7.0 Male 6 70,728 18.4 0.201 0.481 303 4,326,182 7.0 Male 6 70,728 18.4 0.201 0.481 303 4,326,182 7.0 Male 6 70,728 7.1 1.8 0.000 0.200 4,326,182 7.0 Male 6 70,728 7.1 1.8 0.000 0.200 4,326,182 7.0 Male 6 70,728 7.1 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1							7.9	0.554	580	4,326,182	13.4
Lung and Bronchus   Male   53   70,728   74,9   91,1   32,2   0,001 >> 2,399   4,326,182   55,5   Melanoma of the Skin   Total   34   135,215   25,1   28,4   40,4   0,357   2,908   8,636,613   33,7   Melanoma of the Skin   Male   15   70,728   21,2   25,1   24,2   0,064   1,750   4,326,182   40,5   Melanoma of the Skin   Male   15   70,728   21,2   25,1   24,2   0,064   1,750   4,326,182   40,5   Melanoma of the Skin   Female   19   64,487   29,5   31,9   16,0   0,518   1,158   4,310,431   26,9   Myeloma   Total   10   135,215   7,4   8,6   9,4   0,939   698   8,636,613   8,1   Myeloma   Male   5   70,728   7,1   8,6   5,9   0,933   436   4,326,182   10,1   Myeloma   Female   5   64,487   7,8   8,6   3,5   0,559   262   4,310,431   6,1   Non-Hodgkin Lymphoma   Total   29   135,215   21,4   24,4   26,3   0,655   1,911   8,636,613   22,1   Non-Hodgkin Lymphoma   Female   12   64,487   18,6   20,4   10,9   0,817   799   4,310,431   18,5   Oral Cavity and Pharynx   Total   17   135,215   12,6   14,4   17,5   1,000   1,278   8,636,613   14,8   Oral Cavity and Pharynx   Male   9   70,728   12,7   15,1   12,8   0,361   927   4,326,182   21,4   Oral Cavity and Pharynx   Male   9   70,728   12,7   15,1   12,8   0,361   927   4,326,182   21,4   Oral Cavity and Pharynx   Female   8   64,487   12,4   13,6   7,2   0,847   525   4,310,431   12,2   Pancreas   Total   25   135,215   18,5   21,5   18,8   0,200   1,398   8,636,613   14,8   Pancreas   Total   25   135,215   18,5   21,5   18,8   0,200   1,398   8,636,613   14,5   Pancreas   Male   13   70,728   18,4   22,3   10,4   0,495   771   4,326,182   17,8   Pancreas   Male   13   70,728   18,6   20,7   8,4   0,291   62,7   4,310,431   14,5   Pancreas   Male   13   70,728   18,6   20,7   8,4   0,291   62,7   4,310,431   14,5   Pancreas   Male   13   70,728   18,6   20,7   8,4   0,291   62,7   4,310,431   14,5   Pancreas   Male   5   70,728   7,1   6,3   4,8   1,000   260   4,326,182   7,0   Pediatric Age 0 to 19   Male   4   19,397   20,6   20,2   3,5   0,928   219   1,237,			- 1								
Lung and Bronchus											
Melanoma of the Skin         Total Male         34         135,215         25.1         28.4         40.4         0.357         2,908         8,636,613         33.7           Melanoma of the Skin         Male         15         70,728         21.2         25.1         24.2         0.064         1,750         4,326,182         40.5           Melanoma of the Skin         Female         19         64,487         29.5         31.9         16.0         0.518         1,158         4,310,431         26.9           Myeloma         Total         10         135,215         7.4         8.6         9.4         0.939         688         8,636,613         8.1           Myeloma         Female         5         70,728         7.1         8.6         5.9         0.933         436         4,326,182         10.1           Myeloma         Female         5         70,728         7.1         8.6         3.5         0.559         262         4,310,431         6.1           Non-Hodgkin Lymphoma         Total         17         70,728         24.0         28.2         15.5         0.770         1,112         4,366,8613         22.1           Non-Hodgkin Lymphoma         Female         12											
Melanoma of the Skin         Male Nelanoma of the Skin         Male Female         15         70,728         21,2         25,1         24,2         0.064         1,750         4,326,182         40,5           Myeloma         Total         10         135,215         7,4         8.6         9,4         0.939         698         8,636,613         8.1           Myeloma         Male         5         70,728         7,1         8.6         5,9         0.933         436         4,326,182         10,1           Myeloma         Female         5         64,487         7.8         8.6         5,9         0.933         436         4,326,182         10,1           Myeloma         Female         5         64,487         7.8         8.6         5,9         0.933         436         4,326,182         10,1           Myeloma         Female         5         64,487         7.8         8.6         3.5         0.559         262         4,310,431         6.1           Myeloma         Female         12         64,487         18.6         20.4         10.9         0.817         799         4,310,431         18.5           Non-Hodgkin Lymphoma         Female         12         64,4										, , -	
Myeloma         Total         10         135,215         7.4         8.6         9.4         0.939         698         8,636,613         8.1           Myeloma         Female         5         70,728         7.1         8.6         5.9         0.933         436         4,326,182         10.1           Myeloma         Female         5         64,487         7.8         8.6         3.5         0.559         262         4,310,431         6.1           Non-Hodgkin Lymphoma         Male         17         70,728         24.0         28.2         15.5         0.770         1,112         4,326,182         25.7           Non-Hodgkin Lymphoma         Male         17         70,728         24.0         28.2         15.5         0.770         1,112         4,326,182         25.7           Non-Hodgkin Lymphoma         Male         17         70,728         24.0         28.2         15.5         0.770         1,112         4,326,182         25.7           Non-Hodgkin Lymphoma         Female         12         64,487         18.6         20.4         10.9         0.817         799         4,310,431         18.1           Oral Cavity and Pharynx         Male         9         70,72	Melanoma of the Skin									4,326,182	
Myeloma         Male Female         5         70,728         7.1         8.6         5.9         0.933         436         4,326,182         10.1           Myeloma         Female         5         64,487         7.8         8.6         3.5         0.559         262         4,310,431         6.1           Non-Hodgkin Lymphoma         Male         17         70,728         24.0         28.2         15.5         0.770         1,112         4,326,182         25.7           Non-Hodgkin Lymphoma         Female         12         64,487         18.6         20.4         10.9         0.817         799         4,310,431         18.5           Oral Cavity and Pharynx         Total         17         135,215         12.6         14.4         17.5         1.000         1,278         8,636,613         14.8           Oral Cavity and Pharynx         Male         9         70,728         12.7         15.1         12.8         0.361         927         4,326,182         21.4           Oral Cavity and Pharynx         Male         9         70,728         12.7         15.1         12.8         0.361         927         4,326,182         21.4           Oral Cavity and Pharynx         Female											
Myeloma         Female         5         64,487         7.8         8.6         3.5         0.559         262         4,310,431         6.1           Non-Hodgkin Lymphoma         Male         17         70,728         24.0         28.2         15.5         0.770         1,112         4,326,182         25.7           Non-Hodgkin Lymphoma         Female         12         64,487         18.6         20.4         10.9         0.817         799         4,310,431         18.5           Oral Cavity and Pharynx         Total         17         135,215         12.6         14.4         17.5         1.000         1,278         8,636,613         14.8           Oral Cavity and Pharynx         Male         9         70,728         12.7         15.1         12.8         0.361         927         4,326,182         21.4           Oral Cavity and Pharynx         Female         8         64,487         12.4         13.7         4.7         0.216         351         4,310,431         8.1           Ovary         Female         8         64,487         12.4         13.6         7.2         0.847         525         4,310,431         12.2           Pancreas         Male         13         <											
Nón-Hodgkin Lymphoma         Total         29         135,215         21.4         24.4         26.3         0.655         1,911         8,636,613         22.1           Non-Hodgkin Lymphoma         Male         17         70,728         24.0         28.2         15.5         0.770         1,112         4,326,182         25.7           Non-Hodgkin Lymphoma         Female         12         64,487         18.6         20.4         10.9         0.817         799         4,310,431         18.5           Oral Cavity and Pharynx         Total         17         135,215         12.6         14.4         17.5         1.000         1,278         8,636,613         14.8           Oral Cavity and Pharynx         Male         9         70,728         12.7         15.1         12.8         0.361         927         4,326,182         21.4           Oral Cavity and Pharynx         Male         9         70,728         12.7         15.1         12.8         0.361         927         4,326,182         21.4           Oral Cavity and Pharynx         Female         8         64,487         12.4         13.7         4.7         0.216         351         4,310,431         12.2           Ovary         Fema							5.9 3.5			4,320,182 4 310 431	
Non-Hodgkin Lymphoma   Male   17   70,728   24.0   28.2   15.5   0.770   1,112   4,326,182   25.7	Non-Hodgkin Lymphoma						26.3				
Oral Cavity and Pharynx         Total Oral Cavity and Pharynx         Total Male         17         135,215         12.6         14.4         17.5         1.000         1,278         8,636,613         14.8           Oral Cavity and Pharynx         Male         9         70,728         12.7         15.1         12.8         0.361         927         4,326,182         21.4           Oral Cavity and Pharynx         Female         8         64,487         12.4         13.7         4.7         0.216         351         4,310,431         8.1           Ovary         Female         8         64,487         12.4         13.6         7.2         0.847         525         4,310,431         12.2           Pancreas         Total         25         135,215         18.5         21.5         18.8         0.200         1,398         8,636,613         16.2           Pancreas         Male         13         70,728         18.4         22.3         10.4         0.495         771         4,326,182         17.8           Pancreas         Male         13         70,728         18.4         22.3         10.4         0.495         771         4,326,182         17.8           Perostate         Male </td <td>Non-Hodgkin Lymphoma</td> <td>Male</td> <td>17</td> <td>70,728</td> <td>24.0</td> <td>28.2</td> <td>15.5</td> <td>0.770</td> <td>1,112</td> <td>4,326,182</td> <td>25.7</td>	Non-Hodgkin Lymphoma	Male	17	70,728	24.0	28.2	15.5	0.770	1,112	4,326,182	25.7
Oral Cavity and Pharynx         Male Coral Cavity and Pharynx         9 70,728 8 64,487 12.4 13.7 12.4 13.7 12.8 12.8 13.5 12.5 12.4 13.7 12.8 13.5 12.4 13.7 12.4 13.6 13.5 12.4 13.7 12.4 13.6 13.5 12.5 13.5 12.5 13.5 12.5 13.5 12.5 13.5 12.5 13.5 13.5 13.5 13.5 13.5 13.5 13.5 13	Non-Hodgkin Lymphoma										
Oral Cavity and Pharynx         Female         8         64,487         12.4         13.7         4.7         0.216         351         4,310,431         8.1           Ovary         Female         8         64,487         12.4         13.6         7.2         0.847         525         4,310,431         12.2           Pancreas         Total         25         135,215         18.5         21.5         18.8         0.200         1,398         8,636,613         16.2           Pancreas         Male         13         70,728         18.4         22.3         10.4         0.495         771         4,326,182         17.8           Pancreas         Female         12         64,487         18.6         20.7         8.4         0.291         627         4,310,431         14.5           Prostate         Male         88         70,728         124.4         149.4         86.2         0.873         6,329         4,326,182         146.3           Stomach         Total         8         135,215         5.9         6.8         6.3         0.585         459         8,636,613         5.3           Stomach         Female         2         64,487         3.1         3.4	Oral Cavity and Pharynx										
Ovary         Female         8         64,487         12.4         13.6         7.2         0.847         525         4,310,431         12.2           Pancreas         Total         25         135,215         18.5         21.5         18.8         0.200         1,398         8,636,613         16.2           Pancreas         Male         13         70,728         18.4         22.3         10.4         0.495         771         4,326,182         17.8           Pancreas         Female         12         64,487         18.6         20.7         8.4         0.291         627         4,310,431         14.5           Prostate         Male         88         70,728         124.4         149.4         86.2         0.873         6,329         4,326,182         146.3           Stomach         Total         8         135,215         5.9         6.8         6.3         0.585         459         8,636,613         5.3           Stomach         Male         6         70,728         8.5         10.1         4.2         0.481         303         4,326,182         7.0           Stomach         Female         2         64,487         3.1         3.4         2	Oral Cavity and Pharvnx										
Pancreas         Total Male         25         135,215         18.5         21.5         18.8         0.200         1,398         8,636,613         16.2           Pancreas         Male         13         70,728         18.4         22.3         10.4         0.495         771         4,326,182         17.8           Pancreas         Female         12         64,487         18.6         20.7         8.4         0.291         627         4,310,431         14.5           Prostate         Male         88         70,728         124.4         149.4         86.2         0.873         6,329         4,326,182         146.3           Stomach         Total         8         135,215         5.9         6.8         6.3         0.585         459         8,636,613         5.3           Stomach         Male         6         70,728         8.5         10.1         4.2         0.481         303         4,326,182         7.0           Stomach         Female         2         64,487         3.1         3.4         2.1         1.000         156         4,310,431         3.6           Testis         Male         5         70,728         7.1         6.3											
Pancreas         Female         12         64,487         18.6         20.7         8.4         0.291         627         4,310,431         14.5           Prostate         Male         88         70,728         124.4         149.4         86.2         0.873         6,329         4,326,182         146.3           Stomach         Total         8         135,215         5.9         6.8         6.3         0.585         459         8,636,613         5.3           Stomach         Male         6         70,728         8.5         10.1         4.2         0.481         303         4,326,182         7.0           Stomach         Female         2         64,487         3.1         3.4         2.1         1.000         156         4,310,431         3.6           Testis         Male         5         70,728         7.1         6.3         4.8         1.000         260         4,326,182         6.0           Thyroid         Total         22         135,215         16.3         17.0         17.9         0.389         1,198         8,636,613         13.9           Thyroid         Male         5         70,728         7.1         7.8         5.2	Pancreas	Total	25	135,215	18.5	21.5	18.8	0.200	1,398	8,636,613	16.2
Prostate         Male         88         70,728         124.4         149.4         86.2         0.873         6,329         4,326,182         146.3           Stomach         Total         8         135,215         5.9         6.8         6.3         0.585         459         8,636,613         5.3           Stomach         Male         6         70,728         8.5         10.1         4.2         0.481         303         4,326,182         7.0           Stomach         Female         2         64,487         3.1         3.4         2.1         1.000         156         4,310,431         3.6           Testis         Male         5         70,728         7.1         6.3         4.8         1.000         260         4,326,182         6.0           Thyroid         Total         22         135,215         16.3         17.0         17.9         0.389         1,198         8,636,613         13.9           Thyroid         Male         5         70,728         7.1         7.8         5.2         1.000         350         4,326,182         8.1           Thyroid         Female         17         64,487         26.4         27.3         12.3											
Stomach         Total Male         8   135,215   5.9   6.8   6.3   0.585   459   8,636,613   5.3           5.3   5.3   5.3           5.3   5.3   5.3   5.3           5.3   5.3   5.3   5.3           5.3   5.3   5.3   5.3           5.3   5.3   5.3   5.3           5.3   5.3   5.3   5.3   5.3   5.3           5.3   5.3   5.3   5.3   5.3   5.3   5.3           5.3   5											
Stomach         Male         6         70,728         8.5         10.1         4.2         0.481         303         4,326,182         7.0           Stomach         Female         2         64,487         3.1         3.4         2.1         1.000         156         4,310,431         3.6           Testis         Male         5         70,728         7.1         6.3         4.8         1.000         260         4,326,182         6.0           Thyroid         Total         22         135,215         16.3         17.0         17.9         0.389         1,198         8,636,613         13.9           Thyroid         Male         5         70,728         7.1         7.8         5.2         1.000         350         4,326,182         8.1           Thyroid         Female         17         64,487         26.4         27.3         12.3         0.234         848         4,310,431         19.7           Pediatric Age 0 to 19         Total         7         37,552         18.6         18.4         6.5         0.950         414         2,422,971         17.1           Pediatric Age 0 to 19         Male         4         19,397         20.6         20.2							6.3				
Stomach         Female         2         64,487         3.1         3.4         2.1         1.000         156         4,310,431         3.6           Testis         Male         5         70,728         7.1         6.3         4.8         1.000         260         4,326,182         6.0           Thyroid         Total         22         135,215         16.3         17.0         17.9         0.389         1,198         8,636,613         13.9           Thyroid         Male         5         70,728         7.1         7.8         5.2         1.000         350         4,326,182         8.1           Thyroid         Female         17         64,487         26.4         27.3         12.3         0.234         848         4,310,431         19.7           Pediatric Age 0 to 19         Total         7         37,552         18.6         18.4         6.5         0.950         414         2,422,971         17.1           Pediatric Age 0 to 19         Male         4         19,397         20.6         20.2         3.5         0.928         219         1,237,113         17.7	Stomach	Male	6	70,728				0.481		4,326,182	
Thyroid         Total Male         22 135,215 70,728         16.3 7.1 7.8 7.8 7.1 7.8 7.8 7.1 7.8 7.8 7.1 7.8 7.8 7.1 7.8 7.8 7.1 7.8 7.8 7.1 7.8 7.8 7.1 7.8 7.8 7.1 7.8 7.8 7.1 7.8 7.8 7.1 7.8 7.8 7.1 7.8 7.8 7.1 7.8 7.8 7.1 7.8 7.8 7.1 7.8 7.8 7.1 7.8 7.8 7.1 7.8 7.1 7.8 7.1 7.8 7.8 7.1 7.1 7.1 7.1 7.1 7.1 7.1 7.1 7.1 7.1	Stomach			64,487	3.1	3.4	2.1	1.000	156	4,310,431	3.6
Thyroid         Male Female         5         70,728 70,728         7.1 7.8 7.8 7.1 7.8 7.8 7.1 7.8 7.8 7.1 7.8 7.8 7.1 7.8 7.8 7.1 7.8 7.8 7.1 7.8 7.1 7.8 7.8 7.1 7.8 7.1 7.8 7.1 7.8 7.1 7.8 7.1 7.8 7.1 7.8 7.1 7.8 7.1 7.1 7.8 7.1 7.1 7.1 7.1 7.1 7.1 7.1 7.1 7.1 7.1											
Thyroid         Female         17         64,487         26.4         27.3         12.3         0.234         848         4,310,431         19.7           Pediatric Age 0 to 19         Total         7         37,552         18.6         18.4         6.5         0.950         414         2,422,971         17.1           Pediatric Age 0 to 19         Male         4         19,397         20.6         20.2         3.5         0.928         219         1,237,113         17.7	,										
Pediatric Age 0 to 19         Total         7         37,552         18.6         18.4         6.5         0.950         414         2,422,971         17.1           Pediatric Age 0 to 19         Male         4         19,397         20.6         20.2         3.5         0.928         219         1,237,113         17.7	,			,							
Pediatric Age 0 to 19   Male   4   19,397   20.6   20.2   3.5   0.928   219   1,237,113   17.7				,							
	· ·										
	Pediatric Age 0 to 19 Pediatric Age 0 to 19	Female	3	18,155	16.5	16.4	3.0	1.000	195	1,185,858	16.4

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05). Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

<sup>2.</sup> Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

## TABLE 4: CANCER MORTALITY 2017–2021 COMPARISON BETWEEN ELMORE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

Cause of Death   Sex   Death   Vears   Rate (1) Rate (2) Deaths (3)   P-Value (4)   Death   Vears   Rate (1) Rate (2) Deaths (3)   P-Value (4)   Death   Vears   Rate (1) Rate (2) Death (3)   P-Value (4)   Death   Vears   Rate (1) Rate (2) Death (3)   P-Value (4)   Death   Vears   Rate (1) Rate (2) Death (3)   P-Value (4)   Death (4)   De				Elm	nore County	,			Re	Remainder of Idaho		
Cancer SiterType	Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude	
All Causes of Death   Male   601   72,204   832,4   990.7   552.8   0.045 >> 40,455   4,439,664   911.2   All Causes of Death   Famale   493   65,660   750.8   411.1   476.8   0.470   0.000 >> 14,876   8,850,851   188.1   All Malignant Cancers   Male   1245   137,884   127.7   205.5   200.0   0.002 >> 14,876   8,850,851   188.1   All Malignant Cancers   Male   127,722.0   203.0   203.0   200.0   0.002 >> 14,876   8,850,851   188.1   40,861   180.8   40,861   18	Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)	
All Causes of Death Male All Causes of Death Male (a) 72,204 (b) 990.7 (b) 552.8 (b) 4045 (b) 4,439,664 (b) 911.2 All Malignant Cancers (b) 43 (b) 656.60 (b) 750.8 (b) 911.7 (c) 205.9 (c) 200.0 (c) 200.2 (c) 3,881 (d) 4,111.9 (c) 13.4 All Malignant Cancers (b) 14,876 (c) 14,	All Causes of Death	Total	1,094	137,864	793.5	918.5	1,027.3	0.040 >>	76,336	8,850,851	862.5	
All Malignant Cancers   Total   245   137,864   177.7   205.9   200.0   0.002 >>   14,876   8,850,851   188.1   All Malignant Cancers   Female   98   65,660   149.3   165.6   91.8   0.547   6,847   4,411,817   155.2   Bladder   Total   4   137,864   24.5   3.9   61.5   6   91.8   0.547   6,847   4,411,817   155.2   Bladder   Total   4   137,864   24.5   3.9   61.5   6   91.8   0.547   6,847   4,411,817   155.2   Bladder   Total   6   137,864   24.5   3.9   61.5   61.	All Causes of Death	Male			832.4	990.7		0.045 >>		4,439,664	911.2	
All Malignant Cancers   Male   147   72.204   203.6   246.4   107.9   0.000 >> 8.029   4.439.664   180.8   All Malignant Cancers   Female   98   65.660   149.3   165.6   91.8   0.547   455   8.850.851   5.5   Bladder   Total   4   137.864   2.9   3.4   6.4   0.474   485   8.850.851   5.5   Bladder   Male   4   72.204   5.5   6.9   4.8   0.474   485   8.850.851   5.5   Brain and Other Nervous System   Male   4   72.204   5.5   6.9   4.8   0.93   0.932   0.943   2.94   4.411.871   5.6   Brain and Other Nervous System   Male   4   72.204   5.5   6.4   4.1   1.000   294   4.438.664   6.8   Brain and Other Nervous System   Female   2   65.660   3.0   3.3   2.8   0.943   2.04   4.411.871   6.6   Brain and Other Nervous System   Female   2   65.660   3.0   3.3   2.8   0.943   2.04   4.411.871   7.6   Brain and Other Nervous System   Female   2   65.660   3.0   3.3   2.8   0.943   2.04   4.411.871   7.6   Brain and Other Nervous System   Female   2   65.660   3.0   3.3   2.8   0.943   2.04   4.411.871   7.6   Brain and Other Nervous System   Female   2   65.660   3.0   3.3   3.5   3.5   0.943   2.04   4.411.871   7.6   Brain and Other Nervous System   Female   2   65.660   3.0   3.3   3.5   0.943   2.04   4.411.871   7.6   Brain and Other Nervous System   Female   2   65.660   3.0   3.3   3.5   0.943   2.04   4.411.871   7.6   Brain and Other Nervous System   Female   5   65.660   3.0   3.3   3.5   0.943   2.04   4.411.871   7.6   Brain and Other Nervous System   Female   5   65.660   3.0   3.3   3.5   0.943   2.04   4.411.871   7.6   Brain and Other Nervous System   Female   5   65.660   3.0   3.3   3.5   0.943   2.04   4.411.871   7.6   Brain and Other Nervous System   Female   5   65.660   3.0   3.3   3.5   0.943   2.04   4.411.871   7.6   Brain and Other Nervous System   Female   5   65.660   3.0   3.3   3.5   0.953	All Causes of Death	Female	493		750.8	841.1		0.470	35,881		813.4	
All Malighant Cancers   Female   98   65,680   149,3   185,6   91,8   0.547   6,847   4,411,187   155,2   Bladder   Tofal   4   37,864   2.9   3.4   6.4   0,474   485   38,50,281   5.5   Bladder   Tofal   4   37,864   2.9   3.4   6.4   0,474   485   38,50,281   5.5   Bladder   Shadder   Shadder   Shadder   Shadder   5,50   4.9   0,925   374   4,439,664   8.4   Bladder   Shadder   Shadder   Shadder   Shadder   Shadder   5,50   4.9   0,925   374   4,439,664   8.4   Brain and Other Nervous System   Male   4   72,204   5.5   6.4   4.1   1,000   294   4,439,664   6.6   Breast   Shadder   Shadd												
Bladder   Total   4   137,864   2.9   3.4   6.4   0.474   485   8.850,851   5.5   Bladder   Female   - 65,660   1.5   0.463   111   4.411,877   2.5   Brain and Other Nervous System   Total   6   37,864   4.4   4.9   6.9   0.926   488   8.850,851   5.5   Brain and Other Nervous System   Male   4   72,204   5.5   5.5   6.9   4.1   1.000   484   4.493,664   6.6   Brain and Other Nervous System   Male   4   72,204   5.5   5.5   6.3   4.1   1.000   44   4.493,664   6.6   Brain and Other Nervous System   Male   7   72,204   7   7   7   7   7   7   7   7   7				72,204								
Bladder   Male												
Bladder												
Brain and Other Nervous System   Total   6   137,864   4.4   4.9   6.9   0.926   498   8,869,851   5.6   5.			4		5.5	6.9						
Brain and Other Nervous System Male Pemale 4 72,204 5.5 6.4 4.1 1.000 294 4.411,187 4.6 6.6 Breast Total 5 137,864 3.6 4.2 14.8 0.907 4.411,187 4.6 Breast Male - 72,204 0.2 1.000 16 4.439,664 0.4 Breast Female 5 65,660 7.6 8.5 14.1 0.000 4.6 1.000 16 4.439,664 0.4 Breast Female 5 65,660 7.6 8.5 14.1 0.000 4.6 1.000 16 4.439,664 0.4 Breast Female 5 65,660 7.6 8.5 14.1 0.000 4.6 1.000 16 4.439,664 0.4 0.4 Breast Female 5 65,660 7.6 8.5 14.5 0.003 4.1 0.000 16 4.439,664 0.4 0.1 0.1 0.0 0.0			- 6		-	- 40						
Brain and Other Nervous System   Female   2   65,660   3.0   3.3   3.4   2.0   0.943   2.04   4.411,187   4.6   Breast   Male   -   72,204   -   -   -   0.2   1.000   16   4.439,664   0.4   Breast   Female   -   2   65,660   7.6   8.5   14.5   0.008   <   1.081   4.411,187   24.5   6.6   0.4   Breast   Female   -   2   65,660   7.6   8.5   14.5   0.008   <   1.081   4.411,187   24.5   0.008   4.411,187   24.5   0.008   4.411,187   24.5   0.008   4.411,187   24.5   0.008   4.411,187   24.5   0.008   4.411,187   24.5   0.008   4.411,187   24.5   0.008   4.411,187   24.5   0.008   4.411,187   24.5   0.008   4.411,187   24.5   0.008   4.411,187   24.5   0.008   4.411,187   24.5   0.008   4.411,187   24.5   0.008   4.411,187   24.5   0.008   4.411,187   24.5   0.008   4.411,187   3.5   0.008   3.0   3.4   3.5   0.008   3.0   3.4   3.5   0.008   3.0   3.4   3.5   0.008   3.0   3.4   3.5   0.008   3.0   3.4   3.5   0.008   3.0   3.4   3.5   0.008   3.0   3.4   3.5   0.008   3.0   3.4   3.5   0.008   3.0   3.4   3.5   0.008   3.0   3.4   3.5   0.008   3.0   3.4   3.5   0.008   3.0   3.4   3.5   0.008   3.0   3.4   3.5   0.008   3.0   3.0   3.4   3.5   0.008   3.0   3.4   3.5   0.008   3.0   3.4   3.5												
Breast   Total   5   137,864   3.6   4.2   14.8   0.007 < 1,1997   8,850,851   12.4   Breast   Female   5   65,660   7.6   8.5   14.5   0.008 < 1,081   4.411,187   24.5   Cervix   Female   2   65,660   7.6   8.5   14.5   0.008 < 1,081   4.411,187   24.5   Cervix   Female   2   65,660   7.6   8.5   14.5   0.008 < 1,081   4.411,187   24.5   Cervix   Female   2   65,660   7.6   8.5   0.009   7.0   14.39,664   0.4   Colorectal   Total   25   137,864   18.1   21.0   7.7   0.101   1,294   8,830,851   14.6   Colorectal   Female   6   67,204   22.7   26.6   9.5   0.099   7.03   4.439,664   15.6   Colorectal   Female   6   65,660   13.7   75.7   75.7   0.768   591   4.411,187   13.9   Escophagus   Female   9   72,204   12.5   14.9   5.3   0.181   392   4.439,664   8.8   Escophagus   Female   2   65,660   3.0   3.4   1.0   0.526   74   4.411,187   17.8   Hodgkin Lymphoma   Total   2   137,864   1.5   1.7   0.4   0.106   27   4.439,664   0.3   Hodgkin Lymphoma   Female   - 65,660   0.2   1.000   15   4.411,187   1.3   Kidney   Male   2   72,204   2.8   3.2   0.2   0.025 >> 12   4.439,664   0.3   Kidney   Male   2   72,204   2.8   3.3   3.2   0.747   240   4.439,664   0.3   Kidney   Male   2   72,204   2.8   3.3   3.2   0.747   240   4.439,664   0.3   Kidney   Male   2   72,204   2.8   3.3   3.2   0.747   240   4.439,664   0.3   Kidney   Female   - 65,660   0.2   1.000   15   4.411,187   0.3   Kidney   Male   2   72,204   2.8   3.3   3.2   0.747   240   4.439,664   0.3   Kidney   Female   - 65,660   0.2   1.000   15   4.411,187   0.3   Kidney   Male   1   137,864   0.7   0.8   0.7   0.8   0.7   0.7   Kidney   Male   2   72,204   2.8   3.3   0.747   240   4.439,664   0.3   Leukemia   Total   1   137,864   0.7   0.8   0.7   0.7   0.7   0.7   0.7   Kalaman   Total   1   137,864   0.7   0.8   0.7   0.7   0.7   0.7   0.7   Leukemia   Female   4   65,660   6.1   6.8   3.6   0.974   2.7   0.7   0.7   0.7   Leukemia   Female   5   65,660   6.1   6.8   3.6   0.974   2.7   0.7   0.7   0.7   Leukemia   Female   6								0.943				
Breast Male Female - 72,204 0.2 1.000 16 4.439,664 0.4												
Breast         Female Cervix         Bil 4.411,187         24.5           Colorectal         Total Colorectal         Total Colorectal         15         137,864         18.1         21.0         17.4         0.101         1.294         8.850,851         14.6           Colorectal         Male Colorectal         Female Pemale Pemale Pemale Cervix         9         65,660         13.7         15.3         7.9         0.786         591         4.411,187         13.4           Colorectal Female Pemale Cervix         165,660         1.5         1.7         2.3         0.667         712         4.411,187         13.4           Esophagus Female Pemale Pema			-		-	-			,			
Cervix			5		7.6	8.5						
Colorectal			2	65,660	3.0	3.3	1.1		81		1.8	
Colorectal   Female   9   65,660   13,7   15,3   7,9   0,766   591   4,411,187   13,4				137,864								
Corpus Uteri												
Esophagus												
Esophagus	· · · -											
Esophagus												
Hodgin Lymphoma												
Hodgkin Lymphoma   Male												
Hodgish Lymphoma   Female   -												
Kidney				65,660								
Kidney												
Kidney										4.439.664		
Larynx Male 1 70tal 1 137,864 0.7 0.8 1.0 1.000 70 8,850,851 0.8 Larynx Male 1 72,204 1.4 1.6 0.8 1.000 57 4,439,664 1.3 Larynx Female - 65,660 0.2 1.000 13 4,411,187 0.3 Leukemia Male 7 72,204 9.7 11.6 5.1 0.518 379 4,439,664 8.5 Leukemia Male 7 72,204 9.7 11.6 5.1 0.518 379 4,439,664 8.5 Leukemia Male 7 72,204 9.7 11.6 5.1 0.518 379 4,439,664 8.5 Leukemia Male 6 6,5660 6.1 6.8 3.6 0.974 270 4,411,187 6.1 11 137,864 8.0 9.2 8.0 0.365 592 8,850,851 7.3 11 11 137,864 8.0 9.2 8.0 0.365 592 8,850,851 6.7 Liver and Bile Duct Male 6 72,204 8.3 9.9 5.5 0.931 402 4,439,664 9.1 1.2 Liver and Bile Duct Female 5 65,660 7.6 8.4 2.6 0.231 190 4,411,187 4.3 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4												
Larýmx Female - 65,660 0.2 1,000 13 4,411,187 0.3 Leukemia Total 11 137,864 8.0 9.2 8.7 0.529 649 8,850,851 7.3 1.4 Leukemia Male 7 72,204 9.7 11.6 5.1 0.518 379 4,439,664 8.5 Leukemia Male 7 72,204 9.7 11.6 5.1 0.518 379 4,439,664 8.5 Leukemia Female 4 65,660 6.1 6.8 3.6 0.974 270 4,411,187 6.1 Liver and Bile Duct Total 11 137,864 8.0 9.2 8.0 0.365 592 8,850,851 6.7 1.4 Liver and Bile Duct Female 5 65,660 7.6 8.4 2.6 0.231 190 4,411,187 4.3 1.4 Liver and Bile Duct Female 5 65,660 7.6 8.4 2.6 0.231 190 4,411,187 4.3 1.4 Liver and Bile Duct Female 5 65,660 7.6 8.4 2.6 0.231 190 4,411,187 4.3 1.4 Liver and Bile Duct Female 3 65,660 48.7 53.9 18.5 0.005 >> 2,892 8,850,851 32.7 1.4 Ling and Bronchus Female 32 65,660 48.7 53.9 18.5 0.005 >> 1,519 4,439,664 4.2 1.4 1.4 1.7 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4			1					1.000				
Leukemia         Total         11         137,864         8.0         9.2         8.7         0.529         649         8,850,851         7.3           Leukemia         Female         7         72,204         9.7         11.6         5.1         0.518         379         4,439,664         8.5           Leukemia         Female         4         65,660         6.1         6.8         3.6         0.974         270         4,411,187         6.1           Liver and Bile Duct         Male         6         72,204         8.3         9.9         5.5         0,931         402         4,439,664         9.1           Liver and Bile Duct         Female         5         65,660         7.6         8.4         2.6         0.231         190         4,411,187         4.3           Liver and Bile Duct         Female         5         65,660         7.6         8.4         2.6         0.231         190         4,411,187         4.3           Lung and Bronchus         Male         37         72,204         51.2         62.2         20.4         0.001>>>         1,373         4,411,187         31.1           Welanoma of the Skin         Mola         1         127,864 <th< td=""><td>Larynx</td><td></td><td>1</td><td></td><td>1.4</td><td>1.6</td><td></td><td></td><td>57</td><td>4,439,664</td><td></td></th<>	Larynx		1		1.4	1.6			57	4,439,664		
Leukemia         Male         7         7.2.204         9.7         11.6         5.1         0.518         379         4,439,664         8.5           Leukemia         Female         4         65,660         6.1         6.8         3.6         0.974         270         4,411,187         6.1           Liver and Bile Duct         Male         6         72,204         8.3         9.9         5.5         0.931         402         4,439,664         9.1           Liver and Bile Duct         Female         5         65,660         7.6         8.4         2.6         0.231         402         4,439,664         9.1           Liver and Bile Duct         Female         5         65,660         7.6         8.4         2.6         0.231         402         4,439,664         9.1           Liver and Bile Duct         Female         5         65,660         7.6         8.4         2.6         0.231         402         4,439,664         9.1           Liver and Bile Duct         Female         5         65,660         7.6         8.4         2.6         0.231         402         4,439,664         9.1           Lung and Bronchus         Female         7.0         8.3 <td< td=""><td></td><td></td><td>-</td><td></td><td>-</td><td>-</td><td></td><td></td><td></td><td></td><td></td></td<>			-		-	-						
Leukemia         Female         4         65,660         6.1         6.8         3.6         0.974         270         4,411,187         6.1           Liver and Bile Duct         Total         11         137,864         8.0         9.2         8.0         0.365         592         8,850,851         6.7           Liver and Bile Duct         Female         5         65,660         7.6         8.4         2.6         0.231         402         4,439,664         9.1           Liver and Bile Duct         Female         5         65,660         7.6         8.4         2.6         0.231         190         4,411,187         4.3           Lung and Bronchus         Total         69         137,864         50.0         58.0         38.8         0.000 >>         2,892         8,850,851         32.7           Lung and Bronchus         Female         32         65,660         48.7         53.9         18.5         0.005 >>         1,519         4,439,664         34.2           Lung and Bronchus         Female         32         65,660         48.7         75.39         10.535         9.7         4,411,187         31.1           Melanoma of the Skin         Male         1         72,204 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>												
Liver and Bile Duct Male												
Liver and Bile Duct Female 5 6 72,204 8.3 9.9 5.5 0.931 402 4,439,664 9.1 Liver and Bile Duct Female 5 65,660 7.6 8.4 2.6 0.231 190 4,411,187 4.3 Ling and Bronchus Total 69 137,864 50.0 58.0 38.8 0.000 >> 2,892 8,850,851 32.7 Lung and Bronchus Male 37 72,204 51.2 62.2 20.4 0.001 >> 1,519 4,439,664 34.2 Lung and Bronchus Female 32 65,660 48.7 53.9 18.5 0.005 >> 1,373 4,411,187 31.1 Melanoma of the Skin Total 1 137,864 0.7 0.8 3.9 0.196 288 8,850,851 33.1 Melanoma of the Skin Male 1 72,204 1.4 1.7 2.6 0.536 191 4,439,664 4.3 Melanoma of the Skin Female - 65,660 - 1.3 0.535 97 4,411,187 2.2 Melanoma of the Skin Male 3 72,204 4.2 5.1 2.6 0.943 193 4,439,664 4.3 Melanoma of the Skin Female 3 65,660 4.6 5.0 1.8 0.530 132 4,411,187 3.0 Melanoma of the Skin Male 1 172,204 4.2 5.1 2.6 0.943 193 4,439,664 4.3 Melanoma of the Skin Female 3 65,660 4.6 5.0 1.8 0.530 132 4,411,187 3.0 Melanoma of the Skin Male 1 1 72,204 1.2 Melanoma of the Skin Male 3 72,204 4.2 5.1 2.6 0.943 193 4,439,664 4.3 Melanoma of the Skin Male 3 72,204 4.2 5.1 2.6 0.943 193 4,439,664 4.3 Melanoma of the Skin Male 1 1 72,204 15.2 18.3 4.0 0.006 >> 296 4,439,664 6.7 Melanoma of the Skin Male 1 1 72,204 15.2 18.3 4.0 0.006 >> 296 4,439,664 6.7 Melanoma of the Skin Melanoma of the Skin Female 2 65,660 3.0 3.4 3.5 0.640 260 4,411,187 5.9 Oral Cavity and Pharynx Total 1 137,864 0.7 0.8 3.6 0.254 265 8,850,851 3.0 Oral Cavity and Pharynx Male - 72,204 2.5 0.158 187 4,439,664 4.2 Oral Cavity and Pharynx Female 1 65,660 1.5 1.7 1.0 1.000 78 4,411,187 7.8 Oral Cavity and Pharynx Female 1 65,660 1.5 1.7 1.0 1.000 78 4,441,1187 7.8 Oral Cavity and Pharynx Female 1 65,660 1.5 1.7 1.0 1.000 78 4,441,1187 7.8 Oral Cavity and Pharynx Female 1 65,660 1.5 1.7 1.0 1.000 78 4,441,1187 7.8 Oral Cavity and Pharynx Female 1 65,660 1.5 1.7 1.0 1.000 78 4,441,1187 7.8 Oral Cavity and Pharynx Female 1 65,660 1.5 1.7 1.0 1.000 78 4,441,1187 7.2 1.0 1.000 78 4,441,1187 7.2 1.0 1.000 78 4,441,1187 7.8 Oral Cavity and Pharynx Female 1 65,660 1.5 1.7 1.0 1.000 78 4,441,1187											_	
Liver and Bile Duct												
Lung and Bronchus         Total         69         137,864         50.0         58.0         38.8         0.000 >>         2,892         8,850,851         32.7           Lung and Bronchus         Male         37         72,204         51.2         62.2         20.4         0.001 >>         1,519         4,439,664         34.2           Lung and Bronchus         Female         32         65,660         48.7         53.9         18.5         0.005 >>         1,373         4,411,187         31.1           Melanoma of the Skin         Male         1         137,864         0.7         0.8         3.9         0.196         288         8,850,851         3.3           Melanoma of the Skin         Male         1         72,204         1.4         1.7         2.6         0.536         191         4,439,664         4.3           Melanoma of the Skin         Female         -         66,660         -         -         1.3         0.535         97         4,411,187         2.2           Myeloma         Male         3         72,204         4.2         5.1         2.6         0.943         193         4,439,664         4.3           Myeloma         Female         3         65,660												
Lung and Bronchus         Male Lung and Bronchus         72,204         51.2 began and Bronchus         62.2 began and Bronchus         1,519 began and Bronchus         4,439,664 and 34.2 began and Bronchus         37 began and Bronchus         1,519 began and Bronchus         4,439,664 and 34.2 began and 34.2 began and 32 began												
Lung and Bronchus         Female         32         65,660         48.7         53.9         18.5         0.005 >>         1,373         4,411,187         31.1           Melanoma of the Skin         Total         1         137,864         0.7         0.8         3.9         0.196         288         8,850,851         3.3           Melanoma of the Skin         Male         1         72,204         1.4         1.7         2.6         0.536         191         4,439,664         4.3           Melanoma of the Skin         Female         -         65,660         -         -         1.3         0.535         97         4,411,187         2.2           Myeloma         Male         3         72,204         4.4         5.1         4.4         0.544         325         8,850,851         3.7           Myeloma         Male         3         72,204         4.2         5.1         2.6         0.943         193         4,439,664         4.3           Myeloma         Female         3         65,660         4.6         5.0         1.8         0.530         132         4,411,187         3.0           Non-Hodgkin Lymphoma         Male         11         72,204         15.2			37									
Melanoma of the Skin         Total         1         137,864         0.7         0.8         3.9         0.196         288         8,850,851         3.3           Melanoma of the Skin         Male         1         72,204         1.4         1.7         2.6         0.536         191         4,439,664         4.3           Melanoma of the Skin         Female         -         65,660         -         -         1.3         0.535         97         4,411,187         2.2           Myeloma         Male         3         72,204         4.2         5.1         4.4         0.544         325         8,850,851         3.7           Myeloma         Male         3         72,204         4.2         5.1         2.6         0.943         193         4,439,664         4.3           Myeloma         Female         3         65,660         4.6         5.0         1.8         0.530         132         4,411,187         3.0           Myeloma         Female         3         65,660         4.6         5.0         1.8         0.530         132         4,411,187         3.0           Mon-Hodgkin Lymphoma         Male         11         72,204         15.2         18.3 <td></td> <td></td> <td></td> <td>65.660</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>				65.660								
Melanoma of the Skin         Male         1         72,204         1.4         1.7         2.6         0.536         191         4,439,664         4.3           Melanoma of the Skin         Female         -         65,660         -         -         1.3         0.536         97         4,411,187         2.2           Myeloma         Total         6         137,864         4.4         5.1         4.4         0.544         325         8,850,851         3.7           Myeloma         Male         3         72,204         4.2         5.1         2.6         0.943         193         4,439,664         4.3           Myeloma         Female         3         65,660         4.6         5.0         1.8         0.530         132         4,411,187         3.0           Non-Hodgkin Lymphoma         Total         13         137,864         9.4         10.9         7.5         0.085         556         8,850,851         6.3           Non-Hodgkin Lymphoma         Female         2         65,660         3.0         3.4         3.5         0.085         556         8,850,851         6.3           Non-Hodgkin Lymphoma         Female         2         65,660         3.0			1	137,864						8,850,851		
Myeloma         Total         6         137,864         4.4         5.1         4.4         0.544         325         8,850,851         3.7           Myeloma         Male         3         72,204         4.2         5.1         2.6         0.943         193         4,439,664         4.3           Myeloma         Female         3         65,660         4.6         5.0         1.8         0.530         132         4,411,187         3.0           Non-Hodgkin Lymphoma         Total         13         137,864         9.4         10.9         7.5         0.085         556         8,850,851         6.3           Non-Hodgkin Lymphoma         Male         11         72,204         15.2         18.3         4.0         0.006         296         4,439,664         6.7           Non-Hodgkin Lymphoma         Female         2         65,660         3.0         3.4         3.5         0.640         260         4,411,187         5.9           Oral Cavity and Pharynx         Total         1         137,864         0.7         0.8         3.6         0.254         265         8,850,851         3.0           Oral Cavity and Pharynx         Male         1         65,660 <td< td=""><td>Melanoma of the Skin</td><td>Male</td><td>1</td><td></td><td>1.4</td><td></td><td></td><td>0.536</td><td></td><td>4,439,664</td><td></td></td<>	Melanoma of the Skin	Male	1		1.4			0.536		4,439,664		
Myeloma         Male         3         72,204         4.2         5.1         2.6         0.943         193         4,439,664         4.3           Myeloma         Female         3         65,660         4.6         5.0         1.8         0.530         132         4,411,187         3.0           Non-Hodgkin Lymphoma         Total         13         137,864         9.4         10.9         7.5         0.085         556         8,850,851         6.3           Non-Hodgkin Lymphoma         Male         11         72,204         15.2         18.3         4.0         0.006 >>         296         4,439,664         6.7           Non-Hodgkin Lymphoma         Female         2         65,660         3.0         3.4         3.5         0.640         260         4,411,187         5.9           Oral Cavity and Pharynx         Total         1         137,864         0.7         0.8         3.6         0.254         265         8,850,851         3.0           Oral Cavity and Pharynx         Male         -         72,204         -         -         2.5         0.158         187         4,439,664         4.2           Oral Cavity and Pharynx         Female         8         65,660 </td <td>Melanoma of the Skin</td> <td></td> <td>-</td> <td></td> <td>-</td> <td>-</td> <td></td> <td></td> <td></td> <td></td> <td></td>	Melanoma of the Skin		-		-	-						
Myeloma         Female         3         65,660         4.6         5.0         1.8         0.530         132         4,411,187         3.0           Non-Hodgkin Lymphoma         Total         13         137,864         9.4         10.9         7.5         0.085         556         8,850,851         6.3           Non-Hodgkin Lymphoma         Male         11         72,204         15.2         18.3         4.0         0.066 >>         296         4,439,664         6.7           Non-Hodgkin Lymphoma         Female         2         65,660         3.0         3.4         3.5         0.640         260         4,411,187         5.9           Non-Hodgkin Lymphoma         Female         2         65,660         3.0         3.4         3.5         0.640         260         4,431,187         5.9           Oral Cavity and Pharynx         Total         1         137,864         0.7         0.8         3.6         0.254         265         8,850,851         3.0           Oral Cavity and Pharynx         Male         -         72,204         -         -         2.5         0.158         187         4,411,187         1.8           Ovary         Female         8         65,660												
Nón-Hodgkin Lymphoma         Total         13         137,864         9.4         10.9         7.5         0.085         556         8,850,851         6.3           Non-Hodgkin Lymphoma         Male         11         72,204         15.2         18.3         4.0         0.006 >>         296         4,439,664         6.7           Non-Hodgkin Lymphoma         Female         2         65,660         3.0         3.4         3.5         0.640         260         4,411,187         5.9           Oral Cavity and Pharynx         Total         1         137,864         0.7         0.8         3.6         0.254         265         8,850,851         3.0           Oral Cavity and Pharynx         Male         -         72,204         -         -         2.5         0.158         187         4,439,664         4.2           Oral Cavity and Pharynx         Male         -         72,204         -         -         2.5         0.158         187         4,439,664         4.2           Oral Cavity and Pharynx         Female         1         65,660         1.5         1.7         1.0         1.000         78         4,411,187         1.8           Ovary         Female         8 <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>												
Non-Hodgkin Lymphoma         Male         11         72,204         15.2         18.3         4.0         0.006 >>         296         4,439,664         6.7           Non-Hodgkin Lymphoma         Female         2         65,660         3.0         3.4         3.5         0.640         260         4,411,187         5.9           Oral Cavity and Pharynx         Total         1         137,864         0.7         0.8         3.6         0.254         265         8,850,851         3.0           Oral Cavity and Pharynx         Male         -         72,204         -         -         2.5         0.158         187         4,439,664         4.2           Oral Cavity and Pharynx         Female         1         65,660         1.5         1.7         1.0         1.000         78         4,411,187         1.8           Ovary         Female         8         65,660         12.2         13.5         4.6         0.190         342         4,411,187         7.8           Pancreas         Total         21         137,864         15.2         17.7         15.7         0.232         1,169         8,850,851         13.2           Pancreas         Male         15         72,204												
Non-Hodgkin Lymphoma         Female         2         65,660         3.0         3.4         3.5         0.640         260         4,411,187         5.9           Oral Cavity and Pharynx         Total         1         137,864         0.7         0.8         3.6         0.254         265         8,850,851         3.0           Oral Cavity and Pharynx         Male         -         72,204         -         -         2.5         0.158         187         4,439,664         4.2           Oral Cavity and Pharynx         Female         1         65,660         1.5         1.7         1.0         1.000         78         4,411,187         1.8           Ovary         Female         8         65,660         12.2         13.5         4.6         0.190         342         4,411,187         7.8           Pancreas         Total         21         137,864         15.2         17.7         15.7         0.232         1,169         8,850,851         13.2           Pancreas         Male         15         72,204         20.8         25.1         8.4         0.052         627         4,439,664         14.1           Pancreas         Female         6         65,660         9.1										8,850,851		
Oral Cavity and Pharynx         Total         1         137,864         0.7         0.8         3.6         0.254         265         8,850,851         3.0           Oral Cavity and Pharynx         Male         -         72,204         -         -         2.5         0.158         187         4,439,664         4.2           Oral Cavity and Pharynx         Female         1         65,660         1.5         1.7         1.0         1.000         78         4,411,187         1.8           Ovary         Female         8         65,660         12.2         13.5         4.6         0.190         342         4,411,187         7.8           Pancreas         Total         21         137,864         15.2         17.7         15.7         0.232         1,169         8,850,851         13.2           Pancreas         Male         15         72,204         20.8         25.1         8.4         0.052         627         4,439,664         14.1           Pancreas         Female         6         65,660         9.1         10.2         7.2         0.827         542         4,411,187         12.3           Prostate         Male         10         72,204         13.8	Non Hodgkin Lymphoma			12,204						4,439,664		
Oral Cavity and Pharynx         Male         -         72,204         -         -         2.5         0.158         187         4,439,664         4.2           Oral Cavity and Pharynx         Female         1         65,660         1.5         1.7         1.0         1.000         78         4,411,187         1.8           Ovary         Female         8         65,660         12.2         13.5         4.6         0.190         342         4,411,187         7.8           Pancreas         Total         21         137,864         15.2         17.7         15.7         0.232         1,169         8,850,851         13.2           Pancreas         Male         15         72,204         20.8         25.1         8.4         0.052         627         4,439,664         14.1           Pancreas         Female         6         65,660         9.1         10.2         7.2         0.827         542         4,411,187         12.3           Prostate         Male         10         72,204         13.8         17.3         12.2         0.646         939         4,439,664         21.2           Stomach         Total         4         137,864         2.9         3.3 </td <td>Oral Cavity and Pharens</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>ა.5 ვნ</td> <td></td> <td></td> <td></td> <td>3.9</td>	Oral Cavity and Pharens						ა.5 ვნ				3.9	
Oral Cavity and Pharynx         Female         1         65,660         1.5         1.7         1.0         1.000         78         4,411,187         1.8           Ovary         Female         8         65,660         12.2         13.5         4.6         0.190         342         4,411,187         7.8           Pancreas         Total         21         137,864         15.2         17.7         15.7         0.232         1,169         8,850,851         13.2           Pancreas         Male         15         72,204         20.8         25.1         8.4         0.052         627         4,439,664         14.1           Pancreas         Female         6         65,660         9.1         10.2         7.2         0.827         542         4,411,187         1.8           Prostate         Male         10         72,204         13.8         17.3         12.2         0.646         939         4,439,664         21.2           Stomach         Total         4         137,864         2.9         3.3         2.6         0.547         194         8,850,851         2.2           Stomach         Male         4         72,204         5.5         6.6         <			<u>'</u> '		- 0.7	- 0.0						
Ovary         Female         8         65,660         12.2         13.5         4.6         0.190         342         4,411,187         7.8           Pancreas         Total         21         137,864         15.2         17.7         15.7         0.232         1,169         8,850,851         13.2           Pancreas         Male         15         72,204         20.8         25.1         8.4         0.052         627         4,439,664         14.1           Pancreas         Female         6         65,660         9.1         10.2         7.2         0.827         542         4,411,187         12.3           Prostate         Male         10         72,204         13.8         17.3         12.2         0.646         939         4,439,664         21.2           Stomach         Total         4         137,864         2.9         3.3         2.6         0.547         194         8,850,851         2.2           Stomach         Male         4         72,204         5.5         6.6         1.6         0.159         117         4,439,664         2.6			1		1.5	17						
Pancreas         Total         21         137,864         15.2         17.7         15.7         0.232         1,169         8,850,851         13.2           Pancreas         Male         15         72,204         20.8         25.1         8.4         0.052         627         4,439,664         14.1           Pancreas         Female         6         65,660         9.1         10.2         7.2         0.827         542         4,411,187         12.3           Prostate         Male         10         72,204         13.8         17.3         12.2         0.646         939         4,439,664         21.2           Stomach         Total         4         137,864         2.9         3.3         2.6         0.547         194         8,850,851         2.2           Stomach         Male         4         137,864         2.9         3.3         2.6         0.547         194         8,850,851         2.2           Stomach         Male         4         137,864         2.9         3.3         2.6         0.547         194         8,850,851         2.2	,											
Pancreas         Male         15         72,204         20.8         25.1         8.4         0.052         627         4,439,664         14.1           Pancreas         Female         6         65,660         9.1         10.2         7.2         0.827         542         4,411,187         12.3           Prostate         Male         10         72,204         13.8         17.3         12.2         0.646         939         4,439,664         21.2           Stomach         Total         4         137,864         2.9         3.3         2.6         0.547         194         8,850,851         2.2           Stomach         Male         4         72,204         5.5         6.6         1.6         0.159         117         4,439,664         2.6			21		15.2							
Pancreas         Female         6         65,660         9.1         10.2         7.2         0.827         542         4,411,187         12.3           Prostate         Male         10         72,204         13.8         17.3         12.2         0.646         939         4,439,664         21.2           Stomach         Total         4         137,864         2.9         3.3         2.6         0.547         194         8,850,851         2.2           Stomach         Male         4         72,204         5.5         6.6         1.6         0.159         117         4,439,664         2.6						25.1				4,439,664		
Prostate         Male         10         72,204         13.8         17.3         12.2         0.646         939         4,439,664         21.2           Stomach         Total         4         137,864         2.9         3.3         2.6         0.547         194         8,850,851         2.2           Stomach         Male         4         72,204         5.5         6.6         1.6         0.159         117         4,439,664         2.6			6	65,660		10.2	7.2	0.827	542	4,411,187		
Stomach   Male   4   72,204   5.5   6.6   1.6   0.159   117   4,439,664   2.6										4,439,664		
Stomach   Female   -   65,660   -   -   1.0   0.713   77   4,411,187   1.7			4		5.5	6.6						
	Stomach	Female	-	65,660	-	-	1.0	0.713	77	4,411,187	1.7	

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

<sup>2.</sup> Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

### Cancer Screening and Risk Factor Prevalence Estimates, 2011–2021

	State of								Elmore
Measure	Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	County
Access to Care									
Have Health Insurance, Age <65 (2015–2021)	83.1%	82.8%	85.1%	77.2%	85.8%	78.9%	85.4%	85.4%	84.1%
Not See Doctor Due to Cost in Past Year (2015–2021)	12.6%	11.4%	11.8%	14.5%	12.4%	12.3%	11.8%	12.9%	13.8%
Cancer Screening									
Mammogram Past 2 Years, Age 50–74 (2014, 2016, 2018, 2020)	69.1%	67.0%	73.8%	68.2%	73.2%	64.8%	64.5%	67.1%	
Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020)	71.2%	73.6%	73.6%	70.8%	72.9%	69.1%	69.5%	65.9%	
Colorectal Cancer Screening, Age 50–75 (2018, 2020)	67.9%	66.9%	73.6%	71.4%	70.6%	61.7%	61.5%	64.7%	
Tobacco Use									
Current Tobacco User (2016–2021)	22.3%	26.7%	23.1%	23.6%	21.8%	21.4%	22.7%	16.9%	41.6%
Other Cancer-Related									
Healthy Weight by Body Mass Index, Age 20+ (2015–2021)	32.1%	32.8%	31.7%	27.9%	36.1%	29.8%	27.9%	31.9%	28.5%
Any Physical Activity Besides Job Past 30 Days (2015-2021)	78.7%	79.2%	78.1%	74.5%	83.2%	73.4%	76.3%	79.7%	74.0%
Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019)	21.9%	22.8%	19.4%	20.0%	25.2%	19.5%	20.4%	20.2%	21.0%
Home Ever Tested for Radon (2016, 2018, 2020)	23.0%	30.9%	18.2%	16.9%	25.1%	19.9%	23.0%	21.8%	12.3%

### **Access to Care**

### Have Health Insurance - 2015-2021

Statewide, 83.1% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 86.0% of white non-Hispanics, compared to 64.8% of Hispanics and 83.3% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3%) than English-speaking respondents (84.2%). Health care coverage differed significantly by age of respondent, with 79.8% of persons aged 18–29, and 87.8% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 62.1% in Adams County to 91.6% in Oneida County having health insurance.

### Not See Doctor Due to Cost in Past Year – 2015–2021

Statewide, 12.6% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (11.5% of white non-Hispanics, 19.2% of Hispanics, and 21.0% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9% for less than \$15,000, 6.1% for greater than \$50,000). Inability to see a doctor due to cost differed significantly by county, with a range of 7.4% in Franklin County to 17.5% in Power County.

### **Cancer Screening**

<u>Mammogram</u> – 2014, 2016, 2018, 2020

Statewide, 69.1% of women aged 50–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (72.1% versus 36.7%). Mammography rates differed significantly by county, with a range in screening of 45.9% in Benewah County to 77.0% in Nez Perce County. In 2020, Idaho ranked 48<sup>th</sup> among states and the District of Columbia for mammography screening rates among women aged 50–74 and also 48<sup>th</sup> among ages 40+.

### Pap Test - 2018, 2020

Statewide, 71.2% of women with an intact cervix and aged 21–65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.1% versus 52.6% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.7% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49<sup>th</sup> among states and the District of Columbia for Pap screening rate.

### Colorectal Cancer Screening - 2018, 2020

Statewide, 67.9% of adults aged 50–75 reported being current for colorectal cancer screening.\*\* Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked 47<sup>th</sup> among states and the District of Columbia in the percentage of adults aged 50–75 and older who reported being up-to-date for colorectal cancer screening.

<sup>\*\*</sup> Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

### **Tobacco Use**

### Current Tobacco Use - 2016-2021

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.3% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 29.9% of persons aged 18-29, and 11.1% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (22.4%) than among Native Americans (40.0%). Tobacco use differed significantly by county, with a range of 5.4% in Madison County to 41.6% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

### **Other Cancer-Related**

### Healthy Weight by Body Mass Index - 2015-2021

Statewide, 32.1% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 32.5% of white non-Hispanics, compared to 28.2% of Hispanics and 24.6% of Native Americans, being in the healthy weight range. Males (25.5%) were significantly less likely to be in the healthy weight range than females (38.6%). BMI differed significantly by age of respondent, with 43.3% of persons aged 18–29, and 26.0% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 19.8% in Power County to 47.4% in Blaine County of adults being in the healthy weight range.

### Any Physical Activity - 2015-2021

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 78.7% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.3% of persons aged 18–29, and 72.3% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 64.3% in Clark County to 84.6% in Teton County.

Physical Activity Guidelines – 2011, 2013, 2015, 2017, 2019 Statewide, 21.9% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.3% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6% in Franklin County to 30.6% in Blaine County.

### Home Radon Testing - 2016, 2018, 2020

Statewide, 23.0% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.4% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.5% in Cassia County to 54.4% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006l and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.





# FRANKLIN COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016–2020 Cancer Mortality 2017–2021 BRFSS 2011–2021

### **RISK FACTORS AND INTERVENTIONS**

### **CANCER**

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/jama.2016.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

### Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

### **Smoking:**

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

### Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <a href="https://www.dietaryguidelines.gov">https://www.dietaryguidelines.gov</a>

### Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute
Cancer Information Services
1-800-4CANCER
<a href="https://www.cancer.gov/contact">https://www.cancer.gov/contact</a>

American Cancer Society <a href="https://www.cancer.org">https://www.cancer.org</a>

### **CANCER INCIDENCE 2016–2020**

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016–2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 300 cases of invasive cancer were diagnosed among Franklin County residents (Table 1).

**Table 1:** Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Franklin County and the State of Idaho. 2016–2020

Cancer Incidence 2016–2020	Franklin County	State of Idaho
All Sites/Types	300	45,610
Female Breast	48	6,687
Prostate	43	6,417
Lung & Bronchus	8	4,887
Colorectal	34	3,451

Table 3 (Cancer Incidence 2016–2020, Comparison between Franklin County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Franklin County. The table also shows the number of observed cases, person-

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Franklin County was 436.8 cases per 100,000 person-years per year during 2016–2020. Comparing this crude rate with the crude rate for the remainder of Idaho (520.6) gives an estimate of the relative burden of disease in Franklin County.

The age- and sex-adjusted incidence rate of invasive cancer in Franklin County, all sites combined, was 478.5 cases per 100,000 persons per year during 2016–2020. There were fewer cases of cancer in Franklin County (300) than expected (326.4) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

### **CANCER MORTALITY 2017–2021**

During 2017–2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 91 Franklin County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

**Table 2:** Overall and Cancer Mortality in Franklin County and the State of Idaho, 2017–2021

Mortality 2017–2021	Franklin County	State of Idaho
All Deaths	584	77,431
Cancer Deaths	91	15,121
% of All Deaths	15.6%	19.5%
Lung & Bronchus	8	2,961
Colorectal	14	1,319
Pancreas	7	1,190
Female Breast	10	1,086
Prostate	5	949

Table 4 (Cancer Mortality 2017–2021, Comparison between Franklin County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Franklin County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Franklin County, all sites combined, was 140.0 deaths per 100,000 persons per year during 2017–2021, compared with 168.5 for the remainder of the state. There were fewer cancer deaths in Franklin County (91) than expected (109.5) based upon rates in the remainder of the state, but the difference was not statistically significant.

**Statistical Note:** Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

### TABLE 3: CANCER INCIDENCE 2016–2020 COMPARISON BETWEEN FRANKLIN COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Frai	nklin Count	у			Ren	nainder of Ida	aho
Cancer Site/Type	Cov	Observed	Person	Crude	A.A.I.	Expected	D. Volue (4)	Observed	Person	Crude
Site/Type All Sites Combined	Sex	Cases	Years	Rate (1)	Rate (1,2) 478.5	Cases (3)	P-Value (4)	Cases	Years	Rate (1) 520.6
All Sites Combined	Total Male	300 159	68,677 35,105	436.8 452.9	476.5	326.4 178.8	0.149 0.146	45,310 24,130	8,703,151 4,361,805	553.2
All Sites Combined	Female	141	33.572	420.0	460.7	149.3	0.527	21,180	4,341,346	487.9
Bladder	Total	21	68,677	30.6	33.2	15.7	0.233	2,163	8,703,151	24.9
Bladder	Male	19	35,105	54.1	57.8	13.1	0.144	1,732	4,361,805	39.7
Bladder	Female	2	33,572	6.0	6.5	3.0	0.827	431	4,341,346	9.9
Brain - malignant	Total	10	68,677	14.6	15.6	4.5	0.036 >>	615	8,703,151	7.1
Brain - malignant Brain - malignant	Male Female	6 4	35,105 33,572	17.1 11.9	18.3 12.7	2.8 1.8	0.125 0.214	369 246	4,361,805 4.341.346	8.5 5.7
Brain - manghant Brain and other CNS - non-malignant	Total	7	68,677	10.2	11.0	10.4	0.214	1,417	8,703,151	16.3
Brain and other CNS - non-malignant	Male	3	35,105	8.5	9.1	3.6	1.000	477	4,361,805	10.9
Brain and other CNS - non-malignant	Female	4	33,572	11.9	12.9	6.7	0.402	940	4,341,346	21.7
Breast	Total	50	68,677	72.8	80.0	48.1	0.822	6,696	8,703,151	76.9
Breast	Male	2	35,105	5.7	6.1	0.4	0.138	57	4,361,805	1.3
Breast	Female	48	33,572	143.0	157.7	46.6	0.871	6,639	4,341,346	152.9
Breast - in situ	Total	2	68,677	2.9	3.2	8.8	0.015 <b>&lt;&lt;</b> 1.000	1,237	8,703,151	14.2
Breast - in situ Breast - in situ	Male Female	- 2	35,105 33,572	6.0	6.6	0.0 8.6	0.017 <<	5 1,232	4,361,805 4,341,346	0.1 28.4
Cervix	Female	1	33,572	3.0	3.2	2.2	0.714	303	4,341,346	7.0
Colorectal	Total	34	68,677	49.5	53.7	24.8	0.093	3,417	8,703,151	39.3
Colorectal	Male	21	35,105	59.8	64.4	14.1	0.099	1,882	4,361,805	43.1
Colorectal	Female	13	33,572	38.7	42.1	10.9	0.604	1,535	4,341,346	35.4
Corpus Uteri	Female	8	33,572	23.8	26.5	9.2	0.864	1,322	4,341,346	30.5
Esophagus	Total	-	68,677	-	-	3.6	0.052	506	8,703,151	5.8
Esophagus	Male	-	35,105	-	-	3.2	0.085	424	4,361,805	9.7
Esophagus Hodgkin Lymphoma	Female Total	- 1	33,572 68,677	- 1.5	1.5	0.6 1.6	1.000 1.000	82 209	4,341,346 8,703,151	1.9 2.4
Hodgkin Lymphoma	Male	_ '	35,105	1.5	1.5	0.9	0.825	118	4,361,805	2.4
Hodgkin Lymphoma	Female	1	33,572	3.0	3.1	0.7	0.974	91	4,341,346	2.1
Kidney and Renal Pelvis	Total	11	68,677	16.0	17.6	13.0	0.710	1,804	8,703,151	20.7
Kidney and Renal Pelvis	Male	6	35,105	17.1	18.6	8.7	0.470	1,176	4,361,805	27.0
Kidney and Renal Pelvis	Female	5	33,572	14.9	16.4	4.4	0.906	628	4,341,346	14.5
Larynx	Total	-	68,677	-	-	1.5	0.428	215	8,703,151	2.5
Larynx	Male Female	-	35,105 33,572	-	-	1.2 0.4	0.604 1.000	160 55	4,361,805 4,341,346	3.7 1.3
Larynx Leukemia	Total	- 16	68,677	23.3	24.9	11.9	0.303	1,615	8,703,151	18.6
Leukemia	Male	13	35,105	37.0	39.0	7.5	0.082	976	4,361,805	22.4
Leukemia	Female	3	33,572	8.9	9.6	4.6	0.654	639	4,341,346	14.7
Liver and Bile Duct	Total	3	68,677	4.4	4.8	5.9	0.324	826	8,703,151	9.5
Liver and Bile Duct	Male		35,105			4.3	0.027 <<	590	4,361,805	13.5
Liver and Bile Duct	Female	3	33,572	8.9	9.9	1.6	0.459	236	4,341,346	5.4
Lung and Bronchus	Total	8	68,677 35.105	11.6	12.8	35.1	0.000 <<	4,879	8,703,151	56.1
Lung and Bronchus Lung and Bronchus	Male Female	4 4	33,572	11.4 11.9	12.3 13.2	18.2 16.9	0.000 << 0.000 <<	2,448 2,431	4,361,805 4,341,346	56.1 56.0
Melanoma of the Skin	Total	23	68,677	33.5	36.6	21.1	0.735	2,431	8.703.151	33.5
Melanoma of the Skin	Male	17	35,105	48.4	52.3	13.0	0.334	1,748	4,361,805	40.1
Melanoma of the Skin	Female	6	33,572	17.9	19.5	8.3	0.559	1,171	4,341,346	27.0
Myeloma	Total	4	68,677	5.8	6.4	5.1	0.855	704	8,703,151	8.1
Myeloma	Male	3	35,105	8.5	9.2	3.3	1.000	438	4,361,805	10.0
Myeloma	Female		33,572	3.0	3.3	1.8	0.898	266	4,341,346	6.1
Non-Hodgkin Lymphoma Non-Hodgkin Lymphoma	Total Male	9 4	68,677 35,105	13.1 11.4	14.2 12.3	14.0 8.4	0.217 0.159	1,931 1,125	8,703,151 4,361,805	22.2 25.8
Non-Hodgkin Lymphoma	Female	5	33,572	14.9	16.4	5.7	0.159	806	4,361,605	25.6 18.6
Oral Cavity and Pharynx	Total	3	68.677	4.4	4.8	9.2	0.037 <<	1,292	8,703,151	14.8
Oral Cavity and Pharynx	Male	2	35,105	5.7	6.3	6.8	0.067	934	4,361,805	21.4
Oral Cavity and Pharynx	Female	1	33,572	3.0	3.3	2.5	0.575	358	4,341,346	8.2
Ovary	Female	6	33,572	17.9	19.6	3.7	0.346	527	4,341,346	12.1
Pancreas	Total	8	68,677	11.6	12.7	10.3	0.608	1,415	8,703,151	16.3
Pancreas Pancreas	Male Female	3 5	35,105	8.5	9.2	5.8	0.332	781 634	4,361,805	17.9
Pancreas Prostate	Male	43	33,572 35,105	14.9 122.5	16.3 136.4	4.5 46.1	0.930 0.723	6,374	4,341,346 4,361,805	14.6 146.1
Stomach	Total	3	68,677	4.4	4.7	3.4	1.000	464	8,703,151	5.3
Stomach	Male	1	35,105	2.8	3.1	2.3	0.655	308	4,361,805	7.1
Stomach	Female	2	33,572	6.0	6.4	1.1	0.615	156	4,341,346	3.6
Testis	Male	-	35,105	-	-	1.9	0.296	265	4,361,805	6.1
Thyroid	Total	13	68,677	18.9	20.7	8.7	0.211	1,207	8,703,151	13.9
Thyroid	Male	3	35,105	8.5	9.4	2.6	0.955	352	4,361,805	8.1
Thyroid	Female	10	33,572	29.8	32.1	6.1	0.186	855	4,341,346	19.7
Pediatric Age 0 to 19	Total	8	24,005	33.3	33.6	4.0	0.107	413	2,436,518	17.0
Pediatric Age 0 to 19	Male	6	12,680	47.3	47.7	2.2	0.049 >>	217	1,243,830	17.4
Pediatric Age 0 to 19	Female	2	11,325	17.7	17.8	1.8	1.000	196	1,192,688	16.4

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

<sup>2.</sup> Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

<sup>&</sup>quot;<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

### **TABLE 4: CANCER MORTALITY 2017–2021** COMPARISON BETWEEN FRANKLIN COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Fra	nklin Count	у			Re	mainder of Idah	10
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	584	69,998	834.3	871.0	577.7	0.805	76,846	8,918,717	861.6
All Causes of Death	Male	310	35,844	864.9	892.3	316.2	0.753	40,746	4,476,024	910.3
All Causes of Death	Female	274	34,154	802.2	842.6	264.2	0.563	36,100	4,442,693	812.6
All Malignant Cancers	Total	91	69,998	130.0	140.0	109.5	0.079	15,030	8,918,717	168.5
All Malignant Cancers	Male	50	35,844	139.5	147.3	61.6	0.150	8,126	4,476,024	181.5
All Malignant Cancers	Female	41	34,154	120.0	130.7	48.7	0.298	6,904	4,442,693	155.4
Bladder	Total	1	69,998	1.4	1.5	3.7	0.238	488	8,918,717	5.5
Bladder	Male	1	35,844	2.8	2.8	3.0	0.399	377	4,476,024	8.4
Bladder	Female	-	34,154	-	-	0.8	0.898	111	4,442,693	2.5
Brain and Other Nervous System	Total	6	69,998	8.6	9.3	3.6	0.311	498	8,918,717	5.6
Brain and Other Nervous System	Male	4	35,844	11.2	12.0	2.2	0.358	294	4,476,024	6.6
Brain and Other Nervous System	Female	2 10	34,154	5.9	6.4 15.4	1.4	0.845	204	4,442,693	4.6
Breast	Total	10	69,998	14.3	15.4	8.0	0.561 1.000	1,092	8,918,717	12.2 0.4
Breast Breast	Male Female	10	35,844 34,154	29.3	- 31.8	0.1 7.6	0.477	16 1,076	4,476,024 4,442,693	24.2
Cervix	Female	- 10	34,154	29.3	31.0	0.6	1.000	83	4,442,693	1.9
Colorectal	Total	14	69,998	20.0	21.4	9.6	0.211	1,305	8,918,717	14.6
Colorectal	Male	10	35,844	27.9	29.6	5.3	0.093	709	4,476,024	15.8
Colorectal	Female	4	34,154	11.7	12.6	4.3	1.000	596	4,442,693	13.4
Corpus Uteri	Female	- '	34,154	-	-	1.2	0.601	173	4,442,693	3.9
Esophagus	Total	-	69,998	-	-	3.4	0.065	477	8,918,717	5.3
Esophagus	Male	-	35,844	-	-	3.0	0.102	401	4,476,024	9.0
Esophagus	Female	-	34,154	-	-	0.5	1.000	76	4,442,693	1.7
Hodgkin Lymphoma	Total	-	69,998	-	-	0.2	1.000	29	8,918,717	0.3
Hodgkin Lymphoma	Male	-	35,844	-	-	0.1	1.000	14	4,476,024	0.3
Hodgkin Lymphoma	Female	-	34,154	-	-	0.1	1.000	15	4,442,693	0.3
Kidney	Total	2	69,998	2.9	3.1	2.8	0.945	383	8,918,717	4.3
Kidney	Male Female	1 1	35,844	2.8 2.9	3.0 3.2	1.8 1.0	0.922 1.000	241	4,476,024 4,442,693	5.4 3.2
Kidney Larynx	Total	- '	34,154 69,998	2.9	3.2	0.5	1.000	142 71	4,442,693 8.918.717	0.8
Larynx	Male	-	35,844	_	_	0.4	1.000	58	4,476,024	1.3
Larynx	Female	_	34,154	_	_	0.1	1.000	13	4,442,693	0.3
Leukemia	Total	5	69,998	7.1	7.5	4.9	1.000	655	8,918,717	7.3
Leukemia	Male	2	35,844	5.6	5.8	3.0	0.861	384	4,476,024	8.6
Leukemia	Female	3	34,154	8.8	9.4	2.0	0.622	271	4,442,693	6.1
Liver and Bile Duct	Total	2	69,998	2.9	3.2	4.3	0.401	601	8,918,717	6.7
Liver and Bile Duct	Male	-	35,844	-	-	3.0	0.101	408	4,476,024	9.1
Liver and Bile Duct	Female	2	34,154	5.9	6.5	1.3	0.778	193	4,442,693	4.3
Lung and Bronchus	Total	8	69,998	11.4	12.5	21.3	0.002 <<	2,953	8,918,717	33.1
Lung and Bronchus	Male	6	35,844	16.7	18.0	11.5	0.119	1,550	4,476,024	34.6
Lung and Bronchus	Female	2	34,154	5.9	6.4	9.8	0.007 <<	1,403	4,442,693	31.6
Melanoma of the Skin Melanoma of the Skin	Total Male	3	69,998 35,844	4.3 8.4	4.6 8.9	2.1	0.689 0.347	286	8,918,717 4,476,024	3.2 4.2
Melanoma of the Skin	riviale Female	3	35,844 34,154	0.4	0.9	1.4 0.7	1.000	189 97	4,476,024 4.442.693	2.2
Myeloma	Total	3	69,998	4.3	4.6	2.4	0.857	328	8,918,717	3.7
Myeloma	Male	2	35,844	5.6	5.9	1.5	0.872	194	4,476,024	4.3
Myeloma	Female	1	34,154	2.9	3.2	0.9	1.000	134	4,442,693	3.0
Non-Hodgkin Lymphoma	Total	3	69,998	4.3	4.6	4.2	0.804	566	8,918,717	6.3
Non-Hodgkin Lymphoma	Male	1	35,844	2.8	2.9	2.3	0.641	306	4,476,024	6.8
Non-Hodgkin Lýmphoma	Female	2	34,154	5.9	6.4	1.8	1.000	260	4,442,693	5.9
Oral Cavity and Pharynx	Total	-	69,998	-	-	1.9	0.298	266	8,918,717	3.0
Oral Cavity and Pharynx	Male	-	35,844	-	-	1.4	0.507	187	4,476,024	4.2
Oral Cavity and Pharynx	Female	-	34,154	-	-	0.5	1.000	79	4,442,693	1.8
Ovary	Female	2	34,154	5.9	6.5	2.4	1.000	348	4,442,693	7.8
Pancreas	Total	7	69,998	10.0	10.9	8.5	0.774	1,183	8,918,717	13.3
Pancreas	Male	4	35,844	11.2	12.0	4.7	0.976	638	4,476,024	14.3
Pancreas Prostate	Female Male	3 5	34,154 35,844	8.8 13.9	9.7 14.1	3.8 7.5	0.944 0.488	545 944	4,442,693 4,476,024	12.3 21.1
Stomach	Total	3	69,998	4.3	4.6	1.4	0.466	195	8,918,717	2.2
Stomach	Male	3 1	35,844	2.8	2.9	0.9	1.000	120	6,916,717 4,476,024	2.2
Stomach	Female	2	34,154	5.9	6.3	0.9	0.205	75	4,442,693	1.7
			ne number of cases r				0.200	13	<b>₹,</b> ₹₹,∪∂∂	1.7

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

<sup>2.</sup> Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

### Cancer Screening and Risk Factor Prevalence Estimates, 2011–2021

	State of								Franklin
Measure	Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	County
Access to Care									
Have Health Insurance, Age <65 (2015–2021)	83.1%	82.8%	85.1%	77.2%	85.8%	78.9%	85.4%	85.4%	83.4%
Not See Doctor Due to Cost in Past Year (2015–2021)	12.6%	11.4%	11.8%	14.5%	12.4%	12.3%	11.8%	12.9%	7.4%
Cancer Screening									
Mammogram Past 2 Years, Age 50–74 (2014, 2016, 2018, 2020)	69.1%	67.0%	73.8%	68.2%	73.2%	64.8%	64.5%	67.1%	68.3%
Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020)	71.2%	73.6%	73.6%	70.8%	72.9%	69.1%	69.5%	65.9%	
Colorectal Cancer Screening, Age 50–75 (2018, 2020)	67.9%	66.9%	73.6%	71.4%	70.6%	61.7%	61.5%	64.7%	
Tobacco Use									
Current Tobacco User (2016–2021)	22.3%	26.7%	23.1%	23.6%	21.8%	21.4%	22.7%	16.9%	12.0%
Other Cancer-Related									
Healthy Weight by Body Mass Index, Age 20+ (2015–2021)	32.1%	32.8%	31.7%	27.9%	36.1%	29.8%	27.9%	31.9%	30.8%
Any Physical Activity Besides Job Past 30 Days (2015-2021)	78.7%	79.2%	78.1%	74.5%	83.2%	73.4%	76.3%	79.7%	71.7%
Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019)	21.9%	22.8%	19.4%	20.0%	25.2%	19.5%	20.4%	20.2%	9.7%
Home Ever Tested for Radon (2016, 2018, 2020)	23.0%	30.9%	18.2%	16.9%	25.1%	19.9%	23.0%	21.8%	10.8%

### **Access to Care**

### Have Health Insurance - 2015-2021

Statewide, 83.1% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 86.0% of white non-Hispanics, compared to 64.8% of Hispanics and 83.3% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3%) than English-speaking respondents (84.2%). Health care coverage differed significantly by age of respondent, with 79.8% of persons aged 18–29, and 87.8% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 62.1% in Adams County to 91.6% in Oneida County having health insurance.

### Not See Doctor Due to Cost in Past Year – 2015–2021

Statewide, 12.6% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (11.5% of white non-Hispanics, 19.2% of Hispanics, and 21.0% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9% for less than \$15,000, 6.1% for greater than \$50,000). Inability to see a doctor due to cost differed significantly by county, with a range of 7.4% in Franklin County to 17.5% in Power County.

### **Cancer Screening**

Mammogram - 2014, 2016, 2018, 2020

Statewide, 69.1% of women aged 50–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (72.1% versus 36.7%). Mammography rates differed significantly by county, with a range in screening of 45.9% in Benewah County to 77.0% in Nez Perce County. In 2020, Idaho ranked 48<sup>th</sup> among states and the District of Columbia for mammography screening rates among women aged 50–74 and also 48<sup>th</sup> among ages 40+.

### Pap Test - 2018, 2020

Statewide, 71.2% of women with an intact cervix and aged 21–65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.1% versus 52.6% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.7% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49<sup>th</sup> among states and the District of Columbia for Pap screening rate.

### Colorectal Cancer Screening - 2018, 2020

Statewide, 67.9% of adults aged 50–75 reported being current for colorectal cancer screening.\*\* Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked 47<sup>th</sup> among states and the District of Columbia in the percentage of adults aged 50–75 and older who reported being up-to-date for colorectal cancer screening.

<sup>\*\*</sup> Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

### **Tobacco Use**

### Current Tobacco Use - 2016-2021

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.3% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 29.9% of persons aged 18-29, and 11.1% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (22.4%) than among Native Americans (40.0%). Tobacco use differed significantly by county, with a range of 5.4% in Madison County to 41.6% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

### **Other Cancer-Related**

### Healthy Weight by Body Mass Index - 2015-2021

Statewide, 32.1% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 32.5% of white non-Hispanics, compared to 28.2% of Hispanics and 24.6% of Native Americans, being in the healthy weight range. Males (25.5%) were significantly less likely to be in the healthy weight range than females (38.6%). BMI differed significantly by age of respondent, with 43.3% of persons aged 18–29, and 26.0% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 19.8% in Power County to 47.4% in Blaine County of adults being in the healthy weight range.

### Any Physical Activity - 2015-2021

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 78.7% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.3% of persons aged 18–29, and 72.3% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 64.3% in Clark County to 84.6% in Teton County.

Physical Activity Guidelines – 2011, 2013, 2015, 2017, 2019 Statewide, 21.9% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.3% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6% in Franklin County to 30.6% in Blaine County.

### Home Radon Testing - 2016, 2018, 2020

Statewide, 23.0% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.4% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.5% in Cassia County to 54.4% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006l and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.





# FREMONT COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016–2020 Cancer Mortality 2017–2021 BRFSS 2011–2021

### **RISK FACTORS AND INTERVENTIONS**

### CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/jama.2016.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

### Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

### Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

### Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <a href="https://www.dietaryguidelines.gov">https://www.dietaryguidelines.gov</a>

### Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute
Cancer Information Services
1-800-4CANCER
<a href="https://www.cancer.gov/contact">https://www.cancer.gov/contact</a>

American Cancer Society <a href="https://www.cancer.org">https://www.cancer.org</a>

### **CANCER INCIDENCE 2016–2020**

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016–2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 336 cases of invasive cancer were diagnosed among Fremont County residents (Table 1).

**Table 1:** Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Fremont County and the State of Idaho. 2016–2020

Cancer Incidence 2016–2020	Fremont County	State of Idaho
All Sites/Types	336	45,610
Female Breast	43	6,687
Prostate	60	6,417
Lung & Bronchus	31	4,887
Colorectal	28	3,451

Table 3 (Cancer Incidence 2016–2020, Comparison between Fremont County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Fremont County. The table also shows the number of observed cases, person-

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Fremont County was 512.5 cases per 100,000 person-years per year during 2016–2020. Comparing this crude rate with the crude rate for the remainder of Idaho (520.0) gives an estimate of the relative burden of disease in Fremont County.

The age- and sex-adjusted incidence rate of invasive cancer in Fremont County, all sites combined, was 481.6 cases per 100,000 persons per year during 2016–2020. There were fewer cases of cancer in Fremont County (336) than expected (362.8) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

### **CANCER MORTALITY 2017–2021**

During 2017–2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 102 Fremont County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

**Table 2:** Overall and Cancer Mortality in Fremont County and the State of Idaho, 2017–2021

Mortality 2017–2021	Fremont County	State of Idaho
All Deaths	610	77,431
Cancer Deaths	102	15,121
% of All Deaths	16.7%	19.5%
Lung & Bronchus	19	2,961
Colorectal	12	1,319
Pancreas	14	1,190
Female Breast	7	1,086
Prostate	8	949

Table 4 (Cancer Mortality 2017–2021, Comparison between Fremont County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Fremont County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Fremont County, all sites combined, was 144.1 deaths per 100,000 persons per year during 2017–2021, compared with 168.3 for the remainder of the state. There were fewer cancer deaths in Fremont County (102) than expected (119.2) based upon rates in the remainder of the state, but the difference was not statistically significant.

**Statistical Note:** Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

## TABLE 3: CANCER INCIDENCE 2016–2020 COMPARISON BETWEEN FREMONT COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Frer	nont Count	У			Ren	nainder of Ida	aho
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)
All Sites Combined	Total	336	65,557	512.5	481.6	362.8	0.165	45,274	8,706,271	520.0
All Sites Combined All Sites Combined	Male Female	179 157	34,244 31,313	522.7 501.4	475.4 484.4	208.1 157.9	0.044 <b>&lt;&lt;</b> 0.984	24,110 21.164	4,362,666 4,343,605	552.6 487.2
Bladder	Total	15	65,557	22.9	21.2	17.6	0.633	2,169	8,706,271	24.9
Bladder	Male	12	34,244	35.0	31.2	15.4	0.479	1,739	4,362,666	39.9
Bladder	Female	3	31,313	9.6	9.2	3.2	1.000	430	4,343,605	9.9
Brain - malignant Brain - malignant	Total Male	3 1	65,557 34,244	4.6 2.9	4.4 2.7	4.9 3.1	0.562 0.363	622 374	8,706,271 4,362,666	7.1 8.6
Brain - malignant	Female	2	31,313	6.4	6.2	1.8	1.000	248	4,343,605	5.7
Brain and other CNS - non-malignant	Total	11	65,557	16.8	16.0	11.2	1.000	1,413	8,706,271	16.2
Brain and other CNS - non-malignant	Male	2	34,244	5.8	5.5	4.0	0.473	478	4,362,666	11.0
Brain and other CNS - non-malignant Breast	Female Total	9 43	31,313 65,557	28.7 65.6	28.0 62.1	6.9 53.3	0.523 0.171	935 6,703	4,343,605 8,706,271	21.5 77.0
Breast	Male	-	34,244	-	- 02.1	0.5	1.000	59	4,362,666	1.4
Breast	Female	43	31,313	137.3	132.3	49.7	0.380	6,644	4,343,605	153.0
Breast - in situ	Total	6	65,557	9.2	8.7	9.8	0.287	1,233	8,706,271	14.2
Breast - in situ	Male	- 6	34,244	- 10.0	-	0.0	1.000	5	4,362,666	0.1
Breast - in situ Cervix	Female Female	-	31,313 31,313	19.2	18.4	9.2 2.2	0.373 0.231	1,228 304	4,343,605 4,343,605	28.3 7.0
Colorectal	Total	28	65,557	42.7	40.2	27.4	0.959	3,423	8,706,271	39.3
Colorectal	Male	13	34,244	38.0	34.5	16.3	0.499	1,890	4,362,666	43.3
Colorectal	Female	15	31,313	47.9	46.5	11.4	0.351	1,533	4,343,605	35.3
Corpus Uteri	Female Total	13	31,313 65,557	41.5	39.9	9.9 4.1	0.394 0.033 <b>&lt;&lt;</b>	1,317 506	4,343,605 8,706,271	30.3 5.8
Esophagus Esophagus	Male	-	34,244	_	-	3.7	0.050 <<	424	4,362,666	9.7
Esophagus	Female	-	31,313	_	-	0.6	1.000	82	4,343,605	1.9
Hodgkin Lymphoma	Total	1	65,557	1.5	1.5	1.6	1.000	209	8,706,271	2.4
Hodgkin Lymphoma	Male .	- ,	34,244	-	-	0.9	0.775	118	4,362,666	2.7
Hodgkin Lymphoma Kidney and Renal Pelvis	Female Total	1 11	31,313 65,557	3.2 16.8	3.2 15.8	0.7 14.4	0.971 0.451	91 1,804	4,343,605 8,706,271	2.1 20.7
Kidney and Renal Pelvis	Male	7	34,244	20.4	18.8	10.0	0.432	1,004	4,362,666	26.9
Kidney and Renal Pelvis	Female	4	31,313	12.8	12.3	4.7	0.982	629	4,343,605	14.5
Larynx	Total	3	65,557	4.6	4.2	1.7	0.496	212	8,706,271	2.4
Larynx	Male	3	34,244	8.8	7.8	1.4	0.321	157	4,362,666	3.6
Larynx Leukemia	Female Total	- 12	31,313 65,557	18.3	- 17.2	0.4 13.0	1.000 0.933	55 1,619	4,343,605 8,706,271	1.3 18.6
Leukemia	Male	7	34,244	20.4	18.7	8.4	0.787	982	4,362,666	22.5
Leukemia	Female	5	31,313	16.0	15.4	4.8	1.000	637	4,343,605	14.7
Liver and Bile Duct	Total	8	65,557	12.2	11.4	6.6	0.691	821	8,706,271	9.4
Liver and Bile Duct Liver and Bile Duct	Male Female	6 2	34,244 31,313	17.5 6.4	16.0 6.1	5.0 1.8	0.780 1.000	584 237	4,362,666 4,343,605	13.4 5.5
Lung and Bronchus	Total	31	65,557	47.3	43.7	39.6	0.191	4,856	8,706,271	55.8
Lung and Bronchus	Male	14	34,244	40.9	36.6	21.4	0.122	2,438	4,362,666	55.9
Lung and Bronchus	Female	17	31,313	54.3	51.4	18.4	0.864	2,418	4,343,605	55.7
Melanoma of the Skin	Total	20	65,557	30.5	29.0	23.2	0.597	2,922	8,706,271	33.6
Melanoma of the Skin Melanoma of the Skin	Male Female	14 6	34,244 31,313	40.9 19.2	37.3 18.8	15.0 8.6	0.922 0.492	1,751 1,171	4,362,666 4,343,605	40.1 27.0
Myeloma	Total	4	65,557	6.1	5.7	5.7	0.650	704	8.706.271	8.1
Myeloma	Male	2	34,244	5.8	5.2	3.8	0.522	439	4,362,666	10.1
Myeloma	Female	2	31,313	6.4	6.1	2.0	1.000	265	4,343,605	6.1
Non-Hodgkin Lymphoma Non-Hodgkin Lymphoma	Total Male	14 5	65,557 34,244	21.4 14.6	20.0 13.4	15.4 9.6	0.841 0.164	1,926 1,124	8,706,271 4,362,666	22.1 25.8
Non-Hodgkin Lymphoma	Female	9	34,244	28.7	27.7	6.0	0.164	802	4,362,605	18.5
Oral Cavity and Pharynx	Total	13	65,557	19.8	18.6	10.3	0.471	1,282	8,706,271	14.7
Oral Cavity and Pharynx	Male	12	34,244	35.0	32.0	7.9	0.214	924	4,362,666	21.2
Oral Cavity and Pharynx	Female	1	31,313	3.2	3.1	2.7	0.505	358	4,343,605	8.2
Ovary Pancreas	Female Total	3 10	31,313 65,557	9.6 15.3	9.3 14.2	3.9 11.4	0.889 0.821	530 1,413	4,343,605 8,706,271	12.2 16.2
Pancreas	Male	5	34,244	14.6	13.1	6.8	0.651	779	4,362,666	17.9
Pancreas	Female	5	31,313	16.0	15.4	4.8	1.000	634	4,343,605	14.6
Prostate	Male	60	34,244	175.2	159.7	54.7	0.511	6,357	4,362,666	145.7
Stomach Stomach	Total Male	1	65,557 34 244	1.5	1.4	3.7	0.226 0.135	466 300	8,706,271	5.4 7.1
Stomach	Female	- 1	34,244 31,313	3.2	3.1	2.7 1.1	1.000	309 157	4,362,666 4,343,605	7.1 3.6
Testis	Male	3	34,244	8.8	9.2	2.0	0.629	262	4,362,666	6.0
Thyroid	Total	9	65,557	13.7	13.6	9.2	1.000	1,211	8,706,271	13.9
Thyroid	Male	1	34,244	2.9	2.8	2.9	0.433	354	4,362,666	8.1
Thyroid	Female	8	31,313	25.5	25.7	6.1	0.551	857	4,343,605	19.7
Pediatric Age 0 to 19	Total	5	18,570	26.9	26.6	3.2	0.441	416	2,441,953	17.0
Pediatric Age 0 to 19	Male	4	9,666	41.4	41.1	1.7	0.189	219	1,246,844	17.6
Pediatric Age 0 to 19	Female		8,904	11.2	11.1	1.5	1.000	197	1,195,109	16.5

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

<sup>2.</sup> Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

<sup>&</sup>quot;<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

### **TABLE 4: CANCER MORTALITY 2017–2021** COMPARISON BETWEEN FREMONT COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Frei	mont Count	у			Re	mainder of Idah	10
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	610	66,217	921.2	874.7	600.4	0.706	76,820	8,922,498	861.0
All Causes of Death	Male	332	34,675	957.5	852.4	354.3	0.246	40,724	4,477,193	909.6
All Causes of Death	Female	278	31,542	881.4	893.7	252.6	0.120	36,096	4,445,305	812.0
All Malignant Cancers	Total	102	66,217	154.0	144.1	119.2	0.121	15,019	8,922,498	168.3
All Malignant Cancers	Male	49	34,675	141.3	125.5	70.9	0.008 <<	8,127	4,477,193	181.5
All Malignant Cancers	Female	53	31,542	168.0	163.6	50.2	0.731	6,892	4,445,305	155.0
Bladder	Total	4	66,217	6.0	5.7	3.8	1.000	485	8,922,498	5.4
Bladder	Male Female	3	34,675	8.7 3.2	7.5	3.4 0.8	1.000 1.000	375	4,477,193	8.4
Bladder Brain and Other Nervous System	Total	1 4	31,542 66,217	6.0	3.1 5.7	3.9	1.000	110 500	4,445,305 8,922,498	2.5 5.6
Brain and Other Nervous System	Male	2	34,675	5.8	5.3	2.5	1.000	296	4,477,193	6.6
Brain and Other Nervous System	Female	2	31,542	6.3	6.1	1.5	0.884	204	4,445,305	4.6
Breast	Total	7	66,217	10.6	10.0	8.6	0.744	1,095	8,922,498	12.3
Breast	Male	-	34,675	-	-	0.1	1.000	16	4,477,193	0.4
Breast	Female	7	31,542	22.2	21.7	7.8	0.959	1,079	4,445,305	24.3
Cervix	Female	2	31,542	6.3	6.3	0.6	0.228	81	4,445,305	1.8
Colorectal	Total	12	66,217	18.1	17.0	10.3	0.684	1,307	8,922,498	14.6
Colorectal	Male	8	34,675	23.1	20.6	6.2	0.556	711	4,477,193	15.9
Colorectal	Female	4	31,542	12.7	12.5	4.3	1.000	596	4,445,305	13.4
Corpus Uteri	Female Total	1	31,542 66,217	3.2 1.5	3.0 1.4	1.3 3.8	1.000 0.217	172 476	4,445,305	3.9 5.3
Esophagus	Male	1	34,675	2.9	2.6	3.6 3.5	0.217	400	8,922,498 4,477,193	5.3 8.9
Esophagus Esophagus	Female	_ '	31,542	2.9	2.0	0.6	1.000	76	4,445,305	1.7
Hodgkin Lymphoma	Total	_	66,217		_	0.2	1.000	29	8,922,498	0.3
Hodgkin Lymphoma	Male	_	34,675	_	_	0.1	1.000	14	4,477,193	0.3
Hodgkin Lymphoma	Female	-	31,542	-	-	0.1	1.000	15	4,445,305	0.3
Kidney	Total	3	66,217	4.5	4.2	3.0	1.000	382	8,922,498	4.3
Kidney	Male	2	34,675	5.8	5.2	2.1	1.000	240	4,477,193	5.4
Kidney	Female	1	31,542	3.2	3.1	1.0	1.000	142	4,445,305	3.2
Larynx	Total	1	66,217	1.5	1.4	0.6	0.857	70	8,922,498	0.8
Larynx	Male	1	34,675	2.9	2.5	0.5	0.792 1.000	57	4,477,193	1.3 0.3
Larynx Leukemia	Female Total	- 2	31,542 66,217	3.0	2.8	0.1 5.2	0.217	13 658	4,445,305 8,922,498	7.4
Leukemia	Male	1	34,675	2.9	2.6	3.4	0.302	385	4,477,193	8.6
Leukemia	Female	1	31,542	3.2	3.1	2.0	0.831	273	4,445,305	6.1
Liver and Bile Duct	Total	5	66,217	7.6	7.0	4.8	1.000	598	8,922,498	6.7
Liver and Bile Duct	Male	3	34,675	8.7	7.8	3.5	1.000	405	4,477,193	9.0
Liver and Bile Duct	Female	2	31,542	6.3	6.1	1.4	0.834	193	4,445,305	4.3
Lung and Bronchus	Total	19	66,217	28.7	26.6	23.5	0.410	2,942	8,922,498	33.0
Lung and Bronchus	Male	7	34,675	20.2	18.0	13.5	0.085	1,549	4,477,193	34.6
Lung and Bronchus	Female	12	31,542	38.0	36.6	10.3	0.672	1,393	4,445,305	31.3
Melanoma of the Skin Melanoma of the Skin	Total Male	2	66,217 34,675	3.0 2.9	2.8 2.6	2.3 1.6	1.000 1.000	287 191	8,922,498 4,477,193	3.2 4.3
Melanoma of the Skin	Female	1	31,542	3.2	2.6 3.1	0.7	1.000	96	4,445,305	2.2
Myeloma	Total	1	66,217	1.5	1.4	2.6	0.516	330	8,922,498	3.7
Myeloma	Male	_ '	34,675	-	-	1.7	0.354	196	4,477,193	4.4
Myeloma	Female	1	31,542	3.2	3.1	1.0	1.000	134	4,445,305	3.0
Non-Hodgkin Lymphoma	Total	6	66,217	9.1	8.4	4.5	0.589	563	8,922,498	6.3
Non-Hodgkin Lymphoma	Male	1	34,675	2.9	2.6	2.7	0.505	306	4,477,193	6.8
Non-Hodgkin Lymphoma	Female	5	31,542	15.9	15.6	1.9	0.081	257	4,445,305	5.8
Oral Cavity and Pharynx	Total	1	66,217	1.5	1.4	2.1	0.756	265	8,922,498	3.0
Oral Cavity and Phanynx	Male	1	34,675	2.9	2.6	1.6	1.000	186	4,477,193	4.2
Oral Cavity and Pharynx	Female Female	- 3	31,542 31,542	9.5	9.2	0.6 2.6	1.000 0.939	79 347	4,445,305 4,445,305	1.8 7.8
Ovary Pancreas	Total	14	66,217	21.1	19.7	9.4	0.939	1,176	8,922,498	13.2
Pancreas	Male	7	34,675	20.2	18.1	5.5	0.623	635	4,477,193	14.2
Pancreas	Female	7	31,542	22.2	21.4	4.0	0.219	541	4,445,305	12.2
Prostate	Male	8	34,675	23.1	20.0	8.4	1.000	941	4,477,193	21.0
Stomach	Total	-	66,217	-	-	1.6	0.422	198	8,922,498	2.2
Stomach	Male	-	34,675	-	-	1.1	0.698	121	4,477,193	2.7
Stomach	Female	-	31,542	-	-	0.5	1.000	77	4,445,305	1.7
			ne number of cases r		,					

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

<sup>2.</sup> Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

### Cancer Screening and Risk Factor Prevalence Estimates, 2011–2021

	State of								Fremont
Measure	Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	County
Access to Care									
Have Health Insurance, Age <65 (2015–2021)	83.1%	82.8%	85.1%	77.2%	85.8%	78.9%	85.4%	85.4%	78.4%
Not See Doctor Due to Cost in Past Year (2015–2021)	12.6%	11.4%	11.8%	14.5%	12.4%	12.3%	11.8%	12.9%	8.7%
Cancer Screening									
Mammogram Past 2 Years, Age 50–74 (2014, 2016, 2018, 2020)	69.1%	67.0%	73.8%	68.2%	73.2%	64.8%	64.5%	67.1%	49.8%
Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020)	71.2%	73.6%	73.6%	70.8%	72.9%	69.1%	69.5%	65.9%	
Colorectal Cancer Screening, Age 50–75 (2018, 2020)	67.9%	66.9%	73.6%	71.4%	70.6%	61.7%	61.5%	64.7%	
Tobacco Use									
Current Tobacco User (2016–2021)	22.3%	26.7%	23.1%	23.6%	21.8%	21.4%	22.7%	16.9%	17.1%
Other Cancer-Related									
Healthy Weight by Body Mass Index, Age 20+ (2015–2021)	32.1%	32.8%	31.7%	27.9%	36.1%	29.8%	27.9%	31.9%	25.1%
Any Physical Activity Besides Job Past 30 Days (2015-2021)	78.7%	79.2%	78.1%	74.5%	83.2%	73.4%	76.3%	79.7%	78.9%
Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019)	21.9%	22.8%	19.4%	20.0%	25.2%	19.5%	20.4%	20.2%	14.2%
Home Ever Tested for Radon (2016, 2018, 2020)	23.0%	30.9%	18.2%	16.9%	25.1%	19.9%	23.0%	21.8%	14.8%

### **Access to Care**

### Have Health Insurance - 2015-2021

Statewide, 83.1% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 86.0% of white non-Hispanics, compared to 64.8% of Hispanics and 83.3% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3%) than English-speaking respondents (84.2%). Health care coverage differed significantly by age of respondent, with 79.8% of persons aged 18–29, and 87.8% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 62.1% in Adams County to 91.6% in Oneida County having health insurance.

### Not See Doctor Due to Cost in Past Year - 2015-2021

Statewide, 12.6% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (11.5% of white non-Hispanics, 19.2% of Hispanics, and 21.0% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9% for less than \$15,000, 6.1% for greater than \$50,000). Inability to see a doctor due to cost differed significantly by county, with a range of 7.4% in Franklin County to 17.5% in Power County.

### **Cancer Screening**

Mammogram - 2014, 2016, 2018, 2020

Statewide, 69.1% of women aged 50–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (72.1% versus 36.7%). Mammography rates differed significantly by county, with a range in screening of 45.9% in Benewah County to 77.0% in Nez Perce County. In 2020, Idaho ranked 48<sup>th</sup> among states and the District of Columbia for mammography screening rates among women aged 50–74 and also 48<sup>th</sup> among ages 40+.

### Pap Test - 2018, 2020

Statewide, 71.2% of women with an intact cervix and aged 21–65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.1% versus 52.6% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.7% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49<sup>th</sup> among states and the District of Columbia for Pap screening rate.

### Colorectal Cancer Screening – 2018, 2020

Statewide, 67.9% of adults aged 50–75 reported being current for colorectal cancer screening.\*\* Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked 47<sup>th</sup> among states and the District of Columbia in the percentage of adults aged 50–75 and older who reported being up-to-date for colorectal cancer screening.

<sup>\*\*</sup> Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

### **Tobacco Use**

### Current Tobacco Use - 2016-2021

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.3% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 29.9% of persons aged 18-29, and 11.1% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (22.4%) than among Native Americans (40.0%). Tobacco use differed significantly by county, with a range of 5.4% in Madison County to 41.6% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

### **Other Cancer-Related**

### Healthy Weight by Body Mass Index - 2015-2021

Statewide, 32.1% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 32.5% of white non-Hispanics, compared to 28.2% of Hispanics and 24.6% of Native Americans, being in the healthy weight range. Males (25.5%) were significantly less likely to be in the healthy weight range than females (38.6%). BMI differed significantly by age of respondent, with 43.3% of persons aged 18–29, and 26.0% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 19.8% in Power County to 47.4% in Blaine County of adults being in the healthy weight range.

### Any Physical Activity - 2015-2021

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 78.7% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.3% of persons aged 18–29, and 72.3% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 64.3% in Clark County to 84.6% in Teton County.

Physical Activity Guidelines – 2011, 2013, 2015, 2017, 2019 Statewide, 21.9% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.3% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6% in Franklin County to 30.6% in Blaine County.

### Home Radon Testing - 2016, 2018, 2020

Statewide, 23.0% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.4% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.5% in Cassia County to 54.4% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006l and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.





# GEM COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016–2020 Cancer Mortality 2017–2021 BRFSS 2011–2021

### **RISK FACTORS AND INTERVENTIONS**

### CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/jama.2016.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

### Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

### **Smoking:**

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

### Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <a href="https://www.dietaryguidelines.gov">https://www.dietaryguidelines.gov</a>

### Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute
Cancer Information Services
1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society <a href="https://www.cancer.org">https://www.cancer.org</a>

### **CANCER INCIDENCE 2016–2020**

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016–2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 640 cases of invasive cancer were diagnosed among Gem County residents (Table 1).

**Table 1:** Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Gem County and the State of Idaho, 2016–2020

Cancer Incidence 2016–2020	Gem County	State of Idaho
All Sites/Types	640	45,610
Female Breast	78	6,687
Prostate	97	6,417
Lung & Bronchus	70	4,887
Colorectal	63	3,451

Table 3 (Cancer Incidence 2016–2020, Comparison between Gem County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Gem County. The table also shows the number of observed cases, person-years, and

crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Gem County was 720.3 cases per 100,000 person-years per year during 2016–2020. Comparing this crude rate with the crude rate for the remainder of Idaho (517.9) gives an estimate of the relative burden of disease in Gem County.

The age- and sex-adjusted incidence rate of invasive cancer in Gem County, all sites combined, was 558.6 cases per 100,000 persons per year during 2016–2020. There were more cases of cancer in Gem County (640) than expected (593.3) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

### **CANCER MORTALITY 2017–2021**

During 2017–2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 206 Gem County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

**Table 2:** Overall and Cancer Mortality in Gem County and the State of Idaho, 2017–2021

Mortality 2017–2021	Gem County	State of Idaho
All Deaths	1,212	77,431
Cancer Deaths	206	15,121
% of All Deaths	17.0%	19.5%
Lung & Bronchus	48	2,961
Colorectal	20	1,319
Pancreas	16	1,190
Female Breast	13	1,086
Prostate	10	949

Table 4 (Cancer Mortality 2017–2021, Comparison between Gem County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Gem County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Gem County, all sites combined, was 167.7 deaths per 100,000 persons per year during 2017–2021, compared with 167.6 for the remainder of the state. There were more cancer deaths in Gem County (206) than expected (205.9) based upon rates in the remainder of the state, but the difference was not statistically significant.

**Statistical Note:** Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

**TABLE 3: CANCER INCIDENCE 2016–2020** 

		Gem County						Ren	nainder of Ida	aho
Cancer Site/Type	Sex	Observed Cases	Person Years	Crude Rate (1)	A.A.I. Rate (1,2)	Expected Cases (3)	P-Value (4)	Observed Cases	Person Years	Crude Rate (1)
All Sites Combined	Total	640	88,855	720.3	558.6	593.3	0.060	44,970	8,682,973	517.9
All Sites Combined	Male	359	44,532	806.2	596.8	330.7	0.130	23,930	4,352,378	549.8
All Sites Combined	Female	281	44,323	634.0	511.3	267.0	0.408	21,040	4,330,595	485.8
Bladder	Total	37	88,855	41.6	30.5	30.0	0.239	2,147	8,682,973	24.7
Bladder	Male	32	44,532	71.9	50.1	25.2	0.217	1,719	4,352,378	39.5
Bladder	Female	5	44,323	11.3	8.7	5.7	0.987	428	4,330,595	9.9
Brain - malignant	Total	8	88,855	9.0	7.5	7.6	0.969	617	8,682,973	7.1
Brain - malignant Brain - malignant	Male Female	5 3	44,532 44,323	11.2 6.8	9.3 5.7	4.6 3.0	0.968 1.000	370 247	4,352,378 4,330,595	8.5 5.7
Brain and other CNS - non-malignant	Total	18	88,855	20.3	16.4	17.8	1.000	1,406	8,682,973	16.2
Brain and other CNS - non-malignant	Male	6	44,532	13.5	10.8	6.0	1.000	474	4,352,378	10.9
Brain and other CNS - non-malignant	Female	12	44,323	27.1	22.2	11.6	0.988	932	4,330,595	21.5
Breast	Total	78	88,855	87.8	70.1	85.4	0.460	6,668	8,682,973	76.8
Breast	Male		44,532			0.8	0.861	59	4,352,378	1.4
Breast	Female	78	44,323	176.0	142.6	83.5	0.595	6,609	4,330,595	152.6
Breast - in situ	Total	11	88,855	12.4	10.0	15.5	0.307 1.000	1,228	8,682,973	14.1
Breast - in situ Breast - in situ	Male Female	- 11	44,532 44,323	- 24.8	20.2	0.1 15.4	0.324	5 1,223	4,352,378 4,330,595	0.1 28.2
Cervix	Female	5	44,323	11.3	10.7	3.2	0.324	299	4,330,595	6.9
Colorectal	Total	63	88,855	70.9	55.2	44.6	0.430	3,388	8,682,973	39.0
Colorectal	Male	33	44,532	74.1	56.0	25.3	0.161	1,870	4,352,378	43.0
Colorectal	Female	30	44,323	67.7	54.1	19.4	0.031 >>	1,518	4,330,595	35.1
Corpus Uteri	Female	17	44,323	38.4	30.8	16.7	1.000	1,313	4,330,595	30.3
Esophagus	Total	10	88,855	11.3	8.5	6.7	0.290	496	8,682,973	5.7
Esophagus	Male	7	44,532	15.7	11.4	5.9	0.746	417	4,352,378	9.6
Esophagus	Female	3	44,323	6.8	5.2	1.0	0.178	79	4,330,595	1.8
Hodgkin Lymphoma	Total	1	88,855	1.1	1.1	2.2	0.693	209	8,682,973	2.4
Hodgkin Lymphoma Hodgkin Lymphoma	Male Female	- 1	44,532 44,323	2.3	2.2	1.3 0.9	0.557 1.000	118 91	4,352,378 4,330,595	2.7 2.1
Kidney and Renal Pelvis	Total	34	88,855	38.3	30.0	23.2	0.043 >>	1,781	8,682,973	20.5
Kidney and Renal Pelvis	Male	22	44,532	49.4	37.8	15.5	0.139	1,160	4,352,378	26.7
Kidney and Renal Pelvis	Female	12	44,323	27.1	21.7	7.9	0.214	621	4,330,595	14.3
Larynx	Total	-	88,855	-	-	2.9	0.109	215	8,682,973	2.5
Larynx	Male	-	44,532	-	-	2.3	0.210	160	4,352,378	3.7
Larynx	Female		44,323			0.7	0.979	55	4,330,595	1.3
Leukemia	Total	17	88,855	19.1	14.8	21.3	0.419	1,614	8,682,973	18.6
Leukemia Leukemia	Male Female	9 8	44,532 44,323	20.2 18.0	15.2 14.4	13.4 8.1	0.286 1.000	980 634	4,352,378 4,330,595	22.5 14.6
Leukemia Liver and Bile Duct	Total	16	88,855	18.0	13.7	10.9	0.177	813	8,682,973	9.4
Liver and Bile Duct	Male	14	44,532	31.4	23.4	7.9	0.177	576	4,352,378	13.2
Liver and Bile Duct	Female	2	44,323	4.5	3.5	3.1	0.803	237	4,330,595	5.5
Lung and Bronchus	Total	70	88,855	78.8	57.8	67.2	0.764	4,817	8,682,973	55.5
Lung and Bronchus	Male	35	44,532	78.6	55.3	35.2	1.000	2,417	4,352,378	55.5
Lung and Bronchus	Female	35	44,323	79.0	60.1	32.3	0.678	2,400	4,330,595	55.4
Melanoma of the Skin	Total	44	88,855	49.5	39.7	37.0	0.288	2,898	8,682,973	33.4
Melanoma of the Skin	Male	24	44,532	53.9	40.7	23.6	0.982	1,741	4,352,378	40.0
Melanoma of the Skin Mveloma	Female Total	20 3	44,323 88,855	45.1 3.4	38.2 2.5	14.0 9.7	0.153 0.026 <b>&lt;&lt;</b>	1,157 705	4,330,595	26.7 8.1
Myeloma Myeloma	Male	3	44,532	3.4 6.7	2.5 4.8	9.7 6.3	0.026 << 0.253	438	8,682,973 4,352,378	10.1
Myeloma	Female		44,323	- 0.7		3.5	0.255	267	4,332,376	6.2
Non-Hodgkin Lymphoma	Total	21	88,855	23.6	18.4	25.3	0.460	1,919	8,682,973	22.1
Non-Hodgkin Lymphoma	Male	15	44,532	33.7	25.6	15.0	1.000	1,114	4,352,378	25.6
Non-Hodgkin Lýmphoma	Female	6	44,323	13.5	10.7	10.4	0.215	805	4,330,595	18.6
Oral Cavity and Pharynx	Total	17	88,855	19.1	14.8	16.9	1.000	1,278	8,682,973	14.7
Oral Cavity and Pharynx	Male	13	44,532	29.2	22.1	12.5	0.954	923	4,352,378	21.2
Oral Cavity and Pharynx	Female	7	44,323	9.0	7.2 12.9	4.6	1.000	355 526	4,330,595 4,330,595	8.2
Ovary Pancreas	Female Total	21	44,323 88,855	15.8 23.6	12.9	6.6 19.3	0.982 0.750	1,402	4,330,595 8,682,973	12.1 16.1
Pancreas	Male	12	44,532	26.9	17.0	11.0	0.750	772	4,352,378	17.7
Pancreas	Female	9	44,323	20.3	15.7	8.4	0.913	630	4,330,595	14.5
Prostate	Male	97	44,532	217.8	159.2	88.5	0.390	6,320	4,352,378	145.2
Stomach	Total	11	88,855	12.4	9.5	6.1	0.094	456	8,682,973	5.3
Stomach	Male	6	44,532	13.5	9.8	4.2	0.508	303	4,352,378	7.0
Stomach	Female	5	44,323	11.3	9.1	1.9	0.096	153	4,330,595	3.5
Testis	Male	1	44,532	2.2	2.6	2.4	0.639	264	4,352,378	6.1
Thyroid	Total	17	88,855	19.1	17.8	13.2	0.361	1,203	8,682,973	13.9
Thyroid	Male	7	44,532	15.7	13.8	4.0	0.232	348	4,352,378	8.0
Thyroid	Female	10	44,323	22.6	21.3	9.3	0.891	855	4,330,595	19.7
Pediatric Age 0 to 19	Total	2	22,230	9.0	9.0	3.8	0.535	419	2,438,293	17.2
Pediatric Age 0 to 19	Male	2	11,714	17.1	17.1	2.1	1.000	221	1,244,796	17.8
Pediatric Age 0 to 19	Female	-	10,516	-	-	1.7	0.352	198	1,193,497	16.6

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
 Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

<sup>&</sup>quot;<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

### **TABLE 4: CANCER MORTALITY 2017–2021** COMPARISON BETWEEN GEM COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			G	em County				Rer	mainder of Idah	0
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	1,212	91,642	1,322.5	999.3	1,039.0	0.000 >>	76,218	8,897,073	856.7
All Causes of Death	Male	647	46,053	1,404.9	1,015.6	576.4	0.004 >>	40,409	4,465,815	904.9
All Causes of Death	Female	565	45,589	1,239.3	976.7	467.5	0.000 >>	35,809	4,431,258	808.1
All Malignant Cancers All Malignant Cancers	Total Male	206 116	91,642 46,053	224.8 251.9	167.7 178.4	205.9 117.4	1.000 0.949	14,915 8,060	8,897,073 4,465,815	167.6 180.5
All Malignant Cancers All Malignant Cancers	Female	90	45,589	197.4	176.4	90.5	1.000	6,855	4,405,615	154.7
Bladder	Total	11	91,642	12.0	8.7	6.8	0.171	478	8,897,073	5.4
Bladder	Male	9	46,053	19.5	13.2	5.7	0.238	369	4,465,815	8.3
Bladder	Female	2	45,589	4.4	3.3	1.5	0.868	109	4,431,258	2.5
Brain and Other Nervous System	Total	7	91,642	7.6	6.1	6.4	0.925	497	8,897,073	5.6
Brain and Other Nervous System	Male	4	46,053	8.7	6.8	3.9	1.000	294	4,465,815	6.6
Brain and Other Nervous System Breast	Female	3 13	45,589 91,642	6.6 14.2	5.3 10.9	2.6 14.6	0.951 0.795	203 1,089	4,431,258	4.6 12.2
Breast	Total Male	- 13	46,053	14.2	10.9	0.2	1.000	1,069	8,897,073 4,465,815	0.4
Breast	Female	13	45,589	28.5	22.6	13.9	0.940	1,073	4,431,258	24.2
Cervix	Female	2	45,589	4.4	3.9	0.9	0.487	81	4,431,258	1.8
Colorectal	Total	20	91,642	21.8	16.6	17.6	0.630	1,299	8,897,073	14.6
Colorectal	Male	10	46,053	21.7	16.0	9.9	1.000	709	4,465,815	15.9
Colorectal	Female	10	45,589	21.9	17.2	7.7	0.501	590	4,431,258	13.3
Corpus Uteri Esophagus	Female	2 9	45,589 91,642	4.4 9.8	3.4 7.4	2.3 6.4	1.000 0.402	171	4,431,258 8,897,073	3.9 5.3
Esophagus Esophagus	Total Male	7	46,053	15.2	11.0	5.6	0.402	468 394	4,465,815	5.3 8.8
Esophagus	Female	2	45,589	4.4	3.4	1.0	0.509	74	4,403,613	1.7
Hodgkin Lymphoma	Total	-	91,642	-	-	0.4	1.000	29	8,897,073	0.3
Hodgkin Lymphoma	Male	-	46,053	-	-	0.2	1.000	14	4,465,815	0.3
Hodgkin Lymphoma	Female	-	45,589	-	-	0.2	1.000	15	4,431,258	0.3
Kidney	Total	1	91,642	1.1	0.8	5.4	0.060	384	8,897,073	4.3
Kidney	Male	1	46,053	2.2	1.5	3.5	0.274	241	4,465,815	5.4
Kidney	Female	-	45,589 91,642	-	-	1.9 1.0	0.293 0.751	143 71	4,431,258 8,897,073	3.2 0.8
Larynx Larynx	Total Male	_	46,053	-	_	0.8	0.751	58	4,465,815	1.3
Larynx	Female	_	45,589	_	_	0.2	1.000	13	4,431,258	0.3
Leukemia	Total	6	91,642	6.5	4.9	9.1	0.402	654	8,897,073	7.4
Leukemia	Male	5	46,053	10.9	7.7	5.6	1.000	381	4,465,815	8.5
Leukemia	Female	1	45,589	2.2	1.7	3.6	0.249	273	4,431,258	6.2
Liver and Bile Duct	Total	9	91,642	9.8	7.4	8.2	0.858	594	8,897,073	6.7
Liver and Bile Duct	Male Female	7 2	46,053	15.2	11.1	5.7	0.686	401	4,465,815	9.0
Liver and Bile Duct Lung and Bronchus	Total	48	45,589 91,642	4.4 52.4	3.4 38.4	2.6 40.9	1.000 0.302	193 2,913	4,431,258 8,897,073	4.4 32.7
Lung and Bronchus	Male	26	46,053	56.5	39.7	22.5	0.502	1,530	4,465,815	34.3
Lung and Bronchus	Female	22	45,589	48.3	36.9	18.6	0.492	1,383	4,431,258	31.2
Melanoma of the Skin	Total	4	91,642	4.4	3.3	3.8	1.000	285	8,897,073	3.2
Melanoma of the Skin	Male	1	46,053	2.2	1.6	2.7	0.487	191	4,465,815	4.3
Melanoma of the Skin	Female	3	45,589	6.6	5.3	1.2	0.242	94	4,431,258	2.1
Myeloma	Total	1	91,642 46,053	1.1	0.8	4.7	0.104	330	8,897,073	3.7
Myeloma Myeloma	Male Female	- 1	46,053 45,589	2.2	1.7	3.0 1.8	0.103 0.920	196 134	4,465,815 4,431,258	4.4 3.0
Non-Hodgkin Lymphoma	Total	9	91,642	9.8	7.2	7.8	0.920	560	8,897,073	6.3
Non-Hodgkin Lymphoma	Male	6	46,053	13.0	9.2	4.4	0.552	301	4,465,815	6.7
Non-Hodgkin Lymphoma	Female	3	45,589	6.6	5.1	3.5	1.000	259	4,431,258	5.8
Oral Cavity and Pharynx	Total	4	91,642	4.4	3.3	3.6	0.967	262	8,897,073	2.9
Oral Cavity and Pharynx	Male	3	46,053	6.5	4.7	2.6	0.975	184	4,465,815	4.1
Oral Cavity and Pharynx	Female	1	45,589	2.2	1.7	1.0	1.000	78	4,431,258	1.8
Ovary Pancreas	Female Total	4 16	45,589 91,642	8.8 17.5	6.8 12.9	4.6 16.3	1.000 1.000	346 1,174	4,431,258 8,897,073	7.8 13.2
Pancreas Pancreas	Male	9	46,053	17.5	13.9	9.2	1.000	633	4,465,815	14.2
Pancreas	Female	7	45,589	15.4	11.8	7.2	1.000	541	4,431,258	12.2
Prostate	Male	10	46,053	21.7	14.5	14.5	0.295	939	4,465,815	21.0
Stomach	Total	3	91,642	3.3	2.5	2.6	0.970	195	8,897,073	2.2
Stomach	Male	3	46,053	6.5	4.7	1.7	0.474	118	4,465,815	2.6
Stomach	Female	-	45,589		-	1.0	0.758	77	4,431,258	1.7
Nistan	1 Detec		ne number of cases p	100 000						

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

<sup>2.</sup> Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

### Cancer Screening and Risk Factor Prevalence Estimates, 2011–2021

	State of								Gem
Measure	Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	County
Access to Care									
Have Health Insurance, Age <65 (2015–2021)	83.1%	82.8%	85.1%	77.2%	85.8%	78.9%	85.4%	85.4%	82.6%
Not See Doctor Due to Cost in Past Year (2015–2021)	12.6%	11.4%	11.8%	14.5%	12.4%	12.3%	11.8%	12.9%	16.4%
Cancer Screening									
Mammogram Past 2 Years, Age 50–74 (2014, 2016, 2018, 2020)	69.1%	67.0%	73.8%	68.2%	73.2%	64.8%	64.5%	67.1%	61.0%
Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020)	71.2%	73.6%	73.6%	70.8%	72.9%	69.1%	69.5%	65.9%	
Colorectal Cancer Screening, Age 50–75 (2018, 2020)	67.9%	66.9%	73.6%	71.4%	70.6%	61.7%	61.5%	64.7%	73.1%
Tobacco Use									
Current Tobacco User (2016–2021)	22.3%	26.7%	23.1%	23.6%	21.8%	21.4%	22.7%	16.9%	26.4%
Other Cancer-Related									
Healthy Weight by Body Mass Index, Age 20+ (2015–2021)	32.1%	32.8%	31.7%	27.9%	36.1%	29.8%	27.9%	31.9%	27.2%
Any Physical Activity Besides Job Past 30 Days (2015-2021)	78.7%	79.2%	78.1%	74.5%	83.2%	73.4%	76.3%	79.7%	74.1%
Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019)	21.9%	22.8%	19.4%	20.0%	25.2%	19.5%	20.4%	20.2%	16.5%
Home Ever Tested for Radon (2016, 2018, 2020)	23.0%	30.9%	18.2%	16.9%	25.1%	19.9%	23.0%	21.8%	18.5%

### **Access to Care**

### Have Health Insurance - 2015-2021

Statewide, 83.1% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 86.0% of white non-Hispanics, compared to 64.8% of Hispanics and 83.3% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3%) than English-speaking respondents (84.2%). Health care coverage differed significantly by age of respondent, with 79.8% of persons aged 18–29, and 87.8% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 62.1% in Adams County to 91.6% in Oneida County having health insurance.

### Not See Doctor Due to Cost in Past Year – 2015–2021

Statewide, 12.6% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (11.5% of white non-Hispanics, 19.2% of Hispanics, and 21.0% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9% for less than \$15,000, 6.1% for greater than \$50,000). Inability to see a doctor due to cost differed significantly by county, with a range of 7.4% in Franklin County to 17.5% in Power County.

### **Cancer Screening**

Mammogram - 2014, 2016, 2018, 2020

Statewide, 69.1% of women aged 50–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (72.1% versus 36.7%). Mammography rates differed significantly by county, with a range in screening of 45.9% in Benewah County to 77.0% in Nez Perce County. In 2020, Idaho ranked 48th among states and the District of Columbia for mammography screening rates among women aged 50–74 and also 48th among ages 40+.

### Pap Test - 2018, 2020

Statewide, 71.2% of women with an intact cervix and aged 21–65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.1% versus 52.6% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.7% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49<sup>th</sup> among states and the District of Columbia for Pap screening rate.

### Colorectal Cancer Screening – 2018, 2020

Statewide, 67.9% of adults aged 50–75 reported being current for colorectal cancer screening.\*\* Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked 47<sup>th</sup> among states and the District of Columbia in the percentage of adults aged 50–75 and older who reported being up-to-date for colorectal cancer screening.

<sup>\*\*</sup> Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

### **Tobacco Use**

### Current Tobacco Use - 2016-2021

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.3% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 29.9% of persons aged 18-29, and 11.1% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (22.4%) than among Native Americans (40.0%). Tobacco use differed significantly by county, with a range of 5.4% in Madison County to 41.6% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

### **Other Cancer-Related**

### Healthy Weight by Body Mass Index - 2015-2021

Statewide, 32.1% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 32.5% of white non-Hispanics, compared to 28.2% of Hispanics and 24.6% of Native Americans, being in the healthy weight range. Males (25.5%) were significantly less likely to be in the healthy weight range than females (38.6%). BMI differed significantly by age of respondent, with 43.3% of persons aged 18–29, and 26.0% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 19.8% in Power County to 47.4% in Blaine County of adults being in the healthy weight range.

### Any Physical Activity - 2015-2021

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 78.7% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.3% of persons aged 18–29, and 72.3% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 64.3% in Clark County to 84.6% in Teton County.

Physical Activity Guidelines – 2011, 2013, 2015, 2017, 2019 Statewide, 21.9% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.3% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6% in Franklin County to 30.6% in Blaine County.

### Home Radon Testing - 2016, 2018, 2020

Statewide, 23.0% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.4% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.5% in Cassia County to 54.4% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006l and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.





# GOODING COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016–2020 Cancer Mortality 2017–2021 BRFSS 2011–2021

### **RISK FACTORS AND INTERVENTIONS**

### CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/jama.2016.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

### Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

### **Smoking:**

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

### Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <a href="https://www.dietaryguidelines.gov">https://www.dietaryguidelines.gov</a>

### Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute
Cancer Information Services
1-800-4CANCER
<a href="https://www.cancer.gov/contact">https://www.cancer.gov/contact</a>

American Cancer Society <a href="https://www.cancer.org">https://www.cancer.org</a>

### **CANCER INCIDENCE 2016–2020**

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016–2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 402 cases of invasive cancer were diagnosed among Gooding County residents (Table 1).

**Table 1:** Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Gooding County and the State of Idaho, 2016–2020

	,				
Cancer Incidence 2016–2020	3				
All Sites/Types	402	45,610			
Female Breast	56	6,687			
Prostate	43	6,417			
Lung & Bronchus	49	4,887			
Colorectal	34	3,451			

Table 3 (Cancer Incidence 2016–2020, Comparison between Gooding County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Gooding County. The table also shows the number of observed cases, person-

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Gooding County was 526.2 cases per 100,000 person-years per year during 2016–2020. Comparing this crude rate with the crude rate for the remainder of Idaho (519.9) gives an estimate of the relative burden of disease in Gooding County.

The age- and sex-adjusted incidence rate of invasive cancer in Gooding County, all sites combined, was 491.1 cases per 100,000 persons per year during 2016–2020. There were fewer cases of cancer in Gooding County (402) than expected (425.6) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

### **CANCER MORTALITY 2017–2021**

During 2017–2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 146 Gooding County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

**Table 2:** Overall and Cancer Mortality in Gooding County and the State of Idaho, 2017–2021

Mortality 2017–2021	Gooding County	State of Idaho
All Deaths	783	77,431
Cancer Deaths	146	15,121
% of All Deaths	18.6%	19.5%
Lung & Bronchus	36	2,961
Colorectal	7	1,319
Pancreas	9	1,190
Female Breast	10	1,086
Prostate	13	949

Table 4 (Cancer Mortality 2017–2021, Comparison between Gooding County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Gooding County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Gooding County, all sites combined, was 168.4 deaths per 100,000 persons per year during 2017–2021, compared with 168.0 for the remainder of the state. There were more cancer deaths in Gooding County (146) than expected (145.7) based upon rates in the remainder of the state, but the difference was not statistically significant.

**Statistical Note:** Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

## TABLE 3: CANCER INCIDENCE 2016–2020 COMPARISON BETWEEN GOODING COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

		Gooding County						Remainder of Idaho			
Cancer	_	Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude	
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)	
All Sites Combined All Sites Combined	Total Male	402 208	76,400 38,981	526.2 533.6	491.1 486.2	425.6 236.4	0.262 0.066	45,208 24,081	8,695,428 4,357,929	519.9 552.6	
All Sites Combined	Female	194	37,419	518.5	494.2	191.2	0.858	21,127	4,337,499	487.1	
Bladder	Total	19	76,400	24.9	22.2	21.3	0.717	2,165	8,695,428	24.9	
Bladder	Male	18	38,981	46.2	40.0	17.9	1.000	1,733	4,357,929	39.8	
Bladder	Female	1	37,419	2.7	2.4	4.1	0.174	432	4,337,499	10.0	
Brain - malignant Brain - malignant	Total Male	6 4	76,400 38,981	7.9 10.3	7.5 9.8	5.7 3.5	1.000 0.910	619 371	8,695,428 4,357,929	7.1 8.5	
Brain - malignant	Female	2	37,419	5.3	5.1	2.2	1.000	248	4,337,499	5.7	
Brain and other CNS - non-malignant	Total	19	76,400	24.9	23.4	13.1	0.149	1,405	8,695,428	16.2	
Brain and other CNS - non-malignant	Male	8	38,981	20.5	19.1	4.5	0.179	472	4,357,929	10.8	
Brain and other CNS - non-malignant Breast	Female Total	11 57	37,419 76,400	29.4 74.6	28.0 71.2	8.4 61.6	0.460 0.614	933 6,689	4,337,499 8,695,428	21.5 76.9	
Breast	Male	1	38,981	2.6	2.3	0.6	0.889	58	4,357,929	1.3	
Breast	Female	56	37,419	149.7	145.0	59.1	0.754	6,631	4,337,499	152.9	
Breast - in situ	Total	11	76,400	14.4	14.0	11.1	1.000	1,228	8,695,428	14.1	
Breast - in situ Breast - in situ	Male Female	- 11	38,981 37,419	- 29.4	- 29.0	0.0 10.7	1.000 1.000	5 1,223	4,357,929 4,337,499	0.1 28.2	
Cervix	Female	2	37,419	5.3	5.6	2.5	1.000	302	4,337,499	7.0	
Colorectal	Total	34	76,400	44.5	41.2	32.4	0.825	3,417	8,695,428	39.3	
Colorectal	Male	16	38,981	41.0	37.5	18.5	0.669	1,887	4,357,929	43.3	
Colorectal	Female	18	37,419	48.1	45.1	14.1	0.359	1,530	4,337,499	35.3	
Corpus Uteri Esophagus	Female Total	8 11	37,419 76,400	21.4 14.4	20.9 13.2	11.7 4.7	0.354 0.019 >>	1,322 495	4,337,499 8,695,428	30.5 5.7	
Esophagus	Male	10	38,981	25.7	23.0	4.7	0.019 >>	493	4,357,929	9.5	
Esophagus	Female	1	37,419	2.7	2.5	0.7	1.000	81	4,337,499	1.9	
Hodgkin Lymphoma	Total	1	76,400	1.3	1.3	1.8	0.918	209	8,695,428	2.4	
Hodgkin Lymphoma	Male	- 4	38,981	- 0.7	- 0.7	1.0	0.702	118	4,357,929	2.7	
Hodgkin Lymphoma Kidney and Renal Pelvis	Female Total	1 19	37,419 76,400	2.7 24.9	2.7 23.4	0.8 16.8	1.000 0.649	91 1,796	4,337,499 8,695,428	2.1 20.7	
Kidney and Renal Pelvis	Male	11	38,981	28.2	26.2	11.3	1.000	1,171	4,357,929	26.9	
Kidney and Renal Pelvis	Female	8	37,419	21.4	20.3	5.7	0.430	625	4,337,499	14.4	
Larynx	Total	4	76,400	5.2	4.9	2.0	0.282	211	8,695,428	2.4	
Larynx	Male Female	3 1	38,981 37,419	7.7 2.7	7.0 2.6	1.5 0.5	0.399 0.772	157 54	4,357,929 4,337,499	3.6 1.2	
Larynx Leukemia	Total	11	76,400	14.4	13.2	15.6	0.772	1,620	8,695,428	18.6	
Leukemia	Male	5	38,981	12.8	11.6	9.8	0.153	984	4,357,929	22.6	
Leukemia	Female	6	37,419	16.0	14.8	5.9	1.000	636	4,337,499	14.7	
Liver and Bile Duct	Total	6	76,400	7.9	7.4	7.7	0.697	823	8,695,428	9.5	
Liver and Bile Duct Liver and Bile Duct	Male Female	5 1	38,981 37,419	12.8 2.7	11.9 2.5	5.7 2.2	1.000 0.717	585 238	4,357,929 4,337,499	13.4 5.5	
Lung and Bronchus	Total	49	76,400	64.1	58.0	47.0	0.806	4,838	8,695,428	55.6	
Lung and Bronchus	Male	23	38,981	59.0	52.5	24.4	0.875	2,429	4,357,929	55.7	
Lung and Bronchus	Female	26	37,419	69.5	63.7	22.7	0.539	2,409	4,337,499	55.5	
Melanoma of the Skin Melanoma of the Skin	Total Male	16 10	76,400 38,981	20.9 25.7	19.8 23.4	27.2 17.2	0.029 <b>&lt;&lt;</b> 0.089	2,926 1,755	8,695,428 4,357,929	33.6 40.3	
Melanoma of the Skin	Female	6	37,419	16.0	15.7	10.3	0.223	1,733	4,337,499	27.0	
Myeloma	Total	8	76,400	10.5	9.5	6.8	0.735	700	8,695,428	8.1	
Myeloma	Male	5	38,981	12.8	11.4	4.4	0.892	436	4,357,929	10.0	
Myeloma Non-Hodgkin Lymphoma	Female Total	3 20	37,419 76,400	8.0 26.2	7.4 24.3	2.5 18.2	0.895 0.729	264 1,920	4,337,499 8,695,428	6.1 22.1	
Non-Hodgkin Lymphoma Non-Hodgkin Lymphoma	Male	20 10	76,400 38,981	26.2 25.7	24.3	10.9	0.729	1,920	4,357,929	25.7	
Non-Hodgkin Lymphoma	Female	10	37,419	26.7	25.0	7.4	0.422	801	4,337,499	18.5	
Oral Cavity and Pharynx	Total	18	76,400	23.6	22.3	11.9	0.116	1,277	8,695,428	14.7	
Oral Cavity and Pharmy	Male	13	38,981	33.3	31.0	8.9	0.231	923	4,357,929	21.2	
Oral Cavity and Pharynx Ovary	Female Female	5 4	37,419 37,419	13.4 10.7	12.8 10.3	3.2 4.8	0.436 0.970	354 529	4,337,499 4,337,499	8.2 12.2	
Pancreas	Total	13	76,400	17.0	15.4	13.7	0.970	1,410	8,695,428	16.2	
Pancreas	Male	8	38,981	20.5	18.2	7.8	1.000	776	4,357,929	17.8	
Pancreas	Female	5	37,419	13.4	12.2	6.0	0.902	634	4,337,499	14.6	
Prostate Stomach	Male	43 5	38,981	110.3	102.0	61.6	0.016 <<	6,374	4,357,929	146.3	
Stomach Stomach	Total Male	3	76,400 38,981	6.5 7.7	6.0 6.9	4.4 3.0	0.911 1.000	462 306	8,695,428 4,357,929	5.3 7.0	
Stomach	Female	2	37,419	5.3	5.0	1.4	0.849	156	4,337,499	3.6	
Testis	Male	2	38,981	5.1	5.5	2.2	1.000	263	4,357,929	6.0	
Thyroid	Total	7	76,400	9.2	9.3	10.5	0.359	1,213	8,695,428	13.9	
Thyroid	Male	2	38,981	5.1	5.0	3.2	0.755	353	4,357,929	8.1	
Thyroid	Female	5	37,419	13.4	13.8	7.2	0.561	860	4,337,499	19.8	
Pediatric Age 0 to 19	Total	1	22,749	4.4	4.4	3.9	0.201	420	2,437,774	17.2	
Pediatric Age 0 to 19 Pediatric Age 0 to 19	Male Female	_ 1	11,567 11,182	8.6	8.7	2.1 1.8	0.781 0.325	222 198	1,244,943 1,192,831	17.8 16.6	
			ne number of case					190	1,102,001	1 10.0	

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

<sup>2.</sup> Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

<sup>&</sup>quot;<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

### **TABLE 4: CANCER MORTALITY 2017–2021** COMPARISON BETWEEN GOODING COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Goo	ding Count	.y			Remainder of Idaho		10
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	783	77,022	1,016.6	876.7	768.1	0.601	76,647	8,911,693	860.1
All Causes of Death	Male	440	39,280	1,120.2	939.8	425.2	0.484	40,616	4,472,588	908.1
All Causes of Death	Female	343	37,742	908.8	803.6	346.4	0.882	36,031	4,439,105	811.7
All Malignant Cancers	Total	146	77,022	189.6	168.4	145.7	1.000	14,975	8,911,693	168.0
All Malignant Cancers	Male	87	39,280	221.5	189.7	83.0	0.686	8,089	4,472,588	180.9
All Malignant Cancers	Female	59	37,742	156.3	142.8	64.1	0.575	6,886	4,439,105	155.1
Bladder Bladder	Total	4 3	77,022 39,280	5.2 7.6	4.4 6.0	5.0 4.2	0.881 0.795	485 375	8,911,693 4,472,588	5.4 8.4
Bladder	Male Female	1	37,742	2.6	2.3	1.1	1.000	110	4,472,386	2.5
Brain and Other Nervous System	Total	2	77,022	2.6	2.3	4.6	0.323	502	8,911,693	5.6
Brain and Other Nervous System	Male	1	39,280	2.5	2.4	2.8	0.457	297	4,472,588	6.6
Brain and Other Nervous System	Female	1	37,742	2.6	2.5	1.8	0.908	205	4,439,105	4.6
Breast	Total	10	77,022	13.0	11.7	10.5	1.000	1,092	8,911,693	12.3
Breast	Male	-	39,280	-	-	0.2	1.000	16	4,472,588	0.4
Breast	Female	10	37,742	26.5	24.6	9.9	1.000	1,076	4,439,105	24.2
Cervix	Female	2	37,742	5.3	5.3	0.7	0.300	81	4,439,105	1.8
Colorectal	Total	7	77,022	9.1	8.1	12.7	0.127	1,312	8,911,693	14.7
Colorectal	Male	5	39,280	12.7	11.2	7.1	0.570	714	4,472,588	16.0
Colorectal Corpus Uteri	Female Female	2	37,742 37,742	5.3	4.8	5.6 1.6	0.163 0.411	598 173	4,439,105 4,439,105	13.5 3.9
Esophagus	Total	- 11	77,022	14.3	12.9	4.4	0.411	466	8,911,693	5.9
Esophagus	Male	9	39,280	22.9	20.3	3.9	0.012 >>	392	4,472,588	8.8
Esophagus	Female	2	37,742	5.3	4.8	0.7	0.303	74	4,439,105	1.7
Hodgkin Lymphoma	Total	-	77,022	-	-	0.3	1.000	29	8,911,693	0.3
Hodgkin Lymphoma	Male	-	39,280	-	-	0.1	1.000	14	4,472,588	0.3
Hodgkin Lymphoma	Female	-	37,742	-	-	0.1	1.000	15	4,439,105	0.3
Kidney	Total	4	77,022	5.2	4.6	3.7	1.000	381	8,911,693	4.3
Kidney	Male	1	39,280	2.5	2.2	2.4	0.600	241	4,472,588	5.4
Kidney	Female Total	3	37,742	7.9	7.1	1.3	0.303	140	4,439,105	3.2
Larynx Larynx	Male	2 2	77,022 39,280	2.6 5.1	2.4 4.4	0.7 0.6	0.282 0.220	69 56	8,911,693 4,472,588	0.8 1.3
Larynx	Female		37,742	-		0.0	1.000	13	4,439,105	0.3
Leukemia	Total	7	77,022	9.1	7.9	6.5	0.945	653	8,911,693	7.3
Leukemia	Male	3	39,280	7.6	6.4	4.0	0.873	383	4,472,588	8.6
Leukemia	Female	4	37,742	10.6	9.4	2.6	0.524	270	4,439,105	6.1
Liver and Bile Duct	Total	1	77,022	1.3	1.2	5.7	0.045 <<	602	8,911,693	6.8
Liver and Bile Duct	Male	1	39,280	2.5	2.3	4.0	0.186	407	4,472,588	9.1
Liver and Bile Duct	Female	-	37,742	-	-	1.8	0.332	195	4,439,105	4.4
Lung and Bronchus	Total	36 18	77,022	46.7	41.7 39.9	28.4 15.5	0.186	2,925	8,911,693	32.8
Lung and Bronchus Lung and Bronchus	Male Female	18	39,280 37,742	45.8 47.7	39.9 43.2	15.5 13.0	0.592 0.219	1,538 1,387	4,472,588 4,439,105	34.4 31.2
Melanoma of the Skin	Total	3	77,022	3.9	3.5	2.7	1.000	286	8,911,693	31.2
Melanoma of the Skin	Male	3	39,280	7.6	6.6	1.9	0.604	189	4,472,588	4.2
Melanoma of the Skin	Female		37,742	-	-	0.9	0.828	97	4,439,105	2.2
Myeloma	Total	1	77,022	1.3	1.1	3.3	0.323	330	8,911,693	3.7
Myeloma	Male	1	39,280	2.5	2.1	2.0	0.791	195	4,472,588	4.4
Myeloma	Female		37,742	-		1.3	0.551	135	4,439,105	3.0
Non-Hodgkin Lymphoma	Total	5	77,022	6.5	5.7	5.6	1.000	564	8,911,693	6.3
Non-Hodgkin Lymphoma	Male	3	39,280	7.6	6.5	3.1	1.000	304	4,472,588	6.8
Non-Hodgkin Lymphoma	Female	2 4	37,742 77,022	5.3	4.7 4.7	2.5	1.000	260	4,439,105 8,911,693	5.9 2.9
Oral Cavity and Pharynx Oral Cavity and Pharynx	Total Male	4	77,022 39,280	5.2 10.2	9.1	2.5 1.8	0.478 0.217	262 183	4,472,588	4.1
Oral Cavity and Pharynx	Female	- 4	39,260 37,742	- 10.2	9.1	0.7	0.217	79	4,472,366	1.8
Ovary	Female	1	37,742	2.6	2.5	3.2	0.344	349	4,439,105	7.9
Pancreas	Total	9	77,022	11.7	10.5	11.3	0.610	1,181	8,911,693	13.3
Pancreas	Male	6	39,280	15.3	13.4	6.3	1.000	636	4,472,588	14.2
Pancreas	Female	3	37,742	7.9	7.3	5.1	0.515	545	4,439,105	12.3
Prostate	Male	13	39,280	33.1	26.1	10.4	0.500	936	4,472,588	20.9
Stomach	Total	1	77,022	1.3	1.2	1.9	0.874	197	8,911,693	2.2
Stomach	Male	[	39,280	-	-	1.2	0.595	121	4,472,588	2.7
Stomach	Female	1	37,742	2.6	2.5	0.7	1.000	76	4,439,105	1.7

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

<sup>2.</sup> Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

### Cancer Screening and Risk Factor Prevalence Estimates, 2011–2021

	State of								Gooding
Measure	Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	County
Access to Care									
Have Health Insurance, Age <65 (2015–2021)	83.1%	82.8%	85.1%	77.2%	85.8%	78.9%	85.4%	85.4%	72.2%
Not See Doctor Due to Cost in Past Year (2015–2021)	12.6%	11.4%	11.8%	14.5%	12.4%	12.3%	11.8%	12.9%	13.2%
Cancer Screening									
Mammogram Past 2 Years, Age 50–74 (2014, 2016, 2018, 2020)	69.1%	67.0%	73.8%	68.2%	73.2%	64.8%	64.5%	67.1%	52.4%
Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020)	71.2%	73.6%	73.6%	70.8%	72.9%	69.1%	69.5%	65.9%	
Colorectal Cancer Screening, Age 50–75 (2018, 2020)	67.9%	66.9%	73.6%	71.4%	70.6%	61.7%	61.5%	64.7%	
Tobacco Use									
Current Tobacco User (2016–2021)	22.3%	26.7%	23.1%	23.6%	21.8%	21.4%	22.7%	16.9%	21.1%
Other Cancer-Related									
Healthy Weight by Body Mass Index, Age 20+ (2015–2021)	32.1%	32.8%	31.7%	27.9%	36.1%	29.8%	27.9%	31.9%	28.8%
Any Physical Activity Besides Job Past 30 Days (2015-2021)	78.7%	79.2%	78.1%	74.5%	83.2%	73.4%	76.3%	79.7%	66.4%
Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019)	21.9%	22.8%	19.4%	20.0%	25.2%	19.5%	20.4%	20.2%	16.8%
Home Ever Tested for Radon (2016, 2018, 2020)	23.0%	30.9%	18.2%	16.9%	25.1%	19.9%	23.0%	21.8%	12.5%

### **Access to Care**

### Have Health Insurance - 2015-2021

Statewide, 83.1% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 86.0% of white non-Hispanics, compared to 64.8% of Hispanics and 83.3% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3%) than English-speaking respondents (84.2%). Health care coverage differed significantly by age of respondent, with 79.8% of persons aged 18–29, and 87.8% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 62.1% in Adams County to 91.6% in Oneida County having health insurance.

### Not See Doctor Due to Cost in Past Year - 2015-2021

Statewide, 12.6% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (11.5% of white non-Hispanics, 19.2% of Hispanics, and 21.0% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9% for less than \$15,000, 6.1% for greater than \$50,000). Inability to see a doctor due to cost differed significantly by county, with a range of 7.4% in Franklin County to 17.5% in Power County.

### **Cancer Screening**

<u>Mammogram</u> – 2014, 2016, 2018, 2020

Statewide, 69.1% of women aged 50–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (72.1% versus 36.7%). Mammography rates differed significantly by county, with a range in screening of 45.9% in Benewah County to 77.0% in Nez Perce County. In 2020, Idaho ranked 48<sup>th</sup> among states and the District of Columbia for mammography screening rates among women aged 50–74 and also 48<sup>th</sup> among ages 40+.

### Pap Test - 2018, 2020

Statewide, 71.2% of women with an intact cervix and aged 21–65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.1% versus 52.6% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.7% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49<sup>th</sup> among states and the District of Columbia for Pap screening rate.

### Colorectal Cancer Screening – 2018, 2020

Statewide, 67.9% of adults aged 50–75 reported being current for colorectal cancer screening.\*\* Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked 47<sup>th</sup> among states and the District of Columbia in the percentage of adults aged 50–75 and older who reported being up-to-date for colorectal cancer screening.

<sup>\*\*</sup> Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

### **Tobacco Use**

### Current Tobacco Use - 2016-2021

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.3% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 29.9% of persons aged 18-29, and 11.1% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (22.4%) than among Native Americans (40.0%). Tobacco use differed significantly by county, with a range of 5.4% in Madison County to 41.6% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

### **Other Cancer-Related**

### Healthy Weight by Body Mass Index - 2015-2021

Statewide, 32.1% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 32.5% of white non-Hispanics, compared to 28.2% of Hispanics and 24.6% of Native Americans, being in the healthy weight range. Males (25.5%) were significantly less likely to be in the healthy weight range than females (38.6%). BMI differed significantly by age of respondent, with 43.3% of persons aged 18–29, and 26.0% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 19.8% in Power County to 47.4% in Blaine County of adults being in the healthy weight range.

### Any Physical Activity - 2015-2021

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 78.7% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.3% of persons aged 18–29, and 72.3% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 64.3% in Clark County to 84.6% in Teton County.

Physical Activity Guidelines – 2011, 2013, 2015, 2017, 2019 Statewide, 21.9% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.3% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6% in Franklin County to 30.6% in Blaine County.

### Home Radon Testing - 2016, 2018, 2020

Statewide, 23.0% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.4% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.5% in Cassia County to 54.4% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006l and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.





# IDAHO COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

# Cancer Incidence 2016–2020 Cancer Mortality 2017–2021 BRFSS 2011–2021

# **RISK FACTORS AND INTERVENTIONS**

### **CANCER**

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/jama.2016.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

### Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

### **Smoking:**

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

### Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <a href="https://www.dietaryguidelines.gov">https://www.dietaryguidelines.gov</a>

### Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute
Cancer Information Services
1-800-4CANCER
<a href="https://www.cancer.gov/contact">https://www.cancer.gov/contact</a>

American Cancer Society <a href="https://www.cancer.org">https://www.cancer.org</a>

### **CANCER INCIDENCE 2016–2020**

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016–2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 613 cases of invasive cancer were diagnosed among Idaho County residents (Table 1).

**Table 1:** Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Idaho County and the State of Idaho. 2016–2020

Cancer Incidence 2016–2020	Idaho County	State of Idaho
All Sites/Types	613	45,610
Female Breast	76	6,687
Prostate	100	6,417
Lung & Bronchus	77	4,887
Colorectal	51	3,451

Table 3 (Cancer Incidence 2016–2020, Comparison between Idaho County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Idaho County. The table also shows the number of observed cases, person-

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Idaho County was 742.5 cases per 100,000 person-years per year during 2016–2020. Comparing this crude rate with the crude rate for the remainder of Idaho (517.8) gives an estimate of the relative burden of disease in Idaho County.

The age- and sex-adjusted incidence rate of invasive cancer in Idaho County, all sites combined, was 486.2 cases per 100,000 persons per year during 2016–2020. There were fewer cases of cancer in Idaho County (613) than expected (652.9) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

### **CANCER MORTALITY 2017–2021**

During 2017–2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 234 Idaho County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

**Table 2:** Overall and Cancer Mortality in Idaho County and the State of Idaho, 2017–2021

Mortality 2017–2021	Idaho County	State of Idaho
All Deaths	1,042	77,431
Cancer Deaths	234	15,121
% of All Deaths	22.5%	19.5%
Lung & Bronchus	41	2,961
Colorectal	24	1,319
Pancreas	24	1,190
Female Breast	13	1,086
Prostate	18	949

Table 4 (Cancer Mortality 2017–2021, Comparison between Idaho County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Idaho County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Idaho County, all sites combined, was 169.8 deaths per 100,000 persons per year during 2017–2021, compared with 167.2 for the remainder of the state. There were more cancer deaths in Idaho County (234) than expected (230.4) based upon rates in the remainder of the state, but the difference was not statistically significant.

**Statistical Note:** Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

# TABLE 3: CANCER INCIDENCE 2016–2020 COMPARISON BETWEEN IDAHO COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

SileType			Idaho County					Remainder of Idaho			
All Stess Combined Male All Stess Combined Male All Stess Combined Male All Stess Combined Female Step 39, 1945 All Stess Combined Female Step 39, 1955 All Stess Combined Female Step 39, 1955 Bladder Female Bladder Bladder Bladder Female Bladder Female Bladder Female Bladder Bladd	Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude
All Sites Combined All Sites Combined Female 262 39,1915 688,5 499,4 398,5 51 0,422 23,938 4,353,551 58,484 Bladder Total 33 82,555 40.7 23.7 34,2 0,522 1,151 8,882,74 29 Bladder Female 18 39,195 00.4 12,8 61 0,543 1,100 1	Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases		Rate (1)
All Stees Combined   Female   262   39,195   688.5   461.4   275.8   0.424   21,059   4,335,723   488   Bladder   Total   33   82,554   40.0   23.9   34.2   0.523   1.726   4.385,572   38   36.1   0.385   1.726   4.385,572   38   36.1   0.385   1.726   4.385,572   38   36.1   0.385   1.726   4.385,572   38   36.1   0.385   1.726   4.385,572   38   38   38   38   38   38   38   3											517.8
Bladder											549.8 485.7
Bladder   Male   25   43,359   57,7   32,7   30,4   0.382   1,726   4,353,551   31											24.8
Bladder											39.6
Brain - malignant		Female	8	39,195	20.4	12.8	6.1	0.543	425	4,335,723	9.8
Brain and other CNS - non-malignant   Total   19											7.1
Brain and other CNS - non-melignant   Total   19   82,554   23.0   16.2   19.0   1.000   1.405   8,689,274   11   13.9,195   13.9,195   13.9   11.9   0.452   0.33   4.35,723   2   15.2   1.000   1.405   1.405   1			4		9.2	6.7					8.5 5.8
Brain and other CNS - non-malignant   Male   8			19		23.0	16.2					16.2
Breast Male 2 43,359 4.6 2.8 10.0 492 57 4353,57 7 8 8 82,554 3.9 19 0.158 6.688 8,689,274 7 8 8 8 8 1			-						472		10.8
Breast Male Female 76 39,195 139,9 1360 85.2 0.347 6,611 4,335,723 15. Breast - In situ Total 3 82,554 3.6 2.6 16.6 0.000 <1,236 8,689,274 1. Breast - In situ Female 3 39,195 17. 5.5 15.6 0.000 <1,236 8,689,274 1. Breast - In situ Female 4 33,599 7 0.1 1. 000 5 4,353,551 1. Breast - In situ Female 4 33,599 7 0.1 1. 000 5 4,353,551 1. Breast - In situ Female 4 33,599 7 0.1 1. 000 5 4,353,5723 2. Corpus Carlotton 10tal 2 82,554 6 61 4. 40. 3 4. 40. 0. 763 3. 40. 8. 88,5723 2. 0. 10tal 2 82,554 6 61 4. 40. 3 4. 40. 0. 763 3. 40. 8. 88,5723 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.											21.5
Breast   Female   76   39,195   193.9   136.0   85.2   0.347   6.611   4.335,723   1.25   1											76.7
Breast - In situ										4,353,551	1.3 152.5
Breast - in situ											14.2
Cervix	Breast - in situ	Male	-		-	-			5		0.1
Colorectal Male 21 43,359 48.8 0.788 3.400 8.689,274 3. Colorectal Male 21 43,359 48.4 31.3 29.0 0.151 1.882 4,353,551 4. Colorectal Female 30 39,195 76.5 51.9 20.2 0.050 ➤ 1.518 4,335,723 3. Corpus Uteri Female 20 39,195 51.0 35.2 17.2 0.557 1.310 4,355,723 3. Esophagus Total 10 82,554 12.1 7.6 7.5 0.455 496 8.689,274 5. Esophagus Male 9 43,359 20.8 12.5 6.9 0.504 415 4,353,573 4. Hodgkin Lymphoma Male 1 39,195 2.6 1.6 1.1 1.000 81 4,335,723 4. Hodgkin Lymphoma Male 2 43,359 4.6 4.0 1.3 0.763 116 4,353,551 4. Hodgkin Lymphoma Male 2 43,359 4.6 4.0 1.3 0.763 116 4,353,551 4. Hodgkin Lymphoma Female - 39,195 2.7 1.000 0.840 92 4. Kidney and Renal Pelvis Male 4 43,359 32.8 21.2 7 18. 0.490 4. Kidney and Renal Pelvis Male 4 43,359 32.8 21.2 7 18. 0.491 4. Kidney and Renal Pelvis Female 9 39,195 2.6 1.7 8. 0.893 644 4.335.7 3 4. Kidney and Renal Pelvis Male 1 4 43,359 32.3 15.7 8. 0.893 644 4.335.7 3 4. Kidney and Renal Pelvis Female 9 39,195 2.6 1.7 0.7 1.000 54 4.335.7 3 4. Larynx Female 1 39,195 2.6 1.7 0.7 1.000 54 4.335.7 3 4. Larynx Female 1 39,195 2.6 1.7 0.7 1.000 54 4.335.7 3 4. Larynx Female 1 39,195 2.6 1.7 0.7 1.000 54 4.335.7 3 4. Larynx Female 1 39,195 2.6 1.7 0.7 1.000 54 4.335.7 3 4. Larynx Female 1 39,195 2.6 1.7 0.7 1.000 54 4.335.7 3 4. Larynx Female 1 39,195 2.6 1.7 0.7 1.000 54 4.335.7 3 4. Larynx Female 1 39,195 2.6 1.7 0.7 1.000 54 4.335.7 3 4. Larynx Female 1 39,195 2.6 1.7 0.7 1.000 54 4.335.7 3 4. Larynx Female 1 39,195 2.6 1.7 0.7 1.000 580 4.335.7 3 4. Larynx Female 1 39,195 2.6 1.7 0.7 1.000 580 4.335.7 3 4. Larynx Female 1 39,195 2.6 1.7 0.7 1.000 580 4.335.7 3 4. Larynx Female 1 39,195 2.6 1.7 0.7 1.000 580 4.335.7 3 4. Larynx Female 1 39,195 2.6 1.7 0.7 1.000 580 4.335.7 3 4. Larynx Female 1 39,195 2.6 1.7 0.7 1.000 580 4.335.7 3 4. Larynx Female 1 39,195 2.6 1.7 0.7 1.000 580 4.335.7 3 4. Larynx Female 1 39,195 3.0 0.0 19.1 15.3 0.673 976 4.335.7 3 4. Larynx Female 1 39,195 3.0 0.0 19.1 10.3 0.673 976 4.335.7 3 4. Larynx Female 1 39,195 3.0 0.0 19.1 10.3 0.673 976 4.335.7 3 4. Lary											28.4
Colorectal											6.9
Corpus Uteri											39.1 43.2
Corpus Uteri											35.0
Esophagus			20	39,195	51.0	35.2	17.2	0.557	1,310	4,335,723	30.2
Esophagus											5.7
Hodgkin Lymphoma			9								9.5 1.9
Hodgkin Lymphoma			2								2.4
Kidney and Renal Pelvis   Male   14   43,359   32,3   21,2   17,8   0.449   1.168   4,353,551   22   22   23   21,2   17,8   0.449   1.168   4,353,551   22   23   21,2   17,8   0.449   1.168   4,353,551   22   23   23   21,2   17,8   0.449   1.168   4,353,551   22   23   23   21,2   17,8   0.449   1.168   4,353,551   22   23   23   23   21,2   23   23   23   23   23   23   23											2.7
Kidney and Renal Pelvis   Male   14   43,359   32.3   21.2   17.8   0.449   1.168   4.353,551   22   4.315,723   1.4   2.6   0.529   159   4.335,723   1.4   2.6   0.529   159   4.335,723   1.4   2.6   0.529   159   4.353,551   2.4   2.4   1.5   3.2   0.759   213   8.689,274   1.4   2.6   0.529   1.59   4.353,551   2.4   2.4   1.5   3.2   0.759   213   8.689,274   1.4   2.6   0.529   1.59   4.353,551   2.4   2.4   1.5   3.2   0.759   2.5   1.5   3.2   0.759   2.5   1.5   3.2   0.759   2.5   1.5   3.2   0.529   1.5   3.2   3.5			-		-	-					2.1
Kidney and Renal Pelvis   Female   9   39,195   23.0   15.7   8.2   0.881   624   4.335,723   1.4   2.6   1.5   3.2   0.759   213   8.688,274   1.2   2.4   2.4   1.5   3.2   0.759   213   8.688,274   1.2   2.4   2.4   2.6   0.529   1.5   4.353,521   1.2   2.4   2.5   2.3   1.4   2.6   0.529   1.5   4.353,521   1.2   2.5   2.3   1.4   2.6   0.529   1.5   4.353,521   1.2   2.5   2.3   1.4   2.6   0.529   1.5   4.353,521   1.2   2.5   2.3   1.4   2.6   0.529   1.5   4.353,723   1.2   2.5											20.6
Larynx										4,353,551	26.8 14.4
Larymx			-								2.5
Leukemia											3.7
Leukemia			-		2.6						1.2
Leukemia											18.6
Liver and Bile Duct   Total   14   82,554   17.0   10.8   12.2   0.681   815   8,688,274   1.5											22.4 14.7
Liver and Bile Duct         Male         10         43,359         23.1         14.3         9.3         0.909         580         4,353,551         11           Liver and Bile Duct         Female         4         39,195         10.2         6.6         3.3         0.822         235         4,335,723         11           Lung and Bronchus         Male         46         43,359         106.1         60.7         41.9         0.562         2,406         4,353,551         55           Lung and Bronchus         Female         31         39,195         79.1         49.4         34.8         0.587         2,404         4,335,723         55           Melanoma of the Skin         Total         40         82,554         48.5         33.4         40.0         1.000         2,902         8,689,274         33           Melanoma of the Skin         Male         27         43,359         62.3         39.8         27.1         1.000         2,902         8,689,274         33           Melanoma of the Skin         Male         27         43,359         36.2         24.8         14.1         0.918         1,164         4,335,723         22         4.8         14.1         0.918         1,164											9.4
Lung and Bronchus         Total         77         82,554         93.3         56.0         76.1         0.952         4,810         8,689,274         55           Lung and Bronchus         Heal         46         43,359         106.1         60.7         41.9         0.562         2,406         4,353,551         55           Melanoma of the Skin         Total         40         82,554         48.5         33.4         40.0         1,000         2,902         8,689,274         33           Melanoma of the Skin         Male         27         43,359         62.3         39.8         27.1         1,000         1,738         4,353,551         33           Melanoma of the Skin         Female         13         39,195         33.2         24.8         14.1         0.918         1,164         4,335,723         23           Myeloma         Total         5         82,554         6.1         3.7         10.9         0.080         703         8,689,274         3           Myeloma         Male         2         43,359         4.6         2.7         7.5         0.042 <				43,359						4,353,551	13.3
Lung and Bronchus         Male         46         43,359         106.1         60.7         41.9         0.562         2,406         4,353,551         55           Lung and Bronchus         Female         31         39,195         79.1         49.4         34.8         0.587         2,404         4,353,551         55           Melanoma of the Skin         Total         40         82,554         48.5         33.4         40.0         1.000         2,902         8,689,274         55           Melanoma of the Skin         Male         27         43,359         62.3         39.8         27.1         1.000         1,738         4,353,551         33           Melanoma of the Skin         Female         13         39,195         33.2         24.8         14.1         0.918         1,164         4,335,723         20           Myeloma         Total         5         82,554         6.1         3.7         10.9         0.080         703         8,689,274         33           Myeloma         Male         2         43,359         4.6         2.7         7.5         0.042         439         4,353,723         10           Myeloma         Meloma         Total         27											5.4
Lung and Bronchus											55.4 55.3
Melanoma of the Skin         Total         40         82,554         48.5         33.4         40.0         1.000         2,902         8,689,274         33.4           Melanoma of the Skin         Male         27         43,359         62.3         39.8         27.1         1.000         1,738         4,353,551         33           Melanoma of the Skin         Female         13         39,195         33.2         24.8         14.1         0,918         1,164         4,335,2551         33           Myeloma         Total         5         82,554         6.1         3.7         10.9         0.080         703         8,689,274         42           Myeloma         Male         2         43,359         4.6         2.7         7.5         0.042         439         4,353,551         11           Myeloma         Female         3         39,195         7.7         4.9         3.7         0.973         264         4,335,723         10           Non-Hodgkin Lymphoma         Total         27         82,554         32.7         21.5         27.7         0.994         1,913         8,689,274         22           Non-Hodgkin Lymphoma         Male         15         43,359											55.4
Melanoma of the Skin         Female         13         39,195         33.2         24.8         14.1         0.918         1,164         4,335,723         20           Myeloma         Total         5         82,554         6.1         3.7         10.9         0.080         703         8,689,274         3.8           Myeloma         Female         2         43,359         4.6         2.7         7.5         0.042         439         4,353,551         10           Myeloma         Female         3         39,195         7.7         4.9         3.7         0.973         264         4,335,723         6           Non-Hodgkin Lymphoma         Total         27         82,554         32.7         21.5         27.7         0.994         1,913         8,689,274         22           Non-Hodgkin Lymphoma         Male         15         43,359         34.6         22.2         17.3         0.685         1,114         4,353,551         29           Non-Hodgkin Lymphoma         Female         12         39,195         30.6         20.4         10.8         0.802         799         4,335,723         11           Oral Cavity and Pharynx         Total         22         82,554			-								33.4
Myeloma         Total         5         82,554         6.1         3.7         10.9         0.080         703         8,689,274         3.7           Myeloma         Male         2         43,359         4.6         2.7         7.5         0.042 <											39.9
Myeloma         Male         2         43,359         4.6         2.7         7.5         0.042 <         439         4,353,551         10           Myeloma         Female         3         39,195         7.7         4.9         3.7         0.973         264         4,335,723         6           Non-Hodgkin Lymphoma         Total         27         82,554         32.7         21.5         27.7         0.994         1,913         8,689,274         22           Non-Hodgkin Lymphoma         Male         15         43,359         34.6         22.2         17.3         0.685         1,114         4,353,551         22           Non-Hodgkin Lymphoma         Female         12         39,195         30.6         20.4         10.8         0.802         799         4,335,723         18           Oral Cavity and Pharynx         Total         22         82,554         26.6         17.5         18.4         0.457         1,273         8,689,274         14           Oral Cavity and Pharynx         Male         16         43,359         36.9         23.7         14.2         0.709         920         4,353,551         2           Oral Cavity and Pharynx         Female         5											26.8
Myeloma         Female         3         39,195         7.7         4.9         3.7         0.973         264         4,335,723         6           Non-Hodgkin Lymphoma         Total         27         82,554         32.7         21.5         27.7         0.994         1,913         8,689,274         22           Non-Hodgkin Lymphoma         Male         15         43,359         34.6         22.2         17.3         0.685         1,114         4,355,551         22           Non-Hodgkin Lymphoma         Female         12         39,195         30.6         20.4         10.8         0.802         799         4,335,753         11           Oral Cavity and Pharynx         Total         22         82,554         26.6         17.5         18.4         0.457         1,273         8,689,274         14           Oral Cavity and Pharynx         Male         16         43,359         36.9         23.7         14.2         0.709         920         4,353,5551         22           Oral Cavity and Pharynx         Female         6         39,195         15.3         10.3         4.7         0.675         353         4,335,723         12           Oral Cavity and Pharynx         Female			2								8.1 10.1
Nón-Hodgkin Lymphoma         Total         27         82,554         32.7         21.5         27.7         0.994         1,913         8,689,274         22           Non-Hodgkin Lymphoma         Male         15         43,359         34.6         22.2         17.3         0.685         1,114         4,353,551         25           Non-Hodgkin Lymphoma         Female         12         39,195         30.6         20.4         10.8         0.802         799         4,335,723         18           Oral Cavity and Pharynx         Total         22         82,554         26.6         17.5         18.4         0.457         1,273         8,689,274         12           Oral Cavity and Pharynx         Male         16         43,359         36.9         23.7         14.2         0.709         920         4,353,551         22           Oral Cavity and Pharynx         Female         6         39,195         15.3         10.3         4.7         0.675         353         4,335,723         12           Ovary         Female         5         39,195         12.8         9.0         6.8         0.653         528         4,335,723         12           Pancreas         Total         28			_	39.195	7.7		3.7			4.335.723	6.1
Non-Hodgkin Lymphoma         Male         15         43,359         34.6         22.2         17.3         0.685         1,114         4,353,551         25           Non-Hodgkin Lymphoma         Female         12         39,195         30.6         20.4         10.8         0.802         799         4,335,723         11           Oral Cavity and Pharynx         Total         22         82,554         26.6         17.5         18.4         0.457         1,273         8,689,274         14           Oral Cavity and Pharynx         Male         16         43,359         36.9         23.7         14.2         0.709         920         4,353,551         22           Oral Cavity and Pharynx         Male         16         43,359         36.9         23.7         14.2         0.709         920         4,353,551         22           Oral Cavity and Pharynx         Female         6         39,195         15.3         10.3         4.7         0.675         353         4,335,723         12           Oral Cavity and Pharynx         Female         6         39,195         12.8         9.0         6.8         0.653         528         4,335,723         12           Oral Cavity and Pharynx         M	Non-Hodgkin Lymphoma	Total	27	82,554	32.7	21.5	27.7	0.994	1,913	8,689,274	22.0
Oral Cavity and Pharynx         Total         22         82,554         26.6         17.5         18.4         0.457         1,273         8,689,274         14.2           Oral Cavity and Pharynx         Male         16         43,359         36.9         23.7         14.2         0.709         920         4,353,551         2           Oral Cavity and Pharynx         Female         6         39,195         15.3         10.3         4.7         0.675         353         4,335,723         12           Ovary         Female         5         39,195         12.8         9.0         6.8         0.653         528         4,335,723         12           Pancreas         Total         28         82,554         33.9         20.9         21.5         0.205         1,395         8,689,274         11           Pancreas         Male         19         43,359         43.8         26.0         12.8         0.127         765         4,353,551         1           Pancreas         Female         9         39,195         23.0         14.6         9.0         1.000         630         4,335,723         14           Prostate         Male         100         43,359         230.6 </td <td></td> <td></td> <td>15</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>4,353,551</td> <td>25.6</td>			15							4,353,551	25.6
Oral Cavity and Pharynx         Male         16         43,359         36.9         23.7         14.2         0.709         920         4,353,551         2           Oral Cavity and Pharynx         Female         6         39,195         15.3         10.3         4.7         0.675         353         4,335,723         353           Ovary         Female         5         39,195         12.8         9.0         6.8         0.653         528         4,335,723         12           Pancreas         Total         28         82,554         33.9         20.9         21.5         0.620         1,395         8,689,274         11           Pancreas         Male         19         43,359         43.8         26.0         12.8         0.127         765         4,353,551         1           Pancreas         Female         9         39,195         23.0         14.6         9.0         1.000         630         4,335,723         14           Prostate         Male         100         43,359         230.6         138.2         105.0         0.673         6,317         4,353,551         14           Stomach         Total         5         82,554         6.1         3					30.6						18.4
Oral Cavity and Pharynx         Female         6         39,195         15.3         10.3         4.7         0.675         353         4,335,723         35           Ovary         Female         5         39,195         12.8         9.0         6.8         0.653         528         4,335,723         12           Pancreas         Total         28         82,554         33.9         20.9         21.5         0.205         1,395         8,689,274         10           Pancreas         Male         19         43,359         43.8         26.0         12.8         0.127         765         4,353,551         1           Pancreas         Female         9         39,195         23.0         14.6         9.0         1.000         630         4,353,723         14           Prostate         Male         10         43,359         23.0         14.6         9.0         1.000         630         4,353,723         14           Stomach         Total         5         82,554         6.1         3.9         6.9         0.640         462         8,689,274         14           Stomach         Male         4         43,359         9.2         5.6         5.0 <td>Oral Cavity and Pharynx Oral Cavity and Pharynx</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>14.7 21.1</td>	Oral Cavity and Pharynx Oral Cavity and Pharynx										14.7 21.1
Ovary         Female         5         39,195         12.8         9.0         6.8         0.653         528         4,335,723         12.8           Pancreas         Total         28         82,554         33.9         20.9         21.5         0.205         1,395         8,689,274         16           Pancreas         Male         19         43,359         43.8         26.0         12.8         0.127         765         4,353,551         1           Pancreas         Female         9         39,195         23.0         14.6         9.0         1.000         630         4,335,723         14           Prostate         Male         100         43,359         230.6         138.2         105.0         0.673         6,317         4,353,551         14           Stomach         Total         5         82,554         6.1         3.9         6.9         0.640         462         8,689,274         4           Stomach         Male         4         43,359         9.2         5.6         5.0         0.887         305         4,353,551         4           Stomach         Female         1         39,195         2.6         1.7         2.1         <	Oral Cavity and Pharynx									4,335,723	8.1
Pancreas         Male Pancreas         19 Female         43,359 9 39,195         43.8 26.0 23.0 23.0 23.0 23.0 23.0 23.0 23.0 23	Ovary	Female	5	39,195	12.8	9.0	6.8	0.653	528	4,335,723	12.2
Pancreas         Female         9         39,195         23.0         14.6         9.0         1.000         630         4,335,723         14.7           Prostate         Male         100         43,359         230.6         138.2         105.0         0.673         6,317         4,353,551         14.7           Stomach         Total         5         82,554         6.1         3.9         6.9         0.640         462         8,689,274         8.689,274         8.689,274         8.7         9.2         5.6         5.0         0.887         3.5         4,335,753         1.7         1.7         2.1         0.763         157         4,335,723         3.7         1.7         1.7         0.7         0.7         1.7         1.7         0.7         0.7         0.7         0.7 <td></td> <td></td> <td></td> <td></td> <td>33.9</td> <td></td> <td></td> <td></td> <td>1,395</td> <td>8,689,274</td> <td>16.1</td>					33.9				1,395	8,689,274	16.1
Prostate         Male         100         43,359         230.6         138.2         105.0         0.673         6,317         4,353,551         148           Stomach         Total         5         82,554         6.1         3.9         6.9         0.640         462         8,689,274         5           Stomach         Male         4         43,359         9.2         5.6         5.0         0.887         305         4,353,551           Stomach         Female         1         39,195         2.6         1.7         2.1         0.763         157         4,335,723         305           Testis         Male         5         43,359         11.5         13.6         2.2         0.144         260         4,353,551         0										4,353,551	17.6
Stomach         Total         5         82,554         6.1         3.9         6.9         0.640         462         8,689,274         5           Stomach         Male         4         43,359         9.2         5.6         5.0         0.887         305         4,353,551         5           Stomach         Female         1         39,195         2.6         1.7         2.1         0.763         157         4,335,723         3           Testis         Male         5         43,359         11.5         13.6         2.2         0.144         260         4,353,551         6										4,333,723	14.5 145.1
Stomach         Male         4         43,359         9.2         5.6         5.0         0.887         305         4,353,551         5.5           Stomach         Female         1         39,195         2.6         1.7         2.1         0.763         157         4,335,723         305           Testis         Male         5         43,359         11.5         13.6         2.2         0.144         260         4,353,551         6										8,689,274	5.3
Testis Male 5 43,359 11.5 13.6 2.2 0.144 260 4,353,551 0	Stomach	Male	4	43,359	9.2	5.6	5.0	0.887	305	4,353,551	7.0
											3.6
∎inyroiq											6.0
	,			·							13.9
	,										8.1 19.8
											17.2
	· ·		-								17.8
			-		-	-					16.6

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

<sup>2.</sup> Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

<sup>&</sup>quot;<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

# **TABLE 4: CANCER MORTALITY 2017–2021** COMPARISON BETWEEN IDAHO COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

		Idaho County						Remainder of Idaho		
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	1,042	83,347	1,250.2	760.9	1,174.6	0.000 <<	76,388	8,905,368	857.8
All Causes of Death	Male	600	43,796	1,370.0	806.5	673.6	0.004 <<	40,456	4,468,072	905.4
All Causes of Death	Female	442	39,551	1,117.5	695.7	514.5	0.001 <<	35,932	4,437,296	809.8
All Malignant Cancers	Total	234	83,347	280.8	169.8	230.4	0.828	14,887	8,905,368	167.2
All Malignant Cancers	Male	134	43,796	306.0	175.0	137.8	0.786	8,042	4,468,072	180.0
All Malignant Cancers Bladder	Female Total	100 11	39,551 83,347	252.8 13.2	159.9 7.5	96.5 7.9	0.745 0.346	6,845 478	4,437,296 8,905,368	154.3 5.4
Bladder	Male	7	43,796	16.0	7.5 8.5	6.9	1.000	371	4,468,072	8.3
Bladder	Female	4	39,551	10.0	6.0	1.6	0.158	107	4,437,296	2.4
Brain and Other Nervous System	Total	3	83,347	3.6	2.4	6.9	0.169	501	8,905,368	5.6
Brain and Other Nervous System	Male	3	43,796	6.8	4.5	4.4	0.713	295	4,468,072	6.6
Brain and Other Nervous System	Female	-	39,551	-	-	2.7	0.139	206	4,437,296	4.6
Breast	Total	13	83,347	15.6	9.9	16.1	0.534	1,089	8,905,368	12.2
Breast	Male	-	43,796	-	-	0.3	1.000	16	4,468,072	0.4
Breast	Female	13	39,551	32.9	21.5	14.6	0.796	1,073	4,437,296	24.2
Cervix	Female	1	39,551	2.5	2.1	0.9	1.000	82	4,437,296	1.8
Colorectal Colorectal	Total Male	24 9	83,347 43,796	28.8 20.5	18.0 12.6	19.4 11.4	0.349 0.601	1,295 710	8,905,368 4,468,072	14.5 15.9
Colorectal	Female	15	43,796 39,551	37.9	24.1	8.2	0.001	585	4,466,072	13.9
Corpus Uteri	Female	3	39,551	7.6	4.8	2.4	0.042	170	4,437,296	3.8
Esophagus	Total	8	83,347	9.6	5.9	7.2	0.848	469	8,905,368	5.3
Esophagus	Male	6	43,796	13.7	8.1	6.6	1.000	395	4,468,072	8.8
Esophagus	Female	2	39,551	5.1	3.2	1.0	0.561	74	4,437,296	1.7
Hodgkin Lymphoma	Total	-	83,347	-	-	0.4	1.000	29	8,905,368	0.3
Hodgkin Lymphoma	Male	-	43,796	-	-	0.2	1.000	14	4,468,072	0.3
Hodgkin Lymphoma	Female	-	39,551	-	-	0.2	1.000	15	4,437,296	0.3
Kidney	Total	3	83,347	3.6	2.1	6.0	0.296 0.032 <b>&lt;&lt;</b>	382	8,905,368	4.3 5.4
Kidney Kidney	Male Female	3	43,796 39,551	7.6	4.6	4.1 2.1	0.032	242 140	4,468,072 4,437,296	3.4
Larynx	Total	3	83,347	1.0	0.7	1.1	1.000	70	8,905,368	0.8
Larynx	Male	1	43,796	2.3	1.3	1.0	1.000	57	4,468,072	1.3
Larynx	Female		39,551	-	-	0.2	1.000	13	4,437,296	0.3
Leukemia	Total	9	83,347	10.8	6.5	10.2	0.868	651	8,905,368	7.3
Leukemia	Male	8	43,796	18.3	10.4	6.5	0.656	378	4,468,072	8.5
Leukemia	Female	1	39,551	2.5	1.6	3.9	0.194	273	4,437,296	6.2
Liver and Bile Duct	Total	12	83,347	14.4	8.8	9.1	0.406	591	8,905,368	6.6
Liver and Bile Duct	Male	8	43,796	18.3	10.7	6.7	0.703	400	4,468,072	9.0
Liver and Bile Duct	Female	4	39,551	10.1 49.2	6.4	2.7	0.573	191	4,437,296	4.3
Lung and Bronchus Lung and Bronchus	Total Male	41 25	83,347 43,796	49.2 57.1	29.1 32.1	46.3 26.7	0.492 0.846	2,920 1,531	8,905,368 4,468,072	32.8 34.3
Lung and Bronchus	Female	16	39,551	40.5	24.9	20.7	0.646	1,389	4,437,296	31.3
Melanoma of the Skin	Total	3	83,347	3.6	2.3	4.3	0.764	286	8,905,368	3.2
Melanoma of the Skin	Male	3	43,796	6.8	4.0	3.1	1.000	189	4,468,072	4.2
Melanoma of the Skin	Female	-	39,551	-	-	1.3	0.549	97	4,437,296	2.2
Myeloma	Total	7	83,347	8.4	4.8	5.3	0.556	324	8,905,368	3.6
Myeloma	Male	2	43,796	4.6	2.5	3.5	0.632	194	4,468,072	4.3
Myeloma	Female	5	39,551	12.6	7.7	1.9	0.088	130	4,437,296	2.9
Non-Hodgkin Lymphoma	Total	7	83,347	8.4	5.0	8.9	0.674	562	8,905,368	6.3
Non-Hodgkin Lymphoma	Male	2	43,796 30,551	4.6	2.6	5.2	0.214 0.652	305	4,468,072	6.8
Non-Hodgkin Lymphoma Oral Cavity and Pharynx	Female Total	5 4	39,551 83,347	12.6 4.8	7.7 3.0	3.8 4.0	1.000	257 262	4,437,296 8,905,368	5.8 2.9
Oral Cavity and Pharynx	Male	3	43,796	6.8	4.1	3.0	1.000	184	4,468,072	4.1
Oral Cavity and Pharynx	Female	1	39,551	2.5	1.6	1.1	1.000	78	4,437,296	1.8
Ovary	Female	3	39,551	7.6	4.8	4.9	0.573	347	4,437,296	7.8
Pancreas	Total	24	83,347	28.8	17.3	18.1	0.215	1,166	8,905,368	13.1
Pancreas	Male	17	43,796	38.8	22.5	10.6	0.084	625	4,468,072	14.0
Pancreas	Female	7	39,551	17.7	11.0	7.8	0.976	541	4,437,296	12.2
Prostate	Male	18	43,796	41.1	21.6	17.4	0.942	931	4,468,072	20.8
Stomach	Total	-	83,347	-	-	2.9	0.110	198	8,905,368	2.2
Stomach	Male	-	43,796	-	-	2.0	0.283	121	4,468,072	2.7
Stomach	Female	-	39,551	-	-	1.0	0.726	77	4,437,296	1.7

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

<sup>2.</sup> Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

### Cancer Screening and Risk Factor Prevalence Estimates, 2011–2021

	State of								Idaho
Measure	Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	County
Access to Care									
Have Health Insurance, Age <65 (2015–2021)	83.1%	82.8%	85.1%	77.2%	85.8%	78.9%	85.4%	85.4%	63.7%
Not See Doctor Due to Cost in Past Year (2015–2021)	12.6%	11.4%	11.8%	14.5%	12.4%	12.3%	11.8%	12.9%	14.7%
Cancer Screening									
Mammogram Past 2 Years, Age 50–74 (2014, 2016, 2018, 2020)	69.1%	67.0%	73.8%	68.2%	73.2%	64.8%	64.5%	67.1%	74.6%
Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020)	71.2%	73.6%	73.6%	70.8%	72.9%	69.1%	69.5%	65.9%	64.2%
Colorectal Cancer Screening, Age 50–75 (2018, 2020)	67.9%	66.9%	73.6%	71.4%	70.6%	61.7%	61.5%	64.7%	61.7%
Tobacco Use									
Current Tobacco User (2016–2021)	22.3%	26.7%	23.1%	23.6%	21.8%	21.4%	22.7%	16.9%	22.4%
Other Cancer-Related									
Healthy Weight by Body Mass Index, Age 20+ (2015–2021)	32.1%	32.8%	31.7%	27.9%	36.1%	29.8%	27.9%	31.9%	32.3%
Any Physical Activity Besides Job Past 30 Days (2015-2021)	78.7%	79.2%	78.1%	74.5%	83.2%	73.4%	76.3%	79.7%	68.8%
Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019)	21.9%	22.8%	19.4%	20.0%	25.2%	19.5%	20.4%	20.2%	14.3%
Home Ever Tested for Radon (2016, 2018, 2020)	23.0%	30.9%	18.2%	16.9%	25.1%	19.9%	23.0%	21.8%	9.6%

### **Access to Care**

### Have Health Insurance - 2015-2021

Statewide, 83.1% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 86.0% of white non-Hispanics, compared to 64.8% of Hispanics and 83.3% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3%) than English-speaking respondents (84.2%). Health care coverage differed significantly by age of respondent, with 79.8% of persons aged 18–29, and 87.8% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 62.1% in Adams County to 91.6% in Oneida County having health insurance.

### Not See Doctor Due to Cost in Past Year - 2015-2021

Statewide, 12.6% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (11.5% of white non-Hispanics, 19.2% of Hispanics, and 21.0% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9% for less than \$15,000, 6.1% for greater than \$50,000). Inability to see a doctor due to cost differed significantly by county, with a range of 7.4% in Franklin County to 17.5% in Power County.

### **Cancer Screening**

<u>Mammogram</u> – 2014, 2016, 2018, 2020

Statewide, 69.1% of women aged 50–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (72.1% versus 36.7%). Mammography rates differed significantly by county, with a range in screening of 45.9% in Benewah County to 77.0% in Nez Perce County. In 2020, Idaho ranked 48<sup>th</sup> among states and the District of Columbia for mammography screening rates among women aged 50–74 and also 48<sup>th</sup> among ages 40+.

### Pap Test - 2018, 2020

Statewide, 71.2% of women with an intact cervix and aged 21–65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.1% versus 52.6% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.7% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49<sup>th</sup> among states and the District of Columbia for Pap screening rate.

### Colorectal Cancer Screening – 2018, 2020

Statewide, 67.9% of adults aged 50–75 reported being current for colorectal cancer screening.\*\* Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked 47<sup>th</sup> among states and the District of Columbia in the percentage of adults aged 50–75 and older who reported being up-to-date for colorectal cancer screening.

<sup>\*\*</sup> Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

### **Tobacco Use**

### Current Tobacco Use - 2016-2021

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.3% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 29.9% of persons aged 18-29, and 11.1% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (22.4%) than among Native Americans (40.0%). Tobacco use differed significantly by county, with a range of 5.4% in Madison County to 41.6% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

### **Other Cancer-Related**

### Healthy Weight by Body Mass Index - 2015-2021

Statewide, 32.1% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 32.5% of white non-Hispanics, compared to 28.2% of Hispanics and 24.6% of Native Americans, being in the healthy weight range. Males (25.5%) were significantly less likely to be in the healthy weight range than females (38.6%). BMI differed significantly by age of respondent, with 43.3% of persons aged 18–29, and 26.0% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 19.8% in Power County to 47.4% in Blaine County of adults being in the healthy weight range.

### Any Physical Activity - 2015-2021

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 78.7% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.3% of persons aged 18–29, and 72.3% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 64.3% in Clark County to 84.6% in Teton County.

Physical Activity Guidelines – 2011, 2013, 2015, 2017, 2019 Statewide, 21.9% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.3% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6% in Franklin County to 30.6% in Blaine County.

### Home Radon Testing - 2016, 2018, 2020

Statewide, 23.0% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.4% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.5% in Cassia County to 54.4% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006l and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.





# JEFFERSON COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

# Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

# **RISK FACTORS AND INTERVENTIONS**

### **CANCER**

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/jama.2016.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

### Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

### **Smoking:**

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

### Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <a href="https://www.dietaryguidelines.gov">https://www.dietaryguidelines.gov</a>

### Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute
Cancer Information Services
1-800-4CANCER
<a href="https://www.cancer.gov/contact">https://www.cancer.gov/contact</a>

American Cancer Society <a href="https://www.cancer.org">https://www.cancer.org</a>

### **CANCER INCIDENCE 2016–2020**

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016–2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 578 cases of invasive cancer were diagnosed among Jefferson County residents (Table 1).

**Table 1:** Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Jefferson County and the State of Idaho. 2016–2020

Cancer Incidence 2016–2020	Jefferson County	State of Idaho
All Sites/Types	578	45,610
Female Breast	79	6,687
Prostate	83	6,417
Lung & Bronchus	48	4,887
Colorectal	47	3,451

Table 3 (Cancer Incidence 2016–2020, Comparison between Jefferson County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Jefferson County. The table also shows the number of observed cases, person-

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Jefferson County was 395.4 cases per 100,000 person-years per year during 2016–2020. Comparing this crude rate with the crude rate for the remainder of Idaho (522.1) gives an estimate of the relative burden of disease in Jefferson County.

The age- and sex-adjusted incidence rate of invasive cancer in Jefferson County, all sites combined, was 497.4 cases per 100,000 persons per year during 2016–2020. There were fewer cases of cancer in Jefferson County (578) than expected (606.7) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

### **CANCER MORTALITY 2017–2021**

During 2017–2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 172 Jefferson County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

**Table 2:** Overall and Cancer Mortality in Jefferson County and the State of Idaho, 2017–2021

Mortality 2017–2021	Jefferson County	State of Idaho		
All Deaths	969	77,431		
Cancer Deaths	172	15,121		
% of All Deaths	17.8%	19.5%		
Lung & Bronchus	26	2,961		
Colorectal	15	1,319		
Pancreas	17	1,190		
Female Breast	17	1,086		
Prostate	11	949		

Table 4 (Cancer Mortality 2017–2021, Comparison between Jefferson County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Jefferson County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Jefferson County, all sites combined, was 152.5 deaths per 100,000 persons per year during 2017–2021, compared with 169.1 for the remainder of the state. There were fewer cancer deaths in Jefferson County (172) than expected (190.7) based upon rates in the remainder of the state, but the difference was not statistically significant.

**Statistical Note:** Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

# TABLE 3: CANCER INCIDENCE 2016–2020 COMPARISON BETWEEN JEFFERSON COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

		Jefferson County						Remainder of Idaho		
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)
All Sites Combined	Total	578	146,192	395.4	497.4	606.7	0.252	45,032	8,625,636	522.1
All Sites Combined	Male	314	74,341	422.4	528.7	329.4	0.413	23,975	4,322,569	554.6
All Sites Combined	Female	264	71,851	367.4	462.9	279.1	0.384	21,057	4,303,067	489.3
Bladder Bladder	Total	28 21	146,192 74,341	19.2 28.2	25.5 37.1	27.4 22.6	0.961 0.837	2,156 1,730	8,625,636 4,322,569	25.0 40.0
Bladder	Male Female	7	74,341	26.2 9.7	13.1	5.3	0.637	426	4,322,369	9.9
Brain - malignant	Total	10	146,192	6.8	8.0	9.0	0.813	615	8,625,636	7.1
Brain - malignant	Male	5	74,341	6.7	7.7	5.5	1.000	370	4,322,569	8.6
Brain - malignant	Female	5	71,851	7.0	8.2	3.5	0.540	245	4,303,067	5.7
Brain and other CNS - non-malignant	Total	24	146,192	16.4	19.9	19.6	0.368	1,400	8,625,636	16.2
Brain and other CNS - non-malignant	Male	10	74,341	13.5	15.8	6.9	0.314	470	4,322,569	10.9
Brain and other CNS - non-malignant	Female	14	71,851	19.5	24.2	12.5	0.748	930	4,303,067	21.6
Breast Breast	Total Male	80 1	146,192 74,341	54.7 1.3	67.1 1.7	92.2 0.8	0.221 1.000	6,666 58	8,625,636 4,322,569	77.3 1.3
Breast	Female	79	74,341	109.9	137.0	88.6	0.335	6,608	4,322,309	153.6
Breast - in situ	Total	17	146,192	11.6	14.0	17.1	1.000	1,222	8,625,636	14.2
Breast - in situ	Male		74,341	-	-	0.1	1.000	5	4,322,569	0.1
Breast - in situ	Female	17	71,851	23.7	29.1	16.5	0.969	1,217	4,303,067	28.3
Cervix	Female	4	71,851	5.6	6.1	4.6	1.000	300	4,303,067	7.0
Colorectal	Total	47	146,192	32.1	40.5	45.8	0.902	3,404	8,625,636	39.5
Colorectal Colorectal	Male Female	30 17	74,341 71,851	40.4 23.7	49.7 30.4	26.2 19.9	0.504 0.614	1,873 1,531	4,322,569 4,303,067	43.3 35.6
Corpus Uteri	Female	17	71,851	23.7	29.6	19.9	1.000	1,531	4,303,067	30.5
Esophagus	Total	3	146.192	23.7	29.0	6.6	0.210	503	8,625,636	5.8
Esophagus	Male	2	74,341	2.7	3.4	5.7	0.151	422	4,322,569	9.8
Esophagus	Female	1	71,851	1.4	1.8	1.0	1.000	81	4,303,067	1.9
Hodgkin Lymphoma	Total	4	146,192	2.7	3.0	3.2	0.791	206	8,625,636	2.4
Hodgkin Lymphoma	Male	2	74,341	2.7	2.9	1.8	1.000	116	4,322,569	2.7
Hodgkin Lymphoma	Female	2 13	71,851 146.192	2.8 8.9	3.0	1.4	0.806	90	4,303,067	2.1 20.9
Kidney and Renal Pelvis Kidney and Renal Pelvis	Total Male	10	74,341	13.5	11.0 16.4	24.6 16.5	0.016 <b>&lt;&lt;</b> 0.124	1,802 1,172	8,625,636 4,322,569	20.9
Kidney and Renal Pelvis	Female	3	71,851	4.2	5.2	8.4	0.066	630	4,303,067	14.6
Larynx	Total	1	146,192	0.7	0.9	2.8	0.447	214	8,625,636	2.5
Larynx	Male	-	74,341	-	-	2.2	0.224	160	4,322,569	3.7
Larynx	Female	1	71,851	1.4	1.8	0.7	1.000	54	4,303,067	1.3
Leukemia	Total	17	146,192	11.6	14.4	22.1	0.330	1,614	8,625,636	18.7
Leukemia	Male	16	74,341	21.5	26.2	13.8	0.613	973	4,322,569	22.5
Leukemia Liver and Bile Duct	Female Total	1 8	71,851 146,192	1.4 5.5	1.8 6.9	8.5 11.0	0.004 <b>&lt;&lt;</b> 0.469	641 821	4,303,067 8,625,636	14.9 9.5
Liver and Bile Duct	Male	6	74,341	8.1	10.0	8.1	0.409	584	4,322,569	13.5
Liver and Bile Duct	Female	2	71,851	2.8	3.6	3.1	0.821	237	4,303,067	5.5
Lung and Bronchus	Total	48	146,192	32.8	43.4	62.0	0.078	4,839	8,625,636	56.1
Lung and Bronchus	Male	30	74,341	40.4	52.6	32.0	0.817	2,422	4,322,569	56.0
Lung and Bronchus	Female	18	71,851	25.1	33.6	30.1	0.025 <<	2,417	4,303,067	56.2
Melanoma of the Skin	Total	46	146,192	31.5	38.8	39.8	0.362	2,896	8,625,636	33.6
Melanoma of the Skin	Male	24	74,341	32.3	40.0	24.2	1.000	1,741	4,322,569	40.3
Melanoma of the Skin Myeloma	Female Total	22 5	71,851 146,192	30.6 3.4	37.1 4.5	15.9 9.1	0.170 0.219	1,155 703	4,303,067	26.8 8.2
Myeloma	Male	3	74,341	3.4 4.0	4.5 5.2	9.1 5.8	0.219	438	8,625,636 4,322,569	10.1
Myeloma	Female	2	71,851	2.8	3.7	3.4	0.696	265	4,303,067	6.2
Non-Hodgkin Lymphoma	Total	30	146,192	20.5	25.7	25.8	0.461	1,910	8,625,636	22.1
Non-Hodgkin Lymphoma	Male	14	74,341	18.8	23.0	15.7	0.794	1,115	4,322,569	25.8
Non-Hodgkin Lymphoma	Female	16	71,851	22.3	28.6	10.3	0.122	795	4,303,067	18.5
Oral Cavity and Pharmy	Total	18	146,192	12.3	15.4	17.3	0.927	1,277	8,625,636	14.8
Oral Cavity and Pharynx Oral Cavity and Pharynx	Male Female	13 5	74,341 71,851	17.5 7.0	21.4 8.9	13.0 4.6	1.000 0.985	923 354	4,322,569 4,303,067	21.4 8.2
Ovary	Female	6	71,851	8.4	10.4	7.0	0.965	527	4,303,067	12.2
Pancreas	Total	20	146,192	13.7	17.9	18.1	0.722	1,403	8,625,636	16.3
Pancreas	Male	12	74,341	16.1	20.7	10.3	0.683	772	4,322,569	17.9
Pancreas	Female	8	71,851	11.1	14.9	7.9	1.000	631	4,303,067	14.7
Prostate	Male	83	74,341	111.6	141.0	86.2	0.781	6,334	4,322,569	146.5
Stomach	Total	10	146,192	6.8	8.8	6.0	0.174	457	8,625,636	5.3
Stomach	Male	5	74,341	6.7	8.5	4.1	0.796	304	4,322,569	7.0
Stomach	Female	5 3	71,851	7.0 4.0	8.9 4.3	2.0 4.2	0.103 0.778	153	4,303,067	3.6
Testis Thyroid	Male Total	29	74,341 146,192	19.8	22.3	18.0	0.778	262 1 101	4,322,569	6.1 13.8
Thyroid	Male	29 12	74,341	19.8	22.3 18.5	18.0 5.2	0.021 >>	1,191 343	8,625,636 4,322,569	7.9
Thyroid	rviale Female	17	74,341	23.7	18.5 26.4	5.2 12.7	0.014 >>	343 848	4,322,569	19.7
Pediatric Age 0 to 19	Total	6	53,391	11.2	11.4	9.1	0.200	415	2,407,132	17.2
Pediatric Age 0 to 19 Pediatric Age 0 to 19	Male	4	27,191	14.7	14.8	4.8	0.404	219	1,229,319	17.2
Pediatric Age 0 to 19	Female	2	26,200	7.6	7.8	4.2	0.409	196	1,177,813	16.6
			20,200			1.2	550	100	.,,0.0	10.0

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

<sup>2.</sup> Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

<sup>&</sup>quot;<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

# **TABLE 4: CANCER MORTALITY 2017–2021** COMPARISON BETWEEN JEFFERSON COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

		Jefferson County						Remainder of Idaho		
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	969	150,567	643.6	865.8	968.2	0.988	76,461	8,838,148	865.1
All Causes of Death	Male	543	76,770	707.3	921.1	538.5	0.858	40,513	4,435,098	913.5
All Causes of Death	Female	426	73,797	577.3	801.9	433.7	0.735	35,948	4,403,050	816.4
All Malignant Cancers	Total	172	150,567	114.2	152.5	190.7	0.184	14,949	8,838,148	169.1
All Malignant Cancers	Male	103	76,770	134.2	176.7	106.1	0.810	8,073	4,435,098	182.0
All Malignant Cancers	Female	69	73,797	93.5	126.2	85.4	0.079	6,876	4,403,050	156.2
Bladder	Total	8	150,567	5.3	7.5	5.8	0.451	481	8,838,148	5.4
Bladder	Male	7	76,770	9.1	12.7	4.6	0.363	371	4,435,098	8.4
Bladder	Female	1	73,797	1.4	1.9	1.3	1.000	110	4,403,050	2.5
Brain and Other Nervous System	Total	7	150,567	4.6	5.7	6.9	1.000	497	8,838,148	5.6
Brain and Other Nervous System	Male	4	76,770	5.2	6.3	4.2	1.000	294	4,435,098	6.6
Brain and Other Nervous System	Female	3	73,797	4.1	5.1	2.7	1.000	203	4,403,050	4.6
Breast	Total	17	150,567	11.3	14.7	14.2	0.522	1,085	8,838,148	12.3
Breast Breast	Male Female	- 17	76,770 73,797	23.0	30.5	0.2 13.5	1.000 0.412	16 1,069	4,435,098 4,403,050	0.4 24.3
Breast Cervix	Female	- 17	73,797	23.0	- 30.3	13.3	0.412	1,009		1.9
Colorectal	Total	- 15	150,567	10.0	13.1	16.9	0.611	1,304	4,403,050 8,838,148	14.8
Colorectal	Male	9	76,770	11.7	14.9	9.7	0.759	710	4,435,098	16.0
Colorectal	Female	6	73,797	8.1	11.0	7.3	0.804	594	4,403,050	13.5
Corpus Uteri	Female	2	73,797	2.7	3.6	2.1	1.000	171	4,403,050	3.9
Esophagus	Total	3	150,567	2.0	2.6	6.1	0.281	474	8,838,148	5.4
Esophagus	Male	3	76,770	3.9	5.0	5.3	0.440	398	4,435,098	9.0
Esophagus	Female	-	73,797	-	-	0.9	0.783	76	4,403,050	1.7
Hodgkin Lymphoma	Total	1	150,567	0.7	0.9	0.4	0.616	28	8,838,148	0.3
Hodgkin Lymphoma	Male	-	76,770	-	-	0.2	1.000	14	4,435,098	0.3
Hodgkin Lymphoma	Female	1	73,797	1.4	1.8	0.2	0.323	14	4,403,050	0.3
Kidney	Total	3	150,567	2.0	2.7	4.8	0.583	382	8,838,148	4.3
Kidney	Male	1	76,770	1.3	1.7	3.2	0.345	241	4,435,098	5.4
Kidney	Female	2	73,797	2.7	3.8	1.7	1.000	141	4,403,050	3.2
Larynx	Total	-	150,567	-	-	0.9	0.795	71	8,838,148	0.8
Larynx	Male	-	76,770	-	-	0.8	0.925	58	4,435,098	1.3
Larynx	Female	-	73,797	-	-	0.2	1.000	13	4,403,050	0.3
Leukemia	Total	6	150,567	4.0	5.4	8.3	0.567	654	8,838,148	7.4
Leukemia	Male	5 1	76,770 73,797	6.5	8.6	5.0 3.3	1.000 0.312	381 273	4,435,098	8.6 6.2
Leukemia Liver and Bile Duct	Female Total	8	150,567	1.4 5.3	1.9 7.0	7.7	1.000	595	4,403,050 8,838,148	6.7
Liver and Bile Duct	Male	7	76,770	9.1	11.7	7.7 5.4	0.597	401	4,435,098	9.0
Liver and Bile Duct	Female	1	73,797	1.4	1.8	2.4	0.610	194	4,403,050	4.4
Lung and Bronchus	Total	26	150,567	17.3	23.3	37.0	0.073	2,935	8,838,148	33.2
Lung and Bronchus	Male	17	76,770	22.1	29.3	20.1	0.577	1,539	4,435,098	34.7
Lung and Bronchus	Female	9	73,797	12.2	16.7	17.1	0.051	1,396	4,403,050	31.7
Melanoma of the Skin	Total	5	150,567	3.3	4.3	3.7	0.631	284	8,838,148	3.2
Melanoma of the Skin	Male	5	76,770	6.5	8.4	2.5	0.218	187	4,435,098	4.2
Melanoma of the Skin	Female	-	73,797	-	-	1.3	0.571	97	4,403,050	2.2
Myeloma	Total	2	150,567	1.3	1.8	4.1	0.460	329	8,838,148	3.7
Myeloma	Male	2	76,770	2.6	3.6	2.5	1.000	194	4,435,098	4.4
Myeloma	Female		73,797	-		1.6	0.394	135	4,403,050	3.1
Non-Hodgkin Lymphoma	Total	7	150,567	4.6	6.3	7.1	1.000	562	8,838,148	6.4
Non-Hodgkin Lymphoma	Male	4	76,770	5.2	6.9	4.0	1.000	303	4,435,098	6.8
Non-Hodgkin Lymphoma	Female	3	73,797	4.1	5.7	3.1	1.000	259	4,403,050	5.9
Oral Cavity and Pharynx	Total	1 1	150,567	0.7	0.9	3.4	0.285	265	8,838,148	3.0
Oral Cavity and Pharmy	Male	1	76,770	1.3	1.7	2.5	0.574	186	4,435,098	4.2
Oral Cavity and Pharynx	Female		73,797	- 07	-	1.0	0.738	79	4,403,050	1.8
Ovary Pancreas	Female Total	2 17	73,797 150,567	2.7	3.6 15.1	4.4 15.0	0.376 0.665	348	4,403,050 8,838,148	7.9 13.3
Pancreas Pancreas	Male	9	76,770	11.3 11.7	15.1	15.0 8.4	0.005	1,173 633	4,435,098	13.3
Pancreas	Female	8	73,797	10.8	14.8	6.6	0.698	540	4,403,050	12.3
Prostate	Male	11	76,770	14.3	20.1	11.6	1.000	938	4,435,098	21.1
Stomach	Total	1	150,567	0.7	0.9	2.6	0.539	197	8,838,148	2.2
Stomach	Male	1	76,770	1.3	1.7	1.6	1.000	120	4,435,098	2.7
Stomach	Female	_ '	73,797	_	,	1.0	0.734	77	4,403,050	1.7
			ne number of cases	or 100 000 por	cone per vecr (		501		., .00,000	1.7

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

<sup>2.</sup> Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

### Cancer Screening and Risk Factor Prevalence Estimates, 2011–2021

	State of								Jefferson
Measure	Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	County
Access to Care									
Have Health Insurance, Age <65 (2015–2021)	83.1%	82.8%	85.1%	77.2%	85.8%	78.9%	85.4%	85.4%	84.0%
Not See Doctor Due to Cost in Past Year (2015–2021)	12.6%	11.4%	11.8%	14.5%	12.4%	12.3%	11.8%	12.9%	12.3%
Cancer Screening									
Mammogram Past 2 Years, Age 50–74 (2014, 2016, 2018, 2020)	69.1%	67.0%	73.8%	68.2%	73.2%	64.8%	64.5%	67.1%	63.8%
Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020)	71.2%	73.6%	73.6%	70.8%	72.9%	69.1%	69.5%	65.9%	55.3%
Colorectal Cancer Screening, Age 50–75 (2018, 2020)	67.9%	66.9%	73.6%	71.4%	70.6%	61.7%	61.5%	64.7%	59.5%
Tobacco Use									
Current Tobacco User (2016–2021)	22.3%	26.7%	23.1%	23.6%	21.8%	21.4%	22.7%	16.9%	12.2%
Other Cancer-Related									
Healthy Weight by Body Mass Index, Age 20+ (2015–2021)	32.1%	32.8%	31.7%	27.9%	36.1%	29.8%	27.9%	31.9%	26.5%
Any Physical Activity Besides Job Past 30 Days (2015-2021)	78.7%	79.2%	78.1%	74.5%	83.2%	73.4%	76.3%	79.7%	77.1%
Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019)	21.9%	22.8%	19.4%	20.0%	25.2%	19.5%	20.4%	20.2%	16.8%
Home Ever Tested for Radon (2016, 2018, 2020)	23.0%	30.9%	18.2%	16.9%	25.1%	19.9%	23.0%	21.8%	20.5%

### **Access to Care**

### Have Health Insurance - 2015-2021

Statewide, 83.1% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 86.0% of white non-Hispanics, compared to 64.8% of Hispanics and 83.3% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3%) than English-speaking respondents (84.2%). Health care coverage differed significantly by age of respondent, with 79.8% of persons aged 18–29, and 87.8% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 62.1% in Adams County to 91.6% in Oneida County having health insurance.

### Not See Doctor Due to Cost in Past Year - 2015-2021

Statewide, 12.6% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (11.5% of white non-Hispanics, 19.2% of Hispanics, and 21.0% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9% for less than \$15,000, 6.1% for greater than \$50,000). Inability to see a doctor due to cost differed significantly by county, with a range of 7.4% in Franklin County to 17.5% in Power County.

### **Cancer Screening**

Mammogram - 2014, 2016, 2018, 2020

Statewide, 69.1% of women aged 50–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (72.1% versus 36.7%). Mammography rates differed significantly by county, with a range in screening of 45.9% in Benewah County to 77.0% in Nez Perce County. In 2020, Idaho ranked 48<sup>th</sup> among states and the District of Columbia for mammography screening rates among women aged 50–74 and also 48<sup>th</sup> among ages 40+.

### Pap Test - 2018, 2020

Statewide, 71.2% of women with an intact cervix and aged 21–65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.1% versus 52.6% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.7% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49<sup>th</sup> among states and the District of Columbia for Pap screening rate.

### Colorectal Cancer Screening – 2018, 2020

Statewide, 67.9% of adults aged 50–75 reported being current for colorectal cancer screening.\*\* Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked 47<sup>th</sup> among states and the District of Columbia in the percentage of adults aged 50–75 and older who reported being up-to-date for colorectal cancer screening.

<sup>\*\*</sup> Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

### **Tobacco Use**

### Current Tobacco Use - 2016-2021

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.3% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 29.9% of persons aged 18-29, and 11.1% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (22.4%) than among Native Americans (40.0%). Tobacco use differed significantly by county, with a range of 5.4% in Madison County to 41.6% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

### **Other Cancer-Related**

### Healthy Weight by Body Mass Index - 2015-2021

Statewide, 32.1% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 32.5% of white non-Hispanics, compared to 28.2% of Hispanics and 24.6% of Native Americans, being in the healthy weight range. Males (25.5%) were significantly less likely to be in the healthy weight range than females (38.6%). BMI differed significantly by age of respondent, with 43.3% of persons aged 18–29, and 26.0% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 19.8% in Power County to 47.4% in Blaine County of adults being in the healthy weight range.

### Any Physical Activity - 2015-2021

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 78.7% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.3% of persons aged 18–29, and 72.3% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 64.3% in Clark County to 84.6% in Teton County.

Physical Activity Guidelines – 2011, 2013, 2015, 2017, 2019 Statewide, 21.9% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.3% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6% in Franklin County to 30.6% in Blaine County.

### Home Radon Testing - 2016, 2018, 2020

Statewide, 23.0% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.4% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.5% in Cassia County to 54.4% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006l and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.





# JEROME COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

# Cancer Incidence 2016–2020 Cancer Mortality 2017–2021 BRFSS 2011–2021

# **RISK FACTORS AND INTERVENTIONS**

### **CANCER**

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/jama.2016.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

### Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

### **Smoking:**

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

### Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <a href="https://www.dietaryguidelines.gov">https://www.dietaryguidelines.gov</a>

### Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute
Cancer Information Services
1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society <a href="https://www.cancer.org">https://www.cancer.org</a>

### **CANCER INCIDENCE 2016–2020**

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016–2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 489 cases of invasive cancer were diagnosed among Jerome County residents (Table 1).

**Table 1:** Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Jerome County and the State of Idaho, 2016–2020

	,	
Cancer Incidence 2016–2020	Jerome County	State of Idaho
All Sites/Types	489	45,610
Female Breast	61	6,687
Prostate	57	6,417
Lung & Bronchus	54	4,887
Colorectal	42	3,451

Table 3 (Cancer Incidence 2016–2020, Comparison between Jerome County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Jerome County. The table also shows the number of observed cases, person-

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Jerome County was 406.2 cases per 100,000 person-years per year during 2016–2020. Comparing this crude rate with the crude rate for the remainder of Idaho (521.5) gives an estimate of the relative burden of disease in Jerome County.

The age- and sex-adjusted incidence rate of invasive cancer in Jerome County, all sites combined, was 470.7 cases per 100,000 persons per year during 2016–2020. There were statistically significantly fewer cases of cancer in Jerome County (489) than expected (541.8) based upon rates in the remainder of the state (p=.023).

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

### **CANCER MORTALITY 2017–2021**

During 2017–2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 165 Jerome County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

**Table 2:** Overall and Cancer Mortality in Jerome County and the State of Idaho, 2017–2021

Mortality 2017–2021	Jerome County	State of Idaho
All Deaths	925	77,431
Cancer Deaths	165	15,121
% of All Deaths	17.8%	19.5%
Lung & Bronchus	29	2,961
Colorectal	21	1,319
Pancreas	11	1,190
Female Breast	10	1,086
Prostate	16	949

Table 4 (Cancer Mortality 2017–2021, Comparison between Jerome County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Jerome County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Jerome County, all sites combined, was 162.5 deaths per 100,000 persons per year during 2017–2021, compared with 168.7 for the remainder of the state. There were fewer cancer deaths in Jerome County (165) than expected (171.3) based upon rates in the remainder of the state, but the difference was not statistically significant.

**Statistical Note:** Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

# TABLE 3: CANCER INCIDENCE 2016–2020 COMPARISON BETWEEN JEROME COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Jer	ome County	/			Ren	nainder of Ida	aho
Cancer		Observed	Person	Crude	A.A.I.	Expected	D./ I. //	Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)
All Sites Combined All Sites Combined	Total Male	489 245	120,371 61,720	406.2 397.0	470.7 463.4	541.8 293.3	0.023 <b>&lt;&lt;</b> 0.004 <b>&lt;&lt;</b>	45,121 24,044	8,651,457 4,335,190	521.5 554.6
All Sites Combined	Female	245 244	58,651	416.0	403.4 479.3	248.6	0.803	24,044	4,335,190	488.3
Bladder	Total	20	120,371	16.6	19.9	25.1	0.357	2,164	8,651,457	25.0
Bladder	Male	14	61,720	22.7	27.4	20.5	0.174	1,737	4,335,190	40.1
Bladder	Female	6	58,651	10.2	12.2	4.9	0.728	427	4,316,267	9.9
Brain - malignant	Total	5	120,371	4.2	4.6	7.8	0.418	620	8,651,457	7.2
Brain - malignant	Male .		61,720	-	-	4.8	0.016 <<	375	4,335,190	8.7
Brain - malignant	Female Total	5 6	58,651 120,371	8.5 5.0	9.4 5.6	3.0 17.4	0.376 0.003 <b>&lt;&lt;</b>	245 1,418	4,316,267	5.7 16.4
Brain and other CNS - non-malignant Brain and other CNS - non-malignant	Male	3	61,720	4.9	5.4	6.1	0.003	477	8,651,457 4,335,190	11.0
Brain and other CNS - non-malignant	Female	3	58,651	5.1	5.8	11.2	0.009 <<	941	4,316,267	21.8
Breast	Total	61	120,371	50.7	58.0	81.3	0.023 <<	6,685	8,651,457	77.3
Breast	Male	-	61,720	-	-	0.7	0.980	59	4,335,190	1.4
Breast	Female	61	58,651	104.0	119.6	78.3	0.051	6,626	4,316,267	153.5
Breast - in situ	Total	15	120,371	12.5	14.2	15.0	1.000	1,224	8,651,457	14.1
Breast - in situ	Male Female	- 15	61,720 58,651	- 25.6	29.3	0.1 14.4	1.000 0.953	5 1,219	4,335,190 4,316,267	0.1 28.2
Breast - in situ Cervix	Female	5	58,651	8.5	9.2	3.8	0.933	299	4,316,267	6.9
Colorectal	Total	42	120,371	34.9	40.2	41.1	0.045	3,409	8,651,457	39.4
Colorectal	Male	20	61,720	32.4	37.1	23.4	0.560	1,883	4,335,190	43.4
Colorectal	Female	22	58,651	37.5	43.5	17.9	0.386	1,526	4,316,267	35.4
Corpus Uteri	Female	22	58,651	37.5	43.3	15.4	0.133	1,308	4,316,267	30.3
Esophagus	Total	7	120,371	5.8	6.8	5.9	0.757	499	8,651,457	5.8
Esophagus	Male	6	61,720	9.7	11.4	5.1	0.789	418	4,335,190	9.6
Esophagus	Female Total	1 3	58,651 120.371	1.7 2.5	2.0 2.6	0.9 2.7	1.000 1.000	81 207	4,316,267 8,651,457	1.9 2.4
Hodgkin Lymphoma Hodgkin Lymphoma	Male	2	61,720	3.2	3.4	1.6	0.925	116	4,335,190	2.4
Hodgkin Lymphoma	Female	1	58,651	1.7	1.8	1.2	1.000	91	4.316.267	2.1
Kidney and Renal Pelvis	Total	20	120,371	16.6	19.0	21.8	0.806	1,795	8,651,457	20.7
Kidney and Renal Pelvis	Male	15	61,720	24.3	27.7	14.6	0.978	1,167	4,335,190	26.9
Kidney and Renal Pelvis	Female	5	58,651	8.5	9.8	7.4	0.497	628	4,316,267	14.5
Larynx	Total	6	120,371	5.0	5.8	2.5	0.083	209	8,651,457	2.4
Larynx	Male	5	61,720	8.1	9.5	1.9	0.086	155	4,335,190	3.6
Larynx Leukemia	Female Total	1 16	58,651 120,371	1.7 13.3	2.0 15.2	0.6 19.7	0.934 0.484	54 1,615	4,316,267 8,651,457	1.3 18.7
Leukemia	Male	7	61,720	11.3	12.9	12.3	0.157	982	4,335,190	22.7
Leukemia	Female	9	58,651	15.3	17.6	7.5	0.681	633	4,316,267	14.7
Liver and Bile Duct	Total	8	120,371	6.6	7.8	9.8	0.719	821	8,651,457	9.5
Liver and Bile Duct	Male	7	61,720	11.3	13.2	7.1	1.000	583	4,335,190	13.4
Liver and Bile Duct	Female	_1	58,651	1.7	2.0	2.8	0.473	238	4,316,267	5.5
Lung and Bronchus	Total	54	120,371	44.9	53.5	56.4	0.815	4,833	8,651,457	55.9
Lung and Bronchus Lung and Bronchus	Male Female	25 29	61,720 58,651	40.5 49.4	48.7 58.4	28.7 27.7	0.559 0.850	2,427 2,406	4,335,190 4,316,267	56.0 55.7
Melanoma of the Skin	Total	42	120,371	34.9	39.9	35.3	0.830	2,400	8,651,457	33.5
Melanoma of the Skin	Male	28	61,720	45.4	52.4	21.4	0.194	1,737	4,335,190	40.1
Melanoma of the Skin	Female	14	58,651	23.9	27.0	14.0	1.000	1,163	4,316,267	26.9
Myeloma	Total	7	120,371	5.8	6.9	8.2	0.838	701	8,651,457	8.1
Myeloma	Male	5	61,720	8.1	9.6	5.2	1.000	436		10.1
Myeloma	Female		58,651	3.4	4.0	3.1	0.820	265	4,316,267	6.1
Non-Hodgkin Lymphoma Non-Hodgkin Lymphoma	Total	21	120,371	17.4	20.2	23.1	0.762 1.000	1,919	8,651,457	22.2
Non-Hodgkin Lymphoma Non-Hodgkin Lymphoma	Male Female	14 7	61,720 58,651	22.7 11.9	26.1 13.8	13.8 9.4	0.553	1,115 804	4,335,190 4,316,267	25.7 18.6
Oral Cavity and Pharynx	Total	8	120,371	6.6	7.7	15.5	0.058	1,287	8,651,457	14.9
Oral Cavity and Pharynx	Male	3	61,720	4.9	5.6	11.6	0.006 <<	933	4,335,190	21.5
Oral Cavity and Pharynx	Female	5	58,651	8.5	9.9	4.1	0.795	354	4,316,267	8.2
Ovary	Female	. 8	58,651	13.6	15.6	6.2	0.573	525	4,316,267	12.2
Pancreas	Total	20	120,371	16.6	19.7	16.5	0.443	1,403	8,651,457	16.2
Pancreas	Male	8	61,720	13.0	15.4	9.3	0.830	776	4,335,190	17.9
Pancreas Prostate	Female Male	12 57	58,651 61,720	20.5 92.4	24.2 109.3	7.2	0.126 0.024 <b>&lt;&lt;</b>	627	4,316,267	14.5 146.7
Stomach	Total	5 <i>1</i>	61,720 120,371	4.2	4.9	76.5 5.5	1.000	6,360 462	4,335,190 8,651,457	5.3
Stomach	Male	4	61,720	6.5	7.6	3.7	1.000	305	4,335,190	7.0
Stomach	Female	1	58,651	1.7	2.0	1.8	0.910	157	4,316,267	3.6
Testis	Male	4	61,720	6.5	6.6	3.7	0.998	261	4,335,190	6.0
Thyroid	Total	11	120,371	9.1	9.8	15.6	0.295	1,209	8,651,457	14.0
Thyroid	Male	4	61,720	6.5	7.0	4.6	1.000	351	4,335,190	8.1
Thyroid	Female	7	58,651	11.9	12.9	10.8	0.319	858	4,316,267	19.9
Pediatric Age 0 to 19	Total	2	39,823	5.0	5.1	6.8	0.068	419	2,420,700	17.3
Pediatric Age 0 to 19	Male	-	20,169	-	-	3.6	0.053	223	1,236,341	18.0
Pediatric Age 0 to 19	Female	2	19,654	10.2	10.4	3.2	0.768	196	1,184,359	16.5

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

<sup>2.</sup> Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

<sup>&</sup>quot;<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

# **TABLE 4: CANCER MORTALITY 2017–2021** COMPARISON BETWEEN JEROME COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Jer	ome County	/			Re	mainder of Idah	0
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	925	121,595	760.7	913.3	873.8	0.089	76,505	8,867,120	862.8
All Causes of Death	Male	521	62,495	833.7	989.9	479.5	0.064	40,535	4,449,373	911.0
All Causes of Death	Female	404	59,100	683.6	827.4	397.6	0.760	35,970	4,417,747	814.2
All Malignant Cancers	Total	165	121,595	135.7	162.5	171.3	0.668	14,956	8,867,120	168.7
All Malignant Cancers	Male	82	62,495	131.2	157.6	94.6	0.208	8,094	4,449,373	181.9
All Malignant Cancers	Female	83	59,100	140.4	167.5	77.0	0.522	6,862	4,417,747	155.3
Bladder	Total	5	121,595	4.1	5.1	5.4	1.000	484	8,867,120	5.5
Bladder	Male	4	62,495	6.4	8.0	4.2	1.000	374	4,449,373	8.4
Bladder	Female	1	59,100	1.7	2.1	1.2	1.000	110	4,417,747	2.5
Brain and Other Nervous System	Total	4	121,595	3.3	3.8	6.0	0.570	500	8,867,120	5.6
Brain and Other Nervous System	Male	1	62,495	1.6	1.8	3.7	0.241	297	4,449,373	6.7
Brain and Other Nervous System	Female	3	59,100	5.1	5.8	2.4	0.848	203	4,417,747	4.6
Breast	Total	10	121,595	8.2	9.7	12.7	0.559	1,092	8,867,120	12.3
Breast	Male	- 10	62,495	16.0	20.0	0.2	1.000	16	4,449,373	0.4
Breast	Female		59,100 59,100	16.9	1.9	12.2 1.0	0.660 1.000	1,076 82	4,417,747 4,417,747	24.4 1.9
Cervix Colorectal	Female Total	1 21	121,595	1.7 17.3	20.4	15.1	0.171	1,298	8,867,120	14.6
Colorectal	Male	10	62,495	16.0	18.7	8.5	0.171	709	4,449,373	15.9
Colorectal	Female	10	59,100	18.6	22.2	6.6	0.703	709 589	4,449,373	13.9
Corpus Uteri	Female	6	59,100	10.2	12.1	1.9	0.024 >>	167	4,417,747	3.8
Esophagus	Total	5	121,595	4.1	4.9	5.4	1.000	472	8,867,120	5.3
Esophagus	Male	5	62,495	8.0	9.5	4.7	1.000	396	4,449,373	8.9
Esophagus	Female	-	59,100	-	-	0.9	0.854	76	4,417,747	1.7
Hodgkin Lymphoma	Total	-	121,595	-	-	0.3	1.000	29	8,867,120	0.3
Hodgkin Lymphoma	Male	-	62,495	-	-	0.2	1.000	14	4.449.373	0.3
Hodgkin Lymphoma	Female	-	59,100	-	-	0.2	1.000	15	4,417,747	0.3
Kidney	Total	1	121,595	0.8	1.0	4.4	0.137	384	8,867,120	4.3
Kidney	Male	1	62,495	1.6	1.9	2.8	0.455	241	4,449,373	5.4
Kidney	Female	-	59,100	-	-	1.6	0.416	143	4,417,747	3.2
Larynx	Total	1	121,595	0.8	1.0	0.8	1.000	70	8,867,120	0.8
Larynx	Male	1	62,495	1.6	1.9	0.7	0.982	57	4,449,373	1.3
Larynx	Female	-	59,100	-	-	0.1	1.000	13	4,417,747	0.3
Leukemia	Total	2	121,595	1.6	2.0	7.5	0.040 <<	658	8,867,120	7.4
Leukemia	Male	2	62,495 59,100	3.2	3.8	4.5	0.350 0.095	384 274	4,449,373	8.6 6.2
Leukemia Liver and Bile Duct	Female Total	- 4	121,595	3.3	3.9	3.0 6.9	0.095	599	4,417,747 8,867,120	6.8
Liver and Bile Duct	Male	3	62,495	4.8	5.9 5.7	4.8	0.595	405	4,449,373	9.1
Liver and Bile Duct	Female	1	59,100	1.7	2.0	2.2	0.393	194	4,449,373	4.4
Lung and Bronchus	Total	29	121,595	23.8	28.8	33.4	0.515	2,932	8,867,120	33.1
Lung and Bronchus	Male	14	62,495	22.4	27.1	17.9	0.430	1,542	4,449,373	34.7
Lung and Bronchus	Female	15	59,100	25.4	30.4	15.5	1.000	1,390	4,417,747	31.5
Melanoma of the Skin	Total	3	121,595	2.5	2.9	3.3	1.000	286	8,867,120	3.2
Melanoma of the Skin	Male	2	62,495	3.2	3.8	2.2	1.000	190	4,449,373	4.3
Melanoma of the Skin	Female	1	59,100	1.7	2.0	1.1	1.000	96	4,417,747	2.2
Myeloma	Total	2	121,595	1.6	2.0	3.7	0.567	329	8,867,120	3.7
Myeloma	Male	1	62,495	1.6	2.0	2.2	0.693	195	4,449,373	4.4
Myeloma	Female	1	59,100	1.7	2.0	1.5	1.000	134	4,417,747	3.0
Non-Hodgkin Lymphoma	Total	7	121,595	5.8	6.9	6.4	0.917	562	8,867,120	6.3
Non-Hodgkin Lymphoma	Male	2	62,495	3.2	3.8	3.6	0.613	305	4,449,373	6.9
Non-Hodgkin Lymphoma	Female	5	59,100	8.5	10.2	2.9	0.322	257	4,417,747	5.8
Oral Cavity and Pharynx	Total	2	121,595	1.6	2.0	3.1	0.824	264	8,867,120	3.0
Oral Cavity and Pharynx	Male	- 0	62,495	- 2 4	- 4.0	2.2	0.217	187	4,449,373	4.2
Oral Cavity and Pharynx	Female	2	59,100 50,100	3.4 6.8	4.0 8.0	0.9 3.9	0.431 1.000	77 346	4,417,747	1.7 7.8
Ovary Pancreas	Female	11	59,100 121,595	9.0	10.9	13.5	0.618		4,417,747 8,867,120	13.3
Pancreas Pancreas	Total Male	2	62,495	3.2	3.8	7.5	0.018	1,179 640	4,449,373	13.3
Pancreas	Female	9	59,100	15.2	18.3	6.0	0.041	539	4,449,373	12.2
Prostate	Male	16	62,495	25.6	32.0	10.5	0.300	933	4,449,373	21.0
Stomach	Total	10	121,595	0.8	1.0	2.3	0.659	197	8,867,120	2.2
Stomach	Male	- '	62,495	-		1.5	0.464	121	4,449,373	2.7
Stomach	Female	1	59,100	1.7	2.0	0.9	1.000	76	4,417,747	1.7
			ne number of cases p						.,,	

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

<sup>2.</sup> Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

### Cancer Screening and Risk Factor Prevalence Estimates, 2011–2021

		State of								Jerome
	Measure	Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	County
•	Access to Care Have Health Insurance, Age <65 (2015–2021) Not See Doctor Due to Cost in Past Year (2015–2021) Cancer Screening	83.1% 12.6%	82.8% 11.4%	85.1% 11.8%	77.2% 14.5%	85.8% 12.4%	78.9% 12.3%	85.4% 11.8%	85.4% 12.9%	73.7% 14.7%
	Mammogram Past 2 Years, Age 50–74 (2014, 2016, 2018, 2020) Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020) Colorectal Cancer Screening, Age 50–75 (2018, 2020) Tobacco Use	69.1% 71.2% 67.9%	67.0% 73.6% 66.9%	73.8% 73.6% 73.6%	68.2% 70.8% 71.4%	73.2% 72.9% 70.6%	64.8% 69.1% 61.7%	64.5% 69.5% 61.5%	67.1% 65.9% 64.7%	70.5%
	Current Tobacco User (2016–2021) Other Cancer-Related	22.3%	26.7%	23.1%	23.6%	21.8%	21.4%	22.7%	16.9%	23.7%
	Healthy Weight by Body Mass Index, Age 20+ (2015–2021)	32.1%	32.8%	31.7%	27.9%	36.1%	29.8%	27.9%	31.9%	29.2%
	Any Physical Activity Besides Job Past 30 Days (2015-2021)	78.7%	79.2%	78.1%	74.5%	83.2%	73.4%	76.3%	79.7%	70.4%
	Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019)	21.9%	22.8%	19.4%	20.0%	25.2%	19.5%	20.4%	20.2%	14.4%
	Home Ever Tested for Radon (2016, 2018, 2020)	23.0%	30.9%	18.2%	16.9%	25.1%	19.9%	23.0%	21.8%	13.3%

### **Access to Care**

### Have Health Insurance - 2015-2021

Statewide, 83.1% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 86.0% of white non-Hispanics, compared to 64.8% of Hispanics and 83.3% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3%) than English-speaking respondents (84.2%). Health care coverage differed significantly by age of respondent, with 79.8% of persons aged 18–29, and 87.8% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 62.1% in Adams County to 91.6% in Oneida County having health insurance.

### Not See Doctor Due to Cost in Past Year - 2015-2021

Statewide, 12.6% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (11.5% of white non-Hispanics, 19.2% of Hispanics, and 21.0% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9% for less than \$15,000, 6.1% for greater than \$50,000). Inability to see a doctor due to cost differed significantly by county, with a range of 7.4% in Franklin County to 17.5% in Power County.

### **Cancer Screening**

<u>Mammogram</u> – 2014, 2016, 2018, 2020

Statewide, 69.1% of women aged 50–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (72.1% versus 36.7%). Mammography rates differed significantly by county, with a range in screening of 45.9% in Benewah County to 77.0% in Nez Perce County. In 2020, Idaho ranked 48<sup>th</sup> among states and the District of Columbia for mammography screening rates among women aged 50–74 and also 48<sup>th</sup> among ages 40+.

### Pap Test - 2018, 2020

Statewide, 71.2% of women with an intact cervix and aged 21–65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.1% versus 52.6% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.7% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49<sup>th</sup> among states and the District of Columbia for Pap screening rate.

### Colorectal Cancer Screening - 2018, 2020

Statewide, 67.9% of adults aged 50–75 reported being current for colorectal cancer screening.\*\* Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked 47<sup>th</sup> among states and the District of Columbia in the percentage of adults aged 50–75 and older who reported being up-to-date for colorectal cancer screening.

<sup>\*\*</sup> Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

### **Tobacco Use**

### Current Tobacco Use - 2016-2021

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.3% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 29.9% of persons aged 18-29, and 11.1% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (22.4%) than among Native Americans (40.0%). Tobacco use differed significantly by county, with a range of 5.4% in Madison County to 41.6% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

### **Other Cancer-Related**

### Healthy Weight by Body Mass Index - 2015-2021

Statewide, 32.1% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 32.5% of white non-Hispanics, compared to 28.2% of Hispanics and 24.6% of Native Americans, being in the healthy weight range. Males (25.5%) were significantly less likely to be in the healthy weight range than females (38.6%). BMI differed significantly by age of respondent, with 43.3% of persons aged 18–29, and 26.0% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 19.8% in Power County to 47.4% in Blaine County of adults being in the healthy weight range.

### Any Physical Activity - 2015-2021

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 78.7% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.3% of persons aged 18–29, and 72.3% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 64.3% in Clark County to 84.6% in Teton County.

Physical Activity Guidelines – 2011, 2013, 2015, 2017, 2019 Statewide, 21.9% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.3% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6% in Franklin County to 30.6% in Blaine County.

### Home Radon Testing - 2016, 2018, 2020

Statewide, 23.0% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.4% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.5% in Cassia County to 54.4% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006l and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.





# KOOTENAI COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

# Cancer Incidence 2016–2020 Cancer Mortality 2017–2021 BRFSS 2011–2021

# RISK FACTORS AND INTERVENTIONS

### **CANCER**

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/jama.2016.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

### Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

### **Smoking:**

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

### Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <a href="https://www.dietaryguidelines.gov">https://www.dietaryguidelines.gov</a>

### Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute
Cancer Information Services
1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society <a href="https://www.cancer.org">https://www.cancer.org</a>

### **CANCER INCIDENCE 2016–2020**

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016–2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 5,018 cases of invasive cancer were diagnosed among Kootenai County residents (Table 1).

**Table 1:** Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Kootenai County and the State of Idaho, 2016–2020

Cancer Incidence 2016–2020	Kootenai County	State of Idaho
All Sites/Types	5,018	45,610
Female Breast	736	6,687
Prostate	705	6,417
Lung & Bronchus	644	4,887
Colorectal	365	3,451

Table 3 (Cancer Incidence 2016–2020, Comparison between Kootenai County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Kootenai County. The table also shows the number of observed cases, person-

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Kootenai County was 620.7 cases per 100,000 person-years per year during 2016–2020. Comparing this crude rate with the crude rate for the remainder of Idaho (509.7) gives an estimate of the relative burden of disease in Kootenai County.

The age- and sex-adjusted incidence rate of invasive cancer in Kootenai County, all sites combined, was 535.3 cases per 100,000 persons per year during 2016–2020. There were statistically significantly more cases of cancer in Kootenai County (5,018) than expected (4,778.6) based upon rates in the remainder of the state (p<.001).

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

### **CANCER MORTALITY 2017–2021**

During 2017–2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 1,805 Kootenai County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

**Table 2:** Overall and Cancer Mortality in Kootenai County and the State of Idaho, 2017–2021

Mortality 2017–2021	Kootenai County	State of Idaho
All Deaths	8,331	77,431
Cancer Deaths	1,805	15,121
% of All Deaths	21.7%	19.5%
Lung & Bronchus	381	2,961
Colorectal	135	1,319
Pancreas	141	1,190
Female Breast	128	1,086
Prostate	122	949

Table 4 (Cancer Mortality 2017–2021, Comparison between Kootenai County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Kootenai County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Kootenai County, all sites combined, was 184.2 deaths per 100,000 persons per year during 2017–2021, compared with 163.3 for the remainder of the state. There were statistically significantly more cancer deaths in Kootenai County (1,805) than expected (1,600.5) based upon rates in the remainder of the state (p<.001).

**Statistical Note:** Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

# TABLE 3: CANCER INCIDENCE 2016–2020 COMPARISON BETWEEN KOOTENAI COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Koo	tenai Count	iy .			Rem	nainder of Ida	iho
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)
All Sites Combined	Total	5,018	808,378	620.7	535.3	4,778.6	0.001 >>	40,592	7,963,450	509.7
All Sites Combined	Male	2,651	399,587	663.4	569.6 502.5	2,519.4	0.009 >> 0.016 >>	21,638	3,997,323	541.3
All Sites Combined Bladder	Female Total	2,367 235	408,791 808,378	579.0 29.1	24.5	2,251.0 235.1	1.000	18,954 1,949	3,966,127 7,963,450	477.9 24.5
Bladder	Male	182	399,587	45.5	38.3	186.5	0.781	1,569	3,997,323	39.3
Bladder	Female	53	408,791	13.0	11.0	46.3	0.362	380	3,966,127	9.6
Brain - malignant	Total	58	808,378	7.2	6.4	64.1	0.488	567	7,963,450	7.1
Brain - malignant	Male	34	399,587	8.5	7.7	37.8	0.602	341	3,997,323	8.5
Brain - malignant	Female	24	408,791	5.9	5.2	26.1	0.782	226	3,966,127	5.7
Brain and other CNS - non-malignant	Total	138	808,378	17.1	15.1	147.5	0.462	1,286	7,963,450	16.1
Brain and other CNS - non-malignant	Male	45	399,587	11.3	10.1	48.5	0.678 0.534	435	3,997,323	10.9
Brain and other CNS - non-malignant Breast	Female Total	93 743	408,791 808,378	22.8 91.9	20.0 80.1	99.8 699.3	0.534	851 6,003	3,966,127 7,963,450	21.5 75.4
Breast	Male	7 7	399,587	1.8	1.5	6.1	0.809	52	3,997,323	1.3
Breast	Female	736	408,791	180.0	156.2	706.9	0.282	5,951	3,966,127	150.0
Breast - in situ	Total	129	808,378	16.0	13.9	129.0	1.000	1,110	7,963,450	13.9
Breast - in situ	Male	1	399,587	0.3	0.2	0.4	0.714	4	3,997,323	0.1
Breast - in situ	Female	128	408,791	31.3	27.2	131.3	0.817	1,106	3,966,127	27.9
Celoradal	Female	36	408,791	8.8	8.3	29.2	0.249	268	3,966,127	6.8
Colorectal Colorectal	Total Male	365 199	808,378 399,587	45.2 49.8	39.1 43.2	362.0 196.2	0.889 0.863	3,086 1,704	7,963,450 3,997,323	38.8 42.6
Colorectal	Female	166	408.791	49.6	35.1	164.7	0.003	1,704	3,966,127	34.8
Corpus Uteri	Female	155	408,791	37.9	32.7	140.4	0.238	1,175	3,966,127	29.6
Esophagus	Total	45	808,378	5.6	4.7	55.1	0.191	461	7,963,450	5.8
Esophagus	Male	40	399,587	10.0	8.5	45.0	0.511	384	3,997,323	9.6
Esophagus	Female	5	408,791	1.2	1.0	9.4	0.191	77	3,966,127	1.9
Hodgkin Lymphoma	Total	19	808,378	2.4	2.3	19.9	0.955	191	7,963,450	2.4
Hodgkin Lymphoma	Male	12	399,587 408.791	3.0	2.9	11.0	0.846	106	3,997,323	2.7
Hodgkin Lymphoma Kidney and Renal Pelvis	Female Total	7 216	808,378	1.7 26.7	1.7 23.2	8.8 187.3	0.697 0.043 >>	85 1,599	3,966,127 7,963,450	2.1 20.1
Kidney and Renal Pelvis	Male	139	399,587	34.8	30.3	119.8	0.093	1,043	3,997,323	26.1
Kidney and Renal Pelvis	Female	77	408.791	18.8	16.3	66.2	0.211	556	3,966,127	14.0
Larynx	Total	22	808,378	2.7	2.3	23.0	0.946	193	7,963,450	2.4
Larynx	Male	17	399,587	4.3	3.6	16.8	1.000	143	3,997,323	3.6
Larynx	Female	5	408,791	1.2	1.1	6.0	0.904	50	3,966,127	1.3
Leukemia	Total	179	808,378	22.1	19.3	169.2	0.473	1,452	7,963,450	18.2
Leukemia	Male	115	399,587	28.8	25.1	100.2	0.158 0.646	874 578	3,997,323	21.9
Leukemia Liver and Bile Duct	Female Total	64 105	408,791 808,378	15.7 13.0	13.6 11.1	68.4 86.3	0.046	724	3,966,127 7,963,450	14.6 9.1
Liver and Bile Duct	Male	69	399,587	17.3	14.8	60.8	0.324	521	3,997,323	13.0
Liver and Bile Duct	Female	36	408,791	8.8	7.5	24.6	0.036 >>	203	3,966,127	5.1
Lung and Bronchus	Total	644	808,378	79.7	66.9	513.3	0.000 >>	4,243	7,963,450	53.3
Lung and Bronchus	Male	316	399,587	79.1	66.4	254.5	0.000 >>	2,136	3,997,323	53.4
Lung and Bronchus	Female	328	408,791	80.2	67.4	258.4	0.000 >>	2,107	3,966,127	53.1
Melanoma of the Skin	Total	266	808,378	32.9	28.8	310.5	0.011 <<	2,676	7,963,450	33.6
Melanoma of the Skin	Male Female	163	399,587	40.8	35.4	184.7	0.115	1,602	3,997,323	40.1
Melanoma of the Skin Myeloma	Total	103 91	408,791 808,378	25.2 11.3	22.4 9.5	124.8 74.0	0.052 0.062	1,074 617	3,966,127 7,963,450	27.1 7.7
Myeloma	Male	58	399,587	14.5	12.3	45.2	0.002	383	3,997,323	9.6
Myeloma	Female	33	408,791	8.1	6.8	28.5	0.441	234	3,966,127	5.9
Non-Hodgkin Lymphoma	Total	205	808,378	25.4	22.0	203.4	0.930	1,735	7,963,450	21.8
Non-Hodgkin Lymphoma	Male	120	399,587	30.0	26.1	115.9	0.725	1,009	3,997,323	25.2
Non-Hodgkin Lymphoma	Female	85	408,791	20.8	17.9	86.9	0.897	726	3,966,127	18.3
Oral Cavity and Pharynx	Total	142	808,378	17.6	15.1	136.3	0.645	1,153	7,963,450	14.5
Oral Cavity and Pharynx Oral Cavity and Pharynx	Male Female	100 42	399,587 408,791	25.0 10.3	21.6 8.8	96.8 38.0	0.775 0.555	836 317	3,997,323 3,966,127	20.9 8.0
Ovary	Female	56	408,791	13.7	11.9	56.5	1.000	477	3,966,127	12.0
Pancreas	Total	153	808,378	18.9	16.0	152.1	0.964	1,270	7,963,450	15.9
Pancreas	Male	79	399,587	19.8	16.8	83.0	0.716	705	3,997,323	17.6
Pancreas	Female	74	408,791	18.1	15.3	68.7	0.554	565	3,966,127	14.2
Prostate	Male	705	399,587	176.4	149.4	674.4	0.248	5,712	3,997,323	142.9
Stomach	Total	54	808,378	6.7	5.7	48.8	0.492	413	7,963,450	5.2
Stomach	Male Female	40 14	399,587	10.0	8.6	31.4	0.159	269 144	3,997,323	6.7
Stomach Testis	Female Male	14 20	408,791 399,587	3.4 5.0	3.0 5.2	17.1 23.7	0.553 0.521	144 245	3,966,127 3,997,323	3.6 6.1
Thyroid	Total	102	808,378	12.6	11.8	120.9	0.521	1,118	7,963,450	14.0
Thyroid	Male	28	399,587	7.0	6.4	35.6	0.069	327	3,997,323	8.2
Thyroid	Female	74	408,791	18.1	17.1	86.3	0.226	791	3,966,127	19.9
Pediatric Age 0 to 19	Total	28	201,782	13.9	13.9	35.1	0.264	393	2,258,741	17.4
Pediatric Age 0 to 19	Male	14	104,139	13.4	13.4	18.9	0.310	209	1,152,371	18.1
Pediatric Age 0 to 19	Female	14	97,643	14.3	14.4	16.2	0.702	184	1,106,370	16.1
Note:			·	ne per 100 000		ar (person yea			, ,	

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

<sup>2.</sup> Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

<sup>&</sup>quot;<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

# **TABLE 4: CANCER MORTALITY 2017–2021** COMPARISON BETWEEN KOOTENAI COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Koo	tenai Count	.y			Re	mainder of Idah	10
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	8,331	834,946	997.8	864.8	8,163.4	0.065	69,099	8,153,769	847.4
All Causes of Death	Male	4,344	413,567	1,050.4	914.4	4,255.4	0.178	36,712	4,098,301	895.8
All Causes of Death	Female	3,987	421,379	946.2	818.3	3,891.0	0.126	32,387	4,055,468	798.6
All Malignant Cancers	Total	1,805	834,946	216.2	184.2	1,600.5	0.000 >>	13,316	8,153,769	163.3
All Malignant Cancers	Male	972	413,567	235.0	200.3	853.0	0.000 >>	7,204	4,098,301	175.8
All Malignant Cancers	Female	833	421,379	197.7	168.7	744.2	0.001 >>	6,112	4,055,468	150.7
Bladder	Total	55	834,946	6.6	5.6	52.4	0.755	434	8,153,769	5.3
Bladder	Male	42	413,567	10.2	8.6	39.9	0.776	336	4,098,301	8.2
Bladder	Female	13	421,379	3.1	2.6	12.0	0.855	98	4,055,468	2.4
Brain and Other Nervous System	Total	58	834,946	6.9	6.1	52.2	0.461	446	8,153,769	5.5
Brain and Other Nervous System	Male	41 17	413,567	9.9	8.7	29.5 22.6	0.052	257	4,098,301	6.3 4.7
Brain and Other Nervous System Breast	Female Total	129	421,379 834,946	4.0	3.5 13.3	115.5	0.281 0.229	189 973	4,055,468 8,153,769	11.9
Breast	Male	129	413,567	15.5 0.2	0.2	1.8	0.229	15	4,098,301	0.4
Breast	Female	128	421,379	30.4	26.1	115.7	0.931	958	4,055,468	23.6
Cervix	Female	4	421,379	0.9	0.9	9.0	0.108	79	4,055,468	1.9
Colorectal	Total	135	834,946	16.2	13.9	140.9	0.658	1,184	8,153,769	14.5
Colorectal	Male	74	413,567	17.9	15.5	75.2	0.948	645	4,098,301	15.7
Colorectal	Female	61	421,379	14.5	12.4	65.2	0.658	539	4,055,468	13.3
Corpus Uteri	Female	21	421,379	5.0	4.2	18.7	0.646	152	4,055,468	3.7
Esophagus	Total	53	834,946	6.3	5.4	51.1	0.830	424	8,153,769	5.2
Esophagus	Male	47	413,567	11.4	9.7	41.9	0.471	354	4,098,301	8.6
Esophagus	Female	6	421,379	1.4	1.2	8.6	0.500	70	4,055,468	1.7
Hodgkin Lymphoma	Total	-	834,946	-	-	3.4	0.069	29	8,153,769	0.4
Hodgkin Lymphoma	Male	-	413,567	-	-	1.6	0.407	14	4,098,301	0.3
Hodgkin Lymphoma	Female	- 40	421,379	-	-	1.8	0.342	15	4,055,468	0.4
Kidney	Total Male	43 22	834,946 413,567	5.2 5.3	4.4 4.5	41.3 26.0	0.833 0.499	342 220	8,153,769 4,098,301	4.2 5.4
Kidney Kidney	Female	22	413,567 421,379	5.0	4.3	15.0	0.499	122	4.055.468	3.0
Larynx	Total	7	834,946	0.8	0.7	7.7	0.103	64	8,153,769	0.8
Larynx	Male	5	413,567	1.2	1.0	6.3	0.805	53	4,098,301	1.3
Larynx	Female	2	421,379	0.5	0.4	1.3	0.773	11	4,055,468	0.3
Leukemia	Total	72	834,946	8.6	7.4	70.4	0.883	588	8,153,769	7.2
Leukemia	Male	40	413,567	9.7	8.3	40.8	0.978	346	4,098,301	8.4
Leukemia	Female	32	421,379	7.6	6.5	29.4	0.676	242	4,055,468	6.0
Liver and Bile Duct	Total	73	834,946	8.7	7.4	64.0	0.289	530	8,153,769	6.5
Liver and Bile Duct	Male	54	413,567	13.1	11.1	42.0	0.083	354	4,098,301	8.6
Liver and Bile Duct	Female	19	421,379	4.5	3.8	21.6	0.678	176	4,055,468	4.3
Lung and Bronchus	Total	381	834,946	45.6	38.4	313.7	0.000 >>	2,580	8,153,769	31.6
Lung and Bronchus	Male	184	413,567	44.5	37.5	164.2	0.136	1,372	4,098,301	33.5
Lung and Bronchus	Female Total	197	421,379	46.8	39.5	148.7 29.6	0.000 <b>&gt;&gt;</b>	1,208 249	4,055,468	29.8
Melanoma of the Skin Melanoma of the Skin	Male	40 32	834,946 413,567	4.8 7.7	4.1 6.6	29.0 18.8	0.000	160	8,153,769 4,098,301	3.1 3.9
Melanoma of the Skin	Female	8	421,379	1.9	1.6	10.7	0.524	89	4,055,468	2.2
Myeloma	Total	28	834,946	3.4	2.8	37.0	0.324	303	8,153,769	3.7
Myeloma	Male	22	413,567	5.3	4.5	20.9	0.868	174	4,098,301	4.2
Myeloma	Female	6	421,379	1.4	1.2	15.9	0.009 <<	129	4,055,468	3.2
Non-Hodgkin Lymphoma	Total	62	834,946	7.4	6.3	61.1	0.939	507	8,153,769	6.2
Non-Hodgkin Lymphoma	Male	37	413,567	8.9	7.6	31.9	0.412	270	4,098,301	6.6
Non-Hodgkin Lymphoma	Female	25	421,379	5.9	5.0	29.0	0.522	237	4,055,468	5.8
Oral Cavity and Pharynx	Total	37	834,946	4.4	3.8	27.6	0.102	229	8,153,769	2.8
Oral Cavity and Pharynx	Male	27	413,567	6.5	5.5	19.0	0.097	160	4,098,301	3.9
Oral Cavity and Pharynx	Female	10	421,379	2.4	2.0	8.4	0.666	69	4,055,468	1.7
Ovary	Female	34	421,379	8.1	6.9	38.6	0.515	316	4,055,468	7.8
Pancreas Pancreas	Total Male	141 76	834,946 413,567	16.9 18.4	14.3 15.6	127.1 67.3	0.236 0.320	1,049 566	8,153,769 4,098,301	12.9 13.8
Pancreas	Female	65	421,379	15.4	13.0	59.5	0.520	483	4,055,468	11.9
Prostate	Male	122	413,567	29.5	25.0	98.6	0.025 >>	827	4,098,301	20.2
Stomach	Total	16	834,946	1.9	1.7	21.6	0.023	182	8,153,769	2.2
Stomach	Male	10	413,567	2.4	2.1	13.1	0.493	111	4,098,301	2.7
Stomach	Female	6	421,379	1.4	1.2	8.4	0.530	71	4,055,468	1.8
			ne number of cases r				0.000		.,555,156	1.0

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

<sup>2.</sup> Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

### Cancer Screening and Risk Factor Prevalence Estimates, 2011–2021

	State of								Kootenai
Measure	Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	County
Access to Care									
Have Health Insurance, Age <65 (2015–2021)	83.1%	82.8%	85.1%	77.2%	85.8%	78.9%	85.4%	85.4%	83.9%
Not See Doctor Due to Cost in Past Year (2015–2021)	12.6%	11.4%	11.8%	14.5%	12.4%	12.3%	11.8%	12.9%	11.2%
Cancer Screening									
Mammogram Past 2 Years, Age 50–74 (2014, 2016, 2018, 2020)	69.1%	67.0%	73.8%	68.2%	73.2%	64.8%	64.5%	67.1%	72.4%
Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020)	71.2%	73.6%	73.6%	70.8%	72.9%	69.1%	69.5%	65.9%	75.6%
Colorectal Cancer Screening, Age 50–75 (2018, 2020)	67.9%	66.9%	73.6%	71.4%	70.6%	61.7%	61.5%	64.7%	72.9%
Tobacco Use									
Current Tobacco User (2016–2021)	22.3%	26.7%	23.1%	23.6%	21.8%	21.4%	22.7%	16.9%	26.3%
Other Cancer-Related									
Healthy Weight by Body Mass Index, Age 20+ (2015–2021)	32.1%	32.8%	31.7%	27.9%	36.1%	29.8%	27.9%	31.9%	32.4%
Any Physical Activity Besides Job Past 30 Days (2015-2021)	78.7%	79.2%	78.1%	74.5%	83.2%	73.4%	76.3%	79.7%	80.1%
Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019)	21.9%	22.8%	19.4%	20.0%	25.2%	19.5%	20.4%	20.2%	23.3%
Home Ever Tested for Radon (2016, 2018, 2020)	23.0%	30.9%	18.2%	16.9%	25.1%	19.9%	23.0%	21.8%	34.7%

### **Access to Care**

### Have Health Insurance - 2015-2021

Statewide, 83.1% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 86.0% of white non-Hispanics, compared to 64.8% of Hispanics and 83.3% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3%) than English-speaking respondents (84.2%). Health care coverage differed significantly by age of respondent, with 79.8% of persons aged 18–29, and 87.8% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 62.1% in Adams County to 91.6% in Oneida County having health insurance.

### Not See Doctor Due to Cost in Past Year - 2015-2021

Statewide, 12.6% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (11.5% of white non-Hispanics, 19.2% of Hispanics, and 21.0% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9% for less than \$15,000, 6.1% for greater than \$50,000). Inability to see a doctor due to cost differed significantly by county, with a range of 7.4% in Franklin County to 17.5% in Power County.

### **Cancer Screening**

Mammogram - 2014, 2016, 2018, 2020

Statewide, 69.1% of women aged 50–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (72.1% versus 36.7%). Mammography rates differed significantly by county, with a range in screening of 45.9% in Benewah County to 77.0% in Nez Perce County. In 2020, Idaho ranked 48<sup>th</sup> among states and the District of Columbia for mammography screening rates among women aged 50–74 and also 48<sup>th</sup> among ages 40+.

### Pap Test - 2018, 2020

Statewide, 71.2% of women with an intact cervix and aged 21–65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.1% versus 52.6% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.7% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49<sup>th</sup> among states and the District of Columbia for Pap screening rate.

### Colorectal Cancer Screening – 2018, 2020

Statewide, 67.9% of adults aged 50–75 reported being current for colorectal cancer screening.\*\* Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked 47<sup>th</sup> among states and the District of Columbia in the percentage of adults aged 50–75 and older who reported being up-to-date for colorectal cancer screening.

<sup>\*\*</sup> Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

### **Tobacco Use**

### Current Tobacco Use - 2016-2021

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.3% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 29.9% of persons aged 18-29, and 11.1% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (22.4%) than among Native Americans (40.0%). Tobacco use differed significantly by county, with a range of 5.4% in Madison County to 41.6% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

### **Other Cancer-Related**

### Healthy Weight by Body Mass Index - 2015-2021

Statewide, 32.1% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 32.5% of white non-Hispanics, compared to 28.2% of Hispanics and 24.6% of Native Americans, being in the healthy weight range. Males (25.5%) were significantly less likely to be in the healthy weight range than females (38.6%). BMI differed significantly by age of respondent, with 43.3% of persons aged 18–29, and 26.0% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 19.8% in Power County to 47.4% in Blaine County of adults being in the healthy weight range.

### Any Physical Activity - 2015-2021

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 78.7% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.3% of persons aged 18–29, and 72.3% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 64.3% in Clark County to 84.6% in Teton County.

Physical Activity Guidelines – 2011, 2013, 2015, 2017, 2019 Statewide, 21.9% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.3% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6% in Franklin County to 30.6% in Blaine County.

### Home Radon Testing - 2016, 2018, 2020

Statewide, 23.0% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.4% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.5% in Cassia County to 54.4% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006l and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.





# LATAH COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

# Cancer Incidence 2016–2020 Cancer Mortality 2017–2021 BRFSS 2011–2021

# **RISK FACTORS AND INTERVENTIONS**

### **CANCER**

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/jama.2016.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

### Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

### **Smoking:**

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

### Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <a href="https://www.dietaryguidelines.gov">https://www.dietaryguidelines.gov</a>

### Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute
Cancer Information Services
1-800-4CANCER
<a href="https://www.cancer.gov/contact">https://www.cancer.gov/contact</a>

American Cancer Society <a href="https://www.cancer.org">https://www.cancer.org</a>

### **CANCER INCIDENCE 2016–2020**

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016–2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 807 cases of invasive cancer were diagnosed among Latah County residents (Table 1).

**Table 1:** Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Latah County and the State of Idaho, 2016–2020

Cancer Incidence 2016–2020	Latah County	State of Idaho
All Sites/Types	807	45,610
Female Breast	130	6,687
Prostate	149	6,417
Lung & Bronchus	92	4,887
Colorectal	50	3,451

Table 3 (Cancer Incidence 2016–2020, Comparison between Latah County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Latah County. The table also shows the number of observed cases, person-

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Latah County was 403.0 cases per 100,000 person-years per year during 2016–2020. Comparing this crude rate with the crude rate for the remainder of Idaho (522.7) gives an estimate of the relative burden of disease in Latah County.

The age- and sex-adjusted incidence rate of invasive cancer in Latah County, all sites combined, was 468.6 cases per 100,000 persons per year during 2016–2020. There were statistically significantly fewer cases of cancer in Latah County (807) than expected (900.2) based upon rates in the remainder of the state (p=.002).

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

### **CANCER MORTALITY 2017–2021**

During 2017–2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 267 Latah County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

**Table 2:** Overall and Cancer Mortality in Latah County and the State of Idaho, 2017–2021

Mortality 2017–2021	Latah County	State of Idaho
All Deaths	1,189	77,431
Cancer Deaths	267	15,121
% of All Deaths	22.5%	19.5%
Lung & Bronchus	51	2,961
Colorectal	19	1,319
Pancreas	20	1,190
Female Breast	20	1,086
Prostate	17	949

Table 4 (Cancer Mortality 2017–2021, Comparison between Latah County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Latah County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Latah County, all sites combined, was 152.5 deaths per 100,000 persons per year during 2017–2021, compared with 169.0 for the remainder of the state. There were fewer cancer deaths in Latah County (267) than expected (295.9) based upon rates in the remainder of the state, but the difference was not statistically significant.

**Statistical Note:** Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

# TABLE 3: CANCER INCIDENCE 2016–2020 COMPARISON BETWEEN LATAH COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

All Sites Combined  Male  All Sites Combined  Female  Total  Total  Total  All Sites Combined  Female  Total  Tota				La	tah County				Ren	nainder of Ida	aho
All Sites Combined  Male  All Sites Combined  Male  All Sites Combined  Male  All Sites Combined  Male  Female	Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude
All Sines Combined   Male   430   102.192   420.8   483.2   484.4   0.013 < < 2.889   4.294.718   555.5   485.7   485.00   485.00   486.2   486.4   487.8   48	Site/Type	Sex	Cases		Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)			` '
Ail Silase Combined  Fernale  77   98,066   384.4   442.4   417.5   0.049 < 2.944   4.27.6   4.27.6   6.252   4.80.7   Bladder   Total   37   200,258   8.5   2.17.4   4.28   0.285   1.72.4   4.27.6   6.25   Bladder   Total   1.00.165   2.7.6   3.4   0.285   1.72.4   4.27.6   6.25   Bladder   Total   1.00.165   2.7.6   3.4   0.285   1.72.4   4.27.6   6.25   Bladder   Total   1.00.165   2.7.7   3.2.7   0.791   6.17   4.27.6   6.10   Brain - malignant   Male   10   102.192   9.8   11.0   7.7   0.502   365   4.294.118   8.5   Brain - malignant   St non-malignant   Male   10   102.192   9.8   11.0   7.7   0.502   365   4.294.118   8.5   Brain and other CNS - non-malignant   Male   10   102.192   9.8   11.0   9.7   0.986   1.47   4.276.652   8.5   Brain and other CNS - non-malignant   Total   130   200.258   6.49   76.9   130.5   1.000   6.616   8.571.570   77.2   Breast in situ   Fernale   10.292   12.26   13.25   1.000   6.616   8.571.570   77.2   Breast in situ   Fernale   20   98.066   2.96   3.50   0.232   0.232   0.239   8.571.570   77.2   Breast in situ   Fernale   20   98.066   2.96   3.50   0.232   0.232   0.239   8.571.570   77.2   Breast in situ   Fernale   20   98.066   2.96   3.50   0.232   0.232   0.239   8.571.570   77.2   Breast in situ   Fernale   20   98.066   2.96   3.50   0.232   0.232   0.239   8.571.570   77.2   Breast in situ   Fernale   20   98.066   2.96   3.50   0.232   0.232   0.239   8.571.570   0.732   Breast in situ   Fernale   20   98.066   2.96   3.50   0.232   0.232   0.239   8.571.570   0.732   Breast in situ   Fernale   20   98.066   2.96   3.50   0.038   0.232   0.239   8.571.570   0.732   Breast in situ   Fernale   20   98.066   2.96   3.50   0.232   0.232   0.239   8.571.570   0.732   Breast in situ   Fernale   20   98.066   2.96   3.50   0.232   0.232   0.239   8.571.570   0.232	All Sites Combined										
Bladder											
Bladder	Bladder									, -,	
Brain - mailignant	Bladder				27.4					4,294,718	
Brain - malignant Female   10   102,192   9.8   11.0   7.7   0.502   365   248,7187   8.5   5.8   1.5											
Brain - mailgnant   Female   4   98,066   4.1   4.6   5.0   0.866   246   4276,852   5.8   Brain and other CNS - non-mailgnant   Total   28   200,258   4.0   1.0   24,07   1.0   24,07   1.0   24,07   1.0   24,07   1.0   24,07   1.0   24,07   1.0   24,07   1.0   24,07   1.0   24,07   1.0   24,07   1.0   24,07   1.0   24,07   1.0   24,07   1.0   24,07   1.0   24,07   1.0   24,07   1.0   24,07   1.0   24,07   24,0											
Brain and other CNS - non-melignant   Total   28   200,258   14.0   16.0   28.4   1.000   1.396   8.71,570   16.3   16.3   17.0   16.3   17.0   16.3   17.0   16.3   17.0											
Brain and other CNS - non-malignant   Female   18   98,066   18.4   20.9   18.7   1.000   926   4.276,852   21.7   Breast   Mahamata   130   200,258   64.9   76.9   130.5   1.000   6.616   6.57,757   77.2   Breast   Mahamata   130   200,258   64.9   76.9   130.5   1.000   6.616   6.57,757   77.5     1.4   1.4   1.5	Brain and other CNS - non-malignant			200,258	14.0	16.0	28.4	1.000	1,396	8,571,570	16.3
Breast   Total   130   200,258   64,9   76,9   130,5   1,000   6,616   8,571,570   77.2   Breast   Male	Brain and other CNS - non-malignant										
Breast Male - 102,192 1.2 0.612 59 4,294,718 1.4 Perset Frenst Female 100 80,066 132.6 155.7 128.0 0.886 6,557 4,768.52 153.3 Breast - in situ Total 30 200,258 15.0 17.9 23.6 0.232 1,209 8,571,570 14.1 perset - in situ Male 1 102,92 10.0 17.9 23.6 0.232 1,209 8,571,570 14.1 perset - in situ Female 2 80,066 132.6 17.9 23.6 0.232 1,209 8,571,570 14.1 perset - in situ Female 2 80,066 2 28.5 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0											
Breast in situ   Total   130   89.066   132.6   135.7   128.0   0.886   6,557   4,276.852   153.3   Breast in situ   Male   1   102.192   1.0   1.79   2.26   0.232   0.232   1.0   1.53   4   4,294.718   0.1   1.0			-		- 04.9	70.9					
Breast in situ	Breast		130	98,066		155.7	128.0	0.886	6,557		
Breast In situ	Breast - in situ										
Cervix Female 5 98,066 5.1 5.8 6.0 0.899 2.99 4,276,852 7.0 Coloriectal Total 50 200,258 2.50 2.92 68.0 0.028 4.3401 8,571,570 39.7 Coloriectal Male 29 102,192 28.4 33.6 37.6 0.178 1.374 4,294,718 43.6 Coloriectal Female 21 98,066 21.4 24.7 30.4 0.094 1.527 4,276,852 30.5 Corpus Utel Female 27 98,066 27.5 32.2 25.5 0.822 1.303 4,276,852 30.5 Esophagus Total 11 200,258 5.5 6.5 98.0 0.788 485 8,571,570 5.8 Esophagus Male 31 100,258 5.5 6.5 98.0 0.788 485 8,571,570 5.8 Esophagus Male 31 100,258 5.5 6.5 98.0 0.788 485 8,571,570 5.8 Esophagus Male 31 100,258 5.5 6.5 98.0 0.788 485 8,571,570 5.8 Esophagus Male 31 100,258 5.5 6.5 98.0 0.788 485 8,571,570 5.8 Esophagus Male 31 100,258 5.5 6.5 98.0 0.788 485 8,571,570 5.8 Esophagus Male 31 100,258 5.5 6.5 98.0 0.788 485 8,571,570 5.8 Esophagus Male 31 100,258 5.5 6.5 98.0 0.788 485 8,571,570 5.8 Esophagus Male 31 100,258 5.5 6.5 98.0 0.788 485 8,571,570 5.8 Esophagus Male 31 100,258 5.5 6.5 98.0 0.788 485 8,571,570 5.8 Esophagus Male 31 100,258 5.5 6.5 98.0 0.880 116 4,294,718 2.7 Hodgkin Lymphoma Male 2 102,192 2.0 1.9 2.9 0.880 116 4,294,718 2.7 Hodgkin Lymphoma Female 1 98,066 1.0 0.9 2.5 0.580 91 4,276,852 2.7 Esophagus Male 18 100,192 1.0 0.9 2.5 0.580 91 4,276,852 2.7 Esophagus Male 18 100,192 1.0 0.9 2.5 0.580 91 4,294,788 2.7 Hodgkin Lymphoma Female 18 100,192 1.0 0.9 2.2 0.303 < 628 4,276,852 1.47 Larynx Male 18 100,2192 1.0 0.2 2.2 0.303 < 628 4,276,852 1.47 Larynx Male 18 100,2192 1.0 1.2 3.2 0.334 5.59 4.294,718 3.7 Larynx Male 19 100,2192 1.0 1.2 3.2 0.346 5.9 4,294,718 3.7 Larynx Male 19 100,2192 1.0 1.2 3.2 0.346 5.9 4,294,718 3.7 Larynx Male 19 100,2192 1.0 1.2 3.2 0.346 5.9 4,276,852 1.47 Larynx Male 19 100,2192 1.0 1.2 3.2 0.346 5.9 4,276,852 1.47 Larynx Male 19 100,2192 1.0 1.2 3.2 0.346 5.9 4,276,852 1.47 Larynx Male 19 100,2192 1.0 1.2 3.2 0.346 5.9 4,276,852 1.47 Larynx Male 19 100,2192 1.0 1.2 3.2 0.346 5.9 4,276,852 1.47 Larynx Male 19 100,2192 1.0 1.2 3.2 0.346 5.9 4,276,852 1.47 Larynx Male 19 100,2192 1.0 1.0 1.2 4.7 0.100 1.2 4.7 0.100 1.2 4.			• 1								
Colorectal											
Colorectal	Colorectal			200,258							
Corpus   Female   27   98,066   27.5   32.2   25.5   0.822   1,303   4,276,852   30.5   Esophagus   Total   11   200,258   5.5   6.5   9.8   0.789   495   8,571,570   5.8   Esophagus   Male   8   102,192   7.8   9.3   8.3   1,000   416   4,294,718   9.7   Esophagus   Female   3   98,066   3.1   3.6   1.6   0.409   79   4,276,852   1.8   1.6   1	Colorectal	Male	29	102,192	28.4	33.6	37.6	0.178	1,874	4,294,718	43.6
Seophagus	Colorectal			,							
Esophagus											
Esophagius											
Hodgkin Lymphoma   Male   2   102,192   2.0   1.9   2.9   0.890   116   4,294,718   2.7	Esophagus		3		3.1	3.6	1.6			4,276,852	1.8
Hodgkin Lymphoma   Female   1   98,066   1.0   0.9   2.5   0.580   91   4,276,852   2.1   1.0   1.0   2.3   200,258   11.5   13.6   35.4   0.036 < 1.792   8,571,570   20.9   1.0   20.9   2.5   2.0	Hodgkin Lymphoma										
Kidney and Renal Pelvis Kidney and Renal Pelvis Kidney and Renal Pelvis Kidney and Renal Pelvis Kidney and Renal Pelvis Female 5 98.066 5.1 6.0 12.3 0.332 1.164 4.294,718 27.1 Larynx Total Larynx Male 1 102,192 17.6 0.12 3.2 0.329 1.164 4.294,718 3.7 Larynx Male 1 102,192 1.0 1.2 3.2 0.346 159 4.294,718 3.7 Larynx Female 1 1 98.066 1.0 1.1 1.1 1.000 54 4.276,852 1.3 Leukemia Leukemia Leukemia Male 9 102,192 8.8 10.3 19.9 0.011 4.980 4.294,718 3.7 Leukemia Leukemia Buleut Female 14 98.066 1.0 1.1 1.2 8.0 80.0 662 4.276,852 1.3 Leukemia Leukemia Buleut Female 14 98.066 1.0 1.1 1.2 8.0 80.0 662 8.8 15.75.70 18.8 Leukemia Leukemia Buleut Female 14 98.066 1.0 8.2 1.0 8.0 80.0 62 628 4.276,852 1.47 Liver and Bile Duct Male 13 102,192 12.7 15.1 11.6 0.749 57.7 4.294,718 13.4 Leur and Bile Duct Male 13 102,192 12.7 15.1 11.6 0.749 57.7 4.294,718 13.4 Lury and Bile Duct Male 13 102,192 12.7 15.1 11.6 0.749 57.7 4.294,718 13.4 Lury and Bile Duct Female 14 98.066 1.0 1.2 4.7 0.102 2.38 4.276,852 5.6 Lung and Bronchus Male 39 102,192 38.2 45.2 48.5 0.891 2.241 4.294,718 56.2 Lung and Bronchus Male 39 102,192 38.2 45.2 48.5 0.891 2.241 4.294,718 56.2 Lung and Bronchus Male 39 102,192 38.2 45.2 48.5 0.891 2.241 4.294,718 56.2 Lung and Bronchus Male 39 102,192 38.2 45.2 48.5 0.891 2.241 4.294,718 56.2 Lung and Bronchus Male 39 102,192 38.2 45.2 48.5 0.891 2.241 4.294,718 56.2 Lung and Bronchus Male 39 102,192 38.2 45.2 48.5 0.891 2.241 4.294,718 56.2 Lung and Bronchus Male 39 102,192 38.2 45.2 48.5 0.891 2.241 4.294,718 4.294,718 56.2 Lung and Bronchus Male 39 102,192 38.2 45.2 48.6 0.895 8.791,570 55.9 Melanoma of the Skin Male 40 102,192 38.2 45.2 48.8 0.005 \$ 2.994 8.571,570 55.9 Melanoma of the Skin Male 41 70,2192 38.6 5.7 0.898 8.005 \$ 8.598 8.591,570 8.7 1.994 8.294,778 8.7 1.794 8.294,778 8.7 1.794 8.294,778 8.7 1.794 8.294,778 8.7 1.794 8.294,778 8.7 1.794 8.294,778 8.7 1.794 8.294,778 8.7 1.794 8.294,778 8.7 1.794 8.294,778 8.7 1.794 8.294,778 8.7 1.794 8.294,778 8.7 1.794 8.294,778 8.7 1.794 8.294,778 8.7 1.794 8.2											
Kidney and Renal Pelvis Kidney and Renal Pelvis Female 5 98.066 5.1 6.0 12.3 0.0332 5 28.4 276,852 14.7 10 12.3 0.033 6 28.4 276,852 14.7 10 12.3 0.033 6 28.4 276,852 14.7 10 12.3 0.033 6 28.4 276,852 14.7 10 12.3 0.033 6 28.4 276,852 14.7 10 12.3 0.033 6 28.4 276,852 14.7 10 12.3 0.033 6 28.4 294,718 13.7 10 12.3 0.033 6 28.4 294,718 13.7 10 12.3 0.033 6 28.4 294,718 13.7 10 12.3 0.034 159.4 294,718 13.7 10 12.3 200,258 11.5 13.2 0.36 10 0.1 1.608 18.571,570 18.8 12.4 28.6 0.100 1.1 1.1 1.1 1.000 1.54 4,276,852 1.3 1.3 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2											
Kidney and Renal Pelvis	Kidney and Renal Pelvis			102,192							
Larýmx Female 1 102,192 1.0 1.2 3.2 0.346 159 4,294,718 3.7 Larýmx Female 1 98,066 1.0 1.1 1.1 1,000 54 4,276,852 13.7 Leukemia Male 9 102,192 8.8 10.5 13.2 32.6 0.100 1.868 8,571,570 18.8 Leukemia Male 9 102,192 8.8 10.5 18.6 1.0 1.1 1.1 1,000 54 4,276,852 13.7 Leukemia Male 9 102,192 8.8 10.5 18.6 19.9 0.011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9.0011 << 9	Kidney and Renal Pelvis			98,066			12.3				
Larýmx Leukemia											
Leukemia   Total   23   200,258   11.5   13.2   32.6   0.100   1,608   8.571,570   18.8   Leukemia   Male   9   102,192   8.8   10.3   19.9   0.011 <<											
Leukemia Female   9   102,192   8.8   10.3   19.9   0.011 <<   980   4,294,718   22.8											
Liver and Bile Duct Male 13 102.192 12.7 15.1 11.6 0.749 577 4.294.718 13.4 Liver and Bile Duct Female 1 1 98.066 1.0 1.2 4.7 0.102 238 4.276.852 5.6 Lung and Bronchus Male 39 102.192 38.2 45.9 54.1 95.1 0.801 4.795 8.571.570 55.9 Lung and Bronchus Male 39 102.192 38.2 46.7 0.391 2.382 4.276.852 55.7 Melanoma of the Skin Total 38 200.258 19.0 21.9 58.8 0.005 < 2.904 8.571.570 33.9 Melanoma of the Skin Male 17 102.192 16.6 19.5 35.5 0.001 < 1.748 4.294.718 40.7 Melanoma of the Skin Male 17 102.192 16.6 19.5 35.5 0.001 < 1.748 4.294.718 40.7 Melanoma of the Skin Female 21 98.066 21.4 24.2 23.4 0.713 1.156 4.294.718 40.7 Melanoma of the Skin Male 9 102.192 8.8 10.5 8.6 0.991 432 4.294.718 40.7 Melanoma of the Skin Male 9 102.192 8.8 10.5 8.6 0.991 432 4.294.718 10.1 Myeloma Male 9 102.192 8.8 10.5 8.6 0.991 432 4.294.718 10.1 Myeloma Female 4 98.066 4.1 4.8 5.2 0.826 263 4.276.852 61.1 Non-Hodgkin Lymphoma Male 24 102.192 23.5 27.2 22.7 0.838 1.105 4.294.718 25.7 Non-Hodgkin Lymphoma Male 24 102.192 23.5 27.2 27.0 0.338 1.105 4.294.718 25.7 Non-Hodgkin Lymphoma Male 29 102.192 8.8 10.5 8.6 0.991 432 4.294.718 25.7 Non-Hodgkin Lymphoma Male 24 102.192 23.5 27.2 22.7 0.838 1.105 4.294.718 25.7 Non-Hodgkin Lymphoma Male 24 102.192 23.5 27.2 22.7 0.838 1.105 4.294.718 25.7 Non-Hodgkin Lymphoma Male 25 200.258 12.5 14.7 25.2 1.000 1.270 8.571.570 14.8 07al Cavity and Pharynx Male 20 102.192 10.8 12.5 14.7 25.2 1.000 1.270 8.571.570 14.8 07al Cavity and Pharynx Male 20 102.192 10.8 12.7 15.5 0.304 773 4.294.718 13.4 07al Cavity and Pharynx Male 11 102.192 10.8 12.7 15.5 0.304 773 4.294.718 13.0 14.9 Pancreas Female 5 98.066 5.1 5.9 7.0 0.600 354 4.276.852 12.3 Pancreas Female 6 98.066 6.1 7.0 10.6 0.192 527 4.276.852 12.3 Pancreas Female 5 98.066 5.1 5.9 7.0 0.600 354 4.276.852 12.3 Pancreas Female 5 98.066 5.1 5.9 7.0 0.600 354 4.276.852 12.3 Pancreas Female 6 98.066 6.1 7.0 10.6 0.192 527 4.276.852 12.3 Pancreas Female 11 98.066 11.2 13.0 12.4 0.825 628 4.276.852 12.3 Pancreas Female 5 98.066 5.0 0.0 0.0 0.0 0.0 0.0 0			9	102,192			19.9		980	4,294,718	22.8
Liver and Bile Duct   Male   13   102_192   12.7   15.1   11.6   0.749   577   4.294,718   13.4   Liver and Bile Duct   Female   1   98.066   1.0   1.2   4.7   0.102   238   4.276,852   55.5   Lung and Bronchus   Male   39   102_192   38.2   45.9   54.1   95.1   0.801   4.795   8.571,570   55.9   4.294,718   4.294,718   56.2   4.294,718   4											
Liver and Bile Duct Female 1 98,066 1.0 1.2 4.7 0.102 238 4,276,852 5.6 Lung and Bronchus Total 92 200,258 45.9 54.1 95.1 0.801 4,795 8,571,570 55.9 Lung and Bronchus Hale 39 102,192 38.2 45.2 48.5 0.189 2,413 4,294,718 56.2 Lung and Bronchus Female 53 98,066 54.0 63.2 46.7 0.391 2,332 4,276,852 55.7 Melanoma of the Skin Total 38 200,258 19.0 21.9 58.8 0.005 << 2,904 8,571,570 33.9 Melanoma of the Skin Male 17 102,192 16.6 19.5 35.5 0.001 << 1,748 4,294,718 40.7 Melanoma of the Skin Female 21 98,066 21.4 24.2 23.4 0.713 1,156 4,276,852 27.0 Myeloma Total 13 200,258 6.5 7.7 13.8 0.980 695 8,571,570 8.1 Myeloma Male 9 102,192 8.8 10.5 8.6 0.991 432 4,294,718 10.1 Myeloma Female 4 98,066 4.1 4.8 5.2 0.826 263 4,276,852 6.1 Non-Hodgkin Lymphoma Total 36 200,258 18.0 20.7 38.6 0.750 1,904 8,571,570 22.2 Non-Hodgkin Lymphoma Male 24 102,192 23.5 27.2 22.7 0.838 1,105 4,294,718 25.7 Non-Hodgkin Lymphoma Female 12 98,066 12.2 14.0 16.0 0.382 799 4,276,852 18.7 Oral Cavity and Pharynx Total 25 200,258 11.0 12,192 19.6 23.3 18.3 0.752 916 4,294,718 27.3 Oral Cavity and Pharynx Male 20 102,192 19.6 23.3 18.3 0.752 916 4,294,718 21.3 Oral Cavity and Pharynx Female 5 98,066 5.1 5.9 7.0 0.600 354 4,276,852 18.7 Oral Cavity and Pharynx Female 6 98,066 6.1 7.0 10.6 0.192 527 2,244,718 21.3 Oral Cavity and Pharynx Female 6 98,066 6.1 7.0 10.6 0.192 527 2,244,718 21.3 Oral Cavity and Pharynx Female 6 98,066 6.1 7.0 10.6 0.192 527 2,244,718 21.3 Pancreas Pancreas Male 11 192,192 10.8 12.7 15.5 0.304 773 4,294,718 18.0 Pancreas Male 149 102,192 10.8 12.7 15.5 0.304 773 4,294,718 18.0 Pancreas Male 149 102,192 10.8 12.7 15.5 0.304 773 4,294,718 18.0 Pancreas Male 149 102,192 10.8 12.7 15.5 0.304 773 4,294,718 14.5 Pancreas Male 149 102,192 10.8 12.7 15.5 0.304 773 4,294,718 14.5 Pancreas Male 149 102,192 10.8 12.7 15.5 0.304 773 4,294,718 14.5 Pancreas Male 149 102,192 10.8 12.7 15.5 0.304 773 4,294,718 14.5 Pancreas Male 149 102,192 10.8 12.7 15.5 0.304 773 4,294,718 14.5 Pancreas Male 149 102,192 10.8 12.7 15.5 0.304 773 4,294,71											
Lung and Bronchus Male 39 102,192 38.2 45.9 54.1 95.1 0.801 4,795 8,571,570 55.9 Lung and Bronchus Male 39 102,192 38.2 45.2 48.5 0.189 2,413 4,294,718 56.2 Lung and Bronchus Female 53 88,066 54.0 63.2 46.7 0.391 2,382 4,276,852 55.7 Melanoma of the Skin Male 17 102,192 16.6 19.5 35.5 0.001 << 1,748 4,294,718 40.7 Melanoma of the Skin Male 17 102,192 16.6 19.5 35.5 0.001 << 1,748 4,294,718 40.7 Melanoma of the Skin Female 21 88,066 21.4 24.2 23.4 0.713 1,156 4,276,852 27.0 Myeloma Total 13 200,258 6.5 7.7 13.8 0.980 695 8,571,570 8.1 Myeloma Male 9 102,192 8.8 10.5 8.6 0.991 432 4,294,718 10.1 Myeloma Female 4 98,066 4.1 4.8 5.2 0.826 263 4,276,852 6.1 Non-Hodgkin Lymphoma Male 24 102,192 23.5 27.2 22.7 0.838 1,105 4,294,718 25.7 Nor-Hodgkin Lymphoma Female 12 98,066 4.1 4.0 16.0 0.382 799 4,276,852 18.7 Oral Cavity and Pharynx Total 25 200,258 12.5 14.7 25.2 1.000 1,270 8,571,570 14.8 Oral Cavity and Pharynx Male 20 102,192 19.6 23.3 18.3 0.752 916 4,294,718 21.3 Oral Cavity and Pharynx Female 5 98,066 5.1 7.0 10.6 0.382 799 4,276,852 12.3 Pancreas Female 19,8066 11.2 13.0 12.9 27.9 0.303 1,401 8,571,570 16.3 Pancreas Female 19,8066 11.2 13.0 12.9 27.9 0.303 1,401 8,571,570 16.3 Pancreas Female 19,8066 11.2 13.0 12.9 27.9 0.303 1,401 8,571,570 16.3 Pancreas Female 11 98,066 6.1 7.0 10.6 0.192 527 4,276,852 12.3 Pancreas Female 11 98,066 11.2 13.0 12.4 0.825 628 4,276,852 12.3 Pancreas Female 11 98,066 11.2 13.0 12.4 0.825 628 4,276,852 12.3 Pancreas Female 11 98,066 11.2 13.0 12.4 0.825 628 4,276,852 12.3 Pancreas Female 11 98,066 11.2 13.0 12.4 0.825 628 4,276,852 12.3 Pancreas Female 14 90,066 11.2 13.0 12.4 0.825 628 4,276,852 12.3 Pancreas Female 19,8066 11.2 13.0 12.4 0.825 628 4,276,852 12.3 Pancreas Female 11 98,066 11.2 13.0 12.4 0.825 628 4,276,852 12.3 Pancreas Female 11 98,066 11.2 13.0 12.4 0.825 628 4,276,852 12.3 Pancreas Female 11 98,066 11.2 13.0 12.4 0.825 628 4,276,852 12.3 Pancreas Female 14 90,066 11.2 13.0 12.4 0.825 628 4,276,852 12.3 Pancreas Female 14 90,066 11.2 13.0 12.4 0.825 628 4,2										4.276.852	
Lung and Bronchus	Lung and Bronchus		92								
Melanoma of the Skin         Total         38         200,258         19.0         21.9         58.8         0.005 <         2,904         8,571,570         33.9           Melanoma of the Skin         Male         17         102,192         16.6         19.5         35.5         0.001          1,748         4,294,718         40.7           Melanoma of the Skin         Female         21         98,066         21.4         24.2         23.4         0.713         1,156         4,276,852         27.0           Myeloma         Total         13         200,258         6.5         7.7         13.8         0.980         695         8,571,570         8.1           Myeloma         Female         4         98,066         4.1         4.8         5.2         0.826         263         4,276,852         6.1           Non-Hodgkin Lymphoma         Total         36         200,258         18.0         20.7         38.6         0.750         1,904         8,571,570         8.1           Non-Hodgkin Lymphoma         Total         36         200,258         18.0         20.7         38.6         0.750         1,904         8,571,570         22.2           Non-Hodgkin Lymphoma         Total         <	Lung and Bronchus										
Melanoma of the Skin         Male         17         102,192         16.6         19.5         35.5         0.001         1,748         4,294,718         40.7           Myeloma         Total         13         200,258         6.5         7.7         13.8         0.980         695         8,571,570         8.1           Myeloma         Male         9         102,192         8.8         10.5         8.6         0.991         432         4,294,718         10.1           Non-Hodgkin Lymphoma         Total         36         200,258         18.0         20.7         38.6         0.750         1,904         8,571,570         8.1           Non-Hodgkin Lymphoma         Male         24         102,192         23.5         27.2         22.7         0.838         1,105         4,294,718         25.7           Non-Hodgkin Lymphoma         Male         24         102,192         23.5         27.2         22.7         0.838         1,105         4,294,718         25.7           Non-Hodgkin Lymphoma         Female         12         98,066         12.2         14.0         16.0         0.382         799         4,276,852         18.7           Oral Cavity and Pharynx         Total											
Melanoma of the Skin         Female         21         98,066         21.4         24.2         23.4         0.713         1,156         4,276,852         27.0           Myeloma         Male         9         102,192         8.8         10.5         8.6         0.991         432         4,294,718         10.1           Myeloma         Female         4         98,066         4.1         4.8         5.2         0.826         263         4,276,852         6.1           Non-Hodgkin Lymphoma         Total         36         200,258         18.0         20.7         38.6         0.750         1,904         8,71,570         22.2           Non-Hodgkin Lymphoma         Female         24         102,192         23.5         27.2         22.7         0.838         1,105         4,294,718         25.7           Non-Hodgkin Lymphoma         Female         12         98,066         12.2         14.0         16.0         0.382         799         4,276,852         18.7           Non-Hodgkin Lymphoma         Female         12         98,066         12.2         14.0         16.0         0.382         799         4,276,852         18.7           Oral Cavity and Pharynx         Total											
Myeloma         Male         9         102,192         8.8         10.5         8.6         0.991         432         4,294,718         10.1           Myeloma         Female         4         98,066         4.1         4.8         5.2         0.826         263         4,276,852         6.1           Non-Hodgkin Lymphoma         Male         24         102,192         23.5         27.2         22.7         0.838         1,105         4,294,718         25.7           Non-Hodgkin Lymphoma         Female         12         98,066         12.2         14.0         16.0         0.382         799         4,276,852         18.7           Non-Hodgkin Lymphoma         Female         12         98,066         12.2         14.0         16.0         0.382         799         4,276,852         18.7           Oral Cavity and Pharynx         Total         25         200,258         12.5         14.7         25.2         1.000         1,270         8,571,570         14.8           Oral Cavity and Pharynx         Male         20         102,192         19.6         23.3         18.3         0.752         916         4,294,718         21.3           Oral Cavity and Pharynx         Female         <	Melanoma of the Skin										
Myeloma         Female         4         98,066         4.1         4.8         5.2         0.826         263         4,276,852         6.1           Non-Hodgkin Lymphoma         Male         200,258         18.0         20.7         38.6         0.750         1,904         8,571,570         22.2           Non-Hodgkin Lymphoma         Male         24         102,192         23.5         27.2         22.7         0.838         1,105         4,294,718         25.7           Non-Hodgkin Lymphoma         Female         12         98,066         12.2         14.0         16.0         0.382         799         4,276,852         18.7           Oral Cavity and Pharynx         Total         25         200,258         12.5         14.7         25.2         1.000         1,270         8,571,570         14.8           Oral Cavity and Pharynx         Male         20         102,192         19.6         23.3         18.3         0.752         916         4,294,718         21.3           Oral Cavity and Pharynx         Female         5         98,066         5.1         5.9         7.0         0.600         354         4,276,852         18.3           Ovary         Female         6 <td< td=""><td>Myeloma</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>	Myeloma										
Non-Hodgkin Lymphoma   Total   36   200,258   18.0   20.7   38.6   0.750   1,904   8,571,570   22.2   22.7   22.7   0.838   1,105   4,294,718   25.7   25.7   22.7   22.7   22.7   0.838   1,105   4,294,718   25.7   25.7   20.8   25.7   20.8   25.7   20.8   25.7   20.8   25.7   20.8   25.7   20.8   25.7   20.8   20.8   25.7   20.8   20.	Myeloma						8.6			4,294,718	
Non-Hodgkin Lýmphoma         Male Female         24         102,192         23.5         27.2         22.7         0.838         1,105         4,294,718         25.7           Non-Hodgkin Lymphoma         Female         12         98,066         12.2         14.0         16.0         0.382         799         4,276,852         18.7           Oral Cavity and Pharynx         Total         25         200,258         12.5         14.7         25.2         1.000         1,270         8,571,570         14.8           Oral Cavity and Pharynx         Male         20         102,192         19.6         23.3         18.3         0.752         916         4,294,718         21.3           Oral Cavity and Pharynx         Female         5         98,066         5.1         5.9         7.0         0.600         354         4,276,852         8.3           Ovary         Female         6         98,066         6.1         7.0         10.6         0.192         527         4,276,852         12.3           Pancreas         Total         22         200,258         11.0         12.9         27.9         0.303         1,414         8,571,570         16.3         16.3         16.2         16.2         18							38.6				
Non-Hodgkin Lymphoma   Female   12   98,066   12.2   14.0   16.0   0.382   799   4,276,852   18.7	Non-Hodgkin Lymphoma										
Oral Cavity and Pharynx         Male Pemale         20         102,192 98,066         19.6 5.1         23.3 5.9         18.3 7.0         0.752 0.600         354 4,276,852         8.3 8.3 8.3 8.3 8.3 8.3 8.3 8.3 8.3 8.3	Non-Hodgkin Lymphoma	Female	12	98,066	12.2	14.0	16.0	0.382	799	4,276,852	18.7
Oral Cavity and Pharynx         Female         5         98,066         5.1         5.9         7.0         0.600         354         4,276,852         8.3           Ovary         Female         6         98,066         6.1         7.0         10.6         0.192         527         4,276,852         12.3           Pancreas         Total         22         200,258         11.0         12.9         27.9         0.303         1,401         8,571,570         16.3           Pancreas         Male         11         102,192         10.8         12.7         15.5         0.304         773         4,294,718         18.0           Pancreas         Female         11         98,066         11.2         13.0         12.4         0.825         628         4,276,852         14.7           Prostate         Male         149         102,192         145.8         172.7         125.9         0.049         6268         4,276,852         14.7           Stomach         Total         8         200,258         4.0         4.7         9.2         0.864         459         8,571,570         5.4           Stomach         Female         2         98,066         2.0         2.3	Oral Cavity and Pharms										
Ovary         Female Pancreas         6         98,066         6.1         7.0         10.6         0.192         527         4,276,852         12.3           Pancreas         Total         22         200,258         11.0         12.9         27.9         0.303         1,401         8,571,570         16.3           Pancreas         Male         11         102,192         10.8         12.7         15.5         0.304         773         4,294,718         18.0           Pancreas         Female         11         98,066         11.2         13.0         12.4         0.825         628         4,276,852         14.7           Prostate         Male         149         102,192         145.8         172.7         125.9         0.049         6,268         4,294,718         145.9           Stomach         Total         8         200,258         4.0         4.7         9.2         0.864         459         8,571,570         5.4           Stomach         Male         6         102,192         5.9         7.0         6.1         1.000         303         4,294,718         7.1           Stomach         Female         2         98,066         2.0         2.3	Oral Cavity and Pharynx Oral Cavity and Pharynx										
Pancreas         Total Pancreas         22 200,258 Male         11.0 12.9 10.8 12.7 15.5 0.303 1,401 8,571,570 16.3           Pancreas         Male Pancreas         11 102,192 10.8 12.7 15.5 0.304 773 4,294,718 18.0           Prostate         11 98,066 11.2 13.0 12.4 0.825 628 4,276,852 14.7           Prostate         Male 149 102,192 145.8 172.7 125.9 0.049 >> 6,268 4,294,718 145.9           Stomach Total Stomach Male 6 102,192 5.9 7.0 6.1 1.000 303 4,294,718 7.1           Stomach Female 2 98,066 2.0 2.3 3.1 0.785 156 4,276,852 3.6           Testis Male 5 102,192 4.9 4.1 7.3 0.519 260 4,294,718 6.1           Thyroid Total Total 7 200,258 8.5 8.9 26.8 0.061 1,203 8,571,570 14.0           Thyroid Male 4 102,192 3.9 4.4 7.5 0.270 351 4,294,718 8.2           Thyroid Female 13 98,066 13.3 13.6 19.0 0.193 852 4,276,852 19.9           Pediatric Age 0 to 19 Male 5 25,020 20.0 19.5 4.5 0.954 218 1,231,490 17.7											
Pancreas         Female         11         98,066         11.2         13.0         12.4         0.825         628         4,276,852         14.7           Prostate         Male         149         102,192         145.8         172.7         125.9         0.049 >>         6,268         4,294,718         145.9           Stomach         Total         8         200,258         4.0         4.7         9.2         0.864         459         8,571,570         5.4           Stomach         Male         6         102,192         5.9         7.0         6.1         1.000         303         4,294,718         7.1           Stomach         Female         2         98,066         2.0         2.3         3.1         0.785         156         4,276,852         3.6           Testis         Male         5         102,192         4.9         4.1         7.3         0.519         260         4,294,718         6.1           Thyroid         Total         17         200,258         8.5         8.9         26.8         0.061         1,203         8,571,570         14.0           Thyroid         Male         4         102,192         3.9         4.4         7.5 </td <td>Pancreas</td> <td>Total</td> <td>22</td> <td>200,258</td> <td>11.0</td> <td>12.9</td> <td>27.9</td> <td>0.303</td> <td>1,401</td> <td>8,571,570</td> <td>16.3</td>	Pancreas	Total	22	200,258	11.0	12.9	27.9	0.303	1,401	8,571,570	16.3
Prostate         Male         149         102,192         145.8         172.7         125.9         0.049 >>         6,268         4,294,718         145.9           Stomach         Total         8         200,258         4.0         4.7         9.2         0.864         459         8,571,570         5.4           Stomach         Male         6         102,192         5.9         7.0         6.1         1.000         303         4,294,718         7.1           Stomach         Female         2         98,066         2.0         2.3         3.1         0.785         156         4,276,852         3.6           Testis         Male         5         102,192         4.9         4.1         7.3         0.519         260         4,294,718         6.1           Thyroid         Total         17         200,258         8.5         8.9         26.8         0.061         1,203         8,571,570         14.0           Thyroid         Male         4         102,192         3.9         4.4         7.5         0.270         351         4,294,718         8.2           Thyroid         Female         13         98,066         13.3         13.6         19.0 <td>Pancreas</td> <td></td>	Pancreas										
Stomach         Total Male         8   200,258   4.0   4.7   9.2   0.864   459   8,571,570   5.4           5.4   5.5   5.9   7.0   6.1   1.000   303   4,294,718   7.1           5.4   5.5   5.9   7.0   6.1   1.000   303   4,294,718   7.1           5.4   5.5   5.9   7.0   6.1   1.000   303   4,294,718   7.1           5.4   5.5   5.9   7.0   6.1   1.000   303   4,294,718   7.1           5.4   5.5   5.9   7.0   6.1   1.000   303   4,294,718   7.1           7.1   5.4   7.1   7.1   7.3   7.5   7.5           7.5   7										4,276,852	
Stomach         Male         6         102,192         5.9         7.0         6.1         1.000         303         4,294,718         7.1           Stomach         Female         2         98,066         2.0         2.3         3.1         0.785         156         4,276,852         3.6           Testis         Male         5         102,192         4.9         4.1         7.3         0.519         260         4,294,718         6.1           Thyroid         Total         17         200,258         8.5         8.9         26.8         0.061         1,203         8,571,570         14.0           Thyroid         Male         4         102,192         3.9         4.4         7.5         0.270         351         4,294,718         8.2           Thyroid         Female         13         98,066         13.3         13.6         19.0         0.193         852         4,276,852         19.9           Pediatric Age 0 to 19         Total         7         49,640         14.1         13.3         9.0         0.638         414         2,410,883         17.2           Pediatric Age 0 to 19         Male         5         25,020         20.0         19.5										8.571.570	
Testis         Male         5         102,192         4.9         4.1         7.3         0.519         260         4,294,718         6.1           Thyroid         Total         17         200,258         8.5         8.9         26.8         0.061         1,203         8,571,570         14.0           Thyroid         Male         4         102,192         3.9         4.4         7.5         0.270         351         4,294,718         8.2           Thyroid         Female         13         98,066         13.3         13.6         19.0         0.193         852         4,276,852         19.9           Pediatric Age 0 to 19         Total         7         49,640         14.1         13.3         9.0         0.638         414         2,410,883         17.2           Pediatric Age 0 to 19         Male         5         25,020         20.0         19.5         4.5         0.954         218         1,231,490         17.7	Stomach	Male	6	102,192	5.9	7.0	6.1	1.000		4,294,718	7.1
Thyroid         Total Male         17 bigs         200,258 bigs         8.5 bigs         8.9 bigs         26.8 bigs         0.061 bigs         1,203 bigs         8,571,570 bigs         14.0 bigs	Stomach										
Thyroid         Male Female         4 102,192 98,066         3.9 13.3         4.4 19.0 13.3         7.5 19.0 13.3         0.270 13.51 14,294,718 18.2         8.2 19.9 19.9           Pediatric Age 0 to 19         Total Pediatric Age 0 to 19         7 49,640 14.1 13.3 13.3 13.6 19.0 19.5 19.5 19.5 19.5 19.5 19.5 19.5 19.5											
Thyroid         Female         13         98,066         13.3         13.6         19.0         0.193         852         4,276,852         19.9           Pediatric Age 0 to 19         Total         7         49,640         14.1         13.3         9.0         0.638         414         2,410,883         17.2           Pediatric Age 0 to 19         Male         5         25,020         20.0         19.5         4.5         0.954         218         1,231,490         17.7	•			·							
Pediatric Age 0 to 19         Total         7         49,640         14.1         13.3         9.0         0.638         414         2,410,883         17.2           Pediatric Age 0 to 19         Male         5         25,020         20.0         19.5         4.5         0.954         218         1,231,490         17.7	,										
Pediatric Age 0 to 19   Male   5   25,020   20.0   19.5   4.5   0.954   218   1,231,490   17.7											
	Pediatric Age 0 to 19										
1 Salation 190 5 10   100   1,179,000   10.0	Pediatric Age 0 to 19	Female	2	24,620	8.1	7.4	4.5	0.349	196	1,179,393	16.6

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

<sup>2.</sup> Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

<sup>&</sup>quot;<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

# **TABLE 4: CANCER MORTALITY 2017–2021** COMPARISON BETWEEN LATAH COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

Cause of Death   Cancer Stelletype   Sex   Death   Veans   Reale (f) Rafe (2) Death(2)   Death(3)   P.Value (4)   Death   Veans   Reale (1) Rafe (2) Death(3)   P.Value (4)   Death   Veans   Reale (1) Rafe (2) Death(3)   P.Value (4)   Death   Veans   Reale (1) Rafe (2) Death(3)   P.Value (4)   Death   Veans   Reale (1) Rafe (2) Death(3)   P.Value (4)   Death   Veans   Reale (1) Rafe (2) Death(3)   P.Value (4)   Death   Veans   Reale (1) Rafe (2) Death(3)   P.Value (4)   Death   Veans   Reale (1) Rafe (2) Death(3)   P.Value (4)   Death   Veans   Reale (1) Rafe (2) Death   P.Value (4)   Death   Veans   P.Value (4)   P.Value (4)   Death   Veans   P.Value (4)   P.				La	tah County				Re	mainder of Idah	10
All Causes of Death Male (23 102,700 608.6 684.5 1,576.2 0,000 << 7,6,241 8,787,301 887.6 All Causes of Death Male (23 102,700 608.6 681.8 837.9 0,000 << 4,04,33 4,04,91.8 917.0 All Causes of Death Female (28 102,700 608.6 681.8 837.9 0,000 << 4,04,33 4,04,91.8 917.0 All Causes of Death Female (28 102,700 608.6 681.8 837.9 0,000 << 4,04,33 4,04,91.8 917.9 All Malignant Cancers (28 102,700 12 12 12 12 12 12 12 12 12 12 12 12 12	Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
All Causes of Death Male All Causes of Death All Causes of Death Female 56 98,714 573.4 623.9 74.19 0.000 <	Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death Male All Causes of Death All Causes of Death Female 623   102,700   666,6   681.8   837.9   0,000 <	All Causes of Death	Total	1,189	201,414	590.3	654.5	1,576.2	0.000 <<	76,241	8,787,301	867.6
All Malignant Cancers   Total   267   201.414   132.6   132.5   285.9   0.095   14.854   3.787.301   198.0     All Malignant Cancers   Male   11   102.700   137.3   159.2   1614   0.113   0.355   4.409.168   182.0     All Malignant Cancers   Female   126   98.714   127.6   145.6   134.8   0.479   6.919   4.378.133   155.8     Badder   Total   127.6   145.6   134.8   0.479   6.919   4.378.133   155.8     Badder   Total   127.6   145.6   134.8   0.479   6.919   4.378.133   155.8     Badder   Female   2   98.714   2.0   2.3   2.2   1.000   109   4.378.133   2.5     Brain and Other Nervous System   Total   10   201.414   5.0   5.7   5.9   1.000   109   4.378.133   2.5     Brain and Other Nervous System   Female   4   98.714   4.1   4.7   3.9   1.000   202   4.378.133   4.6     Breast   Total   20   2207.471   97.8   11.5   21.5   0.8800   1.002   2.787.301   12.3     Breast   Female   2   98.714   4.1   4.7   3.9   1.000   202   4.378.133   4.6     Breast   Female   2   98.714   4.1   4.7   3.9   1.000   202   4.378.133   4.6     Breast   Female   2   98.714   2.0   2.3   2.1   1.000   202   4.378.133   4.6     Breast   Female   2   98.714   2.0   2.3   2.1   1.000   202   4.378.133   4.6     Breast   Female   2   98.714   2.0   2.3   2.1   1.000   202   4.378.133   4.6     Breast   Female   3   98.714   2.0   2.3   2.1   1.000   2.0   4.378.133   1.1     Colorectal   Male   8   102.700   7.8   9.1   1.4   0.118   7.1   1.068   4.378.133   1.1     Colorectal   Male   8   102.700   7.8   9.1   1.4   0.118   7.1   4.09   1.000	All Causes of Death	Male			606.6	681.8	837.9	0.000 <<	40,433	4,409,168	917.0
All Malignant Cancers   Male	All Causes of Death	Female	566			623.9		0.000 <<			
All Malighant Cancers   Female   126   98,714   127.6   145.6   134.8   0.479   6.819   4.378.133   155.8   Bladder   Total   10   201.414   5.0   5.6   9.7   1.000   479   6.787.301   5.5   Bladder   Female   2   98,714   2.0   2.3   2.2   1.000   109   4.378.133   2.5   Bladder   Seman and Other Nervous System   101   1									14,854		
Bladder											
Bladder   Male   8   102,700   7.8   8.9   7.5   0.958   370   4,409,168   8.4											
Bladder   Female   2   99,714   2.0   2.3   2.2   1.000   109   4,378,133   2.5											
Brain and Other Nervous System   Total   10   201,414   5.0   5.7   9.9   1.000   494   8,787,301   5.6   8   6   6.0   1.000   202   4.409,166   6.6   8   6   6.0   1.000   202   4.409,166   6.6   6   6   6.0   1.000   202   4.409,166   6.6   6   6   6.0   1.000   202   4.409,166   6.6   6   6   6   6   6   6   6   6											
Brain and Other Nervous System Male   6   102,700   5.8   6.6   6.0   1.000   292   4,409,168   6.6   Brain and Other Nervous System Female   4   99,714   4.1   4.7   3.9   1.000   202   4,378,133   4.6   6.6   Breast											
Brain and Other Nervous System   Female   4   98,714   4.1   4.7   3.9   1.000   202   4,378,133   4.6   Breast   Male   - 102,700     0.3   1.000   16   4,409,168   0.4   Breast   Female   - 98,714     -   1.7   0.38   1.000   16   4,409,168   0.4   Breast   Female   - 98,714     -   1.7   0.38   1.000											
Breast   Total   20   201,414   9.9   11.5   21.5   0.860   1,082   8,787,301   12.3   Breast   Female   20   99,714   20.3   23.1   21.1   0.932   1,066   4,409,168   0.4   Breast   Female   20   99,714   20.3   23.1   21.1   0.932   1,066   4,378,133   24.3   Colorectal   Total   19   201,414   9.4   10.9   25.8   0.206   1,300   8,787,301   14.8   Colorectal   Male   8   102,700   7.8   9.1   14.1   0.118   711   4,409,188   16.1   Colorectal   Female   11   98,714   11.1   12.8   11.8   0.990   589   4,378,133   13.9   Colorectal   Female   11   98,714   11.1   12.8   11.8   0.990   589   4,378,133   13.9   Colorectal   Female   11   98,714   11.1   12.8   11.8   0.990   589   4,378,133   13.9   Colorectal   Female   10   102,700   9.7   11.4   7.7   0.505   391   4,409,168   8.9   Escophagus   Female   2   99,714   -											
Breast   Male   - 102,700   - 0. 0.3   1.000   16   4.409,168   0.4   Breast   Female   - 0. 98,714   - 0. 1.7   0.383   83   4.378,133   24.3   Cervix   Female   - 0. 98,714   - 0. 1.7   0.383   83   4.378,133   24.3   Colorectal   Total   19   201,414   9.4   10.9   25.8   Colorectal   Male   8   102,700   7.8   9.1   14.1   0.118   711   4.409,168   16.1   Colorectal   Female   11   98,714   11.1   12.6   11.8   0.18   711   4.409,168   16.1   Colorectal   Female   15   98,714   5.1   5.8   3.3   0.472   168   4.378,133   3.3   Corpus Uteri   Female   5   98,714   5.1   5.8   3.3   0.472   168   4.378,133   3.3   Esophagus   Total   12   201,414   6.0   6.9   9.1   0.421   465   8,78,301   3.3   Esophagus   Male   10   102,700   9.0   11.4   7.7   0.506   391   4.409,168   1.9   Esophagus   Female   2   9.774   2.0   2.3   1.5   8.8   3.3   0.472   1.8   Esophagus   Male   10   102,700   9.0   11.4   7.7   0.506   391   4.409,168   1.9   Esophagus   Male   10   102,700   9.0   11.4   7.7   0.506   391   4.409,168   1.9   Esophagus   Male   10   102,700   9.0   11.4   7.7   0.506   391   4.409,168   1.9   Esophagus   Male   10   102,700   9.0   11.4   7.7   0.506   391   4.409,168   0.3   Esophagus   Male   10   102,700   1.0   1.0   1.1   7.7   0.506   391   4.409,168   0.3   Esophagus   Male   102,700   1.9   2.3   3.8   3.0   Esophagus   Male   102,700   1.9   2.3   3.8   3.0   Esophagus   Male   2   201,414   1.0   1.1   7.6   0.037 ≪   383   8,787,301   4.4   Esophagus   Male   2   201,414   1.0   1.1   7.6   0.037 ≪   383   8,787,301   4.4   Esophagus   Male   2   201,414   1.0   1.1   7.6   0.037 ≪   383   8,787,301   4.4   Esophagus   Male   2   201,414   1.0   1.1   7.6   0.037 ≪   383   8,787,301   4.4   Esophagus   Male   2   201,414   1.0   1.1   7.6   0.037 ≪   383   8,787,301   4.4   Esophagus   Male   2   201,414   1.0   1.1   7.6   0.037 ≪   383   8,787,301   4.4   Esophagus   Male   2   201,414   1.0   1.1   7.6   0.037 ≪   383   8,787,301   4.4   Esophagus   Male   3   201,414   1.0   1.1											
Breast Female 20 98,714 20.3 23.1 21.1 0.932 1.066 4,378,133 24.3 Corivix Female - 98,714 1.7 0.383 83 4,378,133 24.3 Colorectal Total 19 201,414 9.4 10.9 25.8 0.206 1.300 8,787,301 14.8 12.0 Colorectal Male 8 102,700 7.6 9.1 14.1 0.118 7.71 4.09,168 16.1 Colorectal Female 11 98,714 11.1 12.6 11.8 0.980 599 4,378,133 13.5 Esophagus Female 5 98,714 5.1 5.8 3.3 0.4072 1686 4,378,133 13.5 Esophagus Male 10 102,700 9.7 11.4 7.7 0.505 391 44.09,168 63.9 Esophagus Female 2 98,714 2.0 2.3 1.5 0.856 74 4,378,133 1.7 Hodgkin Lymphoma Total - 201,414 0.6 1.000 29 8,787,301 0.3 1.000 11.4 4,409,168 1.0 100,000 11.1 1.0 1.0 1.1 7.0 1.0 1.1 1.1			-		-	-					
Cervix   Female   - 98,714   -   - 1.7   0.383   83   4.378,133   1.9			20	98,714	20.3	23.1					
Colorectal			-	98,714	1	-	1.7	0.383	83	4,378,133	1.9
Colorectal   Female   11   98,714   11.1   12.6   11.8   0.980   589   4,378,133   13.5   Corpus Uteri   Female   5   98,714   5.1   5.8   3.3   0.472   168   4,378,133   3.8   Esophagus   Total   12   201,414   6.0   6.9   9.1   0.421   465   8,787,301   5.3   Esophagus   Female   2   98,714   2.0   2.3   1.5   0.866   74   4,378,133   1.7   1				201,414						8,787,301	
Corpus Uferi											
Esophagus											
Esophagus											
Esophagus											
Hodgin   Jymphoma											
Hodgkin Lymphoma   Male   -   102,700   -   -   0.3   1.000   14   4.409,168   0.3   Nodgkin Lymphoma   Female   -   98,714   -   -   0.3   1.000   15   4.378,133   0.3   Nodgkin Lymphoma   Female   -   201,414   1.0   1.1   7.6   0.037 <<   383   8,787,301   4.4   Nodgkin Lymphoma   Remale   -   98,714   -   -   -   2.9   0.113   143   4.378,133   3.3   3.3   3.3   3.3   Nodgkin Lymphoma   Remale   -   98,714   -   -   2.9   0.113   143   4.378,133   3.3   3.3   3.3   3.3   Nodgkin Lymphoma   Remale   -   201,414   -   -   -   1.2   0.627   58   4.409,168   1.3   3.3											
Hodgikn Lymphoma											
Kidney											
Kidney Male 2 102,700 1.9 2.3 4.8 0.288 240 4,409,168 5.4 Kidney Female - 98,714 2.9 0.113 143 4,378,133 3.3 Larynx Total - 201,414 1,4 0.492 71 8,787,301 0.8 Larynx Male - 102,700 1.2 0.627 58 4,409,168 1.3 Larynx Female - 98,714 0.3 1,000 13 4,378,133 0.3 Larynx Female - 98,714 0.3 1,000 13 4,378,133 0.3 Leukemia Total 18 201,414 8.9 10.1 13.0 0.217 642 8,787,301 7.3 Leukemia Male 9 102,700 8.8 10.0 7.7 0,733 377 4,409,168 8.6 Leukemia Female 9 98,714 9.1 10.2 5.3 0.183 265 4,378,133 6.1 Liver and Bile Duct Total 14 201,414 7.0 8.1 11.6 0.554 589 8,787,301 6.7 Liver and Bile Duct Female 4 98,714 4.1 4.7 3.7 1.000 191 4,378,133 4.4 Lung and Bronchus Total 51 201,414 25.3 29.4 57.4 0.438 2.910 8,787,301 33.1 Lung and Bronchus Male 26 102,700 25.3 29.6 30.5 0.476 1,530 4,409,168 9.0 Lung and Bronchus Male 26 102,700 25.3 29.6 30.5 0.476 1,530 4,409,168 34.7 Lung and Bronchus Female 25 98,714 25.3 29.2 27.0 0,797 1,380 4,378,133 31.5 Melanoma of the Skin Male 4 102,700 3.9 4.5 3.8 1,000 188 4,409,168 34.3 Melanoma of the Skin Male 4 102,700 3.9 4.5 3.8 1.000 188 4,409,168 34.3 Melanoma of the Skin Male 4 102,700 3.9 4.5 3.8 1.000 188 4,409,168 34.3 Melanoma of the Skin Male 4 102,700 3.9 4.5 3.8 1.000 188 4,409,168 34.3 Melanoma of the Skin Male 4 102,700 3.9 4.5 3.8 1.000 188 4,409,168 34.3 Melanoma of the Skin Male 4 102,700 3.9 4.5 3.8 1.000 192 4,409,168 34.3 Melanoma of the Skin Male 4 102,700 3.9 4.5 3.8 1.000 192 4,409,168 34.3 Melanoma of the Skin Male 4 102,700 3.9 4.5 3.8 1.000 192 4,409,168 34.3 Melanoma of the Skin Male 5 98,714 5.1 5.8 5.1 5.6 0.952 32.4 8,787,301 3.7 Meloma Male 5 98,714 5.1 5.8 5.1 5.0 0.952 32.4 8,787,301 3.7 Meloma Male 4 102,700 3.9 4.5 3.8 1.000 192 4,409,168 34.3 Melanoma of the Skin Male 4 102,700 3.9 4.5 3.8 1.000 192 4,409,168 34.3 Melanoma of the Skin Male 4 102,700 3.9 4.5 3.8 1.000 257 4,378,133 3.9 0.000 257 4,378,133 3.9 0.000 257 4,378,133 3.9 0.000 257 4,378,133 3.9 0.000 257 4,378,133 3.9 0.000 257 4,378,133 3.9 0.000 257 4,378,133 3.9 0.000 257											
Kidney											
Larynx Male - 201,414 1,4 0,492 71 8,787,301 0.8 Larynx Male - 102,700 12,0627 58 4,409,168 1.3 Larynx Female - 9,8714 0,3 1,000 13 4,378,133 0.3 Leukemia Male 9,002,700 8.8 10.0 7.7 0,733 377 4,409,168 8.6 Leukemia Female 9,98,714 9.1 10.2 5.3 0,183 265 4,378,133 6.1 Liver and Bile Duct Total 14 201,414 7.0 8.1 11.6 0,554 589 8,787,301 6.7 Liver and Bile Duct Male 10 102,700 9.7 11.4 7.9 0,550 398 4,409,168 9.0 Liver and Bile Duct Female 4 98,714 4.1 4.7 3.7 1,000 191 4,378,133 4.4 Lung and Bronchus Total 51 201,414 25.3 29.4 57.4 0,438 2,910 8,787,301 33.1 Lung and Bronchus Female 25 98,714 25.3 29.4 57.4 0,438 2,910 8,787,301 33.1 Lung and Bronchus Female 25 98,714 25.3 29.2 27.0 0,797 1,380 4,378,133 31.5 Melanoma of the Skin Male 4 102,700 3.9 4.5 3.8 1,000 188 4,409,168 4.3 Melanoma of the Skin Male 4 102,700 3.9 4.5 3.8 1,000 188 4,409,168 4.3 Melanoma of the Skin Male 4 102,700 3.9 4.5 3.8 1,000 188 4,409,168 4.3 Melanoma of the Skin Female 5 98,714 5.1 5.8 1.8 0,076 92 4,378,133 2.1 Myeloma Male 4 102,700 3.9 4.5 3.9 1,000 192 4,478,133 2.1 Myeloma Male 7 201,414 3.5 4.0 6.4 0,924 324 8,787,301 3.7 Myeloma Male 7 201,414 4.0 6.8 1.5 8.8 1.8 0,076 92 4,378,133 3.0 Melanoma of the Skin Female 5 98,714 5.1 5.8 1.8 0,076 92 4,378,133 3.0 Myeloma Male 7 201,414 4.0 6.8 1.2 0,880 557 8,787,301 3.0 Myeloma Male 7 201,414 2.5 2.9 5.1 1,000 257 4,378,133 3.0 Myeloma Male 7 102,700 6.8 7.8 6.1 0,880 557 8,787,301 3.0 Mon-Hodgkin Lymphoma Total 7 201,414 2.5 2.9 5.1 1,000 257 4,378,133 3.0 Mon-Hodgkin Lymphoma Female 5 98,714 5.1 5.8 5.1 1,000 257 4,378,133 3.0 Myeloma Male 7 102,700 6.8 7.8 6.1 1,000 257 4,378,133 3.0 Mon-Hodgkin Lymphoma Female 5 920,414 4.1 4.7 6.7 0,395 346 4,378,133 7.9 Male 7 102,700 6.8 7.8 6.1 1,000 257 4,378,133 3.0 Mon-Hodgkin Lymphoma Female 4 98,714 4.1 4.7 6.7 0,395 346 4,378,133 7.9 Male 7 102,700 6.8 8.0 12.6 0,132 6.35 4,409,168 4.1 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1		Female	-								
Larynx         Female         -         98,714         -         -         0.3         1,000         13         4,378,133         0.3           Leukemia         Male         9         201,414         8.9         10.1         13.0         0.217         642         8,787,301         7.3           Leukemia         Male         9         98,714         9.1         10.2         5.3         0.183         265         4,378,133         6.1           Liver and Bile Duct         Total         14         201,414         7.0         8.1         11.6         0.554         589         8,787,301         6.7           Liver and Bile Duct         Male         10         102,700         9.7         11.4         7.9         0.550         398         4,409,168         9.0           Liver and Bile Duct         Female         4         98,714         4.1         4.7         7.9         0.550         398         4,409,168         9.0           Liver and Bile Duct         Female         4         98,714         4.7         7.9         0.550         398         4,409,168         9.0           Liver and Bile Duct         Female         4         201,414         4.7         7.9			-		-	-		0.492			
Leukemia         Total         18         201/414         8.9         10.1         13.0         0.217         642         8,787,301         7.3           Leukemia         Female         9         102,700         8.8         10.0         7.7         0.733         377         4,409,168         8.6           Leukemia         Female         9         88,714         9.1         10.2         5.3         0.183         265         4,378,133         6.1           Liver and Bile Duct         Male         10         102,700         9.7         11.4         7.9         0.550         398         4,409,168         9.0           Liver and Bile Duct         Female         4         98,714         4.1         4.7         3.7         1,000         191         4,378,133         4.4           Lung and Bronchus         Total         51         201,414         25.3         29.4         57.4         0.438         2,910         8,787,301         33.1           Lung and Bronchus         Male         26         102,700         25.3         29.2         27.0         0.797         1,380         4,378,133         31.5           Melanoma of the Skin         Male         4         102,700	Larynx		-		-	-					
Leukemia         Male         9         102,700         8.8         10.0         7.7         0.733         377         4,409,168         8.6           Leukemia         Female         9         98,714         9.1         10.2         5.3         0.183         265         4,378,133         6.1           Liver and Bile Duct         Total         14         201,414         7.0         8.1         11.6         0.554         589         8,787,301         6.7           Liver and Bile Duct         Heale         10         102,700         9.7         11.4         7.9         0.550         398         4,409,168         9.0           Liver and Bile Duct         Female         4         98,714         4.1         7.9         0.550         398         4,409,168         9.0           Liver and Bile Duct         Female         4         98,714         4.1         4.7         7.9         0.550         398         4,409,168         9.0           Liver and Bile Duct         Female         4         98,714         4.1         4.7         7.3         1.00         191         4.378,133         3.1           Lung and Bronchus         Female         5         98,714         25.3											
Leukemia         Female         9         98,714         9.1         10.2         5.3         0.183         265         4,378,133         6.1           Liver and Bile Duct         Total         14         201,414         7.0         8.1         11.6         0.554         589         8,787,301         6.7           Liver and Bile Duct         Male         10         102,700         9.7         11.4         7.9         0.550         398         4,409,168         9.0           Liver and Bile Duct         Female         4         98,714         4.1         4.7         3.7         1.000         191         4,378,133         4.4           Lung and Bronchus         Total         51         201,414         25.3         29.6         30.5         0.476         1,530         4,409,168         34.7           Lung and Bronchus         Male         26         102,700         25.3         29.6         30.5         0.476         1,530         4,409,168         34.7           Lung and Bronchus         Female         25         98,714         25.3         29.2         27.0         0.797         1,380         4,378,133         31.5           Melanoma of the Skin         Male         4											
Liver and Bile Duct         Total         14         201,414         7.0         8.1         11.6         0.554         589         8,787,301         6.7           Liver and Bile Duct         Male         10         102,700         9.7         11.4         7.9         0.550         398         4,409,168         9.0           Liver and Bile Duct         Female         4         98,714         4.1         4.7         3.7         1.000         191         4,378,133         4.4           Lung and Bronchus         Total         51         201,414         25.3         29.4         57.4         0.438         2.910         8,787,301         33.1           Lung and Bronchus         Melanoma of the Skin         Male         26         102,700         25.3         29.2         27.0         0.797         1,380         4,378,133         31.5           Melanoma of the Skin         Male         4         102,700         3.9         4.5         5.6         0.226         280         8,787,301         3.2           Melanoma of the Skin         Male         4         102,700         3.9         4.5         3.8         1.00         108         4,79,168         4.3           Myeloma         Male											
Liver and Bile Duct Female 4 98,714 4.1 7.9 0.550 398 4,409,168 9.0 Liver and Bile Duct Female 4 98,714 4.1 4.7 3.7 1.000 191 4,378,133 4.4 Lung and Bronchus Total 51 201,414 25.3 29.4 57.4 0.438 2.910 8,787,301 33.1 Lung and Bronchus Male 26 102,700 25.3 29.6 30.5 0.476 1.530 4,409,168 34.7 Lung and Bronchus Female 25 98,714 25.3 29.2 27.0 0.797 1,380 4,378,133 31.5 Melanoma of the Skin Total 9 201,414 4.5 5.1 5.6 0.226 280 8,787,301 3.5 Melanoma of the Skin Male 4 102,700 3.9 4.5 3.8 1.000 188 4,409,168 4.3 Melanoma of the Skin Female 5 98,714 5.1 5.8 1.8 0.076 92 4,378,133 2.1 Myeloma Male 4 102,700 3.9 4.5 3.8 1.000 188 4,409,168 4.3 Myeloma Female 3 98,714 3.5 4.0 6.4 0.924 324 8,787,301 3.2 Myeloma Female 3 98,714 3.0 3.5 2.6 0.952 132 4,378,133 3.0 Non-Hodgkin Lymphoma Total 12 201,414 6.0 6.8 11.2 0.880 557 8,787,301 6.8 Non-Hodgkin Lymphoma Male 7 102,700 6.8 7.8 6.1 0.810 300 4,409,168 6.8 Non-Hodgkin Lymphoma Female 5 98,714 5.1 5.8 5.1 1.000 257 4,378,133 5.9 Oral Cavity and Pharynx Male 5 102,700 4.9 5.7 3.6 0.584 182 4,409,168 4.1 Oral Cavity and Pharynx Male 5 102,700 4.9 5.7 3.6 0.584 182 4,409,168 4.1 Oral Cavity and Pharynx Female 4 98,714 4.1 4.7 6.7 0.395 346 4,378,133 1.8 Oral Cavity and Pharynx Female 13 98,714 1.2 5.2 2.9 5.1 1.000 261 8,787,301 3.3 Pancreas Female 13 98,714 4.1 4.7 6.7 0.395 346 4,378,133 1.8 Oral Cavity and Pharynx Female 4 98,714 4.1 4.7 6.7 0.395 346 4,378,133 1.8 Oral Cavity and Pharynx Female 4 98,714 4.1 4.7 6.7 0.395 346 4,378,133 1.8 Oral Cavity and Pharynx Female 7 102,700 6.8 8.0 12.6 0.132 6.55 4,378,133 1.8 Oral Cavity and Pharynx Female 13 98,714 1.1 4.7 6.7 0.395 346 4,378,133 1.8 Oral Cavity and Pharynx Female 13 98,714 1.1 4.7 6.7 0.395 346 4,378,133 1.8 Oral Cavity and Pharynx Female 13 98,714 1.1 4.7 6.7 0.395 346 4,378,133 1.8 Oral Cavity and Pharynx Female 13 98,714 1.1 4.7 6.7 0.501 3.9 3.9 0.9 32 4,409,168 1.1 4.9 Pancreas Female 13 98,714 1.1 5.1 1.7 3.9 0.9 4 195 8,787,301 1.2 2 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1											
Liver and Bile Duct         Female         4         98,714         4.1         4.7         3.7         1.000         191         4,378,133         4.4           Lung and Bronchus         Total         51         201,414         25.3         29.4         57.4         0.438         2,910         8,787,301         33.1           Lung and Bronchus         Female         25         98,714         25.3         29.2         27.0         0.797         1,380         4,378,133         31.5           Melanoma of the Skin         Total         9         201,414         4.5         5.1         5.6         0.226         280         8,787,301         3.2           Melanoma of the Skin         Male         4         102,700         3.9         4.5         3.8         1.000         188         4,409,168         4.3           Melanoma of the Skin         Female         5         98,714         5.1         5.6         0.226         280         8,787,301         3.2           Myeloma         Male         4         102,700         3.9         4.5         3.8         1.000         102         4,378,133         2.1           Myeloma         Male         4         102,700         3.9											
Lung and Bronchus         Total         51         201,414         25.3         29.4         57.4         0.438         2,910         8,787,301         33.1           Lung and Bronchus         Male         26         102,700         25.3         29.6         30.5         0.476         1,530         4,409,168         34.7           Lung and Bronchus         Female         25         98,714         25.3         29.2         27.0         0.797         1,380         4,378,133         31.5           Melanoma of the Skin         Total         9         201,414         4.5         5.1         5.6         0.226         280         8,787,301         3.2           Melanoma of the Skin         Male         4         102,700         3.9         4.5         3.8         1.000         188         4,409,168         4.3           Melanoma of the Skin         Female         5         98,714         5.1         5.8         1.8         0.076         92         4,378,133         2.1           Myeloma         Male         4         102,700         3.9         4.5         3.9         1.000         192         4,409,168         4.4           Myeloma         Male         4         102,700 </td <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>											
Lung and Bronchus         Male Female         26         102,700         25.3         29.6         30.5         0.476         1,530         4,409,168         34.7           Lung and Bronchus         Female         25         98,714         25.3         29.2         27.0         0.797         1,380         4,378,133         31.5           Melanoma of the Skin         Male         4         102,700         3.9         4.5         3.8         1.000         188         4,409,168         4.3           Melanoma of the Skin         Female         5         98,714         5.1         5.8         1.8         0.076         92         4,378,133         2.1           Myeloma         Total         7         201,414         3.5         4.0         6.4         0.924         324         8,787,301         3.7           Myeloma         Male         4         102,700         3.9         4.5         3.9         1.000         192         4,409,168         4.4           Myeloma         Male         4         102,700         3.9         4.5         3.9         1.000         192         4,409,168         4.9           Myeloma         Total         7         102,700         3.9 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>, ,</td> <td></td>										, ,	
Lung and Bronchus         Female         25         98,714         25.3         29.2         27.0         0.797         1,380         4,378,133         31.5           Melanoma of the Skin         Total         9         201,414         4.5         5.1         5.6         0.226         280         8,787,301         3.2           Melanoma of the Skin         Male         4         102,700         3.9         4.5         3.8         1.000         188         4,409,168         4.3           Melanoma of the Skin         Female         5         98,714         5.1         5.8         1.8         0.076         92         4,378,133         2.1           Myeloma         Total         7         201,414         3.5         4.0         6.4         0.924         324         8,787,301         3.7           Myeloma         Male         4         102,700         3.9         4.5         3.9         1.000         192         4,409,168         4.4           Myeloma         Female         3         98,714         3.0         3.5         2.6         0.952         132         4,378,133         3.0           Non-Hodgkin Lymphoma         Mole         7         102,700         6.8<				102 700							
Melanoma of the Skin         Total         9         201,414         4.5         5.1         5.6         0.226         280         8,787,301         3.2           Melanoma of the Skin         Male         4         102,700         3.9         4.5         3.8         1.000         188         4,409,168         4.3           Melanoma of the Skin         Male         5         98,714         5.1         5.8         1.8         0.076         92         4,378,133         2.1           Myeloma         Total         7         201,414         3.5         4.0         6.4         0.924         324         8,787,301         3.7           Myeloma         Male         4         102,700         3.9         4.5         3.9         1.000         192         4,409,168         4.4           Myeloma         Female         3         98,714         3.0         3.5         2.6         0.952         132         4,378,133         3.0           Mon-Hodgkin Lymphoma         Female         7         102,700         6.8         7.8         6.1         0.810         300         4,409,168         4.4           Non-Hodgkin Lymphoma         Male         7         102,700         6.8											
Melanoma of the Skin         Male         4         102,700         3.9         4.5         3.8         1.000         188         4,409,168         4.3           Melanoma of the Skin         Female         5         98,714         5.1         5.8         1.8         0.076         92         4,378,133         2.1           Myeloma         Total         7         201,414         3.5         4.0         6.4         0.924         324         8,787,301         3.7           Myeloma         Male         4         102,700         3.9         4.5         3.9         1.000         192         4,409,168         4.4           Myeloma         Female         3         98,714         3.0         3.5         2.6         0.952         132         4,378,133         3.0           Non-Hodgkin Lymphoma         Total         12         201,414         6.0         6.8         11.2         0.880         557         8,787,301         6.3           Non-Hodgkin Lymphoma         Male         7         102,700         6.8         7.8         6.1         0.810         300         4,409,168         6.8           Non-Hodgkin Lymphoma         Female         5         98,714         5.1 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>											
Myeloma         Total         7         201,414         3.5         4.0         6.4         0.924         324         8,787,301         3.7           Myeloma         Male         4         102,700         3.9         4.5         3.9         1.000         192         4,409,168         4.4           Myeloma         Female         3         98,714         3.0         3.5         2.6         0.952         132         4,378,133         3.0           Non-Hodgkin Lymphoma         Total         12         201,414         6.0         6.8         11.2         0.880         557         8,787,301         6.3           Non-Hodgkin Lymphoma         Male         7         102,700         6.8         7.8         6.1         0.810         300         4,409,168         6.8           Non-Hodgkin Lymphoma         Female         5         98,714         5.1         5.8         5.1         1.000         257         4,378,133         5.9           Oral Cavity and Pharynx         Total         5         201,414         2.5         2.9         5.1         1.000         261         8,787,301         3.0           Oral Cavity and Pharynx         Male         5         102,700 <td< td=""><td>Melanoma of the Skin</td><td>Male</td><td>4</td><td>102,700</td><td></td><td></td><td></td><td>1.000</td><td></td><td></td><td></td></td<>	Melanoma of the Skin	Male	4	102,700				1.000			
Myeloma         Male         4         102,700         3.9         4.5         3.9         1.000         192         4,409,168         4.4           Myeloma         Female         3         98,714         3.0         3.5         2.6         0.952         132         4,378,133         3.0           Non-Hodgkin Lymphoma         Total         12         201,414         6.0         6.8         11.2         0.880         557         8,787,301         6.3           Non-Hodgkin Lymphoma         Male         7         102,700         6.8         7.8         6.1         0.810         300         4,409,168         6.8           Non-Hodgkin Lymphoma         Female         5         98,714         5.1         5.8         5.1         1.000         257         4,378,133         5.9           Oral Cavity and Pharynx         Total         5         201,414         2.5         2.9         5.1         1.000         261         8,787,301         3.0           Oral Cavity and Pharynx         Male         5         102,700         4.9         5.7         3.6         0.584         182         4,409,168         4.1           Oral Cavity and Pharynx         Female         -         98,714<											
Myeloma         Female         3         99,714         3.0         3.5         2.6         0.952         132         4,378,133         3.0           Non-Hodgkin Lymphoma         Total         12         201,414         6.0         6.8         11.2         0.880         557         8,787,301         6.3           Non-Hodgkin Lymphoma         Male         7         102,700         6.8         7.8         6.1         0.810         300         4,409,168         6.8           Non-Hodgkin Lymphoma         Female         5         98,714         5.1         5.8         5.1         1.000         257         4,378,133         5.9           Oral Cavity and Pharynx         Total         5         201,414         2.5         2.9         5.1         1.000         261         8,787,301         3.0           Oral Cavity and Pharynx         Male         5         102,700         4.9         5.7         3.6         0.584         182         4,409,168         4.1           Oral Cavity and Pharynx         Female         -         98,714         -         -         1.5         0.428         79         4,378,133         1.8           Ovary         Female         -         98,714			-		3.5						
Nón-Hodgkin Lymphoma         Total         12         201,414         6.0         6.8         11.2         0.880         557         8,787,301         6.3           Non-Hodgkin Lymphoma         Male         7         102,700         6.8         7.8         6.1         0.810         300         4,409,168         6.8           Non-Hodgkin Lymphoma         Female         5         98,714         5.1         5.8         5.1         1.000         257         4,378,133         5.9           Oral Cavity and Pharynx         Total         5         201,414         2.5         2.9         5.1         1.000         261         8,787,301         3.0           Oral Cavity and Pharynx         Male         5         201,414         2.5         2.9         5.1         1.000         261         8,787,301         3.0           Oral Cavity and Pharynx         Male         5         102,700         4.9         5.7         3.6         0.584         182         4,409,168         4.1           Oral Cavity and Pharynx         Female         -         98,714         -         -         1.5         0.428         79         4,378,133         1.8           Ovary         Female         - <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>											
Non-Hodgkin Lymphoma         Male         7         102,700         6.8         7.8         6.1         0.810         300         4,409,168         6.8           Non-Hodgkin Lymphoma         Female         5         98,714         5.1         5.8         5.1         1.000         257         4,378,133         5.9           Oral Cavity and Pharynx         Total         5         201,414         2.5         2.9         5.1         1.000         261         8,787,301         3.0           Oral Cavity and Pharynx         Male         5         102,700         4.9         5.7         3.6         0.584         182         4,409,168         4.1           Oral Cavity and Pharynx         Female         -         98,714         -         -         1.5         0.584         182         4,409,168         4.1           Oral Cavity and Pharynx         Female         -         98,714         -         -         1.5         0.584         182         4,409,168         4.1           Oral Cavity and Pharynx         Female         -         98,714         -         -         1.5         0.428         79         4,378,133         1.8           Ovary         Female         -         98,7											
Non-Hodgkin Lýmphoma         Female         5         98,714         5.1         5.8         5.1         1.000         257         4,378,133         5.9           Oral Cavity and Pharynx         Total         5         201,414         2.5         2.9         5.1         1.000         261         8,787,301         3.0           Oral Cavity and Pharynx         Male         5         102,700         4.9         5.7         3.6         0.584         182         4,409,168         4.1           Oral Cavity and Pharynx         Female         -         98,714         -         -         1.5         0.428         79         4,378,133         1.8           Ovary         Female         4         98,714         -         -         1.5         0.428         79         4,378,133         7.9           Pancreas         Total         20         201,414         9.9         11.6         23.1         0.612         1,170         8,787,301         13.3           Pancreas         Male         7         102,700         6.8         8.0         12.6         0.132         635         4,409,168         14.4           Pancreas         Female         13         98,714         13.2											
Oral Cavity and Pharynx         Total         5         201,414         2.5         2.9         5.1         1.000         261         8,787,301         3.0           Oral Cavity and Pharynx         Male         5         102,700         4.9         5.7         3.6         0.584         182         4,409,168         4.1           Oral Cavity and Pharynx         Female         -         98,714         -         -         1.5         0.428         79         4,378,133         1.8           Ovary         Female         4         98,714         4.1         4.7         6.7         0.395         346         4,378,133         7.9           Pancreas         Total         20         201,414         9.9         11.6         23.1         0.612         1,170         8,787,301         13.3           Pancreas         Male         7         102,700         6.8         8.0         12.6         0.132         635         4,409,168         14.4           Pancreas         Female         13         98,714         13.2         15.2         10.5         0.511         535         4,378,133         12.2           Prostate         Male         17         102,700         16.6	Non-Hodakin Lymphoma			102,700							
Oral Cavity and Pharynx         Male         5         102,700         4.9         5.7         3.6         0.584         182         4,409,168         4.1           Oral Cavity and Pharynx         Female         -         98,714         -         -         1.5         0.428         79         4,378,133         1.8           Ovary         Female         4         98,714         4.1         4.7         6.7         0.395         346         4,378,133         7.9           Pancreas         Total         20         201,414         9.9         11.6         23.1         0.612         1,170         8,787,301         13.3           Pancreas         Male         7         102,700         6.8         8.0         12.6         0.132         635         4,409,168         14.4           Pancreas         Female         13         98,714         13.2         15.2         10.5         0.511         535         4,378,133         12.2           Prostate         Male         17         102,700         16.6         19.0         18.9         0.767         932         4,409,168         21.1           Stomach         Total         3         201,414         1.5         1.7<	Oral Cavity and Pharvny		5								
Oral Cavitý and Pharýnx         Female         -         99,714         -         -         1.5         0.428         79         4,378,133         1.8           Ovary         Female         4         98,714         4.1         4.7         6.7         0.395         346         4,378,133         7.9           Pancreas         Total         20         201,414         9.9         11.6         23.1         0.612         1,170         8,787,301         13.3           Pancreas         Male         7         102,700         6.8         8.0         12.6         0.132         635         4,409,168         14.4           Pancreas         Female         13         98,714         13.2         15.2         10.5         0.511         535         4,378,133         12.2           Prostate         Male         17         102,700         16.6         19.0         18.9         0.767         932         4,409,168         21.1           Stomach         Total         3         201,414         1.5         1.7         3.9         0.924         195         8,787,301         2.2           Stomach         Male         2         102,700         1.9         2.3 <th< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th<>											
Ovary         Female         4         98,714         4.1         4.7         6.7         0.395         346         4,378,133         7.9           Pancreas         Total         20         201,414         9.9         11.6         23.1         0.612         1,170         8,787,301         13.3           Pancreas         Male         7         102,700         6.8         8.0         12.6         0.132         635         4,409,168         14.4           Pancreas         Female         13         98,714         13.2         15.2         10.5         0.511         535         4,378,133         12.2           Prostate         Male         17         102,700         16.6         19.0         18.9         0.767         932         4,409,168         21.1           Stomach         Total         3         201,414         1.5         1.7         3.9         0.924         195         8,787,301         2.2           Stomach         Male         2         102,700         1.9         2.3         2.4         1.000         119         4,409,168         2.7					-	5.7					
Pancreas         Total Pancreas         20 Pancreas         201,414         9.9 Pancreas         11.6 Pancreas         23.1 Pancreas         0.612 Pancreas         1,170 Pancreas         8,787,301 Pancreas         13.3 Pancreas           Pancreas         Female Pancreas         13 Pancreas         13 Pancreas         15.2 Pancreas         10.5 Pancreas         15.2 Pancreas         15	,		4		4.1	4.7					
Pancreas         Male         7         102,700         6.8         8.0         12.6         0.132         635         4,409,168         14.4           Pancreas         Female         13         98,714         13.2         15.2         10.5         0.511         535         4,378,133         12.2           Prostate         Male         17         102,700         16.6         19.0         18.9         0.767         932         4,409,168         21.1           Stomach         Total         3         201,414         1.5         1.7         3.9         0.924         195         8,787,301         2.2           Stomach         Male         2         102,700         1.9         2.3         2.4         1.000         119         4,409,168         2.7											
Pancreas         Female         13         98,714         13.2         15.2         10.5         0.511         535         4,378,133         12.2           Prostate         Male         17         102,700         16.6         19.0         18.9         0.767         932         4,409,168         21.1           Stomach         Total         3         201,414         1.5         1.7         3.9         0.924         195         8,787,301         2.2           Stomach         Male         2         102,700         1.9         2.3         2.4         1.000         119         4,409,168         2.7			7								
Stomach         Total         3         201,414         1.5         1.7         3.9         0.924         195         8,787,301         2.2           Stomach         Male         2         102,700         1.9         2.3         2.4         1.000         119         4,409,168         2.7				98,714		15.2	10.5		535		
Stomach   Male   2   102,700   1.9   2.3   2.4   1.000   119   4,409,168   2.7						19.0					
											2.2
Stomach   Female   1   98,714   1.0   1.1   1.5   1.000   76   4,378,133   1.7			2	·							
	Stomach	Female	1	98,714	1.0	1.1	1.5	1.000	76	4,378,133	1.7

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

<sup>2.</sup> Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

### Cancer Screening and Risk Factor Prevalence Estimates, 2011–2021

	State of								Latah
Measure	Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	County
Access to Care									
Have Health Insurance, Age <65 (2015–2021)	83.1%	82.8%	85.1%	77.2%	85.8%	78.9%	85.4%	85.4%	91.1%
Not See Doctor Due to Cost in Past Year (2015–2021)	12.6%	11.4%	11.8%	14.5%	12.4%	12.3%	11.8%	12.9%	11.3%
Cancer Screening									
Mammogram Past 2 Years, Age 50–74 (2014, 2016, 2018, 2020)	69.1%	67.0%	73.8%	68.2%	73.2%	64.8%	64.5%	67.1%	75.8%
Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020)	71.2%	73.6%	73.6%	70.8%	72.9%	69.1%	69.5%	65.9%	76.0%
Colorectal Cancer Screening, Age 50–75 (2018, 2020)	67.9%	66.9%	73.6%	71.4%	70.6%	61.7%	61.5%	64.7%	77.1%
Tobacco Use									
Current Tobacco User (2016–2021)	22.3%	26.7%	23.1%	23.6%	21.8%	21.4%	22.7%	16.9%	21.7%
Other Cancer-Related									
Healthy Weight by Body Mass Index, Age 20+ (2015–2021)	32.1%	32.8%	31.7%	27.9%	36.1%	29.8%	27.9%	31.9%	36.4%
Any Physical Activity Besides Job Past 30 Days (2015-2021)	78.7%	79.2%	78.1%	74.5%	83.2%	73.4%	76.3%	79.7%	84.1%
Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019)	21.9%	22.8%	19.4%	20.0%	25.2%	19.5%	20.4%	20.2%	23.4%
Home Ever Tested for Radon (2016, 2018, 2020)	23.0%	30.9%	18.2%	16.9%	25.1%	19.9%	23.0%	21.8%	21.0%

### **Access to Care**

### Have Health Insurance - 2015-2021

Statewide, 83.1% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 86.0% of white non-Hispanics, compared to 64.8% of Hispanics and 83.3% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3%) than English-speaking respondents (84.2%). Health care coverage differed significantly by age of respondent, with 79.8% of persons aged 18–29, and 87.8% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 62.1% in Adams County to 91.6% in Oneida County having health insurance.

### Not See Doctor Due to Cost in Past Year - 2015-2021

Statewide, 12.6% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (11.5% of white non-Hispanics, 19.2% of Hispanics, and 21.0% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9% for less than \$15,000, 6.1% for greater than \$50,000). Inability to see a doctor due to cost differed significantly by county, with a range of 7.4% in Franklin County to 17.5% in Power County.

### **Cancer Screening**

Mammogram - 2014, 2016, 2018, 2020

Statewide, 69.1% of women aged 50–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (72.1% versus 36.7%). Mammography rates differed significantly by county, with a range in screening of 45.9% in Benewah County to 77.0% in Nez Perce County. In 2020, Idaho ranked 48<sup>th</sup> among states and the District of Columbia for mammography screening rates among women aged 50–74 and also 48<sup>th</sup> among ages 40+.

### Pap Test - 2018, 2020

Statewide, 71.2% of women with an intact cervix and aged 21–65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.1% versus 52.6% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.7% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49<sup>th</sup> among states and the District of Columbia for Pap screening rate.

### Colorectal Cancer Screening – 2018, 2020

Statewide, 67.9% of adults aged 50–75 reported being current for colorectal cancer screening.\*\* Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked 47<sup>th</sup> among states and the District of Columbia in the percentage of adults aged 50–75 and older who reported being up-to-date for colorectal cancer screening.

<sup>\*\*</sup> Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

### **Tobacco Use**

### Current Tobacco Use - 2016-2021

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.3% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 29.9% of persons aged 18-29, and 11.1% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (22.4%) than among Native Americans (40.0%). Tobacco use differed significantly by county, with a range of 5.4% in Madison County to 41.6% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

### **Other Cancer-Related**

### Healthy Weight by Body Mass Index - 2015-2021

Statewide, 32.1% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 32.5% of white non-Hispanics, compared to 28.2% of Hispanics and 24.6% of Native Americans, being in the healthy weight range. Males (25.5%) were significantly less likely to be in the healthy weight range than females (38.6%). BMI differed significantly by age of respondent, with 43.3% of persons aged 18–29, and 26.0% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 19.8% in Power County to 47.4% in Blaine County of adults being in the healthy weight range.

### Any Physical Activity - 2015-2021

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 78.7% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.3% of persons aged 18–29, and 72.3% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 64.3% in Clark County to 84.6% in Teton County.

Physical Activity Guidelines – 2011, 2013, 2015, 2017, 2019 Statewide, 21.9% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.3% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6% in Franklin County to 30.6% in Blaine County.

### Home Radon Testing - 2016, 2018, 2020

Statewide, 23.0% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.4% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.5% in Cassia County to 54.4% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006l and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.





# LEMHI COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

# Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

# **RISK FACTORS AND INTERVENTIONS**

### **CANCER**

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/jama.2016.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

### Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

### **Smoking:**

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

### Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <a href="https://www.dietaryguidelines.gov">https://www.dietaryguidelines.gov</a>

### Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute
Cancer Information Services
1-800-4CANCER
<a href="https://www.cancer.gov/contact">https://www.cancer.gov/contact</a>

American Cancer Society <a href="https://www.cancer.org">https://www.cancer.org</a>

### **CANCER INCIDENCE 2016–2020**

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016–2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 308 cases of invasive cancer were diagnosed among Lemhi County residents (Table 1).

**Table 1:** Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Lemhi County and the State of Idaho, 2016–2020

Cancer Incidence 2016–2020	Lemhi County	State of Idaho
All Sites/Types	308	45,610
Female Breast	33	6,687
Prostate	71	6,417
Lung & Bronchus	33	4,887
Colorectal	24	3,451

Table 3 (Cancer Incidence 2016–2020, Comparison between Lemhi County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Lemhi County. The table also shows the number of observed cases, person-

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Lemhi County was 776.9 cases per 100,000 person-years per year during 2016–2020. Comparing this crude rate with the crude rate for the remainder of Idaho (518.8) gives an estimate of the relative burden of disease in Lemhi County.

The age- and sex-adjusted incidence rate of invasive cancer in Lemhi County, all sites combined, was 476.5 cases per 100,000 persons per year during 2016–2020. There were fewer cases of cancer in Lemhi County (308) than expected (335.4) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

### **CANCER MORTALITY 2017–2021**

During 2017–2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 131 Lemhi County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

**Table 2:** Overall and Cancer Mortality in Lemhi County and the State of Idaho, 2017–2021

Mortality 2017–2021	Lemhi County	State of Idaho			
All Deaths	614	77,431			
Cancer Deaths	131	15,121			
% of All Deaths	21.3%	19.5%			
Lung & Bronchus	29	2,961			
Colorectal	14	1,319			
Pancreas	10	1,190			
Female Breast	10	1,086			
Prostate	11	949			

Table 4 (Cancer Mortality 2017–2021, Comparison between Lemhi County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Lemhi County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Lemhi County, all sites combined, was 182.6 deaths per 100,000 persons per year during 2017–2021, compared with 167.5 for the remainder of the state. There were more cancer deaths in Lemhi County (131) than expected (120.2) based upon rates in the remainder of the state, but the difference was not statistically significant.

**Statistical Note:** Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

# TABLE 3: CANCER INCIDENCE 2016–2020 COMPARISON BETWEEN LEMHI COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

		Lemhi County						Remainder of Idaho			
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude	
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)	
All Sites Combined	Total	308	39,647	776.9	476.5	335.4	0.140	45,302	8,732,181 4.376.838	518.8	
All Sites Combined All Sites Combined	Male Female	191 117	20,072 19,575	951.6 597.7	536.1 396.6	196.2 143.6	0.746 0.025 <b>&lt;&lt;</b>	24,098 21,204	4,376,636	550.6 486.9	
Bladder	Total	18	39,647	45.4	25.0	17.9	1.000	2,166	8,732,181	24.8	
Bladder	Male	14	20,072	69.7	35.5	15.6	0.802	1,737	4,376,838	39.7	
Bladder	Female	4	19,575	20.4	12.1	3.2	0.814	429	4,355,343	9.8	
Brain - malignant	Total	2	39,647	5.0	3.5	4.0	0.466	623	8,732,181	7.1	
Brain - malignant Brain - malignant	Male Female	1 1	20,072 19,575	5.0 5.1	3.4 3.7	2.5 1.6	0.561 1.000	374 249	4,376,838 4,355,343	8.5 5.7	
Brain and other CNS - non-malignant	Total	10	39.647	25.2	16.7	9.7	1.000	1,414	8.732.181	16.2	
Brain and other CNS - non-malignant	Male	3	20,072	14.9	9.8	3.3	1.000	477	4,376,838	10.9	
Brain and other CNS - non-malignant	Female	7	19,575	35.8	24.3	6.2	0.847	937	4,355,343	21.5	
Breast	Total	33	39,647	83.2	54.3	46.7	0.045 <<	6,713	8,732,181	76.9	
Breast	Male Female	33	20,072	160.6	- 114.5	0.5 44.0	1.000 0.103	59 6 65 4	4,376,838	1.3	
Breast Breast - in situ	Total	3	19,575 39,647	168.6 7.6	5.1	8.3	0.103	6,654 1,236	4,355,343 8,732,181	152.8 14.2	
Breast - in situ	Male	-	20,072	-	- 3.1	0.0	1.000	5	4,376,838	0.1	
Breast - in situ	Female	3	19,575	15.3	10.7	7.9	0.089	1,231	4,355,343	28.3	
Cervix	Female	1	19,575	5.1	4.7	1.5	1.000	303	4,355,343	7.0	
Colorectal	Total	24	39,647	60.5	37.7	25.0	0.945	3,427	8,732,181	39.2	
Colorectal Colorectal	Male Female	16 8	20,072 19,575	79.7 40.9	47.4 26.5	14.5 10.7	0.770 0.526	1,887 1,540	4,376,838 4,355,343	43.1 35.4	
Corpus Uteri	Female	7	19,575	35.8	23.8	8.9	0.526	1,340	4,355,343	30.4	
Esophagus	Total	7	39,647	17.7	10.3	3.9	0.198	499	8,732,181	5.7	
Esophagus	Male	7	20,072	34.9	19.1	3.5	0.129	417	4,376,838	9.5	
Esophagus	Female	-	19,575	-	-	0.6	1.000	82	4,355,343	1.9	
Hodgkin Lymphoma	Total	-	39,647	-	-	1.1	0.689	210	8,732,181	2.4	
Hodgkin Lymphoma Hodgkin Lymphoma	Male Female	-	20,072 19,575	-	_	0.6 0.4	1.000 1.000	118 92	4,376,838 4,355,343	2.7 2.1	
Kidney and Renal Pelvis	Total	11	39.647	27.7	17.5	13.0	0.709	1,804	8,732,181	20.7	
Kidney and Renal Pelvis	Male	7	20,072	34.9	21.1	8.9	0.667	1,175	4,376,838	26.8	
Kidney and Renal Pelvis	Female	4	19,575	20.4	13.4	4.3	1.000	629	4,355,343	14.4	
Larynx	Total	-	39,647	-	-	1.6	0.387	215	8,732,181	2.5	
Larynx	Male Female	-	20,072 19,575	-	-	1.3 0.4	0.533 1.000	160 55	4,376,838 4,355,343	3.7 1.3	
Larynx Leukemia	Total	9	39,647	22.7	13.9	12.0	0.485	1,622	8,732,181	18.6	
Leukemia	Male	6	20,072	29.9	17.3	7.8	0.684	983	4,376,838	22.5	
Leukemia	Female	3	19,575	15.3	9.9	4.5	0.699	639	4,355,343	14.7	
Liver and Bile Duct	Total	4	39,647	10.1	6.0	6.3	0.491	825	8,732,181	9.4	
Liver and Bile Duct	Male	1	20,072	5.0	2.8	4.8	0.099	589	4,376,838	13.5	
Liver and Bile Duct Lung and Bronchus	Female Total	33	19,575 39,647	15.3 83.2	9.5 46.2	1.7 39.7	0.491 0.324	236 4,854	4,355,343 8,732,181	5.4 55.6	
Lung and Bronchus	Male	21	20,072	104.6	54.0	21.6	1.000	2,431	4,376,838	55.5	
Lung and Bronchus	Female	12	19,575	61.3	36.4	18.4	0.158	2,423	4,355,343	55.6	
Melanoma of the Skin	Total	12	39,647	30.3	19.6	20.5	0.062	2,930	8,732,181	33.6	
Melanoma of the Skin	Male	7	20,072	34.9	20.4	13.8	0.071	1,758	4,376,838	40.2	
Melanoma of the Skin	Female	5	19,575	25.5	18.5	7.3	0.536	1,172	4,355,343	26.9	
Myeloma Myeloma	Total Male	4 3	39,647 20,072	10.1 14.9	5.7 7.9	5.6 3.8	0.678 0.949	704 438	8,732,181 4.376.838	8.1 10.0	
Myeloma	Female	1	19,575	5.1	3.1	2.0	0.834	266	4,355,343	6.1	
Nón-Hodgkin Lymphoma	Total	9	39,647	22.7	13.9	14.3	0.192	1,931	8,732,181	22.1	
Non-Hodgkin Lymphoma	Male	8	20,072	39.9	23.4	8.8	0.972	1,121	4,376,838	25.6	
Non-Hodgkin Lymphoma Oral Cavity and Pharynx	Female	1	19,575	5.1	3.3	5.7	0.045 <<	810	4,355,343	18.6	
Oral Cavity and Pharynx Oral Cavity and Pharynx	Total Male	12 10	39,647 20,072	30.3 49.8	18.7 29.6	9.4 7.2	0.477 0.371	1,283 926	8,732,181 4,376,838	14.7 21.2	
Oral Cavity and Pharynx	Female	2	19,575	10.2	6.6	2.5	1.000	357	4,355,343	8.2	
Ovary	Female	5	19,575	25.5	17.3	3.5	0.550	528	4,355,343	12.1	
Pancreas	Total	10	39,647	25.2	14.4	11.3	0.860	1,413	8,732,181	16.2	
Pancreas	Male	5	20,072	24.9	13.4	6.6	0.696	779	4,376,838	17.8	
Pancreas Prostate	Female Male	5 71	19,575 20,072	25.5 353.7	15.4 193.4	4.7 53.2	1.000 0.023 >>	634 6,346	4,355,343 4,376,838	14.6 145.0	
Stomach	Total	4	39.647	10.1	6.0	3.5	0.023	463	8,732,181	5.3	
Stomach	Male	3	20,072	14.9	8.3	2.5	0.924	306	4,376,838	7.0	
Stomach	Female	1	19,575	5.1	3.3	1.1	1.000	157	4,355,343	3.6	
Testis	Male	-	20,072	-	-	1.0	0.752	265	4,376,838	6.1	
Thyroid	Total	5	39,647	12.6	10.9	6.4	0.766	1,215	8,732,181	13.9	
Thyroid	Male		20,072		-	2.2	0.233	355	4,376,838	8.1	
Thyroid	Female	5	19,575	25.5	23.2	4.3	0.845	860	4,355,343	19.7	
Pediatric Age 0 to 19	Total	1	8,001	12.5	12.5	1.4	1.000	420	2,452,522	17.1	
Pediatric Age 0 to 19 Pediatric Age 0 to 19	Male Female	- 1	4,206 3,795	- 26.4	- 26.3	0.7 0.6	0.946 0.929	223 197	1,252,304 1,200,218	17.8 16.4	
·		•	ne number of case					197	1,200,210	10.4	

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

<sup>2.</sup> Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

<sup>&</sup>quot;<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

# **TABLE 4: CANCER MORTALITY 2017–2021** COMPARISON BETWEEN LEMHI COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

Cause of Death   Sex   Death   Sex   Death   Veams   Rale (1) Rale (2) Deaths (3)   P-Value (4) Death   Veams   Rale (1) Rale (2) Deaths (3)   P-Value (4) Death   Veams   Rale (1) Rale (2) Deaths (3)   P-Value (4) Death   Veams   Rale (1) Rale (2) Deaths (3)   P-Value (4) Death   Veams   Rale (1) Rale (2) Deaths (3)   P-Value (4) Death   Veams   Rale (1) Rale (2) Deaths (3)   P-Value (4) Death   Veams   Veams   Rale (1) Rale (2) Deaths (3)   P-Value (4) Death (3)   Rale (1) Rale (3)   Ra			Lemhi County							Remainder of Idaho			
All Causes of Death   Total   614   40,094   15,314   85,56   618.0   0,956   76,816   8,948,621   85,84   All Causes of Death   Male   264   19,004   13,331   770.6   277.6   0,435   36,110   4,457,043   810.2   All Causes of Death   Female   264   19,004   13,331   770.6   277.6   0,435   36,110   4,457,043   810.2   All Melignant Cancers   Total   51   40,094   32,57   812.5   20,22   0,334   4,995   8,948,621   167.5   40,094   22,5   160.5   51.4   0,020   6,895   4,457,043   154.7   169.8	Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude		
All Causes of Death   Male   350   20,220   1,750   923.7   343.4   0,736   40,706   4,491,578   906.3   All Causes of Death   Famale   244   19,904   1,333.1   770.6   2,776   0,743   310.2   4,491,578   361.10   4,457,043   810.2   4,441,578   1,445,043	Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)		
All Causes of Death Male All Causes of Death Male All Causes of Death Male All Causes of Death Female 24 19,904 1,333.1 77.0 6, 277.6 0,435 36,110 4,457,043 810.2 All Malignant Cancers Total 131 40,094 382.7 182.5 120.2 0,334.4 14,990 8,348,627 167.5 All Malignant Cancers Male 151 40,094 382.2 182.5 120.2 0,334.4 14,990 8,348,627 167.5 All Malignant Cancers Male 15 40,094 382.2 182.5 160	All Causes of Death	Total	614	40,094	1,531.4	855.6	616.0	0.956	76,816	8,948,621	858.4		
All Malignant Cancers   Total   131   40.094   32.67   182.6   120.2   0.344   14.990   8.948.621   167.5   All Malignant Cancers   Female   50   19.804   252.5   150.5   51.4   0.920   6.955   4.470.703   154.7   Bladder   Total   5   40.090   12.6   61.7   5   6.085   4.470.703   154.7   Bladder   Total   5   40.090   12.6   61.7   5   6.085   4.470.703   154.7   Bladder   Total   5   40.090   12.6   61.7   5   6.085   4.470.703   154.7   Bladder   Total   1   40.094   2.5   1.6   3.5   0.265   6.03   8.948.621   52.5   Brain and Other Nervous System   Total   1   40.094   2.5   1.6   3.5   0.265   503   8.948.621   52.5   Brain and Other Nervous System   Female   1   19.804   5.0   3.3   1.4   1.000   20.5   4.470.43   4.6   Brain and Other Nervous System   Female   1   19.804   5.0   3.3   1.4   1.000   20.5   4.470.43   4.6   Brain and Other Nervous System   Female   1   19.804   5.0   3.3   1.4   1.000   20.5   4.470.43   4.6   Brain and Other Nervous System   Total   10   40.084   24.5   14.7   8.3   0.886   1.092   8.948.621   12.2   Brain Stream   Female   1   19.804   5.0   3.3   1.4   1.000   20.5   4.470.43   4.6   Brain Stream   Female   1   19.804   5.0   3.3   1.4   1.000   20.5   4.470.43   4.6   Brain Stream   Female   1   19.804   5.0   3.1   2.7   0.5   0.088   1.092   8.948.621   12.2   Brain Stream   Female   2   19.804   5.0   3.1   2.7   0.5   0.088   1.092   8.948.621   12.2   Brain Stream   Female   3   19.804   5.0   5.0   1.000   8.3   4.457.043   1.19   Brain Stream   Female   4   19.804   5.0   5.0   1.000   8.3   4.457.043   1.19   Brain Stream   Female   5   19.804   5.0   5.0   1.000   8.3   4.457.043   1.19   Brain Stream   Female   6   19.804   5.0   5.0   1.000   8.3   4.457.043   1.19   Brain Stream   Female   7   19.804   5.0   5.0   1.000   7.0   4.457.043   1.19   Brain Stream   Female   8   19.804   5.0   5.0   1.000   7.0   4.457.043   1.19   Brain Stream   Female   9   19.804   5.0   5.0   5.0   1.000   7.0   4.457.043   1.19   Brain Stream   Female   1   19.804   5.0	All Causes of Death	Male	350	20,290	1,725.0	923.7	343.4	0.736		4,491,578	906.3		
All Meliginant Cancers   Male		Female		19,804			277.6	0.435	36,110	4,457,043			
All Malighant Cancers   Female   50   19,804   252.5   150.5   51.4   0.920   6.895   4.457,043   154.7   Bladder   Tofal   5   40,094   12.5   6.4   4.2   0.822   484   6.948,021   71.7   8.3   Bladder   Tofal   Male   5   20,290   24.6   11.7   3.5   0.508   373   4.491,678   8.3   Bladder   Semale   5   20,290   24.6   11.7   3.5   0.508   373   4.491,678   8.3   Blander   Semale   5   20,290   2.5   6.4   4.2   0.822   484   6.984,021   3.3   Blander   Semale   5   20,290   7.   6   2.2   0.221   2.28   6.44,677,043   3.5   Blander   Semale   1   19,804   5.0   3.3   1.4   1.000   205   4.457,043   6.6   Breast   Female   1   19,804   5.0   3.3   1.4   1.000   205   4.457,043   2.4   Breast   Female   10   19,804   5.0   3.12   7.7   0.500   1.076   4.457,043   2.4   Breast   Female   10   19,804   5.0   3.12   7.7   0.500   1.076   4.457,043   2.4   Breast   Female   10   19,804   5.0   3.12   7.7   0.500   1.076   4.457,043   2.4   Breast   Female   12   20,804   2.0   2.0   2.0   2.0   2.0   2.0   2.0   Breast   Female   12   20,804   2.0   2.0   2.0   2.0   2.0   2.0   2.0   Breast   Female   12   20,804   2.0   2.0   2.0   2.0   2.0   2.0   2.0   Breast   Female   12   20,804   2.0   2.0   2.0   2.0   2.0   2.0   2.0   Breast   Female   12   20,804   2.0   2.0   2.0   2.0   2.0   2.0   2.0   2.0   Breast   Total   14   40,089   2.0   2.0   2.0   2.0   2.0   2.0   2.0   2.0   2.0   2.0   2.0   2.0   Breast   Total   12   20,804   2.0   2.				40,094					14,990	8,948,621			
Bladder				20,290									
Bladder   Male   5   20,290   24.6   11.7   3.5   0.588   373   4,491,578   8.3   Brain and Other Nervous System   Total   1   40,094   2.5   1.6   3.5   0.285   503   8,948,621   2.5   Brain and Other Nervous System   Male   1   40,094   2.5   1.6   3.5   0.285   503   8,948,621   2.5   Brain and Other Nervous System   Male   1   40,094   2.5   1.6   3.5   0.285   503   8,948,621   2.5   Brain and Other Nervous System   Male   1   40,094   2.4   1.4   8.3   0.648   1.092   8,948,621   2.5   Breast   Total   10   40,094   2.4   14.7   8.3   0.648   1.092   8,948,621   2.2   Breast   Female   10   19,804   5.0   3.3   1.000   16   4,491,578   3.4   Colorectal   Total   14   40,094   34.9   2.2   10.1   0.283   1.305   8,948,621   1.2   Colorectal   Total   14   40,094   34.9   2.2   10.1   0.283   1.305   8,948,621   1.5   Colorectal   Total   14   40,094   34.9   2.2   10.1   0.283   1.305   8,948,621   1.5   Colorectal   Female   2   10,804   10.1   0.2   1.3   0.2   0.2   0.1   Colorectal   Female   2   10,804   10.1   0.2   0.3   0													
Biadder   Female   -   19,804   -   -   0.9   0.815   111   4,457,043   2.5     Brain and Other Nervous System   Male   -   20,290   -   -   2.2   0.221   298   4,491,578   6.6     Brain and Other Nervous System   Male   -   20,290   -   -   2.2   0.221   298   4,491,578   6.6     Brain and Other Nervous System   Male   -   20,290   -   -   2.2   0.221   298   4,491,578   6.6     Brain and Other Nervous System   Male   -   20,290   -   -   2.2   0.221   298   4,491,578   6.6     Brain and Other Nervous System   Male   -   19,804   5.0   3.3   1.4   1.000   1.000   1.000   4,457,043   4.5     Brain and Other Nervous System   Male   -   19,804   5.0   3.1   4.7   8.1   0.800   1.096   6.4457,043   4.5     Brain and Other Nervous System   Male   -   19,804   5.0   5.0   5.1   2.7   0.000   1.076   6.4457,043   2.4     Cervix   Female   -   19,804   -   -   0.5   1.000   83   4.457,043   1.9     Colorectal   Total   4   40,094   34.9   20.2   10.1   0.283   1.305   8,948,621   14.6     Colorectal   Male   12   20,290   59.1   33.2   5.7   0.028 >>   707   4,491,578   15.7     Colorectal   Female   -   19,804   -   -   1.3   0.550   1.000   8.9   4,457,043   3.9     Ecophagus   Total   -   19,804   -   -   1.3   0.550   1.73   4,457,043   3.9     Ecophagus   Female   -   19,804   -   -   1.3   0.550   1.73   4,457,043   3.9     Ecophagus   Female   -   19,804   -   -   1.3   0.550   1.73   4,457,043   3.9     Ecophagus   Female   -   19,804   -   -   0.2   1.000   2.9   8,948,621   0.3     Hodgkin Lymphoma   Male   -   20,290   -   -   0.1   1.000   1.6   4,457,043   1.7     Hodgkin Lymphoma   Male   -   20,290   -   -   0.1   1.000   1.4   4,491,678   0.3     Kidney   Total   4   40,094   1.0   5.4   3.1   0.762   381   8,948,621   0.3     Layrox   Female   -   19,804   -   -   0.1   1.000   1.4   4,491,678   0.3     Layrox   Female   -   19,804   -   -   0.1   1.000   1.5   4,457,043   3.9     Layrox   Female   -   19,804   -   -   0.1   1.000   1.5   4,457,043   3.9     Layrox   Female   -   19,804   -   -   0.										8,948,621			
Brain and Other Nervous System   Total   1   40,094   2.5   1.6   3.5   0.265   503   8,948,621   5.6   678			5										
Brain and Other Nervous System Male Pemale - 20,290 2,2 0,221 298 4,491,576 6.6 Breast Brain and Other Nervous System Female 1 19,804 5.0 3.3 1.4 1,000 205 4,457,043 4.6 Breast Nate Pemale 1 19,804 5.0 3.3 1.4 1,000 205 4,457,043 4.6 Breast Male - 20,290 0.1 1,000 16 4,491,578 0.4 Breast Female 10 19,804 50.5 31.2 7.7 0,500 1,076 4,457,043 2.4 Breast Female 10 19,804 50.5 31.2 7.7 0,500 1,076 4,457,043 2.4 Breast Pemale 10 19,804 50.5 31.2 7.7 0,500 1,076 4,457,043 2.4 Breast Pemale 10 19,804 50.5 31.2 7.7 0,500 1,076 4,457,043 2.4 Breast Pemale 10 19,804 50.5 31.2 7.7 0,500 1,076 4,457,043 2.4 Breast Pemale 10 19,804 50.5 31.2 31.2 31.2 31.2 31.2 31.2 31.2 31.2			- 1								2.5 5.6		
Brain and Other Nervous System   Female   1   19,804   5.0   3.3   1.4   1.000   205   4,457,043   4.6   Breast   Male   - 20,290     0.1   1.000   16   4,491,578   0.4   Breast   Female   - 19,804   50.5   31.2   7.7   0.500   1,076   4,467,043   24.1   1.000   1.			_ '		2.5	1.0							
Breast   Total   10   40,094   24,9   14.7   8.3   0.648   1,092   8,948,621   12.2   Breast   Female   10   19,804   50.5   31.2   7.7   0.500   1,076   4,467,043   24.1   Cervix   Female   - 19,804   0.5   1,000   1,076   4,467,043   24.1   Cervix   Female   10   19,804   34.9   20.2   10.1   0.283   1,305   8,948,621   14.6   Colorectal   Total   14   40,094   34.9   20.2   10.1   0.283   1,305   8,948,621   14.6   Colorectal   Female   2   19,804   10.1   6.0   4.3   0.33   1,305   8,948,621   14.6   Colorectal   Female   2   19,804   10.1   6.0   4.3   0.335   579   4,491,578   15.7   Colorectal   Female   2   19,804   10.1   6.0   4.3   0.335   589   4,457,043   1.3   Escophagus   Total   3   40,094   7.5   4.3   3.3   1,000   398   4,491,578   8.9   Escophagus   Male   3   20,290   14.8   8.0   3.3   1,000   398   4,491,578   8.9   Escophagus   Female   - 19,804     0.6   1,000   76   4,457,043   1.7   Hodgkin Lymphoma   Total   - 40,094     0.1   1,000   14   4,491,578   0.3   Hodgkin Lymphoma   Female   - 19,804     0.1   1,000   14   4,491,578   0.3   Hodgkin Lymphoma   Female   - 19,804     0.1   1,000   14   4,491,578   0.3   Hodgkin Lymphoma   Female   - 19,804     0.1   1,000   14   4,491,678   0.3   Kidney   Male   3   20,290   14.8   7.7   2.1   0,880   239   4,491,578   5.3   Kidney   Male   3   20,290   14.8   7.7   2.1   0,880   239   4,491,578   5.3   Kidney   Female   - 19,804     0.1   1,000   14   4,457,043   0.3   Kidney   Female   - 19,804     0.1   1,000   14   4,407,043   0.3   Kidney   Female   - 19,804     0.1   1,000   14   4,407,043   0.3   Kidney   Female   - 19,804     0.1   1,000   14   4,407,043   0.3   Kidney   Female   - 19,804     0.1   1,000   14   4,407,043   0.3   Kidney   Female   - 19,804     0.1   1,000   14   4,407,043   0.3   Kidney   Female   - 19,804     0.1   1,000   14   4,407,043   0.3   Kidney   Kidne					5.0	3.3							
Breast Male Female - 20,290 0.1 1,000 16 4,491,578 0.4 Resats Female - 19,804 0.5 1,000 1,076 4,457,043 2,41 Cervix Female - 19,804 0.5 1,000 83 4,457,043 2,41 Colorectal Total 14 40,094 34.9 20,2 10.1 0,283 1,305 8,948,621 14.9 Colorectal Male 12 20,290 59.1 33.2 5.7 0,028 > 707 4,491,578 15.7 Colorectal Female 2 19,804 10.1 6.0 4.4 0,359 > 708 4,457,043 13.9 Esophiagus Total 3 40,094 13,305 8,948,621 14.9 Colorectal Female 2 19,804 10.1 6.0 4.4 0,359 > 707 4,491,578 15.7 Colorectal Female 3 40,094 13,305 8,948,621 14.9 Colorectal Female 3 40,094 13,305 8,948,621 14.9 Colorectal Female 4 19,804 10.1 6.0 4.4 0,359 > 707 4,491,578 15.7 Colorectal Female 5 19,804 10.1 6.0 4.4 0,359 > 708 4,457,043 3.3 Sesphagus Total 3 40,094 13,305 8,948,621 14.9 Colorectal 14			- 1										
Breast         Female Cervix         Female Pemale         10         19,804         -         -         0.5         0.00         1,076         4,457,043         24,1           Colorectal         Total         14         40,094         34,9         20.2         10.1         0.283         1,305         8,948,621         14.6           Colorectal         Male         12         20,290         59,1         33,2         5,7         0.028 >>         707         74,915,78         13.4           Colorectal         Female         2         19,804         10.1         6.0         4.4         0.359         598         4.457,043         13.4           Corpus Uteri         Female         -         19,804         -         -         -         1.3         0.579         474         8,945,021         53           Esophagus         Male         3         20,290         14.8         8.0         3.3         1,000         398         44,91,578         8.3           Esophagus         Female         -         19,804         -         -         0.6         1,000         76         4,457,043         1.7           Hodgkin Lymphoma         Total         -         10,000 </td <td></td> <td></td> <td>-</td> <td></td> <td>-</td> <td>-</td> <td></td> <td></td> <td></td> <td></td> <td></td>			-		-	-							
Cervix			10		50.5	31.2							
Colorectal   Male   12   20,290   59,1   33.2   5.7   0.028 >> 707   4,491,578   15.7   15.7   Colorectal   Female   2   19,804   10.1   6.0   4.4   0.359   598   4,457,043   3.3   3.3   2.559   3.3   4.559   4.57   4			-	19,804	-	-	0.5		83	4,457,043	1.9		
Colorectal   Female   2   19,804   10.1   6.0   4.4   0.359   598   4,457,043   13.4										8,948,621			
Corpus Uteri													
Esophagus													
Esophagus													
Esophagus													
Hodgin Lymphoma			3		14.8	8.0							
Hodgkin Lymphoma   Male   -   20,290   -   -   0.1   1.000   14   4,491,578   0.3   Nddgkin Lymphoma   Female   -   19,804   -   -   0.1   1.000   15   4,457,043   0.3   Nddgkin Lymphoma   Female   -   19,804   -   -   0.1   1.000   15   4,457,043   0.3   Nddgkin Lymphoma   Female   -   19,804   5.0   2.8   1.1   1.000   142   4,457,043   3.2   2.8   2.8   1.1   1.000   142   4,457,043   3.2   2.8			-		-	-							
Hodgiki Lymphoma   Female   -   19,804   -   -   0.1   1,000   15   4,457,043   0.3													
Kidney				19 804									
Kidney													
Kidney													
Larynx Male - 40,094 0.6 1,000 71 8,948,621 0.8 Larynx Male - 20,290 0.5 1,000 58 4,491,578 1.3 Larynx Female - 19,804 0.1 1,000 13 4,457,043 0.3 Leukemia Male 3 20,290 14.8 7.6 3.4 1,000 383 4,491,578 8.5 Leukemia Female 2 19,804 10.1 5.8 2.1 1,000 272 4,457,043 6.1 Liver and Bile Duct Total 7 40,094 17.5 99 4.7 0,392 596 8,948,621 7.3 1.0 Liver and Bile Duct Male 3 20,290 14.8 8.0 3.4 1,000 405 4,491,578 9.0 1.0 Liver and Bile Duct Female 4 19,804 20.2 12.0 1.4 0,114 191 4,457,043 4.3 1.0 Liver and Bile Duct Female 5 1,804 10.1 5.8 1.0 1.4 0,114 191 4,457,043 4.3 1.0 1.0 1.4 191 191 4,457,043 1.3 1.0 1.4 191 191 191 191 191 191 191 191 191 19		Female						1.000					
Larýnx         Female         -         19,804         -         -         0.1         1,000         13         4,457,043         0.3           Leukemia         Total         5         40,094         12.5         6.9         5.3         1,000         655         8,948,621         7.3           Leukemia         Male         3         20,290         14.8         7.6         3.4         1,000         383         4,491,578         8.5           Leukemia         Female         2         19,804         10.1         5.8         2.1         1,000         272         4,457,043         6.1           Liver and Bile Duct         Male         3         20,290         14.8         8.0         3.4         1,000         405         4,491,578         9.0           Liver and Bile Duct         Male         3         20,290         14.8         8.0         3.4         1,000         405         4,491,578         9.0           Liver and Bile Duct         Female         4         19,804         20.2         12.0         1.4         0.114         191         4,457,043         4.3           Lurg and Bronchus         Total         29         40,094         7.5         4.4 </td <td>Larynx</td> <td></td> <td>-</td> <td></td> <td>-</td> <td>-</td> <td>0.6</td> <td></td> <td>71</td> <td>8,948,621</td> <td></td>	Larynx		-		-	-	0.6		71	8,948,621			
Leukemia	Larynx		-		-	-							
Leukemia         Male         3         20,290         14.8         7.6         3.4         1,000         383         4,491,578         8.5           Leukemia         Female         2         19,804         10.1         5.8         2.1         1,000         272         4,457,043         6.1           Liver and Bile Duct         Male         3         20,290         14.8         8.0         3.4         1,000         405         4,491,578         9.0           Liver and Bile Duct         Female         4         19,804         20.2         12.0         1.4         0.114         191         4,457,043         4.3           Liver and Bile Duct         Female         4         19,804         20.2         12.0         1.4         0.114         191         4,457,7043         3.3           Lung and Bronchus         Total         29         40,094         72.3         39.4         24.1         0.365         2,932         8,948,621         32.8           Lung and Bronchus         Female         12         19,804         6.0         35.1         10.7         0.763         1,393         4,457,043         3.3           Lung and Bronchus         Female         12         19,804 <td></td> <td></td> <td>-</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>			-										
Leukemia         Female         2         19,804         10.1         5.8         2.1         1,000         272         4,457,043         6.1           Liver and Bile Duct         Total         7         40,094         17.5         9.9         4.7         0.392         596         8,948,621         6.7           Liver and Bile Duct         Male         3         20,290         14.8         8.0         3.4         1,000         405         4,491,578         9.0           Liver and Bile Duct         Female         4         19,804         20.2         12.0         1.4         0.114         191         4,457,043         4.3           Lung and Bronchus         Total         29         40,094         72.3         39.4         24.1         0.365         2,932         8,948,621         32.8           Lung and Bronchus         Male         17         20,290         83.8         42.8         13.6         0.425         1,539         4,491,578         34.3           Melanoma of the Skin         Total         3         40,094         7.5         4.4         2.2         0.751         286         8,948,621         3.2           Melanoma of the Skin         Male         3													
Liver and Bile Duct Male 3 20,290 14.8 8.0 3.4 1.000 405 4,491,578 9.0 Liver and Bile Duct Female 4 19,804 20.2 12.0 1.4 0.114 191 4,457,043 4.3 Lung and Bronchus Total 29 40,094 72.3 39.4 24.1 0.365 2,932 8,948,621 32.8 Lung and Bronchus Male 17 20,290 83.8 42.8 13.6 0.425 1,539 4,491,578 34.3 Lung and Bronchus Female 12 19,804 60.6 35.1 10.7 0.763 1,393 4,457,043 31.3 Melanoma of the Skin Male 3 20,290 14.8 7.9 1.6 0.428 189 4,491,578 4.2 Melanoma of the Skin Male 1 3 20,290 14.8 7.9 1.6 0.428 189 4,491,578 4.2 Melanoma of the Skin Male 1 2 40,094 5.0 2.6 2.8 0.946 329 8,948,621 3.7 Myeloma Male 1 2 20,290 4.9 2.4 1.8 0.919 195 4,491,578 4.3 Myeloma Female 1 19,804 5.0 2.9 1.0 1,000 134 4,457,043 3.0 Non-Hodgkin Lymphoma Total 3 40,094 7.5 4.1 4.6 0.641 566 8,948,621 6.3 Non-Hodgkin Lymphoma Male 3 20,290 14.8 7.7 2.6 0.978 304 4,491,578 6.8 Non-Hodgkin Lymphoma Female - 19,804 2.0 0.261 262 4,457,043 5.9 Oral Cavity and Pharynx Male 2 20,290 9.9 5.3 1.6 0.918 185 4,491,578 6.8 Non-Hodgkin Lymphoma Female 1 19,804 5.0 2.9 1.0 1.000 134 4,451,578 6.8 Non-Hodgkin Lymphoma Female - 19,804 2.0 0.261 262 4,457,043 5.9 Oral Cavity and Pharynx Male 2 20,290 9.9 5.3 1.6 0.918 185 4,491,578 4.1 Oral Cavity and Pharynx Female 1 19,804 5.0 3.1 0.6 0.861 78 4,457,043 7.8 Pancreas Female 3 19,804 5.0 3.1 0.6 0.861 78 4,457,043 1.8 Oral Cavity and Pharynx Male 5 20,290 24.6 13.0 5.5 1.000 637 4,491,578 14.2 Pancreas Female 5 19,804 25.2 14.8 4.1 0.791 543 4,457,043 12.2 Prostate Male 11 20,290 54.2 25.5 9.0 0.587 938 4,491,578 20.9 Stomach Male 2 20,290 9.9 5.5 1.0 0.488 119 4,491,578 2.6 Stomach													
Liver and Bile Duct Female													
Liver and Bile Duct Female 4 19,804 20.2 12.0 1.4 0.114 191 4,457,043 4.3 Lung and Bronchus Total 29 40,094 72.3 39.4 24.1 0.365 2,932 8,948,621 32.8 Lung and Bronchus Male 17 20,290 83.8 42.8 13.6 0.425 1,539 4,491,578 34.3 Lung and Bronchus Female 12 19,804 60.6 35.1 10.7 0.763 1,393 4,457,043 31.3 Melanoma of the Skin Male 3 40,094 7.5 4.4 2.2 0.751 286 8,948,621 3.2 Melanoma of the Skin Male 3 20,290 14.8 7.9 1.6 0.428 189 4,491,578 4.2 Melanoma of the Skin Female - 19,804 0.7 1.000 97 4,457,043 2.2 Myeloma Myeloma Male 1 20,290 4.9 2.4 1.8 0.919 195 4,491,578 4.3 Myeloma Female 1 19,804 5.0 2.9 1.0 1.000 134 4,457,043 3.0 Mon-Hodgkin Lymphoma Male 3 40,094 7.5 4.1 4.6 0.641 566 8,948,621 6.3 Non-Hodgkin Lymphoma Male 3 40,094 7.5 4.1 4.6 0.641 566 8,948,621 6.3 Non-Hodgkin Lymphoma Male 3 40,094 7.5 4.3 2.1 0.674 263 8,948,621 2.9 Oral Cavity and Pharynx Total 3 40,094 7.5 4.3 2.1 0.674 263 8,948,621 2.9 Oral Cavity and Pharynx Male 2 20,290 9.9 5.3 1.6 0.918 185 4,491,578 4.1 8.0 0.918 185 4,491,578 4.1 9.9 0ral Cavity and Pharynx Female 1 19,804 5.0 3.1 0.6 0.861 78 4,457,043 7.8 Pancreas Total 19,804 5.0 3.1 0.6 0.861 78 4,457,043 7.8 Pancreas Female 5 19,804 25.2 14.8 4.1 0.791 543 4,457,043 7.8 Pancreas Female 5 19,804 25.2 14.8 4.1 0.791 543 4,457,043 12.2 Prostate Male 5 20,290 54.2 25.5 9.0 0.587 938 4,491,578 20.9 Prostate Male 1 20,290 54.2 25.5 9.0 0.587 938 4,491,578 20.9 Prostate Male 2 20,290 9.9 5.5 1.0 0.988 119 4,491,578 20.9 Prostate Male 2 20,290 9.9 5.5 1.0 0.988 119 4,491,578 20.9 Prostate Male 1 20,290 54.2 25.5 9.0 0.587 938 4,491,578 20.9 Prostate Male 2 20,290 9.9 5.5 1.0 0.988 119 4,491,578 2.2 Extended 1 20,290 9.9 5.5 1.0 0.988 119 4,491,578 2.2 Extended 1 20,290 9.9 5.5 1.0 0.988 119 4,491,578 2.2 Extended 1 20,290 9.9 5.5 1.0 0.988 119 4,491,578 2.2 Extended 1 20,290 9.9 5.5 1.0 0.988 119 4,491,578 2.2 Extended 1 20,290 9.9 5.5 1.0 0.988 119 4,491,578 2.2 Extended 1 20,290 9.9 5.5 1.0 0.988 119 4,491,578 2.2 Extended 1 20,290 9.9 5.5 1.0 0.988 119 4,491,578 2.2 Extended 1													
Lung and Bronchus         Total         29         40,094         72.3         39.4         24.1         0.365         2,932         8,948,621         32.8           Lung and Bronchus         Male         17         20,290         83.8         42.8         13.6         0.425         1,539         4,491,578         34.3           Lung and Bronchus         Female         12         19,804         60.6         35.1         10.7         0.763         1,939         4,457,043         31.3           Melanoma of the Skin         Total         3         40,094         7.5         4.4         2.2         0.751         286         8,948,621         3.2           Melanoma of the Skin         Male         3         20,290         14.8         7.9         1.6         0.428         189         4,491,578         4.2           Melanoma of the Skin         Female         -         19,804         -         -         0.7         1.000         97         4,457,043         2.2           Myeloma         Total         2         40,094         5.0         2.6         2.8         0.946         329         8,948,621         3.7           Myeloma         Male         1         20,290													
Lung and Bronchus         Male Lung and Bronchus         Hemale Female         12         20,290         83.8         42.8         13.6         0.425         1,539         4,491,578         34.3           Lung and Bronchus         Female         12         19,804         60.6         35.1         10.7         0.763         1,393         4,491,578         31.3           Melanoma of the Skin         Male         3         40,094         7.5         4.4         2.2         0.751         286         8,948,621         3.2           Melanoma of the Skin         Male         3         20,290         14.8         7.9         1.6         0.428         189         4,491,578         4.2           Melanoma of the Skin         Female         -         19,804         -         -         0.7         1.000         97         4,457,043         2.2           Melanoma of the Skin         Female         -         19,804         -         -         0.7         1.000         97         4,457,043         3.2           Myeloma         Male         1         20,290         4.9         2.4         1.8         0.919         195         4,491,578         4.3           Myeloma         Total													
Lung and Bronchus         Female         12         19,804         60.6         35.1         10.7         0.763         1,393         4,457,043         31.3           Melanoma of the Skin         Total         3         40,094         7.5         4.4         2.2         0.751         286         8,948,621         3.2           Melanoma of the Skin         Male         3         20,290         14.8         7.9         1.6         0.428         189         4,491,578         4.2           Melanoma of the Skin         Female         -         19,804         -         -         0.7         1.000         97         4,457,043         2.2           Myeloma         Total         2         40,094         5.0         2.6         2.8         0.946         329         8,948,621         3.7           Myeloma         Male         1         20,290         4.9         2.4         1.8         0.919         195         4,491,578         4.3           Myeloma         Female         1         19,804         5.0         2.9         1.0         1.000         134         4,457,043         3.0           Non-Hodgkin Lymphoma         Male         3         20,290         14.8			17	20 290									
Melanoma of the Skin         Total         3         40,094         7.5         4.4         2.2         0.751         286         8,948,621         3.2           Melanoma of the Skin         Male         3         20,290         14.8         7.9         1.6         0.428         189         4,491,578         4.2           Melanoma of the Skin         Female         -         19,804         -         -         0.7         1.000         97         4,457,043         2.2           Myeloma         Male         1         20,290         4.9         2.4         1.8         0.919         195         4,491,578         4.3           Myeloma         Male         1         20,290         4.9         2.4         1.8         0.919         195         4,491,578         4.3           Myeloma         Female         1         19,804         5.0         2.9         1.0         1.000         134         4,491,578         4.3           Myeloma         Male         3         40,094         7.5         4.1         4.6         0.641         366         8,948,621         3.7           Non-Hodgkin Lymphoma         Male         3         20,290         14.8         7.7				19.804					1.393				
Melanoma of the Skin         Male         3         20,290         14.8         7.9         1.6         0.428         189         4,491,578         4.2           Melanoma of the Skin         Female         -         19,804         -         -         0.7         1.000         97         4,457,043         2.2           Myeloma         Total         2         40,094         5.0         2.6         2.8         0.946         329         8,948,621         3.7           Myeloma         Male         1         20,290         4.9         2.4         1.8         0.919         195         4,491,578         4.3           Myeloma         Female         1         19,804         5.0         2.9         1.0         1.000         134         4,457,043         3.0           Non-Hodgkin Lymphoma         Total         3         40,094         7.5         4.1         4.6         0.641         566         8,948,621         6.3           Non-Hodgkin Lymphoma         Female         -         19,804         -         -         2.0         0.261         262         4,457,043         5.9           Oral Cavity and Pharynx         Total         3         40,094         7.5										8,948,621			
Myeloma         Total Male         2         40,094 Male         5.0 Department         2.6 Department         2.8 Department         0.946 Department         329 Septence         8,948,621 Septence         3.7 Department           Myeloma         Male         1         20,290 A.9 Department         4.9 Department         2.4 Department         1.8 Department         0.919 Department         195 Apple Ap	Melanoma of the Skin			20,290		7.9	1.6		189	4,491,578	4.2		
Myeloma         Male         1         20,290         4.9         2.4         1.8         0.919         195         4,491,578         4.3           Myeloma         Female         1         19,804         5.0         2.9         1.0         1.000         134         4,491,578         4.3           Non-Hodgkin Lymphoma         Total         3         40,094         7.5         4.1         4.6         0.641         566         8,948,621         6.3           Non-Hodgkin Lymphoma         Male         3         20,290         14.8         7.7         2.6         0.978         304         4,491,578         6.8           Non-Hodgkin Lymphoma         Female         -         19,804         -         -         2.0         0.261         262         4,457,043         5.9           Oral Cavity and Pharynx         Total         3         40,094         7.5         4.3         2.1         0.674         263         8,948,621         2.9           Oral Cavity and Pharynx         Male         2         20,290         9.9         5.3         1.6         0.918         185         4,491,578         4.1           Ovary         Female         3         19,804         5.0						-					2.2		
Myeloma         Female         1         19,804         5.0         2.9         1.0         1.000         134         4,457,043         3.0           Non-Hodgkin Lymphoma         Total         3         40,094         7.5         4.1         4.6         0.641         566         8,948,621         6.3           Non-Hodgkin Lymphoma         Male         3         20,290         14.8         7.7         2.6         0.978         304         4,491,578         6.8           Non-Hodgkin Lymphoma         Female         -         19,804         -         -         2.0         0.261         262         4,457,043         5.9           Oral Cavity and Pharynx         Total         3         40,094         7.5         4.3         2.1         0.674         263         8,948,621         2.9           Oral Cavity and Pharynx         Male         2         20,290         9.9         5.3         1.6         0.918         185         4,491,578         4.1           Oral Cavity and Pharynx         Female         1         19,804         5.0         3.1         0.6         0.861         78         4,457,043         1.8           Ovary         Female         3         19,804													
Nón-Hodgkin Lymphoma         Total         3         40,094         7.5         4.1         4.6         0.641         566         8,948,621         6.3           Non-Hodgkin Lymphoma         Male         3         20,290         14.8         7.7         2.6         0.978         304         4,491,578         6.8           Non-Hodgkin Lymphoma         Female         -         19,804         -         -         2.0         0.261         262         4,457,043         5.9           Oral Cavity and Pharynx         Total         3         40,094         7.5         4.3         2.1         0.674         263         8,948,621         2.9           Oral Cavity and Pharynx         Male         2         20,290         9.9         5.3         1.6         0.918         185         4,491,578         4.1           Oral Cavity and Pharynx         Male         2         20,290         9.9         5.3         1.6         0.918         185         4,491,578         4.1           Oral Cavity and Pharynx         Female         1         19,804         5.0         3.1         0.6         0.861         78         4,457,043         1.8           Ovary         Female         3         19,8													
Non-Hodgkin Lymphoma         Male         3         20,290         14.8         7.7         2.6         0.978         304         4,491,578         6.8           Non-Hodgkin Lymphoma         Female         -         19,804         -         -         2.0         0.261         262         4,457,043         5.9           Oral Cavity and Pharynx         Total         3         40,094         7.5         4.3         2.1         0.674         263         8,948,621         2.9           Oral Cavity and Pharynx         Male         2         20,290         9.9         5.3         1.6         0.918         185         4,491,578         4.1           Oral Cavity and Pharynx         Female         1         19,804         5.0         3.1         0.6         0.918         185         4,491,578         4.1           Oral Cavity and Pharynx         Female         1         19,804         5.0         3.1         0.6         0.918         185         4,491,578         4.1           Oral Cavity and Pharynx         Female         1         19,804         5.0         3.1         0.6         0.861         78         4.457,043         1.8           Ovary         Female         3 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>													
Non-Hodgkin Lymphoma         Female         -         19,804         -         -         2.0         0.261         262         4,457,043         5.9           Oral Cavity and Pharynx         Total         3         40,094         7.5         4.3         2.1         0.674         263         8,948,621         2.9           Oral Cavity and Pharynx         Male         2         20,290         9.9         5.3         1.6         0.918         185         4,491,578         4.1           Oral Cavity and Pharynx         Female         1         19,804         5.0         3.1         0.6         0.861         78         4,457,043         1.8           Ovary         Female         3         19,804         15.1         9.2         2.5         0.934         347         4,457,043         1.8           Pancreas         Total         10         40,094         24.9         13.9         9.5         0.934         347         4,457,043         7.8           Pancreas         Male         5         20,290         24.6         13.0         5.5         1.000         637         4,491,578         14.2           Pancreas         Female         5         19,804         25.2													
Oral Cavity and Pharynx         Total         3         40,094         7.5         4.3         2.1         0.674         263         8,948,621         2.9           Oral Cavity and Pharynx         Male         2         20,290         9.9         5.3         1.6         0.918         185         4,491,578         4.1           Oral Cavity and Pharynx         Female         1         19,804         5.0         3.1         0.6         0.861         78         4,457,043         1.8           Ovary         Female         3         19,804         15.1         9.2         2.5         0.934         347         4,457,043         7.8           Pancreas         Total         10         40,094         24.9         13.9         9.5         0.960         1,180         8,948,621         13.2           Pancreas         Male         5         20,290         24.6         13.0         5.5         1.000         637         4,491,578         14.2           Pancreas         Female         5         19,804         25.2         14.8         4.1         0.791         543         4,457,043         12.2           Prostate         Male         11         20,290         54.2	Non-Hodakin Lymphoma		_										
Oral Cavity and Pharynx         Male         2         20,290         9.9         5.3         1.6         0.918         185         4,491,578         4.1           Oral Cavity and Pharynx         Female         1         19,804         5.0         3.1         0.6         0.861         78         4,457,043         1.8           Ovary         Female         3         19,804         15.1         9.2         2.5         0.934         347         4,457,043         7.8           Pancreas         Total         10         40,094         24.9         13.9         9.5         0.960         1,180         8,948,621         13.2           Pancreas         Male         5         20,290         24.6         13.0         5.5         1.000         637         4,491,578         14.2           Pancreas         Female         5         19,804         25.2         14.8         4.1         0.791         543         4,457,043         12.2           Prostate         Male         11         20,290         54.2         25.5         9.0         0.587         938         4,491,578         20.9           Stomach         Total         3         40,094         7.5         4.5 <td>Oral Cavity and Pharvny</td> <td></td> <td></td> <td>19,004 40 094</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>2.9</td>	Oral Cavity and Pharvny			19,004 40 094							2.9		
Oral Cavity and Pharynx         Female         1         19,804         5.0         3.1         0.6         0.861         78         4,457,043         1.8           Ovary         Female         3         19,804         15.1         9.2         2.5         0.934         347         4,457,043         7.8           Pancreas         Total         10         40,094         24.9         13.9         9.5         0.960         1,180         8,948,621         13.2           Pancreas         Male         5         20,290         24.6         13.0         5.5         1.000         637         4,491,578         14.2           Pancreas         Female         5         19,804         25.2         14.8         4.1         0.791         543         4,457,043         12.2           Prostate         Male         11         20,290         54.2         25.5         9.0         0.587         938         4,491,578         20.9           Stomach         Total         3         40,094         7.5         4.5         1.5         0.361         195         8,948,621         2.2           Stomach         Male         2         20,290         9.9         5.5         1													
Ovary         Female         3         19,804         15.1         9.2         2.5         0.934         347         4,457,043         7.8           Pancreas         Total         10         40,094         24.9         13.9         9.5         0.960         1,180         8,948,621         13.2           Pancreas         Male         5         20,290         24.6         13.0         5.5         1.000         637         4,491,578         14.2           Pancreas         Female         5         19,804         25.2         14.8         4.1         0.791         543         4,457,043         12.2           Prostate         Male         11         20,290         54.2         25.5         9.0         0.587         938         4,491,578         20.9           Stomach         Total         3         40,094         7.5         4.5         1.5         0.361         195         8,948,621         2.2           Stomach         Male         2         20,290         9.9         5.5         1.0         0.498         119         4,491,578         2.6			1										
Pancreas         Total         10         40,094         24.9         13.9         9.5         0.960         1,180         8,948,621         13.2           Pancreas         Male         5         20,290         24.6         13.0         5.5         1.000         637         4,491,578         14.2           Pancreas         Female         5         19,804         25.2         14.8         4.1         0.791         543         4,457,043         12.2           Prostate         Male         11         20,290         54.2         25.5         9.0         0.587         938         4,491,578         20.9           Stomach         Total         3         40,094         7.5         4.5         1.5         0.361         195         8,948,621         2.2           Stomach         Male         2         20,290         9.9         5.5         1.0         0.498         119         4,491,578         2.6	,		3										
Pancreas         Male         5         20,290         24.6         13.0         5.5         1.000         637         4,491,578         14.2           Pancreas         Female         5         19,804         25.2         14.8         4.1         0.791         543         4,457,043         12.2           Prostate         Male         11         20,290         54.2         25.5         9.0         0.587         938         4,491,578         20.9           Stomach         Total         3         40,094         7.5         4.5         1.5         0.361         195         8,948,621         2.2           Stomach         Male         2         20,290         9.9         5.5         1.0         0.498         119         4,491,578         2.6			10			13.9							
Prostate         Male         11         20,290         54.2         25.5         9.0         0.587         938         4,491,578         20.9           Stomach         Total         3         40,094         7.5         4.5         1.5         0.361         195         8,948,621         2.2           Stomach         Male         2         20,290         9.9         5.5         1.0         0.498         119         4,491,578         2.6		Male	5	20,290	24.6	13.0				4,491,578			
Stomach         Total         3         40,094         7.5         4.5         1.5         0.361         195         8,948,621         2.2           Stomach         Male         2         20,290         9.9         5.5         1.0         0.498         119         4,491,578         2.6											12.2		
Stomach   Male   2   20,290   9.9   5.5   1.0   0.498   119   4,491,578   2.6													
Stomach   Female   1   19,804   5.0   3.2   0.5   0.819   76   4,457,043   1.7			2										
	Stomach	Female	1	19,804	5.0	3.2	0.5	0.819	76	4,457,043	1.7		

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

<sup>2.</sup> Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

### Cancer Screening and Risk Factor Prevalence Estimates, 2011–2021

	State of								Lemhi
Measure	Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	County
Access to Care									
Have Health Insurance, Age <65 (2015–2021)	83.1%	82.8%	85.1%	77.2%	85.8%	78.9%	85.4%	85.4%	82.1%
Not See Doctor Due to Cost in Past Year (2015–2021)	12.6%	11.4%	11.8%	14.5%	12.4%	12.3%	11.8%	12.9%	11.0%
Cancer Screening									
Mammogram Past 2 Years, Age 50–74 (2014, 2016, 2018, 2020)	69.1%	67.0%	73.8%	68.2%	73.2%	64.8%	64.5%	67.1%	49.4%
Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020)	71.2%	73.6%	73.6%	70.8%	72.9%	69.1%	69.5%	65.9%	
Colorectal Cancer Screening, Age 50–75 (2018, 2020)	67.9%	66.9%	73.6%	71.4%	70.6%	61.7%	61.5%	64.7%	65.0%
Tobacco Use									
Current Tobacco User (2016–2021)	22.3%	26.7%	23.1%	23.6%	21.8%	21.4%	22.7%	16.9%	26.4%
Other Cancer-Related									
Healthy Weight by Body Mass Index, Age 20+ (2015–2021)	32.1%	32.8%	31.7%	27.9%	36.1%	29.8%	27.9%	31.9%	38.3%
Any Physical Activity Besides Job Past 30 Days (2015-2021)	78.7%	79.2%	78.1%	74.5%	83.2%	73.4%	76.3%	79.7%	76.0%
Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019)	21.9%	22.8%	19.4%	20.0%	25.2%	19.5%	20.4%	20.2%	18.9%
Home Ever Tested for Radon (2016, 2018, 2020)	23.0%	30.9%	18.2%	16.9%	25.1%	19.9%	23.0%	21.8%	24.3%

### **Access to Care**

### Have Health Insurance - 2015-2021

Statewide, 83.1% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 86.0% of white non-Hispanics, compared to 64.8% of Hispanics and 83.3% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3%) than English-speaking respondents (84.2%). Health care coverage differed significantly by age of respondent, with 79.8% of persons aged 18–29, and 87.8% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 62.1% in Adams County to 91.6% in Oneida County having health insurance.

### Not See Doctor Due to Cost in Past Year - 2015-2021

Statewide, 12.6% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (11.5% of white non-Hispanics, 19.2% of Hispanics, and 21.0% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9% for less than \$15,000, 6.1% for greater than \$50,000). Inability to see a doctor due to cost differed significantly by county, with a range of 7.4% in Franklin County to 17.5% in Power County.

### **Cancer Screening**

Mammogram - 2014, 2016, 2018, 2020

Statewide, 69.1% of women aged 50–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (72.1% versus 36.7%). Mammography rates differed significantly by county, with a range in screening of 45.9% in Benewah County to 77.0% in Nez Perce County. In 2020, Idaho ranked 48<sup>th</sup> among states and the District of Columbia for mammography screening rates among women aged 50–74 and also 48<sup>th</sup> among ages 40+.

### Pap Test - 2018, 2020

Statewide, 71.2% of women with an intact cervix and aged 21–65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.1% versus 52.6% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.7% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49<sup>th</sup> among states and the District of Columbia for Pap screening rate.

### Colorectal Cancer Screening - 2018, 2020

Statewide, 67.9% of adults aged 50–75 reported being current for colorectal cancer screening.\*\* Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked 47<sup>th</sup> among states and the District of Columbia in the percentage of adults aged 50–75 and older who reported being up-to-date for colorectal cancer screening.

<sup>\*\*</sup> Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

### **Tobacco Use**

### Current Tobacco Use - 2016-2021

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.3% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 29.9% of persons aged 18-29, and 11.1% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (22.4%) than among Native Americans (40.0%). Tobacco use differed significantly by county, with a range of 5.4% in Madison County to 41.6% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

### **Other Cancer-Related**

### Healthy Weight by Body Mass Index - 2015-2021

Statewide, 32.1% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 32.5% of white non-Hispanics, compared to 28.2% of Hispanics and 24.6% of Native Americans, being in the healthy weight range. Males (25.5%) were significantly less likely to be in the healthy weight range than females (38.6%). BMI differed significantly by age of respondent, with 43.3% of persons aged 18–29, and 26.0% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 19.8% in Power County to 47.4% in Blaine County of adults being in the healthy weight range.

### Any Physical Activity - 2015-2021

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 78.7% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.3% of persons aged 18–29, and 72.3% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 64.3% in Clark County to 84.6% in Teton County.

Physical Activity Guidelines – 2011, 2013, 2015, 2017, 2019 Statewide, 21.9% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.3% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6% in Franklin County to 30.6% in Blaine County.

### Home Radon Testing - 2016, 2018, 2020

Statewide, 23.0% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.4% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.5% in Cassia County to 54.4% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006l and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.





# LEWIS COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

### Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

### **RISK FACTORS AND INTERVENTIONS**

### CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/jama.2016.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

### Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

### **Smoking:**

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

### Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <a href="https://www.dietaryguidelines.gov">https://www.dietaryguidelines.gov</a>

### Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute
Cancer Information Services
1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society <a href="https://www.cancer.org">https://www.cancer.org</a>

### **CANCER INCIDENCE 2016–2020**

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016–2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 140 cases of invasive cancer were diagnosed among Lewis County residents (Table 1).

**Table 1:** Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Lewis County and the State of Idaho. 2016–2020

Cancer Incidence 2016–2020	Lewis County	State of Idaho		
All Sites/Types	140	45,610		
Female Breast	21	6,687		
Prostate	21	6,417		
Lung & Bronchus	25	4,887		
Colorectal	9	3,451		

Table 3 (Cancer Incidence 2016–2020, Comparison between Lewis County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Lewis County. The table also shows the number of observed cases, person-

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Lewis County was 727.2 cases per 100,000 person-years per year during 2016–2020. Comparing this crude rate with the crude rate for the remainder of Idaho (519.5) gives an estimate of the relative burden of disease in Lewis County.

The age- and sex-adjusted incidence rate of invasive cancer in Lewis County, all sites combined, was 494.1 cases per 100,000 persons per year during 2016–2020. There were fewer cases of cancer in Lewis County (140) than expected (147.2) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

### **CANCER MORTALITY 2017–2021**

During 2017–2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 55 Lewis County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

**Table 2:** Overall and Cancer Mortality in Lewis County and the State of Idaho, 2017–2021

Mortality 2017–2021	Lewis County	State of Idaho
All Deaths	273	77,431
Cancer Deaths	55	15,121
% of All Deaths	20.1%	19.5%
Lung & Bronchus	13	2,961
Colorectal	5	1,319
Pancreas	2	1,190
Female Breast	0	1,086
Prostate	5	949

Table 4 (Cancer Mortality 2017–2021, Comparison between Lewis County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Lewis County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Lewis County, all sites combined, was 179.1 deaths per 100,000 persons per year during 2017–2021, compared with 168.0 for the remainder of the state. There were more cancer deaths in Lewis County (55) than expected (51.6) based upon rates in the remainder of the state, but the difference was not statistically significant.

**Statistical Note:** Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

### TABLE 3: CANCER INCIDENCE 2016–2020 COMPARISON BETWEEN LEWIS COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

		Lewis County						Remainder of Idaho		
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)
All Sites Combined	Total	140	19,251	727.2	494.1	147.2	0.587 0.968	45,470	8,752,577	519.5
All Sites Combined All Sites Combined	Male Female	86 54	9,732 9,519	883.7 567.3	556.2 413.3	85.3 63.7	0.966	24,203 21,267	4,387,178 4,365,399	551.7 487.2
Bladder	Total	9	19,251	46.8	28.8	7.8	0.753	2,175	8,752,577	24.8
Bladder	Male	6	9,732	61.7	35.5	6.7	0.981	1,745	4,387,178	39.8
Bladder	Female	3	9,519	31.5	20.9	1.4	0.341	430	4,365,399	9.9
Brain - malignant Brain - malignant	Total Male	-	19,251 9,732	-	-	1.8 1.1	0.326 0.648	625 375	8,752,577 4,387,178	7.1 8.5
Brain - malignant	Female	_	9,519	_	_	0.7	0.992	250	4,365,399	5.7
Brain and other CNS - non-malignant	Total	3	19,251	15.6	11.3	4.3	0.752	1,421	8,752,577	16.2
Brain and other CNS - non-malignant	Male	2	9,732	20.6	14.8	1.5	0.869	478	4,387,178	10.9
Brain and other CNS - non-malignant Breast	Female Total	1 21	9,519 19,251	10.5 109.1	7.8 78.5	2.8 20.5	0.474 0.978	943 6,725	4,365,399 8,752,577	21.6 76.8
Breast	Male	-	9,732	109.1	70.5	0.2	1.000	59	4,387,178	1.3
Breast	Female	21	9,519	220.6	164.6	19.5	0.790	6,666	4,365,399	152.7
Breast - in situ	Total	2	19,251	10.4	7.8	3.6	0.589	1,237	8,752,577	14.1
Breast - in situ	Male	- 2	9,732	-	-	0.0	1.000	5	4,387,178	0.1
Breast - in situ Cervix	Female Female		9,519 9,519	21.0	16.1	3.5 0.7	0.640 1.000	1,232 304	4,365,399 4,365,399	28.2 7.0
Colorectal	Total	9	19,251	46.8	32.0	11.1	0.668	3,442	8,752,577	39.3
Colorectal	Male	7	9,732	71.9	47.1	6.4	0.921	1,896	4,387,178	43.2
Colorectal	Female	2	9,519	21.0	14.9	4.7	0.297	1,546	4,365,399	35.4
Corpus Uteri	Female	1	9,519 19,251	10.5 10.4	7.8 6.7	3.9 1.7	0.198 1.000	1,329 504	4,365,399	30.4 5.8
Esophagus Esophagus	Total Male	2 1	9,732	10.4	6.7 6.3	1. <i>7</i> 1.5	1.000	504 423	8,752,577 4,387,178	9.6
Esophagus	Female	1	9,519	10.5	7.2	0.3	0.455	81	4,365,399	1.9
Hodgkin Lymphoma	Total	-	19,251	-	-	0.5	1.000	210	8,752,577	2.4
Hodgkin Lymphoma	Male	-	9,732	-	-	0.3	1.000	118	4,387,178	2.7
Hodgkin Lymphoma Kidney and Renal Pelvis	Female Total	- 8	9,519 19,251	- 41.6	- 28.8	0.2 5.7	1.000 0.439	92 1,807	4,365,399	2.1 20.6
Kidney and Renal Pelvis  Kidney and Renal Pelvis	Male	5	9,732	51.4	34.3	3.7	0.439	1,007	8,752,577 4,387,178	26.8
Kidney and Renal Pelvis	Female	3	9,519	31.5	22.6	1.9	0.600	630	4,365,399	14.4
Larynx	Total	2	19,251	10.4	6.8	0.7	0.323	213	8,752,577	2.4
Larynx	Male	2	9,732	20.6	12.6	0.6	0.226	158	4,387,178	3.6
Larynx Leukemia	Female Total	- 3	9,519 19,251	- 15.6	10.5	0.2 5.3	1.000 0.446	55 1,628	4,365,399 8,752,577	1.3 18.6
Leukemia	Male	3	9,732	30.8	19.8	3.4	1.000	986	4,387,178	22.5
Leukemia	Female	-	9,519	-	-	2.0	0.272	642	4,365,399	14.7
Liver and Bile Duct	Total	4	19,251	20.8	13.8	2.7	0.587	825	8,752,577	9.4
Liver and Bile Duct Liver and Bile Duct	Male Female	4	9,732 9,519	41.1	26.1	2.1 0.8	0.304 0.941	586 239	4,387,178 4,365,399	13.4
Lung and Bronchus	Total	25	19,251	129.9	80.5	17.3	0.094	4,862	8,752,577	55.5
Lung and Bronchus	Male	14	9,732	143.9	83.9	9.3	0.177	2,438	4,387,178	55.6
Lung and Bronchus	Female	11	9,519	115.6	75.7	8.1	0.382	2,424	4,365,399	55.5
Melanoma of the Skin	Total	6	19,251	31.2	22.2	9.0	0.405	2,936	8,752,577	33.5
Melanoma of the Skin Melanoma of the Skin	Male Female	5 1	9,732 9,519	51.4 10.5	33.4 8.3	6.0 3.3	0.892 0.329	1,760 1,176	4,387,178 4,365,399	40.1 26.9
Myeloma	Total	4	19,251	20.8	13.1	2.4	0.463	704	8,752,577	8.0
Myeloma	Male	3	9,732	30.8	18.4	1.6	0.449	438	4,387,178	10.0
Myeloma	Female	1	9,519	10.5	7.0	0.9	1.000	266	4,365,399	6.1
Non-Hodgkin Lymphoma Non-Hodgkin Lymphoma	Total Male	3 3	19,251 9,732	15.6 30.8	10.6 20.1	6.3 3.8	0.254 0.932	1,937 1,126	8,752,577 4,387,178	22.1 25.7
Non-Hodgkin Lymphoma Non-Hodgkin Lymphoma	Female	-	9,732 9,519	30.8	∠U. I -	3.8 2.5	0.932	811	4,365,399	18.6
Oral Cavity and Pharynx	Total	6	19,251	31.2	21.5	4.1	0.467	1,289	8,752,577	14.7
Oral Cavity and Pharynx	Male	4	9,732	41.1	27.0	3.1	0.771	932	4,387,178	21.2
Oral Cavity and Pharynx	Female	2	9,519	21.0	15.1	1.1	0.589	357	4,365,399	8.2
Ovary Pancreas	Female Total	- 5	9,519 19,251	26.0	- 16.5	1.6 4.9	0.419 1.000	533 1,418	4,365,399 8,752,577	12.2 16.2
Pancreas	Male	2	9,732	20.6	12.4	2.9	0.900	782	4,387,178	17.8
Pancreas	Female	3	9,519	31.5	21.0	2.1	0.690	636	4,365,399	14.6
Prostate	Male	21	9,732	215.8	133.0	23.0	0.777	6,396	4,387,178	145.8
Stomach Stomach	Total Male	2	19,251 9,732	10.4	6.9	1.5 1.1	0.916 0.658	465 309	8,752,577 4,387,178	5.3 7.0
Stomach	Female	- 2	9,732 9,519	21.0	- 15.0	0.5	0.056	156	4,365,399	3.6
Testis	Male	-	9,732	-	-	0.5	1.000	265	4,387,178	6.0
Thyroid	Total	4	19,251	20.8	19.0	2.9	0.669	1,216	8,752,577	13.9
Thyroid	Male	2	9,732	20.6	16.9	1.0	0.492	353	4,387,178	8.0
Thyroid	Female	2	9,519	21.0	20.0	2.0	1.000	863	4,365,399	19.8
Pediatric Age 0 to 19	Total	2	4,778	41.9	42.4	0.8	0.386	419	2,455,745	17.1
Pediatric Age 0 to 19	Male Female	2	2,525	79.2	79.9	0.4 0.4	0.146	221 198	1,253,985	17.6
Pediatric Age 0 to 19		-	2,253	<u> </u>	-	-	1.000	190	1,201,760	16.5

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

<sup>2.</sup> Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

<sup>&</sup>quot;<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

### **TABLE 4: CANCER MORTALITY 2017–2021** COMPARISON BETWEEN LEWIS COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

		Lewis County						Remainder of Idaho		
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	273	19,116	1,428.1	893.7	262.8	0.543	77,157	8,969,599	860.2
All Causes of Death	Male	168	9,680	1,735.5	1,034.2	147.5	0.105	40,888	4,502,188	908.2
All Causes of Death	Female	105	9,436	1,112.8	727.2	117.2	0.278	36,269	4,467,411	811.9
All Malignant Cancers	Total	55	19,116	287.7	179.1	51.6	0.670	15,066	8,969,599	168.0
All Malignant Cancers	Male	42	9,680	433.9	251.3	30.2	0.048 >>	8,134	4,502,188	180.7
All Malignant Cancers	Female	13	9,436	137.8	91.4	22.1	0.054	6,932	4,467,411	155.2
Bladder	Total	4	19,116	20.9	12.2	1.8	0.211	485	8,969,599	5.4
Bladder	Male	3	9,680	31.0	16.6	1.5	0.387	375	4,502,188	8.3
Bladder	Female	1	9,436	10.6	6.6	0.4	0.625	110	4,467,411	2.5
Brain and Other Nervous System	Total	2	19,116	10.5	7.3	1.5	0.906	502	8,969,599	5.6
Brain and Other Nervous System	Male	2	9,680	20.7	13.8	1.0	0.496	296	4,502,188	6.6
Brain and Other Nervous System	Female	-	9,436	-	-	0.6	1.000	206	4,467,411	4.6
Breast	Total	-	19,116	-	-	3.6	0.055	1,102	8,969,599	12.3
Breast	Male	-	9,680	-	-	0.1	1.000 0.072	16	4,502,188	0.4
Breast	Female	-	9,436 9,436	-	-	3.3 0.2	1.000	1,086 83	4,467,411 4,467,411	24.3 1.9
Cervix Colorectal	Female Total	- 5	19,116	26.2	16.8	4.4	0.880	1,314	8,969,599	14.6
Colorectal	Male	5 4	9,680	41.3	25.6	2.5	0.860	715	4,502,188	15.9
Colorectal	Female	1	9,436	10.6	7.1	1.9	0.477	599	4,302,166	13.4
Corpus Uteri	Female	_ '	9,436	-	7.1	0.5	1.000	173	4,467,411	3.9
Esophagus	Total	2	19,116	10.5	6.6	1.6	0.949	475	8,969,599	5.3
Esophagus	Male	1	9,680	10.3	6.2	1.4	1.000	400	4,502,188	8.9
Esophagus	Female	1	9,436	10.6	7.0	0.2	0.425	75	4,467,411	1.7
Hodgkin Lymphoma	Total	-	19,116	-	-	0.1	1.000	29	8,969,599	0.3
Hodgkin Lymphoma	Male	-	9,680	-	-	0.0	1.000	14	4.502.188	0.3
Hodgkin Lymphoma	Female	-	9,436	-	-	0.0	1.000	15	4,467,411	0.3
Kidney	Total	2	19,116	10.5	6.4	1.3	0.770	383	8,969,599	4.3
Kidney	Male	2	9,680	20.7	12.1	0.9	0.443	240	4,502,188	5.3
Kidney	Female	-	9,436	-	-	0.5	1.000	143	4,467,411	3.2
Larynx	Total	2	19,116	10.5	6.5	0.2	0.048 >>	69	8,969,599	0.8
Larynx	Male	1	9,680	10.3	5.9	0.2	0.387	57	4,502,188	1.3
Larynx	Female	1	9,436	10.6	7.5	0.0	0.070	12	4,467,411	0.3
Leukemia	Total	1	19,116	5.2	3.2	2.3	0.661	659	8,969,599	7.3
Leukemia	Male	1	9,680	10.3	5.9	1.4	1.000 0.811	385 274	4,502,188	8.6
Leukemia Liver and Bile Duct	Female Total	- 2	9,436 19,116	10.5	6.6	0.9 2.0	1.000	601	4,467,411 8,969,599	6.1 6.7
Liver and Bile Duct	Male	2	9,680	20.7	12.4	1.4	0.850	406	4,502,188	9.0
Liver and Bile Duct	Female		9,436	20.7	12.4	0.6	1.000	195	4,467,411	4.4
Lung and Bronchus	Total	13	19,116	68.0	41.3	10.3	0.482	2,948	8,969,599	32.9
Lung and Bronchus	Male	6	9,680	62.0	35.5	5.8	1.000	1,550	4,502,188	34.4
Lung and Bronchus	Female	7	9,436	74.2	47.7	4.6	0.362	1,398	4,467,411	31.3
Melanoma of the Skin	Total		19,116	-	-	1.0	0.768	289	8,969,599	3.2
Melanoma of the Skin	Male	-	9,680	-	-	0.7	1.000	192	4,502,188	4.3
Melanoma of the Skin	Female	-	9,436	-	-	0.3	1.000	97	4,467,411	2.2
Myeloma	Total	3	19,116	15.7	9.2	1.2	0.238	328	8,969,599	3.7
Myeloma	Male	3	9,680	31.0	16.8	8.0	0.085	193	4,502,188	4.3
Myeloma	Female	-	9,436	-		0.5	1.000	135	4,467,411	3.0
Non-Hodgkin Lymphoma	Total	2	19,116	10.5	6.3	2.0	1.000	567	8,969,599	6.3
Non-Hodgkin Lymphoma	Male	2	9,680	20.7	11.9	1.1	0.628	305	4,502,188	6.8
Non-Hodgkin Lymphoma	Female	-	9,436	- 40 -	-	0.9	0.831	262	4,467,411	5.9
Oral Cavity and Pharynx	Total	2	19,116	10.5	6.7	0.9	0.442	264	8,969,599	2.9
Oral Cavity and Pharynx	Male	2	9,680	20.7	12.5	0.7	0.284	185	4,502,188	4.1
Oral Cavity and Pharynx	Female	- 4	9,436	10.6	7.1	0.2 1.1	1.000 1.000	79 349	4,467,411	1.8 7.8
Ovary Pancreas	Female	1	9,436 19,116			4.1	0.452		4,467,411 8,969,599	13.2
Pancreas Pancreas	Total Male	2 2	9,680	10.5 20.7	6.5 12.1	2.3	0.452 1.000	1,188 640	4,502,188	13.2
Pancreas	Female	_	9,436	20.7	14.1	1.8	0.340	548	4,467,411	12.3
Prostate	Male	5	9,680	51.7	27.4	3.8	0.675	944	4,502,188	21.0
Stomach	Total	1	19,116	5.2	3.4	0.6	0.075	197	8,969,599	2.2
Stomach	Male	_ '	9,680	-		0.4	1.000	121	4,502,188	2.7
Stomach	Female	1	9,436	10.6	7.5	0.2	0.405	76	4,467,411	1.7
			ne number of cases p				500	. 5	.,,,,,,	1

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

<sup>2.</sup> Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

### Cancer Screening and Risk Factor Prevalence Estimates, 2011–2021

	State of								Lewis
Measure	Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	County
Access to Care									_
Have Health Insurance, Age <65 (2015–2021)	83.1%	82.8%	85.1%	77.2%	85.8%	78.9%	85.4%	85.4%	85.7%
Not See Doctor Due to Cost in Past Year (2015–2021)	12.6%	11.4%	11.8%	14.5%	12.4%	12.3%	11.8%	12.9%	9.1%
Cancer Screening									
Mammogram Past 2 Years, Age 50–74 (2014, 2016, 2018, 2020)	69.1%	67.0%	73.8%	68.2%	73.2%	64.8%	64.5%	67.1%	
Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020)	71.2%	73.6%	73.6%	70.8%	72.9%	69.1%	69.5%	65.9%	
Colorectal Cancer Screening, Age 50–75 (2018, 2020)	67.9%	66.9%	73.6%	71.4%	70.6%	61.7%	61.5%	64.7%	
Tobacco Use									
Current Tobacco User (2016–2021)	22.3%	26.7%	23.1%	23.6%	21.8%	21.4%	22.7%	16.9%	31.5%
Other Cancer-Related									
Healthy Weight by Body Mass Index, Age 20+ (2015–2021)	32.1%	32.8%	31.7%	27.9%	36.1%	29.8%	27.9%	31.9%	23.5%
Any Physical Activity Besides Job Past 30 Days (2015-2021)	78.7%	79.2%	78.1%	74.5%	83.2%	73.4%	76.3%	79.7%	70.8%
Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019)	21.9%	22.8%	19.4%	20.0%	25.2%	19.5%	20.4%	20.2%	15.6%
Home Ever Tested for Radon (2016, 2018, 2020)	23.0%	30.9%	18.2%	16.9%	25.1%	19.9%	23.0%	21.8%	16.7%

### **Access to Care**

### Have Health Insurance - 2015-2021

Statewide, 83.1% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 86.0% of white non-Hispanics, compared to 64.8% of Hispanics and 83.3% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3%) than English-speaking respondents (84.2%). Health care coverage differed significantly by age of respondent, with 79.8% of persons aged 18–29, and 87.8% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 62.1% in Adams County to 91.6% in Oneida County having health insurance.

### Not See Doctor Due to Cost in Past Year - 2015-2021

Statewide, 12.6% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (11.5% of white non-Hispanics, 19.2% of Hispanics, and 21.0% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9% for less than \$15,000, 6.1% for greater than \$50,000). Inability to see a doctor due to cost differed significantly by county, with a range of 7.4% in Franklin County to 17.5% in Power County.

### **Cancer Screening**

Mammogram - 2014, 2016, 2018, 2020

Statewide, 69.1% of women aged 50–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (72.1% versus 36.7%). Mammography rates differed significantly by county, with a range in screening of 45.9% in Benewah County to 77.0% in Nez Perce County. In 2020, Idaho ranked 48<sup>th</sup> among states and the District of Columbia for mammography screening rates among women aged 50–74 and also 48<sup>th</sup> among ages 40+.

### Pap Test - 2018, 2020

Statewide, 71.2% of women with an intact cervix and aged 21–65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.1% versus 52.6% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.7% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49<sup>th</sup> among states and the District of Columbia for Pap screening rate.

### Colorectal Cancer Screening – 2018, 2020

Statewide, 67.9% of adults aged 50–75 reported being current for colorectal cancer screening.\*\* Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked 47<sup>th</sup> among states and the District of Columbia in the percentage of adults aged 50–75 and older who reported being up-to-date for colorectal cancer screening.

<sup>\*\*</sup> Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

### **Tobacco Use**

### Current Tobacco Use - 2016-2021

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.3% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 29.9% of persons aged 18-29, and 11.1% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (22.4%) than among Native Americans (40.0%). Tobacco use differed significantly by county, with a range of 5.4% in Madison County to 41.6% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

### **Other Cancer-Related**

### Healthy Weight by Body Mass Index - 2015-2021

Statewide, 32.1% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 32.5% of white non-Hispanics, compared to 28.2% of Hispanics and 24.6% of Native Americans, being in the healthy weight range. Males (25.5%) were significantly less likely to be in the healthy weight range than females (38.6%). BMI differed significantly by age of respondent, with 43.3% of persons aged 18–29, and 26.0% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 19.8% in Power County to 47.4% in Blaine County of adults being in the healthy weight range.

### Any Physical Activity - 2015-2021

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 78.7% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.3% of persons aged 18–29, and 72.3% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 64.3% in Clark County to 84.6% in Teton County.

Physical Activity Guidelines – 2011, 2013, 2015, 2017, 2019 Statewide, 21.9% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.3% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6% in Franklin County to 30.6% in Blaine County.

### Home Radon Testing - 2016, 2018, 2020

Statewide, 23.0% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.4% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.5% in Cassia County to 54.4% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006l and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.





## LINCOLN COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

### Cancer Incidence 2016–2020 Cancer Mortality 2017–2021 BRFSS 2011–2021

### RISK FACTORS AND INTERVENTIONS

### **CANCER**

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/jama.2016.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

### Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

### **Smoking:**

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

### Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <a href="https://www.dietaryguidelines.gov">https://www.dietaryguidelines.gov</a>

### Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute
Cancer Information Services
1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society <a href="https://www.cancer.org">https://www.cancer.org</a>

### **CANCER INCIDENCE 2016–2020**

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016–2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 112 cases of invasive cancer were diagnosed among Lincoln County residents (Table 1).

**Table 1:** Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Lincoln County and the State of Idaho, 2016–2020

Cancer Incidence 2016–2020	Lincoln County	State of Idaho
All Sites/Types	112	45,610
Female Breast	15	6,687
Prostate	20	6,417
Lung & Bronchus	20	4,887
Colorectal	3	3,451

Table 3 (Cancer Incidence 2016–2020, Comparison between Lincoln County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Lincoln County. The table also shows the number of observed cases, person-

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Lincoln County was 419.4 cases per 100,000 person-years per year during 2016–2020. Comparing this crude rate with the crude rate for the remainder of Idaho (520.3) gives an estimate of the relative burden of disease in Lincoln County.

The age- and sex-adjusted incidence rate of invasive cancer in Lincoln County, all sites combined, was 457.7 cases per 100,000 persons per year during 2016–2020. There were fewer cases of cancer in Lincoln County (112) than expected (127.3) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

### **CANCER MORTALITY 2017–2021**

During 2017–2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 40 Lincoln County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

**Table 2:** Overall and Cancer Mortality in Lincoln County and the State of Idaho, 2017–2021

Mortality 2017–2021	Lincoln County	State of Idaho
All Deaths	216	77,431
Cancer Deaths	40	15,121
% of All Deaths	18.5%	19.5%
Lung & Bronchus	12	2,961
Colorectal	2	1,319
Pancreas	1	1,190
Female Breast	2	1,086
Prostate	3	949

Table 4 (Cancer Mortality 2017–2021, Comparison between Lincoln County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Lincoln County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Lincoln County, all sites combined, was 165.1 deaths per 100,000 persons per year during 2017–2021, compared with 168.3 for the remainder of the state. There were fewer cancer deaths in Lincoln County (40) than expected (40.8) based upon rates in the remainder of the state, but the difference was not statistically significant.

**Statistical Note:** Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

### TABLE 3: CANCER INCIDENCE 2016–2020 COMPARISON BETWEEN LINCOLN COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

		Lincoln County					Ren	Remainder of Idaho		
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)
All Sites Combined	Total	112	26,708	419.4	457.7	127.3	0.186	45,498	8,745,120	520.3
All Sites Combined All Sites Combined	Male Female	59 53	13,835 12,873	426.5 411.7	452.5 459.7	72.1 56.2	0.132 0.733	24,230 21,268	4,383,075 4,362,045	552.8 487.6
Bladder	Total	5	26,708	18.7	21.0	5.9	0.916	2,179	8,745,120	24.9
Bladder	Male	4	13,835	28.9	31.0	5.1	0.831	1,747	4,383,075	39.9
Bladder	Female	1	12,873	7.8	9.0	1.1	1.000	432	4,362,045	9.9
Brain - malignant Brain - malignant	Total Male	1	26,708 13,835	3.7	4.0	1.8 1.1	0.925 0.639	624 375	8,745,120 4,383,075	7.1 8.6
Brain - malignant	Female	1	12,873	7.8	8.4	0.7	0.986	249	4.362.045	5.7
Brain and other CNS - non-malignant	Total	2	26,708	7.5	8.0	4.0	0.464	1,422	8,745,120	16.3
Brain and other CNS - non-malignant	Male	1	13,835	7.2	7.5	1.5	1.000	479	4,383,075	10.9
Brain and other CNS - non-malignant Breast	Female Total	1 16	12,873 26,708	7.8 59.9	8.7 64.3	2.5 19.1	0.575 0.561	943 6,730	4,362,045 8,745,120	21.6 77.0
Breast	Male	10	13,835	7.2	7.6	0.2	0.319	58	4,383,075	1.3
Breast	Female	15	12,873	116.5	129.0	17.8	0.607	6,672	4,362,045	153.0
Breast - in situ	Total	1	26,708	3.7	4.0	3.6	0.261	1,238	8,745,120	14.2
Breast - in situ Breast - in situ	Male Female	- 1	13,835 12,873	- 7.8	- 8.5	0.0 3.3	1.000 0.313	5 1,233	4,383,075 4,362,045	0.1 28.3
Cervix	Female	1	12,873	7.8	8.0	0.9	1.000	303	4,362,045	6.9
Colorectal	Total	3	26,708	11.2	12.2	9.7	0.026 <<	3,448	8,745,120	39.4
Colorectal	Male .	3	13,835	21.7	22.6	5.8	0.348	1,900	4,383,075	43.3
Colorectal	Female	- 4	12,873 12.873	- 31.1	- 34.2	4.0	0.035 <<	1,548	4,362,045	35.5
Corpus Uteri Esophagus	Female Total	- 4	12,873 26.708	31.1	34.2	3.6 1.4	0.950 0.490	1,326 506	4,362,045 8,745,120	30.4 5.8
Esophagus	Male	-	13,835	_	-	1.3	0.564	424	4,383,075	9.7
Esophagus	Female	-	12,873	-	-	0.2	1.000	82	4,362,045	1.9
Hodgkin Lymphoma	Total	-	26,708	-	-	0.6	1.000	210	8,745,120	2.4
Hodgkin Lymphoma Hodgkin Lymphoma	Male Female	-	13,835 12,873	-	-	0.4 0.3	1.000 1.000	118 92	4,383,075 4,362,045	2.7 2.1
Kidney and Renal Pelvis	Total	- 6	26,708	22.5	24.4	5.1	0.799	1,809	8,745,120	20.7
Kidney and Renal Pelvis	Male	4	13,835	28.9	30.3	3.5	0.945	1,178	4,383,075	26.9
Kidney and Renal Pelvis	Female	2	12,873	15.5	17.5	1.7	0.985	631	4,362,045	14.5
Larynx	Total Male	-	26,708 13,835	-	-	0.6 0.5	1.000 1.000	215 160	8,745,120 4,383,075	2.5 3.7
Larynx Larynx	Female	-	12,873	_	-	0.5	1.000	55	4,362,045	1.3
Leukemia	Total	2	26,708	7.5	8.2	4.6	0.336	1,629	8,745,120	18.6
Leukemia	Male	2	13,835	14.5	15.2	3.0	0.862	987	4,383,075	22.5
Leukemia	Female	-	12,873	-	-	1.7	0.376	642	4,362,045	14.7
Liver and Bile Duct Liver and Bile Duct	Total Male	2 1	26,708 13,835	7.5 7.2	8.2 7.7	2.3 1.8	1.000 0.955	827 589	8,745,120 4,383,075	9.5 13.4
Liver and Bile Duct	Female	i	12,873	7.8	8.9	0.6	0.920	238	4,362,045	5.5
Lung and Bronchus	Total	20	26,708	74.9	84.0	13.2	0.099	4,867	8,745,120	55.7
Lung and Bronchus	Male	9	13,835	65.1	70.3	7.1	0.579	2,443	4,383,075	55.7
Lung and Bronchus Melanoma of the Skin	Female Total	11	12,873 26,708	85.5 22.5	99.0 24.3	6.2 8.3	0.101 0.556	2,424 2,936	4,362,045 8,745,120	55.6 33.6
Melanoma of the Skin	Male	3	13,835	21.7	22.8	5.3	0.453	1,762	4,383,075	40.2
Melanoma of the Skin	Female	3	12,873	23.3	25.5	3.2	1.000	1,174	4,362,045	26.9
Myeloma	Total	-	26,708	-	-	1.9	0.287	708	8,745,120	8.1
Myeloma Myeloma	Male Female	-	13,835 12,873	-	-	1.3 0.7	0.548 1.000	441 267	4,383,075 4,362,045	10.1 6.1
Non-Hodgkin Lymphoma	Total	4	26,708	15.0	16.4	5.4	0.743	1,936	8,745,120	22.1
Non-Hodgkin Lýmphoma	Male	2	13,835	14.5	15.3	3.4	0.695	1,127	4,383,075	25.7
Non-Hodgkin Lymphoma	Female	2	12,873	15.5	17.5	2.1	1.000	809	4,362,045	18.5
Oral Cavity and Pharynx Oral Cavity and Pharynx	Total Male	4 4	26,708 13,835	15.0 28.9	16.2 30.3	3.6 2.8	0.984 0.618	1,291 932	8,745,120 4,383,075	14.8 21.3
Oral Cavity and Pharynx	Female	- 4	12,873	20.9	-	0.9	0.778	359	4,362,045	8.2
Ovary	Female	3	12,873	23.3	25.8	1.4	0.340	530	4,362,045	12.2
Pancreas	Total	2	26,708	7.5	8.3	3.9	0.505	1,421	8,745,120	16.2
Pancreas Pancreas	Male Female	1 1	13,835 12,873	7.2 7.8	7.7 9.0	2.3 1.6	0.651 1.000	783 638	4,383,075 4,362,045	17.9 14.6
Prostate	Male	20	13,835	144.6	155.1	18.8	0.845	6,397	4,383,075	145.9
Stomach	Total	2	26,708	7.5	8.2	1.3	0.746	465	8,745,120	5.3
Stomach	Male	1	13,835	7.2	7.6	0.9	1.000	308	4,383,075	7.0
Stomach	Female	1	12,873	7.8	8.8	0.4	0.672	157	4,362,045	3.6
Testis Thyroid	Male Total	- 2	13,835 26,708	- 7.5	- 7.8	0.8 3.6	0.897 0.614	265	4,383,075 8,745,120	6.0 13.9
Thyroid	Male		26,708 13,835	7.5	7.0	1.1	0.614	1,218 355	4,383,075	8.1
Thyroid	Female	2	12,873	- 15.5	16.2	2.4	1.000	863	4,362,045	19.8
			,0.0						.,,,,,,,,	
Pediatric Age 0 to 19	Total	1	8,431	11.9	12.0	1.4	1.000	420	2,452,092	17.1
Pediatric Age 0 to 19 Pediatric Age 0 to 19		1 1	8,431 4,353 4,078	11.9 23.0	12.0 23.2	1.4 0.8	1.000 1.000	420 222	2,452,092 1,252,157 1,199,935	17.1 17.7

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

<sup>2.</sup> Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

<sup>&</sup>quot;<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

### **TABLE 4: CANCER MORTALITY 2017–2021** COMPARISON BETWEEN LINCOLN COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

		Lincoln County						Remainder of Idaho		
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	216	26,686	809.4	885.2	210.2	0.708	77,214	8,962,029	861.6
All Causes of Death	Male	116	13,829	838.8	858.0	123.1	0.561	40,940	4,498,039	910.2
All Causes of Death	Female	100	12,857	777.8	912.6	89.0	0.269	36,274	4,463,990	812.6
All Malignant Cancers	Total	40	26,686	149.9	165.1	40.8	0.989	15,081	8,962,029	168.3
All Malignant Cancers	Male	19	13,829	137.4	143.5	24.0	0.360	8,157	4,498,039	181.3
All Malignant Cancers	Female	21	12,857	163.3	187.8	17.3	0.438	6,924	4,463,990	155.1
Bladder Bladder	Total	-	26,686	-	-	1.3	0.543 0.638	489	8,962,029	5.5
Bladder	Male Female	-	13,829 12,857	-	-	1.1 0.3	1.000	378 111	4,498,039 4,463,990	8.4 2.5
Brain and Other Nervous System	Total	- 2	26,686	7.5	8.0	1.4	0.815	502	8,962,029	5.6
Brain and Other Nervous System	Male		13,829	7.5	-	0.9	0.827	298	4,498,039	6.6
Brain and Other Nervous System	Female	2	12,857	15.6	17.1	0.5	0.202	204	4,463,990	4.6
Breast	Total	2	26,686	7.5	8.1	3.0	0.837	1,100	8,962,029	12.3
Breast	Male	-	13,829	-	-	0.0	1.000	16	4,498,039	0.4
Breast	Female	2	12,857	15.6	17.6	2.8	0.961	1,084	4,463,990	24.3
Cervix	Female	-	12,857	-		0.2	1.000	83	4,463,990	1.9
Colorectal	Total	2	26,686	7.5	8.2	3.6	0.605	1,317	8,962,029	14.7
Colorectal	Male	2	13,829	14.5	15.0	2.1	1.000	717	4,498,039	15.9
Colorectal	Female	-	12,857	-	-	1.5	0.445	600	4,463,990	13.4
Corpus Uteri	Female	-	12,857 26,686	-	-	0.4 1.3	1.000 0.547	173 477	4,463,990	3.9 5.3
Esophagus Esophagus	Total Male	-	13,829	-	-	1.3	0.547 0.618	477 401	8,962,029 4,498,039	5.3 8.9
Esophagus	Female	-	12,857	_	_	0.2	1.000	76	4,463,990	1.7
Hodgkin Lymphoma	Total	_	26,686	_	_	0.1	1.000	29	8,962,029	0.3
Hodgkin Lymphoma	Male	_	13,829	_	_	0.0	1.000	14	4,498,039	0.3
Hodgkin Lymphoma	Female	-	12,857	-	-	0.0	1.000	15	4,463,990	0.3
Kidney	Total	2	26,686	7.5	8.3	1.0	0.550	383	8,962,029	4.3
Kidney	Male	2	13,829	14.5	15.2	0.7	0.314	240	4,498,039	5.3
Kidney	Female	-	12,857	-	-	0.3	1.000	143	4,463,990	3.2
Larynx	Total	-	26,686	-	-	0.2	1.000	71	8,962,029	0.8
Larynx	Male	-	13,829	-	-	0.2	1.000	58	4,498,039	1.3
Larynx	Female	-	12,857	-	-	0.0 1.8	1.000	13	4,463,990	0.3
Leukemia	Total Male	-	26,686 13,829	-	-	1.8	0.339 0.638	660 386	8,962,029 4,498,039	7.4 8.6
Leukemia Leukemia	Female	-	12,857	_	_	0.7	1.000	274	4,496,039	6.1
Liver and Bile Duct	Total	1	26,686	3.7	4.1	1.6	1.000	602	8,962,029	6.7
Liver and Bile Duct	Male		13,829	-	-	1.2	0.611	408	4,498,039	9.1
Liver and Bile Duct	Female	1	12,857	7.8	8.9	0.5	0.771	194	4,463,990	4.3
Lung and Bronchus	Total	12	26,686	45.0	50.2	7.9	0.206	2,949	8,962,029	32.9
Lung and Bronchus	Male	6	13,829	43.4	46.3	4.5	0.583	1,550	4,498,039	34.5
Lung and Bronchus	Female	6	12,857	46.7	54.1	3.5	0.278	1,399	4,463,990	31.3
Melanoma of the Skin	Total	-	26,686	-	-	0.8	0.907	289	8,962,029	3.2
Melanoma of the Skin	Male	-	13,829	-	-	0.6	1.000	192	4,498,039	4.3
Melanoma of the Skin Myeloma	Female Total	-	12,857 26,686	-	-	0.2 0.9	1.000 0.833	97 331	4,463,990 8,962,029	2.2 3.7
Myeloma	Male		13,829	-	-	0.9	1.000	196	4,498,039	4.4
Myeloma	Female	_	12,857	_	-	0.3	1.000	135	4,463,990	3.0
Non-Hodgkin Lymphoma	Total	3	26,686	11.2	12.4	1.5	0.394	566	8,962,029	6.3
Non-Hodgkin Lymphoma	Male	2	13,829	14.5	15.1	0.9	0.454	305	4,498,039	6.8
Non-Hodgkin Lymphoma	Female	1	12,857	7.8	9.2	0.6	0.943	261	4,463,990	5.8
Oral Cavity and Pharynx	Total	1	26,686	3.7	4.1	0.7	1.000	265	8,962,029	3.0
Oral Cavity and Pharynx	Male	-	13,829	-		0.5	1.000	187	4,498,039	4.2
Oral Cavity and Pharynx	Female	1	12,857	7.8	8.8	0.2	0.359	78	4,463,990	1.7
Ovary	Female	1	12,857	7.8	8.8	0.9	1.000	349	4,463,990	7.8
Pancreas Pancreas	Total	1	26,686 13,829	3.7	4.2	3.2	0.344	1,189	8,962,029 4,498,039	13.3 14.3
Pancreas Pancreas	Male Female	- 1	13,829	- 7.8	9.0	1.9 1.4	0.311 1.000	642 547	4,463,990	14.3
Prostate	Male	3	13,829	21.7	22.2	2.8	1.000	946	4,498,039	21.0
Stomach	Total	1	26,686	3.7	4.0	0.5	0.838	197	8,962,029	2.2
Stomach	Male	_ '	13,829	-		0.4	1.000	121	4,498,039	2.7
Stomach	Female	1	12,857	7.8	8.8	0.2	0.351	76	4,463,990	1.7
			ne number of cases r				0.001	. 5	., .55,550	1

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

<sup>2.</sup> Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

### Cancer Screening and Risk Factor Prevalence Estimates, 2011–2021

	State of								Lincoln
Measure	Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	County
Access to Care									
Have Health Insurance, Age <65 (2015–2021)	83.1%	82.8%	85.1%	77.2%	85.8%	78.9%	85.4%	85.4%	76.5%
Not See Doctor Due to Cost in Past Year (2015–2021)	12.6%	11.4%	11.8%	14.5%	12.4%	12.3%	11.8%	12.9%	11.4%
Cancer Screening									
Mammogram Past 2 Years, Age 50–74 (2014, 2016, 2018, 2020)	69.1%	67.0%	73.8%	68.2%	73.2%	64.8%	64.5%	67.1%	
Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020)	71.2%	73.6%	73.6%	70.8%	72.9%	69.1%	69.5%	65.9%	
Colorectal Cancer Screening, Age 50–75 (2018, 2020)	67.9%	66.9%	73.6%	71.4%	70.6%	61.7%	61.5%	64.7%	
Tobacco Use									
Current Tobacco User (2016–2021)	22.3%	26.7%	23.1%	23.6%	21.8%	21.4%	22.7%	16.9%	17.2%
Other Cancer-Related									
Healthy Weight by Body Mass Index, Age 20+ (2015–2021)	32.1%	32.8%	31.7%	27.9%	36.1%	29.8%	27.9%	31.9%	25.9%
Any Physical Activity Besides Job Past 30 Days (2015-2021)	78.7%	79.2%	78.1%	74.5%	83.2%	73.4%	76.3%	79.7%	69.0%
Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019)	21.9%	22.8%	19.4%	20.0%	25.2%	19.5%	20.4%	20.2%	18.1%
Home Ever Tested for Radon (2016, 2018, 2020)	23.0%	30.9%	18.2%	16.9%	25.1%	19.9%	23.0%	21.8%	14.2%

### **Access to Care**

### Have Health Insurance - 2015-2021

Statewide, 83.1% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 86.0% of white non-Hispanics, compared to 64.8% of Hispanics and 83.3% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3%) than English-speaking respondents (84.2%). Health care coverage differed significantly by age of respondent, with 79.8% of persons aged 18–29, and 87.8% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 62.1% in Adams County to 91.6% in Oneida County having health insurance.

### Not See Doctor Due to Cost in Past Year – 2015–2021

Statewide, 12.6% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (11.5% of white non-Hispanics, 19.2% of Hispanics, and 21.0% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9% for less than \$15,000, 6.1% for greater than \$50,000). Inability to see a doctor due to cost differed significantly by county, with a range of 7.4% in Franklin County to 17.5% in Power County.

### **Cancer Screening**

Mammogram - 2014, 2016, 2018, 2020

Statewide, 69.1% of women aged 50–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (72.1% versus 36.7%). Mammography rates differed significantly by county, with a range in screening of 45.9% in Benewah County to 77.0% in Nez Perce County. In 2020, Idaho ranked 48th among states and the District of Columbia for mammography screening rates among women aged 50–74 and also 48th among ages 40+.

### Pap Test - 2018, 2020

Statewide, 71.2% of women with an intact cervix and aged 21–65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.1% versus 52.6% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.7% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49<sup>th</sup> among states and the District of Columbia for Pap screening rate.

### Colorectal Cancer Screening – 2018, 2020

Statewide, 67.9% of adults aged 50–75 reported being current for colorectal cancer screening.\*\* Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked 47<sup>th</sup> among states and the District of Columbia in the percentage of adults aged 50–75 and older who reported being up-to-date for colorectal cancer screening.

<sup>\*\*</sup> Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

### **Tobacco Use**

### Current Tobacco Use - 2016-2021

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.3% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 29.9% of persons aged 18-29, and 11.1% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (22.4%) than among Native Americans (40.0%). Tobacco use differed significantly by county, with a range of 5.4% in Madison County to 41.6% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

### **Other Cancer-Related**

### Healthy Weight by Body Mass Index - 2015-2021

Statewide, 32.1% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 32.5% of white non-Hispanics, compared to 28.2% of Hispanics and 24.6% of Native Americans, being in the healthy weight range. Males (25.5%) were significantly less likely to be in the healthy weight range than females (38.6%). BMI differed significantly by age of respondent, with 43.3% of persons aged 18–29, and 26.0% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 19.8% in Power County to 47.4% in Blaine County of adults being in the healthy weight range.

### Any Physical Activity - 2015-2021

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 78.7% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.3% of persons aged 18–29, and 72.3% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 64.3% in Clark County to 84.6% in Teton County.

Physical Activity Guidelines – 2011, 2013, 2015, 2017, 2019 Statewide, 21.9% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.3% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6% in Franklin County to 30.6% in Blaine County.

### Home Radon Testing - 2016, 2018, 2020

Statewide, 23.0% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.4% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.5% in Cassia County to 54.4% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006l and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.





## MADISON COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

### Cancer Incidence 2016–2020 Cancer Mortality 2017–2021 BRFSS 2011–2021

### **RISK FACTORS AND INTERVENTIONS**

### **CANCER**

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/jama.2016.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

### Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

### **Smoking:**

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

### Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <a href="https://www.dietaryguidelines.gov">https://www.dietaryguidelines.gov</a>

### Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute
Cancer Information Services
1-800-4CANCER
<a href="https://www.cancer.gov/contact">https://www.cancer.gov/contact</a>

American Cancer Society <a href="https://www.cancer.org">https://www.cancer.org</a>

### **CANCER INCIDENCE 2016–2020**

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016–2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 466 cases of invasive cancer were diagnosed among Madison County residents (Table 1).

**Table 1:** Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Madison County and the State of Idaho, 2016–2020

Cancer Incidence 2016–2020	Madison County	State of Idaho
All Sites/Types	466	45,610
Female Breast	72	6,687
Prostate	70	6,417
Lung & Bronchus	15	4,887
Colorectal	35	3,451

Table 3 (Cancer Incidence 2016–2020, Comparison between Madison County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Madison County. The table also shows the number of observed cases, person-

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Madison County was 234.6 cases per 100,000 person-years per year during 2016–2020. Comparing this crude rate with the crude rate for the remainder of Idaho (526.6) gives an estimate of the relative burden of disease in Madison County.

The age- and sex-adjusted incidence rate of invasive cancer in Madison County, all sites combined, was 469.7 cases per 100,000 persons per year during 2016–2020. There were statistically significantly fewer cases of cancer in Madison County (466) than expected (522.4) based upon rates in the remainder of the state (p=.013).

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

### **CANCER MORTALITY 2017–2021**

During 2017–2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 112 Madison County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

**Table 2:** Overall and Cancer Mortality in Madison County and the State of Idaho, 2017–2021

Mortality 2017–2021	Madison County	State of Idaho
All Deaths	911	77,431
Cancer Deaths	112	15,121
% of All Deaths	12.3%	19.5%
Lung & Bronchus	8	2,961
Colorectal	11	1,319
Pancreas	11	1,190
Female Breast	11	1,086
Prostate	10	949

Table 4 (Cancer Mortality 2017–2021, Comparison between Madison County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Madison County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Madison County, all sites combined, was 110.8 deaths per 100,000 persons per year during 2017–2021, compared with 171.0 for the remainder of the state. There were statistically significantly fewer cancer deaths in Madison County (112) than expected (172.9) based upon rates in the remainder of the state (p<.001).

**Statistical Note:** Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

### TABLE 3: CANCER INCIDENCE 2016–2020 COMPARISON BETWEEN MADISON COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

		Madison County						Ren	nainder of Ida	aho
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)
All Sites Combined	Total	466	198,625	234.6	469.7	522.4	0.013 <<	45,144	8,573,203	526.6
All Sites Combined All Sites Combined	Male Female	233 233	100,762 97,863	231.2 238.1	482.4 458.1	270.4 250.8	0.022 <b>&lt;&lt;</b> 0.274	24,056 21,088	4,296,148 4,277,055	559.9 493.0
Bladder	Total	10	198,625	5.0	11.1	22.8	0.004 <<	2,174	8,573,203	25.4
Bladder	Male	8	100,762	7.9	18.0	18.0	0.014 <<	1,743	4,296,148	40.6
Bladder	Female	2	97,863	2.0	4.3	4.6	0.318	431	4,277,055	10.1
Brain - malignant Brain - malignant	Total Male	8 5	198,625 100.762	4.0 5.0	6.4 7.9	9.0 5.4	0.916 1.000	617 370	8,573,203 4,296,148	7.2 8.6
Brain - malignant	Female	3	97,863	3.1	4.9	3.6	1.000	247	4,277,055	5.8
Brain and other CNS - non-malignant	Total	22	198,625	11.1	20.2	17.8	0.379	1,402	8,573,203	16.4
Brain and other CNS - non-malignant	Male	7	100,762	6.9	12.3	6.3	0.870	473	4,296,148	11.0
Brain and other CNS - non-malignant Breast	Female Total	15 74	97,863 198,625	15.3 37.3	28.0 77.0	11.6 74.8	0.393 0.988	929 6,672	4,277,055 8,573,203	21.7 77.8
Breast	Male	2	190,023	2.0	4.4	0.6	0.986	57	4,296,148	1.3
Breast	Female	72	97,863	73.6	149.0	74.8	0.808	6,615	4,277,055	154.7
Breast - in situ	Total	7	198,625	3.5	7.4	13.7	0.076	1,232	8,573,203	14.4
Breast - in situ	Male	- 7	100,762	- 70	- 14.6	0.1	1.000	5	4,296,148	0.1
Breast - in situ Cervix	Female Female	7	97,863 97,863	7.2 4.1	14.6 6.8	13.7 4.1	0.073 1.000	1,227 300	4,277,055 4,277,055	28.7 7.0
Colorectal	Total	35	198,625	17.6	35.8	39.0	0.591	3,416	8,573,203	39.8
Colorectal	Male	15	100,762	14.9	31.3	21.1	0.218	1,888	4,296,148	43.9
Colorectal	Female	20	97,863	20.4	40.1	17.8	0.666	1,528	4,277,055	35.7
Corpus Uteri	Female Total	17 2	97,863 198,625	17.4 1.0	35.7 2.2	14.6 5.4	0.601 0.192	1,313 504	4,277,055	30.7 5.9
Esophagus Esophagus	Male	1	196,625	1.0	2.2	4.5	0.192	423	8,573,203 4,296,148	9.8
Esophagus	Female	i	97,863	1.0	2.2	0.9	1.000	81	4,277,055	1.9
Hodgkin Lymphoma	Total	1	198,625	0.5	0.5	5.2	0.070	209	8,573,203	2.4
Hodgkin Lymphoma	Male	- ,	100,762	-	-	2.6	0.142	118	4,296,148	2.7
Hodgkin Lymphoma Kidney and Renal Pelvis	Female Total	1 14	97,863 198,625	1.0 7.0	0.8 14.4	2.6 20.4	0.551 0.179	91 1,801	4,277,055 8,573,203	2.1 21.0
Kidney and Renal Pelvis	Male	9	100,762	8.9	18.8	13.0	0.179	1,001	4,296,148	27.3
Kidney and Renal Pelvis	Female	5	97,863	5.1	10.1	7.3	0.528	628	4,277,055	14.7
Larynx	Total	2	198,625	1.0	2.0	2.4	1.000	213	8,573,203	2.5
Larynx	Male	2	100,762	2.0	4.4	1.7	0.992	158	4,296,148	3.7
Larynx Leukemia	Female Total	- 17	97,863 198,625	- 8.6	- 15.4	0.7 20.7	0.950 0.488	55 1,614	4,277,055 8,573,203	1.3 18.8
Leukemia	Male	11	100,762	10.9	20.4	12.3	0.855	978	4,296,148	22.8
Leukemia	Female	6	97,863	6.1	10.5	8.5	0.517	636	4,277,055	14.9
Liver and Bile Duct	Total	6	198,625	3.0	6.4	9.0	0.417	823	8,573,203	9.6
Liver and Bile Duct Liver and Bile Duct	Male Female	4 2	100,762 97,863	4.0 2.0	8.8 4.1	6.2 2.7	0.510 0.990	586 237	4,296,148 4,277,055	13.6 5.5
Lung and Bronchus	Total	15	198,625	7.6	16.7	51.2	0.000 <<	4,872	8,573,203	56.8
Lung and Bronchus	Male	5	100,762	5.0	11.3	25.2	0.000 <<	2,447	4,296,148	57.0
Lung and Bronchus	Female	10	97,863	10.2	21.9	25.9	0.001 <<	2,425	4,277,055	56.7
Melanoma of the Skin	Total	29	198,625	14.6	27.9	35.3	0.325	2,913	8,573,203	34.0
Melanoma of the Skin Melanoma of the Skin	Male Female	16 13	100,762 97,863	15.9 13.3	32.6 23.4	20.0 15.1	0.447 0.703	1,749 1,164	4,296,148 4,277,055	40.7 27.2
Myeloma	Total	7	198,625	3.5	7.7	7.4	1.000	701	8,573,203	8.2
Myeloma	Male	3	100,762	3.0	6.7	4.6	0.666	438	4,296,148	10.2
Myeloma	Female	4	97,863	4.1	8.7	2.8	0.630	263	4,277,055	6.1
Non-Hodgkin Lymphoma Non-Hodgkin Lymphoma	Total Male	23 15	198,625 100.762	11.6 14.9	22.1 28.5	23.2 13.6	1.000 0.783	1,917 1,114	8,573,203 4,296,148	22.4 25.9
Non-Hodgkin Lymphoma	Female	8	97,863	8.2	15.7	9.6	0.763	803	4,290,146	18.8
Oral Cavity and Pharynx	Total	8	198,625	4.0	8.5	14.1	0.118	1,287	8,573,203	15.0
Oral Cavity and Pharynx	Male	6	100,762	6.0	13.0	10.0	0.262	930	4,296,148	21.6
Oral Cavity and Pharynx	Female	2	97,863	2.0	4.1 13.2	4.0	0.469 0.952	357	4,277,055	8.3
Ovary Pancreas	Female Total	7 16	97,863 198,625	7.2 8.1	17.5	6.5 15.0	0.952	526 1,407	4,277,055 8,573,203	12.3 16.4
Pancreas	Male	11	100,762	10.9	24.3	8.2	0.399	773	4,296,148	18.0
Pancreas	Female	5	97,863	5.1	10.8	6.9	0.637	634	4,277,055	14.8
Prostate	Male	70	100,762	69.5	158.5	65.3	0.589	6,347	4,296,148	147.7
Stomach Stomach	Total Male	2 2	198,625 100,762	1.0 2.0	2.1 4.3	5.2 3.3	0.223 0.722	465 307	8,573,203 4,296,148	5.4 7.1
Stomach	Female		97,863	Z.U -	- 4.3	1.8	0.722	158	4,290,146	3.7
Testis	Male	10	100,762	9.9	7.9	7.5	0.458	255	4,296,148	5.9
Thyroid	Total	40	198,625	20.1	27.0	20.4	0.000 >>	1,180	8,573,203	13.8
Thyroid	Male	10	100,762	9.9	15.5	5.2	0.078	345	4,296,148	8.0
Thyroid	Female	30	97,863	30.7	39.3	14.9	0.001 >>	835	4,277,055	19.5
Pediatric Age 0 to 19	Total	8	68,037	11.8	10.8	12.8	0.217	413	2,392,486	17.3
Pediatric Age 0 to 19 Pediatric Age 0 to 19	Male Female	4 4	31,564 36,473	12.7 11.0	11.9 9.5	6.0 7.0	0.571 0.341	219 194	1,224,946 1,167,540	17.9 16.6
			30,473			1.0	0.041	194	1,107,340	10.0

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

<sup>2.</sup> Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

<sup>&</sup>quot;<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

### **TABLE 4: CANCER MORTALITY 2017–2021** COMPARISON BETWEEN MADISON COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Mad	lison Count	у			Re	mainder of Idah	10
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	911	213,395	426.9	822.6	965.7	0.079	76,519	8,775,320	872.0
All Causes of Death	Male	457	108,581	420.9	792.6	531.6	0.001 <<	40,599	4,403,287	922.0
All Causes of Death	Female	454	104,814	433.1	859.0	434.2	0.355	35,920	4,372,033	821.6
All Malignant Cancers	Total	112	213,395	52.5	110.8	172.9	0.000 <<	15,009	8,775,320	171.0
All Malignant Cancers	Male	59	108,581	54.3	117.1	92.9	0.000 <<	8,117	4,403,287	184.3
All Malignant Cancers	Female	53	104,814	50.6	104.6	79.9	0.002 <<	6,892	4,372,033	157.6
Bladder Bladder	Total Male	6 6	213,395 108,581	2.8 5.5	6.1 12.3	5.4	0.901 0.474	483	8,775,320 4,403,287	5.5 8.4
Bladder	Female	- 0	104,814	5.5	12.3	4.1 1.2	0.474	372 111	4,372,033	2.5
Brain and Other Nervous System	Total	5	213,395	2.3	4.2	6.7	0.5678	499	8,775,320	5.7
Brain and Other Nervous System	Male	3	108,581	2.8	4.9	4.1	0.831	295	4,403,287	6.7
Brain and Other Nervous System	Female	2	104,814	1.9	3.6	2.6	1.000	204	4,372,033	4.7
Breast	Total	12	213,395	5.6	11.9	12.6	1.000	1,090	8,775,320	12.4
Breast	Male	1	108,581	0.9	2.0	0.2	0.311	15	4,403,287	0.3
Breast	Female	11	104,814	10.5	21.7	12.5	0.816	1,075	4,372,033	24.6
Cervix	Female	- , ,	104,814	-	-	1.1	0.642	83	4,372,033	1.9
Colorectal	Total	11	213,395	5.2	10.9	15.1	0.359	1,308	8,775,320	14.9
Colorectal	Male	5	108,581	4.6	9.9	8.2	0.344	714 504	4,403,287	16.2
Colorectal Corpus Uteri	Female Female	- 6	104,814 104,814	5.7	11.9	6.8 2.0	0.945 0.282	594 173	4,372,033 4,372,033	13.6 4.0
Esophagus	Total	3	213,395	1.4	3.0	5.3	0.262	474	8,775,320	5.4
Esophagus	Male	3	108,581	2.8	6.1	4.4	0.705	398	4,403,287	9.0
Esophagus	Female	-	104,814	-	-	0.9	0.842	76	4,372,033	1.7
Hodgkin Lymphoma	Total	-	213,395	-	-	0.5	1.000	29	8,775,320	0.3
Hodgkin Lymphoma	Male	-	108,581	-	-	0.3	1.000	14	4,403,287	0.3
Hodgkin Lymphoma	Female	-	104,814	-	-	0.2	1.000	15	4,372,033	0.3
Kidney	Total	2	213,395	0.9	2.0	4.3	0.393	383	8,775,320	4.4
Kidney	Male	1	108,581	0.9	2.0	2.7	0.497	241	4,403,287	5.5
Kidney	Female	1	104,814 213,395	1.0	2.0	1.6	1.000	142	4,372,033	3.2
Larynx Larynx	Total Male	-	108,581	-	-	0.8 0.7	0.890 1.000	71 58	8,775,320 4,403,287	0.8 1.3
Larynx	Female	_	104,814	_	_	0.7	1.000	13	4,372,033	0.3
Leukemia	Total	10	213,395	4.7	9.3	8.0	0.557	650	8,775,320	7.4
Leukemia	Male	7	108,581	6.4	12.8	4.7	0.396	379	4,403,287	8.6
Leukemia	Female	3	104,814	2.9	5.7	3.3	1.000	271	4,372,033	6.2
Liver and Bile Duct	Total	5	213,395	2.3	5.1	6.7	0.671	598	8,775,320	6.8
Liver and Bile Duct	Male	3	108,581	2.8	6.1	4.5	0.675	405	4,403,287	9.2
Liver and Bile Duct	Female	2	104,814	1.9	4.0	2.2	1.000	193	4,372,033	4.4
Lung and Bronchus	Total	8	213,395	3.7	8.2	32.9	0.000 <<	2,953	8,775,320	33.7
Lung and Bronchus	Male	2 6	108,581 104,814	1.8 5.7	4.1 12.1	17.1 15.8	0.000 << 0.009 <<	1,554 1,399	4,403,287	35.3 32.0
Lung and Bronchus Melanoma of the Skin	Female Total	1	213,395	0.5	12.1	3.4	0.009 <<	288	4,372,033 8,775,320	3.3
Melanoma of the Skin	Male	_ '	108,581	-	- 1.0	2.2	0.200	192	4,403,287	4.4
Melanoma of the Skin	Female	1	104,814	1.0	1.8	1.2	1.000	96	4,372,033	2.2
Myeloma	Total	6	213,395	2.8	6.1	3.6	0.318	325	8,775,320	3.7
Myeloma	Male	4	108,581	3.7	8.3	2.1	0.328	192	4,403,287	4.4
Myeloma	Female	2	104,814	1.9	4.0	1.5	0.887	133	4,372,033	3.0
Non-Hodgkin Lymphoma	Total	3	213,395	1.4	2.9	6.6	0.208	566	8,775,320	6.4
Non-Hodgkin Lymphoma	Male	2	108,581	1.8	3.8	3.6	0.590	305	4,403,287	6.9
Non-Hodgkin Lymphoma	Female	1	104,814 213,395	1.0	2.0	3.0	0.407	261	4,372,033	6.0 3.0
Oral Cavity and Pharynx Oral Cavity and Pharynx	Total Male	-	108,581	-	-	3.0 2.1	0.100 0.251	266 187	8,775,320 4,403,287	4.2
Oral Cavity and Pharynx	Female	-	104,814	-		0.9	0.251	79	4,372,033	1.8
Ovary	Female	6	104,814	5.7	12.0	3.9	0.408	344	4,372,033	7.9
Pancreas	Total	11	213,395	5.2	11.2	13.2	0.665	1,179	8,775,320	13.4
Pancreas	Male	5	108,581	4.6	10.3	7.1	0.587	637	4,403,287	14.5
Pancreas	Female	6	104,814	5.7	12.1	6.1	1.000	542	4,372,033	12.4
Prostate	Male	10	108,581	9.2	20.5	10.4	1.000	939	4,403,287	21.3
Stomach	Total	1	213,395	0.5	1.0	2.3	0.667	197	8,775,320	2.2
Stomach	Male	1	108,581	0.9	2.0	1.4	1.000	120	4,403,287	2.7
Stomach	Female	-	104,814	-	-	0.9	0.802	77	4,372,033	1.8

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

<sup>2.</sup> Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

### Cancer Screening and Risk Factor Prevalence Estimates, 2011–2021

	State of								Madison
Measure	Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	County
Access to Care									
Have Health Insurance, Age <65 (2015–2021)	83.1%	82.8%	85.1%	77.2%	85.8%	78.9%	85.4%	85.4%	89.9%
Not See Doctor Due to Cost in Past Year (2015–2021)	12.6%	11.4%	11.8%	14.5%	12.4%	12.3%	11.8%	12.9%	11.0%
Cancer Screening									
Mammogram Past 2 Years, Age 50–74 (2014, 2016, 2018, 2020)	69.1%	67.0%	73.8%	68.2%	73.2%	64.8%	64.5%	67.1%	70.5%
Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020)	71.2%	73.6%	73.6%	70.8%	72.9%	69.1%	69.5%	65.9%	66.8%
Colorectal Cancer Screening, Age 50–75 (2018, 2020)	67.9%	66.9%	73.6%	71.4%	70.6%	61.7%	61.5%	64.7%	62.0%
Tobacco Use									
Current Tobacco User (2016–2021)	22.3%	26.7%	23.1%	23.6%	21.8%	21.4%	22.7%	16.9%	5.4%
Other Cancer-Related									
Healthy Weight by Body Mass Index, Age 20+ (2015–2021)	32.1%	32.8%	31.7%	27.9%	36.1%	29.8%	27.9%	31.9%	36.2%
Any Physical Activity Besides Job Past 30 Days (2015-2021)	78.7%	79.2%	78.1%	74.5%	83.2%	73.4%	76.3%	79.7%	84.5%
Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019)	21.9%	22.8%	19.4%	20.0%	25.2%	19.5%	20.4%	20.2%	21.3%
Home Ever Tested for Radon (2016, 2018, 2020)	23.0%	30.9%	18.2%	16.9%	25.1%	19.9%	23.0%	21.8%	15.2%

### **Access to Care**

### Have Health Insurance - 2015-2021

Statewide, 83.1% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 86.0% of white non-Hispanics, compared to 64.8% of Hispanics and 83.3% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3%) than English-speaking respondents (84.2%). Health care coverage differed significantly by age of respondent, with 79.8% of persons aged 18–29, and 87.8% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 62.1% in Adams County to 91.6% in Oneida County having health insurance.

### Not See Doctor Due to Cost in Past Year - 2015-2021

Statewide, 12.6% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (11.5% of white non-Hispanics, 19.2% of Hispanics, and 21.0% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9% for less than \$15,000, 6.1% for greater than \$50,000). Inability to see a doctor due to cost differed significantly by county, with a range of 7.4% in Franklin County to 17.5% in Power County.

### **Cancer Screening**

<u>Mammogram</u> – 2014, 2016, 2018, 2020

Statewide, 69.1% of women aged 50–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (72.1% versus 36.7%). Mammography rates differed significantly by county, with a range in screening of 45.9% in Benewah County to 77.0% in Nez Perce County. In 2020, Idaho ranked 48<sup>th</sup> among states and the District of Columbia for mammography screening rates among women aged 50–74 and also 48<sup>th</sup> among ages 40+.

### Pap Test - 2018, 2020

Statewide, 71.2% of women with an intact cervix and aged 21–65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.1% versus 52.6% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.7% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49<sup>th</sup> among states and the District of Columbia for Pap screening rate.

### Colorectal Cancer Screening – 2018, 2020

Statewide, 67.9% of adults aged 50–75 reported being current for colorectal cancer screening.\*\* Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked 47<sup>th</sup> among states and the District of Columbia in the percentage of adults aged 50–75 and older who reported being up-to-date for colorectal cancer screening.

<sup>\*\*</sup> Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

### **Tobacco Use**

### Current Tobacco Use - 2016-2021

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.3% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 29.9% of persons aged 18-29, and 11.1% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (22.4%) than among Native Americans (40.0%). Tobacco use differed significantly by county, with a range of 5.4% in Madison County to 41.6% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

### **Other Cancer-Related**

### Healthy Weight by Body Mass Index - 2015-2021

Statewide, 32.1% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 32.5% of white non-Hispanics, compared to 28.2% of Hispanics and 24.6% of Native Americans, being in the healthy weight range. Males (25.5%) were significantly less likely to be in the healthy weight range than females (38.6%). BMI differed significantly by age of respondent, with 43.3% of persons aged 18–29, and 26.0% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 19.8% in Power County to 47.4% in Blaine County of adults being in the healthy weight range.

### Any Physical Activity - 2015-2021

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 78.7% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.3% of persons aged 18–29, and 72.3% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 64.3% in Clark County to 84.6% in Teton County.

Physical Activity Guidelines – 2011, 2013, 2015, 2017, 2019 Statewide, 21.9% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.3% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6% in Franklin County to 30.6% in Blaine County.

### Home Radon Testing - 2016, 2018, 2020

Statewide, 23.0% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.4% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.5% in Cassia County to 54.4% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006l and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.





# MINIDOKA COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

### Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

### **RISK FACTORS AND INTERVENTIONS**

### **CANCER**

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/jama.2016.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

### Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

### **Smoking:**

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

### Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <a href="https://www.dietaryguidelines.gov">https://www.dietaryguidelines.gov</a>

### Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute
Cancer Information Services
1-800-4CANCER
<a href="https://www.cancer.gov/contact">https://www.cancer.gov/contact</a>

American Cancer Society <a href="https://www.cancer.org">https://www.cancer.org</a>

### **CANCER INCIDENCE 2016–2020**

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016–2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 509 cases of invasive cancer were diagnosed among Minidoka County residents (Table 1).

**Table 1:** Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Minidoka County and the State of Idaho. 2016–2020

Cancer Incidence 2016–2020	Minidoka County	State of Idaho
All Sites/Types	509	45,610
Female Breast	78	6,687
Prostate	63	6,417
Lung & Bronchus	42	4,887
Colorectal	48	3,451

Table 3 (Cancer Incidence 2016–2020, Comparison between Minidoka County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Minidoka County. The table also shows the number of observed cases, person-

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Minidoka County was 489.0 cases per 100,000 person-years per year during 2016–2020. Comparing this crude rate with the crude rate for the remainder of Idaho (520.3) gives an estimate of the relative burden of disease in Minidoka County.

The age- and sex-adjusted incidence rate of invasive cancer in Minidoka County, all sites combined, was 484.8 cases per 100,000 persons per year during 2016–2020. There were fewer cases of cancer in Minidoka County (509) than expected (546.3) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

### **CANCER MORTALITY 2017–2021**

During 2017–2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 178 Minidoka County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

**Table 2:** Overall and Cancer Mortality in Minidoka County and the State of Idaho, 2017–2021

Mortality 2017–2021	Minidoka County	State of Idaho
All Deaths	1,051	77,431
Cancer Deaths	178	15,121
% of All Deaths	16.9%	19.5%
Lung & Bronchus	19	2,961
Colorectal	17	1,319
Pancreas	16	1,190
Female Breast	12	1,086
Prostate	15	949

Table 4 (Cancer Mortality 2017–2021, Comparison between Minidoka County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Minidoka County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Minidoka County, all sites combined, was 160.7 deaths per 100,000 persons per year during 2017–2021, compared with 168.2 for the remainder of the state. There were fewer cancer deaths in Minidoka County (178) than expected (186.3) based upon rates in the remainder of the state, but the difference was not statistically significant.

**Statistical Note:** Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

### TABLE 3: CANCER INCIDENCE 2016–2020 COMPARISON BETWEEN MINIDOKA COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

		Minidoka County						Ren	Remainder of Idaho		
Cancer	0	Observed	Person	Crude	A.A.I.	Expected	D \/alua (4)	Observed	Person	Crude	
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years 8,667,743	Rate (1) 520.3	
All Sites Combined All Sites Combined	Total Male	509 278	104,085 52,090	489.0 533.7	484.8 527.1	546.3 291.5	0.113 0.450	45,101 24,011	4,344,820	552.6	
All Sites Combined	Female	231	51,995	444.3	443.4	254.2	0.450	21,090	4,322,923	487.9	
Bladder	Total	29	104.085	27.9	26.6	27.1	0.765	2,155	8,667,743	24.9	
Bladder	Male	23	52,090	44.2	42.3	21.6	0.828	1,728	4,344,820	39.8	
Bladder	Female	6	51,995	11.5	11.1	5.4	0.895	427	4,322,923	9.9	
Brain - malignant	Total	11	104,085	10.6	10.5	7.4	0.257	614	8,667,743	7.1	
Brain - malignant	Male	10	52,090	19.2	19.3	4.3	0.028 >>	365	4,344,820 4.322.923	8.4	
Brain - malignant Brain and other CNS - non-malignant	Female Total	1 20	51,995 104,085	1.9 19.2	1.9 19.1	3.0 17.0	0.384 0.524	249 1,404	8.667.743	5.8 16.2	
Brain and other CNS - non-malignant	Male	5	52,090	9.6	9.5	5.7	0.976	475	4,344,820	10.2	
Brain and other CNS - non-malignant	Female	15	51,995	28.8	28.7	11.2	0.325	929	4,322,923	21.5	
Breast	Total	79	104,085	75.9	76.9	79.0	1.000	6,667	8,667,743	76.9	
Breast	Male	1	52,090	1.9	1.8	0.7	1.000	58	4,344,820	1.3	
Breast	Female	78	51,995	150.0	153.2	77.9	1.000	6,609	4,322,923	152.9	
Breast - in situ	Total	15	104,085	14.4	14.9	14.2	0.898	1,224	8,667,743	14.1	
Breast - in situ	Male Female	- 15	52,090 51,995	28.8	30.2	0.1 14.0	1.000 0.862	5 1,219	4,344,820 4,322,923	0.1 28.2	
Breast - in situ Cervix	Female	5	51,995	9.6	10.4	3.3	0.662	299	4,322,923	6.9	
Colorectal	Total	48	104,085	46.1	45.3	41.6	0.465	3,403	8,667,743	39.3	
Colorectal	Male	31	52.090	59.5	58.7	22.8	0.115	1,872	4,344,820	43.1	
Colorectal	Female	17	51,995	32.7	31.9	18.9	0.779	1,531	4,322,923	35.4	
Corpus Uteri	Female	24	51,995	46.2	47.4	15.3	0.047 >>	1,306	4,322,923	30.2	
Esophagus	Total	7	104,085	6.7	6.6	6.1	0.828	499	8,667,743	5.8	
Esophagus	Male	7	52,090	13.4	13.1	5.1	0.508	417	4,344,820	9.6	
Esophagus	Female	- 3	51,995 104,085	2.9	3.0	1.0 2.4	0.725 0.862	82 207	4,322,923 8.667.743	1.9 2.4	
Hodgkin Lymphoma Hodgkin Lymphoma	Total Male	1	52,090	1.9	2.0	1.4	1.000	117	4,344,820	2.4	
Hodgkin Lymphoma	Female	2	51,995	3.8	3.9	1.1	0.569	90	4.322.923	2.1	
Kidney and Renal Pelvis	Total	31	104,085	29.8	29.7	21.5	0.062	1,784	8,667,743	20.6	
Kidney and Renal Pelvis	Male	20	52,090	38.4	38.3	14.0	0.149	1,162	4,344,820	26.7	
Kidney and Renal Pelvis	Female	11	51,995	21.2	21.0	7.5	0.279	622	4,322,923	14.4	
Larynx	Total	6	104,085	5.8	5.7	2.5	0.090	209	8,667,743	2.4	
Larynx	Male	3	52,090	5.8	5.7	1.9	0.598	157	4,344,820	3.6	
Larynx Leukemia	Female Total	3 16	51,995 104,085	5.8 15.4	5.7 14.8	0.6 20.1	0.053 0.427	52 1,615	4,322,923 8,667,743	1.2 18.6	
Leukemia	Male	11	52,090	21.1	20.4	12.1	0.427	978	4,344,820	22.5	
Leukemia	Female	5	51,995	9.6	9.2	8.0	0.387	637	4,322,923	14.7	
Liver and Bile Duct	Total	3	104,085	2.9	2.9	9.9	0.022 <<	826	8,667,743	9.5	
Liver and Bile Duct	Male	3	52,090	5.8	5.8	7.0	0.159	587	4,344,820	13.5	
Liver and Bile Duct	Female	-	51,995	-	-	2.9	0.108	239	4,322,923	5.5	
Lung and Bronchus	Total	42	104,085	40.4	39.1	60.0	0.018 <<	4,845	8,667,743	55.9	
Lung and Branchus	Male	25	52,090	48.0	46.8	29.9	0.431	2,427	4,344,820	55.9	
Lung and Bronchus Melanoma of the Skin	Female Total	17 29	51,995 104,085	32.7 27.9	31.6 27.8	30.1 35.0	0.014 <b>&lt;&lt;</b> 0.351	2,418 2,913	4,322,923 8.667.743	55.9 33.6	
Melanoma of the Skin	Male	19	52,090	36.5	36.0	21.2	0.736	1,746	4,344,820	40.2	
Melanoma of the Skin	Female	10	51,995	19.2	19.6	13.8	0.382	1,167	4,322,923	27.0	
Myeloma	Total	7	104,085	6.7	6.5	8.7	0.731	701	8,667,743	8.1	
Myeloma	Male	4	52,090	7.7	7.5	5.4	0.753	437	4,344,820	10.1	
Myeloma	Female	3	51,995	5.8	5.6	3.3	1.000	264	4,322,923	6.1	
Non-Hodgkin Lymphoma	Total	16	104,085	15.4	15.1	23.4	0.139	1,924	8,667,743	22.2	
Non-Hodgkin Lymphoma	Male Female	9 7	52,090 51,995	17.3 13.5	17.1 13.2	13.6 9.9	0.264 0.460	1,120 804	4,344,820	25.8 18.6	
Non-Hodgkin Lymphoma Oral Cavity and Pharynx	Total	12	104.085	11.5	11.6	15.3	0.483	1,283	4,322,923 8,667,743	14.8	
Oral Cavity and Pharynx	Male	7	52,090	13.4	13.5	11.1	0.463	929	4,344,820	21.4	
Oral Cavity and Pharynx	Female	5	51,995	9.6	9.6	4.2	0.839	354	4,322,923	8.2	
Ovary	Female	8	51,995	15.4	15.5	6.3	0.590	525	4,322,923	12.1	
Pancreas	Total	16	104,085	15.4	14.8	17.5	0.837	1,407	8,667,743	16.2	
Pancreas	Male .	12	52,090	23.0	22.4	9.5	0.504	772	4,344,820	17.8	
Pancreas	Female	4	51,995	7.7	7.4	8.0	0.202	635	4,322,923	14.7	
Prostate Stomach	Male Total	63 4	52,090 104,085	120.9 3.8	121.5 3.7	75.8 5.7	0.151 0.645	6,354 463	4,344,820 8,667,743	146.2 5.3	
Stomach Stomach	Male	1	52,090	3.8 1.9	3.7 1.9	3.8	0.645	308	4,344,820	7.1	
Stomach	Female	3	51,995	5.8	5.5	1.9	0.218	155	4,344,020	3.6	
Testis	Male	3	52,090	5.8	6.1	2.9	1.000	262	4,344,820	6.0	
Thyroid	Total	11	104,085	10.6	11.1	13.8	0.550	1,209	8,667,743	13.9	
Thyroid	Male	6	52,090	11.5	11.9	4.1	0.449	349	4,344,820	8.0	
Thyroid	Female	5	51,995	9.6	10.2	9.7	0.157	860	4,322,923	19.9	
Pediatric Age 0 to 19	Total	3	32,401	9.3	9.3	5.5	0.397	418	2,428,122	17.2	
Pediatric Age 0 to 19	Male	[	16,437	-		3.0	0.104	223	1,240,073	18.0	
Pediatric Age 0 to 19	Female	3	15,964	18.8	19.2	2.6	0.943	195	1,188,049	16.4	

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

<sup>2.</sup> Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

<sup>&</sup>quot;<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

### **TABLE 4: CANCER MORTALITY 2017–2021** COMPARISON BETWEEN MINIDOKA COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Mini	doka Count	.y			Re	mainder of Idah	10
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	1,051	105,431	996.9	909.2	993.9	0.074	76,379	8,883,284	859.8
All Causes of Death	Male	578	52,768	1,095.4	1,027.7	510.5	0.004 >>	40,478	4,459,100	907.8
All Causes of Death	Female	473	52,663	898.2	795.3	482.6	0.683	35,901	4,424,184	811.5
All Malignant Cancers	Total	178	105,431	168.8	160.7	186.3	0.574	14,943	8,883,284	168.2
All Malignant Cancers	Male	107	52,768	202.8	194.3	99.6	0.486	8,069	4,459,100	181.0
All Malignant Cancers	Female	71	52,663	134.8	127.8	86.3	0.104	6,874	4,424,184	155.4
Bladder	Total	9	105,431	8.5	7.6	6.4	0.387	480	8,883,284	5.4
Bladder	Male	7	52,768	13.3	12.0	4.9	0.439	371	4,459,100	8.3
Bladder	Female	2	52,663	3.8	3.4	1.4	0.848	109	4,424,184	2.5
Brain and Other Nervous System	Total	7	105,431	6.6	6.6	5.9	0.753	497	8,883,284	5.6
Brain and Other Nervous System	Male	6	52,768	11.4	11.4	3.4	0.269 0.596	292	4,459,100	6.5
Brain and Other Nervous System Breast	Female Total	1 12	52,663 105,431	1.9 11.4	1.9 10.9	2.4 13.5	0.596	205 1,090	4,424,184 8,883,284	4.6 12.3
Breast	Male	12	52,768	11.4	10.9	0.2	1.000	1,090	4,459,100	0.4
Breast	Female	12	52,7663	22.8	21.9	13.3	0.860	1,074	4,424,184	24.3
Cervix	Female	12	52,663	1.9	2.0	0.9	1.000	82	4,424,184	1.9
Colorectal	Total	17	105,431	16.1	15.4	16.2	0.904	1,302	8,883,284	14.7
Colorectal	Male	9	52,768	17.1	16.6	8.6	0.987	710	4,459,100	15.9
Colorectal	Female	8	52,663	15.2	14.1	7.6	0.971	592	4,424,184	13.4
Corpus Uteri	Female	1	52,663	1.9	1.9	2.1	0.766	172	4,424,184	3.9
Esophagus	Total	3	105,431	2.8	2.8	5.8	0.345	474	8,883,284	5.3
Esophagus	Male	3	52,768	5.7	5.6	4.8	0.589	398	4,459,100	8.9
Esophagus	Female	-	52,663	-	-	1.0	0.765	76	4,424,184	1.7
Hodgkin Lymphoma	Total	-	105,431	-	-	0.4	1.000	29	8,883,284	0.3
Hodgkin Lymphoma	Male	-	52,768	-	-	0.2	1.000	14	4,459,100	0.3
Hodgkin Lymphoma	Female	-	52,663	-	-	0.2	1.000	15	4,424,184	0.3
Kidney	Total Male	4 3	105,431 52,768	3.8 5.7	3.6 5.5	4.8 2.9	0.964 1.000	381 239	8,883,284 4,459,100	4.3 5.4
Kidney Kidney	Female	1	52,766	1.9	1.7	1.8	0.898	142	4,424,184	3.4
Larynx	Total	1	105,431	0.9	0.9	0.9	1.000	70	8,883,284	0.8
Larynx	Male	i	52,768	1.9	1.8	0.7	1.000	57	4,459,100	1.3
Larynx	Female		52,663	-	-	0.2	1.000	13	4,424,184	0.3
Leukemia	Total	8	105,431	7.6	7.0	8.4	1.000	652	8,883,284	7.3
Leukemia	Male	5	52,768	9.5	8.9	4.8	1.000	381	4,459,100	8.5
Leukemia	Female	3	52,663	5.7	5.2	3.6	1.000	271	4,424,184	6.1
Liver and Bile Duct	Total	8	105,431	7.6	7.5	7.1	0.846	595	8,883,284	6.7
Liver and Bile Duct	Male	6	52,768	11.4	11.3	4.8	0.689	402	4,459,100	9.0
Liver and Bile Duct	Female	2	52,663	3.8	3.7	2.4	1.000	193	4,424,184	4.4
Lung and Bronchus	Total	19	105,431	18.0	17.3	36.3	0.002 <<	2,942	8,883,284	33.1
Lung and Bronchus	Male	10	52,768	19.0	18.5	18.8	0.041 <<	1,546	4,459,100	34.7
Lung and Bronchus Melanoma of the Skin	Female Total	9	52,663 105,431	17.1 1.9	16.2 1.8	17.5 3.5	0.040 <b>&lt;&lt;</b> 0.629	1,396 287	4,424,184 8,883,284	31.6 3.2
Melanoma of the Skin	Male		52.768	1.9	1.0	2.4	0.029	192	4,459,100	4.3
Melanoma of the Skin	Female	2	52,663	3.8	3.7	1.2	0.643	95	4,424,184	2.1
Myeloma	Total	6	105,431	5.7	5.3	4.1	0.466	325	8,883,284	3.7
Myeloma	Male	5	52,768	9.5	9.0	2.4	0.188	191	4,459,100	4.3
Myeloma	Female	1	52,663	1.9	1.8	1.7	0.977	134	4,424,184	3.0
Non-Hodgkin Lymphoma	Total	8	105,431	7.6	7.1	7.1	0.840	561	8,883,284	6.3
Non-Hodgkin Lymphoma	Male	5	52,768	9.5	9.1	3.7	0.640	302	4,459,100	6.8
Non-Hodgkin Lymphoma	Female	3	52,663	5.7	5.2	3.4	1.000	259	4,424,184	5.9
Oral Cavity and Pharynx	Total	1	105,431	0.9	0.9	3.2	0.339	265	8,883,284	3.0
Oral Cavity and Pharynx	Male		52,768	-		2.2	0.213	187	4,459,100	4.2
Oral Cavity and Pharynx	Female	1	52,663	1.9	1.8	1.0	1.000	78	4,424,184	1.8
Ovary	Female	3	52,663	5.7	5.5	4.2	0.774	347	4,424,184	7.8
Pancreas	Total	16 12	105,431	15.2	14.7	14.4	0.733	1,174	8,883,284	13.2
Pancreas Pancreas	Male Female	4	52,768 52,663	22.7 7.6	22.3 7.3	7.6 6.7	0.172 0.399	630 544	4,459,100 4,424,184	14.1 12.3
Prostate	Male	15	52,768	28.4	25.7	12.2	0.399	934	4,459,100	20.9
Stomach	Total	5	105,431	4.7	4.5	2.4	0.490	193	8,883,284	20.9
Stomach	Male	3	52,768	5.7	5.5	1.4	0.354	118	4,459,100	2.6
Stomach	Female	2	52,663	3.8	3.6	0.9	0.491	75	4,424,184	1.7
			ne number of cases i				0.101	, 0	1, 127, 107	1.7

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

<sup>2.</sup> Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

### Cancer Screening and Risk Factor Prevalence Estimates, 2011–2021

	State of								Minidoka
Measure	Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	County
Access to Care									
Have Health Insurance, Age <65 (2015–2021)	83.1%	82.8%	85.1%	77.2%	85.8%	78.9%	85.4%	85.4%	78.9%
Not See Doctor Due to Cost in Past Year (2015–2021)	12.6%	11.4%	11.8%	14.5%	12.4%	12.3%	11.8%	12.9%	9.6%
Cancer Screening									
Mammogram Past 2 Years, Age 50–74 (2014, 2016, 2018, 2020)	69.1%	67.0%	73.8%	68.2%	73.2%	64.8%	64.5%	67.1%	65.5%
Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020)	71.2%	73.6%	73.6%	70.8%	72.9%	69.1%	69.5%	65.9%	
Colorectal Cancer Screening, Age 50–75 (2018, 2020)	67.9%	66.9%	73.6%	71.4%	70.6%	61.7%	61.5%	64.7%	65.1%
Tobacco Use									
Current Tobacco User (2016–2021)	22.3%	26.7%	23.1%	23.6%	21.8%	21.4%	22.7%	16.9%	23.1%
Other Cancer-Related									
Healthy Weight by Body Mass Index, Age 20+ (2015–2021)	32.1%	32.8%	31.7%	27.9%	36.1%	29.8%	27.9%	31.9%	19.8%
Any Physical Activity Besides Job Past 30 Days (2015-2021)	78.7%	79.2%	78.1%	74.5%	83.2%	73.4%	76.3%	79.7%	71.0%
Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019)	21.9%	22.8%	19.4%	20.0%	25.2%	19.5%	20.4%	20.2%	13.9%
Home Ever Tested for Radon (2016, 2018, 2020)	23.0%	30.9%	18.2%	16.9%	25.1%	19.9%	23.0%	21.8%	18.3%

### **Access to Care**

### Have Health Insurance - 2015-2021

Statewide, 83.1% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 86.0% of white non-Hispanics, compared to 64.8% of Hispanics and 83.3% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3%) than English-speaking respondents (84.2%). Health care coverage differed significantly by age of respondent, with 79.8% of persons aged 18–29, and 87.8% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 62.1% in Adams County to 91.6% in Oneida County having health insurance.

### Not See Doctor Due to Cost in Past Year - 2015-2021

Statewide, 12.6% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (11.5% of white non-Hispanics, 19.2% of Hispanics, and 21.0% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9% for less than \$15,000, 6.1% for greater than \$50,000). Inability to see a doctor due to cost differed significantly by county, with a range of 7.4% in Franklin County to 17.5% in Power County.

### **Cancer Screening**

Mammogram - 2014, 2016, 2018, 2020

Statewide, 69.1% of women aged 50–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (72.1% versus 36.7%). Mammography rates differed significantly by county, with a range in screening of 45.9% in Benewah County to 77.0% in Nez Perce County. In 2020, Idaho ranked 48th among states and the District of Columbia for mammography screening rates among women aged 50–74 and also 48th among ages 40+.

### Pap Test - 2018, 2020

Statewide, 71.2% of women with an intact cervix and aged 21–65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.1% versus 52.6% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.7% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49<sup>th</sup> among states and the District of Columbia for Pap screening rate.

### Colorectal Cancer Screening - 2018, 2020

Statewide, 67.9% of adults aged 50–75 reported being current for colorectal cancer screening.\*\* Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked 47<sup>th</sup> among states and the District of Columbia in the percentage of adults aged 50–75 and older who reported being up-to-date for colorectal cancer screening.

<sup>\*\*</sup> Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

### **Tobacco Use**

### Current Tobacco Use - 2016-2021

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.3% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 29.9% of persons aged 18-29, and 11.1% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (22.4%) than among Native Americans (40.0%). Tobacco use differed significantly by county, with a range of 5.4% in Madison County to 41.6% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

### **Other Cancer-Related**

### Healthy Weight by Body Mass Index - 2015-2021

Statewide, 32.1% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 32.5% of white non-Hispanics, compared to 28.2% of Hispanics and 24.6% of Native Americans, being in the healthy weight range. Males (25.5%) were significantly less likely to be in the healthy weight range than females (38.6%). BMI differed significantly by age of respondent, with 43.3% of persons aged 18–29, and 26.0% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 19.8% in Power County to 47.4% in Blaine County of adults being in the healthy weight range.

### Any Physical Activity - 2015-2021

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 78.7% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.3% of persons aged 18–29, and 72.3% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 64.3% in Clark County to 84.6% in Teton County.

Physical Activity Guidelines – 2011, 2013, 2015, 2017, 2019 Statewide, 21.9% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.3% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6% in Franklin County to 30.6% in Blaine County.

### Home Radon Testing - 2016, 2018, 2020

Statewide, 23.0% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.4% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.5% in Cassia County to 54.4% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006l and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.





# NEZ PERCE COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

### Cancer Incidence 2016–2020 Cancer Mortality 2017–2021 BRFSS 2011–2021

### **RISK FACTORS AND INTERVENTIONS**

### **CANCER**

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/jama.2016.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

### Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

### **Smoking:**

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

### Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <a href="https://www.dietaryguidelines.gov">https://www.dietaryguidelines.gov</a>

### Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute
Cancer Information Services
1-800-4CANCER
<a href="https://www.cancer.gov/contact">https://www.cancer.gov/contact</a>

American Cancer Society <a href="https://www.cancer.org">https://www.cancer.org</a>

### **CANCER INCIDENCE 2016–2020**

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016–2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 1,221 cases of invasive cancer were diagnosed among Nez Perce County residents (Table 1).

**Table 1:** Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Nez Perce County and the State of Idaho. 2016–2020

,	,	
Cancer Incidence 2016–2020	Nez Perce County	State of Idaho
All Sites/Types	1,221	45,610
Female Breast	179	6,687
Prostate	162	6,417
Lung & Bronchus	184	4,887
Colorectal	99	3,451

Table 3 (Cancer Incidence 2016–2020, Comparison between Nez Perce County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Nez Perce County. The table also shows the number of observed cases,

person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Nez Perce County was 603.4 cases per 100,000 person-years per year during 2016–2020. Comparing this crude rate with the crude rate for the remainder of Idaho (518.0) gives an estimate of the relative burden of disease in Nez Perce County.

The age- and sex-adjusted incidence rate of invasive cancer in Nez Perce County, all sites combined, was 503.5 cases per 100,000 persons per year during 2016–2020. There were fewer cases of cancer in Nez Perce County (1,221) than expected (1,256.2) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

### **CANCER MORTALITY 2017–2021**

During 2017–2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 502 Nez Perce County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

**Table 2:** Overall and Cancer Mortality in Nez Perce County and the State of Idaho, 2017–2021

Mortality 2017–2021	Nez Perce County	State of Idaho
All Deaths	2,695	77,431
Cancer Deaths	502	15,121
% of All Deaths	18.6%	19.5%
Lung & Bronchus	119	2,961
Colorectal	43	1,319
Pancreas	36	1,190
Female Breast	28	1,086
Prostate	35	949

Table 4 (Cancer Mortality 2017–2021, Comparison between Nez Perce County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Nez Perce County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Nez Perce County, all sites combined, was 189.1 deaths per 100,000 persons per year during 2017–2021, compared with 166.4 for the remainder of the state. There were statistically significantly more cancer deaths in Nez Perce County (502) than expected (441.8) based upon rates in the remainder of the state (p=.005).

**Statistical Note:** Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

### TABLE 3: CANCER INCIDENCE 2016–2020 COMPARISON BETWEEN NEZ PERCE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Nez	Perce Cour	ity			Ren	nainder of Ida	aho
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)
All Sites Combined	Total	1,221	202,340	603.4	503.5	1,256.2	0.328	44,389	8,569,488	518.0
All Sites Combined All Sites Combined	Male	642 579	99,902 102.438	642.6	534.5 475.1	661.0	0.474 0.621	23,647	4,297,008	550.3 485.5
Bladder	Female Total	579 52	202,340	565.2 25.7	20.1	591.7 64.4	0.021	20,742 2,132	4,272,480 8,569,488	24.9
	Male	40	99,902	40.0	31.5	50.5	0.152	1,711	4,297,008	39.8
Bladder	Female	12	102,438	11.7	9.2	12.9	0.945	421	4,272,480	9.9
Brain - malignant	Total	19	202,340	9.4	8.3	16.2	0.555	606	8,569,488	7.1
Brain - malignant Brain - malignant	Male Female	12 7	99,902 102,438	12.0 6.8	10.7 5.9	9.5 6.7	0.491 1.000	363 243	4,297,008 4,272,480	8.4 5.7
	Total	28	202,340	13.8	11.7	38.8	0.087	1,396	8,569,488	16.3
	Male	6	99,902	6.0	5.2	12.7	0.062	474	4,297,008	11.0
•	Female	22	102,438	21.5	18.0	26.4	0.461	922	4,272,480	21.6
Breast	Total	179	202,340	88.5	76.3	179.8	0.992	6,567	8,569,488	76.6
Breast Breast	Male Female	- 179	99,902 102,438	- 174.7	- 150.9	1.7 180.6	0.358 0.942	59 6,508	4,297,008 4,272,480	1.4 152.3
Breast - in situ	Total	31	202,340	15.3	13.6	32.0	0.949	1,208	8,569,488	14.1
Breast - in situ	Male	-	99,902	-	-	0.1	1.000	5	4,297,008	0.1
Breast - in situ	Female	31	102,438	30.3	27.0	32.3	0.906	1,203	4,272,480	28.2
Cervix	Female	4	102,438	3.9	3.8	7.4	0.278	300	4,272,480 8.569.488	7.0
Colorectal Colorectal	Total Male	99 54	202,340 99,902	48.9 54.1	40.3 45.2	96.0 51.4	0.786 0.755	3,352 1,849	4,297,008	39.1 43.0
Colorectal	Female	45	102,438	43.9	35.7	44.4	0.968	1,503	4,272,480	35.2
Corpus Uteri	Female	33	102,438	32.2	28.0	35.7	0.727	1,297	4,272,480	30.4
Esophagus	Total	16	202,340	7.9	6.4	14.2	0.710	490	8,569,488	5.7
Esophagus Esophagus	Male Female	12 4	99,902 102.438	12.0 3.9	9.8 3.2	11.8 2.3	1.000 0.401	412 78	4,297,008 4,272,480	9.6 1.8
Hodgkin Lymphoma	Total	3	202,340	1.5	1.4	5.1	0.515	207	8,569,488	2.4
	Male	1	99,902	1.0	1.0	2.8	0.455	117	4,297,008	2.7
Hodgkin Lymphoma	Female	2	102,438	2.0	1.9	2.2	1.000	90	4,272,480	2.1
Kidney and Renal Pelvis	Total	48	202,340	23.7	20.1	49.2	0.937	1,767	8,569,488	20.6
Kidney and Renal Pelvis Kidney and Renal Pelvis	Male Female	32 16	99,902 102,438	32.0 15.6	27.3 13.2	31.4 17.6	0.962 0.829	1,150 617	4,297,008 4,272,480	26.8 14.4
Larynx	Total	8	202,340	4.0	3.3	5.9	0.829	207	8,569,488	2.4
	Male	6	99,902	6.0	4.9	4.4	0.544	154	4,297,008	3.6
Larynx	Female	2	102,438	2.0	1.6	1.5	0.895	53	4,272,480	1.2
Leukemia	Total Male	36	202,340	17.8	14.7	45.7	0.165 0.393	1,595	8,569,488	18.6
Leukemia Leukemia	Female	22 14	99,902 102,438	22.0 13.7	18.4 11.1	27.0 18.5	0.353	967 628	4,297,008 4,272,480	22.5 14.7
Liver and Bile Duct	Total	21	202,340	10.4	8.7	22.8	0.803	808	8,569,488	9.4
	Male	13	99,902	13.0	10.9	16.0	0.552	577	4,297,008	13.4
Liver and Bile Duct	Female	8	102,438	7.8	6.4	6.8	0.729	231	4,272,480	5.4
Lung and Bronchus Lung and Bronchus	Total Male	184 86	202,340 99,902	90.9 86.1	72.6 69.5	139.1 68.1	0.000 >> 0.041 >>	4,703 2,366	8,569,488 4,297,008	54.9 55.1
Lung and Bronchus	Female	98	102,438	95.7	75.8	70.7	0.002 >>	2,300	4,272,480	54.7
Melanoma of the Skin	Total	64	202,340	31.6	26.8	80.1	0.075	2,878	8,569,488	33.6
	Male	34	99,902	34.0	28.4	48.2	0.041 <<	1,731	4,297,008	40.3
Melanoma of the Skin	Female	30	102,438	29.3	25.6	31.4	0.893	1,147	4,272,480	26.8
Myeloma Myeloma	Total Male	15 11	202,340 99,902	7.4 11.0	5.9 8.9	20.4 12.4	0.274 0.842	693 430	8,569,488 4,297,008	8.1 10.0
Myeloma	Female	4	102,438	3.9	3.1	7.9	0.214	263	4,272,480	6.2
Nón-Hodgkin Lymphoma	Total	53	202,340	26.2	21.8	53.6	1.000	1,887	8,569,488	22.0
	Male	31	99,902	31.0	26.2	30.2	0.934	1,098	4,297,008	25.6
Non-Hodgkin Lymphoma Oral Cavity and Pharynx	Female	22 34	102,438	21.5	17.5	23.2	0.915	789 1 261	4,272,480	18.5 14.7
	Total Male	34 27	202,340 99,902	16.8 27.0	14.2 22.9	35.2 25.0	0.923 0.734	1,261 909	8,569,488 4,297,008	21.2
	Female	7	102,438	6.8	5.7	10.1	0.429	352	4,272,480	8.2
Ovary	Female	9	102,438	8.8	7.5	14.8	0.153	524	4,272,480	12.3
Pancreas	Total	42	202,340	20.8	16.5	41.1	0.924	1,381	8,569,488	16.1
Pancreas Pancreas	Male Female	28 14	99,902 102,438	28.0 13.7	22.6 10.7	21.8 19.1	0.228 0.285	756 625	4,297,008 4,272,480	17.6 14.6
	Male	162	99,902	162.2	136.3	173.0	0.426	6,255	4,272,480	145.6
	Total	13	202,340	6.4	5.2	13.3	1.000	454	8,569,488	5.3
Stomach	Male	8	99,902	8.0	6.6	8.5	1.000	301	4,297,008	7.0
Stomach	Female	5	102,438	4.9	3.9	4.6	0.984	153	4,272,480	3.6
	Male	4	99,902	4.0	4.1	6.0	0.580	261	4,297,008	6.1
Thyroid Thyroid	Total Male	27 8	202,340 99,902	13.3 8.0	12.6	29.8	0.697 0.972	1,193	8,569,488 4,297,008	13.9
Thyroid	Female	8 19	102,438	18.5	7.4 17.8	8.8 21.1	0.972	347 846	4,297,008	8.1 19.8
Pediatric Age 0 to 19	Total	7	48,091	14.6	14.4	8.3	0.734	414	2,412,432	17.2
· ·	Male	2	24,492	8.2	8.1	4.4	0.363	221	1,232,018	17.9
Pediatric Age 0 to 19	Female	5	23,599	21.2	20.9	3.9	0.709	193	1,180,414	16.4

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

<sup>2.</sup> Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

<sup>&</sup>quot;<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

### **TABLE 4: CANCER MORTALITY 2017–2021** COMPARISON BETWEEN NEZ PERCE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Nez	Perce Cour	nty			Re	mainder of Idah	10
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	2,695	204,594	1,317.2	967.0	2,371.1	0.000 >>	74,735	8,784,121	850.8
All Causes of Death	Male	1,397	100,999	1,383.2	1,059.9	1,185.1	0.000 >>	39,659	4,410,869	899.1
All Causes of Death	Female	1,298	103,595	1,253.0	882.5	1,179.7	0.001 >>	35,076	4,373,252	802.1
All Malignant Cancers	Total	502	204,594	245.4	189.1	441.8	0.005 >>	14,619	8,784,121	166.4
All Malignant Cancers	Male	281	100,999	278.2	216.6	232.2	0.002 >>	7,895	4,410,869	179.0
All Malignant Cancers	Female	221	103,595	213.3	163.5	207.9	0.380	6,724	4,373,252	153.8
Bladder	Total	19	204,594	9.3	6.5	15.6	0.449	470	8,784,121	5.4
Bladder	Male	14	100,999	13.9	9.9	11.7	0.580	364	4,410,869	8.3
Bladder	Female	5	103,595	4.8	3.4	3.6	0.583	106	4,373,252	2.4
Brain and Other Nervous System	Total	17	204,594	8.3	7.1	13.3	0.380	487	8,784,121	5.5
,	Male	11	100,999	10.9	9.3	7.7	0.310	287	4,410,869	6.5
Brain and Other Nervous System Breast	Female Total	6 28	103,595 204,594	5.8 13.7	4.9 10.7	5.6 31.9	0.974 0.563	200 1,074	4,373,252 8,784,121	4.6 12.2
Breast	Male	20	100,999	13.7	10.7	0.5	1.000	1,074	4,410,869	0.4
Breast	Female	28	103,595	27.0	21.2	32.0	0.548	1,058	4,373,252	24.2
Cervix	Female	3	103,595	2.9	2.6	2.1	0.704	80	4,373,252	1.8
Colorectal	Total	43	204,594	21.0	16.3	38.2	0.479	1,276	8,784,121	14.5
Colorectal	Male	18	100,999	17.8	14.3	20.0	0.765	701	4,410,869	15.9
Colorectal	Female	25	103,595	24.1	18.1	18.2	0.147	575	4,373,252	13.1
Corpus Uteri	Female	4	103,595	3.9	3.1	5.0	0.867	169	4,373,252	3.9
Esophagus	Total	14	204,594	6.8	5.4	13.6	0.976	463	8,784,121	5.3
Esophagus	Male	9	100,999	8.9	7.2	11.1	0.653	392	4,410,869	8.9
Esophagus	Female	5	103,595	4.8	3.7	2.2	0.150	71	4,373,252	1.6
Hodgkin Lymphoma	Total	-	204,594	-	-	0.8	0.862	29	8,784,121	0.3
Hodgkin Lymphoma	Male	-	100,999	-	-	0.4	1.000	14	4,410,869	0.3
Hodgkin Lymphoma	Female	-	103,595	-	-	0.5	1.000	15	4,373,252	0.3
Kidney	Total	13	204,594	6.4	4.8	11.4	0.707	372	8,784,121	4.2
Kidney	Male	9	100,999	8.9	7.0	6.8	0.485	233	4,410,869	5.3
Kidney	Female Total	4	103,595	3.9	2.8	4.5	1.000	139	4,373,252	3.2
Larynx Larynx	Male	1	204,594 100,999	0.5 1.0	0.4 0.8	2.1 1.7	0.766 0.995	70 57	8,784,121 4,410,869	0.8 1.3
Larynx	Female	_ '	103,595	1.0	0.8	0.4	1.000	13	4,373,252	0.3
Leukemia	Total	21	204,594	10.3	7.7	19.9	0.859	639	8,784,121	7.3
Leukemia	Male	14	100,999	13.9	10.7	11.1	0.450	372	4,410,869	8.4
Leukemia	Female	7	103,595	6.8	4.9	8.7	0.722	267	4,373,252	6.1
Liver and Bile Duct	Total	12	204,594	5.9	4.7	17.1	0.264	591	8,784,121	6.7
Liver and Bile Duct	Male	7	100,999	6.9	5.7	11.2	0.257	401	4,410,869	9.1
Liver and Bile Duct	Female	5	103,595	4.8	3.8	5.7	0.987	190	4,373,252	4.3
Lung and Bronchus	Total	119	204,594	58.2	45.2	85.2	0.001 >>	2,842	8,784,121	32.4
Lung and Bronchus	Male	63	100,999	62.4	49.3	43.2	0.006 >>	1,493	4,410,869	33.8
Lung and Bronchus	Female	56	103,595	54.1	41.3	41.8	0.042 >>	1,349	4,373,252	30.8
Melanoma of the Skin	Total	4	204,594	2.0	1.5	8.4	0.156	285	8,784,121	3.2
Melanoma of the Skin	Male	4	100,999	4.0	3.1	5.5	0.721	188	4,410,869	4.3
Melanoma of the Skin	Female	- 10	103,595	-	- 1	2.9	0.114	97	4,373,252	2.2 3.6
Myeloma Myeloma	Total Male	12 10	204,594 100,999	5.9 9.9	4.4 7.5	9.9 5.6	0.591 0.121	319 186	8,784,121 4,410,869	3.6 4.2
Myeloma Myeloma	riviale Female	2	100,999	1.9	1.4	4.2	0.121	133	4,410,669	3.0
Non-Hodgkin Lymphoma	Total	21	204,594	10.3	7.7	17.0	0.409	548	8,784,121	6.2
	Male	10	100,999	9.9	7.7	8.7	0.759	297	4,410,869	6.7
Non-Hodgkin Lymphoma	Female	11	103,595	10.6	7.7	8.2	0.414	251	4,373,252	5.7
Oral Cavity and Pharynx	Total	11	204,594	5.4	4.3	7.4	0.264	255	8,784,121	2.9
Oral Cavity and Pharynx	Male	7	100,999	6.9	5.6	5.1	0.498	180	4,410,869	4.1
Oral Cavity and Pharynx	Female	4	103,595	3.9	3.0	2.3	0.393	75	4,373,252	1.7
Ovary	Female	7	103,595	6.8	5.3	10.3	0.394	343	4,373,252	7.8
Pancreas	Total	36	204,594	17.6	13.8	34.2	0.799	1,154	8,784,121	13.1
Pancreas	Male	17	100,999	16.8	13.5	17.9	0.958	625	4,410,869	14.2
Pancreas	Female	19	103,595	18.3	14.2	16.2	0.544	529	4,373,252	12.1
Prostate	Male	35	100,999	34.7	24.8	29.3	0.333	914	4,410,869	20.7
Stomach	Total	11	204,594	5.4	4.2	5.6	0.053	187	8,784,121	2.1
Stomach	Male	9	100,999	8.9	7.1	3.2	0.012 >>	112	4,410,869	2.5
Stomach	Female	2	103,595	1.9	1.5	2.3	1.000	75	4,373,252	1.7

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

<sup>2.</sup> Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

### Cancer Screening and Risk Factor Prevalence Estimates, 2011–2021

	State of								Nez Perce
Measure	Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	County
Access to Care									
Have Health Insurance, Age <65 (2015–2021)	83.1%	82.8%	85.1%	77.2%	85.8%	78.9%	85.4%	85.4%	86.5%
Not See Doctor Due to Cost in Past Year (2015–2021)	12.6%	11.4%	11.8%	14.5%	12.4%	12.3%	11.8%	12.9%	10.8%
Cancer Screening									
Mammogram Past 2 Years, Age 50–74 (2014, 2016, 2018, 2020)	69.1%	67.0%	73.8%	68.2%	73.2%	64.8%	64.5%	67.1%	77.0%
Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020)	71.2%	73.6%	73.6%	70.8%	72.9%	69.1%	69.5%	65.9%	72.1%
Colorectal Cancer Screening, Age 50–75 (2018, 2020)	67.9%	66.9%	73.6%	71.4%	70.6%	61.7%	61.5%	64.7%	75.1%
Tobacco Use									
Current Tobacco User (2016–2021)	22.3%	26.7%	23.1%	23.6%	21.8%	21.4%	22.7%	16.9%	23.1%
Other Cancer-Related									
Healthy Weight by Body Mass Index, Age 20+ (2015–2021)	32.1%	32.8%	31.7%	27.9%	36.1%	29.8%	27.9%	31.9%	28.2%
Any Physical Activity Besides Job Past 30 Days (2015-2021)	78.7%	79.2%	78.1%	74.5%	83.2%	73.4%	76.3%	79.7%	77.2%
Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019)	21.9%	22.8%	19.4%	20.0%	25.2%	19.5%	20.4%	20.2%	18.3%
Home Ever Tested for Radon (2016, 2018, 2020)	23.0%	30.9%	18.2%	16.9%	25.1%	19.9%	23.0%	21.8%	18.8%

### **Access to Care**

### Have Health Insurance – 2015–2021

Statewide, 83.1% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 86.0% of white non-Hispanics, compared to 64.8% of Hispanics and 83.3% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3%) than English-speaking respondents (84.2%). Health care coverage differed significantly by age of respondent, with 79.8% of persons aged 18–29, and 87.8% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 62.1% in Adams County to 91.6% in Oneida County having health insurance.

### Not See Doctor Due to Cost in Past Year - 2015-2021

Statewide, 12.6% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (11.5% of white non-Hispanics, 19.2% of Hispanics, and 21.0% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9% for less than \$15,000, 6.1% for greater than \$50,000). Inability to see a doctor due to cost differed significantly by county, with a range of 7.4% in Franklin County to 17.5% in Power County.

### **Cancer Screening**

Mammogram - 2014, 2016, 2018, 2020

Statewide, 69.1% of women aged 50–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (72.1% versus 36.7%). Mammography rates differed significantly by county, with a range in screening of 45.9% in Benewah County to 77.0% in Nez Perce County. In 2020, Idaho ranked 48<sup>th</sup> among states and the District of Columbia for mammography screening rates among women aged 50–74 and also 48<sup>th</sup> among ages 40+.

### Pap Test - 2018, 2020

Statewide, 71.2% of women with an intact cervix and aged 21–65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.1% versus 52.6% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.7% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49<sup>th</sup> among states and the District of Columbia for Pap screening rate.

### Colorectal Cancer Screening – 2018, 2020

Statewide, 67.9% of adults aged 50–75 reported being current for colorectal cancer screening.\*\* Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked 47<sup>th</sup> among states and the District of Columbia in the percentage of adults aged 50–75 and older who reported being up-to-date for colorectal cancer screening.

<sup>\*\*</sup> Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

### **Tobacco Use**

### Current Tobacco Use - 2016-2021

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.3% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 29.9% of persons aged 18-29, and 11.1% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (22.4%) than among Native Americans (40.0%). Tobacco use differed significantly by county, with a range of 5.4% in Madison County to 41.6% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

### **Other Cancer-Related**

### Healthy Weight by Body Mass Index - 2015-2021

Statewide, 32.1% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 32.5% of white non-Hispanics, compared to 28.2% of Hispanics and 24.6% of Native Americans, being in the healthy weight range. Males (25.5%) were significantly less likely to be in the healthy weight range than females (38.6%). BMI differed significantly by age of respondent, with 43.3% of persons aged 18–29, and 26.0% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 19.8% in Power County to 47.4% in Blaine County of adults being in the healthy weight range.

### Any Physical Activity - 2015-2021

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 78.7% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.3% of persons aged 18–29, and 72.3% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 64.3% in Clark County to 84.6% in Teton County.

Physical Activity Guidelines – 2011, 2013, 2015, 2017, 2019 Statewide, 21.9% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.3% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6% in Franklin County to 30.6% in Blaine County.

### Home Radon Testing - 2016, 2018, 2020

Statewide, 23.0% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.4% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.5% in Cassia County to 54.4% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006l and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.





## ONEIDA COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

### Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

### **RISK FACTORS AND INTERVENTIONS**

### CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/jama.2016.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

### **Aging:**

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

### **Smoking:**

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

### Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <a href="https://www.dietaryguidelines.gov">https://www.dietaryguidelines.gov</a>

### Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute
Cancer Information Services
1-800-4CANCER
<a href="https://www.cancer.gov/contact">https://www.cancer.gov/contact</a>

American Cancer Society <a href="https://www.cancer.org">https://www.cancer.org</a>

### **CANCER INCIDENCE 2016–2020**

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016–2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 104 cases of invasive cancer were diagnosed among Oneida County residents (Table 1).

**Table 1:** Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Oneida County and the State of Idaho, 2016–2020

Cancer Incidence 2016–2020				
All Sites/Types	104	45,610		
Female Breast	9	6,687		
Prostate	12	6,417		
Lung & Bronchus	11	4,887		
Colorectal	7	3,451		

Table 3 (Cancer Incidence 2016–2020, Comparison between Oneida County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Oneida County. The table also shows the number of observed cases, person-

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Oneida County was 469.7 cases per 100,000 person-years per year during 2016–2020. Comparing this crude rate with the crude rate for the remainder of Idaho (520.1) gives an estimate of the relative burden of disease in Oneida County.

The age- and sex-adjusted incidence rate of invasive cancer in Oneida County, all sites combined, was 398.0 cases per 100,000 persons per year during 2016–2020. There were statistically significantly fewer cases of cancer in Oneida County (104) than expected (135.9) based upon rates in the remainder of the state (p=.005).

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

### **CANCER MORTALITY 2017–2021**

During 2017–2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 35 Oneida County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

**Table 2:** Overall and Cancer Mortality in Oneida County and the State of Idaho, 2017–2021

Mortality 2017–2021	Oneida County	State of Idaho
All Deaths	249	77,431
Cancer Deaths	35	15,121
% of All Deaths	14.1%	19.5%
Lung & Bronchus	4	2,961
Colorectal	1	1,319
Pancreas	2	1,190
Female Breast	2	1,086
Prostate	6	949

Table 4 (Cancer Mortality 2017–2021, Comparison between Oneida County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Oneida County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Oneida County, all sites combined, was 121.6 deaths per 100,000 persons per year during 2017–2021, compared with 168.3 for the remainder of the state. There were fewer cancer deaths in Oneida County (35) than expected (48.4) based upon rates in the remainder of the state, but the difference was not statistically significant.

**Statistical Note:** Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

### TABLE 3: CANCER INCIDENCE 2016–2020 COMPARISON BETWEEN ONEIDA COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

		Oneida County						Remainder of Idaho			
Cancer	0	Observed	Person	Crude	A.A.I.	Expected	D. Vl (4)	Observed	Person	Crude	
Site/Type All Sites Combined	Sex	Cases	Years	Rate (1)	Rate (1,2) 398.0	Cases (3) 135.9	P-Value (4)	Cases	Years	Rate (1) 520.1	
All Sites Combined	Total Male	104 68	22,144 11,095	469.7 612.9	396.0 499.4	75.2	0.005 <b>&lt;&lt;</b> 0.445	45,506 24,221	8,749,684 4.385.815	552.3	
All Sites Combined	Female	36	11,049	325.8	285.8	61.4	0.001 <<	21,285	4,363,869	487.8	
Bladder	Total	7	22,144	31.6	25.0	7.0	1.000	2,177	8,749,684	24.9	
Bladder	Male	7	11,095	63.1	48.5	5.7	0.705	1,744	4,385,815	39.8	
Bladder	Female		11,049			1.3	0.522	433	4,363,869	9.9	
Brain - malignant	Total	2	22,144 11.095	9.0	8.1	1.8	1.000	623	8,749,684	7.1	
Brain - malignant Brain - malignant	Male Female	2	11,095	18.0	16.0	1.1 0.7	0.577 0.981	373 250	4,385,815 4,363,869	8.5 5.7	
Brain - manghant Brain and other CNS - non-malignant	Total	- 1	22,144	4.5	3.9	4.1	0.961	1,423	8,749,684	16.3	
Brain and other CNS - non-malignant	Male	i I	11,095	9.0	7.8	1.4	1.000	479	4,385,815	10.9	
Brain and other CNS - non-malignant	Female	-	11,049	-	-	2.7	0.132	944	4,363,869	21.6	
Breast	Total	9	22,144	40.6	35.7	19.4	0.014 <<	6,737	8,749,684	77.0	
Breast	Male .	-	11,095		-	0.2	1.000	59	4,385,815	1.3	
Breast	Female	9	11,049	81.5	73.3	18.8	0.020 <<	6,678	4,363,869	153.0	
Breast - in situ Breast - in situ	Total Male	4	22,144 11,095	18.1	16.4	3.4 0.0	0.902 1.000	1,235 5	8,749,684 4,385,815	14.1 0.1	
Breast - in situ	Female	- 4	11,049	36.2	33.7	3.3	0.860	1,230	4,363,869	28.2	
Cervix	Female	-	11,049	-	-	0.8	0.942	304	4,363,869	7.0	
Colorectal	Total	7	22,144	31.6	26.6	10.3	0.382	3,444	8,749,684	39.4	
Colorectal	Male	5	11,095	45.1	37.4	5.8	0.964	1,898	4,385,815	43.3	
Colorectal	Female	2	11,049	18.1	15.4	4.6	0.324	1,546	4,363,869	35.4	
Corpus Uteri	Female	1	11,049	9.1	8.2	3.7	0.228	1,329	4,363,869	30.5	
Esophagus	Total Male	1	22,144	4.5	3.7	1.6	1.000	505	8,749,684	5.8	
Esophagus Esophagus	маіе Female	_ 1	11,095 11,049	9.0	7.2	1.3 0.2	1.000 1.000	423 82	4,385,815 4,363,869	9.6 1.9	
Hodgkin Lymphoma	Total		22.144			0.2	1.000	210	8,749,684	2.4	
Hodgkin Lymphoma	Male	_	11.095	_	_	0.3	1.000	118	4,385,815	2.7	
Hodgkin Lymphoma	Female	-	11,049	-	-	0.2	1.000	92	4,363,869	2.1	
Kidney and Renal Pelvis	Total	6	22,144	27.1	23.3	5.3	0.880	1,809	8,749,684	20.7	
Kidney and Renal Pelvis	Male .	5	11,095	45.1	38.0	3.5	0.562	1,177	4,385,815	26.8	
Kidney and Renal Pelvis	Female	1	11,049	9.1	7.9	1.8	0.908	632	4,363,869	14.5	
Larynx Larynx	Total Male	-	22,144 11,095	-	-	0.7 0.5	1.000 1.000	215 160	8,749,684 4,385,815	2.5 3.6	
Larynx	Female	_ [	11,049	-	-	0.3	1.000	55	4,363,869	1.3	
Leukemia	Total	7	22,144	31.6	26.3	4.9	0.461	1,624	8,749,684	18.6	
Leukemia	Male	6	11,095	54.1	44.2	3.0	0.177	983	4,385,815	22.4	
Leukemia	Female	1	11,049	9.1	7.6	1.9	0.852	641	4,363,869	14.7	
Liver and Bile Duct	Total	3	22,144	13.5	11.4	2.5	0.906	826	8,749,684	9.4	
Liver and Bile Duct	Male	3	11,095	27.0	22.0	1.8	0.554	587	4,385,815	13.4	
Liver and Bile Duct Lung and Bronchus	Female Total	- 11	11,049 22,144	49.7	- 40.0	0.7 15.3	0.986 0.329	239 4,876	4,363,869 8,749,684	5.5 55.7	
Lung and Bronchus	Male	8	11,095	72.1	56.4	7.9	1.000	2,444	4,385,815	55.7 55.7	
Lung and Bronchus	Female	3	11,049	27.2	22.5	7.4	0.123	2,432	4,363,869	55.7	
Melanoma of the Skin	Total	7	22,144	31.6	27.5	8.5	0.760	2,935	8,749,684	33.5	
Melanoma of the Skin	Male	5	11,095	45.1	37.3	5.4	1.000	1,760	4,385,815	40.1	
Melanoma of the Skin	Female	2	11,049	18.1	16.6	3.2	0.743	1,175	4,363,869	26.9	
Myeloma	Total	1	22,144	4.5	3.7	2.2	0.710	707	8,749,684	8.1	
Myeloma Myeloma	Male Female	1	11,095 11,049	9.0	7.1	1.4 0.8	1.000 0.890	440 267	4,385,815 4,363,869	10.0 6.1	
Non-Hodgkin Lymphoma	Total	- 3	22,144	13.5	- 11.4	5.8	0.890	1,937	8,749,684	22.1	
Non-Hodgkin Lymphoma	Male	1	11,095	9.0	7.4	3.5	0.337	1,937	4,385,815	25.7	
Non-Hodgkin Lýmphoma	Female	2	11,049	18.1	15.4	2.4	1.000	809	4,363,869	18.5	
Oral Cavity and Pharynx	Total	-	22,144	•	-	3.8	0.044 <<	1,295	8,749,684	14.8	
Oral Cavity and Pharynx	Male	-	11,095	-	-	2.8	0.116	936	4,385,815	21.3	
Oral Cavity and Pharynx	Female	-	11,049	-	-	1.0	0.710	359	4,363,869	8.2	
Ovary	Female	4	11,049	36.2	32.2	1.5	0.133	529	4,363,869	12.1	
Pancreas Pancreas	Total Male	3 2	22,144 11,095	13.5 18.0	10.9 14.2	4.5 2.5	0.698 1.000	1,420 782	8,749,684 4,385,815	16.2 17.8	
Pancreas	Female	1	11,095	9.1	7.4	2.5	0.826	638	4,363,869	14.6	
Prostate	Male	12	11,095	108.2	87.8	20.0	0.079	6,405	4,385,815	146.0	
Stomach	Total	1	22,144	4.5	3.7	1.4	1.000	466	8,749,684	5.3	
Stomach	Male	1	11,095	9.0	7.2	1.0	1.000	308	4,385,815	7.0	
Stomach	Female	-	11,049	-	-	0.5	1.000	158	4,363,869	3.6	
Testis	Male		11,095	-	-	0.6	1.000	265	4,385,815	6.0	
Thyroid	Total	2	22,144	9.0	9.1	3.1	0.818	1,218	8,749,684	13.9	
Thyroid	Male		11,095	-	-	0.9	0.774	355	4,385,815	8.1	
Thyroid	Female	2	11,049	18.1	18.7	2.1	1.000	863	4,363,869	19.8	
Pediatric Age 0 to 19	Total	3	6,798	44.1	45.0	1.1	0.214	418	2,453,725	17.0	
Pediatric Age 0 to 19 Pediatric Age 0 to 19	Male Female	- 3	3,480	- 90.4	- 92.6	0.6 0.5	1.000 0.033 >>	223 195	1,253,030 1,200,695	17.8 16.2	
·	1. Rates ar		3,318					193	1,200,093	10.2	

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

<sup>2.</sup> Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

<sup>&</sup>quot;<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

### **TABLE 4: CANCER MORTALITY 2017–2021** COMPARISON BETWEEN ONEIDA COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			On	eida County	/			Re	Remainder of Idaho			
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude		
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)		
All Causes of Death	Total	249	22,453	1,109.0	833.4	257.2	0.637	77,181	8,966,262	860.8		
All Causes of Death	Male	145	11,293	1,284.0	984.5	133.9	0.357	40,911	4,500,575	909.0		
All Causes of Death	Female	104	11,160	931.9	679.9	124.2	0.071	36,270	4,465,687	812.2		
All Malignant Cancers	Total	35	22,453	155.9	121.6	48.4	0.054	15,086	8,966,262	168.3		
All Malignant Cancers	Male	25	11,293	221.4	168.9	26.8	0.824	8,151	4,500,575	181.1		
All Malignant Cancers	Female	10	11,160	89.6	71.4	21.8	0.008 <<	6,935	4,465,687	155.3		
Bladder	Total	1	22,453	4.5	3.2	1.7	0.986	488	8,966,262	5.4		
Bladder Bladder	Male	1	11,293 11,160	8.9	6.3	1.3 0.4	1.000	377	4,500,575	8.4		
Brain and Other Nervous System	Female Total	- 2	22,453	8.9	7.6	1.5	1.000 0.865	111 502	4,465,687 8,966,262	2.5 5.6		
Brain and Other Nervous System	Male	2	11,293	17.7	14.8	0.9	0.448	296	4,500,575	6.6		
Brain and Other Nervous System	Female		11,160	-	-	0.6	1.000	206	4,465,687	4.6		
Breast	Total	2	22,453	8.9	7.1	3.5	0.660	1,100	8,966,262	12.3		
Breast	Male	-	11,293	-	-	0.1	1.000	16	4,500,575	0.4		
Breast	Female	2	11,160	17.9	14.6	3.3	0.705	1,084	4,465,687	24.3		
Cervix	Female	-	11,160	-	-	0.2	1.000	83	4,465,687	1.9		
Colorectal	Total	1	22,453	4.5	3.5	4.2	0.159	1,318	8,966,262	14.7		
Colorectal	Male	1	11,293	8.9	7.0	2.3	0.671	718	4,500,575	16.0		
Colorectal	Female	-	11,160	-	-	1.9	0.293	600	4,465,687	13.4		
Corpus Uteri	Female Total	- 1	11,160 22,453	4.5	3.6	0.5 1.5	1.000 1.000	173 476	4,465,687	3.9 5.3		
Esophagus Esophagus	Male	1	11,293	4.5 8.9	3.0 6.9	1.3	1.000	400	8,966,262 4,500,575	5.3 8.9		
Esophagus Esophagus	Female	_ '	11,160	0.9	0.9	0.2	1.000	76	4,465,687	1.7		
Hodgkin Lymphoma	Total	_	22,453	-	_	0.1	1.000	29	8,966,262	0.3		
Hodgkin Lymphoma	Male	_	11,293	_	_	0.0	1.000	14	4,500,575	0.3		
Hodgkin Lymphoma	Female	-	11,160	-	-	0.0	1.000	15	4,465,687	0.3		
Kidney	Total	2	22,453	8.9	6.9	1.2	0.707	383	8,966,262	4.3		
Kidney	Male	2	11,293	17.7	13.6	0.8	0.370	240	4,500,575	5.3		
Kidney	Female	-	11,160	-	-	0.5	1.000	143	4,465,687	3.2		
Larynx	Total	1	22,453	4.5	3.5	0.2	0.400	70	8,966,262	0.8		
Larynx	Male	1	11,293	8.9	6.6	0.2	0.347	57	4,500,575	1.3		
Larynx	Female	- 1	11,160	4.5	3.4	0.0	1.000	13	4,465,687	0.3		
Leukemia Leukemia	Total Male	1	22,453 11,293	4.5 8.9	3.4 6.7	2.2 1.3	0.722 1.000	659 385	8,966,262 4,500,575	7.3 8.6		
Leukemia	Female	_ '	11,160	6.9	0.7	0.9	0.805	274	4,465,687	6.1		
Liver and Bile Duct	Total	1	22,453	4.5	3.6	1.9	0.892	602	8,966,262	6.7		
Liver and Bile Duct	Male	1	11,293	8.9	7.0	1.3	1.000	407	4,500,575	9.0		
Liver and Bile Duct	Female	-	11,160	-	-	0.6	1.000	195	4,465,687	4.4		
Lung and Bronchus	Total	4	22,453	17.8	13.9	9.5	0.082	2,957	8,966,262	33.0		
Lung and Bronchus	Male	4	11,293	35.4	27.1	5.1	0.849	1,552	4,500,575	34.5		
Lung and Bronchus	Female	-	11,160	-	-	4.4	0.024 <<	1,405	4,465,687	31.5		
Melanoma of the Skin	Total	-	22,453	-	-	0.9	0.808	289	8,966,262	3.2		
Melanoma of the Skin	Male	-	11,293	-	-	0.6	1.000	192	4,500,575	4.3		
Melanoma of the Skin	Female Total	- 1	11,160 22,453	4.5	3.4	0.3 1.1	1.000 1.000	97 330	4,465,687 8,966,262	2.2 3.7		
Myeloma Myeloma	Male	1	11,293	4.5 8.9	5.4 6.6	0.7	0.967	195	4,500,575	4.3		
Myeloma	Female	_ '	11,160	- 0.9	- 0.0	0.7	1.000	135	4,465,687	3.0		
Non-Hodgkin Lymphoma	Total	3	22,453	13.4	10.2	1.9	0.569	566	8,966,262	6.3		
Non-Hodgkin Lymphoma	Male	-	11,293	-	-	1.0	0.728	307	4,500,575	6.8		
Non-Hodgkin Lymphoma	Female	3	11,160	26.9	20.3	0.9	0.112	259	4,465,687	5.8		
Oral Cavity and Pharynx	Total	-	22,453	-	-	8.0	0.877	266	8,966,262	3.0		
Oral Cavity and Pharynx	Male	-	11,293	-	-	0.6	1.000	187	4,500,575	4.2		
Oral Cavity and Pharynx	Female	-	11,160	-	-	0.2	1.000	79	4,465,687	1.8		
Ovary	Female	1	11,160	9.0	7.4	1.1	1.000	349	4,465,687	7.8		
Pancreas Pancreas	Total	2 1	22,453 11,293	8.9 8.9	7.1 6.0	3.8	0.553 0.775	1,188 641	8,966,262 4,500,575	13.2 14.2		
Pancreas Pancreas	Male Female	1	11,293	9.0	6.9 7.2	2.1 1.7	0.775	641 547	4,500,575 4,465,687	14.2		
Prostate	Male	6	11,100	53.1	37.7	3.3	0.969	943	4,500,575	21.0		
Stomach	Total	-	22,453	-	-	0.6	1.000	198	8,966,262	2.2		
Stomach	Male	-	11,293	-	-	0.4	1.000	121	4,500,575	2.7		
Stomach	Female	-	11,160	_	_	0.2	1.000	77	4,465,687	1.7		
		a avaraged on the	ne number of cases i	100 000					,,			

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

<sup>2.</sup> Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

### Cancer Screening and Risk Factor Prevalence Estimates, 2011–2021

	State of								Oneida
Measure	Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	County
Access to Care									
Have Health Insurance, Age <65 (2015–2021)	83.1%	82.8%	85.1%	77.2%	85.8%	78.9%	85.4%	85.4%	91.6%
Not See Doctor Due to Cost in Past Year (2015–2021)	12.6%	11.4%	11.8%	14.5%	12.4%	12.3%	11.8%	12.9%	12.0%
Cancer Screening									
Mammogram Past 2 Years, Age 50–74 (2014, 2016, 2018, 2020)	69.1%	67.0%	73.8%	68.2%	73.2%	64.8%	64.5%	67.1%	
Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020)	71.2%	73.6%	73.6%	70.8%	72.9%	69.1%	69.5%	65.9%	
Colorectal Cancer Screening, Age 50–75 (2018, 2020)	67.9%	66.9%	73.6%	71.4%	70.6%	61.7%	61.5%	64.7%	56.3%
Tobacco Use									
Current Tobacco User (2016–2021)	22.3%	26.7%	23.1%	23.6%	21.8%	21.4%	22.7%	16.9%	26.1%
Other Cancer-Related									
Healthy Weight by Body Mass Index, Age 20+ (2015–2021)	32.1%	32.8%	31.7%	27.9%	36.1%	29.8%	27.9%	31.9%	30.6%
Any Physical Activity Besides Job Past 30 Days (2015-2021)	78.7%	79.2%	78.1%	74.5%	83.2%	73.4%	76.3%	79.7%	66.8%
Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019)	21.9%	22.8%	19.4%	20.0%	25.2%	19.5%	20.4%	20.2%	11.1%
Home Ever Tested for Radon (2016, 2018, 2020)	23.0%	30.9%	18.2%	16.9%	25.1%	19.9%	23.0%	21.8%	12.6%

### **Access to Care**

### Have Health Insurance – 2015–2021

Statewide, 83.1% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 86.0% of white non-Hispanics, compared to 64.8% of Hispanics and 83.3% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3%) than English-speaking respondents (84.2%). Health care coverage differed significantly by age of respondent, with 79.8% of persons aged 18–29, and 87.8% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 62.1% in Adams County to 91.6% in Oneida County having health insurance.

### Not See Doctor Due to Cost in Past Year - 2015-2021

Statewide, 12.6% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (11.5% of white non-Hispanics, 19.2% of Hispanics, and 21.0% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9% for less than \$15,000, 6.1% for greater than \$50,000). Inability to see a doctor due to cost differed significantly by county, with a range of 7.4% in Franklin County to 17.5% in Power County.

### **Cancer Screening**

Mammogram - 2014, 2016, 2018, 2020

Statewide, 69.1% of women aged 50–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (72.1% versus 36.7%). Mammography rates differed significantly by county, with a range in screening of 45.9% in Benewah County to 77.0% in Nez Perce County. In 2020, Idaho ranked 48<sup>th</sup> among states and the District of Columbia for mammography screening rates among women aged 50–74 and also 48<sup>th</sup> among ages 40+.

### Pap Test - 2018, 2020

Statewide, 71.2% of women with an intact cervix and aged 21–65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.1% versus 52.6% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.7% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49<sup>th</sup> among states and the District of Columbia for Pap screening rate.

### Colorectal Cancer Screening – 2018, 2020

Statewide, 67.9% of adults aged 50–75 reported being current for colorectal cancer screening.\*\* Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked 47<sup>th</sup> among states and the District of Columbia in the percentage of adults aged 50–75 and older who reported being up-to-date for colorectal cancer screening.

<sup>\*\*</sup> Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

### **Tobacco Use**

### Current Tobacco Use - 2016-2021

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.3% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 29.9% of persons aged 18-29, and 11.1% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (22.4%) than among Native Americans (40.0%). Tobacco use differed significantly by county, with a range of 5.4% in Madison County to 41.6% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

### **Other Cancer-Related**

### Healthy Weight by Body Mass Index - 2015-2021

Statewide, 32.1% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 32.5% of white non-Hispanics, compared to 28.2% of Hispanics and 24.6% of Native Americans, being in the healthy weight range. Males (25.5%) were significantly less likely to be in the healthy weight range than females (38.6%). BMI differed significantly by age of respondent, with 43.3% of persons aged 18–29, and 26.0% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 19.8% in Power County to 47.4% in Blaine County of adults being in the healthy weight range.

### Any Physical Activity - 2015-2021

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 78.7% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.3% of persons aged 18–29, and 72.3% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 64.3% in Clark County to 84.6% in Teton County.

Physical Activity Guidelines – 2011, 2013, 2015, 2017, 2019 Statewide, 21.9% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.3% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6% in Franklin County to 30.6% in Blaine County.

### Home Radon Testing - 2016, 2018, 2020

Statewide, 23.0% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.4% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.5% in Cassia County to 54.4% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006l and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.





# OWYHEE COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

### Cancer Incidence 2016–2020 Cancer Mortality 2017–2021 BRFSS 2011–2021

### **RISK FACTORS AND INTERVENTIONS**

### CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/jama.2016.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

### Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

### **Smoking:**

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

### Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <a href="https://www.dietaryguidelines.gov">https://www.dietaryguidelines.gov</a>

### Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute
Cancer Information Services
1-800-4CANCER
<a href="https://www.cancer.gov/contact">https://www.cancer.gov/contact</a>

American Cancer Society <a href="https://www.cancer.org">https://www.cancer.org</a>

### **CANCER INCIDENCE 2016–2020**

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016–2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 309 cases of invasive cancer were diagnosed among Owyhee County residents (Table 1).

**Table 1:** Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Owyhee County and the State of Idaho, 2016–2020

Cancer Incidence 2016–2020	Owyhee County	State of Idaho
All Sites/Types	309	45,610
Female Breast	56	6,687
Prostate	42	6,417
Lung & Bronchus	30	4,887
Colorectal	22	3,451

Table 3 (Cancer Incidence 2016–2020, Comparison between Owyhee County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Owyhee County. The table also shows the number of observed cases, person-

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Owyhee County was 527.1 cases per 100,000 person-years per year during 2016–2020. Comparing this crude rate with the crude rate for the remainder of Idaho (519.9) gives an estimate of the relative burden of disease in Owyhee County.

The age- and sex-adjusted incidence rate of invasive cancer in Owyhee County, all sites combined, was 481.6 cases per 100,000 persons per year during 2016–2020. There were fewer cases of cancer in Owyhee County (309) than expected (333.6) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

### **CANCER MORTALITY 2017–2021**

During 2017–2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 112 Owyhee County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

**Table 2:** Overall and Cancer Mortality in Owyhee County and the State of Idaho, 2017–2021

Mortality 2017–2021	Owyhee County	State of Idaho
All Deaths	591	77,431
Cancer Deaths	112	15,121
% of All Deaths	19.0%	19.5%
Lung & Bronchus	16	2,961
Colorectal	14	1,319
Pancreas	16	1,190
Female Breast	5	1,086
Prostate	9	949

Table 4 (Cancer Mortality 2017–2021, Comparison between Owyhee County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Owyhee County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Owyhee County, all sites combined, was 170.3 deaths per 100,000 persons per year during 2017–2021, compared with 168.1 for the remainder of the state. There were more cancer deaths in Owyhee County (112) than expected (110.5) based upon rates in the remainder of the state, but the difference was not statistically significant.

**Statistical Note:** Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

### TABLE 3: CANCER INCIDENCE 2016–2020 COMPARISON BETWEEN OWYHEE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

		Owyhee County						Remainder of Idaho		
Cancer		Observed	Person	Crude	A.A.I.	Expected	D./ I. //	Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)
All Sites Combined All Sites Combined	Total	309 163	58,620 29,887	527.1 545.4	481.6 474.1	333.6 190.0	0.185 0.051	45,301 24,126	8,713,208 4,367,023	519.9 552.5
All Sites Combined	Male Female	146	29,007	545.4 508.1	483.4	190.0	0.051	24,126	4,367,023	487.2
Bladder	Total	9	58.620	15.4	13.8	16.3	0.074	2,175	8,713,208	25.0
Bladder	Male	9	29,887	30.1	25.5	14.1	0.210	1,742	4,367,023	39.9
Bladder	Female	-	28,733	-	-	3.0	0.096	433	4,346,185	10.0
Brain - malignant	Total	2	58,620	3.4	3.2	4.5	0.356	623	8,713,208	7.2
Brain - malignant	Male	1	29,887	3.3	3.1	2.8	0.464	374	4,367,023	8.6
Brain - malignant	Female	1	28,733	3.5	3.4	1.7	0.981	249	4,346,185	5.7
Brain and other CNS - non-malignant	Total Male	7 2	58,620 29,887	11.9 6.7	11.1 6.1	10.2 3.6	0.397 0.602	1,417	8,713,208 4,367,023	16.3 10.9
Brain and other CNS - non-malignant Brain and other CNS - non-malignant	Female	5	29,007	17.4	16.6	6.5	0.002	478 939	4,346,185	21.6
Breast	Total	56	58,620	95.5	88.1	48.8	0.338	6,690	8,713,208	76.8
Breast	Male	-	29,887	-	-	0.5	1.000	59	4,367,023	1.4
Breast	Female	56	28,733	194.9	184.7	46.3	0.180	6,631	4,346,185	152.6
Breast - in situ	Total	9	58,620	15.4	14.2	9.0	1.000	1,230	8,713,208	14.1
Breast - in situ	Male	- 0	29,887	-		0.0	1.000	5	4,367,023	0.1
Breast - in situ	Female	9	28,733	31.3	29.5	8.6	0.980	1,225	4,346,185	28.2
Cervix Colorectal	Female Total	2 22	28,733 58,620	7.0 37.5	7.0 34.2	2.0 25.3	1.000 0.596	302 3,429	4,346,185 8,713,208	6.9 39.4
Colorectal	Male	15	29,887	50.2	43.9	14.8	1.000	1,888	4,367,023	43.2
Colorectal	Female	7	28,733	24.4	23.1	10.7	0.323	1,541	4,346,185	35.5
Corpus Uteri	Female	12	28,733	41.8	39.6	9.2	0.434	1,318	4,346,185	30.3
Esophagus	Total	1	58,620	1.7	1.5	3.8	0.220	505	8,713,208	5.8
Esophagus	Male	1	29,887	3.3	2.9	3.4	0.299	423	4,367,023	9.7
Esophagus	Female		28,733			0.6	1.000	82	4,346,185	1.9
Hodgkin Lymphoma	Total	2	58,620	3.4	3.4	1.4	0.824	208	8,713,208	2.4
Hodgkin Lymphoma	Male	2	29,887	6.7	6.6	0.8	0.388	116	4,367,023	2.7
Hodgkin Lymphoma Kidney and Renal Pelvis	Female Total	- 15	28,733 58,620	- 25.6	23.4	0.6 13.2	1.000 0.698	92 1,800	4,346,185 8,713,208	2.1 20.7
Kidney and Renal Pelvis	Male	12	29,887	40.2	35.4	9.1	0.409	1,000	4,367,023	26.8
Kidney and Renal Pelvis	Female	3	28,733	10.4	9.9	4.4	0.717	630	4,346,185	14.5
Larynx	Total	3	58,620	5.1	4.6	1.6	0.426	212	8,713,208	2.4
Larynx	Male	3	29,887	10.0	8.5	1.3	0.269	157	4,367,023	3.6
Larynx	Female	-	28,733	-	-	0.4	1.000	55	4,346,185	1.3
Leukemia	Total	7	58,620	11.9	10.9	12.0	0.183	1,624	8,713,208	18.6
Leukemia	Male	5	29,887	16.7	14.6	7.7	0.442	984	4,367,023	22.5
Leukemia Liver and Bile Duct	Female Total	7	28,733 58,620	7.0 11.9	6.6 10.8	4.5 6.1	0.355 0.822	640 822	4,346,185 8,713,208	14.7 9.4
Liver and Bile Duct	Male	4	29,887	13.4	11.6	4.6	1.000	586	4,367,023	13.4
Liver and Bile Duct	Female	3	28,733	10.4	9.8	1.7	0.462	236	4,346,185	5.4
Lung and Bronchus	Total	30	58,620	51.2	45.8	36.5	0.319	4,857	8,713,208	55.7
Lung and Bronchus	Male	17	29,887	56.9	48.4	19.6	0.659	2,435	4,367,023	55.8
Lung and Bronchus	Female	13	28,733	45.2	42.3	17.1	0.387	2,422	4,346,185	55.7
Melanoma of the Skin	Total	12	58,620	20.5	19.0	21.3	0.043 <<	2,930	8,713,208	33.6
Melanoma of the Skin	Male	8	29,887	26.8	23.5	13.7	0.144	1,757	4,367,023	40.2
Melanoma of the Skin	Female	4	28,733	13.9	13.5	8.0 5.3	0.200	1,173	4,346,185	27.0
Myeloma Myeloma	Total Male	2 2	58,620 29,887	3.4 6.7	3.1 5.7	3.5	0.205 0.640	706 439	8,713,208 4,367,023	8.1 10.1
Myeloma Myeloma	Female		29,007	0.7	5.7	1.9	0.040	267	4,367,023	6.1
Non-Hodgkin Lymphoma	Total	21	58,620	35.8	32.7	14.1	0.103	1,919	8,713,208	22.0
Non-Hodgkin Lymphoma	Male	8	29,887	26.8	23.6	8.7	0.995	1,121	4,367,023	25.7
Non-Hodgkin Lymphoma	Female	13	28,733	45.2	42.9	5.6	0.010 >>	798	4,346,185	18.4
Oral Cavity and Pharynx	Total	10	58,620	17.1	15.5	9.5	0.955	1,285	8,713,208	14.7
Oral Cavity and Pharynx	Male	8	29,887	26.8	23.4	7.3	0.881	928	4,367,023	21.3
Oral Cavity and Pharynx	Female	2	28,733	7.0	6.6	2.5	1.000	357	4,346,185	8.2
Ovary Pancreas	Female Total	8 17	28,733 58,620	27.8 29.0	26.4 26.1	3.7 10.5	0.066 0.079	525 1,406	4,346,185 8,713,208	12.1 16.1
Pancreas	Male	9	29,887	30.1	25.7	6.2	0.349	775	4,367,023	17.7
Pancreas	Female	8	28,733	27.8	26.3	4.4	0.159	631	4,346,185	14.5
Prostate	Male	42	29,887	140.5	121.4	50.5	0.257	6,375	4,367,023	146.0
Stomach	Total	4	58,620	6.8	6.2	3.4	0.897	463	8,713,208	5.3
Stomach	Male	4	29,887	13.4	11.5	2.4	0.457	305	4,367,023	7.0
Stomach	Female	-	28,733	-	-	1.1	0.680	158	4,346,185	3.6
Testis	Male	1	29,887	3.3	3.6	1.7	1.000	264	4,367,023	6.0
Thyroid	Total	5	58,620	8.5	8.4	8.3	0.334	1,215	8,713,208	13.9
Thyroid	Male	3	29,887	10.0	9.5	2.5	0.932	352	4,367,023	8.1
Thyroid	Female	2	28,733	7.0	7.0	5.7	0.154	863	4,346,185	19.9
Pediatric Age 0 to 19	Total	2	16,664	12.0	12.0	2.9	0.913	419	2,443,859	17.1
Pediatric Age 0 to 19	Male	1	8,485	11.8	11.8	1.5	1.000	222	1,248,025	17.8
Pediatric Age 0 to 19	Female	1	8,179	12.2	12.2	1.3	1.000	197	1,195,834	16.5

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

<sup>2.</sup> Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

<sup>&</sup>quot;<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

### **TABLE 4: CANCER MORTALITY 2017–2021** COMPARISON BETWEEN OWYHEE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

		Owyhee County					Remainder of Idaho			
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	591	59,588	991.8	906.6	561.0	0.214	76,839	8,929,127	860.5
All Causes of Death	Male	350	30,387	1,151.8	986.7	322.2	0.131	40,706	4,481,481	908.3
All Causes of Death	Female	241	29,201	825.3	805.3	243.1	0.925	36,133	4,447,646	812.4
All Malignant Cancers	Total	112	59,588	188.0	170.3	110.5	0.914	15,009	8,929,127	168.1
All Malignant Cancers	Male	68	30,387	223.8	190.6	64.5	0.700	8,108	4,481,481	180.9
All Malignant Cancers	Female	44	29,201	150.7	143.8	47.5	0.679	6,901	4,447,646	155.2
Bladder	Total	2	59,588	3.4	3.0	3.6	0.602	487	8,929,127	5.5
Bladder	Male	1	30,387	3.3	2.7	3.1	0.368	377	4,481,481	8.4
Bladder	Female	1	29,201	3.4	3.3	0.7	1.000	110	4,447,646	2.5
Brain and Other Nervous System	Total	-	59,588	-	-	3.6	0.052	504	8,929,127	5.6
Brain and Other Nervous System Brain and Other Nervous System	Male Female	-	30,387 29,201	-	-	2.3 1.4	0.206 0.486	298 206	4,481,481 4,447,646	6.6 4.6
Breast	Total	5	59,588	8.4	7.7	8.0	0.480	1,097	8.929.127	12.3
Breast	Male	-	30,387	-	7.7	0.1	1.000	1,037	4,481,481	0.4
Breast	Female	5	29,201	17.1	16.4	7.4	0.503	1,081	4,447,646	24.3
Cervix	Female	-	29,201	-	-	0.6	1.000	83	4,447,646	1.9
Colorectal	Total	14	59,588	23.5	21.4	9.6	0.213	1,305	8,929,127	14.6
Colorectal	Male	11	30,387	36.2	31.3	5.6	0.054	708	4,481,481	15.8
Colorectal	Female	3	29,201	10.3	9.8	4.1	0.829	597	4,447,646	13.4
Corpus Uteri	Female	2	29,201	6.8	6.5	1.2	0.660	171	4,447,646	3.8
Esophagus	Total	3	59,588	5.0	4.6	3.5	1.000	474	8,929,127	5.3
Esophagus	Male	3	30,387	9.9	8.5	3.1	1.000	398	4,481,481	8.9
Esophagus	Female	-	29,201	-	-	0.5	1.000	76	4,447,646	1.7
Hodgkin Lymphoma	Total	-	59,588	-	-	0.2	1.000	29	8,929,127	0.3
Hodgkin Lymphoma	Male	-	30,387	-	-	0.1	1.000	14	4,481,481	0.3 0.3
Hodgkin Lymphoma Kidney	Female Total		29,201 59,588	8.4	7.6	0.1 2.8	1.000 0.306	15 380	4,447,646 8,929,127	4.3
Kidney	Male	5 2	30,387	6.6	7.6 5.6	1.9	1.000	240	4,481,481	5.4
Kidney	Female	3	29,201	10.3	9.8	1.9	0.147	140	4,447,646	3.4
Larynx	Total	-	59,588	-	-	0.5	1.000	71	8,929,127	0.8
Larynx	Male	_	30,387	_	_	0.5	1.000	58	4,481,481	1.3
Larynx	Female	-	29,201	_	-	0.1	1.000	13	4,447,646	0.3
Leukemia	Total	2	59,588	3.4	3.0	4.8	0.278	658	8,929,127	7.4
Leukemia	Male	1	30,387	3.3	2.8	3.1	0.379	385	4,481,481	8.6
Leukemia	Female	1	29,201	3.4	3.3	1.9	0.885	273	4,447,646	6.1
Liver and Bile Duct	Total	4	59,588	6.7	6.1	4.4	1.000	599	8,929,127	6.7
Liver and Bile Duct	Male	3	30,387	9.9	8.5	3.2	1.000	405	4,481,481	9.0
Liver and Bile Duct	Female	1	29,201	3.4	3.2	1.3	1.000	194	4,447,646	4.4
Lung and Bronchus	Total	16	59,588	26.9	24.2	21.8	0.249	2,945	8,929,127	33.0
Lung and Bronchus	Male	6 10	30,387 29,201	19.7 34.2	16.9 32.4	12.3 9.7	0.077 1.000	1,550 1,395	4,481,481 4,447,646	34.6 31.4
Lung and Bronchus Melanoma of the Skin	Female Total	2	59,588	34.2	32.4	2.1	1.000	287	8,929,127	31.4
Melanoma of the Skin	Male	1	30,387	3.4	2.8	1.5	1.000	191	4,481,481	4.3
Melanoma of the Skin	Female	1	29,201	3.4	3.3	0.7	0.966	96	4,447,646	2.2
Myeloma	Total	3	59,588	5.0	4.5	2.4	0.884	328	8,929,127	3.7
Myeloma	Male	3	30,387	9.9	8.3	1.6	0.411	193	4,481,481	4.3
Myeloma	Female	-	29,201	-	-	0.9	0.781	135	4,447,646	3.0
Nón-Hodgkin Lymphoma	Total	4	59,588	6.7	6.0	4.2	1.000	565	8,929,127	6.3
Non-Hodgkin Lymphoma	Male	2	30,387	6.6	5.6	2.4	1.000	305	4,481,481	6.8
Non-Hodgkin Lymphoma	Female	2	29,201	6.8	6.5	1.8	1.000	260	4,447,646	5.8
Oral Cavity and Pharynx	Total	2	59,588	3.4	3.0	1.9	1.000	264	8,929,127	3.0
Oral Cavity and Pharmy	Male	1 1	30,387	3.3	2.8	1.5	1.000	186	4,481,481	4.2
Oral Cavity and Pharynx	Female	1	29,201	3.4	3.3	0.5	0.829	78	4,447,646	1.8
Ovary	Female	1 16	29,201 59,588	3.4 26.9	3.3 24.3	2.4	0.611 0.032 >>	349	4,447,646 8,929,127	7.8
Pancreas Pancreas	Total Male	10	30,387	26.9 32.9	24.3 28.3	8.7 5.0	0.032 >>	1,174 632	8,929,12 <i>1</i> 4,481,481	13.1 14.1
Pancreas	Female	6	29,201	20.5	19.5	3.7	0.003	542	4,447,646	12.2
Prostate	Male	9	30,387	29.6	24.4	7.7	0.332	940	4,481,481	21.0
Stomach	Total	4	59,588	6.7	6.1	1.4	0.112	194	8,929,127	2.2
Stomach	Male	4	30,387	13.2	11.3	0.9	0.030 >>	117	4,481,481	2.6
Stomach	Female	_ `	29,201	-	-	0.5	1.000	77	4,447,646	1.7
			ne number of cases i	100.000					., , 0	

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

<sup>2.</sup> Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

### Cancer Screening and Risk Factor Prevalence Estimates, 2011–2021

	State of								Owyhee
Measure	Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	County
Access to Care									
Have Health Insurance, Age <65 (2015–2021)	83.1%	82.8%	85.1%	77.2%	85.8%	78.9%	85.4%	85.4%	69.1%
Not See Doctor Due to Cost in Past Year (2015–2021)	12.6%	11.4%	11.8%	14.5%	12.4%	12.3%	11.8%	12.9%	12.2%
Cancer Screening									
Mammogram Past 2 Years, Age 50–74 (2014, 2016, 2018, 2020)	69.1%	67.0%	73.8%	68.2%	73.2%	64.8%	64.5%	67.1%	
Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020)	71.2%	73.6%	73.6%	70.8%	72.9%	69.1%	69.5%	65.9%	
Colorectal Cancer Screening, Age 50–75 (2018, 2020)	67.9%	66.9%	73.6%	71.4%	70.6%	61.7%	61.5%	64.7%	
Tobacco Use									
Current Tobacco User (2016–2021)	22.3%	26.7%	23.1%	23.6%	21.8%	21.4%	22.7%	16.9%	22.1%
Other Cancer-Related									
Healthy Weight by Body Mass Index, Age 20+ (2015–2021)	32.1%	32.8%	31.7%	27.9%	36.1%	29.8%	27.9%	31.9%	23.4%
Any Physical Activity Besides Job Past 30 Days (2015-2021)	78.7%	79.2%	78.1%	74.5%	83.2%	73.4%	76.3%	79.7%	71.5%
Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019)	21.9%	22.8%	19.4%	20.0%	25.2%	19.5%	20.4%	20.2%	25.9%
Home Ever Tested for Radon (2016, 2018, 2020)	23.0%	30.9%	18.2%	16.9%	25.1%	19.9%	23.0%	21.8%	16.7%

### **Access to Care**

### Have Health Insurance - 2015-2021

Statewide, 83.1% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 86.0% of white non-Hispanics, compared to 64.8% of Hispanics and 83.3% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3%) than English-speaking respondents (84.2%). Health care coverage differed significantly by age of respondent, with 79.8% of persons aged 18–29, and 87.8% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 62.1% in Adams County to 91.6% in Oneida County having health insurance.

### Not See Doctor Due to Cost in Past Year – 2015–2021

Statewide, 12.6% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (11.5% of white non-Hispanics, 19.2% of Hispanics, and 21.0% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9% for less than \$15,000, 6.1% for greater than \$50,000). Inability to see a doctor due to cost differed significantly by county, with a range of 7.4% in Franklin County to 17.5% in Power County.

### **Cancer Screening**

Mammogram - 2014, 2016, 2018, 2020

Statewide, 69.1% of women aged 50–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (72.1% versus 36.7%). Mammography rates differed significantly by county, with a range in screening of 45.9% in Benewah County to 77.0% in Nez Perce County. In 2020, Idaho ranked 48<sup>th</sup> among states and the District of Columbia for mammography screening rates among women aged 50–74 and also 48<sup>th</sup> among ages 40+.

### Pap Test – 2018, 2020

Statewide, 71.2% of women with an intact cervix and aged 21–65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.1% versus 52.6% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.7% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49<sup>th</sup> among states and the District of Columbia for Pap screening rate.

### Colorectal Cancer Screening – 2018, 2020

Statewide, 67.9% of adults aged 50–75 reported being current for colorectal cancer screening.\*\* Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked 47<sup>th</sup> among states and the District of Columbia in the percentage of adults aged 50–75 and older who reported being up-to-date for colorectal cancer screening.

<sup>\*\*</sup> Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

### **Tobacco Use**

### Current Tobacco Use - 2016-2021

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.3% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 29.9% of persons aged 18-29, and 11.1% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (22.4%) than among Native Americans (40.0%). Tobacco use differed significantly by county, with a range of 5.4% in Madison County to 41.6% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

### **Other Cancer-Related**

### Healthy Weight by Body Mass Index - 2015-2021

Statewide, 32.1% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 32.5% of white non-Hispanics, compared to 28.2% of Hispanics and 24.6% of Native Americans, being in the healthy weight range. Males (25.5%) were significantly less likely to be in the healthy weight range than females (38.6%). BMI differed significantly by age of respondent, with 43.3% of persons aged 18–29, and 26.0% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 19.8% in Power County to 47.4% in Blaine County of adults being in the healthy weight range.

### Any Physical Activity - 2015-2021

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 78.7% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.3% of persons aged 18–29, and 72.3% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 64.3% in Clark County to 84.6% in Teton County.

Physical Activity Guidelines – 2011, 2013, 2015, 2017, 2019 Statewide, 21.9% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.3% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6% in Franklin County to 30.6% in Blaine County.

### Home Radon Testing - 2016, 2018, 2020

Statewide, 23.0% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.4% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.5% in Cassia County to 54.4% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006l and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.





# PAYETTE COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

### Cancer Incidence 2016–2020 Cancer Mortality 2017–2021 BRFSS 2011–2021

### **RISK FACTORS AND INTERVENTIONS**

### **CANCER**

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/jama.2016.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

### Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

### **Smoking:**

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

### Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <a href="https://www.dietaryguidelines.gov">https://www.dietaryguidelines.gov</a>

### Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute
Cancer Information Services
1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society <a href="https://www.cancer.org">https://www.cancer.org</a>

### **CANCER INCIDENCE 2016–2020**

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016–2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 737 cases of invasive cancer were diagnosed among Payette County residents (Table 1).

**Table 1:** Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Payette County and the State of Idaho. 2016–2020

Cancer Incidence 2016–2020	Payette County	State of Idaho
All Sites/Types	737	45,610
Female Breast	98	6,687
Prostate	92	6,417
Lung & Bronchus	116	4,887
Colorectal	68	3,451

Table 3 (Cancer Incidence 2016–2020, Comparison between Payette County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Payette County. The table also shows the number of observed cases, person-

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Payette County was 621.8 cases per 100,000 person-years per year during 2016–2020. Comparing this crude rate with the crude rate for the remainder of Idaho (518.6) gives an estimate of the relative burden of disease in Payette County.

The age- and sex-adjusted incidence rate of invasive cancer in Payette County, all sites combined, was 558.3 cases per 100,000 persons per year during 2016–2020. There were statistically significantly more cases of cancer in Payette County (737) than expected (684.6) based upon rates in the remainder of the state (p=.049).

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

### **CANCER MORTALITY 2017–2021**

During 2017–2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 287 Payette County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

**Table 2:** Overall and Cancer Mortality in Payette County and the State of Idaho, 2017–2021

Mortality 2017–2021	Payette County	State of Idaho
All Deaths	1,346	77,431
Cancer Deaths	287	15,121
% of All Deaths	21.3%	19.5%
Lung & Bronchus	73	2,961
Colorectal	29	1,319
Pancreas	17	1,190
Female Breast	26	1,086
Prostate	18	949

Table 4 (Cancer Mortality 2017–2021, Comparison between Payette County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Payette County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Payette County, all sites combined, was 204.6 deaths per 100,000 persons per year during 2017–2021, compared with 167.3 for the remainder of the state. There were statistically significantly more cancer deaths in Payette County (287) than expected (234.7) based upon rates in the remainder of the state (p=.001).

**Statistical Note:** Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

### TABLE 3: CANCER INCIDENCE 2016–2020 COMPARISON BETWEEN PAYETTE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

		Payette County					Remainder of Idaho			
Cancer		Observed	Person	Crude	A.A.I.	Expected	D ) / - l (4)	Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)
All Sites Combined All Sites Combined	Total Male	737 403	118,527 59.188	621.8 680.9	558.3 596.3	684.6 372.2	0.049 <b>&gt;&gt;</b> 0.119	44,873 23,886	8,653,301 4,337,722	518.6 550.7
All Sites Combined	Female	334	59,166	562.9	515.5	315.1	0.119	20,987	4,337,722	486.3
Bladder	Total	27	118,527	22.8	19.7	34.2	0.247	2,157	8,653,301	24.9
Bladder	Male	20	59,188	33.8	28.3	28.2	0.133	1,731	4,337,722	39.9
Bladder	Female	7	59,339	11.8	10.5	6.6	0.964	426	4,315,579	9.9
Brain - malignant	Total	8	118,527	6.7	6.3	9.1	0.890	617	8,653,301	7.1
Brain - malignant	Male .	4	59,188	6.8	6.3	5.5	0.726	371	4,337,722	8.6
Brain - malignant	Female Total	4 16	59,339 118,527	6.7 13.5	6.3 12.3	3.6 21.1	0.974 0.315	246 1,408	4,315,579 8.653.301	5.7 16.3
Brain and other CNS - non-malignant Brain and other CNS - non-malignant	Male	5	59,188	8.4	7.7	7.1	0.569	475	4,337,722	11.0
Brain and other CNS - non-malignant	Female	11	59,339	18.5	17.1	13.9	0.531	933	4,315,579	21.6
Breast	Total	99	118,527	83.5	76.3	99.6	1.000	6,647	8,653,301	76.8
Breast	Male	1	59,188	1.7	1.4	0.9	1.000	58	4,337,722	1.3
Breast	Female	98	59,339	165.2	151.8	98.6	1.000	6,589	4,315,579	152.7
Breast - in situ	Total	16	118,527	13.5	12.5	18.1	0.726	1,223	8,653,301	14.1
Breast - in situ	Male Female	- 16	59,188 59,339	- 27.0	- 24.9	0.1 18.1	1.000 0.724	5 1,218	4,337,722	0.1 28.2
Breast - in situ Cervix	Female	9	59,339	15.2	15.0	4.1	0.724	295	4,315,579 4,315,579	6.8
Colorectal	Total	68	118,527	57.4	51.3	51.8	0.049 >>	3,383	8,653,301	39.1
Colorectal	Male	45	59,188	76.0	67.0	28.8	0.006 >>	1,858	4,337,722	42.8
Colorectal	Female	23	59,339	38.8	35.2	23.1	1.000	1,525	4,315,579	35.3
Corpus Uteri	Female	12	59,339	20.2	18.7	19.6	0.095	1,318	4,315,579	30.5
Esophagus	Total	7	118,527	5.9	5.2	7.7	0.982	499	8,653,301	5.8
Esophagus	Male	6	59,188	10.1	8.8	6.6	1.000	418	4,337,722	9.6
Esophagus	Female Total	1 2	59,339 118,527	1.7 1.7	1.5 1.7	1.2 2.9	1.000 0.909	81 208	4,315,579 8,653,301	1.9 2.4
Hodgkin Lymphoma Hodgkin Lymphoma	Male	1	59,188	1.7	1.7	1.6	1.000	117	4,337,722	2.4
Hodgkin Lymphoma	Female	1	59,339	1.7	1.7	1.3	1.000	91	4,315,579	2.1
Kidney and Renal Pelvis	Total	32	118,527	27.0	24.3	27.2	0.398	1,783	8,653,301	20.6
Kidney and Renal Pelvis	Male	25	59,188	42.2	37.6	17.7	0.119	1,157	4,337,722	26.7
Kidney and Renal Pelvis	Female	7	59,339	11.8	10.7	9.5	0.536	626	4,315,579	14.5
Larynx	Total	6	118,527	5.1	4.5	3.2	0.212	209	8,653,301	2.4
Larynx	Male	6	59,188	10.1	8.8	2.4	0.073	154	4,337,722	3.6
Larynx Leukemia	Female Total	- 27	59,339 118,527	22.8	20.2	0.8 24.8	0.876 0.712	55 1,604	4,315,579 8,653,301	1.3 18.5
Leukemia	Male	18	59,188	30.4	26.4	15.3	0.550	971	4,337,722	22.4
Leukemia	Female	9	59,339	15.2	13.7	9.7	1.000	633	4,315,579	14.7
Liver and Bile Duct	Total	19	118,527	16.0	14.4	12.3	0.093	810	8,653,301	9.4
Liver and Bile Duct	Male	14	59,188	23.7	21.1	8.8	0.130	576	4,337,722	13.3
Liver and Bile Duct	Female	5	59,339	8.4	7.6	3.6	0.572	234	4,315,579	5.4
Lung and Bronchus	Total	116	118,527	97.9	84.7	75.5	0.000 >>	4,771	8,653,301	55.1
Lung and Bronchus	Male Female	58 58	59,188 59,339	98.0 97.7	82.8 86.3	38.7 37.0	0.004 >> 0.002 >>	2,394 2,377	4,337,722 4,315,579	55.2 55.1
Lung and Bronchus Melanoma of the Skin	Total	26	118,527	21.9	20.0	43.8	0.002 >>	2,377	8,653,301	33.7
Melanoma of the Skin	Male	19	59,188	32.1	28.3	27.1	0.134	1,746	4,337,722	40.3
Melanoma of the Skin	Female	7	59,339	11.8	11.1	17.1	0.010 <<	1,170	4,315,579	27.1
Myeloma	Total	10	118,527	8.4	7.3	11.0	0.918	698	8,653,301	8.1
Myeloma	Male	6	59,188	10.1	8.6	7.0	0.897	435		10.0
Myeloma	Female	4	59,339	6.7	6.0	4.1	1.000	263	4,315,579	6.1
Non-Hodgkin Lymphoma Non-Hodgkin Lymphoma	Total	38	118,527	32.1	28.7	29.1	0.128 0.535	1,902	8,653,301 4,337,722	22.0
Non-Hodgkin Lymphoma Non-Hodgkin Lymphoma	Male Female	14 24	59,188 59,339	23.7 40.4	21.0 36.7	17.2 11.9	0.535	1,115 787	4,337,722	25.7 18.2
Oral Cavity and Pharynx	Total	19	118,527	16.0	14.6	19.2	1.000	1,276	8,653,301	14.7
Oral Cavity and Pharynx	Male	13	59,188	22.0	19.7	14.0	0.927	923	4,337,722	21.3
Oral Cavity and Pharynx	Female	6	59,339	10.1	9.3	5.3	0.872	353	4,315,579	8.2
Ovary	Female	9	59,339	15.2	14.0	7.8	0.756	524	4,315,579	12.1
Pancreas	Total	21	118,527	17.7	15.5	21.9	0.952	1,402	8,653,301	16.2
Pancreas	Male	13	59,188	22.0	18.8	12.3	0.920	771	4,337,722	17.8
Pancreas Prostate	Female Male	8 92	59,339 59,188	13.5 155.4	12.1 137.4	9.7	0.735 0.614	631	4,315,579	14.6 145.8
Stomach	Total	3	118,527	2.5	2.2	97.6 7.2	0.014	6,325 464	4,337,722 8,653,301	5.4
Stomach	Male	3	59,188	5.1	4.4	4.9	0.140	306	4,337,722	7.1
Stomach	Female	-	59,339	-		2.4	0.188	158	4,315,579	3.7
Testis	Male	2	59,188	3.4	3.7	3.3	0.738	263	4,337,722	6.1
Thyroid	Total	22	118,527	18.6	18.3	16.6	0.236	1,198	8,653,301	13.8
Thyroid	Male	9	59,188	15.2	14.6	4.9	0.124	346	4,337,722	8.0
Thyroid	Female	13	59,339	21.9	21.7	11.8	0.810	852	4,315,579	19.7
Pediatric Age 0 to 19	Total	9	33,858	26.6	26.8	5.7	0.249	412	2,426,665	17.0
Pediatric Age 0 to 19	Male	4	17,594	22.7	22.9	3.1	0.747	219	1,238,916	17.7
Pediatric Age 0 to 19	Female	5	16,264	30.7	31.0	2.6	0.250	193	1,187,749	16.2

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

<sup>2.</sup> Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

<sup>&</sup>quot;<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

### **TABLE 4: CANCER MORTALITY 2017–2021** COMPARISON BETWEEN PAYETTE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

		Payette County					Remainder of Idaho			
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	1,346	121,950	1,103.7	965.1	1,196.7	0.000 >>	76,084	8,866,765	858.1
All Causes of Death	Male	768	61,008	1,258.9	1,055.9	658.4	0.000 >>	40,288	4,450,860	905.2
All Causes of Death	Female	578	60,942	948.4	867.0	540.4	0.113	35,796	4,415,905	810.6
All Malignant Cancers	Total	287	121,950	235.3	204.6	234.7	0.001 >>	14,834	8,866,765	167.3
All Malignant Cancers	Male	162	61,008	265.5	222.3	131.2	0.010 >>	8,014	4,450,860	180.1
All Malignant Cancers	Female	125	60,942	205.1	183.6	105.1	0.064	6,820	4,415,905	154.4
Bladder	Total	10	121,950	8.2	6.9	7.8	0.512	479	8,866,765	5.4
Bladder	Male	9	61,008	14.8	11.7	6.4	0.386	369	4,450,860	8.3
Bladder	Female	1	60,942	1.6	1.4	1.7	0.973	110	4,415,905	2.5
Brain and Other Nervous System	Total	8	121,950	6.6	6.0	7.5	0.951	496	8,866,765	5.6
Brain and Other Nervous System	Male	2	61,008	3.3	2.9	4.5	0.341	296	4,450,860	6.7
Brain and Other Nervous System Breast	Female Total	6 26	60,942 121,950	9.8 21.3	9.1 19.0	3.0 16.6	0.167 0.040 >>	200 1,076	4,415,905	4.5 12.1
Breast	Male	20	61,008	21.3	19.0	0.3	1.000	1,076	8,866,765 4,450,860	0.4
Breast	Female	26	60,942	42.7	38.9	16.1	0.027 >>	1,060	4,415,905	24.0
Cervix	Female	-	60,942	-	-	1.2	0.612	83	4,415,905	1.9
Colorectal	Total	29	121,950	23.8	20.9	20.2	0.075	1,290	8,866,765	14.5
Colorectal	Male	19	61,008	31.1	26.8	11.1	0.039 >>	700	4,450,860	15.7
Colorectal	Female	10	60,942	16.4	14.8	9.0	0.836	590	4,415,905	13.4
Corpus Uteri	Female	2	60,942	3.3	3.0	2.6	1.000	171	4,415,905	3.9
Esophagus	Total	8	121,950	6.6	5.7	7.4	0.913	469	8,866,765	5.3
Esophagus	Male	8	61,008	13.1	11.2	6.3	0.592	393	4,450,860	8.8
Esophagus	Female	-	60,942	-	-	1.2	0.617	76	4,415,905	1.7
Hodgkin Lymphoma	Total	-	121,950	-	-	0.4	1.000	29	8,866,765	0.3
Hodgkin Lymphoma	Male	-	61,008	-	-	0.2	1.000	14	4,450,860	0.3
Hodgkin Lymphoma	Female	-	60,942	- 0.0	-	0.2	1.000	15	4,415,905	0.3
Kidney	Total Male	4 4	121,950 61,008	3.3 6.6	2.8 5.6	6.0 3.9	0.559 1.000	381 238	8,866,765 4,450,860	4.3 5.3
Kidney Kidney	Female	- 4	60,942	-	5.0	2.2	0.219	143	4,415,905	3.2
Larynx	Total		121,950	-	_	1.1	0.653	71	8,866,765	0.8
Larynx	Male	_	61,008	_	_	1.0	0.772	58	4,450,860	1.3
Larynx	Female	_	60,942	_	_	0.2	1.000	13	4,415,905	0.3
Leukemia	Total	11	121,950	9.0	7.7	10.4	0.943	649	8,866,765	7.3
Leukemia	Male	9	61,008	14.8	12.2	6.3	0.364	377	4,450,860	8.5
Leukemia	Female	2	60,942	3.3	2.9	4.2	0.408	272	4,415,905	6.2
Liver and Bile Duct	Total	10	121,950	8.2	7.2	9.2	0.887	593	8,866,765	6.7
Liver and Bile Duct	Male	8	61,008	13.1	11.4	6.3	0.598	400	4,450,860	9.0
Liver and Bile Duct	Female	2	60,942	3.3	2.9	3.0	0.856	193	4,415,905	4.4
Lung and Bronchus	Total	73	121,950	59.9	51.5	46.2	0.000 >>	2,888	8,866,765	32.6
Lung and Bronchus	Male	40	61,008	65.6	55.0	24.8	0.006 >>	1,516	4,450,860	34.1
Lung and Bronchus Melanoma of the Skin	Female Total	33 4	60,942 121,950	54.1 3.3	47.6 2.9	21.6 4.5	0.026 >> 1.000	1,372 285	4,415,905 8,866,765	31.1 3.2
Melanoma of the Skin	Male	2	61,008	3.3	2.9	3.1	0.820	190	4,450,860	4.3
Melanoma of the Skin	Female	2	60,942	3.3	2.0	1.5	0.858	95	4,415,905	2.2
Myeloma	Total	4	121,950	3.3	2.8	5.4	0.760	327	8,866,765	3.7
Myeloma	Male	3	61,008	4.9	4.0	3.3	1.000	193	4,450,860	4.3
Myeloma	Female	1	60,942	1.6	1.4	2.2	0.733	134	4,415,905	3.0
Non-Hodgkin Lymphoma	Total	12	121,950	9.8	8.4	9.0	0.392	557	8,866,765	6.3
Non-Hodgkin Lymphoma	Male	4	61,008	6.6	5.4	5.0	0.879	303	4,450,860	6.8
Non-Hodgkin Lymphoma	Female	8	60,942	13.1	11.5	4.0	0.102	254	4,415,905	5.8
Oral Cavity and Pharynx	Total	7	121,950	5.7	5.0	4.1	0.234	259	8,866,765	2.9
Oral Cavity and Pharynx	Male	5	61,008	8.2	7.1	2.9	0.336	182	4,450,860	4.1
Oral Cavity and Pharynx	Female	2	60,942	3.3	3.0	1.2	0.660	77	4,415,905	1.7
Ovary Paneroas	Female	8	60,942	13.1	11.8	5.3	0.324	342	4,415,905	7.7
Pancreas Pancreas	Total Male	17 11	121,950 61,008	13.9 18.0	12.1 15.3	18.6 10.2	0.829 0.887	1,173	8,866,765 4,450,860	13.2 14.2
Pancreas	Female	6	60,942	9.8	8.7	8.4	0.528	631 542	4,415,905	12.3
Prostate	Male	18	61,008	29.5	23.4	16.1	0.703	931	4,450,860	20.9
Stomach	Total	10	121,950	0.8	0.7	3.1	0.376	197	8,866,765	2.2
Stomach	Male	1	61,008	1.6	1.4	1.9	0.844	120	4,450,860	2.7
Stomach	Female		60,942	-		1.2	0.631	77	4,415,905	1.7
			ne number of cases i				0.00.		., ,	

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

<sup>2.</sup> Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

### Cancer Screening and Risk Factor Prevalence Estimates, 2011–2021

	State of								Payette
Measure	Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	County
Access to Care Have Health Insurance, Age <65 (2015–2021) Not See Doctor Due to Cost in Past Year (2015–2021) Cancer Screening	83.1% 12.6%	82.8% 11.4%	85.1% 11.8%	77.2% 14.5%	85.8% 12.4%	78.9% 12.3%	85.4% 11.8%	85.4% 12.9%	78.4% 15.8%
Mammogram Past 2 Years, Age 50–74 (2014, 2016, 2018, 2020) Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020) Colorectal Cancer Screening, Age 50–75 (2018, 2020) Tobacco Use	69.1% 71.2% 67.9%	67.0% 73.6% 66.9%	73.8% 73.6% 73.6%	68.2% 70.8% 71.4%	73.2% 72.9% 70.6%	64.8% 69.1% 61.7%	64.5% 69.5% 61.5%	67.1% 65.9% 64.7%	75.3% 77.9%
Current Tobacco User (2016–2021) Other Cancer-Related	22.3%	26.7%	23.1%	23.6%	21.8%	21.4%	22.7%	16.9%	28.6%
Healthy Weight by Body Mass Index, Age 20+ (2015–2021) Any Physical Activity Besides Job Past 30 Days (2015-2021) Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019)	32.1% 78.7% 21.9%	32.8% 79.2% 22.8%	31.7% 78.1% 19.4%	27.9% 74.5% 20.0%	36.1% 83.2% 25.2%	29.8% 73.4% 19.5%	27.9% 76.3% 20.4%	31.9% 79.7% 20.2%	26.7% 73.3% 14.1%
Home Ever Tested for Radon (2016, 2018, 2020)	23.0%	30.9%	18.2%	16.9%	25.1%	19.9%	23.0%	21.8%	14.8%

### **Access to Care**

### Have Health Insurance – 2015–2021

Statewide, 83.1% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 86.0% of white non-Hispanics, compared to 64.8% of Hispanics and 83.3% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3%) than English-speaking respondents (84.2%). Health care coverage differed significantly by age of respondent, with 79.8% of persons aged 18–29, and 87.8% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 62.1% in Adams County to 91.6% in Oneida County having health insurance.

### Not See Doctor Due to Cost in Past Year – 2015–2021

Statewide, 12.6% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (11.5% of white non-Hispanics, 19.2% of Hispanics, and 21.0% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9% for less than \$15,000, 6.1% for greater than \$50,000). Inability to see a doctor due to cost differed significantly by county, with a range of 7.4% in Franklin County to 17.5% in Power County.

### **Cancer Screening**

<u>Mammogram</u> – 2014, 2016, 2018, 2020

Statewide, 69.1% of women aged 50–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (72.1% versus 36.7%). Mammography rates differed significantly by county, with a range in screening of 45.9% in Benewah County to 77.0% in Nez Perce County. In 2020, Idaho ranked 48<sup>th</sup> among states and the District of Columbia for mammography screening rates among women aged 50–74 and also 48<sup>th</sup> among ages 40+.

### Pap Test - 2018, 2020

Statewide, 71.2% of women with an intact cervix and aged 21–65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.1% versus 52.6% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.7% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49<sup>th</sup> among states and the District of Columbia for Pap screening rate.

### Colorectal Cancer Screening – 2018, 2020

Statewide, 67.9% of adults aged 50–75 reported being current for colorectal cancer screening.\*\* Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked 47<sup>th</sup> among states and the District of Columbia in the percentage of adults aged 50–75 and older who reported being up-to-date for colorectal cancer screening.

<sup>\*\*</sup> Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

### **Tobacco Use**

### Current Tobacco Use - 2016-2021

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.3% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 29.9% of persons aged 18-29, and 11.1% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (22.4%) than among Native Americans (40.0%). Tobacco use differed significantly by county, with a range of 5.4% in Madison County to 41.6% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

### **Other Cancer-Related**

### Healthy Weight by Body Mass Index - 2015-2021

Statewide, 32.1% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 32.5% of white non-Hispanics, compared to 28.2% of Hispanics and 24.6% of Native Americans, being in the healthy weight range. Males (25.5%) were significantly less likely to be in the healthy weight range than females (38.6%). BMI differed significantly by age of respondent, with 43.3% of persons aged 18–29, and 26.0% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 19.8% in Power County to 47.4% in Blaine County of adults being in the healthy weight range.

### Any Physical Activity - 2015-2021

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 78.7% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.3% of persons aged 18–29, and 72.3% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 64.3% in Clark County to 84.6% in Teton County.

Physical Activity Guidelines – 2011, 2013, 2015, 2017, 2019 Statewide, 21.9% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.3% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6% in Franklin County to 30.6% in Blaine County.

### Home Radon Testing - 2016, 2018, 2020

Statewide, 23.0% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.4% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.5% in Cassia County to 54.4% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006l and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.





# POWER COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

### Cancer Incidence 2016–2020 Cancer Mortality 2017–2021 BRFSS 2011–2021

### **RISK FACTORS AND INTERVENTIONS**

### CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/jama.2016.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

### Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

### **Smoking:**

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

### Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <a href="https://www.dietaryguidelines.gov">https://www.dietaryguidelines.gov</a>

### Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute
Cancer Information Services
1-800-4CANCER
<a href="https://www.cancer.gov/contact">https://www.cancer.gov/contact</a>

American Cancer Society <a href="https://www.cancer.org">https://www.cancer.org</a>

### **CANCER INCIDENCE 2016–2020**

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016–2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 160 cases of invasive cancer were diagnosed among Power County residents (Table 1).

**Table 1:** Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Power County and the State of Idaho, 2016–2020

Cancer Incidence 2016–2020	Power County	State of Idaho
All Sites/Types	160	45,610
Female Breast	24	6,687
Prostate	20	6,417
Lung & Bronchus	15	4,887
Colorectal	15	3,451

Table 3 (Cancer Incidence 2016–2020, Comparison between Power County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Power County. The table also shows the number of observed cases, person-

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Power County was 419.1 cases per 100,000 person-years per year during 2016–2020. Comparing this crude rate with the crude rate for the remainder of Idaho (520.4) gives an estimate of the relative burden of disease in Power County.

The age- and sex-adjusted incidence rate of invasive cancer in Power County, all sites combined, was 429.1 cases per 100,000 persons per year during 2016–2020. There were statistically significantly fewer cases of cancer in Power County (160) than expected (194.1) based upon rates in the remainder of the state (p=.013).

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

### **CANCER MORTALITY 2017–2021**

During 2017–2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 58 Power County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

**Table 2:** Overall and Cancer Mortality in Power County and the State of Idaho, 2017–2021

Mortality 2017–2021	Power County	State of Idaho
All Deaths	344	77,431
Cancer Deaths	58	15,121
% of All Deaths	16.9%	19.5%
Lung & Bronchus	9	2,961
Colorectal	7	1,319
Pancreas	3	1,190
Female Breast	5	1,086
Prostate	4	949

Table 4 (Cancer Mortality 2017–2021, Comparison between Power County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Power County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Power County, all sites combined, was 152.4 deaths per 100,000 persons per year during 2017–2021, compared with 168.3 for the remainder of the state. There were fewer cancer deaths in Power County (58) than expected (64.1) based upon rates in the remainder of the state, but the difference was not statistically significant.

**Statistical Note:** Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

### TABLE 3: CANCER INCIDENCE 2016–2020 COMPARISON BETWEEN POWER COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

		Power County							Remainder of Idaho			
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude		
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)		
All Sites Combined	Total	160	38,173	419.1	429.1	194.1	0.013 <<	45,450	8,733,655	520.4		
All Sites Combined	Male	82	19,348	423.8	420.2 436.1	107.9	0.011 <<	24,207	4,377,562	553.0		
All Sites Combined Bladder	Female Total	78 5	18,825 38.173	414.3 13.1	13.2	87.2 9.4	0.351 0.183	21,243 2,179	4,356,093 8,733,655	487.7 24.9		
Bladder	Male	4	19,348	20.7	20.3	7.9	0.163	1,747	4,377,562	39.9		
Bladder	Female		18,825	5.3	5.5	1.8	0.926	432	4,356,093	9.9		
Brain - malignant	Total	1	38,173	2.6	2.7	2.7	0.507	624	8,733,655	7.1		
Brain - malignant	Male	-	19,348	-	-	1.6	0.386	375	4,377,562	8.6		
Brain - malignant	Female	1	18,825	5.3	5.4	1.1	1.000	249	4,356,093	5.7		
Brain and other CNS - non-malignant	Total	7	38,173	18.3	18.9	6.0	0.788	1,417	8,733,655	16.2		
Brain and other CNS - non-malignant Brain and other CNS - non-malignant	Male Female	2 5	19,348 18,825	10.3 26.6	10.5 28.0	2.1 3.9	1.000 0.686	478 939	4,377,562 4,356,093	10.9 21.6		
Breast	Total	24	38,173	62.9	65.3	28.3	0.487	6,722	8,733,655	77.0		
Breast	Male		19,348	-	-	0.3	1.000	59	4,377,562	1.3		
Breast	Female	24	18,825	127.5	135.3	27.1	0.630	6,663	4,356,093	153.0		
Breast - in situ	Total	7	38,173	18.3	19.2	5.1	0.520	1,232	8,733,655	14.1		
Breast - in situ	Male .		19,348	-		0.0	1.000	5	4,377,562	0.1		
Breast - in situ	Female	7	18,825	37.2	39.7	5.0	0.468	1,227	4,356,093	28.2		
Cervix Colorectal	Female Total	1 15	18,825 38,173	5.3 39.3	5.9 40.3	1.2 14.7	1.000 0.998	303 3,436	4,356,093 8,733,655	7.0 39.3		
Colorectal	Male	13	19,348	67.2	67.0	8.4	0.996	1,890	4,377,562	43.2		
Colorectal	Female	2	18,825	10.6	11.1	6.4	0.095	1,546	4,356,093	35.5		
Corpus Uteri	Female	6	18,825	31.9	33.6	5.4	0.918	1,324	4,356,093	30.4		
Esophagus	Total	2	38,173	5.2	5.3	2.2	1.000	504	8,733,655	5.8		
Esophagus	Male	2	19,348	10.3	10.2	1.9	1.000	422	4,377,562	9.6		
Esophagus	Female	- ,	18,825	-	- 2.7	0.3	1.000	82	4,356,093	1.9		
Hodgkin Lymphoma Hodgkin Lymphoma	Total Male	1	38,173 19,348	2.6 5.2	2.7 5.4	0.9 0.5	1.000 0.783	209 117	8,733,655 4,377,562	2.4 2.7		
Hodgkin Lymphoma	Female	_ '	18,825	5.2	5.4	0.3	1.000	92	4,377,302	2.1		
Kidney and Renal Pelvis	Total	11	38,173	28.8	29.6	7.7	0.308	1,804	8,733,655	20.7		
Kidney and Renal Pelvis	Male	8	19,348	41.3	41.5	5.2	0.303	1,174	4,377,562	26.8		
Kidney and Renal Pelvis	Female	3	18,825	15.9	16.6	2.6	0.968	630	4,356,093	14.5		
Larynx	Total	1	38,173	2.6	2.7	0.9	1.000	214	8,733,655	2.5		
Larynx	Male	1	19,348	5.2	5.1	0.7	1.000 1.000	159	4,377,562	3.6		
Larynx Leukemia	Female Total	- 9	18,825 38,173	23.6	23.7	0.2 7.0	0.554	55 1,622	4,356,093 8,733,655	1.3 18.6		
Leukemia	Male	1	19,348	5.2	5.1	4.4	0.128	988	4,377,562	22.6		
Leukemia	Female	8	18,825	42.5	43.7	2.7	0.012 >>	634	4,356,093	14.6		
Liver and Bile Duct	Total	-	38,173	-	-	3.6	0.056	829	8,733,655	9.5		
Liver and Bile Duct	Male	-	19,348	-	-	2.6	0.143	590	4,377,562	13.5		
Liver and Bile Duct	Female	-	18,825	-	-	1.0	0.740	239	4,356,093	5.5		
Lung and Bronchus	Total	15	38,173	39.3	39.6 40.5	21.1	0.214 0.460	4,872 2,444	8,733,655	55.8 55.8		
Lung and Bronchus Lung and Bronchus	Male Female	8 7	19,348 18,825	41.3 37.2	38.5	11.0 10.1	0.400	2,444	4,377,562 4,356,093	55.7		
Melanoma of the Skin	Total	9	38,173	23.6	24.5	12.4	0.425	2,933	8,733,655	33.6		
Melanoma of the Skin	Male	5	19,348	25.8	25.9	7.7	0.431	1,760	4,377,562	40.2		
Melanoma of the Skin	Female	4	18,825	21.2	22.7	4.7	0.972	1,173	4,356,093	26.9		
Myeloma	Total	1	38,173	2.6	2.7	3.0	0.385	707	8,733,655	8.1		
Myeloma	Male	1	19,348	5.2	5.1	2.0	0.825	440	4,377,562	10.1		
Myeloma Non-Hodgkin Lymphoma	Female Total	- 2	18,825 38,173	5.2	5.3	1.1 8.3	0.665 0.022 <b>&lt;&lt;</b>	267 1,938	4,356,093 8,733,655	6.1 22.2		
Non-Hodgkin Lymphoma	Male		19,348	J.Z		5.0	0.022 <<	1,936	4,377,562	25.8		
Non-Hodgkin Lymphoma	Female	2	18,825	10.6	11.1	3.3	0.700	809	4,356,093	18.6		
Oral Cavity and Pharynx	Total	3	38,173	7.9	8.0	5.5	0.399	1,292	8,733,655	14.8		
Oral Cavity and Pharynx	Male .	1	19,348	5.2	5.1	4.2	0.161	935	4,377,562	21.4		
Oral Cavity and Pharynx	Female	2	18,825	10.6	11.2	1.5	0.863	357	4,356,093	8.2		
Ovary Pancreas	Female Total	2 6	18,825 38,173	10.6 15.7	11.2 16.0	2.2 6.1	1.000 1.000	531 1,417	4,356,093 8,733,655	12.2 16.2		
Pancreas	Male	4	19,348	20.7	20.4	3.5	0.923	780	4,377,562	17.8		
Pancreas	Female	2	18,825	10.6	11.0	2.6	1.000	637	4,356,093	14.6		
Prostate	Male	20	19,348	103.4	101.9	28.7	0.115	6,397	4,377,562	146.1		
Stomach	Total	3	38,173	7.9	8.0	2.0	0.640	464	8,733,655	5.3		
Stomach	Male	1	19,348	5.2	5.1	1.4	1.000	308	4,377,562	7.0		
Stomach	Female	2	18,825	10.6	11.2	0.6	0.269	156	4,356,093	3.6		
Testis	Male	-	19,348	-	-	1.1	0.699	265	4,377,562	6.1		
Thyroid	Total	4	38,173	10.5	11.3	4.9	0.902	1,216	8,733,655	13.9		
Thyroid	Male	1	19,348	5.2	5.4	1.5	1.000	354	4,377,562	8.1		
Thyroid	Female	3	18,825	15.9	17.4	3.4	1.000	862	4,356,093	19.8		
Pediatric Age 0 to 19	Total	3	12,818	23.4	23.7	2.2	0.736	418	2,447,705	17.1		
Pediatric Age 0 to 19 Pediatric Age 0 to 19	Male Female	3	6,525 6,293	- 47.7	- 48.7	1.2 1.0	0.628 0.161	223 195	1,249,985 1,197,720	17.8 16.3		
Notes:	1 Pates ar		0,293			ar (person yea	0.101	190	1,191,120	10.3		

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

<sup>2.</sup> Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

<sup>&</sup>quot;<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

### **TABLE 4: CANCER MORTALITY 2017–2021** COMPARISON BETWEEN POWER COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

	Remainder of Idaho			
AIR Causes of Death	son Crude			
AII Causes of Death   Male   177   19.514   898.6   179.2   0.906   40.879   4.492.354     AII Causes of Death   Female   167   18.556   881.0   899.1   159.0   0.206   36.207   4.457.891     AII Malignant Cancers   Total   4.457.891     AII Malignant Cancers   Male   34   19.514   174.2   171.8   35.9   0.841   8.142   4.492.354     AII Malignant Cancers   Female   24   18.956   126.6   130.6   28.5   0.458   6.921   4.457.891     Biadder   Total   1   38.470   2.6   2.6   2.1   0.750   488   8.592.245     Bladder   Male   1   19.514   5.1   5.0   1.7   0.998   377   4.492.354     Bladder   Male   1   19.514   5.1   5.0   1.7   0.998   377   4.492.354     Bladder   Male   1   19.514   5.1   5.0   1.7   0.998   377   4.492.354     Brain and Other Nervous System   Total   1   38.470   2.6   2.7   2.1   0.750   503   8.592.245     Brain and Other Nervous System   Female   1   18.956   5.3   5.5   0.8   1.000   205   4.457.891     Breast   Total   5   38.470   13.0   13.3   46   0.980   1.097   8.3592.245     Breast   Female   5   18.956   5.3   5.5   0.8   1.000   205   4.457.891     Breast   Female   5   18.956   5.3   5.7   0.3   0.548   82   4.492.354     Breast   Female   7   18.956   5.3   5.7   0.3   0.548   82   4.492.354     Breast   Female   7   18.956   5.3   5.7   0.3   0.548   82   4.457.891     Cervix   Female   7   18.956   5.3   5.7   0.3   0.548   82   4.457.891     Cervix   Female   8   18.956   5.3   5.7   0.3   0.548   82   4.457.891     Colorectal   Total   7   38.470   2.6   2.6   2.0   0.801   476   8.950.245     Colorectal   Female   - 18.956     0.7   0.987   173   4.457.891     Esophagus   Total   1   38.470     0.9   0.7   0.987   173   4.457.891     Esophagus   Female   - 18.956     0.1   1.000   14   4.492.354     Esophagus   Female   - 18.956     0.1   1.000	ars Rate (1)			
AII Causes of Death   Male   177   19.514   898.6   179.2   0.906   40.879   4.492.354     AII Causes of Death   Female   167   18.556   881.0   899.1   159.0   0.206   36.207   4.457.891     AII Malignant Cancers   Total   4.457.891     AII Malignant Cancers   Male   34   19.514   174.2   171.8   35.9   0.841   8.142   4.492.354     AII Malignant Cancers   Female   24   18.956   126.6   130.6   28.5   0.458   6.921   4.457.891     Biadder   Total   1   38.470   2.6   2.6   2.1   0.750   488   8.592.245     Bladder   Male   1   19.514   5.1   5.0   1.7   0.998   377   4.492.354     Bladder   Male   1   19.514   5.1   5.0   1.7   0.998   377   4.492.354     Bladder   Male   1   19.514   5.1   5.0   1.7   0.998   377   4.492.354     Brain and Other Nervous System   Total   1   38.470   2.6   2.7   2.1   0.750   503   8.592.245     Brain and Other Nervous System   Female   1   18.956   5.3   5.5   0.8   1.000   205   4.457.891     Breast   Total   5   38.470   13.0   13.3   46   0.980   1.097   8.3592.245     Breast   Female   5   18.956   5.3   5.5   0.8   1.000   205   4.457.891     Breast   Female   5   18.956   5.3   5.7   0.3   0.548   82   4.492.354     Breast   Female   7   18.956   5.3   5.7   0.3   0.548   82   4.492.354     Breast   Female   7   18.956   5.3   5.7   0.3   0.548   82   4.457.891     Cervix   Female   7   18.956   5.3   5.7   0.3   0.548   82   4.457.891     Cervix   Female   8   18.956   5.3   5.7   0.3   0.548   82   4.457.891     Colorectal   Total   7   38.470   2.6   2.6   2.0   0.801   476   8.950.245     Colorectal   Female   - 18.956     0.7   0.987   173   4.457.891     Esophagus   Total   1   38.470     0.9   0.7   0.987   173   4.457.891     Esophagus   Female   - 18.956     0.1   1.000   14   4.492.354     Esophagus   Female   - 18.956     0.1   1.000	50,245 861.3			
All Causes of Death   Female   167   13,956   881.0   899.1   150.9   0,206   36,207   4,457,891				
All Malignant Cancers   Male   34   19.514   174.2   171.8   35.9   0.841   8,142   4,492,354     All Malignant Cancers   Female   24   18,956   126.6   130.6   28.5   0.458   6,921   4,457,891     Bladder   Male   1   19.514   5.1   5.0   1.7   0.998   377   4,492,354     Bladder   Male   -				
All Malignant Cancers   Female   24   18,956   126,6   130,6   28,5   0.458   6,921   4,457,891     Bladder   Total   1   38,470   2.6   2.6   2.6   2.1   0.750   488   8,950,245     Bladder   Female   -				
Bladder	2,354 181.2			
Bladder   Male	57,891 155.3			
Bladder				
Brain and Other Nervous System   fotal   1   38,470   2.6   2.7   2.1   0.750   503   8,950,245   Brain and Other Nervous System   Female   1   18,956   5.3   5.5   0.8   1.000   205   4,457,891   1.000   2.5   4,457,891   1.000   2.5   4,457,891   1.000   2.5   4,457,891   1.000   2.5   4,457,891   1.000   2.5   4,457,891   1.000   2.5   4,457,891   1.000   2.5   4,457,891   1.000   2.5   4,457,891   1.000   2.5   4,457,891   1.000   2.5   4,457,891   1.000   2.5   4,457,891   1.000   2.5   4,457,891   1.000   2.5   4,457,891   1.000   2.5   2.000   2.000   2.5   2.000   2.5   2.000   2.5   2.000   2.5   2.000   2.000   2.5   2.000   2.5   2.000   2.5   2.000   2.5   2.000   2.000   2.5   2.000   2.5   2.000   2.5   2.000   2.5   2.000   2.000   2.5   2.000				
Brain and Other Nervous System   Male   -				
Brain and Other Nervous System   Female   1   18,956   5.3   5.5   0.8   1,000   205   4,457,891				
Breast         Total         5         38,470         13.0         13.3         4.6         0.980         1,097         8,950,245           Breast         Male         -         19,514         -         -         0.1         1,000         16         4,492,354           Breast         Female         5         18,956         26.4         27.4         4.4         0.905         1,081         4,457,891           Cervix         Female         1         18,956         5.3         5.7         0.3         0.548         82         4,457,891           Colorectal         Total         7         38,470         18.2         18.5         5.5         0.643         1,312         8,950,245           Colorectal         Female         2         18,956         1.0         10.9         2.5         1,000         598         4,457,891           Corpus Uteri         Female         -         18,956         -         -         0.7         0.987         173         4,457,891           Esophagus         Male         1         19,514         5.1         1.8         0.954         400         4492,354           Esophagus         Female         -         18,956 <td></td>				
Breast   Male	,			
Breast				
Cervix				
Colorectal   Total   7   38,470   18.2   18.5   5.5   0.643   1.312   8.950,245	57,891 1.8			
Colorectal   Female   2   18,956   10.6   10.9   2.5   1.000   598   4,457,891				
Corpus Uteri				
Esophagus				
Esophagus				
Esophagus				
Hodgkin Lymphoma				
Hodgkin Lymphoma   Male   -   19,514   -   -   0.1   1.000   14   4,492,354     Hodgkin Lymphoma   Female   -   18,956   -   -   0.1   1.000   15   4,457,891     Kidney   Total   1   38,470   2.6   2.6   1.6   1.000   384   8,950,245     Kidney   Male   1   19,514   5.1   5.1   1.1   1.000   241   4,492,354     Kidney   Female   -   18,956   -   -   0.6   1.000   143   4,457,891     Larynx   Total   -   38,470   -   -   0.3   1.000   71   8,950,245     Larynx   Male   -   18,956   -   -   0.1   1.000   13   4,457,891     Larynx   Female   -   18,956   -   -   0.1   1.000   13   4,457,891     Leukemia   Total   3   38,470   7.8   7.8   2.8   1.000   657   8,950,245     Leukemia   Male   1   19,514   5.1   5.0   1.7   0.987   385   4,492,354     Leukemia   House   House   House   House   House   House   House   House     Liver and Bile Duct   Total   -   38,470   -   -   2.6   0.155   603   8,950,245     Liver and Bile Duct   Male   -   19,514   -   -   2.6   0.155   603   8,950,245     Liver and Bile Duct   Female   -   18,956   -   -   0.8   0.894   195   4,457,891     Lung and Bronchus   Total   9   38,470   23.4   23.5   12.6   0.387   2,952   8,950,245     Lung and Bronchus   House				
Hodgkin Lymphoma   Female   -   18,956   -   -   0.1   1.000   15   4,457,891   Kidney   Total   1   38,470   2.6   2.6   1.6   1.000   384   8,950,245   Kidney   Female   -   18,956   -   -   0.6   1.000   241   4,492,354   Kidney   Female   -   18,956   -   -   0.6   1.000   143   4,457,891   Larynx   Total   -   38,470   -   -   0.3   1.000   71   8,950,245   Larynx   Male   -   19,514   -   -   0.3   1.000   58   4,492,354   Larynx   Female   -   18,956   -   -   0.1   1.000   13   4,457,891   Leukemia   Total   3   38,470   7.8   7.8   2.8   1.000   657   8,950,245   Leukemia   Male   1   19,514   5.1   5.0   1.7   0.987   385   4,492,354   Leukemia   Female   2   18,956   10.6   10.8   1.1   0.628   272   4,457,891   Liver and Bile Duct   Total   -   38,470   -   -   2.6   0.155   603   8,950,245   Liver and Bile Duct   Male   -   19,514   -   -   2.6   0.155   603   8,950,245   Liver and Bile Duct   Male   -   19,514   -   -   2.6   0.155   603   8,950,245   Liver and Bile Duct   Female   -   18,956   -   -   0.8   0.894   195   4,457,891   Lung and Bronchus   Total   9   38,470   23.4   23.5   12.6   0.387   2,952   8,950,245   Lung and Bronchus   Female   3   18,956   15.8   16.2   5.8   0.338   1,402   4,457,891   Melanoma of the Skin   Male   -   19,514   -   -   0.8   0.866   192   4,492,354   Melanoma of the Skin   Male   -   19,514   -   -   0.8   0.866   192   4,492,354   Melanoma of the Skin   Female   1   18,956   5.3   5.5   0.4   0.646   96   4,457,891				
Kidney         Total         1         38,470         2.6         2.6         1.6         1.000         384         8,950,245         Kidney         Kidney         Male         1         19,514         5.1         5.1         1.1         1.000         241         4,492,354         Kidney         Female         -         0.6         1.000         241         4,492,354         Kidney         Female         -         18,956         -         -         0.6         1.000         143         4,492,354         Kidney         Female         -         18,956         -         -         0.6         1.000         143         4,457,891         14,457,891 <th< td=""><td></td></th<>				
Kidney         Male         1         19,514         5.1         5.1         1.1         1.000         241         4,492,354           Kidney         Female         -         18,956         -         -         0.6         1.000         143         4,457,891           Larynx         Total         -         38,470         -         -         0.3         1.000         71         8,950,245           Larynx         Female         -         18,956         -         -         0.1         1.000         58         4,492,354           Larynx         Female         -         18,956         -         -         0.1         1.000         58         4,492,354           Larynx         Female         -         18,956         -         -         0.1         1.000         58         4,492,354           Leukemia         Male         1         19,514         5.1         5.0         1.7         0.987         385         4,492,354           Leukemia         Female         2         18,956         10.6         10.8         1.1         0.628         272         4,457,891           Liver and Bile Duct         Total         -         38,470				
Kidney         Female         -         18,956         -         -         0.6         1.000         143         4,457,891           Larynx         Total         -         38,470         -         -         0.3         1.000         71         8,950,245           Larynx         Male         -         19,514         -         -         0.3         1.000         58         4,492,354           Larynx         Female         -         18,956         -         -         0.1         1.000         13         4,457,891           Leukemia         Total         3         38,470         7.8         7.8         2.8         1.000         657         8,950,245           Leukemia         Male         1         19,514         5.1         5.0         1.7         0.987         385         4,492,354           Leukemia         Female         2         18,956         10.6         10.8         1.1         0.628         272         4,457,891           Liver and Bile Duct         Total         -         38,470         -         -         2.6         0.155         603         8,950,245           Liver and Bile Duct         Female         -				
Larynx         Male Larynx         -         19,514         -         0.3   1.000   1.				
Larýnx         Female         -         18,956         -         -         0.1         1.000         13         4,457,891           Leukemia         Total         3         38,470         7.8         7.8         2.8         1.000         657         8,950,245           Leukemia         Male         1         19,514         5.1         5.0         1.7         0.987         385         4,492,354           Leukemia         Female         2         18,956         10.6         10.8         1.1         0.628         272         4,457,891           Liver and Bile Duct         Total         -         38,470         -         -         2.6         0.155         603         8,950,245           Liver and Bile Duct         Male         -         19,514         -         -         1.8         0.335         408         4,492,354           Liver and Bile Duct         Female         -         18,956         -         -         0.8         0.894         195         4,457,891           Lung and Bronchus         Total         9         38,470         23.4         23.5         12.6         0.387         2,952         8,950,245           Lung and Bronchus         <				
Leukemia         Total         3         38,470         7.8         7.8         2.8         1.000         657         8,950,245           Leukemia         Male         1         19,514         5.1         5.0         1.7         0.987         385         4,492,354           Leukemia         Female         2         18,956         10.6         10.8         1.1         0.628         272         4,457,891           Liver and Bile Duct         Total         -         38,470         -         -         2.6         0.155         603         8,950,245           Liver and Bile Duct         Male         -         19,514         -         -         1.8         0.335         408         4,492,354           Liver and Bile Duct         Female         -         18,956         -         -         0.8         0.894         195         4,457,891           Lung and Bronchus         Total         9         38,470         23.4         23.5         12.6         0.387         2,952         8,950,245           Lung and Bronchus         Male         6         19,514         30.7         30.3         6.8         0.948         1,550         4,492,354           Lung and Bronc				
Leukemia         Male Leukemia         1         19,514 5.1 5.0 10.8         5.0 1.7 0.987 1385 4,492,354 10.6         1.7 0.987 1385 4,492,354 10.6         1.7 0.987 1385 4,492,354 10.6         1.7 0.987 1385 4,492,354 10.6         1.8 0.628 272 4,457,891 10.6         1.8 0.628 272 4,457,891 10.6         1.8 0.628 272 4,457,891 10.6         1.8 0.628 272 4,457,891 10.6         1.8 0.628 272 4,457,891 10.6         1.8 0.628 272 4,457,891 10.6         1.8 0.628 272 2,45 10.6         1.8 0.628 272 2,45 10.6         1.8 0.628 272 2,45 10.6         1.8 0.628 272 2,45 10.6         1.8 0.628 272 2,45 10.6         1.8 0.628 272 2,45 12.6         1.8 0.628 272 2,45 12.6         1.8 0.628 2.7 2,45 12.6         1.8 0.628 2.7 2,45 12.6         1.8 0.628 2.7 2,45 12.6         1.8 0.628 2.7 2,45 12.6         1.8 0.628 2.7 2,45 12.6         1.8 0.628 2.7 2,45 12.6         1.8 0.628 2.7 2,45 12.6         1.8 0.628 2.7 2,45 12.6         1.8 0.628 2.7 2,45 12.6         1.8 0.668 2.7 2,45 2.7 2,45 12.6         1.8 0.668 2.7 2,45 2,45 2,45 2,45 2,45 2,45 2,45 2,45				
Leukemia         Female         2         18,956         10.6         10.8         1.1         0.628         272         4,457,891           Liver and Bile Duct         Total         -         38,470         -         -         2.6         0.155         603         8,950,245           Liver and Bile Duct         Male         -         19,514         -         -         1.8         0.335         408         4,492,354           Liver and Bile Duct         Female         -         18,956         -         -         0.8         0.894         195         4,457,891           Lung and Bronchus         Total         9         38,470         23.4         23.5         12.6         0.387         2,952         8,950,245           Lung and Bronchus         Male         6         19,514         30.7         30.3         6.8         0.948         1,550         4,492,354           Lung and Bronchus         Female         3         18,956         15.8         16.2         5.8         0.338         1,402         4,457,891           Melanoma of the Skin         Total         1         38,470         2.6         2.7         1.2         1.000         288         8,950,245				
Liver and Bile Duct         Total         -         38,470         -         -         2.6         0.155         603         8,950,245           Liver and Bile Duct         Male         -         19,514         -         -         1.8         0.335         408         4,492,354           Liver and Bile Duct         Female         -         18,956         -         -         0.8         0.894         195         4,457,891           Lung and Bronchus         Total         9         38,470         23.4         23.5         12.6         0.387         2,952         8,950,245           Lung and Bronchus         Male         6         19,514         30.7         30.3         6.8         0.948         1,550         4,492,354           Lung and Bronchus         Female         3         18,956         15.8         16.2         5.8         0.338         1,402         4,457,891           Melanoma of the Skin         Total         1         38,470         2.6         2.7         1.2         1.000         288         8,950,245           Melanoma of the Skin         Male         -         19,514         -         -         0.8         0.866         192         4,492,354				
Liver and Bile Duct     Male     -     19,514     -     -     1.8     0.335     408     4,492,354       Liver and Bile Duct     Female     -     18,956     -     -     0.8     0.894     195     4,457,891       Lung and Bronchus     Total     9     38,470     23.4     23.5     12.6     0.387     2,952     8,950,245       Lung and Bronchus     Male     6     19,514     30.7     30.3     6.8     0.948     1,550     4,492,354       Lung and Bronchus     Female     3     18,956     15.8     16.2     5.8     0.338     1,402     4,457,891       Melanoma of the Skin     Total     1     38,470     2.6     2.7     1.2     1.000     288     8,950,245       Melanoma of the Skin     Male     -     19,514     -     -     0.8     0.866     192     4,492,354       Melanoma of the Skin     Female     1     18,956     5.3     5.5     0.4     0.646     96     4,457,891				
Liver and Bile Duct         Female         -         18,956         -         -         0.8         0.894         195         4,457,891           Lung and Bronchus         Total         9         38,470         23.4         23.5         12.6         0.387         2,952         8,950,245           Lung and Bronchus         Male         6         19,514         30.7         30.3         6.8         0.948         1,550         4,492,354           Lung and Bronchus         Female         3         18,956         15.8         16.2         5.8         0.338         1,402         4,457,891           Melanoma of the Skin         Total         1         38,470         2.6         2.7         1.2         1.000         288         8,950,245           Melanoma of the Skin         Male         -         19,514         -         -         0.8         0.866         192         4,492,354           Melanoma of the Skin         Female         1         18,956         5.3         5.5         0.4         0.646         96         4,457,891				
Lung and Bronchus         Total         9         38,470         23.4         23.5         12.6         0.387         2,952         8,950,245           Lung and Bronchus         Male         6         19,514         30.7         30.3         6.8         0.948         1,550         4,492,354           Lung and Bronchus         Female         3         18,956         15.8         16.2         5.8         0.338         1,402         4,457,891           Melanoma of the Skin         Total         1         38,470         2.6         2.7         1.2         1.000         288         8,950,245           Melanoma of the Skin         Male         -         19,514         -         -         0.8         0.866         192         4,492,354           Melanoma of the Skin         Female         1         18,956         5.3         5.5         0.4         0.646         96         4,457,891				
Lung and Bronchus         Male Lung and Bronchus         Male Female         6         19,514 30.7 15.8 16.2 15.2 15.2 15.2 15.2 15.2 15.2 15.2 15				
Lung and Bronchus         Female         3         18,956         15.8         16.2         5.8         0.338         1,402         4,457,891           Melanoma of the Skin         Total         1         38,470         2.6         2.7         1.2         1.000         288         8,950,245           Melanoma of the Skin         Male         -         19,514         -         -         0.8         0.866         192         4,492,354           Melanoma of the Skin         Female         1         18,956         5.3         5.5         0.4         0.646         96         4,457,891				
Melanoma of the Skin         Total         1         38,470         2.6         2.7         1.2         1.000         288         8,950,245           Melanoma of the Skin         Male         -         19,514         -         -         0.8         0.866         192         4,492,354           Melanoma of the Skin         Female         1         18,956         5.3         5.5         0.4         0.646         96         4,457,891				
Melanoma of the Skin         Male         -         19,514         -         -         0.8         0.866         192         4,492,354           Melanoma of the Skin         Female         1         18,956         5.3         5.5         0.4         0.646         96         4,457,891	50,245 3.2			
Melanoma of the Skin         Female         1         18,956         5.3         5.5         0.4         0.646         96         4,457,891           Myeloma         Total         -         38,470         -         -         1,4         0,481         331         8,950,245				
■Myeloma   ITotal   -   38.470   -   -   1.4.1.0.481   33.1.1.8.950.245				
Myeloma Male - 19,514 0.9 0.835 196 4,492,354	92,354 4.4			
Myeloma         Female         -         18,956         -         -         0.6         1.000         135         4,457,891           Non-Hodgkin Lymphoma         Total         3         38,470         7.8         7.8         2.4         0.874         566         8,950,245				
Non-Hodgkin Lymphoma         Total         3         38,470         7.8         7.8         2.4         0.874         566         8,950,245           Non-Hodgkin Lymphoma         Male         -         19,514         -         -         1.4         0.515         307         4,492,354				
Non-Hodgkin Lymphoma   Male   -   19,514   -   -   1.4   0.515   307   4,492,354   Non-Hodgkin Lymphoma   Female   3   18,956   15.8   16.2   1.1   0.191   259   4,457,891				
Oral Cavity and Pharynx Total - 38,470 1.1 0.649 266 8,950,245				
Oral Cavity and Pharynx Male - 19,514 0.8 0.883 187 4,492,354				
Oral Cavity and Pharynx Female - 18,956 0.3 1.000 79 4,457,891				
Ovary Female 4 18,956 21.1 21.9 1.4 0.112 346 4,457,891	7.891			
Pancreas Total 3 38,470 7.8 7.9 5.0 0.520 1,187 8,950,245	0,245 13.3			
Pancreas   Male   3   19,514   15.4   15.3   2.8   1.000   639   4,492,354				
Pancreas Female - 18,956 2.3 0.208 548 4,457,891				
Prostate Male 4 19,514 20.5 20.0 4.2 1.000 945 4,492,354				
Stomach Total 1 38,470 2.6 2.7 0.8 1.000 197 8,950,245	50,245 2.2			
Stomach Male - 19,514 0.5 1.000 121 4,492,354				
Stomach         Female         1         18,956         5.3         5.5         0.3         0.531         76         4,457,891   Notes: 1. Rates are expressed as the number of cases per 100.000 persons per year (person-years).	57,891 1.7			

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

<sup>2.</sup> Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

### Cancer Screening and Risk Factor Prevalence Estimates, 2011–2021

	State of								Power
Measure	Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	County
Access to Care									
Have Health Insurance, Age <65 (2015–2021)	83.1%	82.8%	85.1%	77.2%	85.8%	78.9%	85.4%	85.4%	75.7%
Not See Doctor Due to Cost in Past Year (2015–2021)	12.6%	11.4%	11.8%	14.5%	12.4%	12.3%	11.8%	12.9%	17.5%
Cancer Screening									
Mammogram Past 2 Years, Age 50–74 (2014, 2016, 2018, 2020)	69.1%	67.0%	73.8%	68.2%	73.2%	64.8%	64.5%	67.1%	
Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020)	71.2%	73.6%	73.6%	70.8%	72.9%	69.1%	69.5%	65.9%	
Colorectal Cancer Screening, Age 50–75 (2018, 2020)		66.9%	73.6%	71.4%	70.6%	61.7%	61.5%	64.7%	
Tobacco Use									
Current Tobacco User (2016–2021)	22.3%	26.7%	23.1%	23.6%	21.8%	21.4%	22.7%	16.9%	22.5%
Other Cancer-Related									
Healthy Weight by Body Mass Index, Age 20+ (2015–2021)	32.1%	32.8%	31.7%	27.9%	36.1%	29.8%	27.9%	31.9%	19.8%
Any Physical Activity Besides Job Past 30 Days (2015-2021)	78.7%	79.2%	78.1%	74.5%	83.2%	73.4%	76.3%	79.7%	69.5%
Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019)	21.9%	22.8%	19.4%	20.0%	25.2%	19.5%	20.4%	20.2%	16.2%
Home Ever Tested for Radon (2016, 2018, 2020)	23.0%	30.9%	18.2%	16.9%	25.1%	19.9%	23.0%	21.8%	21.0%

### Access to Care

### Have Health Insurance - 2015-2021

Statewide, 83.1% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 86.0% of white non-Hispanics, compared to 64.8% of Hispanics and 83.3% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3%) than English-speaking respondents (84.2%). Health care coverage differed significantly by age of respondent, with 79.8% of persons aged 18–29, and 87.8% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 62.1% in Adams County to 91.6% in Oneida County having health insurance.

### Not See Doctor Due to Cost in Past Year - 2015-2021

Statewide, 12.6% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (11.5% of white non-Hispanics, 19.2% of Hispanics, and 21.0% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9% for less than \$15,000, 6.1% for greater than \$50,000). Inability to see a doctor due to cost differed significantly by county, with a range of 7.4% in Franklin County to 17.5% in Power County.

### **Cancer Screening**

Mammogram - 2014, 2016, 2018, 2020

Statewide, 69.1% of women aged 50–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (72.1% versus 36.7%). Mammography rates differed significantly by county, with a range in screening of 45.9% in Benewah County to 77.0% in Nez Perce County. In 2020, Idaho ranked 48<sup>th</sup> among states and the District of Columbia for mammography screening rates among women aged 50–74 and also 48<sup>th</sup> among ages 40+.

### Pap Test - 2018, 2020

Statewide, 71.2% of women with an intact cervix and aged 21–65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.1% versus 52.6% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.7% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49<sup>th</sup> among states and the District of Columbia for Pap screening rate.

### Colorectal Cancer Screening – 2018, 2020

Statewide, 67.9% of adults aged 50–75 reported being current for colorectal cancer screening.\*\* Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked 47<sup>th</sup> among states and the District of Columbia in the percentage of adults aged 50–75 and older who reported being up-to-date for colorectal cancer screening.

<sup>\*\*</sup> Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

### **Tobacco Use**

### Current Tobacco Use - 2016-2021

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.3% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 29.9% of persons aged 18-29, and 11.1% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (22.4%) than among Native Americans (40.0%). Tobacco use differed significantly by county, with a range of 5.4% in Madison County to 41.6% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

### **Other Cancer-Related**

### Healthy Weight by Body Mass Index - 2015-2021

Statewide, 32.1% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 32.5% of white non-Hispanics, compared to 28.2% of Hispanics and 24.6% of Native Americans, being in the healthy weight range. Males (25.5%) were significantly less likely to be in the healthy weight range than females (38.6%). BMI differed significantly by age of respondent, with 43.3% of persons aged 18–29, and 26.0% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 19.8% in Power County to 47.4% in Blaine County of adults being in the healthy weight range.

### Any Physical Activity - 2015-2021

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 78.7% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.3% of persons aged 18–29, and 72.3% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 64.3% in Clark County to 84.6% in Teton County.

Physical Activity Guidelines – 2011, 2013, 2015, 2017, 2019 Statewide, 21.9% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.3% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6% in Franklin County to 30.6% in Blaine County.

### Home Radon Testing - 2016, 2018, 2020

Statewide, 23.0% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.4% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.5% in Cassia County to 54.4% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006l and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.





# SHOSHONE COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

### Cancer Incidence 2016–2020 Cancer Mortality 2017–2021 BRFSS 2011–2021

### **RISK FACTORS AND INTERVENTIONS**

### **CANCER**

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/jama.2016.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

### Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

### **Smoking:**

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

### Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <a href="https://www.dietaryguidelines.gov">https://www.dietaryguidelines.gov</a>

### Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute
Cancer Information Services
1-800-4CANCER
<a href="https://www.cancer.gov/contact">https://www.cancer.gov/contact</a>

American Cancer Society <a href="https://www.cancer.org">https://www.cancer.org</a>

### **CANCER INCIDENCE 2016–2020**

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016–2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 500 cases of invasive cancer were diagnosed among Shoshone County residents (Table 1).

**Table 1:** Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Shoshone County and the State of Idaho. 2016–2020

Cancer Incidence 2016–2020	Shoshone County	State of Idaho
All Sites/Types	500	45,610
Female Breast	49	6,687
Prostate	72	6,417
Lung & Bronchus	93	4,887
Colorectal	52	3,451

Table 3 (Cancer Incidence 2016–2020, Comparison between Shoshone County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Shoshone County. The table also shows the number of observed cases,

person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Shoshone County was 787.4 cases per 100,000 person-years per year during 2016–2020. Comparing this crude rate with the crude rate for the remainder of Idaho (518.0) gives an estimate of the relative burden of disease in Shoshone County.

The age- and sex-adjusted incidence rate of invasive cancer in Shoshone County, all sites combined, was 582.1 cases per 100,000 persons per year during 2016–2020. There were statistically significantly more cases of cancer in Shoshone County (500) than expected (444.9) based upon rates in the remainder of the state (p=.011).

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

### **CANCER MORTALITY 2017–2021**

During 2017–2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 171 Shoshone County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

**Table 2:** Overall and Cancer Mortality in Shoshone County and the State of Idaho, 2017–2021

Mortality 2017–2021	Shoshone County	State of Idaho
All Deaths	998	77,431
Cancer Deaths	171	15,121
% of All Deaths	17.1%	19.5%
Lung & Bronchus	53	2,961
Colorectal	19	1,319
Pancreas	14	1,190
Female Breast	6	1,086
Prostate	12	949

Table 4 (Cancer Mortality 2017–2021, Comparison between Shoshone County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Shoshone County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Shoshone County, all sites combined, was 190.1 deaths per 100,000 persons per year during 2017–2021, compared with 167.5 for the remainder of the state. There were more cancer deaths in Shoshone County (171) than expected (150.7) based upon rates in the remainder of the state, but the difference was not statistically significant.

**Statistical Note:** Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

## TABLE 3: CANCER INCIDENCE 2016–2020 COMPARISON BETWEEN SHOSHONE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Shos	shone Cour		Remainder of Idaho				
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)
All Sites Combined	Total	500 295	63,499	787.4	582.1	444.9	0.011 >>	45,110	8,708,329 4.364.953	518.0
All Sites Combined All Sites Combined	Male Female	295	31,957 31,542	923.1 649.9	666.9 492.9	243.2 202.2	0.001 <b>&gt;&gt;</b> 0.862	23,994 21.116	4,364,953	549.7 486.2
Bladder	Total	21	63,499	33.1	23.2	22.5	0.867	2,163	8,708,329	24.8
Bladder	Male	17	31,957	53.2	37.4	18.1	0.927	1,734	4,364,953	39.7
Bladder	Female	4	31,542	12.7	9.0	4.4	1.000	429	4,343,376	9.9
Brain - malignant	Total	4 2	63,499	6.3 6.3	5.1	5.6	0.671	621	8,708,329	7.1
Brain - malignant Brain - malignant	Male Female	2	31,957 31,542	6.3	5.0 5.1	3.4 2.3	0.673 1.000	373 248	4,364,953 4,343,376	8.5 5.7
Brain and other CNS - non-malignant	Total	11	63,499	17.3	13.5	13.2	0.664	1,413	8,708,329	16.2
Brain and other CNS - non-malignant	Male	3	31,957	9.4	7.5	4.4	0.719	477	4,364,953	10.9
Brain and other CNS - non-malignant	Female	8	31,542	25.4	19.7	8.8	0.976	936	4,343,376	21.6
Breast	Total	50	63,499	78.7	59.8	64.3	0.077	6,696	8,708,329	76.9
Breast Breast	Male Female	1 49	31,957 31,542	3.1 155.3	2.3 119.2	0.6 62.8	0.884 0.084	58 6,638	4,364,953 4,343,376	1.3 152.8
Breast - in situ	Total	7	63,499	11.0	8.4	11.7	0.204	1,232	8,708,329	14.1
Breast - in situ	Male	_ '	31,957	-	-	0.0	1.000	5	4,364,953	0.1
Breast - in situ	Female	7	31,542	22.2	17.3	11.4	0.233	1,227	4,343,376	28.2
Cervix	Female	4	31,542	12.7	11.8	2.3	0.415	300	4,343,376	6.9
Colorectal Colorectal	Total	52 31	63,499	81.9	60.9 71.9	33.3	0.003 >>	3,399	8,708,329	39.0
Colorectal	Male Female	31 21	31,957 31,542	97.0 66.6	71.9 49.6	18.5 14.9	0.010 <b>&gt;&gt;</b> 0.157	1,872 1,527	4,364,953 4,343,376	42.9 35.2
Corpus Uteri	Female	16	31,542	50.7	38.5	12.6	0.137	1,327	4,343,376	30.3
Esophagus	Total	4	63,499	6.3	4.5	5.1	0.840	502	8,708,329	5.8
Esophagus	Male	4	31,957	12.5	8.9	4.3	1.000	420	4,364,953	9.6
Esophagus	Female	-	31,542	-	-	0.8	0.867	82	4,343,376	1.9
Hodgkin Lymphoma	Total Male	-	63,499 31,957	-	-	1.6 0.9	0.394 0.779	210 118	8,708,329 4,364,953	2.4 2.7
Hodgkin Lymphoma Hodgkin Lymphoma	Female	_	31,542	_		0.9	1.000	92	4,364,953	2.7
Kidney and Renal Pelvis	Total	18	63,499	28.3	21.2	17.6	0.978	1,797	8,708,329	20.6
Kidney and Renal Pelvis	Male	11	31,957	34.4	25.5	11.6	1.000	1,171	4,364,953	26.8
Kidney and Renal Pelvis	Female	7	31,542	22.2	16.7	6.0	0.796	626	4,343,376	14.4
Larynx	Total	2	63,499	3.1	2.3	2.2	1.000	213	8,708,329	2.4
Larynx Larynx	Male Female	1	31,957 31,542	3.1 3.2	2.2 2.3	1.6 0.5	1.000 0.822	159 54	4,364,953 4,343,376	3.6 1.2
Leukemia	Total	18	63,499	28.3	21.2	15.7	0.628	1,613	8,708,329	18.5
Leukemia	Male	13	31,957	40.7	30.5	9.5	0.332	976	4,364,953	22.4
Leukemia	Female	5	31,542	15.9	11.9	6.2	0.833	637	4,343,376	14.7
Liver and Bile Duct	Total	12	63,499	18.9	13.6	8.3	0.266	817	8,708,329	9.4
Liver and Bile Duct Liver and Bile Duct	Male Female	8 4	31,957 31,542	25.0 12.7	17.8 9.3	6.0 2.3	0.510 0.415	582 235	4,364,953 4,343,376	13.3 5.4
Lung and Bronchus	Total	93	63,499	146.5	102.6	49.9	0.413	4,794	8,708,329	55.1
Lung and Bronchus	Male	54	31,957	169.0	117.5	25.3	0.000 >>	2,398	4,364,953	54.9
Lung and Bronchus	Female	39	31,542	123.6	87.4	24.6	0.009 >>	2,396	4,343,376	55.2
Melanoma of the Skin	Total	16	63,499	25.2	19.3	27.9	0.021 <<	2,926	8,708,329	33.6
Melanoma of the Skin	Male	13	31,957	40.7	30.2	17.3	0.367	1,752	4,364,953	40.1
Melanoma of the Skin Myeloma	Female Total	3 5	31,542 63,499	9.5 7.9	7.6 5.6	10.6 7.2	0.013 <b>&lt;&lt;</b> 0.549	1,174 703	4,343,376 8,708,329	27.0 8.1
Myeloma	Male	1	31.957	3.1	2.2	4.6	0.349	440		10.1
Myeloma	Female		31,542	12.7	9.1	2.7	0.557	263	4,343,376	6.1
Non-Hodgkin Lymphoma	Total	16	63,499	25.2	18.7	18.9	0.600	1,924	8,708,329	22.1
Non-Hodgkin Lymphoma	Male	7	31,957	21.9	16.3	11.1	0.279	1,122	4,364,953	25.7
Non-Hodgkin Lymphoma Oral Cavity and Pharynx	Female Total	9 16	31,542 63,499	28.5 25.2	21.1 18.5	7.9 12.7	0.784 0.425	802 1,279	4,343,376 8,708,329	18.5 14.7
Oral Cavity and Pharynx Oral Cavity and Pharynx	Male	16	31,957	25.2 43.8	31.7	9.3	0.425	922	4,364,953	21.1
Oral Cavity and Pharynx	Female	2	31,542	6.3	4.7	3.5	0.653	357	4,343,376	8.2
Ovary	Female	5	31,542	15.9	12.1	5.0	1.000	528	4,343,376	12.2
Pancreas	Total	16	63,499	25.2	18.0	14.4	0.738	1,407	8,708,329	16.2
Pancreas	Male	7	31,957	21.9	15.6	8.0	0.911	777	4,364,953	17.8
Pancreas Prostate	Female Male	9 72	31,542 31,957	28.5 225.3	20.4 156.5	6.4 66.9	0.392 0.564	630 6,345	4,343,376 4,364,953	14.5 145.4
Stomach	Total	4	63.499	6.3	4.6	4.6	1.000	463	8,708,329	5.3
Stomach	Male	4	31,957	12.5	9.0	3.1	0.752	305	4,364,953	7.0
Stomach	Female	-	31,542	-	-	1.5	0.429	158	4,343,376	3.6
Testis	Male	5	31,957	15.6	17.4	1.7	0.061	260	4,364,953	6.0
Thyroid	Total	7	63,499	11.0	9.9	9.8	0.469	1,213	8,708,329	13.9
Thyroid	Male	5	31,957	15.6	13.2	3.0	0.383	350	4,364,953	8.0
Thyroid	Female	2	31,542	6.3	5.9	6.7	0.072	863	4,343,376	19.9
Pediatric Age 0 to 19	Total	3	14,059	21.3	21.0	2.4	0.882	418	2,446,464	17.1
Pediatric Age 0 to 19 Pediatric Age 0 to 19	Male Female	3	7,242 6,817	41.4	40.4	1.3 1.1	0.289 0.642	220 198	1,249,268 1,197,196	17.6 16.5
1 541411071g0 0 10 10	i omale	-			persons per ve			190	1,107,100	1 10.3

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

<sup>2.</sup> Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

<sup>&</sup>quot;<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

### **TABLE 4: CANCER MORTALITY 2017–2021** COMPARISON BETWEEN SHOSHONE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

		Shoshone County							Remainder of Idaho		
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude	
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)	
All Causes of Death	Total	998	64,683	1,542.9	1,131.9	755.2	0.000 >>	76,432	8,924,032	856.5	
All Causes of Death	Male	553	32,642	1,694.1	1,303.0	383.8	0.000 >>	40,503	4,479,226	904.2	
All Causes of Death	Female	445	32,041	1,388.8	966.1	372.3	0.000 >>	35,929	4,444,806	808.3	
All Malignant Cancers	Total	171	64,683	264.4	190.1	150.7	0.111	14,950	8,924,032	167.5	
All Malignant Cancers	Male	100	32,642	306.4	223.8	80.6	0.040 >>	8,076	4,479,226	180.3	
All Malignant Cancers	Female	71	32,041	221.6	158.1	69.4	0.884	6,874	4,444,806	154.7	
Bladder	Total	2	64,683	3.1	2.2	5.0	0.245	487	8,924,032	5.5	
Bladder	Male	2	32,642	6.1	4.6	3.7	0.577	376	4,479,226	8.4	
Bladder	Female	-	32,041	-	-	1.2	0.619	111	4,444,806	2.5	
Brain and Other Nervous System	Total	3	64,683	4.6	3.5	4.8	0.600	501	8,924,032	5.6	
Brain and Other Nervous System	Male	1	32,642	3.1	2.3	2.9	0.444	297	4,479,226	6.6	
Brain and Other Nervous System Breast	Female Total	2	32,041 64,683	6.2 10.8	4.8 8.0	1.9 10.8	1.000 0.320	204 1,095	4,444,806 8,924,032	4.6 12.3	
Breast	Male	1	32,642	3.1	2.3	0.1	0.320	1,095	4,479,226	0.3	
Breast	Female	6	32,042	18.7	13.6	10.7	0.185	1,080	4,444,806	24.3	
Cervix	Female	-	32,041	-	-	0.7	0.103	83	4,444,806	1.9	
Colorectal	Total	19	64,683	29.4	21.5	12.9	0.131	1,300	8,924,032	14.6	
Colorectal	Male	11	32,642	33.7	25.1	6.9	0.185	708	4,479,226	15.8	
Colorectal	Female	8	32,041	25.0	17.7	6.0	0.516	592	4,444,806	13.3	
Corpus Uteri	Female	2	32,041	6.2	4.5	1.7	1.000	171	4,444,806	3.8	
Esophagus	Total	6	64,683	9.3	6.7	4.8	0.681	471	8,924,032	5.3	
Esophagus	Male	6	32,642	18.4	13.3	4.0	0.426	395	4,479,226	8.8	
Esophagus	Female	-	32,041	-	-	0.8	0.921	76	4,444,806	1.7	
Hodgkin Lymphoma	Total	-	64,683	-	-	0.3	1.000	29	8,924,032	0.3	
Hodgkin Lymphoma	Male	-	32,642	-	-	0.1	1.000	14	4,479,226	0.3	
Hodgkin Lymphoma	Female		32,041	- 40.0	- 77	0.1	1.000	15	4,444,806	0.3	
Kidney	Total Male	7 4	64,683 32,642	10.8 12.3	7.7 8.9	3.9 2.4	0.193 0.442	378 238	8,924,032 4,479,226	4.2 5.3	
Kidney Kidney	Female	3	32,042 32,041	9.4	6.4	1.5	0.442	140	4,444,806	3.1	
Larynx	Total	-	64,683	-	- 0.4	0.7	0.966	71	8,924,032	0.8	
Larynx	Male	_	32,642	_	_	0.6	1.000	58	4,479,226	1.3	
Larynx	Female	_	32,041	_	_	0.1	1.000	13	4,444,806	0.3	
Leukemia	Total	3	64,683	4.6	3.3	6.6	0.210	657	8,924,032	7.4	
Leukemia	Male	3	32,642	9.2	6.8	3.8	0.964	383	4,479,226	8.6	
Leukemia	Female	-	32,041	-	-	2.8	0.119	274	4,444,806	6.2	
Liver and Bile Duct	Total	10	64,683	15.5	11.1	6.0	0.167	593	8,924,032	6.6	
Liver and Bile Duct	Male	8	32,642	24.5	17.5	4.1	0.112	400	4,479,226	8.9	
Liver and Bile Duct	Female	2	32,041	6.2	4.5	1.9	1.000	193	4,444,806	4.3	
Lung and Bronchus	Total	53	64,683	81.9	57.9	29.8	0.000 >>	2,908	8,924,032	32.6	
Lung and Bronchus	Male	29	32,642	88.8	63.1	15.7	0.003 >>	1,527	4,479,226	34.1	
Lung and Bronchus Melanoma of the Skin	Female Total	24 6	32,041 64,683	74.9 9.3	52.6 6.8	14.2 2.8	0.021 <b>&gt;&gt;</b> 0.130	1,381 283	4,444,806 8,924,032	31.1 3.2	
Melanoma of the Skin	Male	3	32,642	9.3	6.9	1.8	0.130	189	4,479,226	4.2	
Melanoma of the Skin	Female	3	32,042	9.4	6.9	0.9	0.303	94	4,444,806	2.1	
Myeloma	Total	2	64,683	3.1	2.2	3.4	0.675	329	8,924,032	3.7	
Myeloma	Male		32,642	-		2.0	0.270	196	4,479,226	4.4	
Myeloma	Female	2	32,041	6.2	4.3	1.4	0.806	133	4,444,806	3.0	
Non-Hodgkin Lymphoma	Total	2	64,683	3.1	2.2	5.8	0.144	567	8,924,032	6.4	
Non-Hodgkin Lymphoma	Male	1	32,642	3.1	2.2	3.0	0.386	306	4,479,226	6.8	
Non-Hodgkin Lymphoma	Female	1	32,041	3.1	2.1	2.7	0.482	261	4,444,806	5.9	
Oral Cavity and Pharynx	Total	3	64,683	4.6	3.3	2.6	0.987	263	8,924,032	2.9	
Oral Cavity and Pharynx	Male	3	32,642	9.2	6.6	1.9	0.572	184	4,479,226	4.1	
Oral Cavity and Pharynx	Female	-	32,041	-		0.8	0.902	79	4,444,806	1.8	
Ovary	Female	3	32,041	9.4	6.7	3.5	1.000	347	4,444,806	7.8	
Pancreas	Total	14 7	64,683	21.6	15.4	11.9	0.625	1,176	8,924,032	13.2	
Pancreas Pancreas	Male Female	7 7	32,642 32,041	21.4 21.8	15.4 15.5	6.5 5.5	0.932 0.622	635 541	4,479,226 4.444.806	14.2 12.2	
Prostate	Male	12	32,642	36.8	27.2	9.2	0.622	937	4,444,606	20.9	
Stomach	Total	12	64,683	1.5	1.1	1.9	0.441	197	8,924,032	20.9	
Stomach	Male	1	32,642	3.1	2.3	1.2	1.000	120	4,479,226	2.7	
Stomach	Female	_ '	32.041	-	-	0.7	0.948	77	4,444,806	1.7	
			ne number of cases i				0.070	, ,	1, 177,000	1.7	

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

<sup>2.</sup> Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

### Cancer Screening and Risk Factor Prevalence Estimates, 2011–2021

	State of								Shoshone
Measure	Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	County
Access to Care									
Have Health Insurance, Age <65 (2015–2021)	83.1%	82.8%	85.1%	77.2%	85.8%	78.9%	85.4%	85.4%	87.0%
Not See Doctor Due to Cost in Past Year (2015–2021)	12.6%	11.4%	11.8%	14.5%	12.4%	12.3%	11.8%	12.9%	11.6%
Cancer Screening									
Mammogram Past 2 Years, Age 50–74 (2014, 2016, 2018, 2020)	69.1%	67.0%	73.8%	68.2%	73.2%	64.8%	64.5%	67.1%	52.2%
Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020)	71.2%	73.6%	73.6%	70.8%	72.9%	69.1%	69.5%	65.9%	
Colorectal Cancer Screening, Age 50–75 (2018, 2020)		66.9%	73.6%	71.4%	70.6%	61.7%	61.5%	64.7%	58.3%
Tobacco Use									
Current Tobacco User (2016–2021)	22.3%	26.7%	23.1%	23.6%	21.8%	21.4%	22.7%	16.9%	29.0%
Other Cancer-Related									
Healthy Weight by Body Mass Index, Age 20+ (2015–2021)	32.1%	32.8%	31.7%	27.9%	36.1%	29.8%	27.9%	31.9%	28.5%
Any Physical Activity Besides Job Past 30 Days (2015-2021)	78.7%	79.2%	78.1%	74.5%	83.2%	73.4%	76.3%	79.7%	75.5%
Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019)	21.9%	22.8%	19.4%	20.0%	25.2%	19.5%	20.4%	20.2%	19.0%
Home Ever Tested for Radon (2016, 2018, 2020)	23.0%	30.9%	18.2%	16.9%	25.1%	19.9%	23.0%	21.8%	29.2%

### **Access to Care**

### Have Health Insurance - 2015-2021

Statewide, 83.1% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 86.0% of white non-Hispanics, compared to 64.8% of Hispanics and 83.3% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3%) than English-speaking respondents (84.2%). Health care coverage differed significantly by age of respondent, with 79.8% of persons aged 18–29, and 87.8% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 62.1% in Adams County to 91.6% in Oneida County having health insurance.

### Not See Doctor Due to Cost in Past Year – 2015–2021

Statewide, 12.6% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (11.5% of white non-Hispanics, 19.2% of Hispanics, and 21.0% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9% for less than \$15,000, 6.1% for greater than \$50,000). Inability to see a doctor due to cost differed significantly by county, with a range of 7.4% in Franklin County to 17.5% in Power County.

### **Cancer Screening**

Mammogram - 2014, 2016, 2018, 2020

Statewide, 69.1% of women aged 50–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (72.1% versus 36.7%). Mammography rates differed significantly by county, with a range in screening of 45.9% in Benewah County to 77.0% in Nez Perce County. In 2020, Idaho ranked 48<sup>th</sup> among states and the District of Columbia for mammography screening rates among women aged 50–74 and also 48<sup>th</sup> among ages 40+.

### Pap Test - 2018, 2020

Statewide, 71.2% of women with an intact cervix and aged 21–65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.1% versus 52.6% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.7% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49<sup>th</sup> among states and the District of Columbia for Pap screening rate.

### Colorectal Cancer Screening – 2018, 2020

Statewide, 67.9% of adults aged 50–75 reported being current for colorectal cancer screening.\*\* Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked 47<sup>th</sup> among states and the District of Columbia in the percentage of adults aged 50–75 and older who reported being up-to-date for colorectal cancer screening.

<sup>\*\*</sup> Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

### **Tobacco Use**

### Current Tobacco Use - 2016-2021

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.3% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 29.9% of persons aged 18-29, and 11.1% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (22.4%) than among Native Americans (40.0%). Tobacco use differed significantly by county, with a range of 5.4% in Madison County to 41.6% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

### **Other Cancer-Related**

### Healthy Weight by Body Mass Index - 2015-2021

Statewide, 32.1% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 32.5% of white non-Hispanics, compared to 28.2% of Hispanics and 24.6% of Native Americans, being in the healthy weight range. Males (25.5%) were significantly less likely to be in the healthy weight range than females (38.6%). BMI differed significantly by age of respondent, with 43.3% of persons aged 18–29, and 26.0% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 19.8% in Power County to 47.4% in Blaine County of adults being in the healthy weight range.

### Any Physical Activity - 2015-2021

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 78.7% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.3% of persons aged 18–29, and 72.3% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 64.3% in Clark County to 84.6% in Teton County.

Physical Activity Guidelines – 2011, 2013, 2015, 2017, 2019 Statewide, 21.9% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.3% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6% in Franklin County to 30.6% in Blaine County.

### Home Radon Testing - 2016, 2018, 2020

Statewide, 23.0% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.4% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.5% in Cassia County to 54.4% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006l and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.





# TETON COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

### Cancer Incidence 2016–2020 Cancer Mortality 2017–2021 BRFSS 2011–2021

### **RISK FACTORS AND INTERVENTIONS**

### CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/jama.2016.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

### Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

### **Smoking:**

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

### Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <a href="https://www.dietaryguidelines.gov">https://www.dietaryguidelines.gov</a>

### Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute
Cancer Information Services
1-800-4CANCER
<a href="https://www.cancer.gov/contact">https://www.cancer.gov/contact</a>

American Cancer Society <a href="https://www.cancer.org">https://www.cancer.org</a>

### **CANCER INCIDENCE 2016–2020**

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016–2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 220 cases of invasive cancer were diagnosed among Teton County residents (Table 1).

**Table 1:** Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Teton County and the State of Idaho. 2016–2020

	,				
Cancer Incidence	Teton	State of			
2016–2020	County	ldaho			
All Sites/Types	220	45,610			
Female Breast	35	6,687			
Prostate	35	6,417			
Lung & Bronchus	15	4,887			
Colorectal	11	3,451			

Table 3 (Cancer Incidence 2016–2020, Comparison between Teton County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Teton County. The table also shows the number of observed cases, person-

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Teton County was 373.6 cases per 100,000 person-years per year during 2016–2020. Comparing this crude rate with the crude rate for the remainder of Idaho (520.9) gives an estimate of the relative burden of disease in Teton County.

The age- and sex-adjusted incidence rate of invasive cancer in Teton County, all sites combined, was 427.9 cases per 100,000 persons per year during 2016–2020. There were statistically significantly fewer cases of cancer in Teton County (220) than expected (267.8) based upon rates in the remainder of the state (p=.003).

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

### **CANCER MORTALITY 2017–2021**

During 2017–2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 70 Teton County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

**Table 2:** Overall and Cancer Mortality in Teton County and the State of Idaho, 2017–2021

Mortality 2017–2021	Teton County	State of Idaho
All Deaths	264	77,431
Cancer Deaths	70	15,121
% of All Deaths	26.5%	19.5%
Lung & Bronchus	13	2,961
Colorectal	8	1,319
Pancreas	9	1,190
Female Breast	4	1,086
Prostate	0	949

Table 4 (Cancer Mortality 2017–2021, Comparison between Teton County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Teton County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Teton County, all sites combined, was 147.8 deaths per 100,000 persons per year during 2017–2021, compared with 168.6 for the remainder of the state. There were fewer cancer deaths in Teton County (70) than expected (79.8) based upon rates in the remainder of the state, but the difference was not statistically significant.

**Statistical Note:** Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

### TABLE 3: CANCER INCIDENCE 2016–2020 COMPARISON BETWEEN TETON COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

		Teton County						Remainder of Idaho			
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude	
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)	
All Sites Combined	Total	220	58,879	373.6	427.9	267.8	0.003 <<	45,390	8,712,949	520.9	
All Sites Combined All Sites Combined	Male Female	135 85	30,793 28,086	438.4 302.6	497.1 346.3	150.2 119.9	0.226 0.001 <b>&lt;&lt;</b>	24,154 21,236	4,366,117 4,346,832	553.2 488.5	
Bladder	Total	6	58,879	10.2	13.2	11.4	0.130	2,178	8,712,949	25.0	
Bladder	Male	6	30,793	19.5	24.3	9.9	0.277	1,745	4,366,117	40.0	
Bladder	Female	-	28,086	-	-	2.1	0.235	433	4,346,832	10.0	
Brain - malignant Brain - malignant	Total Male	4 4	58,879 30.793	6.8 13.0	7.3 13.6	3.9 2.5	1.000 0.486	621 371	8,712,949 4,366,117	7.1 8.5	
Brain - malignant	Female	_ ~	28,086	-	-	1.5	0.466	250	4,346,832	5.8	
Brain and other CNS - non-malignant	Total	6	58,879	10.2	11.2	8.7	0.470	1,418	8,712,949	16.3	
Brain and other CNS - non-malignant	Male	3	30,793	9.7	10.3	3.2	1.000	477	4,366,117	10.9	
Brain and other CNS - non-malignant Breast	Female Total	3 36	28,086 58,879	10.7 61.1	12.1 64.9	5.3 42.7	0.439 0.343	941 6,710	4,346,832 8,712,949	21.6 77.0	
Breast	Male	1	30,793	3.2	3.9	0.3	0.576	58	4,366,117	1.3	
Breast	Female	35	28,086	124.6	135.3	39.6	0.527	6,652	4,346,832	153.0	
Breast - in situ	Total	8	58,879	13.6	13.7	8.2	1.000	1,231	8,712,949	14.1	
Breast - in situ	Male	- 8	30,793 28,086	- 28.5	- 29.5	0.0	1.000 0.991	5 1,226	4,366,117	0.1 28.2	
Breast - in situ Cervix	Female Female	- 0	28,086	20.5	29.0	7.6 2.2	0.991	304	4,346,832 4,346,832	7.0	
Colorectal	Total	11	58,879	18.7	21.3	20.4	0.035 <<	3,440	8,712,949	39.5	
Colorectal	Male	7	30,793	22.7	24.9	12.2	0.161	1,896	4,366,117	43.4	
Colorectal	Female	4	28,086	14.2	17.0	8.4	0.160	1,544	4,346,832	35.5	
Corpus Uteri Esophagus	Female Total	5 3	28,086 58,879	17.8 5.1	19.3 6.1	7.9 2.8	0.401 1.000	1,325 503	4,346,832 8,712,949	30.5 5.8	
Esophagus	Male	3	30,793	9.7	11.2	2.6	0.950	421	4,366,117	9.6	
Esophagus	Female		28,086	-	-	0.4	1.000	82	4,346,832	1.9	
Hodgkin Lymphoma	Total	1	58,879	1.7	1.8	1.4	1.000	209	8,712,949	2.4	
Hodgkin Lymphoma	Male Female	1	30,793	3.2	3.3	0.8	1.000	117	4,366,117	2.7	
Hodgkin Lymphoma Kidney and Renal Pelvis	Total	- 5	28,086 58.879	- 8.5	9.4	0.5 11.0	1.000 0.074	92 1,810	4,346,832 8,712,949	2.1 20.8	
Kidney and Renal Pelvis	Male	3	30,793	9.7	10.4	7.8	0.099	1,179	4,366,117	27.0	
Kidney and Renal Pelvis	Female	2	28,086	7.1	8.3	3.5	0.636	631	4,346,832	14.5	
Larynx	Total	2	58,879	3.4	4.0	1.2	0.695	213	8,712,949	2.4	
Larynx Larynx	Male Female	2	30,793 28,086	6.5	7.4	1.0 0.3	0.514 1.000	158 55	4,366,117 4,346,832	3.6 1.3	
Leukemia	Total	12	58,879	20.4	24.4	9.1	0.418	1,619	8,712,949	18.6	
Leukemia	Male	11	30,793	35.7	41.3	6.0	0.082	978	4,366,117	22.4	
Leukemia	Female	1	28,086	3.6	4.4	3.3	0.311	641	4,346,832	14.7	
Liver and Bile Duct Liver and Bile Duct	Total Male	2	58,879 30,793	3.4 3.2	3.9 3.6	4.9 3.8	0.273 0.217	827 589	8,712,949 4,366,117	9.5 13.5	
Liver and Bile Duct	Female		28,086	3.2	4.4	1.3	1.000	238	4,346,832	5.5	
Lung and Bronchus	Total	15	58,879	25.5	32.3	26.0	0.029 <<	4,872	8,712,949	55.9	
Lung and Bronchus	Male	6	30,793	19.5	23.7	14.2	0.025 <<	2,446	4,366,117	56.0	
Lung and Bronchus	Female	9	28,086	32.0	42.2	11.9	0.503	2,426	4,346,832	55.8	
Melanoma of the Skin Melanoma of the Skin	Total Male	28 17	58,879 30,793	47.6 55.2	52.4 61.1	17.9 11.1	0.032 <b>&gt;&gt;</b> 0.122	2,914 1,748	8,712,949 4,366,117	33.4 40.0	
Melanoma of the Skin	Female	11	28,086	39.2	41.8	7.1	0.206	1,166	4,346,832	26.8	
Myeloma	Total	3	58,879	5.1	6.3	3.8	0.929	705	8,712,949	8.1	
Myeloma	Male	1	30,793	3.2	3.9	2.6	0.537	440		10.1	
Myeloma Non-Hodgkin Lymphoma	Female Total	2 8	28,086 58,879	7.1 13.6	9.1 15.8	1.3 11.2	0.778 0.422	265 1,932	4,346,832 8,712,949	6.1 22.2	
Non-Hodgkin Lymphoma	Male	7	30,793	22.7	25.4	7.1	1.000	1,122	4,366,117	25.7	
Non-Hodgkin Lymphoma	Female	1	28,086	3.6	4.3	4.3	0.141	810	4,346,832	18.6	
Oral Cavity and Pharynx	Total	9	58,879	15.3	16.9	7.9	0.779	1,286	8,712,949	14.8	
Oral Cavity and Pharynx Oral Cavity and Pharynx	Male Female	7 2	30,793 28,086	22.7 7.1	24.3 8.2	6.1 2.0	0.831 1.000	929 357	4,366,117 4,346,832	21.3 8.2	
Ovary	Female	2	28,086	7.1	7.9	3.1	0.813	531	4,346,832	12.2	
Pancreas	Total	9	58,879	15.3	18.9	7.7	0.734	1,414	8,712,949	16.2	
Pancreas	Male	6	30,793	19.5	23.0	4.7	0.647	778	4,366,117	17.8	
Pancreas	Female	3	28,086	10.7	13.9	3.2	1.000	636	4,346,832	14.6	
Prostate Stomach	Male Total	35 -	30,793 58,879	113.7	127.5	40.1 2.6	0.474 0.141	6,382 467	4,366,117 8,712,949	146.2 5.4	
Stomach	Male	-	30,793	-	-	1.9	0.141	309	4,366,117	7.1	
Stomach	Female	-	28,086	-	-	0.8	0.857	158	4,346,832	3.6	
Testis	Male	1	30,793	3.2	3.1	2.0	0.837	264	4,366,117	6.0	
Thyroid	Total	4	58,879	6.8	6.5	8.6	0.144	1,216	8,712,949	14.0	
Thyroid	Male	2	30,793	6.5	6.3	2.6	1.000	353	4,366,117	8.1	
Thyroid Pediatric Age 0 to 19	Female Total	3	28,086 15,658	7.1 19.2	6.8 19.6	5.8 2.6	0.139 0.974	863 418	4,346,832 2,444,865	19.9	
Pediatric Age 0 to 19 Pediatric Age 0 to 19	Male	1	15,658 8,086	19.2	19.6	2.6 1.4	1.000	222	1,248,424	17.1 17.8	
Pediatric Age 0 to 19 Pediatric Age 0 to 19	Female	2	7,572	26.4	27.3	1.4	0.675	196	1,196,441	16.4	
			no number of case			· ··-			.,,		

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

<sup>2.</sup> Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

<sup>&</sup>quot;<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

## TABLE 4: CANCER MORTALITY 2017–2021 COMPARISON BETWEEN TETON COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Te		Remainder of Idaho					
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	264	59,967	440.2	583.0	391.4	0.000 <<	77,166	8,928,748	864.2
All Causes of Death	Male	143	31,343	456.2	558.8	233.7	0.000 <<	40,913	4,480,525	913.1
All Causes of Death	Female	121	28,624	422.7	607.1	162.4	0.001 <<	36,253	4,448,223	815.0
All Malignant Cancers	Total	70	59,967	116.7	147.8	79.8	0.295	15,051	8,928,748	168.6
All Malignant Cancers	Male	39	31,343	124.4	151.3	46.8	0.283	8,137	4,480,525	181.6
All Malignant Cancers	Female	31	28,624	108.3	141.6	34.0	0.682	6,914	4,448,223	155.4
Bladder	Total	2	59,967	3.3	4.9	2.2	1.000	487	8,928,748	5.5
Bladder	Male	2	31,343	6.4	8.7	1.9	1.000	376	4,480,525	8.4
Bladder	Female		28,624			0.5	1.000	111	4,448,223	2.5
Brain and Other Nervous System	Total	1	59,967	1.7	1.8	3.1	0.379	503	8,928,748	5.6
Brain and Other Nervous System Brain and Other Nervous System	Male Female	1	31,343 28,624	3.2	3.4	1.9 1.2	0.845 0.619	297 206	4,480,525 4,448,223	6.6 4.6
Breast	Total	- 6	59,967	10.0	11.8	6.2	1.000	1,096	8,928,748	12.3
Breast	Male	2	31,343	6.4	7.3	0.1	0.007 >>	1,090	4,480,525	0.3
Breast	Female	4	28,624	14.0	17.1	5.7	0.654	1,082	4,448,223	24.3
Cervix	Female	1	28,624	3.5	3.3	0.6	0.847	82	4,448,223	1.8
Colorectal	Total	8	59,967	13.3	16.2	7.3	0.883	1,311	8,928,748	14.7
Colorectal	Male	4	31,343	12.8	14.4	4.4	1.000	715	4,480,525	16.0
Colorectal	Female	4	28,624	14.0	18.4	2.9	0.666	596	4,448,223	13.4
Corpus Uteri	Female	-	28,624	-	-	0.9	0.814	173	4,448,223	3.9
Esophagus	Total	1	59,967	1.7	2.0	2.6	0.522	476	8,928,748	5.3
Esophagus	Male	1	31,343	3.2	3.7	2.4	0.607	400	4,480,525	8.9
Esophagus	Female	-	28,624	-	-	0.4	1.000	76	4,448,223	1.7
Hodgkin Lymphoma	Total	-	59,967	-	-	0.2	1.000	29	8,928,748	0.3
Hodgkin Lymphoma	Male	-	31,343 28,624	-	-	0.1	1.000	14	4,480,525	0.3 0.3
Hodgkin Lymphoma Kidney	Female Total	- 2	59,967	3.3	4.3	0.1 2.0	1.000 1.000	15 383	4,448,223 8,928,748	4.3
Kidney	Male		31,343	3.3 -	4.3	1.4	0.483	242	4,480,525	5.4
Kidney	Female	2	28,624	7.0	10.0	0.6	0.465	141	4,448,223	3.2
Larynx	Total	-	59,967	- 7.0	-	0.4	1.000	71	8,928,748	0.8
Larynx	Male	-	31,343	-	-	0.3	1.000	58	4,480,525	1.3
Larynx	Female	-	28,624	-	-	0.1	1.000	13	4,448,223	0.3
Leukemia	Total	3	59,967	5.0	6.8	3.2	1.000	657	8,928,748	7.4
Leukemia	Male	3	31,343	9.6	12.2	2.1	0.702	383	4,480,525	8.5
Leukemia	Female	-	28,624	-	-	1.2	0.595	274	4,448,223	6.2
Liver and Bile Duct	Total	2	59,967	3.3	4.0	3.4	0.687	601	8,928,748	6.7
Liver and Bile Duct	Male	1	31,343	3.2	3.6	2.5	0.569	407	4,480,525	9.1
Liver and Bile Duct	Female	1	28,624	3.5	4.5	1.0	1.000	194	4,448,223	4.4
Lung and Bronchus	Total	13	59,967	21.7	27.9	15.4	0.658	2,948	8,928,748	33.0
Lung and Bronchus Lung and Bronchus	Male Female	8 5	31,343 28,624	25.5 17.5	31.0 23.8	8.9 6.6	0.937 0.705	1,548 1,400	4,480,525 4,448,223	34.5 31.5
Melanoma of the Skin	Total	2	59,967	3.3	4.0	1.6	0.703	287	8,928,748	3.2
Melanoma of the Skin	Male		31,343		-	1.1	0.644	192	4,480,525	4.3
Melanoma of the Skin	Female	2	28,624	7.0	8.5	0.5	0.183	95	4.448.223	2.1
Myeloma	Total	3	59,967	5.0	7.0	1.6	0.425	328	8,928,748	3.7
Myeloma	Male	-	31,343	-	-	1.0	0.705	196	4,480,525	4.4
Myeloma	Female	3	28,624	10.5	15.4	0.6	0.042 >>	132	4,448,223	3.0
Non-Hodgkin Lymphoma	Total	2	59,967	3.3	4.5	2.8	0.921	567	8,928,748	6.4
Non-Hodgkin Lymphoma	Male	2	31,343	6.4	7.9	1.7	1.000	305	4,480,525	6.8
Non-Hodgkin Lymphoma	Female	-	28,624	-	-	1.1	0.638	262	4,448,223	5.9
Oral Cavity and Pharynx	Total	3	59,967	5.0	6.0	1.5	0.369	263	8,928,748	2.9
Oral Cavity and Pharynx	Male	2 1	31,343 28,624	6.4 3.5	7.3 4.4	1.1 0.4	0.623 0.658	185 78	4,480,525 4,448,223	4.1 1.8
Oral Cavity and Pharynx Ovary	Female Female	1	28,624	3.5	4.4	1.8	0.658	78 349	4,448,223	7.8
Pancreas	Total	9	59,967	15.0	18.8	6.3	0.927	1,181	8,928,748	13.2
Pancreas	Male	7	31,343	22.3	26.5	3.7	0.378	635	4,480,525	14.2
Pancreas	Female	2	28,624	7.0	9.2	2.7	1.000	546	4,448,223	12.3
Prostate	Male	-	31,343	-	-	4.8	0.016 <<	949	4,480,525	21.2
Stomach	Total	-	59,967	-	-	1.1	0.656	198	8,928,748	2.2
Stomach	Male	-	31,343	-	-	0.7	0.959	121	4,480,525	2.7
Stomach	Female	-	28,624	-	_	0.4	1.000	77	4,448,223	1.7
			ne number of cases r	400.000				•	, -, -,	

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

<sup>2.</sup> Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

### Cancer Screening and Risk Factor Prevalence Estimates, 2011–2021

	State of								Teton
Measure	Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	County
Access to Care									
Have Health Insurance, Age <65 (2015–2021)	83.1%	82.8%	85.1%	77.2%	85.8%	78.9%	85.4%	85.4%	79.8%
Not See Doctor Due to Cost in Past Year (2015–2021)	12.6%	11.4%	11.8%	14.5%	12.4%	12.3%	11.8%	12.9%	9.6%
Cancer Screening									
Mammogram Past 2 Years, Age 50–74 (2014, 2016, 2018, 2020)	69.1%	67.0%	73.8%	68.2%	73.2%	64.8%	64.5%	67.1%	
Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020)	71.2%	73.6%	73.6%	70.8%	72.9%	69.1%	69.5%	65.9%	
Colorectal Cancer Screening, Age 50–75 (2018, 2020)	67.9%	66.9%	73.6%	71.4%	70.6%	61.7%	61.5%	64.7%	
Tobacco Use									
Current Tobacco User (2016–2021)	22.3%	26.7%	23.1%	23.6%	21.8%	21.4%	22.7%	16.9%	21.4%
Other Cancer-Related									
Healthy Weight by Body Mass Index, Age 20+ (2015–2021)	32.1%	32.8%	31.7%	27.9%	36.1%	29.8%	27.9%	31.9%	46.9%
Any Physical Activity Besides Job Past 30 Days (2015-2021)	78.7%	79.2%	78.1%	74.5%	83.2%	73.4%	76.3%	79.7%	84.6%
Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019)	21.9%	22.8%	19.4%	20.0%	25.2%	19.5%	20.4%	20.2%	20.5%
Home Ever Tested for Radon (2016, 2018, 2020)	23.0%	30.9%	18.2%	16.9%	25.1%	19.9%	23.0%	21.8%	40.6%

### **Access to Care**

### Have Health Insurance – 2015–2021

Statewide, 83.1% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 86.0% of white non-Hispanics, compared to 64.8% of Hispanics and 83.3% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3%) than English-speaking respondents (84.2%). Health care coverage differed significantly by age of respondent, with 79.8% of persons aged 18–29, and 87.8% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 62.1% in Adams County to 91.6% in Oneida County having health insurance.

### Not See Doctor Due to Cost in Past Year - 2015-2021

Statewide, 12.6% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (11.5% of white non-Hispanics, 19.2% of Hispanics, and 21.0% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9% for less than \$15,000, 6.1% for greater than \$50,000). Inability to see a doctor due to cost differed significantly by county, with a range of 7.4% in Franklin County to 17.5% in Power County.

### **Cancer Screening**

Mammogram - 2014, 2016, 2018, 2020

Statewide, 69.1% of women aged 50–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (72.1% versus 36.7%). Mammography rates differed significantly by county, with a range in screening of 45.9% in Benewah County to 77.0% in Nez Perce County. In 2020, Idaho ranked 48th among states and the District of Columbia for mammography screening rates among women aged 50–74 and also 48th among ages 40+.

### Pap Test - 2018, 2020

Statewide, 71.2% of women with an intact cervix and aged 21–65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.1% versus 52.6% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.7% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49<sup>th</sup> among states and the District of Columbia for Pap screening rate.

### Colorectal Cancer Screening – 2018, 2020

Statewide, 67.9% of adults aged 50–75 reported being current for colorectal cancer screening.\*\* Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked 47<sup>th</sup> among states and the District of Columbia in the percentage of adults aged 50–75 and older who reported being up-to-date for colorectal cancer screening.

<sup>\*\*</sup> Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

### **Tobacco Use**

### Current Tobacco Use - 2016-2021

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.3% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 29.9% of persons aged 18-29, and 11.1% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (22.4%) than among Native Americans (40.0%). Tobacco use differed significantly by county, with a range of 5.4% in Madison County to 41.6% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

### **Other Cancer-Related**

### Healthy Weight by Body Mass Index - 2015-2021

Statewide, 32.1% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 32.5% of white non-Hispanics, compared to 28.2% of Hispanics and 24.6% of Native Americans, being in the healthy weight range. Males (25.5%) were significantly less likely to be in the healthy weight range than females (38.6%). BMI differed significantly by age of respondent, with 43.3% of persons aged 18–29, and 26.0% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 19.8% in Power County to 47.4% in Blaine County of adults being in the healthy weight range.

### Any Physical Activity - 2015-2021

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 78.7% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.3% of persons aged 18–29, and 72.3% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 64.3% in Clark County to 84.6% in Teton County.

Physical Activity Guidelines – 2011, 2013, 2015, 2017, 2019 Statewide, 21.9% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.3% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6% in Franklin County to 30.6% in Blaine County.

### Home Radon Testing - 2016, 2018, 2020

Statewide, 23.0% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.4% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.5% in Cassia County to 54.4% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006l and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.





# TWIN FALLS COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

### Cancer Incidence 2016–2020 Cancer Mortality 2017–2021 BRFSS 2011–2021

### **RISK FACTORS AND INTERVENTIONS**

### **CANCER**

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/jama.2016.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

### Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

### **Smoking:**

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

### Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <a href="https://www.dietaryguidelines.gov">https://www.dietaryguidelines.gov</a>

### Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute
Cancer Information Services
1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society <a href="https://www.cancer.org">https://www.cancer.org</a>

### **CANCER INCIDENCE 2016–2020**

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016–2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 2,116 cases of invasive cancer were diagnosed among Twin Falls County residents (Table 1).

**Table 1:** Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Twin Falls County and the State of Idaho. 2016–2020

Cancer Incidence 2016–2020	Twin Falls	State of Idaho
All Sites/Types	County 2,116	45,610
Female Breast	266	6,687
Prostate	222	6,417
Lung & Bronchus	243	4,887
Colorectal	166	3,451

Table 3 (Cancer Incidence 2016–2020, Comparison between Twin Falls County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Twin Falls County. The table also shows the number of observed cases,

person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Twin Falls County was 491.0 cases per 100,000 person-years per year during 2016–2020. Comparing this crude rate with the crude rate for the remainder of Idaho (521.5) gives an estimate of the relative burden of disease in Twin Falls County.

The age- and sex-adjusted incidence rate of invasive cancer in Twin Falls County, all sites combined, was 507.0 cases per 100,000 persons per year during 2016–2020. There were fewer cases of cancer in Twin Falls County (2,116) than expected (2,176.2) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

### **CANCER MORTALITY 2017–2021**

During 2017–2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 772 Twin Falls County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

**Table 2:** Overall and Cancer Mortality in Twin Falls County and the State of Idaho, 2017–2021

Mortality 2017–2021	Twin Falls County	State of Idaho
All Deaths	4,315	77,431
Cancer Deaths	772	15,121
% of All Deaths	17.9%	19.5%
Lung & Bronchus	156	2,961
Colorectal	62	1,319
Pancreas	53	1,190
Female Breast	44	1,086
Prostate	57	949

Table 4 (Cancer Mortality 2017–2021, Comparison between Twin Falls County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Twin Falls County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Twin Falls County, all sites combined, was 177.3 deaths per 100,000 persons per year during 2017–2021, compared with 167.8 for the remainder of the state. There were more cancer deaths in Twin Falls County (772) than expected (731.0) based upon rates in the remainder of the state, but the difference was not statistically significant.

**Statistical Note:** Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

## TABLE 3: CANCER INCIDENCE 2016–2020 COMPARISON BETWEEN TWIN FALLS COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

		Twin Falls County						Remainder of Idaho			
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude	
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)	
All Sites Combined	Total	2,116	430,990	491.0	507.0	2,176.2	0.199	43,494	8,340,838	521.5	
All Sites Combined	Male	1,125	212,388	529.7	553.7	1,124.7	1.000	23,164	4,184,522	553.6	
All Sites Combined Bladder	Female	991 124	218,602	453.3 28.8	465.8 29.2	1,040.6	0.126 0.074	20,330	4,156,316	489.1	
Bladder	Total Male	108	430,990 212,388	20.0 50.9	29.2 52.6	104.9 80.6	0.074	2,060 1,643	8,340,838 4,184,522	24.7 39.3	
Bladder	Female	16	218,602	7.3	7.4	21.8	0.254	417	4,156,316	10.0	
Brain - malignant	Total	29	430,990	6.7	6.9	30.1	0.937	596	8,340,838	7.1	
Brain - malignant	Male	16	212,388	7.5	7.8	17.7	0.813	359	4,184,522	8.6	
Brain - malignant	Female	13	218,602	5.9	6.0	12.3	0.913	237	4,156,316	5.7	
Brain and other CNS - non-malignant	Total	66	430,990	15.3	15.7	68.5	0.827	1,358	8,340,838	16.3	
	Male	20	212,388	9.4	9.7	22.6	0.679	460	4,184,522	11.0	
Brain and other CNS - non-malignant Breast	Female Total	46 268	218,602 430,990	21.0 62.2	21.4 65.0	46.3 320.1	1.000 0.003 <b>&lt;&lt;</b>	898 6,478	4,156,316	21.6 77.7	
Breast	Male	200	212,388	0.9	1.0	2.8	0.934	57	8,340,838 4,184,522	1.4	
Breast	Female	266	218,602	121.7	127.2	323.1	0.001 <<	6,421	4,156,316	154.5	
Breast - in situ	Total	32	430,990	7.4	7.9	58.7	0.000 <<	1,207	8,340,838	14.5	
Breast - in situ	Male	-	212,388	_	-	0.2	1.000	5	4,184,522	0.1	
Breast - in situ	Female	32	218,602	14.6	15.6	59.2	0.000 <<	1,202	4,156,316	28.9	
Cervix	Female	10	218,602	4.6	4.7	14.9	0.245	294	4,156,316	7.1	
Colorectal	Total	166	430,990	38.5	39.6	165.2	0.968	3,285	8,340,838	39.4	
Colorectal	Male	94 72	212,388	44.3	46.1	88.2 76.5	0.562 0.658	1,809	4,184,522	43.2 35.5	
Colorectal Corpus Uteri	Female Female	77	218,602 218,602	32.9 35.2	33.4 37.2	76.5 62.5	0.658	1,476 1,253	4,156,316 4,156,316	35.5 30.1	
Esophagus	Total	27	430,990	6.3	6.4	24.0	0.063	479	8,340,838	5.7	
Esophagus	Male	21	212,388	9.9	10.3	19.6	0.811	403	4,184,522	9.6	
Esophagus	Female	6	218,602	2.7	2.8	3.9	0.400	76	4,156,316	1.8	
Hodgkin Lymphoma	Total	16	430,990	3.7	3.8	9.8	0.086	194	8,340,838	2.3	
Hodgkin Lymphoma	Male	13	212,388	6.1	6.3	5.2	0.006 >>	105	4,184,522	2.5	
Hodgkin Lymphoma	Female	3	218,602	1.4	1.4	4.6	0.647	89	4,156,316	2.1	
Kidney and Renal Pelvis	Total	74	430,990	17.2	17.8	86.8	0.181	1,741	8,340,838	20.9	
Kidney and Renal Pelvis	Male	51	212,388	24.0	25.1	54.9	0.664	1,131	4,184,522	27.0	
Kidney and Renal Pelvis	Female Total	23 13	218,602 430,990	10.5 3.0	10.8 3.1	31.3 10.1	0.151 0.430	610 202	4,156,316	14.7 2.4	
Larynx Larynx	Male	8	212,388	3.8	3.1	7.4	0.430	152	8,340,838 4,184,522	3.6	
Larynx	Female	5	218,602	2.3	2.4	2.5	0.228	50	4,156,316	1.2	
Leukemia	Total	88	430,990	20.4	20.7	78.8	0.326	1,543	8,340,838	18.5	
Leukemia	Male	46	212,388	21.7	22.2	46.7	0.997	943	4,184,522	22.5	
Leukemia	Female	42	218,602	19.2	19.3	31.5	0.084	600	4,156,316	14.4	
Liver and Bile Duct	Total	21	430,990	4.9	5.1	40.0	0.001 <<	808	8,340,838	9.7	
Liver and Bile Duct	Male	12	212,388	5.7	6.0	27.7	0.001 <<	578	4,184,522	13.8	
Liver and Bile Duct	Female	9	218,602	4.1	4.2	11.9	0.509	230	4,156,316	5.5	
Lung and Bronchus	Total Male	243 131	430,990 212,388	56.4 61.7	57.7 64.3	234.5 113.0	0.597 0.106	4,644 2,321	8,340,838	55.7 55.5	
Lung and Bronchus Lung and Bronchus	Female	112	212,300	51.2	51.8	120.9	0.100	2,321	4,184,522 4,156,316	55.5 55.9	
Melanoma of the Skin	Total	152	430.990	35.3	36.3	140.3	0.341	2,790	8,340,838	33.4	
Melanoma of the Skin	Male	90	212,388	42.4	44.0	81.9	0.397	1,675	4,184,522	40.0	
Melanoma of the Skin	Female	62	218,602	28.4	29.1	57.1	0.550	1,115	4,156,316	26.8	
Myeloma	Total	30	430,990	7.0	7.1	34.3	0.527	678	8,340,838	8.1	
Myeloma	Male	22	212,388	10.4	10.8	20.5	0.796	419	4,184,522	10.0	
Myeloma	Female	8	218,602	3.7	3.7	13.5	0.159	259	4,156,316	6.2	
Non-Hodgkin Lymphoma	Total	110	430,990	25.5	26.3	91.9	0.073	1,830	8,340,838	21.9	
Non-Hodgkin Lymphoma Non-Hodgkin Lymphoma	Male Female	59 51	212,388 218,602	27.8 23.3	28.9 23.7	52.1 39.3	0.374 0.083	1,070 760	4,184,522 4,156,316	25.6 18.3	
Oral Cavity and Pharynx	Total	67	430,990	23.3 15.5	16.3	60.5	0.063	1,228	8,340,838	14.7	
Oral Cavity and Pharynx	Male	49	212,388	23.1	24.4	42.6	0.439	887	4,184,522	21.2	
Oral Cavity and Pharynx	Female	18	218,602	8.2	8.5	17.3	0.939	341	4,156,316	8.2	
Ovary	Female	31	218,602	14.2	14.7	25.4	0.316	502	4,156,316	12.1	
Pancreas	Total	70	430,990	16.2	16.6	68.5	0.890	1,353	8,340,838	16.2	
Pancreas	Male	44	212,388	20.7	21.6	36.1	0.222	740	4,184,522	17.7	
Pancreas	Female	26	218,602	11.9	11.9	32.1	0.321	613	4,156,316	14.7	
Prostate	Male	222	212,388	104.5	111.1	295.7	0.000 <<	6,195	4,184,522	148.0	
Stomach	Total Male	22 12	430,990 212,388	5.1 5.7	5.2 5.0	22.6 14.5	1.000 0.623	445 297	8,340,838	5.3 7.1	
Stomach Stomach	Female	12	212,388	5.7 4.6	5.9 4.6	7.8	0.623	297 148	4,184,522 4,156,316	7.1 3.6	
Testis	Male	20	212,388	9.4	9.5	12.3	0.054	245	4,184,522	5.9	
Thyroid	Total	46	430,990	10.7	11.0	58.7	0.034	1,174	8,340,838	14.1	
Thyroid	Male	11	212,388	5.2	5.4	16.9	0.103	344	4,184,522	8.2	
Thyroid	Female	35	218,602	16.0	16.6	42.2	0.178	830	4,156,316	20.0	
Pediatric Age 0 to 19	Total	29	128,767	22.5	22.8	21.4	0.302	392	2,331,756	16.8	
Pediatric Age 0 to 19 Pediatric Age 0 to 19	Male	17	65,255	26.1	26.1	11.3	0.130	206	1,191,255	17.3	
Pediatric Age 0 to 19 Pediatric Age 0 to 19	Female	12	63,512	18.9	19.3	10.1	0.640	186	1,140,501	16.3	
Notes:			•	ne per 100 000		ar (person yea		.50	., 5,001	. 5.5	

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

<sup>2.</sup> Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

<sup>&</sup>quot;<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

### **TABLE 4: CANCER MORTALITY 2017–2021** COMPARISON BETWEEN TWIN FALLS COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Twin	Falls Coun	ıty			Remainder of Idaho		10
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	4,315	439,386	982.1	966.9	3,816.6	0.000 >>	73,115	8,549,329	855.2
All Causes of Death	Male	2,208	216,870	1,018.1	1,037.8	1,924.4	0.000 >>	38,848	4,294,998	904.5
All Causes of Death	Female	2,107	222,516	946.9	904.4	1,876.5	0.000 >>	34,267	4,254,331	805.5
All Malignant Cancers	Total	772	439,386	175.7	177.3	731.0	0.136	14,349	8,549,329	167.8
All Malignant Cancers	Male	418	216,870	192.7	198.8	379.7	0.055	7,758	4,294,998	180.6
All Malignant Cancers	Female	354	222,516	159.1	158.3	346.4	0.697	6,591	4,254,331	154.9
Bladder	Total	28	439,386	6.4	6.2	24.3	0.502	461	8,549,329	5.4
Bladder	Male	21	216,870	9.7	9.8	17.9	0.516	357	4,294,998	8.3
Bladder	Female	7	222,516	3.1	3.0	5.7	0.678	104	4,254,331	2.4
Brain and Other Nervous System	Total	23	439,386	5.2	5.4	23.9	0.955	481	8,549,329	5.6
Brain and Other Nervous System	Male	9	216,870	4.1	4.3	14.0	0.219	289	4,294,998	6.7
Brain and Other Nervous System	Female	14	222,516	6.3	6.4	9.8	0.243	192	4,254,331	4.5
Breast	Total	44	439,386	10.0	10.2	53.6	0.210	1,058	8,549,329	12.4
Breast	Male	-	216,870	-	-	0.8	0.920	16	4,294,998	0.4
Breast Consis	Female	44 5	222,516	19.8	19.9	54.2 3.9	0.183	1,042	4,254,331	24.5
Cervix Colorectal	Female Total	62	222,516 439,386	2.2 14.1	2.3 14.3	63.9	0.707 0.882	78 1,257	4,254,331 8,549,329	1.8 14.7
Colorectal	Male	36	216,870	16.6	17.2	33.3	0.680	683	6,549,529 4,294,998	15.9
Colorectal	Female	26	222,516	11.7	11.5	30.4	0.485	574	4,254,331	13.5
Corpus Uteri	Female	10	222,516	4.5	4.6	8.3	0.463	163	4,254,331	3.8
Esophagus	Total	20	439,386	4.6	4.7	22.9	0.631	457	8,549,329	5.3
Esophagus	Male	13	216,870	6.0	6.3	18.8	0.213	388	4,294,998	9.0
Esophagus	Female	7	222,516	3.1	3.2	3.6	0.147	69	4,254,331	1.6
Hodgkin Lymphoma	Total	-	439,386	-	-	1.5	0.456	29	8,549,329	0.3
Hodgkin Lymphoma	Male	-	216,870	-	-	0.7	1.000	14	4,294,998	0.3
Hodgkin Lymphoma	Female	-	222,516	-	-	0.8	0.908	15	4,254,331	0.4
Kidney	Total	21	439,386	4.8	4.8	18.5	0.626	364	8,549,329	4.3
Kidney	Male	16	216,870	7.4	7.7	11.0	0.183	226	4,294,998	5.3
Kidney	Female	5	222,516	2.2	2.2	7.4	0.504	138	4,254,331	3.2
Larynx	Total	4	439,386	0.9	0.9	3.4	0.876	67	8,549,329	0.8
Larynx	Male	3	216,870	1.4	1.4	2.7	1.000	55	4,294,998	1.3
Larynx	Female	1	222,516	0.4	0.5	0.6	0.902	12	4,254,331	0.3
Leukemia	Total	40 24	439,386	9.1	9.0	32.2	0.205	620	8,549,329	7.3
Leukemia Leukemia	Male Female	24 16	216,870 222,516	11.1 7.2	11.3 6.9	17.9 14.0	0.197 0.656	362 258	4,294,998 4,254,331	8.4 6.1
Liver and Bile Duct	Total	27	439,386	6.1	6.3	28.7	0.843	576	8,549,329	6.7
Liver and Bile Duct	Male	19	216,870	8.8	9.2	18.7	1.000	389	4,294,998	9.1
Liver and Bile Duct	Female	8	222,516	3.6	3.6	9.7	0.737	187	4,254,331	4.4
Lung and Bronchus	Total	156	439,386	35.5	36.0	142.2	0.265	2,805	8,549,329	32.8
Lung and Bronchus	Male	86	216,870	39.7	41.2	71.4	0.102	1,470	4,294,998	34.2
Lung and Bronchus	Female	70	222,516	31.5	31.3	70.2	1.000	1,335	4,254,331	31.4
Melanoma of the Skin	Total	13	439,386	3.0	3.0	14.1	0.918	276	8,549,329	3.2
Melanoma of the Skin	Male	6	216,870	2.8	2.8	9.1	0.390	186	4,294,998	4.3
Melanoma of the Skin	Female	7	222,516	3.1	3.2	4.7	0.390	90	4,254,331	2.1
Myeloma	Total	21	439,386	4.8	4.8	16.0	0.264	310	8,549,329	3.6
Myeloma	Male	12	216,870	5.5	5.7	9.1	0.407	184	4,294,998	4.3
Myeloma	Female	9	222,516	4.0	4.0	6.7	0.476	126	4,254,331	3.0
Non-Hodgkin Lymphoma	Total	33	439,386	7.5	7.5	27.6	0.352	536	8,549,329	6.3
Non-Hodgkin Lymphoma	Male	19	216,870	8.8	9.0	14.1	0.250	288	4,294,998	6.7
Non-Hodgkin Lymphoma	Female	14	222,516	6.3	6.1	13.4	0.944	248	4,254,331	5.8
Oral Cavity and Pharynx Oral Cavity and Pharynx	Total	20	439,386 316,870	4.6 5.1	4.7 5.3	12.3	0.054	246 176	8,549,329	2.9
Oral Cavity and Pharynx  Oral Cavity and Pharynx	Male Female	11 9	216,870 222,516	5.1 4.0	5.3 4.1	8.5 3.6	0.475 0.025 >>	176 70	4,294,998 4,254,331	4.1 1.6
Ovary	Female	19	222,516	8.5	8.6	17.1	0.025	331	4,254,331	7.8
Pancreas	Total	53	439,386	12.1	12.3	57.3	0.707	1,137	8,549,329	13.3
Pancreas	Male	34	216,870	15.7	16.3	29.5	0.020	608	4,294,998	14.2
Pancreas	Female	19	222,516	8.5	8.6	27.6	0.433	529	4,254,331	12.4
Prostate	Male	57	216,870	26.3	26.6	44.6	0.082	892	4,294,998	20.8
Stomach	Total	7	439,386	1.6	1.6	9.7	0.495	191	8,549,329	2.2
Stomach	Male	4	216,870	1.8	1.9	5.7	0.652	117	4,294,998	2.7
Stomach	Female	3	222,516	1.3	1.3	3.9	0.898	74	4,254,331	1.7
			ne number of cases r						.,_0.,001	

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

<sup>2.</sup> Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

### Cancer Screening and Risk Factor Prevalence Estimates, 2011–2021

	State of								Twin Falls
Measure	Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	County
Access to Care									
Have Health Insurance, Age <65 (2015–2021)	83.1%	82.8%	85.1%	77.2%	85.8%	78.9%	85.4%	85.4%	81.7%
Not See Doctor Due to Cost in Past Year (2015–2021)	12.6%	11.4%	11.8%	14.5%	12.4%	12.3%	11.8%	12.9%	12.0%
Cancer Screening									
Mammogram Past 2 Years, Age 50–74 (2014, 2016, 2018, 2020)	69.1%	67.0%	73.8%	68.2%	73.2%	64.8%	64.5%	67.1%	65.7%
Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020)	71.2%	73.6%	73.6%	70.8%	72.9%	69.1%	69.5%	65.9%	66.1%
Colorectal Cancer Screening, Age 50–75 (2018, 2020)	67.9%	66.9%	73.6%	71.4%	70.6%	61.7%	61.5%	64.7%	62.1%
Tobacco Use									
Current Tobacco User (2016–2021)	22.3%	26.7%	23.1%	23.6%	21.8%	21.4%	22.7%	16.9%	22.3%
Other Cancer-Related									
Healthy Weight by Body Mass Index, Age 20+ (2015–2021)	32.1%	32.8%	31.7%	27.9%	36.1%	29.8%	27.9%	31.9%	27.3%
Any Physical Activity Besides Job Past 30 Days (2015-2021)	78.7%	79.2%	78.1%	74.5%	83.2%	73.4%	76.3%	79.7%	75.2%
Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019)	21.9%	22.8%	19.4%	20.0%	25.2%	19.5%	20.4%	20.2%	20.8%
Home Ever Tested for Radon (2016, 2018, 2020)	23.0%	30.9%	18.2%	16.9%	25.1%	19.9%	23.0%	21.8%	16.8%

### **Access to Care**

### Have Health Insurance - 2015-2021

Statewide, 83.1% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 86.0% of white non-Hispanics, compared to 64.8% of Hispanics and 83.3% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3%) than English-speaking respondents (84.2%). Health care coverage differed significantly by age of respondent, with 79.8% of persons aged 18–29, and 87.8% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 62.1% in Adams County to 91.6% in Oneida County having health insurance.

### Not See Doctor Due to Cost in Past Year – 2015–2021

Statewide, 12.6% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (11.5% of white non-Hispanics, 19.2% of Hispanics, and 21.0% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9% for less than \$15,000, 6.1% for greater than \$50,000). Inability to see a doctor due to cost differed significantly by county, with a range of 7.4% in Franklin County to 17.5% in Power County.

### **Cancer Screening**

<u>Mammogram</u> – 2014, 2016, 2018, 2020

Statewide, 69.1% of women aged 50–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (72.1% versus 36.7%). Mammography rates differed significantly by county, with a range in screening of 45.9% in Benewah County to 77.0% in Nez Perce County. In 2020, Idaho ranked 48th among states and the District of Columbia for mammography screening rates among women aged 50–74 and also 48th among ages 40+.

### Pap Test - 2018, 2020

Statewide, 71.2% of women with an intact cervix and aged 21–65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.1% versus 52.6% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.7% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49<sup>th</sup> among states and the District of Columbia for Pap screening rate.

### Colorectal Cancer Screening – 2018, 2020

Statewide, 67.9% of adults aged 50–75 reported being current for colorectal cancer screening.\*\* Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked 47<sup>th</sup> among states and the District of Columbia in the percentage of adults aged 50–75 and older who reported being up-to-date for colorectal cancer screening.

<sup>\*\*</sup> Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

#### **Tobacco Use**

#### Current Tobacco Use - 2016-2021

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.3% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 29.9% of persons aged 18-29, and 11.1% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (22.4%) than among Native Americans (40.0%). Tobacco use differed significantly by county, with a range of 5.4% in Madison County to 41.6% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

#### **Other Cancer-Related**

#### Healthy Weight by Body Mass Index - 2015-2021

Statewide, 32.1% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 32.5% of white non-Hispanics, compared to 28.2% of Hispanics and 24.6% of Native Americans, being in the healthy weight range. Males (25.5%) were significantly less likely to be in the healthy weight range than females (38.6%). BMI differed significantly by age of respondent, with 43.3% of persons aged 18–29, and 26.0% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 19.8% in Power County to 47.4% in Blaine County of adults being in the healthy weight range.

#### Any Physical Activity - 2015-2021

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 78.7% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.3% of persons aged 18–29, and 72.3% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 64.3% in Clark County to 84.6% in Teton County.

Physical Activity Guidelines – 2011, 2013, 2015, 2017, 2019 Statewide, 21.9% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.3% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6% in Franklin County to 30.6% in Blaine County.

#### Home Radon Testing - 2016, 2018, 2020

Statewide, 23.0% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.4% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.5% in Cassia County to 54.4% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006l and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.





## VALLEY COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

#### Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

#### **RISK FACTORS AND INTERVENTIONS**

#### CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/jama.2016.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

#### Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

#### **Smoking:**

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

#### Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <a href="https://www.dietaryguidelines.gov">https://www.dietaryguidelines.gov</a>

#### Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute
Cancer Information Services
1-800-4CANCER
<a href="https://www.cancer.gov/contact">https://www.cancer.gov/contact</a>

American Cancer Society <a href="https://www.cancer.org">https://www.cancer.org</a>

#### **CANCER INCIDENCE 2016–2020**

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016–2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 379 cases of invasive cancer were diagnosed among Valley County residents (Table 1).

**Table 1:** Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Valley County and the State of Idaho, 2016–2020

Cancer Incidence 2016–2020						
All Sites/Types	379	45,610				
Female Breast	53	6,687				
Prostate	73	6,417				
Lung & Bronchus	28	4,887				
Colorectal	26	3,451				

Table 3 (Cancer Incidence 2016–2020, Comparison between Valley County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Valley County. The table also shows the number of observed cases, person-

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Valley County was 683.8 cases per 100,000 person-years per year during 2016–2020. Comparing this crude rate with the crude rate for the remainder of Idaho (518.9) gives an estimate of the relative burden of disease in Valley County.

The age- and sex-adjusted incidence rate of invasive cancer in Valley County, all sites combined, was 478.1 cases per 100,000 persons per year during 2016–2020. There were fewer cases of cancer in Valley County (379) than expected (411.3) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

#### **CANCER MORTALITY 2017–2021**

During 2017–2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 104 Valley County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

**Table 2:** Overall and Cancer Mortality in Valley County and the State of Idaho, 2017–2021

Mortality 2017–2021	Valley County	State of Idaho
All Deaths	414	77,431
Cancer Deaths	104	15,121
% of All Deaths	25.1%	19.5%
Lung & Bronchus	16	2,961
Colorectal	7	1,319
Pancreas	7	1,190
Female Breast	7	1,086
Prostate	7	949

Table 4 (Cancer Mortality 2017–2021, Comparison between Valley County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Valley County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Valley County, all sites combined, was 128.0 deaths per 100,000 persons per year during 2017–2021, compared with 168.1 for the remainder of the state. There were statistically significantly fewer cancer deaths in Valley County (104) than expected (136.6) based upon rates in the remainder of the state (n= 004)

**Statistical Note:** Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

#### TABLE 3: CANCER INCIDENCE 2016–2020 COMPARISON BETWEEN VALLEY COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Va	Remainder of Idaho						
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)
All Sites Combined	Total	379	55,427	683.8	478.1	411.3	0.114	45,231	8,716,401	518.9
All Sites Combined	Male	231 148	28,610	807.4	519.1	245.1	0.386	24,058	4,368,300	550.7
All Sites Combined Bladder	Female Total	20	26,817 55,427	551.9 36.1	416.3 24.5	173.1 20.2	0.057 1.000	21,173 2,164	4,348,101 8,716,401	486.9 24.8
Bladder	Male	20 17	28,610	59.4	37.0	18.2	0.896	1,734	4,368,300	39.7
Bladder	Female	3	26,817	11.2	8.2	3.6	1.000	430	4,348,101	9.9
Brain - malignant	Total	3	55,427	5.4	4.1	5.2	0.486	622	8,716,401	7.1
Brain - malignant	Male	2	28,610	7.0	5.1	3.4	0.697	373	4,368,300	8.5
Brain - malignant	Female	1	26,817	3.7	3.0	1.9	0.867	249	4,348,101	5.7
Brain and other CNS - non-malignant	Total	1	55,427	1.8	1.4	12.1	0.000 <<	1,423	8,716,401	16.3
Brain and other CNS - non-malignant Brain and other CNS - non-malignant	Male Female	- 1	28,610 26,817	3.7	- 2.9	4.3 7.4	0.026 <b>&lt;&lt;</b> 0.010 <b>&lt;&lt;</b>	480 943	4,368,300 4,348,101	11.0 21.7
Breast	Total	53	55,427	95.6	67.7	60.1	0.398	6,693	8,716,401	76.8
Breast	Male	-	28,610	-	-	0.6	1.000	59	4,368,300	1.4
Breast	Female	53	26,817	197.6	146.2	55.3	0.825	6,634	4,348,101	152.6
Breast - in situ	Total	9	55,427	16.2	11.4	11.2	0.643	1,230	8,716,401	14.1
Breast - in situ	Male .	-	28,610	-	-	0.0	1.000	5	4,368,300	0.1
Breast - in situ	Female	9	26,817	33.6	24.3	10.4	0.810	1,225	4,348,101	28.2
Cervix Colorectal	Female Total	3 26	26,817 55,427	11.2 46.9	9.8 33.7	2.1 30.3	0.716 0.499	301 3,425	4,348,101 8,716,401	6.9 39.3
Colorectal	Male	18	28,610	62.9	42.4	18.3	1.000	1,885	4,368,300	43.2
Colorectal	Female	8	26,817	29.8	23.0	12.3	0.269	1,540	4,348,101	35.4
Corpus Uteri	Female	7	26,817	26.1	18.7	11.4	0.240	1,323	4,348,101	30.4
Esophagus	Total	4	55,427	7.2	4.9	4.7	0.994	502	8,716,401	5.8
Esophagus	Male .	3	28,610	10.5	6.7	4.3	0.743	421	4,368,300	9.6
Esophagus	Female	1	26,817	3.7	2.7	0.7	0.994	81	4,348,101	1.9
Hodgkin Lymphoma Hodgkin Lymphoma	Total Male	3 3	55,427 28,610	5.4 10.5	5.0 9.1	1.4 0.9	0.347 0.116	207 115	8,716,401 4,368,300	2.4 2.6
Hodgkin Lymphoma	Female	-	26,817	10.5	9.1	0.9	1.000	92	4,348,101	2.0
Kidney and Renal Pelvis	Total	15	55,427	27.1	19.1	16.2	0.896	1,800	8.716.401	20.7
Kidney and Renal Pelvis	Male	11	28,610	38.4	25.7	11.5	1.000	1,171	4,368,300	26.8
Kidney and Renal Pelvis	Female	4	26,817	14.9	11.2	5.2	0.819	629	4,348,101	14.5
Larynx	Total	1	55,427	1.8	1.2	2.0	0.810	214	8,716,401	2.5
Larynx	Male	1	28,610	3.5	2.2	1.6	1.000 1.000	159	4,368,300	3.6
Larynx Leukemia	Female Total	- 13	26,817 55,427	23.5	- 17.2	0.5 14.0	0.920	55 1,618	4,348,101 8,716,401	1.3 18.6
Leukemia	Male	8	28,610	28.0	19.1	9.4	0.813	981	4,368,300	22.5
Leukemia	Female	5	26,817	18.6	14.6	5.0	1.000	637	4,348,101	14.7
Liver and Bile Duct	Total	6	55,427	10.8	7.2	7.9	0.662	823	8,716,401	9.4
Liver and Bile Duct	Male	5	28,610	17.5	10.9	6.1	0.849	585	4,368,300	13.4
Liver and Bile Duct	Female	1	26,817	3.7	2.7	2.0	0.797	238	4,348,101	5.5
Lung and Bronchus	Total Male	28 11	55,427 28,610	50.5 38.4	33.7 23.6	46.3 26.1	0.005 <b>&lt;&lt;</b> 0.002 <b>&lt;&lt;</b>	4,859 2,441	8,716,401	55.7 55.9
Lung and Bronchus Lung and Bronchus	Female	17	26,817	63.4	45.8	20.1	0.501	2,441	4,368,300 4,348,101	55.6
Melanoma of the Skin	Total	36	55,427	65.0	47.3	25.3	0.053	2,906	8,716,401	33.3
Melanoma of the Skin	Male	21	28,610	73.4	49.1	17.1	0.401	1,744	4,368,300	39.9
Melanoma of the Skin	Female	15	26,817	55.9	44.1	9.1	0.089	1,162	4,348,101	26.7
Myeloma	Total	10	55,427	18.0	12.3	6.5	0.247	698	8,716,401	8.0
Myeloma	Male	6	28,610	21.0	13.3	4.5	0.596	435	4,368,300	10.0
Myeloma Non-Hodgkin Lymphoma	Female Total	4 16	26,817 55,427	14.9 28.9	10.9 20.4	2.2 17.3	0.367 0.882	263 1,924	4,348,101 8,716,401	6.0 22.1
Non-Hodgkin Lymphoma	Male	12	28,610	41.9	27.9	17.3	0.839	1,924	4,368,300	25.6
Non-Hodgkin Lymphoma	Female	4	26,817	14.9	11.2	6.6	0.425	807	4,348,101	18.6
Oral Cavity and Pharynx	Total	19	55,427	34.3	23.4	11.9	0.070	1,276	8,716,401	14.6
Oral Cavity and Pharynx	Male .	17	28,610	59.4	38.4	9.3	0.030 >>	919	4,368,300	21.0
Oral Cavity and Pharynx	Female	2	26,817	7.5	5.4	3.0	0.837	357	4,348,101	8.2
Ovary	Female	4 6	26,817 55,427	14.9 10.8	11.3 7.4	4.3	1.000 0.049 <b>&lt;&lt;</b>	529 1,417	4,348,101	12.2
Pancreas Pancreas	Total Male	2	55,427 28,610	7.0	7.4 4.4	13.1 8.1	0.049 <<	782	8,716,401 4,368,300	16.3 17.9
Pancreas	Female	4	26,817	14.9	11.2	5.2	0.800	635	4,348,101	14.6
Prostate	Male	73	28,610	255.2	154.1	68.8	0.646	6,344	4,368,300	145.2
Stomach	Total	1	55,427	1.8	1.3	4.2	0.160	466	8,716,401	5.3
Stomach	Male	1	28,610	3.5	2.3	3.1	0.370	308	4,368,300	7.1
Stomach	Female		26,817	-	-	1.2	0.587	158	4,348,101	3.6
Testis	Male	2	28,610	7.0	7.9	1.5	0.898	263	4,368,300	6.0
Thyroid	Total	4	55,427	7.2	6.1	9.1	0.103	1,216	8,716,401	14.0
Thyroid	Male	1	28,610	3.5	2.7	3.0	0.398	354	4,368,300	8.1
Thyroid	Female	3	26,817	11.2	9.9	6.0	0.297	862	4,348,101	19.8
Pediatric Age 0 to 19	Total	1	10,886	9.2	9.3	1.8	0.898	420	2,449,637	17.1
Pediatric Age 0 to 19 Pediatric Age 0 to 19	Male Female	1	5,599 5,287	17.9	17.9	1.0 0.9	1.000 0.852	222 198	1,250,911 1,198,726	17.7 16.5
Notes:	i ciliale	-	o number of case	-	_	0.9	0.002	190	1,100,120	10.5

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

<sup>2.</sup> Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

<sup>&</sup>quot;<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

#### **TABLE 4: CANCER MORTALITY 2017–2021** COMPARISON BETWEEN VALLEY COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

All Causes of Death				Va	Remainder of Idaho						
Cancer Site/Type	Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
All Causes of Death		Sex	Deaths					P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death   Male   234   29,499   783,2   542,0   393,2   0.000 << 40,822   4,482,369   910.7   All Causes of Death   Female   168   27,731   649,1   552,0   265,3   0.000 << 4,6194   4,449,16   181,3   All Malignant Cancers   Total   104   37,7231   173,1   1	All Causes of Death		414	57 230	, ,	, ,	. ,	, ,	77 016	8 931 485	862.3
All Causes of Death   Female   180   27,731   649,1   552,0   265,3   0,000 < 36,194   4,449,116   181,5   181										4 482 369	
All Malgnant Cancers   Total   104   57,230   181.7   128.0   136.6   0.004 << 15.017   8,391,485   168.1										4.449.116	813.5
All Malignant Cancers   Male   66   29,499   189.8   121.7   83.3   0.002 << 8,120   4.482,369   1812.8   181	All Malignant Cancers							0.004 <<			168.1
All Malighant Cancers   Female   48   27,731   132,8   56.0   0.315   6,897   4.449,116   155.0   Bladder   Total   5   57,230   8.7   6.4   4.2   0.829   4.84   8,931,485   5.5   Bladder   Male   3   29,499   10.2   6.6   3.8   0.955   375   4.482,369   8.4   Bladder   Semale   2   27,731   7.2   5.8   0.8   0.413   10.9   4.449,116   2.4   Bladder   Semale   1.2   27,731   7.2   5.8   0.8   0.413   10.9   4.449,116   2.4   Bladder   Semale   1.2   27,731   3.6   6.7   6.2   4.5   0.825   4.99   5.831,1485   3.6   Breat and Other Nervous System   1012   5   57,239   8.7   6.2   4.5   0.825   4.99   5.831,1485   3.6   Breat   Semale   1.2   27,731   3.6   2.7   7.7   0.989   1.095   8.331,485   1.2   Breast   Female   7   27,731   3.6   2.7   7.7   0.989   1.095   8.331,485   1.2   Breast   Female   7   27,731   3.6   2.9   0.6   0.336   8.2   4.449,116   2.4   Colorectal   Total   7   57,230   12.2   8.8   11.7   0.209   1.312   8.331,485   1.2   Colorectal   Male   3   29,499   1.2   6.7   7.1   0.159   1.312   8.331,485   1.3   Colorectal   Male   4   27,731   3.6   2.9   0.6   0.336   8.2   4.449,116   13.4   Colorectal   Female   4   27,731   3.6   2.9   0.6   0.336   8.2   4.449,116   13.4   Colorectal   Female   4   27,731   3.6   2.9   0.6   0.336   8.2   4.449,116   13.4   Colorectal   Female   4   27,731   3.6   2.9   0.6   0.336   8.2   4.449,116   13.4   Colorectal   Female   4   27,731   3.6   2.5   0.6   0.336   8.2   4.449,116   13.4   Escophagus   Otal   Female   4   27,731   3.6   2.5   0.6   0.336   8.2   4.449,116   13.4   Escophagus   Otal   Female   4   27,731   3.6   2.5   0.000   3.6   3.8   3.8   3.8   3.8   3.8   Escophagus   Otal   Female   4   27,731   3.6   2.5   0.000   3.8				29,499				0.002 <<	8,120		181.2
Bladder Male 3 29,499 10.2 6.6 3.8 0.955 375 4,482,369 8.4 Brad and Other Nervous System Total 5 57,230 8.7 6.2 4.5 0.925 499 8331,485 6.8 e.8 0.413 109 4.449,116 2.4 Brain and Other Nervous System Total 5 57,230 8.7 6.2 4.5 0.925 499 8331,485 6.8 e.8 0.413 109 4.449,116 2.4 Brain and Other Nervous System Male 4 29,499 13.6 9.2 2.9 0.645 294 4,482,369 6.8 Brain and Other Nervous System Female 1 27,731 3.6 9.2 2.9 0.645 294 4,482,369 6.8 Brain and Other Nervous System Female 1 27,731 3.6 9.2 2.9 0.0 0.993 0.0 0.0 10.0 10.0 10.0 10.0 10.0 10.0		Female	48	27,731	173.1	132.8	56.0	0.315	6,897		155.0
Bladder	Bladder			57,230	8.7	6.4	4.2	0.829	484		5.4
Brain and Other Nervous System   Total   5   57,230   8.7   6.2   4.5   0,925   4.99   4,482,399   6.6   6.6   6.6   6.7											8.4
Brain and Other Nervous System Male											
Brain and Other Nervous System Female 1 27,731 3.6 2.7 1.7 0.990 205 4,449,116 4.6 Breast Total 7 57,230 1.2 8.8 9.7 0.489 1.95 8,931,485 12.3 Breast Male - 29,499 0.0 1.000 16 4,482,369 0.4 Breast Female 7 27,731 3.6 2.5 19.5 8.7 0.718 1.079 4,449,116 2.4 3.6 Circuital Total 7 57,230 1.2 8.8 17.7 0.200 1.3	Brain and Other Nervous System			57,230							5.6
Breast   Total   7   57,230   12.2   8.8   9.7   0.489   1,095   8,931,485   12.3   Breast   Female   7   77,731   25.2   19.5   8.7   0.718   1,079   4,449,116   24.3   Breast   Female   7   77,731   25.2   19.5   8.7   0.718   1,079   4,449,116   24.3   Colorectal   Total   7   57,230   12.2   8.8   11.7   0.209   1,312   8,931,485   14.7   Colorectal   Male   3   29,499   10.2   6.7   7.1   0.152   716   4482,369   16.0   Colorectal   Female   4   27,731   14.4   11.4   4   1.0   992   596   4.449,116   13.4   Colorectal   Female   7   27,733   14.4   11.4   4   1.4   0.992   596   4.449,116   13.4   Esophagus   Total   7   7,733   1.0   1.0   1.0   1.0   Esophagus   Total   7   7,733   1.0   1.0   1.0   1.0   Esophagus   Female   - 27,731     0.6   1.000   29   8,931,485   5.3   Esophagus   Female   - 27,731     0.2   1.000   29   8,931,485   0.3   Hodgkin Lymphoma   Total   - 57,230     0.2   1.000   29   8,931,485   0.3   Hodgkin Lymphoma   Female   -   27,731     0.1   1.000   15   4,449,116   0.3   Esophagus   Female   -   27,731     0.1   1.000   15   4,449,116   0.3   Esophagus   Female   -   27,731     0.1   1.000   15   4,449,116   0.3   Esophagus   Female   -   27,731     0.1   1.000   15   4,449,116   0.3   Esophagus   Female   -   27,731     0.1   1.000   15   4,449,116   0.3   Esophagus   Female   -   27,731     0.1   1.000   15   4,449,116   0.3   Esophagus   Female   -   27,731     0.1   1.000   15   4,449,116   0.3   Esophagus   Female   -   27,731     0.1   0.03   1.4   4.49,116   0.3   Esophagus   Female   -   27,731     0.1   0.00   15   4.449,116   0.3   Esophagus   Female   -   27,731     0.1   0.00   15   4.449,116   0.3   Esophagus   Female   -   27,731     0.1   0.00   15   4.449,116   0.3   Esophagus   Female   -   27,731     0.1   0.00   15   4.449,116   0.3   Esophagus   Female   -   27,731     0.1   0.00   15   4.449,116   0.3   Esophagus   Female   -   27,731     0.1   0.00   15   4.449,116   0.3   Esophagus   F											
Breast Male Female 7 29,499 - 10.2 1.000 16 4,482,369 0.4 Rerast Female 7 27,731 3.6 2.9 10.6 0.936 82 4,449,116 1.8 Cervix Female 1 27,731 3.6 2.9 0.6 0.936 82 4,449,116 1.8 Cervix Female 1 27,731 3.6 2.9 0.6 0.936 82 4,449,116 1.8 Cervix Female 1 27,731 3.6 2.9 0.6 0.936 82 4,449,116 1.8 Cervix Female 3 29,499 10.2 6.7 7.1 0.152 716 4,482,369 16.0 Colorectal Male 3 29,499 10.2 6.7 7.1 0.152 716 4,482,369 16.0 Colorectal Female 4 27,731 14.4 11.4 4.7 0.992 596 4,449,116 3.9 Esophagus Total - 57,230 - 4.4 0.032 < 477 8,331,485 5.3 Esophagus Male - 29,499 4.2 0.031 < 401 4,482,369 8.9 Esophagus Male - 29,499 4.2 0.031 < 401 4,482,369 8.9 Esophagus Female - 27,731 0.8 1.000 75 4,449,116 1.7 Female - 27,731 0.1 1.000 170 170 170 170 170 170 170 170 170			_	27,731							
Breast			/		12.2	8.8					
Cervix			- 7	29,499	25.2	10.5					
Colorectal   Total   7   57,230   12,2   8.8   11,7   0.209   1.312   8,931,485   14,7   Colorectal   Male   3   29,499   10,2   6,7   7.1   0.152   716   4,482,369   16,0   Colorectal   Female   1   27,731   14,4   11,4   4,7   0.992   596   4,449,116   13,4   5,3   5,3   5,3   5,3   5,3   6,3											
Colorectal Male											
Colorectal   Female   4   27,731   14,4   11,4   4,7   0.992   596   4,449,116   13,4	=			29,499							16.0
Corpus Uteri											13.4
Esophagus			1	27,731							3.9
Esophagus			-	57,230				0.023 <<			5.3
Hodgiki Lymphoma	Esophagus	Male	-	29,499	-	-	4.2		401		8.9
Hodgkin Lymphoma   Male			-		-	-					1.7
Hodgikin Lymphoma   Female   -			-	57,230	-	-					0.3
Kidney					-	-					
Kidney			_			-					
Kidney			-	57,230							4.3
Larynx   Male   -   29,499   -   -   -   0.6   0.951   70   8,931,485   0.8											
Larymx Female - 29,499 0.6 1.000 58 4.482,369 1.3 Larymx Female 1 27,731 3.6 2.5 0.1 0.203 12 4.49,116 0.3   Leukemia Total 7 57,230 12.2 9.0 5.7 0.689 653 8,931,485 7.3   Leukemia Female 5 29,499 16.9 11.2 3.8 0.658 381 4,482,369 8.5   Leukemia Female 2 27,731 7.2 5.9 2.1 1.000 272 4,449,116 6.1   Liver and Bile Duct Male 4 29,499 13.6 8.4 4.3 1.000 404 4,482,369 9.0   Liver and Bile Duct Female 1 27,731 3.6 2.6 1.7 1.000 194 4,49,116 4.4   Lung and Bronchus Total 16 57,230 28.0 19.0 27.8 0.023 < 2,945 8,931,485 33.0   Lung and Bronchus Male 6 29,499 20.3 12.6 16.5 0.006 < 1,550 4,482,316 34.6   Lung and Bronchus Female 10 27,731 36.1 27.0 11.6 0.775 1,395 4,449,116 31.4   Melanoma of the Skin Total 3 57,230 5.2 3.8 2.6 0.942 286 8,931,485 3.2   Melanoma of the Skin Male 1 29,499 3.4 2.2 1.9 0.858 191 4,482,369 4.3   Melanoma of the Skin Female 2 27,731 7.2 5.6 0.8 0.358 95 4,49,116 2.1   Myeloma Total 5 57,230 8.7 6.1 3.0 0.367 326 8,931,485 3.7   Myeloma Total 5 57,230 8.7 6.1 3.0 0.367 326 8,931,485 3.7   Myeloma Female 1 29,499 3.4 2.2 1.9 0.858 191 4,482,369 4.3   Myeloma Female 2 29,499 6.8 4.3 2.0 1.000 194 4,482,369 4.3   Myeloma Female 3 27,731 10.8 8.4 1.1 0.184 132 4,49,116 2.1   Myeloma Female 1 27,731 3.6 2.9 2.1 1.000 194 4,482,369 4.3   Mon-Hodgkin Lymphoma Male 4 29,499 13.6 8.8 3.1 0.731 30.3 4,49,116 3.0   Non-Hodgkin Lymphoma Female 1 27,731 3.6 2.9 2.1 1.0 1.000 194 4,482,369 4.3   Non-Hodgkin Lymphoma Female 1 27,731 3.6 2.9 2.1 1.0 1.000 564 8,931,485 6.3   Non-Hodgkin Lymphoma Female 1 27,731 3.6 2.9 2.1 1.0 1.000 544 4,49,116 3.0   Non-Hodgkin Lymphoma Female 1 27,731 3.6 2.9 2.1 1.0 1.0 1.8   Non-Hodgkin Lymphoma Female 1 27,731 3.6 2.9 2.1 1.0 1.0 1.0 1.8   Non-Hodgkin Lymphoma Female 1 27,731 3.6 2.9 2.1 0.784 2.6 1 4,49,116 5.9   Non-Hodgkin Lymphoma Female 1 27,731 3.6 2.9 2.1 0.784 2.6 1 4,49,116 3.0   Non-Hodgkin Lymphoma Female 1 27,731 3.6 2.9 2.1 0.784 2.6 1 4,49,116 5.9   Non-Hodgkin Lymphoma Female 1 27,731 3.6 2.9 2.1 0.784 2.6 1 4,49,116 5.9   Non-Hodgkin Lymphoma Fem				27,731							
Larynx         Female         1         27,731         3.6         2.5         0.1         0.203         12         4,449,116         0.3           Leukemia         Male         5         7,230         12.2         9.0         5.7         0.689         653         8,931,485         7.3           Leukemia         Male         5         29,499         16.9         11.2         3.8         0.658         381         4,482,369         8.5           Leukemia         Female         2         27,731         7.2         5.9         2.1         1.000         272         4,449,116         6.1           Liver and Bile Duct         Male         4         29,499         13.6         8.4         4.3         1.000         404         4,482,369         9.0           Liver and Bile Duct         Male         4         29,499         13.6         8.4         4.3         1.000         404         4,449,116         6.1           Liver and Bile Duct         Female         1         27,731         3.6         2.6         1.7         1.000         444,49,116         4.4           Liver and Bile Duct         Female         1         27,731         3.6         2.6         1.			= -			1.2					
Leukemia						25					
Leukemia         Male         5         29,499         16,9         11,2         3,8         0,658         381         4,482,369         8,5           Leukemia         Female         2         27,731         7,2         5,9         2,1         1,000         272         4,449,116         6,1           Liver and Bile Duct         Male         4         29,499         13,6         8,4         4,3         1,000         404         4,482,369         9,0           Liver and Bile Duct         Female         1         27,731         3,6         2,6         1,7         1,000         404         4,482,369         9,0           Liver and Bile Duct         Female         1         27,731         3,6         2,6         1,7         1,000         194         4,449,116				57 230							
Leukemia         Female         2         27,731         7.2         5.9         2.1         1.000         272         4,449,116         6.1           Liver and Bile Duct         Total         5         57,230         8.7         5.8         5.7         0.977         598         8,931,485         6.7           Liver and Bile Duct         Female         1         27,731         3.6         8.4         4.3         1.000         404         4,482,369         9.0           Liver and Bile Duct         Female         1         27,731         3.6         2.6         1.7         1.000         194         4,449,116         4.4           Lung and Bronchus         Total         16         57,230         28.0         19.0         27.8         0.023         2.945         8,931,485         33.0           Lung and Bronchus         Female         10         27,731         36.1         27.0         11.6         0.775         1,550         4,449,116         34.           Lung and Bronchus         Female         10         27,731         36.1         27.0         11.6         0.775         1,595         4,449,116         31.           Melanoma of the Skin         Male         1 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>											
Liver and Bile Duct   Male   4   29,499   13.6   8.7   5.8   5.7   0.977   598   8,931,485   6.7			2	27.731							
Liver and Bile Duct Female				57,230							6.7
Liver and Bile Duct         Female         1         27,731         3.6         2.6         1.7         1.000         194         4,449,116         4.4           Lung and Bronchus         Male         6         57,230         28.0         19.0         27.8         0.023 <	Liver and Bile Duct	Male	4		13.6	8.4	4.3	1.000	404		9.0
Lung and Bronchus         Male Lung and Bronchus         6         29,499         20.3         12.6         16.5         0.006         <         1,550         4,482,369         34.6           Lung and Bronchus         Female         10         27,731         36.1         27.0         11.6         0.775         1,395         4,449,116         31.4           Melanoma of the Skin         Male         1         29,499         3.4         2.2         1.9         0.858         191         4,482,369         4.3           Melanoma of the Skin         Female         2         27,731         7.2         5.6         0.8         0.358         95         4,449,116         2.1           Myeloma         Total         5         57,230         8.7         6.1         3.0         0.367         326         8,931,485         3.7           Myeloma         Male         2         29,499         6.8         4.3         2.0         1.000         194         4,482,369         4.3           Myeloma         Female         3         27,731         10.8         8.4         1.1         0.184         132         4,449,116         3.0           Non-Hodgkin Lymphoma         Total         5	Liver and Bile Duct	Female		27,731						4,449,116	4.4
Lung and Bronchus         Female         10         27,731         36.1         27.0         11.6         0.775         1,395         4,449,116         31.4           Melanoma of the Skin         Total         3         57,230         5.2         3.8         2.6         0.942         286         8,931,485         3.2           Melanoma of the Skin         Male         1         29,499         3.4         2.2         1.9         0.858         191         4,482,369         4.3           Melanoma of the Skin         Female         2         27,731         7.2         5.6         0.8         0.358         95         4,449,116         2.1           Myeloma         Male         2         29,499         6.8         4.3         2.0         1.000         194         4,482,369         4.3           Myeloma         Male         2         29,499         6.8         4.3         2.0         1.000         194         4,482,369         4.3           Myeloma         Female         3         27,731         10.8         8.4         1.1         0.184         132         4,449,116         3.0           Non-Hodgkin Lymphoma         Total         5         57,230         8.7		Total		57,230							33.0
Melanoma of the Skin         Total         3         57,230         5.2         3.8         2.6         0.942         286         8,931,485         3.2           Melanoma of the Skin         Male         1         29,499         3.4         2.2         1.9         0.858         191         4,482,369         4.3           Melanoma of the Skin         Female         2         27,731         7.2         5.6         0.8         0.358         95         4,449,116         2.1           Myeloma         Male         2         29,499         8.8         6.1         3.0         0.367         326         8,931,485         3.7           Myeloma         Male         2         29,499         6.8         4.3         2.0         1.000         194         4,482,369         4.3           Myeloma         Female         3         27,731         10.8         8.4         1.1         0.184         132         4,449,116         3.0           Non-Hodgkin Lymphoma         Total         5         57,230         8.7         6.3         5.0         1.000         564         8,931,485         6.3           Non-Hodgkin Lymphoma         Male         4         29,499         13.6											34.6
Melanoma of the Skin         Male         1         29,499         3.4         2.2         1.9         0.858         191         4,482,369         4.3           Melanoma of the Skin         Female         2         27,731         7.2         5.6         0.8         0.358         95         4,449,116         2.1           Myeloma         Total         5         57,230         8.7         6.1         3.0         0.367         326         8,931,485         3.7           Myeloma         Male         2         29,499         6.8         4.3         2.0         1.000         194         4,482,369         4.3           Myeloma         Female         3         27,731         10.8         8.4         1.1         0.184         132         4,449,116         3.0           Non-Hodgkin Lymphoma         Total         5         57,230         8.7         6.3         5.0         1.000         564         8,931,485         6.3           Non-Hodgkin Lymphoma         Male         4         29,499         13.6         8.8         3.1         0.731         303         4,482,369         6.8           Non-Hodgkin Lymphoma         Female         1         27,731         3.6											
Melanoma of the Skin         Female         2         27,731         7.2         5.6         0.8         0.358         95         4,449,116         2.1           Myeloma         Total         5         57,230         8.7         6.1         3.0         0.367         326         8,931,485         3.7           Myeloma         Male         2         29,499         6.8         4.3         2.0         1.000         194         4,482,369         4.3           Myeloma         Female         3         27,731         10.8         8.4         1.1         0.184         132         4,449,116         3.0           Non-Hodgkin Lymphoma         Total         5         57,230         8.7         6.3         5.0         1.000         564         8,931,485         6.3           Non-Hodgkin Lymphoma         Male         4         29,499         13.6         8.8         3.1         0.731         303         4,482,369         6.8           Non-Hodgkin Lymphoma         Female         1         27,731         3.6         2.9         2.1         0.784         261         4,449,116         5.9           Oral Cavity and Pharynx         Male         1         29,499         3.4				57,230		3.8					
Myeloma         Total         5         57,230         8.7         6.1         3.0         0.367         326         8,931,485         3.7           Myeloma         Male         2         29,499         6.8         4.3         2.0         1.000         194         4,482,369         4.3           Myeloma         Female         3         27,731         10.8         8.4         1.1         0.184         132         4,449,116         3.0           Non-Hodgkin Lymphoma         Total         5         57,230         8.7         6.3         5.0         1.000         564         8,931,485         6.3           Non-Hodgkin Lymphoma         Male         4         29,499         13.6         8.8         3.1         0.731         303         4,482,369         6.8           Non-Hodgkin Lymphoma         Female         1         27,731         3.6         2.9         2.1         0.784         261         4,449,116         5.9           Oral Cavity and Pharynx         Total         1         57,230         1.7         1.2         2.5         0.584         265         8,931,485         3.0           Oral Cavity and Pharynx         Male         1         29,499         3.4 </td <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>											
Myeloma         Male         2         29,499         6.8         4.3         2.0         1.000         194         4,482,369         4.3           Myeloma         Female         3         27,731         10.8         8.4         1.1         0.184         132         4,449,116         3.0           Non-Hodgkin Lymphoma         Total         5         57,230         8.7         6.3         5.0         1.000         564         8,931,485         6.3           Non-Hodgkin Lymphoma         Male         4         29,499         13.6         8.8         3.1         0.731         303         4,482,369         6.8           Non-Hodgkin Lymphoma         Female         1         27,731         3.6         2.9         2.1         0.784         261         4,449,116         5.9           Oral Cavity and Pharynx         Total         1         57,230         1.7         1.2         2.5         0.584         265         8,931,485         3.0           Oral Cavity and Pharynx         Male         1         29,499         3.4         2.1         1.9         0.846         186         4,482,369         4.1           Ovary         Female         -         27,731         -											
Myeloma         Female         3         27,731         10.8         8.4         1.1         0.184         132         4,449,116         3.0           Non-Hodgkin Lymphoma         Total         5         57,230         8.7         6.3         5.0         1.000         564         8,931,485         6.3           Non-Hodgkin Lymphoma         Male         4         29,499         13.6         8.8         3.1         0.731         303         4,482,369         6.8           Non-Hodgkin Lymphoma         Female         1         27,731         3.6         2.9         2.1         0.784         261         4,449,116         5.9           Oral Cavity and Pharynx         Total         1         57,230         1.7         1.2         2.5         0.584         265         8,931,485         3.0           Oral Cavity and Pharynx         Male         1         29,499         3.4         2.1         1.9         0.846         186         4,482,369         4.1           Ovary         Female         -         27,731         -         -         0.6         1.000         79         4,449,116         1.8           Ovary         Female         -         27,731         -				37,23U							
Non-Hodgkin Lymphoma         Total         5         57,230         8.7         6.3         5.0         1.000         564         8,931,485         6.3           Non-Hodgkin Lymphoma         Male         4         29,499         13.6         8.8         3.1         0.731         303         4,482,369         6.8           Non-Hodgkin Lymphoma         Female         1         27,731         3.6         2.9         2.1         0.784         261         4,449,116         5.9           Oral Cavity and Pharynx         Total         1         57,230         1.7         1.2         2.5         0.584         265         8,931,485         3.0           Oral Cavity and Pharynx         Male         1         29,499         3.4         2.1         1.9         0.846         186         4,482,369         4.1           Oral Cavity and Pharynx         Female         -         27,731         -         -         0.6         1.000         79         4,449,116         1.8           Ovary         Female         -         27,731         -         -         2.9         0.105         350         4,449,116         7.9           Pancreas         Total         7         57,230 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>											
Non-Hodgkin Lymphoma         Male         4         29,499         13.6         8.8         3.1         0.731         303         4,482,369         6.8           Non-Hodgkin Lymphoma         Female         1         27,731         3.6         2.9         2.1         0.784         261         4,449,116         5.9           Oral Cavity and Pharynx         Total         1         57,230         1.7         1.2         2.5         0.584         265         8,931,485         3.0           Oral Cavity and Pharynx         Male         1         29,499         3.4         2.1         1.9         0.846         186         4,482,369         4.1           Oral Cavity and Pharynx         Female         -         27,731         -         -         0.6         1.000         79         4,449,116         1.8           Oral Cavity and Pharynx         Female         -         27,731         -         -         0.6         1.000         79         4,449,116         1.8           Ovary         Female         -         27,731         -         -         2.9         0.105         350         4,449,116         7.9           Pancreas         Male         3         29,499											6.3
Non-Hodgkin Lymphoma         Female         1         27,731         3.6         2.9         2.1         0.784         261         4,449,116         5.9           Oral Cavity and Pharynx         Total         1         57,230         1.7         1.2         2.5         0.584         265         8,931,485         3.0           Oral Cavity and Pharynx         Male         1         29,499         3.4         2.1         1.9         0.846         186         4,482,369         4.1           Oral Cavity and Pharynx         Female         -         27,731         -         -         0.6         1.000         79         4,449,116         1.8           Ovary         Female         -         27,731         -         -         2.9         0.105         350         4,449,116         7.9           Pancreas         Total         7         57,230         12.2         8.3         11.1         0.270         1,183         8,931,485         13.2           Pancreas         Male         3         29,499         10.2         6.4         6.7         0.197         639         4,482,369         14.3           Prostate         Male         7         29,499         23.7											6.8
Oral Cavity and Pharynx         Total         1         57,230         1.7         1.2         2.5         0.584         265         8,931,485         3.0           Oral Cavity and Pharynx         Male         1         29,499         3.4         2.1         1.9         0.846         186         4,482,369         4.1           Oral Cavity and Pharynx         Female         -         27,731         -         -         0.6         1.000         79         4,449,116         1.8           Ovary         Female         -         27,731         -         -         2.9         0.105         350         4,449,116         7.9           Pancreas         Total         7         57,230         12.2         8.3         11.1         0.270         1,183         8,931,485         13.2           Pancreas         Male         3         29,499         10.2         6.4         6.7         0.197         639         4,482,369         14.3           Pancreas         Female         4         27,731         14.4         10.7         4.6         1.000         544         4,449,116         12.2           Prostate         Male         7         29,499         23.7         15.3											5.9
Oral Cavity and Pharynx         Male         1         29,499         3.4         2.1         1.9         0.846         186         4,482,369         4.1           Oral Cavity and Pharynx         Female         -         27,731         -         -         0.6         1.000         79         4,449,116         1.8           Ovary         Female         -         27,731         -         -         2.9         0.105         350         4,449,116         7.9           Pancreas         Total         7         57,230         12.2         8.3         11.1         0.270         1,183         8,931,485         13.2           Pancreas         Male         3         29,499         10.2         6.4         6.7         0.197         639         4,482,369         14.3           Pancreas         Female         4         27,731         14.4         10.7         4.6         1.000         544         4,449,116         12.2           Prostate         Male         7         29,499         23.7         15.3         9.6         0.517         942         4,482,369         21.0           Stomach         Total         1         57,230         1.7         1.3         <			1								3.0
Oral Cavity and Pharynx         Female         -         27,731         -         -         0.6         1.000         79         4,449,116         1.8           Ovary         Female         -         27,731         -         -         2.9         0.105         350         4,449,116         7.9           Pancreas         Total         7         57,230         12.2         8.3         11.1         0.270         1,183         8,931,485         13.2           Pancreas         Male         3         29,499         10.2         6.4         6.7         0.197         639         4,482,369         14.3           Pancreas         Female         4         27,731         14.4         10.7         4.6         1.000         544         4,449,116         12.2           Prostate         Male         7         29,499         23.7         15.3         9.6         0.517         942         4,482,369         21.0           Stomach         Total         1         57,230         1.7         1.3         1.7         0.984         197         8,931,485         2.2			l i								4.1
Ovary         Female         -         27,731         -         -         2.9         0.105         350         4,449,116         7.9           Pancreas         Total         7         57,230         12.2         8.3         11.1         0.270         1,183         8,931,485         13.2           Pancreas         Male         3         29,499         10.2         6.4         6.7         0.197         639         4,482,369         14.3           Pancreas         Female         4         27,731         14.4         10.7         4.6         1.000         544         4,449,116         12.2           Prostate         Male         7         29,499         23.7         15.3         9.6         0.517         942         4,482,369         21.0           Stomach         Total         1         57,230         1.7         1.3         1.7         0.984         197         8,931,485         2.2			- 1	27,731			0.6	1.000	79		1.8
Pancreas         Total         7         57,230         12.2         8.3         11.1         0.270         1,183         8,931,485         13.2           Pancreas         Male         3         29,499         10.2         6.4         6.7         0.197         639         4,482,369         14.3           Pancreas         Female         4         27,731         14.4         10.7         4.6         1.000         544         4,449,116         12.2           Prostate         Male         7         29,499         23.7         15.3         9.6         0.517         942         4,482,369         21.0           Stomach         Total         1         57,230         1.7         1.3         1.7         0.984         197         8,931,485         2.2	Ovary	Female	-	27,731			2.9			4,449,116	7.9
Pancreas         Female         4         27,731         14.4         10.7         4.6         1.000         544         4,449,116         12.2           Prostate         Male         7         29,499         23.7         15.3         9.6         0.517         942         4,482,369         21.0           Stomach         Total         1         57,230         1.7         1.3         1.7         0.984         197         8,931,485         2.2				57,230					1,183		13.2
Prostate         Male         7         29,499         23.7         15.3         9.6         0.517         942         4,482,369         21.0           Stomach         Total         1         57,230         1.7         1.3         1.7         0.984         197         8,931,485         2.2				29,499							14.3
Stomach Total 1 57,230 1.7 1.3 1.7 0.984 197 8,931,485 2.2						10.7					12.2
						15.3					21.0
otomacn   Male   1   29,499   3.4   2.3   1.2   1.000   120   4,482,369   2.7											2.2
			1		3.4	2.3					
Stomach   Female   -   27,731   -   -   0.6   1.000   77   4,449,116   1.7	Stomach	Female	-	27,731	-	-	0.6	1.000	77	4,449,116	1.7

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

<sup>2.</sup> Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

#### Cancer Screening and Risk Factor Prevalence Estimates, 2011–2021

	State of								Valley
Measure	Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	County
Access to Care									
Have Health Insurance, Age <65 (2015–2021)	83.1%	82.8%	85.1%	77.2%	85.8%	78.9%	85.4%	85.4%	78.0%
Not See Doctor Due to Cost in Past Year (2015–2021)	12.6%	11.4%	11.8%	14.5%	12.4%	12.3%	11.8%	12.9%	13.4%
Cancer Screening									
Mammogram Past 2 Years, Age 50-74 (2014, 2016, 2018, 2020)	69.1%	67.0%	73.8%	68.2%	73.2%	64.8%	64.5%	67.1%	
Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020)	71.2%	73.6%	73.6%	70.8%	72.9%	69.1%	69.5%	65.9%	
Colorectal Cancer Screening, Age 50–75 (2018, 2020)	67.9%	66.9%	73.6%	71.4%	70.6%	61.7%	61.5%	64.7%	
Tobacco Use									
Current Tobacco User (2016–2021)	22.3%	26.7%	23.1%	23.6%	21.8%	21.4%	22.7%	16.9%	25.5%
Other Cancer-Related \									
Healthy Weight by Body Mass Index, Age 20+ (2015–2021)	32.1%	32.8%	31.7%	27.9%	36.1%	29.8%	27.9%	31.9%	46.7%
Any Physical Activity Besides Job Past 30 Days (2015-2021)	78.7%	79.2%	78.1%	74.5%	83.2%	73.4%	76.3%	79.7%	83.5%
Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019)	21.9%	22.8%	19.4%	20.0%	25.2%	19.5%	20.4%	20.2%	26.1%
Home Ever Tested for Radon (2016, 2018, 2020)	23.0%	30.9%	18.2%	16.9%	25.1%	19.9%	23.0%	21.8%	29.5%

#### **Access to Care**

#### Have Health Insurance - 2015-2021

Statewide, 83.1% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 86.0% of white non-Hispanics, compared to 64.8% of Hispanics and 83.3% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3%) than English-speaking respondents (84.2%). Health care coverage differed significantly by age of respondent, with 79.8% of persons aged 18–29, and 87.8% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 62.1% in Adams County to 91.6% in Oneida County having health insurance.

#### Not See Doctor Due to Cost in Past Year - 2015-2021

Statewide, 12.6% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (11.5% of white non-Hispanics, 19.2% of Hispanics, and 21.0% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9% for less than \$15,000, 6.1% for greater than \$50,000). Inability to see a doctor due to cost differed significantly by county, with a range of 7.4% in Franklin County to 17.5% in Power County.

#### **Cancer Screening**

<u>Mammogram</u> – 2014, 2016, 2018, 2020

Statewide, 69.1% of women aged 50–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (72.1% versus 36.7%). Mammography rates differed significantly by county, with a range in screening of 45.9% in Benewah County to 77.0% in Nez Perce County. In 2020, Idaho ranked 48<sup>th</sup> among states and the District of Columbia for mammography screening rates among women aged 50–74 and also 48<sup>th</sup> among ages 40+.

#### Pap Test - 2018, 2020

Statewide, 71.2% of women with an intact cervix and aged 21–65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.1% versus 52.6% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.7% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49<sup>th</sup> among states and the District of Columbia for Pap screening rate.

#### Colorectal Cancer Screening – 2018, 2020

Statewide, 67.9% of adults aged 50–75 reported being current for colorectal cancer screening.\*\* Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked 47<sup>th</sup> among states and the District of Columbia in the percentage of adults aged 50–75 and older who reported being up-to-date for colorectal cancer screening.

<sup>\*\*</sup> Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

#### **Tobacco Use**

#### Current Tobacco Use - 2016-2021

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.3% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 29.9% of persons aged 18-29, and 11.1% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (22.4%) than among Native Americans (40.0%). Tobacco use differed significantly by county, with a range of 5.4% in Madison County to 41.6% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

#### **Other Cancer-Related**

#### Healthy Weight by Body Mass Index - 2015-2021

Statewide, 32.1% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 32.5% of white non-Hispanics, compared to 28.2% of Hispanics and 24.6% of Native Americans, being in the healthy weight range. Males (25.5%) were significantly less likely to be in the healthy weight range than females (38.6%). BMI differed significantly by age of respondent, with 43.3% of persons aged 18–29, and 26.0% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 19.8% in Power County to 47.4% in Blaine County of adults being in the healthy weight range.

#### Any Physical Activity - 2015-2021

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 78.7% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.3% of persons aged 18–29, and 72.3% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 64.3% in Clark County to 84.6% in Teton County.

Physical Activity Guidelines – 2011, 2013, 2015, 2017, 2019 Statewide, 21.9% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.3% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6% in Franklin County to 30.6% in Blaine County.

#### Home Radon Testing - 2016, 2018, 2020

Statewide, 23.0% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.4% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.5% in Cassia County to 54.4% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006l and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.





# WASHINGTON COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

#### Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

#### **RISK FACTORS AND INTERVENTIONS**

#### **CANCER**

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/jama.2016.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

#### Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

#### **Smoking:**

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

#### Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <a href="https://www.dietaryguidelines.gov">https://www.dietaryguidelines.gov</a>

#### Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute
Cancer Information Services
1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society <a href="https://www.cancer.org">https://www.cancer.org</a>

#### **CANCER INCIDENCE 2016–2020**

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016–2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 405 cases of invasive cancer were diagnosed among Washington County residents (Table 1).

**Table 1:** Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Washington County and the State of Idaho. 2016–2020

	,	
Cancer Incidence 2016–2020	Washington County	State of Idaho
All Sites/Types	405	45,610
Female Breast	49	6,687
Prostate	62	6,417
Lung & Bronchus	45	4,887
Colorectal	42	3,451

Table 3 (Cancer Incidence 2016–2020, Comparison between Washington County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Washington County. The table also shows the number of observed cases,

person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Washington County was 799.7 cases per 100,000 person-years per year during 2016–2020. Comparing this crude rate with the crude rate for the remainder of Idaho (518.3) gives an estimate of the relative burden of disease in Washington County.

The age- and sex-adjusted incidence rate of invasive cancer in Washington County, all sites combined, was 573.8 cases per 100,000 persons per year during 2016–2020. There were statistically significantly more cases of cancer in Washington County (405) than expected (365.9) based upon rates in the remainder of the state (p=.046).

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

#### **CANCER MORTALITY 2017–2021**

During 2017–2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 152 Washington County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

**Table 2:** Overall and Cancer Mortality in Washington County and the State of Idaho, 2017–2021

Mortality 2017–2021	Washington County	State of Idaho
All Deaths	712	77,431
Cancer Deaths	152	15,121
% of All Deaths	21.3%	19.5%
Lung & Bronchus	32	2,961
Colorectal	15	1,319
Pancreas	15	1,190
Female Breast	6	1,086
Prostate	6	949

Table 4 (Cancer Mortality 2017–2021, Comparison between Washington County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Washington County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Washington County, all sites combined, was 195.5 deaths per 100,000 persons per year during 2017–2021, compared with 167.5 for the remainder of the state. There were more cancer deaths in Washington County (152) than expected (130.2) based upon rates in the remainder of the state, but the difference was not statistically significant.

**Statistical Note:** Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

### TABLE 3: CANCER INCIDENCE 2016–2020 COMPARISON BETWEEN WASHINGTON COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Wash	Remainder of Idaho						
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)
All Sites Combined	Total	405	50,641	799.7	573.8 599.4	365.9	0.046 >>	45,205	8,721,187	518.3
All Sites Combined All Sites Combined	Male Female	223 182	25,185 25,456	885.4 715.0	541.3	204.8 163.4	0.219 0.161	24,066 21,139	4,371,725 4,349,462	550.5 486.0
Bladder	Total	18	50,641	35.5	23.3	19.2	0.899	2,166	8,721,187	24.8
Bladder	Male	13	25,185	51.6	32.2	16.1	0.538	1,738	4,371,725	39.8
Bladder	Female	5	25,456	19.6	13.6	3.6	0.595	428	4,349,462	9.8
Brain - malignant Brain - malignant	Total Male	1	50,641 25,185	2.0	1.6	4.6 2.8	0.114 0.123	624 375	8,721,187 4,371,725	7.2 8.6
Brain - malignant	Female	1	25,165	3.9	3.1	1.8	0.123	249	4,349,462	5.7
Brain and other CNS - non-malignant	Total	14	50,641	27.6	21.0	10.8	0.400	1,410	8,721,187	16.2
Brain and other CNS - non-malignant	Male .	5	25,185	19.9	15.1	3.6	0.590	475	4,371,725	10.9
Brain and other CNS - non-malignant Breast	Female Total	9 49	25,456 50,641	35.4 96.8	27.3 72.9	7.1 51.6	0.568 0.787	935 6,697	4,349,462 8,721,187	21.5 76.8
Breast	Male	49	25,185	90.0	72.9	0.5	1.000	59	4,371,725	1.3
Breast	Female	49	25,456	192.5	149.0	50.2	0.942	6,638	4,349,462	152.6
Breast - in situ	Total	7	50,641	13.8	10.7	9.2	0.601	1,232	8,721,187	14.1
Breast - in situ	Male		25,185	- 07.5	- 0	0.0	1.000	5	4,371,725	0.1
Breast - in situ Cervix	Female Female	7	25,456 25,456	27.5 3.9	21.8 3.8	9.0 1.8	0.639 0.918	1,227 303	4,349,462 4,349,462	28.2 7.0
Colorectal	Total	42	50,641	82.9	59.8	27.5	0.916	3,409	8,721,187	39.1
Colorectal	Male	19	25,185	75.4	53.1	15.4	0.425	1,884	4,371,725	43.1
Colorectal	Female	23	25,456	90.4	66.7	12.1	0.007 >>	1,525	4,349,462	35.1
Corpus Uteri	Female	8	25,456	31.4	24.4 10.9	10.0	0.670 0.127	1,322 498	4,349,462	30.4 5.7
Esophagus Esophagus	Total Male	8 7	50,641 25,185	15.8 27.8	10.9	4.2 3.6	0.127	498 417	8,721,187 4,371,725	9.5
Esophagus	Female	1	25,456	3.9	2.8	0.7	0.973	81	4,349,462	1.9
Hodgkin Lymphoma	Total	-	50,641	-	-	1.3	0.545	210	8,721,187	2.4
Hodgkin Lymphoma	Male .	-	25,185	-	-	0.7	0.950	118	4,371,725	2.7
Hodgkin Lymphoma	Female Total	- 15	25,456 50.641	- 29.6	- 21.7	0.6 14.3	1.000 0.918	92 1,800	4,349,462	2.1 20.6
Kidney and Renal Pelvis Kidney and Renal Pelvis	Male	12	25,185	47.6	33.9	9.5	0.916	1,000	8,721,187 4,371,725	26.8
Kidney and Renal Pelvis	Female	3	25,456	11.8	8.9	4.9	0.556	630	4,349,462	14.5
Larynx	Total	3	50,641	5.9	4.1	1.8	0.517	212	8,721,187	2.4
Larynx	Male	3	25,185	11.9	7.9	1.4	0.312	157	4,371,725	3.6
Larynx Leukemia	Female Total	- 16	25,456 50,641	31.6	22.4	0.4 13.2	1.000 0.513	55 1,615	4,349,462 8,721,187	1.3 18.5
Leukemia	Male	7	25,185	27.8	19.1	8.2	0.841	982	4,371,725	22.5
Leukemia	Female	9	25,456	35.4	25.8	5.1	0.147	633	4,349,462	14.6
Liver and Bile Duct	Total	13	50,641	25.7	18.2	6.7	0.040 >>	816	8,721,187	9.4
Liver and Bile Duct	Male	6 7	25,185	23.8	16.4	4.9	0.729	584	4,371,725	13.4
Liver and Bile Duct Lung and Bronchus	Female Total	45	25,456 50.641	27.5 88.9	19.9 58.7	1.9 42.6	0.006 <b>&gt;&gt;</b> 0.751	232 4,842	4,349,462 8,721,187	5.3 55.5
Lung and Bronchus	Male	20	25,185	79.4	50.0	22.3	0.732	2,432	4,371,725	55.6
Lung and Bronchus	Female	25	25,456	98.2	67.7	20.4	0.366	2,410	4,349,462	55.4
Melanoma of the Skin	Total	16	50,641	31.6	23.6	22.8	0.179	2,926	8,721,187	33.6
Melanoma of the Skin	Male	11 5	25,185 25,456	43.7 19.6	30.3 15.9	14.6 8.5	0.432 0.306	1,754 1,172	4,371,725 4,349,462	40.1 26.9
Melanoma of the Skin Myeloma	Female Total	11	50,641	21.7	14.6	6.0	0.300	697	8,721,187	8.0
Myeloma	Male	9	25,185	35.7	23.0	3.9	0.036 >>	432	4,371,725	9.9
Myeloma	Female		25,456	7.9	5.5	2.2	1.000	265	4,349,462	6.1
Non-Hodgkin Lymphoma	Total	23	50,641	45.4 50.6	32.5	15.6	0.091	1,917	8,721,187	22.0
Non-Hodgkin Lymphoma Non-Hodgkin Lymphoma	Male Female	15 8	25,185 25,456	59.6 31.4	41.5 23.0	9.2 6.4	0.097 0.634	1,114 803	4,371,725 4,349,462	25.5 18.5
Oral Cavity and Pharynx	Total	9	50,641	17.8	13.0	10.2	0.858	1,286	8,721,187	14.7
Oral Cavity and Pharynx	Male	5	25,185	19.9	14.1	7.6	0.471	931	4,371,725	21.3
Oral Cavity and Pharynx	Female	4	25,456	15.7	11.8	2.8	0.604	355	4,349,462	8.2
Ovary Pancreas	Female	4 15	25,456 50,641	15.7 29.6	12.1 20.0	4.0	1.000 0.480	529 1.408	4,349,462 8,721,187	12.2
Pancreas Pancreas	Total Male	15	25,185	29.6 47.6	31.0	12.1 6.8	0.480	1,408 772	4,371,725	16.1 17.7
Pancreas	Female	3	25,456	11.8	8.2	5.3	0.440	636	4,349,462	14.6
Prostate	Male	62	25,185	246.2	164.1	54.9	0.372	6,355	4,371,725	145.4
Stomach	Total	3	50,641	5.9	4.1	3.9	0.922	464	8,721,187	5.3
Stomach Stomach	Male Female	2 1	25,185 25,456	7.9 3.9	5.3 2.9	2.7 1.3	1.000 1.000	307 157	4,371,725 4,349,462	7.0 3.6
Testis	Male	1	25,456	4.0	4.7	1.3	1.000	264	4,349,462	6.0
Thyroid	Total	3	50,641	5.9	5.5	7.6	0.109	1,217	8,721,187	14.0
Thyroid	Male	1	25,185	4.0	3.4	2.4	0.611	354	4,371,725	8.1
Thyroid	Female	2	25,456	7.9	7.6	5.2	0.215	863	4,349,462	19.8
Pediatric Age 0 to 19	Total	1	12,774	7.8	7.8	2.2	0.711	420	2,447,749	17.2
Pediatric Age 0 to 19	Male	1	6,428	15.6	15.6	1.1	1.000	222	1,250,082	17.8
Pediatric Age 0 to 19	Female	-	6,346	-	-	1.1	0.694	198	1,197,667	16.5

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

<sup>2.</sup> Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

<sup>&</sup>quot;<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

#### **TABLE 4: CANCER MORTALITY 2017–2021** COMPARISON BETWEEN WASHINGTON COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Wash	Remainder of Idaho						
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	712	51,509	1,382.3	914.4	668.4	0.098	76,718	8,937,206	858.4
All Causes of Death	Male	368	25,661	1,434.1	929.9	358.9	0.646	40,688	4,486,207	907.0
All Causes of Death	Female	344	25,848	1,330.9	890.8	312.6	0.084	36,030	4,450,999	809.5
All Malignant Cancers	Total	152	51,509	295.1	195.5	130.2	0.067	14,969	8,937,206	167.5
All Malignant Cancers	Male	81	25,661	315.7	198.9	73.5	0.410	8,095	4,486,207	180.4
All Malignant Cancers	Female	71 3	25,848	274.7	190.3	57.6	0.097 0.673	6,874	4,450,999	154.4 5.4
Bladder Bladder	Total Male	3 1	51,509 25,661	5.8 3.9	3.6 2.3	4.5 3.7	0.673	486 377	8,937,206 4,486,207	5.4 8.4
Bladder	Female	2	25,848	7.7	5.0	1.0	0.514	109	4.450.999	2.4
Brain and Other Nervous System	Total	2	51,509	3.9	2.9	3.9	0.500	502	8,937,206	5.6
Brain and Other Nervous System	Male	2	25,661	7.8	5.5	2.4	1.000	296	4,486,207	6.6
Brain and Other Nervous System	Female	-	25,848	-	-	1.6	0.415	206	4,450,999	4.6
Breast	Total	6	51,509	11.6	8.1	9.1	0.395	1,096	8,937,206	12.3
Breast	Male	-	25,661	-	-	0.1	1.000	16	4,486,207	0.4
Breast	Female	6	25,848	23.2	16.6	8.8	0.460	1,080	4,450,999	24.3
Cervix	Female	-	25,848	-	-	0.6	1.000	83	4,450,999	1.9
Colorectal	Total	15	51,509	29.1	19.9	11.0	0.294	1,304	8,937,206	14.6
Colorectal	Male	7	25,661 25,848	27.3	18.3	6.1	0.812	712 502	4,486,207	15.9
Colorectal Corpus Uteri	Female Female	8 2	25,848 25,848	31.0 7.7	21.4 5.4	5.0 1.4	0.261 0.827	592 171	4,450,999 4,450,999	13.3 3.8
Esophagus	Total	3	51,509	5.8	3.9	4.0	0.849	474	8,937,206	5.3
Esophagus	Male	2	25,661	7.8	5.1	3.5	0.638	399	4,486,207	8.9
Esophagus	Female	l - 1	25,848	3.9	2.7	0.6	0.937	75	4,450,999	1.7
Hodgkin Lymphoma	Total	-	51,509	-	-	0.2	1.000	29	8,937,206	0.3
Hodgkin Lymphoma	Male	-	25,661	-	-	0.1	1.000	14	4,486,207	0.3
Hodgkin Lymphoma	Female	-	25,848	-	-	0.1	1.000	15	4,450,999	0.3
Kidney	Total	2	51,509	3.9	2.5	3.4	0.686	383	8,937,206	4.3
Kidney	Male	2	25,661	7.8	5.0	2.2	1.000	240	4,486,207	5.3
Kidney	Female	-	25,848	-	-	1.3	0.570	143	4,450,999	3.2
Larynx	Total	2	51,509	3.9	2.6	0.6	0.240	69 50	8,937,206	0.8
Larynx	Male	2	25,661	7.8	4.9	0.5 0.1	0.188 1.000	56	4,486,207 4,450,999	1.2 0.3
Larynx Leukemia	Female Total	- 3	25,848 51,509	- 5.8	3.8	5.8	0.330	13 657	8,937,206	7.4
Leukemia	Male	-	25,661	5.0	5.0	3.6	0.330	386	4,486,207	8.6
Leukemia	Female	3	25,848	11.6	7.7	2.4	0.839	271	4,450,999	6.1
Liver and Bile Duct	Total	11	51,509	21.4	14.5	5.0	0.029 >>	592	8,937,206	6.6
Liver and Bile Duct	Male	5	25,661	19.5	12.7	3.5	0.561	403	4,486,207	9.0
Liver and Bile Duct	Female	6	25,848	23.2	16.2	1.6	0.011 >>	189	4,450,999	4.2
Lung and Bronchus	Total	32	51,509	62.1	40.4	26.0	0.280	2,929	8,937,206	32.8
Lung and Bronchus	Male	16	25,661	62.4	38.7	14.2	0.697	1,540	4,486,207	34.3
Lung and Bronchus	Female	16	25,848	61.9	41.9	11.9	0.297	1,389	4,450,999	31.2
Melanoma of the Skin	Total	1	51,509	1.9	1.3	2.4	0.603	288	8,937,206	3.2
Melanoma of the Skin	Male	1	25,661	3.9	2.5	1.7	0.998	191	4,486,207	4.3
Melanoma of the Skin Myeloma	Female Total	- 4	25,848 51,509	7.8	4.9	0.8 3.0	0.922 0.710	97 327	4,450,999 8,937,206	2.2 3.7
Myeloma	Male	3	25,661	7.0 11.7	4.9 6.9	1.9	0.710	327 193	4,486,207	4.3
Myeloma	Female	1	25,848	3.9	2.6	1.2	1.000	134	4,450,999	3.0
Non-Hodgkin Lymphoma	Total	11	51,509	21.4	13.7	5.0	0.027 >>	558	8,937,206	6.2
Non-Hodgkin Lymphoma	Male	6	25,661	23.4	14.6	2.7	0.121	301	4,486,207	6.7
Non-Hodgkin Lymphoma	Female	5	25,848	19.3	12.8	2.3	0.158	257	4,450,999	5.8
Oral Cavity and Pharynx	Total	2	51,509	3.9	2.6	2.2	1.000	264	8,937,206	3.0
Oral Cavity and Pharynx	Male	1	25,661	3.9	2.5	1.6	1.000	186	4,486,207	4.1
Oral Cavity and Pharynx	Female	1	25,848	3.9	2.7	0.6	0.949	78	4,450,999	1.8
Ovary	Female	4	25,848	15.5	10.9	2.8	0.637	346	4,450,999	7.8
Pancreas	Total	15	51,509	29.1	19.3	10.2	0.193	1,175	8,937,206	13.1
Pancreas	Male	12	25,661	46.8	29.7	5.7	0.027 >>	630	4,486,207	14.0
Pancreas Prostate	Female	3 6	25,848 25,661	11.6 23.4	8.0 13.7	4.6 9.2	0.648 0.374	545 943	4,450,999 4,486,207	12.2
Stomach	Male Total	4	25,661 51,509	7.8	5.4	1.6	0.374	194	4,486,207 8,937,206	21.0 2.2
Stomach	Male	2	25,661	7.8 7.8	5.4 5.1	1.0	0.160	119	4,486,207	2.2
Stomach	Female	2	25,848	7.7	5.6	0.6	0.331	75	4,450,999	1.7
			ne number of cases p				U.442	13	<b>⊤,</b> ⊤ਹ∪,ਹਹਰ	1.7

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

<sup>2.</sup> Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

<sup>3.</sup> Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

<sup>4.</sup> P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

#### Cancer Screening and Risk Factor Prevalence Estimates, 2011–2021

	State of								Washington
Measure	Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	County
Access to Care									
Have Health Insurance, Age <65 (2015–2021)	83.1%	82.8%	85.1%	77.2%	85.8%	78.9%	85.4%	85.4%	77.8%
Not See Doctor Due to Cost in Past Year (2015–2021)	12.6%	11.4%	11.8%	14.5%	12.4%	12.3%	11.8%	12.9%	14.5%
Cancer Screening									
Mammogram Past 2 Years, Age 50–74 (2014, 2016, 2018, 2020)	69.1%	67.0%	73.8%	68.2%	73.2%	64.8%	64.5%	67.1%	70.5%
Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020)	71.2%	73.6%	73.6%	70.8%	72.9%	69.1%	69.5%	65.9%	
Colorectal Cancer Screening, Age 50–75 (2018, 2020)	67.9%	66.9%	73.6%	71.4%	70.6%	61.7%	61.5%	64.7%	62.0%
Tobacco Use									
Current Tobacco User (2016–2021)	22.3%	26.7%	23.1%	23.6%	21.8%	21.4%	22.7%	16.9%	29.1%
Other Cancer-Related									
Healthy Weight by Body Mass Index, Age 20+ (2015–2021)	32.1%	32.8%	31.7%	27.9%	36.1%	29.8%	27.9%	31.9%	25.7%
Any Physical Activity Besides Job Past 30 Days (2015-2021)	78.7%	79.2%	78.1%	74.5%	83.2%	73.4%	76.3%	79.7%	70.0%
Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019)	21.9%	22.8%	19.4%	20.0%	25.2%	19.5%	20.4%	20.2%	23.2%
Home Ever Tested for Radon (2016, 2018, 2020)	23.0%	30.9%	18.2%	16.9%	25.1%	19.9%	23.0%	21.8%	14.2%

#### **Access to Care**

#### Have Health Insurance - 2015-2021

Statewide, 83.1% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 86.0% of white non-Hispanics, compared to 64.8% of Hispanics and 83.3% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3%) than English-speaking respondents (84.2%). Health care coverage differed significantly by age of respondent, with 79.8% of persons aged 18–29, and 87.8% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 62.1% in Adams County to 91.6% in Oneida County having health insurance.

#### Not See Doctor Due to Cost in Past Year - 2015-2021

Statewide, 12.6% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (11.5% of white non-Hispanics, 19.2% of Hispanics, and 21.0% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9% for less than \$15,000, 6.1% for greater than \$50,000). Inability to see a doctor due to cost differed significantly by county, with a range of 7.4% in Franklin County to 17.5% in Power County.

#### **Cancer Screening**

Mammogram - 2014, 2016, 2018, 2020

Statewide, 69.1% of women aged 50–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (72.1% versus 36.7%). Mammography rates differed significantly by county, with a range in screening of 45.9% in Benewah County to 77.0% in Nez Perce County. In 2020, Idaho ranked 48<sup>th</sup> among states and the District of Columbia for mammography screening rates among women aged 50–74 and also 48<sup>th</sup> among ages 40+.

#### Pap Test – 2018, 2020

Statewide, 71.2% of women with an intact cervix and aged 21–65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.1% versus 52.6% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.7% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49<sup>th</sup> among states and the District of Columbia for Pap screening rate.

#### Colorectal Cancer Screening – 2018, 2020

Statewide, 67.9% of adults aged 50–75 reported being current for colorectal cancer screening.\*\* Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked 47<sup>th</sup> among states and the District of Columbia in the percentage of adults aged 50–75 and older who reported being up-to-date for colorectal cancer screening.

<sup>\*\*</sup> Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

#### **Tobacco Use**

#### Current Tobacco Use - 2016-2021

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.3% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 29.9% of persons aged 18-29, and 11.1% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (22.4%) than among Native Americans (40.0%). Tobacco use differed significantly by county, with a range of 5.4% in Madison County to 41.6% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

#### **Other Cancer-Related**

#### Healthy Weight by Body Mass Index - 2015-2021

Statewide, 32.1% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 32.5% of white non-Hispanics, compared to 28.2% of Hispanics and 24.6% of Native Americans, being in the healthy weight range. Males (25.5%) were significantly less likely to be in the healthy weight range than females (38.6%). BMI differed significantly by age of respondent, with 43.3% of persons aged 18–29, and 26.0% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 19.8% in Power County to 47.4% in Blaine County of adults being in the healthy weight range.

#### Any Physical Activity - 2015-2021

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 78.7% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.3% of persons aged 18–29, and 72.3% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 64.3% in Clark County to 84.6% in Teton County.

Physical Activity Guidelines – 2011, 2013, 2015, 2017, 2019 Statewide, 21.9% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.3% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6% in Franklin County to 30.6% in Blaine County.

#### Home Radon Testing - 2016, 2018, 2020

Statewide, 23.0% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.4% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.5% in Cassia County to 54.4% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006l and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.



